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Abstract 
 
This thesis focused on the long-term mental health and quality of life of breast 
cancer survivors, compared to women with no prior cancer. 
The first study was a systematic review of studies that assessed adverse mental 
health outcomes in women who had breast cancer and non-cancer controls. This 
found evidence suggestive of an increased risk of anxiety, depression, suicide, and 
neurocognitive and sexual dysfunctions in breast cancer survivors. 
The second study systematically summarised the lists of Read codes and clinical 
definitions used in previous studies of mental health-related outcomes in primary 
care databases of electronic health records in the UK. The results showed 
substantial heterogeneity across studies and informed the definition of the outcomes 
in this thesis. 
The third study used data from the UK Clinical Practice Research Datalink (CPRD) 
GOLD primary care database to quantify the risk of adverse mental health-related 
outcomes in 57,571 breast cancer survivors and 230,067 women with no previous 
cancer. Breast cancer survivorship was positively associated with anxiety, 
depression, fatigue, pain, sexual dysfunction, sleep disorder and being prescribed 
opioid analgesics, but there was no evidence of association with cognitive 
dysfunction or fatal and non-fatal self-harm. 
The fourth study included 353 breast cancer survivors and 252 women with no prior 
cancer who replied to questionnaires assessing quality of life and mental health. 
Compared to women with no prior cancer, breast cancer survivors had poorer 
quality of life in the domains of cognitive problems, sexual function, and fatigue, but 
no evidence of difference in negative feelings, positive feelings, pain, or social 
avoidance. Women with advanced-stage cancer at diagnosis, and/or prior receipt of 
chemotherapy, had poorer quality of life and mental health. 
In conclusion, breast cancer survivorship is associated with impaired quality of life 
and raised risk of adverse mental health-related outcomes, persisting well into the 
survivorship period. 
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1 Background 
1.1 Introduction 
This thesis focuses on the mental health and quality of life of breast cancer 
survivors in the UK, compared to women with no history of cancer. This opening 
chapter provides background information on the current knowledge of the aetiology 
and epidemiology of mental health conditions and breast cancer, the potential 
intersection between the two, and plausible implications for health-related quality of 
life (HRQoL). This motivated the aims and objectives of this thesis, which are 
provided in Chapter 2. 
1.2 Mental disorders 
Mental disorders are very common conditions. A meta-analysis of 155 studies from 
55 countries, estimated a one-year prevalence of all mental disorders of 17.6% 
(95% confidence interval (95%CI): 16.3% to 18.9%) [1]. Anxiety and mood disorders 
represented 88% of all diagnosis [1], therefore the following sections focus in detail 
on these two groups of disorders, and briefly on other mental disorders. 
1.2.1 Depressive disorders 
Definition 
Depressive disorders are characterised by cardinal feelings of sadness, anhedonia, 
lack of interest, feelings of helplessness, irritability, and tearfulness, among others 
[2]. These negative feelings are amongst the panoply that occur normally in 
mammals, and short periods of sadness are part of everyday life [2, 3]. Depression 
in the pathological sense occurs when the severity and duration of these symptoms 
are exaggerated, so much so that they disrupt daily life. Major depressive disorder 
(MDD) is the terminology used to refer to the most severe cases, and is defined by 
the following criteria in the Diagnostic and Statistical Manual of Mental Disorders, 
5th Edition (DSM-V): the presence of 1) an abnormal depressed mood most of the 
day, nearly every day, for at least two weeks; or an abnormal loss of all interest and 
pleasure most of the day, nearly every day, for at least two weeks; and 2) at least 
two of the following symptoms during those same two weeks: depressed mood, loss 
of all pleasure, appetite or weight disturbance, sleep disturbance, agitation or 
27
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slowing, fatigue or loss of energy, abnormal inappropriate guilt, poor concentration, 
thoughts of death or suicide [4]. 
Historically, the terms ‘depressive disorders’, ‘mood disorders’ and ‘affective 
disorders’ have all been used to describe a group of disorders that are 
characterised by depressive episodes. These groups included unipolar depressive 
disorder and bipolar disorder (sometimes referred to as manic depression), among 
other less common disorders. In DSM-V, published in 2013, the category of ‘Mood 
disorders’ was replaced by two categories: ‘Bipolar and related disorders’ and 
‘Depressive disorders’. This split was motivated by the similarities in 
symptomatology, family history and genetics between psychotic disorders and 
bipolar disorders. Unipolar depressive disorder has always represented the vast 
majority of the cases in any group of ‘mood disorders’, and it is the focus of the 
following section on aetiology. For simplicity, unipolar depressive disorder is 
hereafter referred to as depression. 
Aetiology 
The aetiology of depression is complex. Early studies showed that depression 
tended to occur in those with a family history of the disorder, suggesting that genetic 
components could be involved [5]. Adoption studies explored the role of 
environmental exposures, as families tend to share both genetics and habits. The 
higher frequency of major depression in adoptees with biological family history of 
depression, compared to adoptees without, further lent support to the theory of 
genetic susceptibility [5]. Heritability for depression has now been estimated at 
around 30-40% (at population level), based on studies with monozygotic and 
dizygotic twins [5]. Studies on the specific genes involved revealed a multifaceted 
picture of polygenic inheritance, where several genes contribute a small or modest 
effect independently [5, 6]. 
Stress plays a central role in the aetiology of depression [7]. The Oxford dictionary 
defines stress as ‘a state of mental or emotional strain or tension resulting from 
adverse or demanding circumstances’ [8]. Adverse psychological exposures during 
childhood appear to affect one’s predisposition to subsequently develop depression 
[9]. In addition, there is vast empirical evidence that recent stressful events, 
measured in several forms, may precipitate episodes of depression [10-12]. 
Increasing odds of depression were also found for more long-lasting forms of stress, 
such as lower socio-economic status [13], distressed partnered relationships [14], 
singlehood at older ages [15], motherhood with low social support [16], and work-
28
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related factors, such as job strain, workplace bullying, lack of autonomy and 
decision capacity [17]. 
Stress is often induced by change [7]. Whilst some changes may be avoided, those 
arising from one’s life course trajectories are less so. The life course social field 
model (Figure 1.1) puts forward a number of life span events that may act as 
stressors during an individual’s lifetime and trigger episodes of depression; these 
events are thought to be closely related to the higher incidence of depression in 
certain age groups (vide section 1.2.1.4) [7]. 
Figure 1.1   Life course social field model. Figure adapted from [7]; reproduced with 
permission from Oxford Publishing Limited. 
 
The diathesis stress model (Figure 1.2) explains the interaction between genes and 
stress in the aetiology of depression. The model postulates that neither genes nor 
stress alone invoke most pathological events, but instead it is the combination of 
sufficient components of the two that are implicated [18, 19]. 
Several factors, at individual and societal levels, have been described as modifiers 
of the association between stress and depression in susceptible individuals. For 
example, personality traits, such as higher levels of neuroticism, have been shown 
to interact with stress and potentiate the risk of depression [20]. Increased social 
support, measured as higher perceived social support, higher number of social 
relationships, working outside home, or having someone to confide in, have been 
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shown to buffer some of the negative effects of stress, particularly among women, 
and protect against depression [21, 22]. 
 
Figure 1.2   The diathesis stress model. Figure from [7]; reproduced with permission from 
Oxford Publishing Limited. 
 
Physical activity appears to also protect against the onset of depression [23], and 
part of this effect may be due to increased social interaction. 
Natural course of depression 
Diagnosed episodes of depression usually last for months, and are on average for 
four weeks longer in women compared to men [24]. A 12-year longitudinal study on 
the prognosis of depression reported that 50% of the patients did not observe any 
further episode, 35% achieved remission but later relapsed, and 15% had 
unremitting disease during the 12-year period [24]. Depression has also a lengthy 
prodromal period, often longer than the depressive episode itself [24].  
Epidemiology 
The risk of depression varies by age and sex, typically following the distribution 
shown in Figure 1.3 in high-income settings. The higher risk of depression in 
females starts around puberty, and rates increase rapidly in both sexes, peaking 
around the mid-twenties and early thirties [25]. Incidence rates tend to decline in 
both sexes until the mid to late 50s, when small increases have been noted [24, 25]. 
One may observe that these peaks coincide with life stages when major changes 
occur (Figure 1.1). In young adulthood, the societal expectations are for one to start 
a career, be financially independent, have a partner, start a family, etc., which may 
be a reasonable source of emotional strain for many [7]. In the late 50s, many 
experience angst over their own children’s independence, illnesses, loss of loved 
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ones, retirement and defining a meaning for the fewer years ahead [7]. Social 
interactions often change around these stages in life, possibly adding further strain 
through reduced social support. 
  
 
 
 
Figure 1.3   Sex- and age-specific incidence rate and cumulative incidence, for treated 
mood disorders in Denmark. Limit lines show the 95% confidence intervals. Figure adapted 
from [25]; reproduced with permission from the American Medical Association. 
 
In 2000, unipolar depressive disorder accounted for 4% of all disability adjusted life 
years (DALYs) in the world, ranking only below infections of the lower respiratory 
tract and human immunodeficiency virus [26, 27]. In the most affluent regions, it 
accounted for nearly 8% of the DALYs, ranking only after ischaemic heart disease 
[26, 27]. Years of life lost due to depression are few (usually attributed to suicide) 
but the number of years lived with disability (YLDs) is phenomenally high. Women 
have the largest share of this burden, due to higher prevalence and duration of the 
disease. In women, YLDs increased 32.2% from 1990 to 2007 and 14.1% from 
2007 to 2017 (Figure 1.4). Depressive disorders rank third in the global rank of 
YLDs in women since 2007 [28]. 
 
 
Figure 1.4   Leading causes of global years lived with disability (YLDs) for women in 2017, 
and percentage change in the number of YLDs and all-age and age-standardised rates. 
Figure adapted from [28]; reproduced under the terms of a Creative Commons (CC) By 
Attribution (BY) license. 
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The global variation in burden of disease may be partially explained by differences 
in the prevalence of depression across settings. For example, the one-year 
prevalence of depression was found to vary in a systematic review from <1% in 
Taipei, Taiwan, to 15.4% in the Republic of Udmurtia, Russia [29]. Several factors 
may contribute to this disparity, including true heterogeneity in the risk and course of 
the disease, differential reporting of negative feelings in settings where mental 
health conditions are stigmatised, and differences in the criteria used to establish 
‘caseness’ (e.g. inclusion/exclusion of dysthymia and bipolar disorders in 
‘depression’). 
In the UK, the 2014 Adult Psychiatric Morbidity Survey estimated that 4% of women 
and 3% of men aged 16-64 met the criteria for a depressive episode in the past 
week, and a further 11% and 6%, respectively, had symptoms of mixed anxiety and 
depression [30]. This represented an increase of 2% in the frequency of depressive 
episodes in both sexes since 1993 (Figure 1.5). 
  
Depression in the last week  
 
 
 
 
 
Figure 1.5   Results from the Adult Psychiatric Morbidity Surveys1 [30] for the prevalence of 
depressive episodes and mixed depression and anxiety in the week before interview by 
calendar year of data collection and sex. 
 
In summary, depression affects approximately a fifth of women and a tenth of men 
during their lifetime. Episodes of depression, even when of mild severity, are 
debilitating, affecting the individual and their social groups. The high prevalence, 
duration and impairments generated by the disorder are translated into large 
numbers of years lived with disability, and demand for public health strategies that 
mitigate these effects. 
 
1 The Adult Psychiatric Morbidity Survey includes a large probability sample of the adult general population (aged ≥16 years) living in 
private households [15] and evaluated the presence of common mental health conditions in the previous week using the revised 
Clinical Interview Schedule (CIS-R) [16]. Participants were aged 16-64; data for subjects aged over 64 were collected in the two 
most recent waves, but were not included in the graph to retain comparability over time. The three first waves include data for the 
whole UK, while only England has been included in 2014. 
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1.2.2 Anxiety disorders 
Definition 
Anxiety is the physiological response to situations perceived as dangerous, an 
ancient biological programming to survive [2]. Low to moderate levels of anxiety are 
normally associated with enhanced performance but high levels are counter-
productive [31]. Anxiety disorders are characterised by exaggerated mental 
symptoms of fears and anxiousness, physical symptoms, and respective 
behavioural reactions [4]. Fear is defined in DSM-V as ‘the emotional response to a 
real or perceived immediate threat’, while anxiety is ‘the anticipation of future threat’ 
[4]. Anxiety disorders have several components, including psychological (feelings of 
dread, restlessness, narrowed attention, increased alertness and irritability), somatic 
(hyperventilation and muscle tension), autonomic (increased heart rate and 
sweating) and avoidance (phobia) [2]. 
DSM-V includes five anxiety disorders common in adults: specific phobias, social 
anxiety disorder (social phobia), panic disorder, agoraphobia, and generalised 
anxiety disorder [4]. Whilst all have symptoms of fear and anxiety at their core, they 
are differentiated by different patterns in cognition, behaviour, physiology and 
temporal aspects [7]. 
Phobias, including specific phobias, social phobia, and agoraphobia, are marked by 
sporadic anxiety that occurs when one is exposed to a particular object, place or 
situation, and it causes anxious anticipation and avoidance. Specific phobias refer 
to fear of specific objects or situations (e.g. heights, blood, flying), while social 
phobia refers to the fear and anxiety caused by social situations (e.g. meeting 
strangers). Agoraphobia is characterised by fears related to places and/or situations 
from which escaping might be, or is perceived as, difficult, and these situations are 
intensely avoided (e.g. public transportation, crowed spaces, going outside home). 
Even though the individual recognises these fears as irrational, anticipation or 
exposure to the object/situation inevitably triggers intense anxiety, causing one to 
markedly avoid the situation [4]. 
Anxiety in panic disorder is also intermittent, but unrelated to a particular exposure 
[2]. Panic disorder is defined by spontaneous and recurrent panic attacks, and at 
least one month of concerns about additional attacks and their consequences, or 
changes in behaviour because of the panic attacks [4]. A panic attack, in turn, is 
defined by fear, with four or more of the following symptoms developing and 
peaking within 10 minutes: palpitations, sweating, shaking or trembling, shortness of 
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breath, feeling of chocking, chest pain, nausea, feeling dizzy or faint, de-realization, 
numbing or tingling sensation, chills or hot flushes [4]. 
Generalised anxiety disorder is defined by a continuum of excessive and 
uncontrollable anxiety and worry, in more days than not, for at least six months. 
Anxiety in generalised anxiety disorder is linked to three or more of the following: 
restlessness, fatigue, concentration problems, irritability, muscle tension and sleep 
disturbance [4]. 
Traditionally, anxiety disorders also included obsessive-compulsive, acute stress-
related disorders, and post-traumatic stress disorder (PTSD) [32]. In DSM-V, 
obsessive-compulsive and stress-related disorders were separated from anxiety 
disorders. In their new categories, diagnostic criteria remained similar, with 
obsessive-compulsive disorders having as central features compulsions guided by 
obsessions (e.g. hoarding) and stress-related disorders originating from a well-
defined traumatic situation [4]. 
Aetiology 
The aetiology of anxiety is also complex, and has several similarities to the 
aetiology of depression. Anxiety disorders are thought to also have a genetic 
component [33], with studies with twins estimating heritability at ~10-15% at 
population level [5]. The individual susceptibility to anxiety disorders, however, is 
thought to be the product of several gene-environment interactions (Figure 1.6) [34]. 
 
 
 
Figure 1.6   Model of anxiety aetiology. Figure from [35]; reproduced with permission from 
Oxford Publishing Limited. 
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Environmental factors that appear to contribute to increased susceptibility to anxiety 
disorders include some that negatively affect personality development during 
childhood, including parental indifference, physical or sexual abuse, parenting styles 
dominated by overprotection and lack of emotional warmth [36-39]. Individual 
personality traits, such as neuroticism may also be implicated [2]. 
In individuals with increased susceptibility, stress also plays a major role in the 
incidence of anxiety disorders [2, 35]. Compared to depression, evidence on the 
stressors for anxiety disorders is scarcer. Lower socio-economic status (measured 
through levels of income and years of education) was a strong predictor of panic 
attacks (odds ratio (OR) for <12 years vs. >15 years of schooling: 4.9), panic 
disorder (OR: 10.4) and panic disorder with agoraphobia (OR: 7.6) [40-42]. Social 
support has been associated with better outcomes in the treatment of anxiety 
disorders [43]. Higher levels of physical activity also protect against the onset of 
anxiety [44]. 
Epidemiology 
Steel et al. estimated the lifetime prevalence of anxiety disorders was 18.2% in 
women and 10.1% in men based on comprehensive systematic review of studies 
conducted between 1980 and 2013 [1]. However, there has been considerable 
variation in the prevalence estimates of anxiety disorders available in the literature, 
and results from studies using stricter, diagnostic manual, definitions of anxiety 
disorders tend to show lower estimates. For example, the World Health 
Organization (WHO) reported that the prevalence of anxiety disorders worldwide in 
2015 was 3.6% [45]. 
Considering specific anxiety disorders, Eaton et al. found that 4% of patients met 
the criteria for a lifetime DSM-III-R diagnosis of panic disorder, and 16% met the 
criteria for lifetime fearful spell (i.e. met some but not all DSM-III-R criteria for panic 
disorder) [40]. Phobias, including agoraphobia, social phobia and specific phobias, 
are quite common in the population. In the United States, the lifetime prevalence of 
agoraphobia has been estimated at 9.0% in women and 4.1% in men, while social 
phobia affected 15.5% of women and 11.1% of men during their life time [42]. 
Incidence of anxiety disorders registered in EHRs of patients attending primary care 
practices in 1998-2008 in the UK was estimated at 7.4 per 1000 person-years in 
women (95%CI: 7.4 to 7.5), and 3.9 per 1000 in men (95%CI: 3.9 to 4.0) [46]. A 
declining trend in recording of diagnosis of anxiety, accompanied by an increasing 
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recording of symptoms for anxiety, was observed during the 10-year period [46]. 
The risk of having an anxiety diagnosis recorded was 58% (95%CI: 37% to 82%) 
higher in patients in the most deprived areas, compared to those least deprived 
ones [46]. Incidence of anxiety disorders was lowest in the age group 16 to 24 years 
and highest among those aged 45-64 years [46]. Figure 1.7 describes the 
prevalence of each anxiety disorder in the UK Adult Psychiatric Morbidity Surveys. 
In 2014, 24.6% of the women and 15.9% of the men met the criteria for an anxiety 
disorder in the week before [30]. Although these figures are not directly comparable 
to those from EHRs, it is still interesting to observe the increasing trends in patient-
reported anxiety. 
 
 
 
 
Figure 1.7   Results from the Adult Psychiatric Morbidity Surveys [30] for the prevalence of 
anxiety disorders in the week before interview by calendar year of data collection and sex.  
  
Anxiety disorders rank eight in the global rank of YLDs (Figure 1.3). The burden of 
anxiety is particularly high in countries with high socio-demographic index (Figure 
1.8). This might be partially explained by the higher lifetime prevalence of anxiety 
disorders diagnosed in high-income countries (19.4%), compared to low- and 
middle-income countries (16.0%) [1]. 
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Figure 1.8   Trends of age-standardised YLD rates per 100,000 for the top eight causes of  
non-fatal burden in 2017 for each sex by socio-economic development index (SDI) quintile, 
1990-2017. Figure adapted from [28]; reproduced under the terms of a CC BY license. 
 
In summary, anxiety disorders arise from stressful situations in anxiety personality-
prone individuals. The burden generated by anxiety disorders is high, particularly in 
high-income countries. Women and those with lower socio-economic status are 
more likely to have an anxiety disorder during their lifetime. 
1.2.3 Relationship between anxiety & depression 
Descriptive data on anxiety and depressive disorders show considerable similarities 
[7]. It was postulated that anxiety disorders themselves may also include depressive 
symptoms [47], with increased stress causing dysthymia, and if these persist, 
symptoms of panic and agoraphobia may also appear (Figure 1.9). This explains 
the high co-morbidity of anxiety and depression at individual level. 
Data from prospective studies have shown that anxiety and depression are 
positively correlated both at baseline and at follow-up, in addition to being correlated 
with the incidence of the other between baseline and follow-up [48]; this means that 
these conditions predict one another, and share syndrome (i.e. anxiety symptoms 
may be present in depressive disorders, anxiety disorders may include depressive 
symptoms). So, while these conditions may be considered as two broad entities, 
part of the symptomatology will overlap, and many patients present with mixed 
symptomatology of anxiety and depression. 
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Figure 1.9   Model of stress-reactive neurosis. As the levels of stress increase, dysthymia is 
present. This explains the high comorbidity of depressive and anxiety symptoms. Figure  
from [49]; reproduced under the terms of a CC BY Non-Commercial (NC) license. 
 
In addition, for both conditions, lower socio-economic status is associated with 
raised risks, while social support exerts protective effects [50]. Further evidence for 
the overlap between these two conditions is provided by genetic studies where, for 
example, a family history of depression has been shown to increase the odds of 
having been diagnosed with panic disorder [51]. The natural course of anxiety and 
depression is also somehow similar, varying from patients who recover fully, 
patients who keep relapsing over time, and who have unremitting course [52]. Both 
conditions are more frequent in women, are precipitated by similar stressors, and 
respond to treatment with similar pharmacological agents [53]. History of depressive 
disorder appears to increase the risk of panic disorder [41], and both disorders are 
strong predictors of suicide [54]. 
1.2.4 Other mental health conditions 
Mental disorders other than depressive and anxiety disorders listed in DSM-V are 
provided in Table 1.1. 
Table 1.1   DSM-V categories for mental disorders other than anxiety and depression. 
 
Neurodevelopmental disorders 
Schizophrenia spectrum and other psychotic disorders 
Bipolar and related disorders 
Obsessive compulsive and related disorders 
Somatic symptoms and related disorders 
Feeding and eating disorders 
Elimination disorders 
Trauma and stressor related disorders 
 
(continued) 
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Table 1.1   (continued) 
 
Dissociative disorders 
Sleep-wake disorders 
Sexual dysfunctions 
Gender dysphoria 
Disruptive, impulse-control, and conduct disorders 
Substance-related and addictive disorders 
Neurocognitive disorders 
Personality disorders 
Paraphilic disorders 
 
 
The aetiology of these disorders is varied. Some disorders have typical onset during 
childhood (e.g. neurodevelopmental disorders), and thus are unlikely to be 
associated with exposures characteristic of adult life. A few disorders are known to 
be associated with biological changes in the central nervous system due to a 
specific medical condition (e.g. dementia in multiple sclerosis, or after stroke). Other 
disorders can have both physical and psychological origin (e.g. sexual dysfunction). 
And several disorders are defined by similar symptoms (e.g. anxiety as symptom in 
sleep disorders). 
The following paragraphs briefly describe sleep-wake disorders, sexual 
dysfunctions, neurocognitive disorders, and self-harm. There were chosen due to 
their onset in adult life, and potential association with stress. Self-harm is also 
described because it is the manifestation of mental distress, even though it is not a 
mental disorder per se. 
Sleep disorders 
Sleep disorders are related to impairments in sleep quantity, quality or timing [4]. 
Insomnia and hypersomnia are the most common conditions. Insomnia is 
characterised by difficulties in initiating or maintaining sleep, causing sleep 
deprivation that can cause substantial distress to the patient [4]. Hypersomnia refers 
to prolonged sleep (>9 hours or recurrent episodes sleep) that is not restorative [4]. 
Sleep disorders are relatively common [55]. A review showed prevalences in the 
general population that varied from 8% to 33%, depending on the definitions used 
[56]. In the UK, a survey of the general population in 1994 described a prevalence 
of insomnia of 6.8% in men and 10.6% in women [57]. 
Risk factors for sleep disorders include female gender, depression, chronic physical 
illnesses, and possibly lower socio-economic status, widowhood, and loneliness and 
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perceived stress [58-60]. Insomnia becomes chronic in nearly 50% of the patients 
[61] and is often comorbid with other distressing conditions (most often anxiety, pain 
and dementia) or excess use of substances such as caffeine or ethanol [2].  
Female sexual dysfunction 
Sexual dysfunctions refer to impaired or unsatisfied sexual experiences [2]. In 
females, the most common sexual dysfunctions are orgasmic disorders, arousal 
disorders, and genito-pelvic pain [4]. Orgasmic disorder is defined by the absence 
or substantial delay in reaching orgasm in most (75-100%) of the sexual activity 
events, which can cause distress to the individual [4]. Arousal disorder occurs when 
the woman has persistent (>6 months) lack of, or importantly reduced, sexual 
interest that causes clinically significant distress [4]. Genito-pain disorders (including 
vaginismus and dyspaneuria) include difficulties with vaginal penetration or pain 
during vaginal penetration, with or without constriction of the pelvic floor muscle that 
prevent penetration, that last for six or more months and causes distress [4].  
The advances in the understanding of sexual dysfunctions are great challenges for 
the definition of objective criteria to establish a diagnosis and, consequently, for 
research in this area. All revisions of the DSM have included changes related to 
sexual dysfunctions [62]. DSM-V reduced the categories of sexual dysfunctions 
compared to DSM-IV, and included stricter criteria for diagnoses of sexual 
dysfunction (e.g. present in 75-100% of the time, for ≥6 months, and causing 
significant distress), aiming at reducing the over-diagnoses of sexual dysfunctions 
with DSM-IV criteria and better represent the most recent model of female sexual 
function [63, 64].  
In 2003, a survey of women aged 15-44 in Britain reported that 10% had a lack of 
sexual interest, 14% were unable to reach orgasm, and 12% had painful intercourse 
[65]. In a more recent survey (2010-2012), lack of sexual activity in the previous 
year was associated with problems in sexual function, and 10.9% of women who 
had had sex during the previous year were distressed about their sex life [66]. 
Decreased sexual activity in post-menopausal women may be explained by a wide 
range of factors, including lack of partner available (e.g. widowhood, separation), 
presence of medical conditions more common older ages (back pain, dementia, 
erectile dysfunction), bereavement for loved ones, relationship difficulties, fatigue, 
among others [58]. Psychiatric disorders, such as depression and/or anxiety, and 
some psychotropic drugs, such as selective serotonin receptors inhibitors (SSRI) or 
tricyclic antidepressants, may also impair the female sexual function [2]. 
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Neurocognitive dysfunction 
Neurocognitive dysfunctions have impairments of the intellect, memory and 
personality as central features; 95% of cases are irreversible [2]. The main 
conditions in this category are Alzheimer’s disease, vascular dementia, 
frontotemporal dementia, Lewy bodies disease, and dementia in Parkinson’s 
disease [4]. Neurodegenerative alterations in the central nervous system, usually 
visible through brain atrophy, are often observed in patients with these conditions, 
and explain the pathophysiology. In cases where impairments to the domains of 
cognitive function are not sufficient for a specific diagnosis, the term mild cognitive 
dysfunction is used [4]. Between 10% and 20% of the cases mild cognitive 
impairment are expected to progress to dementia [67]. 
Incidence of dementia was estimated at 14.3 per 1000 person years in men and 
17.0/1000 person years in women aged 50 or more in England in 2010 [68]. In 
those aged ≥60 years, prevalence was estimated to vary between 5 and 7% [69]. 
Alzheimer’s disease usually accounts for 50-60% of all dementia cases, followed by 
vascular dementia (20-25%) and dementia with Lewy bodies (15-20%) [2].  
Several factors have been pointed out to increase the risk of dementia, such as 
hypertension, diabetes, obesity, and alcohol use [70-73]. Trends in the incidence of 
Alzheimer’s disease appear to be stable in western countries, but the burden has 
almost doubled between 1990 and 2013 due to the increased survival [74]. 
Fatal and non-fatal self-harm 
Intentional self-harm is commonly associated with an underlying mental condition, 
and it may occur for several reasons, including a desire to punishing oneself, to 
express distress to others, to escape or avoid situations, to release feelings of 
anger, tension, anxiety or depression, among others [75-77]. The severity of self-
harm ranges from injuring behaviour with no suicidal intent, to suicide. 
Figure 1.10 shows some of the most relevant risk factors for self-harm and suicide 
in adolescents and young adults, and the mechanisms that may be involved [78]; 
the model for adults is likely to be similar. Alcohol consumption, previous psychiatric 
disorder, previous self-harm attempts that led to health-service contact, among 
others, appear to be strong predictors of self-harm [77, 79]. Risk factors for suicide 
are in all similar to those for self-harm. There is also a considerable body of 
research on chronic diseases as a risk factor for suicide, including heart failure [80], 
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chronic obstructive pulmonary disease [81], atopic dermatitis [82], multiple sclerosis 
[83], chronic pain [84], among others. 
 
 
Figure 1.10   Risk factors for self-harm and suicide. Figure from reference [78]; reproduced 
with permission from Elsevier. 
 
Self-harm is most common in adolescents and young adults, but the proportion of 
subjects who self-harm around midlife in England is not negligible [77] (Figure 1.11). 
In addition, the prevalence of intentional self-harm without suicidal ideation in 
England increased from 2.4% in 2000 to 6.4% in 2014 [77]. 
 
Males Females 
 
Figure 1.11 Prevalence of self-harm without suicidal intention in males (panel A) and 
females (panel B) in England. Figure from [77]; reproduced under the terms of a CC BY 
license.  
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Self-poisoning, commonly with paracetamol or anti-depressants, accounted for 
78.6% of the men, and 86.8% of the women, aged 40-59 years old that presented to 
hospital with self-harm; the remaining were cases of self-injury and/or self-poisoning 
[85]. 
Self-harm is a strong risk factor for suicide [86] but only a small proportion of the 
self-harm cases result in death (Figure 1.12) [87]. 
 
 
Figure 1.12 Venn diagram showing the relation between suicide attempts, suicides and 
mood disorders. Adapted from [88]; reproduced with permission from Wolters Kluwer Health. 
 
Following the global trends, the rate of suicide has increased in the UK since 1950 
[2]. Even though self-harm is more common among women, completed suicide is 
more common in men. The highest risk of suicide in the UK in 2014 was observed 
for men aged 45-59 years (23.9 deaths per 100,000 population). The corresponding 
highest risk estimate for women was also in the age group of 45-59 years, with 7.3 
deaths per 100,000 population [89]. 
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1.3 Breast cancer 
1.3.1 Incidence 
Breast cancer incidence markedly increased during the last decades (Figure 1.13) 
and it is currently the most frequently diagnosed malignancy in women in the UK, 
excluding non-melanoma skin cancer [90, 91]. 
 
 
Figure 1.13   Trends (full line) and linear trend (dashed line) of the age-standardised 
incidence rates of breast cancer in England (1995-2011). Figure from [92]. reproduced ‘as is’ 
for research and education purposes. 
 
Breast cancer is currently understood as being a disease closely related to 
exposure to hormones. The female breast is composed of glandular tissue whose 
primary function is milk production after parturition [93]. The development of the 
breast tissue during adolescence relates to the effects of oestrogen and 
progesterone, two hormones that start to be produced with the onset of the luteal 
phase of the ovary [94]. During the subsequent menstrual cycles, if no pregnancy 
occurs, the breast develops and then regresses [95]. However, if a pregnancy 
occurs, the placenta produces hormones that stimulate the development of the 
breast tissue (e.g. oestrogen, progesterone and placental lactogen [94]) causing the 
expansion of the ducts and lobules [95]. Women exposed to a higher number of 
menstrual cycles during their lifetime, through menarche at younger age [96], late 
menopause [96], or no pregnancy- or lactation-related amenorrhea [97, 98], have an 
increased risk of breast cancer [96]. Use of exogenous hormones, such as oral 
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contraceptives and hormone replacement therapy, are also associated with an 
increased risk of breast cancer [99]. 
It is estimated that around 10% of the breast cancer cases occurring the western 
world are due to genetic predisposition [100], even though not much is known about 
how many and which genes increase the risk of breast cancer. Identified genes 
have been shown to have autosomal dominance with limited penetrance, passing to 
the next generations through either parent, and not leading to cancer development 
in all carriers. BRCA1 and BRCA2 are two notable oncogenes in this area, located 
on chromosomes 17 and 13, respectively [100]. BRCA1 and BRCA2 are tumour 
suppressor genes, involved in the regulation of transcription and reparation of DNA. 
Alterations in these genes are rare in the general population, at about 0.1% [95]. 
However, approximately 60-80% of the women who carry these mutations develop 
breast cancer, usually around the age of 50 years [95]. 
Several lifestyle risk factors for breast cancer have been identified and some of 
these vary by women’s menopausal status [101]. The World Cancer Research Fund 
International and the American Institute for Cancer Research have produced robust 
evidence on the effect of food, nutrition and physical activity in the development of 
breast cancer [101-103]. According to the latest revision of the evidence, based on 
comprehensive systematic reviews and meta-analyses, there is strong evidence 
that lactation, physical activity and body fatness in young adulthood are associated 
with a decreased risk of breast cancer in both pre- and post-menopausal women 
(Table 1.2) [103]. 
Table 1.2   Lifestyle risk factors for breast cancer: levels of evidence. 
 Protective factors (level of evidence) Risk factors (level of evidence) 
Pre-
menopause 
Lactation (P) Alcoholic drinks (P) 
Body fatness (P) Adult attained height (C) 
Vigorous physical activity (P) Greater birth weight (P) 
Non-starchy vegetables (ER- only) (S)   
Dairy products (S)   
Carotenoid rich foods (S)   
Diets high in calcium (S)   
Physical activity (S)   
     
Post-
menopause 
Lactation (P) Alcoholic drinks (C) 
Physical activity of all types (P) Body fatness (C) 
Body fatness in young adulthood (P) Adult attained height (C) 
Non-starchy vegetables (ER- only) (S) Adult weight gain (C) 
Carotenoid rich foods (S)   
Diets high in calcium (S)   
C = convincing; P = probable; S = suggestive. 
Convincing and probable levels of evidence are supported by strong evidence from the literature; 
suggestive is supported by limited evidence. 
Table adapted from [103]. 
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Of the established risk factors for breast cancer, only a few are amenable to 
change: exogenous hormone use, post-menopausal excess of body weight and 
alcohol intake. Reproductive factors are less likely to be changed for cancer 
prevention purposes in modern societies. Therefore, breast cancer will continue to 
have high incidence globally in the foreseeable future. With the gains in life 
expectancy observed in the last century [104], the aging of the population alone will 
result in increased numbers of breast cancer patients. 
1.3.2 Control 
Breast cancer control strategies have mainly focused on early detection and 
treatment. A mass-screening programme targeting women aged 50-64 years old 
has been operating since 1988 [105]; in 2000, screening was extended up to the 
age of 70 years [106]. Tumours detected through mammography tend to have a 
lower stage at diagnosis, and consequent better survival, than tumours detected 
when the disease is symptomatic [107]. Even for late-stage tumours, the (neo-
)adjuvant hormonal and immune therapies, introduced in the last decades, resulted 
in notable improvements in survival. In England and Wales, for example, 5-year 
age-adjusted net survival from breast cancer increased from 53% in 1971-72 to 
87% in 2010-11 (Figure 1.14) [108]. 
 
 
Figure 1.14   Five-year net survival, adjusted for age, for patients diagnosed in 2010-2011, 
and absolute change since 1971 in England and Wales. Figure adapted from [108]; 
reproduced under the terms of a CC BY license. 
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This is translated into unprecedented numbers of breast cancer survivors in the 
general population. Approximately 570,000 women in the UK were estimated to 
have a history of breast cancer in 2010 [109]. 
A comparison of the survival estimates estimated for the UK with those from three 
Nordic countries (Figure 1.15), which have similar national health systems, shows 
that there is still margin for improvements, and therefore the number of breast 
cancer survivors is still expected to increase in the decades to come. 
 
 
Figure 1.15   Trends in five-year age-standardised net survival (%) from breast cancer in the 
United Kingdom (UK) and in three Nordic countries from 1995-99 to 2010-14.  
Figure created using data publicly available from [110, 111]. 
 
By 2040, projections indicate that there will be 1.5 million women with history of 
breast cancer living in the UK [109]. 
1.3.3 Treatment 
Current treatment modalities with curative intent include combinations of surgery 
(mastectomy or breast conserving surgery, with sentinel lymph node biopsy or 
axillary dissection), radiotherapy, chemotherapy (e.g. antracyclines and/or taxanes), 
endocrine therapy (tamoxifen or aromatase inhibitors) for oestrogen receptor (ER) 
positive tumours, and monoclonal antibody therapy (trastuzumab) for Human 
Epidermal growth factor Receptor 2 (HER2) positive tumours [112]. An example of 
the combinations recommended by the European Society for Medical Oncology 
(ESMO) for treatment of early breast cancer is given in Figure 1.16. 
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Figure 1.16   Early breast cancer treatment algorithm [16].  
 
Reproduced with permission from Oxford University Press. Cht = chemotherapy;  
BCS = breast-conserving surgery; ET = endocrine therapy; RT = radiotherapy.  
 
Surgery is an essential treatment offered to all patients treated with curative intent. 
Currently, 60-80% of the breast cancer patients are eligible for breast-conserving 
surgery and mastectomy is only recommended for a subset of patients with specific 
characteristics or who prefer it [112]. Assessment of the lymph nodes status is 
mandatory for the determination of the stage of the disease and is generally carried 
out by axillary lymph node dissection or sentinel lymph node biopsy during surgery. 
Treatment pathways after surgery largely depend on the biological characteristics of 
the tumour, stage of the disease and patient’s physical condition [112]. For early-
stage breast cancer, adjuvant radiotherapy is effective in reducing breast cancer 
related mortality [113], and thus almost always offered to women who have breast-
conserving surgery. Six months of chemotherapy regimens have been shown to 
decrease the annual breast cancer death rate by 20-38% [114]. 
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Adjuvant systemic treatments for breast cancer, other than chemotherapy, include 
hormone and immune therapies. Endocrine therapy is currently recommended for 
patients with tumours whose cells express high proportions of ER (70% of breast 
cancers) to reduce the risk of recurrence [112]. Tamoxifen, a selective oestrogen 
receptor modulator, given for 5-10 years is usually the primary choice for pre-
menopausal women [112]. Five years of tamoxifen decreased breast cancer death 
rates by 31%, independently of the use of chemotherapy [114] and improved 
survival of women with metastatic breast cancer [115]. For post-menopausal women 
both tamoxifen (5-10 years) and aromatase inhibitors (AI) (5 years) have been used 
[112], but AIs have become the preferred choice, as meta-analyses indicated lower 
risk of recurrence compared to tamoxifen [116, 117]. Approximately 10-20% of 
breast cancer patients have tumours that overexpress proteins encoded by the 
HER2 [118], an oncogene that belongs to the epidermal growth factor receptor 
(EGFR) family, which is involved in the cell growth and differentiation [119]. 
Trastuzumab is a monoclonal antibody therapy effective in treating HER2+ tumours 
[120]. 
1.4 Common physical consequences of breast cancer treatments 
All breast cancer treatments carry the risk of long-term iatrogenic effects. 
Surgery inevitably results in a life-long scar and may change women’s body image. 
Women who had mastectomy have reported more body image concerns compared 
to women who had breast-conserving surgery [121, 122]. 
The axillary lymph node dissection, conducted for the purposes of breast cancer 
staging, carries the risk of intercostobrachial nerve damage [123], which is located 
close to the lymph nodes and has many anatomical variants [124, 125]. Persistent 
pain after breast cancer treatment has been estimated to affect 25-60% of women 
[126], depending on patients’ selection and methodology of pain assessment. Pain 
usually affects the axilla, medial upper arm, breast and/or chest wall [126]. Women 
who had axillary lymph node dissection reported more frequently persistent pain 
than women who had sentinel lymph node biopsy [127-129].  
Axillary surgery and/or radiotherapy may lead to lymphoedema [130], a chronic 
condition characterised by the accumulation of fluids in the interstitial tissues due to 
incapacity of the lymphatic system to effectively distribute lymph [131]. The most 
common symptoms include shoulder, arm and hand swelling, heaviness, tightness, 
firmness, pain, numbness, and impaired upper member mobility [132]. The 
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incidence of lymphoedema in patients who had axillary lymph node dissection is 
estimated at around 19.9% (95%CI: 13.5-28.2%), while the corresponding figure for 
women who had sentinel lymph node biopsy is 5.6% (95%CI: 6.1-7.9%) [133].  
Other important side effects of radiotherapy include skin reactions (e.g. dermatitis, 
skin thickening, hyperpigmentation, ulceration), oedema, pain, stunning or burning 
bothers, and fatigue [134]. Radiotherapy may also result in irradiation to the heart 
and blood vessels [135], oesophagus and lungs. Radiotherapy administered in the 
1970s was shown to increase mortality from heart disease [136, 137] and lung 
cancer 10-20 years after irradiation [136]. Radiotherapy technologies and 
techniques have changed since then, and it is unclear whether increased 
cardiovascular risk persists [138, 139]. Women also often experience fatigue during 
the chemotherapy and radiotherapy; around 30% of women continue experiencing 
fatigue after treatment [140]. The aetiology of fatigue is unclear, but most likely 
includes psychological and biological factors, such as depression and increased 
pro-inflammatory cytokines [140].  
The side effects of chemotherapy highly depend on the regimen used [141]. 
Common acute side effects of chemotherapy and their adjuvant treatments, such as 
granulocyte colony stimulating factor (G-CSF), include nausea, gum bleeding, 
diarrhoea, constipation, increased risk of infection, anaemia, insomnia, alopecia, 
bone pain and fatigue [142, 143]. Alopecia in some cases becomes permanent 
[144, 145]. Chemotherapy induced amenorrhea has long been described in 
premenopausal women [146-148]. The proportion of women aged 50 year or 
younger at diagnosis who become post-menopausal after adjuvant chemotherapy 
varied between 33% and 77% [149]. In addition, neurocognitive changes affect 13-
70% of the cancer patients within two years of treatment [150] and may be long-
lasting [151, 152]. These neurocognitive changes, also known as “chemo fog”, are a 
form of cognitive impairment that usually involving memory deficits, reduced 
concentration and executive function [151, 153]. The pathophysiology of cognitive 
dysfunction in these patients is unknown, but chemotherapy may have direct toxic 
effect to neurons and other non-neuronal structures of the central nervous system 
[154, 155]. Chemotherapy may also induce damages to the pelvic nerves, causing 
neuropathy, which may lessen body sensations and impair the ability to reach 
orgasm [156]. Another adverse effect of the chemotherapy is loss of bone mineral 
density [157-159], through direct toxic effect and indirect effects related to ovarian 
failure in pre-menopausal women. Use of anthracyclines regimens has also been 
also linked to cardiomyopathy and congestive heart failure, especially if 
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concomitantly used with trastuzumab [160]. Most cases of cardiac dysfunction are 
detected after one year of treatment completion and are often irreversible [142]. 
Hormonal treatments, including both tamoxifen and aromatase inhibitors, have been 
associated with increased risk of uterine and endometrial cancers (tamoxifen), 
arthralgias/myalgias, fatigue, deep venous thrombosis (tamoxifen) besides 
climacteric symptoms induced by oestrogen deprivation [161]. It is unclear whether 
aromatase inhibitors are associated with higher risk of cardiovascular events, but 
tamoxifen has been suggested to have cardioprotective effects by reducing levels of 
total cholesterol and low-density lipoproteins [161, 162]. The reductions of 
oestrogen levels, which can be caused either by endocrine treatments or 
chemotherapy-induced ovarian failure, have physical implications similar to those 
experienced in menopause – vaginal atrophy and dryness – and make sexual 
intercourse painful [163]. 
Adverse effects of trastuzumab include a non-negligible cardio-toxic effect, as noted 
by significantly decreases in left ventricular ejection fraction and increased risk of 
congestive heart failure [164, 165]. Presently trastuzumab is administered with 
taxanes, for which cardiotoxicity is thought to be much lower [112].  
1.5 Mental health and quality of life beyond breast cancer 
The period of breast cancer survivorship starts at diagnosis, which is often a major 
cause of emotional distress for a patient [166]. The general population perceives 
breast cancer as life threatening and many women report traumatic experiences 
with the diagnosis [167, 168]. Common reactions to this ominous diagnosis include 
anxiety, fear of death, hopelessness, anger, suicidal thoughts, among others [169, 
170]. 
The main treatments for breast cancer have also been associated with substantial 
emotional and physical distress, and there are many stressors for this. During the 
treatment period women are forced to adjust to a new reality that includes a new 
body image with alterations that may go beyond the breast disfiguration or 
amputation. Alopecia due to chemotherapy treatments, for example, has been often 
reported as is highly distressing [171], not only due to the altered body appearance 
also because it allows other people to become aware of the patient’s cancer 
diagnosis and treatment. Lymphoedema is also perceptible to others, and often 
associated pain, numbness, tightness, increased risk of infections, among others, 
and all of these are distressing for the patients [152, 172, 173]. Breast cancer 
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survivors sometimes find social relationships challenging, as they have to adapt to 
the uncertainty brought by their diagnosis, which affects themselves and their 
significant others, including their offspring and spouse [174-176]. Neurocognitive 
changes, even of the milder severity, are also reported as distressing by the 
patients, as they interfere with important aspects of everyday life, including work 
performance [177]. Fatigue and persistent pain have been shown to be associated 
with low health-related quality of life and functional impairments [178-181]. Early 
menopause brings fertility concerns for women who want more children, and force 
women to take life-long reproductive decisions, which affect their partners as well 
[149, 182]. With the panoply of life-changing events, the possible presence of acute 
and long-term symptoms resulting from the cancer treatments, and the need to deal 
with the fear of cancer recurrence and death [183], it is not surprising that clinically 
relevant symptoms of anxiety and/or depression are common during the treatment 
period [184, 185]. Virtually all domains of HRQoL, including mental health, have 
been described as impaired in women who had recently been diagnosed with breast 
cancer [186, 187]. 
Longitudinal studies on the HRQoL of breast cancer survivors showed that mean 
scores for the mental health domain tend to improve over time, reaching similar 
levels to those of the general population around the first anniversary of diagnosis 
[188, 189]. This is consistent with women psychologically adjusting to a life beyond 
the traumatic event of breast cancer. In addition, not all changes induced by the 
cancer are negative. Studies have described that up to 60% of women experience 
post-traumatic growth, a phenomenon of heightened well-being with one-self after a 
stressful event, where life is seen through different lenses [190]. Women have 
described feeling improved empathy, closer relationships, healthy lifestyle changes, 
greater appreciation for life and oneself, among others. This is likely to have a 
positive impact in the women’s quality of life and mental health [191]. However, 
carrying on a life after breast cancer implies coping with the negative effects of 
cancer as well, and positive and negative aspects most likely interact in and with 
time, and offset some of the negative effects [191]. 
Some particular groups of breast cancer survivors, however, have been described 
to have poorer long-term HRQoL. Examples reported in the literature include those 
with younger age at diagnosis [192, 193], lower socio-economic status [194], having 
persistent fatigue [195], lymphedema or arm symptoms [196, 197], or having had 
chemotherapy [198, 199]. In addition, previous research on the trajectories of 
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depressive symptoms after a breast cancer diagnosis showed that the symptoms 
persisted for at least two years in one out of every five women [200]. 
The long-term mental health and quality of life implications of having been 
diagnosed and treated for a breast cancer have not been extensively studied, 
partially because only relatively recently the number of women living beyond breast 
cancer has reached considerable numbers at population level. This increase in the 
prevalence of breast cancer survivors in the general population raises questions on 
the specific long-term health care needs of this group, and whether they might 
benefit from increased opportunistic screening for mental disorders. Even though 
depression and anxiety are the most commonly studied outcomes in the literature, it 
was still unclear whether breast cancer survivors had an increased risk compared to 
women with no history of cancer. This was because most studies involved breast 
cancer survivors only, without comparing the results with a group without cancer, 
making it difficult to ascertain whether the reported changes in the mental health of 
the breast cancer survivors can be attributed to the previous cancer diagnosis or are 
only characteristic of the aging process. In addition, little is known about the 
frequency of sleep disturbances, sexual disorders and post-traumatic stress 
disorder in breast cancer survivors, compared to women with no history of cancer. 
Research on the HRQoL of breast cancer survivors is scarce in the UK, and mostly 
has focused on establishing the feasibility of widespread collection of patient-
reported outcomes [201, 202]. 
With the increasing numbers of breast cancer survivors, the potential for mental 
health impact of their medical history, and the burden generated by mental 
disorders, it is imperative to generate evidence on the absolute and relative risk of 
mental disorders in this key patient group. This may in turn be used to underpin 
public health strategies that aim to mitigate the burden of mental disorders in these 
patients, and ultimately provide breast cancer patients with evidence-based care 
that meets their specific needs. 
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1.6 Summary 
• The lifetime risk of a depressive or anxiety disorder is one in five for women, 
and one in 10 for men. Stress acts as the precipitating factor for the onset of 
mental disorders in susceptible individuals. 
• Episodes of the mental disorders are highly incapacitating. Only half of the 
patients achieve lifetime remission, with the remaining having unremitting or 
recurrent episodes. 
• Women in the UK currently have a one in seven risk of being diagnosed with 
breast cancer during their lifetime. This is the most common cancer diagnosed 
in the UK, except for non-melanoma skin cancer, and 5-year net survival is now 
approaching 90%, resulting in a record number of women carrying on post-
breast cancer. 
• Women with history of breast cancer may have long-term physical 
consequences of their cancer and treatments, some of which are debilitating 
and may affect patients’ mental health and health-related quality of life (Table 
1.3). 
 
 
Table 1.3   Possible physical and psychological consequences of breast cancer treatments. 
  
Treatment * 
Consequences (definitive or possible) 
Physical Psychological 
Surgery1 
[121, 123, 125, 133] 
Breast shape alteration (BCS) 
Breast amputation (mastectomy) 
Life-long scar 
Intercostobrachial nerve damage (ALND)  
Lymphoedema 
Body image concerns  
Low self-esteem 
Persistent pain  
Psychological distress 
Radiotherapy 
[134, 136] 
Skin reactions (e.g. hyperpigmentation)  
Oedema 
Fatigue 
Heart disease  
Lung cancer 
Pain 
Psychological distress 
Chemotherapy2 
[143, 144, 147, 153, 157, 
171] 
Alopecia   
Amenorrhea (if premenopausal)  
Cardiac dysfunction (anthracyclines) 
Fatigue 
Loss of bone mineral density 
Vasomotor symptoms 
Body image concerns 
Cognitive impairment 
Psychological distress 
Endocrine therapy3 
[161, 162] 
Deep venous thrombosis  
Vasomotor symptoms 
Arthralgias 
Fatigue 
Uterine cancer (tamoxifen and AI) 
Endometrial cancer (tamoxifen) 
Psychological distress 
Sexual dysfunction 
Immune therapy4 
[164, 165] 
Left ventricular dysfunction  
Congestive heart failure  
Psychological distress 
 
BCS – breast conserving surgery; ALND – axillary lymph node dissection; AI – aromatase inhibitors. 
* Most women receive more than one treatment. 
1 Refers to the procedures for tumour removal (breast-conserving surgery or mastectomy) and evaluation 
of the presence of metastasis in the lymph nodes (axillary lymph node dissection or sentinel lymph node 
biopsy). 2 Regimens with taxanes or anthracyclines. 3 Includes selective oestrogen receptors modulators 
and aromatase inhibitors. 4 Trastuzumab. 
55
56 
 
 
• Even though depression and anxiety are the most commonly studied outcomes 
in the literature, it is still unclear whether there is an increased risk in breast 
cancer survivors. Most studies involved breast cancer survivors only, without 
comparing the results with a group without cancer, and it is not possible to 
ascertain if the reported changes in the mental health of the breast cancer 
survivors can be attributed to the previous cancer. 
• Little is known about the frequency of sleep disturbances, sexual disorders and 
post-traumatic stress disorder in breast cancer survivors, compared to women 
with no history of cancer. 
• With the increasing numbers of breast cancer survivors, the potential impact of 
their medical history on their mental health, and the burden generated by 
mental disorders, it is imperative to generate evidence on the absolute and 
relative risk of mental disorders in this key patient group, to inform prevention 
and mitigation strategies. 
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2 Aims and objectives 
Progress in breast cancer control has resulted in large and growing numbers of 
women living with and beyond breast cancer. The long-term mental health and 
quality of life impact of having a history of breast cancer is largely unknown. 
The research in this thesis addresses these gaps in knowledge, and had two aims: 
Aim 1   To quantify the relative risk of adverse mental health outcomes in women 
with a history of breast cancer, compared to women who have never had 
cancer, using routinely collected primary and secondary care data from the 
UK. 
Aim 2   To investigate the health-related quality of life and the severity of symptoms 
of anxiety and depression in women with a history of breast cancer (>1 
year), compared to women with no history of cancer. 
 
The specific objectives were: 
 
Objective 1: To systematically review and summarise the studies that quantified the 
frequency or severity of adverse mental health outcomes in women with a 
history of breast cancer, compared with women with no history of cancer 
(Chapter 3); 
Objective 2: To systematically review the strategies used to identify adverse mental 
health outcome in studies that used electronic health records (EHRs) from 
primary care databases in the UK (Chapter 5); 
Objective 3: To quantify the risk of adverse mental health outcomes in women who 
had breast cancer, compared to women with no history of cancer, using primary 
care EHRs data (Chapter 6); 
Objective 4: To compare patient-reported measures of HRQoL, anxiety, and 
depressive symptoms, between breast cancer survivors and women with no 
prior cancer, and to explore the impact of demographic and clinical factors 
(Chapter 7); 
Objective 5: To describe cancer-specific measures of HRQoL in breast cancer 
survivors and explore the effect of demographic and clinical factors (Chapter 7); 
Objective 6: To compare patient-reported HRQoL, and anxiety and depressive 
symptoms, with the information in the EHRs for similar constructs (Chapter 8). 
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3 Review of the associations between breast cancer 
survivorship and adverse mental health outcomes 
3.1 Introduction 
The first objective of this thesis was to systematically review the studies that 
quantified the frequency and/or severity of adverse mental health outcomes in 
women with a history of breast cancer, compared with women with no history of 
cancer. The research in this chapter directly addresses this objective. The results of 
this review informed the selection of the specific adverse mental health outcomes to 
be studied in this thesis. 
3.2 Systematic review protocol 
A study protocol was created prior to carrying out the systematic review, following 
best practice recommendations in systematic review studies. The protocol was 
published in a peer-reviewed scientific journal. The article is provided in the 
following pages. 
3.3 Article 
The results of the systematic review were reported in an article that has been 
published in a peer-reviewed scientific journal. This article is also provided in the 
following pages. The lengthy supplementary appendix referred to in this systematic 
review is provided in Appendix 1 of this thesis. 
Dr Hulliard et al. inquired whether there were data available on the incidence of 
mental health outcomes by history of the condition prior to the cancer diagnosis, as 
their data suggested that a ‘the diagnosis of cancer itself may not be a sufficient 
psychological and physical burden to trigger a mental disorder according to the 
DSM-V’ [203]. The response to this letter is included after the systematic review. 
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Background
Survival from breast cancer increased markedly during the
last decades [1]. In 2005–2009, 5-year age-standardised net
survival was higher than 85% in North America and be-
tween 71 and 87% in 29 European countries [1]. Consider-
ing that breast cancer is the most frequent malignancy
diagnosed in women worldwide, after non-melanoma skin
cancer [2], this has already translated into an unprecedent-
edly large number of breast cancer survivors in the general
population. Many women find the diagnosis a traumatic ex-
perience [3], and the usual reactions include anxiety, hope-
lessness, anger and negative and suicidal thoughts [4, 5].
Some of the treatments can also cause severe long-term
suffering. For example, surgery usually results in a lifelong
scar and may cause breast shape alteration, persistent pain
and/or lymphoedema [6–8]. The diagnosis and treatment
of the breast cancer might also affect the woman’s family,
including intimacy with their partners [9] and relationships
with their offspring [10]. Women who return to work may
also face new challenges, not only in the relationship with
their work colleagues [11] but also in their cognitive func-
tioning [12, 13]. Women must also deal with the fear of
cancer recurrence and death [14]. All of these factors may
have a long-term negative impact on the mental health of
breast cancer survivors.
Several systematic reviews summarised the frequency
of selected mental health outcomes in oncological pa-
tients under and post-treatment [15–22]. Two reviews
focused on breast cancer survivors [16, 22]. Howard-
Anderson et al. [22] focused on younger breast cancer
survivors (<50 years at diagnosis), an important group
but who represent a small proportion of all breast cancer
survivors. The systematic review by Maass et al. [16] re-
ported prevalences of anxiety between 18 and 33% and
of depression between 9 and 66%; however, most of the
studies included in this review did not involve a compari-
son group, and therefore, it is unclear how the figures
compare to those of women who did not have cancer. The
range of adverse mental health outcomes in breast cancer
survivors is also unlikely to be limited to anxiety and de-
pressive disorders alone. Other outcomes, such as sleep
disturbances, have been reported as frequent during the
treatment period and afterwards [23, 24], and very little is
known about the long-term impact of these in breast can-
cer patients.
The overall aim of this study is to identify and sum-
marise studies that have quantitatively compared mental
health outcomes in breast cancer survivors of at least
1 year since diagnosis, versus women who did not have
cancer. Specifically, through summarising such studies,
this systematic review will:
 Identify mental disorders that may be associated
with a history of breast cancer
 Summarise and, where possible, synthesise
quantitative estimates of associations between breast
cancer history and a range of specific psychiatric
outcomes
 Summarise the instruments used to evaluate mental
disorders or their severity in breast cancer survivors
Methods
This systematic review protocol follows the guidance
outlined by the Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P) [25].
Additional file 1 provides information for each item of
the PRISMA-P checklist. This review has been registered
in the International prospective register of systematic re-
views (PROSPERO 2017:CRD42017056946).
Eligibility
Inclusion criteria
Manuscripts reporting studies satisfying the following cri-
teria will be eligible for inclusion:
– Based on original data.
– Uses any observational study design (i.e. cohort,
case-control, cross-sectional designs).
– Includes adult women (≥18 years) diagnosed with
breast cancer and who survived the first year after
the diagnosis.
– Includes a population-based adult female comparison
group with no prior cancer.
– Provides data on at least one of our pre-specified
mental health outcomes of interest, namely the
following: anxiety disorders; bipolar and related
disorders; disruptive, impulse control and conduct
disorders; feeding and eating disorders; mood
disorders; neurocognitive disorders; neurotic
disorders; personality disorders; schizophrenia
spectrum and other psychotic disorders; sexual
dysfunctions of a psychological nature; sleep-wake
disorders; somatoform disorders; substance-related
disorders (including alcoholism); and trauma- and
stressor-related disorders. Studies providing data on
self-injurious behaviour (including self-harm, suicide
and suicidal ideation) will also be included. These
outcomes were selected by reviewing the list of
mental disorders available in the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition
[26] and the ICD-10 Classification of Mental and
Behavioural Disorders [27].
Exclusions
Articles will be excluded according to the following criteria:
– Review articles, editorials, commentaries, conference
abstracts, case reports and studies involving animals.
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– Studies in which the selection of the breast cancer
survivors depended on symptoms (e.g. only patients
with persistent pain or fatigued) or on a mental
health outcome (e.g. only women with depression).
– Studies which only presented data for the first year
after the breast cancer diagnosis; however, studies
following women from diagnosis may still be eligible
if outcomes at ≥ 1 year or more since diagnosis are
reported separately.
– Studies in which all breast cancer patients remain
under treatment for cancer (except for long-term
endocrine therapy) at the time of outcome
ascertainment.
– Studies in which all women are institutionalised
(e.g. hospitalised or in hospices).
Search strategy
We will consider as potentially eligible all studies pub-
lished in the journals indexed in MEDLINE, PsycINFO,
the Cumulative Index to Nursing and Allied Health
Literature (CINAHL) and the Social Sciences Citation
Index, since the inception of each database up to when
the database was last updated at the time of the search.
A search expression will be defined with a Boolean logic,
including terms for the target population (breast cancer
patients), outcome (psychiatric disorder) and compara-
tors (risk, hazard, etc.). The search expression used in
MEDLINE includes terms for Medical Subject Headings
(MeSH) as well as key text words with truncation to
allow for variations in terminology (Table 1). The search
expression will be adapted to each database, to take into
account the specificities of the search algorithms.
We will restrict the search to studies including humans.
We will not apply any time, geographic or language re-
striction. If a study is published in a language not suffi-
ciently understood by the authors, we will seek assistance
to translate/understand the content.
Backwards and forward citation tracking will also be
used to identify additional potential eligible studies that
were not captured by the database searches.
Data management and selection process
All records will be imported into EndNote X7 (EndNote
X7, Thomson Reuters, NY, USA), and studies identified
as duplicates by the software will be removed. A backup
of the search expression and the records obtained from
each database, as well as the date of last update and run,
will be saved.
The references will be screened in two consecutive
phases by two authors (HC and MM, or HC and RH). In
the first phase, the title and the abstract of each study
will be read to determine their eligibility for the study by
applying the pre-defined inclusion and exclusion criteria
(see the “Eligibility” section above). If the information
provided in the title and abstract does not allow the un-
equivocal exclusion of the study, the full text will be
considered. In the second phase, the full text of each
study considered eligible in the first phase will be ob-
tained and read in order to determine the eligibility con-
sidering all the information in the paper. The studies
will be reassessed for data extraction.
The decisions taken independently by each of the in-
vestigators will be compared, and discrepancies will be
Table 1 MEDLINE search expression, via OVID®
1 exp Breast Neoplasms/
2 (breast and (cancer* or carcinoma* or tumo?r* or neoplas*)).
mp. [mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary
concept word, unique identifier]
3 1 or 2
4 exp catatonia/ or exp depression/ or exp self-injurious behavior/
or exp anxiety/
5 mental disorders/ or exp anxiety disorders/ or exp “bipolar and
related disorders”/ or exp “disruptive, impulse control, and
conduct disorders”/ or exp dissociative disorders/ or “feeding
and eating disorders”/ or anorexia nervosa/ or binge-eating
disorder/ or bulimia nervosa/ or pica/ or exp mood disorders/
or exp motor disorders/ or neurocognitive disorders/ or amnesia/
or cognition disorders/ or auditory perceptual disorders/ or mild
cognitive impairment/ or consciousness disorders/ or delirium/
or dementia/ or exp neurotic disorders/ or exp personality
disorders/ or exp “schizophrenia spectrum and other psychotic
disorders”/ or sexual dysfunctions, psychological/ or exp sleep
wake disorders/ or exp somatoform disorders/ or exp substance-
related disorders/ or exp “trauma and stressor related disorders”/
6 (depressi* or dysthymia or catatonia or self-injur* or self-injury
or self-injurious or self-mutilation or “self mutilation” or suicid*
or self-harm or “self harm” or “self injury” or anxious* or anxiety
or (panic adj1 (disorder# or attack#)) or catastrophi* or (mental
adj1 (disorder or disorders)) or phobia or phobic or neurotic or
(compulsive adj1 disorder) or bipolar or neurotic or (personality
adj1 disorder) or psychotic or psychosis or paranoid or delusional
or (sexual adj1 (disorder or dysfunction or problem#)) or
insomnias or (sleep adj1 (disorder or dysfunction or problem#))
or somatoform or (substance adj3 (disorder or problem#)) or
stress ajd3 disorder or (adjustment adj3 disorder)).mp. [mp=title,
abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier]
7 4 or 5 or 6
8 (prevalence# or frequenc* or incidence# or risk or rate* or ratio
or odds or epidemiolog* or percent* or outcomes or hazard).mp.
[mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique
identifier]
9 3 and 7 and 8
10 Humans/
11 Animals/
12 10 and 11
13 11 not 12
14 9 not 13
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resolved, involving a third investigator when necessary
(RW or KB). The agreement between the two investiga-
tors will be calculated (kappa statistics).
If more than one study reports data on the same study
population, we will include only the study providing data
for the largest sample; if the sample size is the same, we
will consider the study providing more detailed informa-
tion on outcomes (e.g. results stratified for age or type
of treatment received) and consider both studies for ab-
straction of information on the participants’ characteris-
tics (e.g. age, menopausal status, stage at diagnosis).
A record of excluded/included studies, with the re-
spective exclusion criterion, will be kept, and the selec-
tion process including numbers excluded at each stage
for different criteria will be summarised in a flow chart.
Data extraction
Two authors (HC and MM, or HC and RH) will extract
data from each included study into a pre-defined form
in Microsoft Office Excel (2013). The form will be
piloted using four studies and adapted if necessary. In-
formation will be collected on (1) study characteristics
(e.g. authors, year of publication, country where the
sample was obtained or duration of follow-up if applic-
able); (2) characteristics of the breast cancer survivors
(details on participant recruitment, sample size, demo-
graphics, distribution of stage at diagnosis, time since
diagnosis and type of treatments); (3) characteristics of
the women who did not have cancer (recruitment of the
participants, sample size, demographics); (4) information
on the mental health outcomes (name of the mental
condition, diagnostic criteria, instruments applied); and
(5) quantitative information on the mental health out-
come (e.g. prevalence or mean/median score in each
group and/or relative risk comparing groups) and vari-
ables considered as potential confounders.
If a prospective study provides data for more than one
point in time, we will abstract all available information.
The data extracted by each author will be compared
and discrepancies resolved by consensus or involving a
third researcher (KB or RW) if necessary.
Risk of bias in individual studies
We will evaluate study quality and risk of bias in the ori-
ginal studies by assessing the main domains identified by
Sanderson et al. as important for observational study
quality and bias assessment [28], informed by the
“STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE)” guidelines [29]. These do-
mains are: methods for selecting study participants,
methods for measuring the exposure and the outcome
variables, design-specific sources of bias (excluding con-
founding), methods to control for confounding, statis-
tical methods (excluding confounding) and conflict of
interest [28]. Within each of the above domains, individual
studies will be rated as at high risk of bias, low risk of bias
or unclear risk of bias, following the Cochrane Collabor-
ation approach formulated for clinical trials [30].
Data analysis and synthesis
The results will be reported according to the PRISMA
guidelines [31]. Tables and descriptive text will be used
to summarise study characteristics and results, stratified
by outcome and likely sources of heterogeneity (e.g.
study design, type of population).
Quantitative synthesis of results (meta-analysis) will
only be attempted for selected outcomes where deemed
appropriate, taking into account the number of studies
available, study designs and methods and equivalence of
outcome measures and effect estimates used. Where
quantitative synthesis is attempted, the DerSimonian
and Laird method [32] will be used to compute sum-
mary estimates of the association between breast cancer
and the discrete psychiatric outcome in question, along
with 95% confidence intervals. Sub-group analyses by
time since diagnosis will be conducted if possible. Pro-
spective studies providing data for two or more time
points after the first anniversary of diagnosis will be in-
cluded once in meta-analysis; the relative risk estimate
for the first eligible time point will be chosen. Hetero-
geneity will be quantified using Higgins and Thompson’s
I-squared statistic [33]. The meta-analysis will be re-
peated excluding any studies identified as at high risk of
bias in the quality assessment. For outcomes deemed
suitable for meta-analysis as described above, funnel
plots and Egger’s regression asymmetry test [34] will be
used to assess publication bias and small study effects if
more than ten studies are available [35].
Discussion
The number of women who have had breast cancer is
higher than ever before. These women may face many
challenges when trying to assimilate back into life fol-
lowing their cancer diagnosis and treatment, and it is
imperative to understand the long-term psychological
consequences. This systematic review aims to provide a
comprehensive overview of the associations between
breast cancer history and mental health conditions.
Most reviews on the topic have been restricted to study-
ing the prevalence of depression among cancer patients
[15, 20]. We opted for considering a much broader list of
mental disorders that have their onset during adulthood
as outcomes, to give a more comprehensive picture of the
spectrum of mental disorders that may affect breast can-
cer survivors. We also chose to include only studies in
which a comparison group was available, so that the rela-
tive frequency or severity of these conditions compared to
the general population could be studied.
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We will include studies in which women were diag-
nosed with breast cancer at least one year prior to out-
come measurement. Women who completed breast
cancer treatments with curative intent (i.e. surgery,
chemotherapy and/or radiotherapy) are often considered
as survivors; however, the precise point in time when
the treatments end is frequently unknown and a widely
accepted definition of cancer survivor does not exist
[36]. Researchers commonly use a fixed point in time to
capture, in a pragmatic way, the moment at which the
main course of treatment is likely to have been com-
pleted. At 1 year after the diagnosis, the vast majority of
women are expected to have completed the main treat-
ments and many have returned to their pre-cancer rou-
tines. The effect of having been diagnosed and treated for
breast cancer may also vary over time [37], and thus, an
adequate characterisation of the risk of mental disorders
requires a known time since diagnosis.
Studies involving mental health outcomes are prone to
selection bias. We will report the characteristics of the
samples involved in the original studies, including the
details on the recruitment of the participants. We will
also evaluate and report the risk of bias and use this in-
formation to help interpret the results.
Mental disorders largely interfere with the functioning
of the patients and are leading causes of disability world-
wide [38]. The mean prevalence of depression among
women who had breast cancer has been described in the
range between 10 and 20%, depending on the methods
used to evaluate it [15]. This indicates that the burden of
at least depressive disorders in this population is far
from negligible. The impairments caused by depression
are likely to be higher in these women than in women
with depression alone [39].
Even though there are several pharmacological and
non-pharmacological treatments available, mental disor-
ders are often undiagnosed and untreated. The results of
this review can be used to inform health professionals
about the range, frequency and severity of mental disor-
ders among breast cancer survivors.
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Associations Between Breast Cancer Survivorship and
Adverse Mental Health Outcomes: A Systematic Review
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Abstract
Background: We aimed to systematically review the evidence on adverse mental health outcomes in breast cancer survivors
(1 year) compared with women with no history of cancer.
Methods: Studies were identified by searching MEDLINE, PsycINFO, the Cumulative Index to Nursing and Allied Health
Literature, and the Social Sciences Citation Index, and through backward citation tracking. Two researchers selected the
studies, extracted data, and assessed the risk of bias.
Results: Sixty studies were included. Of 38 studies of depression, 33 observed more depression in breast cancer survivors; this
was statistically significant in 19 studies overall, including six of seven where depression was ascertained clinically, three of
four studies of antidepressants, and 13 of 31 that quantified depressive symptoms. Of 21 studies of anxiety, 17 observed more
anxiety in breast cancer survivors, statistically significant in 11 studies overall, including two of four with clinical/
prescription-based outcomes, and in eight of 17 of anxiety symptoms. Breast cancer survivors also had statistically signifi-
cantly increased symptoms/frequency of neurocognitive dysfunction (18 of 24 studies), sexual dysfunctions (5 of 6 studies),
sleep disturbance (5 of 5 studies), stress-related disorders/PTSD (2 of 3 studies), suicide (2 of 2 studies), somatisation (2 of 2
studies), and bipolar and obsessive-compulsive disorders (1 of 1 study each). Studies were heterogeneous in terms of partici-
pants’ characteristics, time since diagnosis, ascertainment of outcomes, and measures reported. Approximately one-half of
the studies were at high risk of selection bias and confounding by socio-economic status.
Conclusions: There is compelling evidence of an increased risk of anxiety, depression and suicide, and neurocognitive and
sexual dysfunctions in breast cancer survivors compared with women with no prior cancer. This information can be used to
support evidence-based prevention and management strategies. Further population-based and longitudinal research would
help to better characterize these associations.
Women with a history of breast cancer are the largest group of
cancer survivors in high-income countries (1). In the United
States alone, more than 2.9 million women were estimated in
2012 to be living with a previous diagnosis of breast cancer (2).
By 2022, this number is estimated to approach 4 million (2).
Similarly, in the United Kingdom, the number of women living
beyond breast cancer is expected to surpass 1.5 million during
the next 20 years (3).
A diagnosis of breast cancer is often overwhelmingly dis-
tressing (4). Women frequently experience some combination
of anger, anxiety, despair, helplessness, fear of death, and sui-
cidal thoughts (5,6). Clinically relevant symptoms of anxiety
and/or depression are common during the treatment period
(7,8), when acute treatment side effects may restrict daily activi-
ties (9). High prevalence of depressive symptoms and anxiety
have also been observed during survivorship (10,11), with one
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study finding depressive symptoms persisting for at least two
years after diagnosis in one in five women (12). Other adverse
mental health outcomes, such as sleep disturbance, have also
been reported both during cancer treatment and afterwards
(13). A substantial proportion of the breast cancer survivors ex-
perience long-term iatrogenic effects of treatment, including fa-
tigue, persistent pain, lymphedema, vasomotor symptoms, and
infertility, all of which may negatively affect quality of life and
mental health (14). Other important psychological challenges in
the long term can include difficulties in re-adapting to profes-
sional, social, and intimate relationships and coping with the
uncertainty about the future (15).
To our knowledge, no systematic review to date has summa-
rized the evidence from studies comparing breast cancer survi-
vors with a noncancer control group for a broad spectrum of
adverse mental health outcomes. Therefore, the aim of this
study was to identify and summarize the studies that have
quantitatively compared mental health outcomes in breast can-
cer survivors (1 year) vs women who did not have cancer; we
also assessed the quality of the evidence on this topic by apply-
ing objective quality assessment criteria.
Methods
This review was registered in the International Prospective
Register of Systematic Reviews (PROSPERO 2017:
CRD42017056946) and followed the a priori methods outlined in
the protocol (published elsewhere [16]). Results were reported in
accordance with the guidance of the Preferred Reporting Items
for Systematic review and Meta-Analysis (17).
Outcomes
The predefined outcomes of interest were anxiety disorders; bi-
polar and related disorders; disruptive, impulse control, and con-
duct disorders; feeding and eating disorders; mood disorders;
neurocognitive disorders; neurotic disorders; personality disor-
ders; schizophrenia spectrum and other psychotic disorders;
sexual dysfunctions of psychological nature; sleep wake disor-
ders; somatoform disorders; substance-related disorders (includ-
ing alcoholism); and trauma- and stressor-related disorders. We
also considered eligible the studies providing data on self-
injurious behavior (including self-harm, suicide, and suicidal
ideation). These categories were selected after systematically
reviewing those listed in the Diagnostic and Statistical Manual
of Mental Disorders, 5th edition (18) and in the ICD-10
Classification of Mental and Behavioural Disorder (19) to exclude
conditions with usual onset during childhood or with strong ge-
netic component (eg Huntington’s disease). The comprehensive
list of outcomes was aimed at exploring what evidence was
available on the topic without making strong assumptions as to
whether the stress induced by the breast cancer diagnosis and
treatment could trigger the condition. The outcomes of interest
were disorders clinically diagnosed, but we also considered
symptomatology evaluated with psychometric instruments.
Data Sources and Identification
Potentially eligible studies were identified in four databases:
MEDLINE, PsycINFO, the Cumulative Index to Nursing and
Allied Health Literature, and the Social Sciences Citation Index.
A search expression tailored for each database was created in-
cluding terms for the exposure (breast cancer), outcomes (the
predefined mental disorders), and comparators (eg, risk) (full
MEDLINE search string provided in the Appendix [Supplementary
Table 1, available online]). Results retrieved from the inception of
the databases up to November 1, 2017 were considered for this
study. Two authors screened the list of references by applying
the same inclusion and exclusion criteria to determine each
study’s eligibility. The bibliographic references of eligible studies
were manually screened to detect additional studies.
Study Eligibility
We considered as eligible observational studies that provided
original data comparing the prevalence, incidence, or odds/haz-
ard of at least one of the predefined lists of mental health out-
comes (see above), clinically diagnosed or their
symptomatology assessed through validated instruments, be-
tween adult female breast cancer survivors and a comparison
group of women with no prior cancer. Female breast cancer sur-
vivors were defined as women with a history of breast cancer or
in situ tumor for one year or longer. Studies with patients diag-
nosed with breast carcinomas in situ were included because de-
spite of their excellent prognosis (20), they receive similar
treatment to invasive breast cancers (21), and patients often ex-
perience substantial psychological distress both during and af-
ter the treatment period (22,23). Studies with no control group
but reporting standardized incidence ratios were also eligible if
the standardization was against a general female population.
Studies that used psychometric instruments that had been al-
tered from the standard/validated version were excluded, ex-
cept where the alteration was limited to omission of questions
that would not apply to the population under study. Studies in-
cluding women who were institutionalized, under active treat-
ment for breast cancer (excluding endocrine therapy), or who
were specifically selected based on distressing psychological
and/or physical symptoms were excluded. Studies evaluating
the effect of further screening or diagnostic tests for cancer on
the mental health of breast cancer survivors were excluded.
There was no restriction in the language of study publication.
The eligibility of individual studies was assessed by two
reviewers (HC and MM, or HC and RH) who independently applied
the predefined inclusion/exclusion criteria. Initial agreement be-
tween reviewers in the assessment of abstracts was 92.5% for HC/
MM and 81.3% for HC/RH (Cohen’s kappa [j] ¼ 0.51 and 0.32, re-
spectively), and initial agreement in the full-text assessment was
95.9% (j¼ 0.69) and 90.6% (j¼ 0.54), respectively. All discordant
assessments were discussed and successfully resolved.
Data Extraction
We systematically abstracted data on the characteristics of the
study and study samples. We extracted quantitative data on the
frequency (incidence or prevalence) or severity (mean scores) of
adverse mental health outcomes for each participant’s group or
for the comparison between groups (eg, relative risk, hazard ra-
tio, odds ratio), as available, and the results of any hypothesis
testing reported in the original studies. Prevalences from stud-
ies involving psychometric instruments were based on the cut-
offs defined by the authors of the original studies. When two or
more studies reported data on the same study population, we
extracted data from the study with largest sample size, or if
equal, the one providing more detailed outcome information.
Data were extracted independently by two investigators (HC
and MM, or HC and RH) and discrepancies were resolved.
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Risk of Bias in Individual Studies
The risk of bias in the included studies was assessed by two
reviewers who independently evaluated domains previously
identified as important in observational studies (24). The
domains were: participants’ selection, outcome assessment,
temporality (breast cancer diagnosed prior to the onset of the
mental health outcome), control for confounding by age and
socio-economic status, statistical methods, handling of missing
data, and disclosure of conflicts of interest. Within each do-
main, the studies were rated as having a high, low, or unclear
risk of bias; some criteria were not applicable to all studies.
Supplementary Table 2 (available online) provides the criteria
used for each category and domain.
Statistical Methods
Tables, graphs, and descriptive text were used to summarize
study characteristics and results stratified by mental health out-
come and method used to define outcomes (ie, clinical diagnosis,
drug prescription, or symptoms). When sufficient information
was provided in the original studies, we calculated the preva-
lence ratio for each outcome (25) if this was not directly reported
in the paper. If prevalence data were provided by severity catego-
ries, we computed prevalence ratios for the comparison of mild
to severe symptoms of the outcome between the two groups;
this was the most common dichotomization in the studies that
did not provide results by severity. The 95% confidence intervals
(CIs) for derived prevalence ratios were estimated using the delta
method (25). P values for the comparison of mean scores from
psychometric instruments between breast cancer survivors and
women who did not have cancer were estimated with the inde-
pendent samples t test; all tests were two-sided. To ensure com-
parability of the results across studies, we applied a type-1 error
rate (a) of .05 when summarizing statistical significance even if
studies themselves had provided results using a different statis-
tical significance level. A quantitative synthesis of the results (ie,
meta-analysis), as planned in the study protocol (16), was not
possible due to the heterogeneity of the eligible studies in the
clinical characteristics of the cancer survivors, time elapsed
since breast cancer diagnosis, and instruments used to evaluate
symptoms of mental health disorders.
Results
Characteristics of Included Studies
Of the 7517 individual publications identified, 729 studies were
eligible for full-text evaluation, and 60 (26–85) were ultimately
included (Figure 1). The most commonly evaluated outcomes
were anxiety (n¼ 21 studies), depression (n¼ 38), neurocogni-
tive dysfunction (n¼ 24), and sexual dysfunction (n¼ 6)
(Table 1). Schairer et al. (41) estimated the risk of suicide in
more than 720 000 women diagnosed with breast cancer in 1953
to 2001, using data from 16 population-based cancer registries
in Scandinavia and the United States; thus, only two studies
were eligible for suicide, because smaller studies with overlap-
ping data were excluded. The studies were heterogeneous in
study design, participants’ characteristics, and methods in-
volved to assess outcomes. A total 38 of 60 studies (63.3%) in-
cluded small, nonprobabilistic samples of breast cancer
survivors. Mental health outcomes were most commonly evalu-
ated with psychometric instruments (50/60 studies¼ 83.3%),
followed by clinical diagnoses registered in electronic health-
care databases (10/60¼ 16.7%).
Findings for Specific Mental Health Outcomes
Table 2 provides an overview of the directions of association
reported for all studies/outcomes and statistical significance of
the between-group comparisons. Figure 2 summarizes the rela-
tive measures of effect for the most commonly studied out-
comes in the studies where these were available. Figure 3
shows the prevalence (for cross-sectional analyses) or cumula-
tive incidence (for follow-up analyses) of outcomes in the sam-
ples of breast cancer survivors included in the original studies.
Anxiety
Twenty-one eligible studies reported data for anxiety (Table 1;
Supplementary Table 3, available online). Of 21 studies, 17
(81.0%) observed increased anxiety in the breast cancer survivor
group compared with the noncancer group; the difference was
statistically significant in 11 of 21 (52.4%) studies (Table 2).
Four longitudinal, population-based studies evaluated anxi-
ety with clinical diagnoses (n¼ 2) or clinical diagnoses and anx-
iolytics prescription (n¼ 2); all used electronic health records
data and pointed towards an increased risk in breast cancer sur-
vivors, but this was supported by strong statistical evidence in
two studies only (Figure 2). The relative risk estimates in the
four studies of clinically assessed anxiety varied between 1.06
(95% CI ¼ 0.97 to 1.16) and 2.00 (95% CI ¼ 1.69 to 2.37). The two
studies that reported on anxiolytics prescription reported an 8%
(95% CI ¼ 1% to 15%) and 47% (95% CI ¼ 35% to 61%) increase in
breast cancer survivors compared with women who did not
have cancer (Figure 2).
Seventeen studies investigated symptoms of anxiety us-
ing scales (Table 2). There was strong statistical evidence of
increased symptoms of anxiety in eight of 17 studies, includ-
ing in the six of 12 studies that focused on comparing mean
scores between groups, and in two of five studies that
reported prevalence of scoring above a clinically relevant
threshold. For all of the latter, observed prevalence was
higher in cancer survivors but confidence intervals were gen-
erally wide (Figure 2).
Prevalences of anxiety were generally less than 20% when
electronic health records or anxiolytics were studied and in the
range of 20% to 50% when scales were used (Figure 3).
Determinants of clinically assessed anxiety were provided in
one study. Clinically diagnosed anxiety in breast cancer survi-
vors tended to decrease over time since diagnosis (58) and was
independently associated with younger age and presence of
comorbidities at diagnosis, having less favorable tumor charac-
teristics, and receiving chemotherapy (58).
Depression and Suicide
Thirty-eight studies provided data on depression (Table 1;
Supplementary Table 4, available online), and 33 of 38 (86.8%)
described more depression in the breast cancer survivor group
compared with women who did not have cancer, with 19 fo 38
(50.0%) reporting statistical evidence of increased depression
(Table 2).
Of seven studies that analyzed depression based on clinical
diagnoses, six found strong evidence of an elevated risk among
breast cancer survivors, with relative risk estimates ranging
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from 1.06 (95% CI ¼ 1.00 to 1.12) to 2.04 (95% CI ¼ 1.76 to 2.36)
(Figure 2). All four studies defining depression by antidepres-
sant use found higher use in breast cancer survivors, though for
one smaller study the confidence interval was wide and over-
lapped the null; relative risk estimates ranged between 1.16
(95% CI ¼ 1.11 to 1.22) and 2.06 (95% CI ¼ 1.94 to 2.18).
Of 31 studies that evaluated depressive symptoms with
scales, 13 reported strong statistical evidence of higher severity
of depressive symptoms among women who had breast cancer
(Table 2); among these, eight of nine studies that focused on the
prevalence of scoring above a clinically relevant threshold
found higher prevalence in breast cancer survivors, but this was
No. of studies Adverse mental health outcome 
21 Anxiety 
1 Bipolar disorder 
38 Depression 
24 Neurocognitive dysfunction 
1 Obsessive compulsion 
3 Post-traumatic stress 
6 Sexual dysfunction 
5 Sleep disturbances 
2 Somatization 
2 Suicide 
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n 9,392 records identified in MEDLINE, PsycINFO, CINAHL and SSCI 
669 articles excluded: 
  62  review articles, comments, editorials or conference abstracts 
  90  studies with no data for an adverse mental health outcome
        measured with a validated instrument or clinical diagnosis 
349  studies did not provide data for a female population based
        comparison group 
  26  studies in which the selection of the participants 
        depended on a mental health outcome 
  98  studies including patients undergoing the core treatment 
        for breast cancer or patients diagnosed with breast cancer 
        less than 1 year prior, or at unknown time 
    43  studies providing data that were not possible to be extracted 
    1  study provided data for the same sample as another study
60 studies eligible for the systematic review 
7,517 records screened (title and abstract)
Sc
re
en
in
g
1,875 duplicate records excluded 
729 full-text articles screened for eligibility
6,809 records excluded: 
1,530  review articles, comments, editorials, conference 
           abstracts, case reports and studies involving animals 
   727  studies not including adult women who had a diagnosis of 
           breast cancer 
2,410  studies did not provide data for an adverse mental health 
           outcome in women who had breast cancer 
   374  studies including patients undergoing the treatment 
           for breast cancer or who were institutionalised 
1,538  studies did not provide data for a female comparison 
           group without breast cancer 
   230  studies in which the selection of the participants 
           depended on a mental health outcome
21 studies 
identified from the 
list of references 
Figure 1. Systematic review flowchart. CINAHL¼Cumulative Index to Nursing and Allied Health Literature; SSCI¼Social Sciences Citation Index.
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statistically significant in only three studies and most estimates
again had wide confidence intervals (Figure 2).
The prevalence of depression in breast cancer survivors was
highest when evaluated with self-reported instruments (with
most estimates >30%) and lower for clinically diagnosed de-
pression (most estimates <10%; Figure 3). Determinants of de-
pression clinically assessed in breast cancer survivors were
seldom reported. Independent predictors of clinically diagnosed
depression included younger age, having comorbidities at diag-
nosis and less favorable tumor characteristics (42,58), living
alone, and having lower levels of education (42).
Two studies of suicide found breast cancer survivors to have
37% (95% CI ¼ 28% to 47%) to 60% (95% CI ¼ 21% and 112%)
higher risk than women in the comparison group (Figure 2).
Neurocognitive Dysfunction
Twenty-four studies evaluated domains of neurocognitive func-
tion (Table 1; Supplementary Table 5, available online). All stud-
ies described that breast cancer survivors performed worse
than noncancer controls for one or more domains of neurocog-
nitive function (Table 2); this was supported by strong statistical
evidence in 18 of 24 (75.0%) studies. When prevalence estimates
were provided, all seven studies showed point estimates tend-
ing towards an increased neurocognitive dysfunction in breast
cancer survivors compared with control subjects, even though
this was supported by strong statistical evidence in only three
instances; prevalence ratio estimates varied between 1.54 (95%
CI ¼ 0.95 to 2.49) and 5.51 (95% CI ¼ 1.86 to 16.30) (Figure 2).
Of the 24 studies of neurocognitive dysfunction, 21 investi-
gated the effect of being exposed to chemotherapy vs no che-
motherapy; these studies consistently showed increased risk of
neurocognitive impairments in breast cancer survivors exposed
to chemotherapy. Three studies evaluated the effect of being
exposed to hormone therapy in chemotherapy-naı¨ve patients
(29,82,85); two found strong evidence of increased neurocogni-
tive dysfunction among breast cancer survivors exposed to hor-
mone therapy. In most studies, neurocognitive impairments
were described to affect 20% to 40% of women one year post-
diagnosis (Figure 3).
Table 1. Summary of the main characteristics of the eligible studies
(N¼ 60)
Study characteristic
Studies,
n (%)
Type of study
Cohort 22 (36.7)
Cross-sectional 38 (63.3)
Type of population
Population-based 10 (16.7)
Convenience samples recruited at health institutions 43 (71.7)
Randomly selected 3 (5.0)
Convenience samples recruited from the community 7 (11.7)
Randomly selected 0 (0.0)
Characteristics of the women with history of breast cancer
Mean/median age
49 y 16 (26.7)
50–69 y 41 (68.3)
70 y 3 (5.0)
Mean/median time since diagnosis*
1 y 12 (20.0)
>1 and 5 y 26 (43.3)
>5 and 10 y 17 (28.3)
>10 y 5 (8.3)
Sample size†
<50 18 (30.0)
50–100 20 (33.3)
101–1000 14 (23.3)
>1000 8 (13.3)
Stage at diagnosis inclusion criteria
In situ only 1 (1.7)
In situ and nonmetastatic invasive 6 (10.0)
In situ and invasive all stages 3 (5.0)
Invasive, nonmetastatic 30 (50.0)
Invasive, all stages 20 (33.3)
Treatment-related inclusion criteria
Breast-conserving surgery 1 (1.7)
Mastectomy 5 (8.3)
Breast reconstruction 2 (3.3)
Chemotherapy 13 (21.7)
No chemotherapy 1 (1.7)
Hormone therapy 3 (5.0)
Radiotherapy 2 (3.3)
Immunotherapy 0 (0.0)
All treatments 33 (55.0)
Disease progression related inclusion criteria
Only patients who did not have recurrence or relapse 15 (25.0)
Only patients who were tumor free at recruitment 12 (20.0)
Patients with disease recurrence included‡ 19 (31.7)
Unclear 14 (23.3)
Adverse mental health outcome§
Anxiety 21 (35.0)
Bipolar disorder 1 (1.7)
Depression 38 (63.3)
Neurocognitive dysfunction 24 (40.0)
Obsessive compulsion 1 (1.7)
Sexual dysfunction 6 (10.0)
Sleep disturbances 5 (8.3)
Stress-related / posttraumatic stress 3 (5.0)
Somatization 2 (3.3)
Suicide 2 (3.3)
(continued)
Table 1. (continued)
Study characteristic
Studies,
n (%)
Adverse mental health outcome assessment§
Clinical diagnosis 10 (16.7)
Pharmacological treatmentk 5 (8.3)
Psychometric instruments 50 (83.3)
*Or mean/median time since treatment completion, as reported in the original
studies.
†Refers to patients included in analysis.
‡Includes studies that explicitly stated the inclusion of patients with recurrence,
and longitudinal studies including newly diagnosed patients and that did not re-
port exclusions related to recurrence/relapse during follow-up.
§Studies may have provided data for more than one outcome and may have
assessed one outcome by more than one method.
kIncludes self-reported medication intake.
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Sexual Dysfunction
Six studies, all involving convenience samples, reported data
for sexual dysfunction (Table 1). Five of these reported impair-
ments in one or more domains of sexual function (Table 2). All
studies for which prevalence ratios were available showed in-
creased dysfunction in breast cancer survivors, with relative
risk estimates between 1.25 (95% CI ¼ 1.05 to 1.49) and 2.03 (95%
CI ¼ 0.56 to 7.42) (Figure 2), but the width of the confidence
intervals did not exclude the probability of this being due to
Anxiety, clinical diagnosis
Khan et al. 2010 (36)
Hung et al. 2013 (52)
Hjerl et al. 2002 (51)*
Yang et al. 2017 (58) (invasive)
Anxiety, drug treatment
Khan et al. 2010 (36)
Yang et al. 2017 (58) (invasive)
Boehmer et al. 2015 (28) (self-reported)
Anxiety, scale
Boehmer et al. 2015 (28) (HADS≥8)
McDonald et al. 2010 (78) (STAI-T≥65)
Rubino et al. 2007 (38) (HRS-A≥15)†
Saleeba et al. 1996 (40) (STAI-S>85%)
Weitzner et al. 1997 (43) (STAI-T>1SD)
Depression, clinical diagnosis
Khan et al. 2010 (36)
Earle et al. 2007 (34)
Kim et al. 2017 (62)
Hung et al. 2013 (52)
Suppli et al. 2014 (42)
Hjerl et al. 2002 (51)*
Yang et al. 2017 (58) (invasive)
Depression, drug treatment
Suppli et al. 2014 (42)
Khan et al. 2010 (36)
Yang et al. 2017 (58) (invasive)
Boehmer et al. 2015 (28) (self-reported)
Depression, scale
Bailey et al. 2010 (46) (CESD≥16)
Bizetti Pelai et al. 2012 (60) (BDI≥10)
Boehmer et al. 2015 (28) (HADS≥8)
Frazzetto et al. 2012 (49) (GDS≥10)‡
Garcia Torres et al. 2013 (35) (BDI-II≥14)
Lee et al. 2011 (61) (SDS≥50)
McDonald et al. 2010 (78) (CESD≥16)
Rubino et al. 2007 (38) (HRS-D≥8)†
Weitzner et al. 1997 (43) (BDI>12)
Neurocognitive dysfunction
Schagen et al. 2006 (69)
Brezden et al. 2000 (70)
Collins et al. 2014 (67)
Fan et al. 2005 (68)
Jenkins et al. 2006 (75)
Hermelink et al. 2017 (59)
Kreukels et al. 2008 (72)
Sexual dysfunction
Rubino et al. 2007 (38)†
Boehmer et al. 2014 (47)
Claus et al. 2006 (48) (in situ)
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Figure 2. Associations between breast cancer history and anxiety, depression, neurocognitive and sexual dysfunctions, and suicide. We considered that anxiolytics
were being taken to treat anxiety and antidepressants to treat depression. Time since diagnosis refers to the mean/median time elapsed since the breast cancer diag-
nosis or completion of initial course of treatment, as reported in the original studies, for the sample of cancer survivors. When this information was not reported in the
original studies, we presented the lower limit of survivorship time reported in the inclusion criteria of the study. The minimum, mean/median, and maximum follow-
up of longitudinal studies are reported in the Supplementary Appendix (available online). *The original study provided relative risk estimates stratified by area of resi-
dence (urban/rural). The combined estimate presented in the forest plot was computed with inverse-variance-weighted meta-analysis methods using the command
“metan” in Stata v14. BDI(-II) ¼ Beck Depression Inventory(-II); CESD ¼ The Center for Epidemiologic Studies, Depression Scale; GDS ¼ Geriatric Depression Scale; HADS
¼ Hospital Anxiety and Depression Scale; HRS-A ¼ Hamilton Rating Scale for Anxiety; HRS-D ¼ Hamilton Rating Scale for Depression; OR ¼ odds ratio; PR ¼ prevalence
ratio; RR ¼ relative risk; SD ¼ standard deviation; SDS ¼ Self-rating Depression Scale; SIR ¼ standardized incidence ratio; SMR ¼ standardized mortality ratio; STAI-S ¼
State-Trait Anxiety Inventory (state anxiety subscale); STAI-T ¼ State-Trait Anxiety Inventory (trait anxiety subscale). †Women who have had breast reconstruction af-
ter mastectomy. ‡Refers to a group of women who had breast cancer recurrence 10 years after the first diagnosis.
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chance in two studies. The prevalence of reported impaired sex-
ual function overall or for specific domains was generally in the
range of 20% to 60% (Figure 3). Safarinejad et al. (39) reported
that women who had radiotherapy, chemotherapy, and hor-
mone therapy had four to six times higher odds of disorder for
all domains, compared with women who did not have cancer
(39) (Supplementary Table 6, available online).
Other Outcomes: Bipolar Disorder, Obsessive-
Compulsive Problems, Stress-Related and Posttraumatic
Stress, Sleep Disturbance, and Somatization
Other outcomes were infrequently studied, but five of five stud-
ies of sleep disturbance found a statistically significantly higher
prevalence in breast cancer survivors, as did two of three stud-
ies of stress-related disorders, two of two studies of
somatization, and the single studies identified with bipolar dis-
order and obsessive-compulsive outcomes (Table 2).
Quality of the Studies
Approximately 50% of the studies were rated at high risk of se-
lection bias, mostly because of the nonprobabilistic recruitment
of participants (eg, fliers and advertisements [28,31,44,47,56,57])
and the low proportion of women who accepted to participate
in the studies (30,45,50,53,54) (Figure 4). In most studies (>70%),
the risk of information bias was unclear, and the cross-sectional
design precluded the unequivocal assertion that the onset of
the mental disorder was posterior to the breast cancer diagno-
sis. Approximately 40% of studies reported results likely to have
been affected by confounding by age and socio-economic status,
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Figure 3. Absolute frequency of anxiety, depression, and neurocognitive and sexual dysfunctions reported in the original studies for breast cancer survivors. Estimates
for cognitive and sexual dysfunctions refer to the prevalence of women impaired for the condition or specific domains, as reported in the original studies. EHR ¼ elec-
tronic health records. Black triangle ¼ cumulative incidence, diagnoses in EHR; white triangle ¼ cumulative incidence, drug treatment; white diamond ¼ prevalence,
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and strategies to handle missing data were seldom reported.
Individual study ratings are provided in Table 2.
Discussion
Anxiety, depression, neurocognitive dysfunction, sexual dys-
function, and suicide appear to be more common in breast can-
cer survivors compared with noncancer groups. Scarcer data
were available for other adverse mental health outcomes, but
they were also reported as increased among breast cancer survi-
vors. Common limitations of the current available evidence in-
clude use of nonprobabilistic samples, cross-sectional study
designs making temporality of events difficult to assess, lack of
power, and lack of consideration for important confounders
such as socio-economic status.
Strengths of this review include the extensive search of
multiple databases, the duplicated screening of the references
and data extraction, and the systematic evaluation of the
quality of the studies. The restriction to studies involving non-
hospitalized samples and the inclusion of studies with in situ
tumors allowed for a more generalizable characterization of
the long-term burden of mental disorders in women in the
community who have had breast cancer. We aimed to reduce
the potential for information bias in the outcomes by consid-
ering only studies in which outcomes were assessed clinically
or with validated instruments. However, this review also has
limitations. Studies that reported mood assessments as sec-
ondary outcomes may not have been identified in the searches
of electronic publication databases if the mental health out-
come was not mentioned in the title, abstract, keywords, or
indexing terms. This problem should have been minimized by
our use of the four largest and most relevant databases in this
field, supplemented by manual searches of all reference lists
to further reduce the chances of major studies being missed.
The comparability of clinically diagnosed outcomes over time
may be limited by the changes in the diagnostic criteria, espe-
cially in cases such as sexual dysfunction where the criteria
became narrower over time (87). We defined explicit criteria to
evaluate the risk of bias in the studies, but our assessment
may have been affected by the quality of the reporting of the
original studies. We considered that confounding by age and
socio-economic status had been accounted for when the stud-
ies matched participants for these factors, even though we ac-
knowledge that matching per se may not completely remove
the confounding effect (88).
The population-based studies included in this review consis-
tently described more depression and anxiety in breast cancer
survivors compared with the general population when these
outcomes were clinically assessed. The group of breast cancer
patients who receive a psychiatric diagnosis or who contact
clinical services in relation to their mental health are likely to
represent the most severe cases only; these patients are likely
to benefit from medical treatment. Studies using receipt of anti-
depressants and anxiolytics prescriptions to define depression
and anxiety, respectively, are likely to capture the specific group
of patients who were thought to benefit from pharmacological
intervention, which is only a subset of all patients with anxiety
and depression. The indication of these drugs was not explored
in any of the original studies, and misclassification of the out-
come may have occurred because some of these drugs have
other indications and are routinely used to manage vasomotor
symptoms secondary to breast cancer treatments (89,90). In ad-
dition, we cannot rule out that patients with breast cancer
Figure 4. Summary of the risk of bias in the studies included in the systematic review. The risk of bias in statistical methods was considered not applicable when for-
mal statistical comparisons between the two groups were not presented in the original study. Missing data criteria were not applicable for studies involving electronic
health records.
R
EV
IEW
1322 | JNCI J Natl Cancer Inst, 2018, Vol. 110, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/article-abstract/110/12/1311/5164282 by London School of H
ygiene & Tropical M
edicine user on 09 D
ecem
ber 2019
82
history may have been more likely to be diagnosed with a men-
tal health outcome due to increased contact with the health
services compared with participants who did not have cancer.
The results from the original studies involving self-
assessment scales, especially to assess symptoms of anxiety
and depression, need to be interpreted with caution. These
were often small, low-powered, cross-sectional studies using
nonprobabilistic samples. Several of the original studies ex-
cluded women with psychiatric conditions and relied on volun-
tary participation. This may have resulted in an
overrepresentation of psychologically healthier women, be-
cause diseased people are less likely to volunteer to participate
in epidemiological studies (91,92); it is unclear if this would be
differential between breast cancer survivors and control groups.
The clinical profile of the patents included in these studies may
also have been more favorable, because 45% of the studies in-
cluded only patients with no recurrence and who were disease
free at recruitment. In addition, misclassification of the out-
come may have occurred, because these scales are screening
tools and not suitable to establish definitive diagnoses. For ex-
ample, the Hospital Anxiety and Depression Scale had only 50%
sensitivity as a screening test for major depressive disorder in
breast cancer survivors compared with the Structured Clinical
Interview for the Diagnostic and Statistical Manual of Mental
Disorders (93). Despite these limitations, scales are widely used
in psychiatric epidemiology and in psycho-oncology research,
and their results in this review are helpful to show the consis-
tency of the results across methods of assessment.
For all methods of outcome definition, selective reporting in
the original studies cannot be ruled out. Information on missing
data was rarely well reported, and there was limited adjustment
for potentially important confounders such as age and socio-
economic status; residual confounding is still likely to be pre-
sent in the studies that adjusted for education only.
Clinically relevant symptoms of anxiety and stress-related/
adjustment disorders are common shortly after diagnosis (94),
which is an expected response to a stressor that may be per-
ceived as life-threatening and considering the uncertainty
about the future that women may feel at this point (95).
Declining trajectories of anxiety suggest that most women
adjust to the diagnosis over time (96), but clinically relevant
symptoms may persist in subgroups of women. Evidence on
long-term trajectories of outcomes is scarce and needs to be fur-
ther explored. Reported determinants of anxiety included youn-
ger age at diagnosis and having comorbidities; this is consistent
with literature reporting that young breast cancer survivors
have specific concerns, for example, fertility issues for women
who want more children or weight gain during and after treat-
ments (10). The increased symptoms of posttraumatic stress is
consistent with a meta-analysis reporting that 10% of breast
cancer survivors have posttraumatic stress disorder (97).
Results for somatic and obsessive-compulsive symptoms must
be interpreted with caution because they come from a small
number of studies.
The increased frequency of depression in breast cancer sur-
vivors is plausible considering that many report unmet needs in
several domains that affect quality of life (98), including impact
on relationships, lifestyle changes induced by the cancer, lack
of psychological support, and difficulties obtaining understand-
able information about the physical long-term effects of the
treatments (99–101). Risk factors for depression in breast cancer
patients appear to be similar to those for the general female
population, including less social support and lower
socio-economic status (46). Suicide almost always occurs
among people suffering from a mental health disorder, most of-
ten depression (102,103). The increased risk of suicide in breast
cancer survivors is likely to be underestimated, because suicide
is often classified under other causes of death, and this may
happen more often in women who have had cancer.
Neurocognitive dysfunction, also known as chemo-fog, has
been linked to the neurotoxic effects of chemotherapy (104).
Other determinants of neurocognitive dysfunction recently pos-
tulated include posttraumatic stress disorder (59) and exposure
to hormone therapy due the effects of estrogen deprivation in
the neuronal structures (82). Impairments for one or more
domains of neurocognitive function (eg, memory [65,83] and
processing speed [77,81]) were often described, but the method-
ological heterogeneity of the studies (105) as well as the chal-
lenge to measure neurocognitive function (106) hamper
comparisons, and it is currently debatable which specific
domains are impaired.
The narrow inclusion/exclusion criteria in some eligible
studies of sexual dysfunction preclude generalizability to the
general population of breast cancer survivors. For example,
Safarinejad et al. (39) excluded women who did not attempt sex-
ual intercourse weekly and Boehmer et al. (47) included only in
lesbian or bisexual women. The aetiology of sexual dysfunction
in women with a history of breast cancer is thought to be multi-
factorial. Vaginal dryness is a common iatrogenic effect of hor-
mone therapy or chemotherapy-induced ovarian failure and
may lead to dyspareunia (14). However, impaired sexual func-
tion, compared with healthy women, has also been reported in
women treated with surgery only (48), indicating that factors
other than the physical ones may be involved. Indeed, the dis-
tress in partnered relationships (107–110), body image concerns
(111,112), depressive feelings (113), younger age at diagnosis
(113), and presence of comorbidities (114) have all been reported
amongst the most important determinants of female sexual
dysfunction.
Mitchell et al. (115) systematically reviewed studies provid-
ing data for depression and anxiety in survivors from several
types of cancer (>2 years since diagnosis) and in healthy sub-
jects. The results indicated that anxiety, but not depression,
may be increased among cancer survivors (115). This conclusion
arose from the meta-analysis of nine studies that provided data
for anxiety and included patients diagnosed with breast, colo-
rectal, prostate, testicular, and cervical cancers or Hodgkin’s
lymphomas as well as patients diagnosed with cancers during
adolescence and young adulthood. It is currently unknown if,
and how, the risk of anxiety and depression varies by cancer
type, and thus we cannot directly compare our results. Other
systematic reviews on the topic assessed the prevalence of anx-
iety and depressive symptoms in cancer survivors (11,116–118),
including studies without a comparison group. Maass et al. (11)
described a higher frequency of depressive symptoms among
breast cancer survivors (>1 year since diagnosis) compared with
normative data found in the literature. The results for cognitive
dysfunction are in accordance with those reported by Jim et al.
(119), who found small but increased cognitive deficits in breast
cancer survivors treated with chemotherapy compared with
noncancer and cancer controls.
Several studies have reported no differences in most
domains of health-related quality of life (HRQoL) between long-
term breast cancer survivors and women in the general popula-
tion (120–122). The interpretation of our results in the context of
the literature for HRQoL is not straightforward, and the appar-
ent difference is likely to be explained by the combination of
several factors, including the differential participation of
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psychologically healthier women in HRQoL surveys and positive
effects of surviving breast cancer. Patients with adverse mental
health outcomes, especially those with the most severe catego-
ries, may be less likely to participate in HRQoL surveys. This
contrasts with the studies in this review that included women
with a clinical diagnosis and/or treated for a mental health dis-
order and were thus likely to capture the most severe cases. In
addition, long-term breast cancer survivors report changes in
several aspects of their lives, but not all of them are negative.
Women in the survivorship period have described feeling im-
proved empathy, closer relationships, and a greater apprecia-
tion for life (123). This phenomenon of heightened well-being
after a stressful event—known as posttraumatic stress
growth—has been described to affect up to 60% of breast cancer
survivors (124). Quality of life reflects how women perceive their
current status, and the occurrence of posttraumatic growth
may offset some of the negative feelings associated with breast
cancer (125). In addition, studies of HRQoL often reported mean
scores of overall and domain-specific measures of HRQoL; sub-
groups that have a different trajectory of symptoms can be hard
to disentangle based on standard analyses.
This study has several implications for clinical practice. It is
important to raise awareness amongst health care professionals
acting at various levels of the health care system of the in-
creased risk of mental health symptoms among breast cancer
survivors, in particular anxiety, depression, and neurocognitive
and sexual dysfunctions. Screening for mental health disorders
in some or all of the breast cancer survivor population may be
warranted. Predictors of distress among breast cancer survivors
include having perceived functioning limitations, fatigue, youn-
ger age, lower socioeconomic status, and psychiatric history,
and modifiable factors such as vasomotor symptoms, pain, less
social support, physical activity, and cigarette smoking (126). As
such, screening for anxiety and depression may be especially
relevant for younger patients, and all those within the first few
years of survivorship, with co-morbidities, living alone, or diag-
nosed with more advanced disease; patients with depression
should be assessed for suicidal ideation. Patients who experi-
enced treatment-induced menopause are likely to benefit from
being asked about their sexual function, because they may
avoid this topic with their clinicians; patients who received che-
motherapy may also benefit from assessment for clinically sig-
nificant cognitive impairments. Psychosocial support and
routine monitoring of patient-reported outcomes during survi-
vorship care are likely to help reduce the burden of these condi-
tions. Differentiated psychological services are becoming the
norm in specialized breast cancer clinics; however, only a frac-
tion of the breast cancer survivors are followed-up in these
settings (127). The holistic approach to the patients’ unmet
needs also requires equipping health care professionals with
evidence-based information on the optimal management
strategies. For example, treatment for sexual dysfunction
may require not only management of anxiety and depressive
symptoms, but also vaginal dryness, which may be under-
treated in women with history of estrogen-receptor positive
breast cancer due to concerns over the effect of hormonal
vaginal treatments (128) and unawareness of the recommen-
dations for lubricants and moisturizers (129). Patients’ edu-
cation on common changes post breast cancer, and the
strategies available to manage these, may help women to
better understand and cope with their disease, increase
patients’ awareness of common symptomatology, and help
to decrease the stigma associated with mental health
disorders.
Our review also identified areas for further research. There
is a pressing need for studies evaluating clinically diagnosed ad-
verse mental health outcomes in samples of women likely to
represent the cohort of survivors in the general population and
with sufficient numbers to allow effects to be detected. Further
research is particularly needed to better characterize the trajec-
tories of mental health outcomes over time, particularly of anxi-
ety, depression, and neurocognitive dysfunction. The long-term
risk of sleep disorders needs clarification, because breast cancer
treatments such as chemotherapy and steroids have been sug-
gested to be associated with impaired sleep (130,131), possibly
due to increased risk of vasomotor symptoms that affect the
sleep quality and quantity (132). Evidence on the long-term ef-
fect of being diagnosed in situ vs invasive tumors and on having
undergone breast reconstructive surgery is scarce despite the
increasing numbers of ductal carcinoma in situ diagnoses and
aesthetics surgeries performed. The role of systemic treatments
other than chemotherapy on neurocognitive function also
needs clarification, including the role of the different types of
hormonal treatments (selective oestrogen receptors modulators
vs aromatase inhibitors). Efforts should be made to employ
standardized definitions of the outcomes, because the heteroge-
neity of diagnostic codes and psychometric instruments ham-
pers comparability of results across studies. Further research is
also needed on the performance of commonly used scales for
anxiety and depression as screening tools for these conditions
in breast cancer survivors. Studies should also consider that the
incidence of mental health disorders after a breast cancer diag-
nosis may vary with age, socio-economic status, time, stage of
disease, recurrence, type of treatment, and sequelae from can-
cer among other factors. The inclusion of a comparison group is
essential to estimate the excess risk of the breast cancer
survivorship.
In conclusion, women with a history of breast cancer appear
to be at higher risk of a wide range of adverse mental health
outcomes up to several years post diagnosis and treatment
compared with women who did not have cancer. The evidence
was particularly compelling for anxiety, depression and neuro-
cognitive and sexual dysfunctions, and suicide, which were
most often studied. However, there is a pressing need for more
population-based research to better characterize the associa-
tion between breast cancer history and mental health. Our
results can be used to inform prevention and management
strategies directed at tackling the burden of adverse mental
health outcomes in breast cancer survivors.
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Dr Huillard et al. suggested that we report on mental health out-
comes in breast cancer survivors with and without history of
mental disorders. Twenty-two of the 60 studies excluded partic-
ipants with history of mental disorders. Of the 38 studies that
did not mention psychiatric history in their exclusion criteria,
three accounted for it either through matching or adjustment in
multivariable analyses; only one study explored the role of psy-
chiatric history (it showed no correlation between psychiatric
history and symptoms of posttraumatic stress).
Dr Huillard et al. noted that in a previous study, an increased
risk of mental disorders was only observed among cancer
patients who had a history of mental disorder (1). As noted
above, results stratified by psychiatric history were seldom
available in studies that we reviewed. However, we believe that
the results of the studies that included only participants with
no history of mental disorders are informative. Four
population-based studies included in our review, in which out-
comes were clinically ascertained, showed an increased risk of
anxiety and/or depression in breast cancer survivors with no
history of mental disorders, relative to comparable women
without cancer (2–5). This shows that for breast cancer survivors
(>1 year), the risk of first-ever disorders is increased relative to
women who never had cancer. If the hypothesis of Dr Huillard
et al. is correct, the burden of mental disorders is likely to be
underestimated in the studies restricted to women with no his-
tory of mental disorders. We should also note that our study fo-
cused solely on female breast cancer survivors at least 1 year
after diagnosis, whereas the Huillard et al. study included
patients with a wide range of cancers (16% were of the breast). It
is plausible that the effect of a cancer diagnosis on the patients’
mental health varies by cancer site. We thank Dr Huillard et al.
for their interest in our study.
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3.4 Systematic review update 
The research described in the systematic review was based on search expressions 
that had been last run on the 1st of November 2017. The search was updated on the 
2nd of October 2019, with a total of 2,041 new records identified. Using the same 
inclusion/exclusion criteria, 126 studies were eligible for full text assessment and 
ultimately six studies were eligible for the systematic review update (Table 3.1). In 
total, 66 studies, covering nine mental health outcomes, were eligible (60 from the 
original search, six from the update). 
The most commonly evaluated outcomes were anxiety (n=23 studies) and 
depression (n=41). Of 23 studies of anxiety, 12 observed more anxiety in breast 
cancer survivors, including two of four studies with clinical/ prescription-based 
outcomes, and in 10 of 19 of anxiety symptoms. Of 41 studies of depression, 22 
reported some statistical evidence of more depression in breast cancer survivors, 
compared to the non-cancer group; this included seven of eight studies where 
depression was ascertained clinically, and 15 of 33 studies that quantified 
depressive symptoms. Breast cancer survivors also had statistically significantly 
increased symptoms/frequency of neurocognitive dysfunction (21 of 28 studies), 
sexual dysfunctions (6 of 7 studies), sleep disturbance (5 of 5 studies), stress-
related disorders (2 of 3 studies), suicide (2 of 2 studies), somatisation (2 of 2 
studies), and bipolar and obsessive-compulsive disorders (1 of one study each).  
Studies were heterogeneous in terms of participants’ characteristics, time since 
diagnosis, ascertainment of outcomes, and measures reported. This precluded a 
quantitative summary of the data. A total 44 of 66 studies (66.7%) included small, 
non-probabilistic samples of breast cancer survivors. Mental health outcomes were 
most commonly evaluated with psychometric instruments (55/66 studies=83.3%), 
followed by clinical diagnoses registered in electronic healthcare databases 
(11/66=16.7%). Approximately one-half of the studies were at high risk of selection 
bias due to non-probabilistic recruitment of participants or low participation rates. In 
most studies (>70%), the risk of information bias was unclear and the cross-
sectional design precluded the unequivocal assertion that the onset of the mental 
disorder was posterior to the breast cancer diagnosis. Approximately 40% of studies 
reported results likely to have been affected by confounding by age and socio-
economic status. 
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Table 3.1   Results of the studies eligible in the update of the systematic review. 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome 
assessment 
Quantitative measure of the 
outcome  
Relative 
risk 
estimate 
(RR, OR, 
SIR, PR) 
P-value* or 
95% 
confidence 
interval 
Notes 
Type of population 
and 
main 
characteristics 
 
Stage at 
diagnosis (%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis† in 
years: 
mean/median 
(SD), range 
Type of population 
and 
main 
characteristics 
 
Breast cancer 
survivors 
Comparison 
group 
Anxiety            
Cheng, 
2018 [204] 
 
China 
Convenience sample 
 
Patients aged 20-60 
years, with non-
metastatic disease, 
working at least 20h 
per week recruited 
from hospitals in four 
regions of China 
 
I (47.2%) 
II (46.8%) 
III (6.0%) 
Srg only (13.5%) 
RT only (6.7%) 
Srg + RT (34.5%) 
Srg + CT (7.1%) 
Srg + RT + CT 
(38.2%) 
3.2 (ND), 
2-ND 
Convenience sample 
 
Women with no 
history of cancer, 
aged 20 to 60 years, 
working >20h per 
week and in the 
current job for >1yr 
HADS 
Mean score 
(SD): 
5.43 (3.51) 
Mean score 
(SD): 
2.89 (1.37) 
- P<0.0001 
Higher scores 
represent more 
anxiety. 
Wirkner, 
2017 [205] 
 
Germany 
Convenience sample 
 
20 breast cancer 
survivors recruited 
from one center 
ND (ND) Srg (ND%) 
RT (85%) 
CT (100% 
HT (75%) 
3.43 (1.9), 
ND-7 
Convenience sample  
 
31 healthy controls 
recruited via bulletin 
boards 
STAI (trait 
anxiety only) 
Mean score 
(SD): 
48.40 (2.09) 
Mean score 
(SD): 
31.67 (1.70) 
 P<0.001 
Cases and 
controls 
matched for age, 
education and 
handedness 
            
Depression           
Cheng, 
2018 [204] 
 
China 
Convenience sample 
 
Patients aged 20-60 
years, with non-
metastatic disease, 
working at least 20h 
per week recruited 
from hospitals in four 
regions of China 
 
I (47.2%) 
II (46.8%) 
III (6.0%) 
Srg only (13.5%) 
RT only (6.7%) 
Srg + RT (34.5%) 
Srg + CT (7.1%) 
Srg + RT + CT 
(38.2%) 
 
3.2 (ND), 
2-ND 
Convenience sample 
 
Women with no 
history of cancer, 
aged 20 to 60 years, 
working >20h per 
week and in the 
current job for >1yr 
HADS 
Mean score 
(SD): 
6.71 (3.56) 
Mean score 
(SD): 
2.30 (1.26) 
- P<0.0001 
Higher scores 
represent more 
depression. 
Wirkner, 
2017 [205] 
 
Germany 
Convenience sample 
 
20 breast cancer 
survivors recruited 
from one center 
 
 
 
ND (ND) Srg (ND%) 
RT (85%) 
CT (100% 
HT (75%) 
3.43 (1.9),  
ND-7 
Convenience sample  
 
31 healthy controls 
recruited via bulletin 
boards 
BDI-II 
Mean score 
(SD): 
16.20 (1.64) 
Mean score 
(SD): 
4.57 (1.34) 
 P<0.001 
Cases and 
controls 
matched for age, 
education and 
handedness 
           (Continued) 
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Table 3.1   Continued 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome 
assessment 
Quantitative measure of the 
outcome  
Relative 
risk 
estimate 
(RR, OR, 
SIR, PR) 
P-value* or 
95% 
confidence 
interval 
Notes 
Type of population 
and 
main 
characteristics 
 
Stage at 
diagnosis (%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis† in 
years: 
mean/median 
(SD), range 
Type of population 
and 
main 
characteristics 
 
Depression           
Ng, 2019 
[206] 
 
Canada 
Convenience sample 
 
12,127 women aged 
>18, diagnosed with 
breast cancer 
between 2005-2009, 
from the cancer 
registry. Women who 
did not have health 
insurance were 
excluded.  
I (40.8%) 
II (30.9%) 
III (12.4%) 
IV (3.9%) 
Unknown 
(12.0%)  
ND (ND) ND (ND),  
4-9 
Convenience sample 
 
Women with no 
cancer history or 
history of prescription 
of chemotherapy 
agents, selected at 
random from primary 
care databases.   
Primary care 
diagnosis of 
depression, 
ICD codes or 
antidepressant 
prescription 
Incidence 
rate: 5.57 
(5.34-5.82) 
Incidence 
rate: 3.05 
(2.94-3.17) 
HR=1.68 
95%CI:  
1.60-1.76 
Adjusted for 
neighborhood 
quintile of 
deprivation, 
presence of 
comorbidity at 
baseline.  
            
Neurocognitive dysfunction           
Cheng, 
2018 [204] 
 
China 
Convenience sample 
 
Patients aged 20-60 
years, with non-
metastatic disease, 
working at least 20h 
per week recruited 
from hospitals in four 
regions of China 
 
I (47.2%) 
II (46.8%) 
III (6.0%) 
Srg only (13.5%) 
RT only (6.7%) 
Srg + RT (34.5%) 
Srg + CT (7.1%) 
Srg + RT + CT 
(38.2%) 
 
3.2 (ND), 
2-ND 
Convenience sample 
 
Women with no 
history of cancer, 
aged 20 to 60 years, 
working >20h per 
week and in the 
current job for >1yr 
CSC-W21 
Mean score 
(SD): 
6.43 (18.32) 
Mean score 
(SD): 
0.32 (0.71) 
- P<0.0001 
Higher scores 
represent more 
problems. 
Jung, 
2016[207] 
 
United 
States 
Convenience sample 
 
62 right-handed 
women recruited 
from one breast 
cancer center 
I (18%) 
II (57%) 
IIIa (25%) 
Srg, M (54%) 
Srg, BC (46%) 
RT (90.3%) 
CT (45.2% 
HT (80.6%) 
~1 year Convenience sample 
 
30 healthy women 
with no cancer 
VWMT 
Overall deficit 
score, CT 
group: +0.4 
 
Overall deficit 
score, non-CT 
group: 0.0 
Overall deficit 
score: -0.6 
 
- P=0.007 
The group 
exposed to CT 
had significantly 
worse 
performance at 1 
year evaluation 
compared to 
women in the 
control group. 
 
           (Continued) 
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Table 3.1   Continued 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome 
assessment 
Quantitative measure of the 
outcome  
Relative 
risk 
estimate 
(RR, OR, 
SIR, PR) 
P-value* or 
95% 
confidence 
interval 
Notes 
Type of population 
and 
main 
characteristics 
 
Stage at 
diagnosis (%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis† in 
years: 
mean/median 
(SD), range 
Type of population 
and 
main 
characteristics 
 
Neurocognitive dysfunction           
Wirkner, 
2017 [205] 
 
Germany 
Convenience sample 
 
20 breast cancer 
survivors recruited 
from one center 
ND (ND) Srg (ND%) 
RT (85%) 
CT (100% 
HT (75%) 
3.43 (1.9), ND-7 Convenience sample  
 
31 healthy controls 
recruited via bulletin 
boards 
WMS-R 
Mean score 
(SD): 
 
Digit span 
forward:  
33.90 (6.22) 
Digit span 
backward: 
60.84 (6.69) 
Logical 
memory I: 
67.12 (6.39) 
Logical 
memory II: 
61.40 (6.26) 
 
Mean score 
(SD): 
 
Digit span 
forward:  
53.32 (5.26) 
Digit span 
backward: 
61.61 (5.51) 
Logical 
memory I: 
84.66 (5.40) 
Logical  
memory II: 
89.02 (5.29) 
 
- 
Digit span 
forward: 
P=0.021 
 
Digit span 
backward: 
P=0.930 
 
Logical 
memory I: 
P=0.042 
 
Logical 
memory II: 
P=0.002 
 
Cases and 
controls 
matched for age, 
education and 
handedness 
Kesler, 
2017 [208] 
 
China 
 
Convenience sample 
 
31 newly diagnosed 
breast cancer 
patients aged 34-65 
years recruited from 
one center 
I (16%) 
II (65%) 
III (19%) 
Srg (ND%) 
RT (65%) 
CT (100% 
HT (71%) 
~1 year Convenience sample  
 
43 frequency 
matched healthy 
controls  
RAVLT A1 Mean score 
(SD): 
54 (8.3) 
Mean score 
(SD): 
57 (8.8) 
- P>0.193 
- 
RAVLT A6 Mean score 
(SD): 
10 (3.0) 
Mean score 
(SD): 
11 (2.8) 
- P>0.193 
CTMT 1 Mean score 
(SD): 
53 (9.7) 
Mean score 
(SD): 
58 (9.6) 
- P>0.193 
CTMT 5 Mean score 
(SD): 
53 (9.5) 
Mean score 
(SD): 
57 (8.9) 
- P>0.193 
COWA Mean score 
(SD): 
47 (9.0) 
Mean score 
(SD): 
52 (13) 
- P>0.193 
MCAB 
Adjustment 
Index 
Mean score 
(SD): 
1.7 (1.9) 
Mean score 
(SD): 
0.73 (1.2) 
- P>0.193 
           (Continued) 
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Table 3.1   Continued 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome 
assessment 
Quantitative measure of the 
outcome  
Relative 
risk 
estimate 
(RR, OR, 
SIR, PR) 
P-value* or 
95% 
confidence 
interval 
Notes 
Type of population 
and 
main 
characteristics 
 
Stage at 
diagnosis (%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis† in 
years: 
mean/median 
(SD), range 
Type of population 
and 
main 
characteristics 
 
Sexual dysfunction           
Soldera, 
2018 [209] 
 
Canada 
Convenience sample 
 
248 women who had 
been newly 
diagnosed with 
breast cancer at one 
of three metropolitan 
hospitals, who didn’t 
not have neo 
adjuvant 
chemotherapy and 
lived within 1 hour 
distance of the 
hospital.  
: 
I-III (100%) Srg, M (25%) 
Srg, BC (75%) 
RT (28%) 
CT (29% 
HT (27%) 
12.5 (ND), 9.4-
17.6 
Convenience sample 
 
159 Women 
undergoing 
screening 
mammography at the 
same hospitals, age-
matched to the 
breast cancer group. 
Abnormalities in the 
mammography were 
excluded as well as 
women with previous 
cancer diagnosis.  
SAQ: Pleasure 
Mean score 
(SD): 
12 (4.25) 
Mean score 
(SD): 
12 (4.41) 
- P=0.56 
Adjusted for age. 
 
There was a 
significant 
interaction 
between 
menopausal 
status and type 
of population, 
with pre- and 
peri-menopausal 
women being 
less likely to be 
sexually active 
compared to 
controls (Odds 
ratio=0.12, 
P=0.012).  
SAQ: 
Discomfort 
Mean score 
(SD): 
2 (2) 
Mean score 
(SD): 
2 (2.02) 
- P=0.14 
SAQ: Habit 
Mean score 
(SD): 
1 (0.46) 
Mean score 
(SD): 
1 (0.54) 
- P=0.49 
* Underlined text is used to denote that the differences between the two groups were supported by some statistical evidence (P<0.05). 
 
BDI-II = Beck Depression Inventory-II; COWA = Controlled Oral Word Association; CT = chemotherapy; CTMT = Comprehensive Trail Making Test; CSC-W21 = Chinese version of the Cognitive 
symptoms Checklist; HADS = Hospital Anxiety and Depression Scale; HR = hazard ratio; HT = hormone therapy; MCAB = Mobile Cognitive Assessment Battery; ND = not defined; RAVLT = Rey 
Auditory Verbal Learning Test; RT = radiotherapy; SAQ = Sexual Activity Questionnaire; STAI = State-Trait Anxiety Inventory; Srg, M = mastectomy; Srg, BC = breast conserving surgery; SD = 
Standard deviation; TAP = Test battery for Assessment of Attention; VWMT = Verbal Working Memory Test; 95%CI = 95% confidence interval.
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3.5 Summary 
 
• This systematic review summarised the evidence of the studies that quantified 
differences in the frequency and/or severity of adverse mental health outcomes 
between women with a history of breast cancer (>1 year) and women who never 
had cancer. 
 
• 66 studies were included after updating the searches in October 2019. These 
studies provided data for 9 mental health outcomes. Depression (n=41 studies), 
neurocognitive dysfunction (n=28) and anxiety (n=23) were the most commonly 
studied outcomes. Fewer studies provided data for sexual dysfunction (n=7), sleep 
disturbances (n=5), post-traumatic stress (n=3), obsessive compulsion (n=1), 
somatization (n=2), bipolar disorder (n=1), and suicide (n=2). 
 
• Overall, the studies provided some evidence of a raised risk of anxiety, depression 
and suicide, and neurocognitive and sexual dysfunctions, in breast cancer 
survivors compared with women with no prior cancer, persisting for several years 
post-treatment. Sleep disturbances, sexual disorders and post-traumatic stress 
disorder, also appear to be increased in breast cancer survivors, but the smaller 
number of studies precludes firm conclusions. 
 
• However, the quality of most studies investigating mental health outcomes in 
breast cancer survivors, compared to women with no prior cancer, was suboptimal. 
Studies often relied on small convenience samples that are likely to lack statistical 
power. There was a large potential for misclassification of the outcomes in several 
studies and outcomes were rarely based on clinical assessments. Confounding by 
age and socio-economic status is also likely to have affected 40% of the studies. 
 
• The current body of research lacks-well powered studies involving samples of 
breast cancer survivors broadly representative of those in the general population, 
and with clinically assessed outcomes. 
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4 Description of the data sources 
4.1 Introduction 
The research in this thesis is based on electronic health records (EHRs) of patients 
attending primary care practices that contributed with data to the Clinical Practice 
Research Datalink (CPRD) General Practitioner Online Database (GOLD) (hereafter 
referred to as CPRD GOLD primary care database). For Aim 1 (i.e. quantifying the risk 
of adverse mental health outcomes in breast cancer survivors compared to women with 
no history of cancer), the data in the CPRD GOLD primary care database were linked 
to EHRs from secondary care, official death registration data, and area- and patient-
level deprivation data. The research to address Aim 2 (i.e. investigating the HRQoL 
and presence/severity of anxiety and depressive symptoms breast cancer survivors 
compared to non-cancer controls) involved using the CPRD primary care database to 
select both women with a history of breast cancer and women who never had cancer, 
and invite them to respond to questionnaires on their HRQoL, anxiety and depressive 
symptoms. This chapter provides the description of the data. 
4.2 Clinical Practice Research Datalink General Practitioner Online 
Database 
CPRD is a UK government research service supported by the Medicines and 
Healthcare products Regulatory Agency (MHRA) and the National Institute for Health 
Research (NIHR). CPRD has been collecting, processing, and releasing anonymised 
EHRs from patients attending primary and secondary care in the UK since 1987 [210]. 
4.2.1 Data and database version 
The CPRD GOLD primary care database is one of the largest and longest-established 
databases of EHRs in the world. Data come from primary care practices that use the 
general practitioner (GP) software system InPS Vision, which is one of the four main 
systems in use in the NHS GP practices (TPP SystmOne, EMIS Web, and Microtest 
Evolution are the others) [211]. The number of practices using InPS Vision has 
decreased during the recent years, with several practices opting to move to EMIS Web 
or TPP SystmOne. Figure 4.1 shows the spatial distribution of the percentage of the 
population share and number of practices using the InPS Vision software system in 
2016 at both Clinical Commissioning Group and NHS region levels. 
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Figure 4.1   Spatial distribution of the 7526 general practices in the UK by number of general 
practices using InPS Vision, and percentage of the population share, at both Clinical 
Commissioning Group (thinner borders) and NHS region (thicker border) levels. 
Figure from [212]; reproduced under the terms of a CC BY license. 
 
The data in the InPS Vision system are routinely entered by the patient’s GP or the 
health care team, at the point of providing care, for consultations occurring at the 
participating practices [213]. The resulting clinical record includes information collected 
prospectively on demographics, lifestyles, biochemical analysis results, diagnoses, 
prescriptions, and referrals to secondary and tertiary care. When a patient is referred 
for secondary care, information from inpatient and outpatient care is usually sent back 
to the GP to be added to their clinical record. It should be noted that the availability of 
this information may differ from the information that is collected during primary care 
appointments (e.g. conditions added to the free text section of the clinical record would 
not be included in CPRD GOLD data; nor would discharge letters scanned and kept as 
attachments to the patient record). 
Much of the information (but not all) recorded in the InPS Vision system uses version 2 
Read codes [214]. The Read code classification includes approximately 250,000 codes 
that allow for the recording of a wide range of information, such as diagnoses and 
symptoms, biochemistry laboratory results, tests, family history of diseases, therapeutic 
and surgical procedures and surgeries carried out, ethnicity, religion, occupation, social 
circumstances, and administrative details related to patient care. To enter data in the 
patient record during consultations, the GP searches for relevant codes using 
keywords, which prompts a list of potential codes with the keyword in their description 
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to come up. The GP then selects the preferred code from the list; the consultation 
manager interface also includes a section for comments where free text can be added. 
If no suitable code is found, a new code may be added. Data can also be added 
retrospectively, with a past event date, which in this case will be different from the 
system date. Prescription data are recorded at the point of issue using product codes, 
which are based on the drugs listed in the British National Formulary (BNF). 
The CPRD periodically retrieves data and processes and releases data for wider use in 
public health research. Procedures are in place to ensure the confidentiality of the data. 
Identifiable information in the patients’ EHR, such as name, address, telephone 
number, or day and month of birth in adults, is sent to a trusted third party (NHS Digital, 
the statutory body in England that is allowed to receive identifiable patient information), 
where a set of anonymised patient identifiers are generated. CPRD automatically 
retrieves from the system InPS Vision anonymised clinical data, to which the 
anonymised patient identifiers are added. The information in the free text notes added 
by the GP is not sent to CPRD, as this may contain identifiable information. This 
process ensures that there is total separation, with the trusted third party never seeing 
the patient medical information, and CPRD never receiving information that allows for 
patients to be identified.  
4.2.2 Quality control 
At CPRD, the quality of the data is checked both at patient- and practice-level. Data 
quality controls at patient-level include internal consistency checks such as having a 
date of registration with the practice that is later than the date of birth, among others  
(Table 4.1). At the end of the checks, a flag is added to the data indicating whether the 
patient record failed one or more of the checks; patients who pass all checks are 
considered to have medical records of acceptable data quality for research purposes. 
 
Table 4.1   Example of internal consistency checks performed by CPRD on the data collected 
from the InPS Vision software. 
Valid gender and birth date 
First registration posterior to birth date 
Current registration date:  
Valid 
After the first registration date 
After date of birth 
Permanent registration with the practice 
Transferred out of the practice & reason: either both missing or both completed 
If transferred out of the practice, dates consistent with registration and birth dates. 
Valid event date recording (e.g. not a future date, or <1st Jan 1980).  
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The data are also checked at practice-level for completeness, internal consistency and 
external validity. Examples of these checks at practice-level include assessing whether 
there are temporal gaps in the data provided by the practice to CPRD, and whether the 
mortality rates observed for patients registered with the practice lie within reasonable 
expected limits. A field is also added to the data indicating the date after which the data 
in that practice is considered of sufficient quality to be used for research (termed by 
CPRD as the “up to standard date”). 
4.2.3 Representativeness of the broad UK general population 
The representativeness of the data included in the CPRD GOLD primary care database 
needs some consideration. In the UK, virtually all inhabitants are registered with a GP 
practice [215]. Access to NHS services is free of charge, following the principle that 
‘access to NHS services is based on clinical need, not an individual’s ability to pay’ 
[216]. The GP practices throughout the UK provide the first level of care to the 
population within the NHS, and are responsible for providing preventive care, treatment 
for suitable illnesses and act as gatekeepers to other levels of care. The data gathered 
by CPRD comes from computer software systems that are used in clinical practice to 
create, add and manage information in patients’ EHR. As of January 2019, the CPRD 
GOLD primary care database included data from 18.4 million patients from 761 GP 
practices. Within each contributing GP practice, patients may opt out of having their 
data transferred to other entities or used for research purposes, which is a threat to the 
population-based nature of the data. In July of 2013, the CPRD GOLD primary care 
database included data for 11.3 million patients, of which 4.4 million were alive and 
registered (7% of the UK population). It is known that the distribution of the GP 
practices contributing data in the most recent years is not geographically representative 
of the UK as a whole (Figure 4.1); this may potentially lead to overrepresentation of 
wealthier areas in the UK. Nevertheless, patients in the database were shown to be 
broadly representative of the UK general population in terms of age, sex and ethnicity 
[210, 213].  
4.2.4 Validity and completeness of the data 
The completeness and validity of the information in CPRD GOLD primary care 
database is of major interest. The CPRD GOLD primary care database has been 
shown to capture more than 90% of the cancer diagnoses registered in the cancer 
registries (gold-standard) [217]. The completeness of the information on mental health 
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is more difficult to ascertain, as a gold standard for comparisons has not been available 
until recently (the CPRD Mental Health Dataset). The absence of a Read code for a 
mental health condition is typically interpreted as evidence of the patient not having the 
condition, but one has to acknowledge the potential for low sensitivity [213]. For other 
types of information, such as weight or smoking habits, absence of the information may 
be related to the information itself; for example, it is plausible that obese patients are 
more likely to have their weight recorded compared to those who have healthy weight 
[213]. 
Several studies employed strategies to validate outcomes defined in CPRD primary 
care data [218, 219]. These most often ascertained positive predictive values (i.e. the 
proportion of cases who are confirmed to have the disease), using as gold-standard 
information requested from the patient’s GP (e.g. GP questionnaires) [219]. The 
proportion of cases confirmed varies by disease type; for infectious disease, 
neoplasms, skin diseases, genitourinary conditions, congenital disorders and external 
causes of morbidity and mortality the median proportion of cases confirmed was >90% 
[219]. For mental and behavioural disorders, the median proportion of cases confirmed 
in 20 validation studies was 83.0% (95%CI: 52-100) [219]. 
4.2.5 Linkage to other sources of data 
The data in the CPRD GOLD primary care dataset are linked to other databases 
containing health care data at individual patient level [220]. Examples of established 
linkages include the Hospital Episode Statistics Admitted Patient Care (HES-APC), the 
National Cancer Registration and Analysis Service data from Public Health England, 
and Office of National Statistics (ONS) death registration data. 
The data flow from the other data sources is similar to the one described for the CPRD 
GOLD primary care database. Data from the external sources is sent to CPRD, 
alongside a link identifier, at the same time that identifiable patient data (NHS number, 
date of birth, postcode, gender and link identifier) is sent to a trusted third party (NHS 
Digital). The trusted third party then links the data of the two datasets, and generates 
the IDs that allow the sources of data to be linked. Once the process is completed, the 
identifiers are provided to CPRD, allowing for in-house linkage of the data [220]. 
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Figure 4.2   Data flow for primary care data linkage. Figure from [220]; reproduced under the 
terms of a CC BY license. 
 
The linkage of the data is done using deterministic methods, involving eight steps with 
decreasing specificity [220]. The first step involving matching on exact NHS number, 
gender, date of birth and postcode; patients who do not match on all of these 
characteristics between the two databases are considered for the subsequent steps. In 
the second step, the criterion for post code match is dropped, and during the following 
five steps the linkage is attempted after removing one or more variables. The last step 
involves searching for the same exact NHS number only [220]. Linkage between the 
CPRD GOLD June 2018 version and HES showed that over 95% of the patients 
eligible for linkage are linked within the first two steps (67.6% in the first, and 28.7% in 
the second). 
It should be noted that linkage is only available for GP practices geographically located 
in England and that consented to take part in the linkage scheme (80% of the practices 
in England, 60% of those in the UK). In the practices participating in the linkage 
scheme, patients can opt out of having their data linked to other sources of data. 
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4.3 Hospital Episodes Statistics, Admitted Patient Care 
The HES database includes information on all contacts with NHS hospitals in England, 
including outpatients appointments, hospitalizations and emergency visits [221]. All 
patients receiving care in NHS Clinical Commissioning Groups (CCGs) in England are 
present in HES, including private patients treated in the NHS, residents outside of 
England treated in England, and care outside of the NHS but funded by the NHS [221]. 
This database is maintained by NHS Digital, and extraction from the main database 
occurs on a monthly basis [221]. There are different versions of the database, which 
differ on the type of contact with the hospital: accident and emergency attendance, 
outpatient appointments and attendances, critical care, and admitted patient care 
(APC); the latter includes inpatients and day case admissions to the hospital [221]. 
The research in this thesis used data from the HES-APC database. Data on APC have 
been collected since 1989, and are available for linkage with CPRD GOLD primary 
care data from 1997 onwards. In this thesis, HES-APC set 16 data were used linked to 
the CPRD GOLD primary care database, covering the period between April 1997 and 
December 2017 [222]. The linkage process has been described before (see section 
4.2.5). Patients in the HES-APC database may not be eligible for linkage with CPRD 
primary care data, as they may live outside England and attended care in England, or 
have invalid identifiers for linkage. Source files were available identifying each patients’ 
eligibility for linkage.  
The data in the HES-APC are organized by hospitalisations and episodes. 
Hospitalisations are defined by the period between admission and discharge from the 
hospital [222]. Episodes are defined by the period during which a patient is under 
continuous care of one consultant in one health care institution [222]. Patients may be 
transferred to the care of another consultant during the same hospital stay, generating 
another episode within the same hospitalisation [222]. Each episode may be recorded 
with up to 20 diagnosis, which are coded using the International Statistical 
Classification of Diseases and Related Health Problems, 10th revision (ICD-10) [223]. 
The data from this database were used to identify outcomes of self-harm, which have 
been described as imperfectly recorded in the CPRD GOLD primary care database 
[224]. 
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4.4 Index of Multiple Deprivation 
The Index of Multiple Deprivation (IMD) is a widely used measure of relative 
deprivation in England, and similar measures are available for Wales [225], Scotland 
[226] and Northern Ireland [227]. This measure was used to account for the potential 
confounding effect of socio-economic status (vide Chapters 6 and 7). 
The IMD is an ecological measure based on the premise that deprivation can be 
measured by different dimensions at small area level, and that individuals living in 
these areas share these dimensions of deprivation [228].  
The IMD is calculated for small geographical areas including approximately 1,500 
residents, which are known as Lower-layer Super Output Areas (LSOA). Based on the 
2011 Census, there were 32,844 LSOA in England. Mathematically, the IMD is 
calculated by using a set of indicators (at LSOA level) to produce information for seven 
domain indices that are related to material deprivation (income deprivation; 
employment deprivation; education, skills and training deprivation; health deprivation 
and disability; crime; barriers to housing and services; and living environment 
deprivation) [228]. The data from these seven domains are combined using specified 
weights to produce a single measure for each LSOA. The 32,844 LSOA are then 
sorted by measure of deprivation, and assigned a rank from one to 32,844, creating a 
relative measure of deprivation. For research purposes, IMD is typically categorised in 
percentile-based groups (e.g. quintiles) [228]. The IMD has been estimated 
periodically, and the most recent version (2015) has been used for this thesis. 
All GP practices contributing with data to the CPRD GOLD primary care database can 
be assigned IMD rank based on the GP practice post-code. This has been used in 
several studies as a proxy measure for socio-economic status at individual level 
because it is available for all patients, even though the ecological fallacy might apply 
(i.e. the individual experience may be different that the group). IMD based on the LSOA 
of the individual patient’s residential address allows for a finer adjustment for 
confounding by socio-economic status, even though it is still based on area and 
therefore may not correspond to the patient’s true socio-economic status. IMD for 
patient postcode has the disadvantage of only being available for patients in England 
and whose data are eligible for linkage. 
Data from the IMD at practice level were used in the analyses presented in Chapters 6 
and 7, to adjust for the potential confounding effect of deprivation on the associations 
between breast cancer survivorship and adverse mental health outcomes and quality of 
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life. Patient level IMD were limited to patients eligible for linkage and used in sensitivity 
analyses only. 
4.5 Office for National Statistics mortality data 
The Office for National Statistics (ONS) mortality data include all deaths occurring in 
the UK, and are the basis of the official mortality statistics issued on behalf of the UK 
government [229]. In the UK, by law, all deaths must be registered with the General 
Register Office within five days (8 in Scotland), and to do so, one needs to provide 
either a Medical Certificate of Cause of Death issued by the attending doctor (most 
cases), or permission from the coroner to report the death, if that has been reported to 
a coroner [230]. Cremation or burial are not allowed before death registration [230].  
The ONS mortality data include information entered in the death certificate by the 
doctor attending the deceased. This includes the primary cause of death, which is 
defined by the World Health Organization as ‘the disease or injury which initiated the 
train of morbid events leading directly to death, or the circumstances of the accident or 
violence which produced the fatal injury’ [231], and space for up to 15 contributory 
causes of death.  
Some deaths are referred to a coroner for investigation. Reasons for this include an 
unknown cause of death, suspicious or violent causes of death, possible suicide, 
among others [229]. The rules specify that the certifying doctor must have seen the 
deceased during the last two weeks of life to complete a certificate, otherwise it has to 
be referred to a coroner [229]. Deaths referred to the coroner are subsequently 
investigated, and assigned a primary cause of death, using post-mortem examinations 
to ascertain whether it was a natural death if needed [229]. In cases where a natural 
death cannot be unequivocally ascertained, there is a coroner’s inquest and the 
primary cause of death, if ascertained, is registered later [229]. 
To assign a primary cause of death, the text of the death certificate is converted to ICD 
codes, using computerised algorithms [229]. Since 2010, the data have been coded 
using ICD-10 codes, with ICD-9 codes being used prior to that [223, 232]. 
Data on cause-specific deaths were used in this thesis to define suicide (one of the 
outcomes of interest, vide Chapter 6), which is poorly captured in the CPRD GOLD 
primary care database [224]. 
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4.6  Patient-reported outcomes 
HRQoL refers to how a patient perceives their overall health status, and is a 
multidimensional construct that encompasses physical, psychological, social and 
spiritual dimensions of well-being [233, 234]. Standard methods for HRQoL 
assessment involve collecting information directly from the patients using validated 
questionnaires [235]. A similar approach was used in this thesis. The following 
paragraphs described the scales that were used the study of patient-reported 
outcomes that assessed quality of life and symptoms of anxiety and depression.  
4.6.1 Quality of Life 
Ideally, a tool to measure HRQoL would include items for several dimensions of quality 
of life (e.g. physical, emotional, social, role performance, pain and other symptoms 
relevant to the patient population). In addition, the tools should produce the same 
results on repeated use of the instrument (reliability), measure the concept they intend 
to measure (validity), provide different results when circumstances change (sensitivity 
to change), be appropriate to the question being assessed (appropriateness to the 
question) and have the potential for clinical interpretability (practicality) [236, 237]. 
Several tools have been used to assess HRQoL in breast cancer survivors [238]. Some 
tools were developed to assess HRQoL during the main treatments for cancer, and 
include items that may not apply to long-term survivors (e.g. nausea secondary to 
cytotoxic drugs), besides lacking items that are specific to cancer survivors’ long-term 
concerns such as fear of cancer recurrence. Recognising the need for tools that 
address concerns beyond the treatment phase of the disease, researchers have 
developed disease-specific tools specifically for long-term cancer survivors [239]. 
Chopra et al conducted a systematic review of validated quality of life instruments that 
have been used in studies of breast cancer survivors [239]. 10 instruments were 
identified; their properties are listed in Table 4.2 [239]. Most scales have been shown to 
have good reliability and validity, but few were ever tested for sensitivity to changes 
(responsiveness). This is an important disadvantage because breast cancer 
survivorship is a journey, and it is important that tools are able to detect changes in 
HRQoL [239]. 
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Table 4.2 Instruments identified by Chopra et al. as having been used to assess HRQoL in 
samples of breast cancer survivors, with respective domains and psychometric properties. 
Table adapted from [237]; reproduced under the terms of a CC BY license. 
       
Instrument  HRQoL domain  Properties 
  Physical Mental Social Spiritual  Reliability Validity† Responsiveness 
BIRS       Internal 
consistency: 
0.94 
Convergent & 
divergent 
Not Reported 
CARES-SF       Internal 
consistency:  
0.85-0.61 
Concurrent Not Reported 
EORTC 
QLQ-30 
      Internal 
consistency 
>0.70 
Content, 
concurrent, 
discriminant 
Not Reported 
EORTC 
QLQ-BR23 
      Internal 
consistency: 
0.46-0.94 
Content, 
construct, 
criterion-related
Responsiveness in 
side effects & body 
image 
QLI-CV       Internal 
consistency: 
0.95 
Concurrent 
(criterion 
related, r=0.80), 
construct. 
Not Reported 
FACT-B       Internal 
consistency: 
0.90 
Test-
retest=0.85 
Content, 
construct, 
concurrent 
(r=0.87), 
divergent, 
known group 
Sensitive to 2-month 
changes  
FACT-G       Internal 
consistency: 
0.89 
Test-
retest=0.92 
Content, 
construct, 
divergent, 
known group. 
Not Reported 
FACIT-SP       Internal 
consistency: 
0.81-0.88 
Discriminant, 
convergent 
Not Reported 
QOL-CS       Internal 
consistency: 
0.93 
Test-retest: 
0.89 
Content, 
concurrent 
(r=0.78), 
predictive, 
construct, 
discriminant 
Not Reported 
QLACS       Internal 
consistency: 
generic=0.95; 
cancer-
specific=0.98 
Concurrent, 
retrospective 
Change in health 
status 
BIRS = Body Image and Relationship Scale; CARES-SF = Cancer Rehabilitation Evaluation System Cancer -Short 
Form; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer; EORTC QLQ-BR23 = 
European Organization for Research and Treatment of Cancer - Breast module; QLI-CV = Ferrans and Powers’s 
Quality of Life Index -Cancer Version; FACT-B = Functional Assessment of Cancer Therapy-Breast; FACT-G = 
Functional Assessment of Cancer Therapy-General; FACIT-SP = Functional Assessment of Chronic Illness Therapy- 
Spiritual Well Being Scale; QOL-CS = Quality of life-Cancer Survivor; QLACS = Quality of Life-Cancer Survivors. 
 
† Construct validity assesses if a test measures what it aims to measure; it is composed of convergent and discriminant 
validity. Convergent validity refers to how well a scale is related to other measures of the same construct. Discriminant 
validity aims to assess that variables that should not be associated with a given factor, are found to not be associated 
in the study. Divergent validity aims to establish how one concept is different from the others included in the scale. 
Concurrent validity refers to the performance of a test against another test that has been previously validated. 
          
          
Of the scales that addressed HRQoL specifically in cancer survivors beyond the 
treatment phase, the Quality of Life in Adult Cancer Survivors Scale (QLACS) [240] 
showed good validity, reliability and responsiveness compared to the other scales. In 
addition, it was one of the only three instruments that included items for physical, 
mental, social and spiritual domains of HRQoL [239]. Further investigation showed that 
the QLACS scale was developed to take into account the specific needs of long-term 
cancer survivors (≥5 years), including issues that continue after treatment, new issues 
111
112 
 
that arise during the period post-cancer, late physical effects of the cancer treatments 
and positive aspects of surviving to cancer [240]. The QLACS scale has also been 
used to evaluate HRQoL in a sample of early post-treatment (18-24 months) breast 
cancer survivors [241]. This scale was therefore chosen to assess HRQoL in this 
thesis. 
The QLACS scale includes 47 items, divided between seven generic and five cancer-
specific domains (specific domains shown in Table 4.3) [240]. Answers to the QLACS 
scale are provided on an ordinal Likert-type of scale, with values for individual items 
ranging from 1 to 7. Breast cancer survivors were asked to reply to all 47 items. 
Women who never had cancer replied to the 28 items of the generic domains only. 
 
Table 4.3 Items of the Quality of Life in Adult Cancer Survivors scale grouped by domain.  
 
Generic domains 
 Negative feelings 
  19 Bothered by mood swings 
  7   Felt blue or depressed 
  9   Worried about little things 
  24 Felt anxious 
 Positive feelings 
  8   Enjoyed life 
  28 Content with life 
  6   Felt happy 
  22 Had a positive outlook on life 
 Cognitive problems 
  3   Bothered by having a short attention span 
  4   Had trouble remembering things 
  2   Difficulty doing things requiring concentration 
  23 Bothered by forgetting what started to do 
 Pain 
  13 Bothered by pain preventing activities 
  17 Mood disrupted by pain or its treatment 
  27 Pain interfered with social activities 
  21 Had aches or pains 
 Sexual interest/ function 
  16 Lacked interest in sex 
  26 Avoided sexual activity 
  12 Dissatisfied with sex life 
  10 Bothered by inability to function sexually 
 Energy/fatigue 
  11 Lacked energy to do things wanted to 
  14 Felt tired a lot 
  1 Had energy to do things wanted to do 
  5 Felt fatigued 
 Social avoidance 
  18 Avoided social gatherings 
  20 Avoided friends 
  25 Reluctant to meet new people 
  15 Reluctant to start new relationships 
  (Continued) 
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Table 4.3 Items of the Quality of Life in Adult Cancer Survivors scale grouped by domain.  
 
Cancer-specific domains 
 Financial problems 
  43 Had money problems from cancer 
  45 Financial problems from loss of income due to cancer 
  30 Financial problems from cost of cancer surgery or treatment 
  37 Problems with insurance because of cancer 
 Benefits of cancer 
  40 Cancer helped recognize what important in life 
  41 Better able to deal with stress because of cancer 
  32 Cancer helped cope better w/problems 
  29 Appreciated life more because of cancer 
 Distress-family 
  34 Worried whether family had cancer causing genes 
  31 Worried family members were at risk for cancer 
  42 Worried family should have genetic tests - cancer 
 Appearance 
  35 Felt unattractive because of cancer or its treatment 
  33 Self-conscious about appearance because of cancer 
  44 Felt treated differently because of changes in appearance 
  38 Bothered by hair loss from cancer treatments 
 Distress-recurrence 
  39 Worried about cancer coming back 
  46 When felt pain, worried it was cancer again 
  36 Worried about dying from cancer 
  47 Preoccupied with concerns about cancer 
4.6.2 Symptoms of anxiety and depression 
Symptoms of anxiety and depression were assessed with the Hospital Anxiety and 
Depression Scale (HADS) [242]. This scale has been widely used in samples of the 
general population as well as hospitalized patients, as it excludes somatic symptoms of 
anxiety/depression that may be disease manifestations. This scale has been validated 
for use in primary care [243] and was used in primary care studies in the UK [244-246]. 
HADS is a 14-item self-reported screening tool capturing anxiety and depressive 
symptoms in the past week. It contains two subscales, one for anxiety (HADS-A) and 
another for depression (HADS-D), with seven items each [242]. The scale then uses 
cut-off points to identify patients who are likely to have clinically relevant symptoms of 
depression and anxiety. 
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4.7 Demographic data 
Information on education, ethnicity and living arrangements (as a proxy for social 
support) were collected directly from the patients alongside the patient-reported 
outcomes, as this information is known to be incompletely recorded in the patients’ 
EHR. Education was evaluated by qualifications held (up to GCSEs, O levels, or 
equivalent; A levels or equivalent; undergraduate degree; post-graduate degree; trade, 
technical or vocational training). Ethnicity categories were based on the 2011 census 
categories, without sub-specification of the White and Asian categories (White; 
Asian/Asian British; Black/African/Caribbean/Black British; Mixed/Multiple ethnic 
groups; Other ethnic group). Living arrangements options were: living with 
partner/spouse; living with family/friends; living alone; in a long term care facility; other). 
4.8 Clinical data 
Information regarding treatments received for breast cancer, stage of the disease at 
diagnosis, current status of the disease and menopausal status are also sub optimally 
reported in the EHRs. A questionnaire was therefore used to collect information directly 
from the patients.  
4.9 Data collection procedures 
The operational aspects of my study on patient-reported outcomes were conducted in 
collaboration with CPRD, to enable active data collection from CPRD participants 
(study protocol in Appendix 4). The Interventional Research Team is able to liaise with 
primary care practices actively contributing with data to the CPRD GOLD primary care 
database, and holds both CPRD GOLD and InPS Vision patient identifiers. 
At the beginning of the study, the Interventional Research Team at CPRD identified a 
list of 253 GP practices that were actively contributing with data to CPRD in December 
of 2018, and invited them to participate in the study by email and post. The 
Interventional Research Team sent a further reminder to all those that did not reply. 
I generated lists of potentially eligible patients from each GP practice using data from 
the CPRD GOLD primary care database, and passed these on to the Interventional 
Research Team at CPRD.  
Practices that agreed to participate in the study were sent the list of potentially eligible 
patients from their practice, and asked to confirm each patient’s eligibility. A 
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compensatory payment of £40 per list checked was provided in line with common 
practice for other studies at CPRD. 
Upon receiving a list of eligible patients back fro the GPs, the Interventional Research 
Team at CPRD prepared packs containing all materials to be sent to the patients, and 
sent these by post to the GP practice. Each questionnaire included an InPS Vision 
software identifier, referring to the patient to be sent. 
At the GP practice, members of staff used the InPS Vision software identify the 
patient’s name and address, added these to the respective envelope, and posted these 
out to the patients. 
Women received in their home address the envelope sent by their primary care 
practice, which contained an invitation letter, study participant information sheet, 
anonymised questionnaires and a pre-paid envelope to return the questionnaires. The 
envelopes were pre-addressed to the Interventional Research Team at CPRD. 
Once the completed questionnaires were received at CPRD, the Interventional 
Research Team replaced the InPS Vision software identifier with the CPRD GOLD 
patient identifier, ensured that no identifiable information had been included, and sent 
the scanned questionnaires to me for data entry and analysis. 
The data in the questionnaire were entered, cleaned and analysed. A broad description 
of the methods, and the full results of this study are reported in Chapters 6, 7 and 8. 
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4.10 Summary 
• The research in this thesis is largely based on data stored in the CPRD GOLD 
primary care database. This is one of the largest databases of primary care 
electronic health records in the world, with data for >18.6 million patients from 
over 760 GP practices in the whole UK.  
 
•  Information in the CPRD GOLD primary care database comes directly from GP 
practices that use InPS Vision software to manage patient records. The data 
are recorded during consultations by the patients’ GP using Read codes, a 
clinical terminology that captures a wide range of information including 
symptoms, diagnoses, social characteristics, among others. 
 
• Major strengths of the UK CPRD GOLD primary care database are the 
prospective nature of the data routinely collected at the point of patient care, the 
representativeness of the data in terms of age, sex and ethnicity of the broad 
UK population. 
 
• Weaknesses of this data source include the lack of geographical 
representativeness, the potential for missing data, and misclassification of 
exposures and outcomes due to the lack of validated definitions of several 
conditions. Even though the validity of outcomes defined in the CPRD GOLD 
primary care database has been generally high, the variation by group of 
diseases warrants consideration. 
 
• The CPRD GOLD primary care database can be linked to other sources of data 
using deterministic methods. The research in Chapter 6 includes analyses of 
primary care data linked to HES-APC, practice- and patient-level linked IMD, 
and ONS mortality data. 
 
• Data on patient-reported outcomes were collected with collaboration with the 
Interventional Studies Team at CPRD and the patients’ primary care practices. 
 
• HRQoL was evaluated with the QLACS, which has been developed to take into 
account the specific needs of long-term cancer survivors. It includes 47 items, 
divided between seven generic and five cancer-specific domains. 
 
• Depressive and anxiety symptoms were assessed with HADS. This is a 14-item 
self-reported screening tool addressing symptoms in the past week. 
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5 Review of the identification of mental health and quality of 
life-related outcomes in primary care databases in the UK 
5.1 Introduction 
Chapter 5 directly addresses Objective 2 of this thesis (i.e. to systematically review the 
strategies used to identify adverse mental health outcome in studies that used EHRs 
from primary care databases in the UK). This chapter arose from the necessity to better 
understand the definition of mental health conditions in CPRD using codelists. The 
CPRD GOLD primary care database contains a vast amount of information primarily 
collected to support patient care, and its use for research purposes needs careful 
consideration of the completeness and accuracy of the data. This systematic review 
aimed to summarise the lists of Read codes used in studies that looked at these 
outcomes before, as well as gather information on the results from validation studies 
carried out, and the range of clinical conditions that authors included in their definitions 
of the outcomes (e.g. bipolar disorder in depression studies). In addition to mental 
health outcomes selected from Chapter 3, I also reviewed studies of pain and fatigue, 
because these conditions affect a large proportion of breast cancer survivors (as 
described in Chapter 1) and are relevant to the HRQoL-related objectives in this thesis. 
The definition of the outcomes in the studies presented in Chapter 6, 7 and 8 were 
informed by this systematic review. 
5.2 Systematic review protocol 
The systematic review protocol is included in Appendix 2, as it was included in the 
supplementary materials to the paper (see below).  
5.3 Article 
The results of the systematic review were reported in an article that has been published 
in a peer-reviewed scientific journal. The article is provided in the following pages; the 
lengthy supplementary materials referred to in this systematic review paper are 
provided in Appendix 2 of this thesis. 
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AbstrACt
Objectives To summarise the definitions and 
combinations of codes used to identify outcomes of 
anxiety, depression, fatigue, cognitive dysfunction 
(including mild cognitive dysfunction and dementia), sexual 
dysfunction, pain, sleep disorders, and fatal and non-fatal 
self-harm in studies using electronic health records from 
primary care databases in the UK.
Design Systematic review.
Data sources Medline, Embase and lists of publications 
of the main primary care databases in the UK.
Eligibility criteria Included data from a UK primary care 
database and studied outcome(s) of interest.
Data extraction and synthesis We abstracted 
information on the outcomes definition and codelists. 
When necessary, authors were contacted to request 
codelists.
results 120 studies were eligible. Codelists were 
available for 17/42 studies of depression; 21/41 studies of 
fatal and non-fatal self-harm; 17/27 studies of dementia/
cognitive dysfunction; 5/12 studies of anxiety; 4/8 studies 
of pain; 3/6 studies of fatigue and sexual dysfunction; 1/2 
studies of sleep disorders. Depression was most often 
defined using codes for diagnoses (37/42 studies) and/or 
antidepressants prescriptions (21/42 studies); six studies 
reported including symptoms in their definition. Anxiety 
was defined with codes for diagnoses (12/12 studies); four 
studies also reported including symptoms. Fatal self-harm 
was ascertained in primary care data linked to the Office 
for National Statistics mortality database in nine studies. 
Most studies of cognitive dysfunction included Alzheimer’s 
disease, and vascular and frontotemporal dementia. 
Fatigue definitions varied little, including chronic fatigue 
syndrome, neurasthenia and postviral fatigue syndrome. 
All studies of sexual dysfunction focused on male 
conditions, principally erectile dysfunction. Sleep disorders 
included insomnia and hypersomnia. There was substantial 
variability in the codelists; validation was carried out 
i21/120 studies.
Conclusions There is a need for standardised definitions 
and validated list of codes to assess mental health and 
quality of life outcomes in primary care databases in the UK.
IntrODuCtIOn
Primary care databases of electronic health 
records (EHRs) in the UK such as The Clin-
ical Practice Research Datalink (CPRD), 
QResearch or The Health Improvement 
Network (THIN) have been widely used to 
study mental health outcomes such as depres-
sion,1 2 and other key aspects of quality of 
life (QoL), such as fatigue and pain,3 4 even 
though the identification of patients with 
these conditions is not straightforward.
Strategies to identify patients with a given 
condition in the EHRs typically include gener-
ating lists of relevant codes, then searching 
the patients’ record for these codes to identify 
symptoms, diagnoses, referrals, appointments 
for disease management and monitoring, 
and/or prescriptions of interest.5 The process 
of developing a list of codes of interest, and 
deciding how to apply them, may be subjec-
tive. For example, a study on the selection of 
codes for stroke, a relatively well-defined clin-
ical outcome, showed that researchers with 
clinical and epidemiological experience may 
have differing interpretations of the relevance 
of each code.6 A systematic review on the iden-
tification of patients with cancer in UK primary 
care databases described several combinations 
of Read codes used across studies.7 Estimates 
of validity of diagnoses in these databases 
have been generally high across disease 
types,8 9 but the heterogeneity in the codelists 
raises issues of misclassification, and hampers 
strengths and limitations of this study
 ► Comprehensive systematic review of the literature 
aiming at describing the definitions and combination 
of codes used to identify outcomes of mental health 
and quality of life in electronic health records data-
bases in the UK.
 ► Potential for error in the selection of the eligible 
studies minimised by duplication of the screening.
 ► The authors of the original studies were contacted to 
obtain the list of Read codes used when these were 
not publicly available.
 ► We only considered definitions of study outcomes, 
and did not consider studies where mental health or 
quality of life variables were covariates or exposure 
variables, limiting the generalisability of our results 
to these other contexts.
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the comparability of studies using the same data to assess 
the same outcome.10 The pattern of use of the codes by 
the general practitioners (GPs) also needs consideration. 
For example, in recording depression, it has been shown 
that GPs have switched from diagnostic to symptom codes 
in recent years11; this may have a large impact on outcome 
definitions based around diagnostic codes. In addition, 
outcome definitions using prescription data may lead to 
misclassification where drugs have multiple indications: for 
example, sertraline, paroxetine or escitalopram, among 
the most commonly used antidepressants, are also first-line 
treatments for generalised anxiety disorder12; and amitrip-
tyline, a tricyclic antidepressant, is also a first-line treatment 
for neuropathic pain.13
Given the broad interest in mental health and QoL 
outcomes, and the strong potential for primary care data 
to contribute to studying these outcomes, our aim was to 
systematically review and summarise the strategies used to 
define such outcomes in previous studies, and the extent 
to which case definitions have been validated.
MEthODs
This review followed the a priori defined methods speci-
fied in the systematic review protocol (online supplemen-
tary appendix 1).
Outcomes of interest
The outcomes of interest for this review were: anxiety, 
depression, fatigue, cognitive dysfunction, pain, sexual 
dysfunction, sleep disorder and fatal and non-fatal self-
harm. We considered that a study provided data for cogni-
tive dysfunction when dementia, mild cognitive impairment 
or single domains of cognitive function were studied (ie, 
attention, executive function, memory, language, motor 
and social). Composite outcomes of two or more of these 
outcomes (eg, psychological impairment defined by anxiety 
or depression) were also eligible.
Information sources and search strategy
We searched MEDLINE and Embase via Ovid, from incep-
tion up to 28 June 2018, to identify studies that involved 
EHRs from primary care databases and studied one of the 
outcomes of interest (see above). The search expressions 
are provided in online supplementary appendix 1, and 
combined terms to identify primary care databases, terms 
to identify mental health and QoL outcomes, and terms 
indicating UK-based research. The CPRD, THIN and 
QResearch list of publications, available in their websites, 
were manually revised to identify additional studies. The 
lists of bibliographical references of the studies consid-
ered eligible for the review were also screened by hand to 
identify additional studies.
studies eligibility
We considered eligible the studies that used data from 
a primary care database that routinely gathers EHR data 
from primary care practices in the UK, and in which the 
outcome of interest was one of those of interest for this 
study (see list above). This included purely descriptive 
studies on the incidence/prevalence of the outcome and 
analytical studies where the condition of interest was one 
of the main outcomes of the study. Studies of primary care 
data linked to other sources of data, such as the Hospital 
Episode Statistics (HES) or the Office for National Statis-
tics (ONS) mortality data, were also considered eligible.
Abstracts from conferences were excluded, as it was 
unlikely that the methods section would provide suffi-
ciently detailed information on the definition of the 
outcomes. Studies of pain caused by infectious agents 
(eg, herpes zoster) were excluded; similarly, studies of 
sleep apnoea and narcolepsy were excluded due to their 
unlikely psychological origin.14 15 Studies reporting only 
on patterns of treatment of the conditions of interest 
were excluded, unless pharmacological treatment was 
clearly used as a proxy for the definition of the condition. 
Studies, where the outcome of interest was comorbidity, 
were also excluded. Where there were multiple studies 
from the same group of authors, we considered these 
separately, since the definition of the same outcomes 
could have been updated over time.
The eligibility of the studies was determined by two 
authors (HC and HS) reviewing all records retrieved from 
the publications databases. First, the title of each study 
was read to determine the eligibility for the review; when 
the information provided in the title was insufficient for a 
clear exclusion of the study, the study was considered for 
further assessment. Second, the full text of each study not 
previously excluded was read, in order to determine the 
eligibility. Disagreements over study eligibility between 
the two reviewers were resolved by discussion, including 
with a third researcher (KB or RW) where needed.
Data acquisition and extraction
We abstracted data on study characteristics (title, study 
design), the primary care database used, any database(s) 
linked to the primary care data, outcome(s) reported, 
definition of the outcome(s) (ie, Read codes, drug 
prescriptions, International Classification of Diseases 
(ICD) codes, etc) and any codelist available. When there 
were two or more definitions of the outcome (eg, used 
in sensitivity analyses), we abstracted all information 
but considered only the main outcome for data analysis 
in this review. We also abstracted data on whether the 
codelist had been validated, and any description related 
to the handling of past or prevalent (at baseline in cohort 
studies) episodes of these outcomes. We considered that 
the study had attempted to validate the list of codes when 
the results were compared with data from another source, 
or when outcomes were confirmed by enquiring the 
patients’ GP or by reviewing the patients’ medical record. 
The data extraction process was repeated by a second 
author (HS) for 10% of the papers included for each 
outcome, to check for reliability in the extraction process.
When a study did not provide the codelist for the 
definition of the outcome in the original publication 
or in a publicly available repository, we contacted the 
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corresponding author of the study by email seeking this 
information (online supplementary appendix 2). In the 
case of emails that could not be delivered to the corre-
sponding author, we searched the contact of another study 
author, usually the first or the last author, and addressed the 
email to her/him; if this failed to be delivered, no further 
attempt of contact was made. For all delivered emails, if no 
response was received within 2 weeks, a follow-up email was 
sent.
Data analysis
We produced descriptive tables showing the number and 
proportion of studies eligible for each outcome, by primary 
care database and codelist availability. We described, for 
each outcome, the types of codes used in the definition 
of the outcomes (eg, diagnosis codes, symptom codes, 
prescription codes). The lists of codes were also reviewed to 
assess the clinical characteristics of the disorders included 
(eg, whether mixed anxiety and depression was included 
in the definition of anxiety or depression); this was done 
by manually reviewing the list of codes to identify codes 
related to different clinical characteristics of the specific 
outcome. To describe the Read codes most commonly used 
to identify these outcomes in the data, we produced a list 
of Read codes sorted by number of studies that used the 
code. The results of the validation studies described in the 
original papers were reported descriptively.
Patient and public involvement
No patients or public were involved in the design and 
conduct of this study.
rEsults
Of 5946 records initially identified in the bibliographical 
references search, 2979 were discarded as being dupli-
cated, which left 2967 records to be assessed for eligibility 
(figure 1). The title assessment resulted in the exclusion 
of 2485 records, and 482 studies were considered for 
full-text assessment. Of these, 368 studies were excluded, 
mostly because they were abstracts from conferences or 
did not evaluate relevant outcomes. Six papers were iden-
tified from the screening of the references. A total of 120 
studies were eligible for the systematic review; a list of 
codes were obtained for nearly half of the studies. The 
definitions and combinations of codes used to identify 
Figure 1 Systematic review flow chart. CPRD, Clinical Practice Research Datalink; THIN, The Health Improvement Network. 
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mental health and QoL outcomes from UK primary care 
databases were heterogeneous for all outcomes; there was 
particular variability in the inclusion/exclusion of codes 
for symptoms of the mental disorders. Prescriptions were 
not frequently used as proxy for mental disorders. Vali-
dation efforts were rarely employed. Detailed results for 
each outcome are provided below.
Anxiety
Twelve studies had anxiety as an outcome (table 1 and 
online supplementary appendix 3 table 1); of these, two 
studied panic only.2 16 The list of codes used to identify 
outcomes of anxiety was available for 5 of the 12 studies 
(41.7%); in one study, the cases of anxiety were identified 
in CPRD data linked to HES. All 12 studies included codes 
for diagnosis of anxiety, and 4 (33.3%) included also codes 
for anxiety symptoms. Prescriptions were considered in the 
definition of the outcome in one study only (8.3%).
Of the five studies for which codelists were available, five 
included codes for generalised anxiety disorder (100%), 
four for phobia (80.0%), four for panic disorder/attacks 
(80.0%), three for mixed anxiety and depression (60.0%), 
and two for stress-related disorders (40.0%) (table 2). 
Codes for post-traumatic stress disorder and obsession-com-
pulsion were less often included (one study each, 20.0%).
Only one study reported including drugs prescriptions 
in the definition of the outcome17; this considered diaz-
epam and lorazepam only (table 3).
Two studies2 18 assessed the validity of the codelists 
(table 4). The proportion of cases confirmed was reported 
in one study: 73.5% for cases treated with anxiolytics, anti-
depressants and hypnotics, and 89.6% in those not phar-
macologically treated.18
Online supplementary appendix 4 table 1 provides the 
list of Read codes used to identify patients with anxiety 
in the eligible studies; online supplementary appendix 4 
table 2 provides the list of ICD-10 codes.
Depression
Forty-two studies identified outcomes of depression 
(table 1 and online supplementary appendix 3 table 2). 
The list of codes used to identify outcomes of depression 
was available for 17 of the 42 studies (40.5%); 2 studies 
identified cases of depression in primary care data linked 
to HES data, using ICD-10 codes. Six studies defined 
depression by proxy of antidepressants intake only; the 
remaining 36 studies described to have included codes 
for diagnoses of depression and 6 (14.3%) studies also 
considered symptoms of depression in the definition of 
the outcome. Fifteen studies (35.7%) reported having 
excluded patients with history of depression.
Of the 17 studies for which the codelists were avail-
able, 10 included codes for mixed anxiety and depression 
(58.8%), 4 for bipolar disorder (23.5%) and 3 for depres-
sion in dementia (17.6%) (table 2).
Antidepressant prescriptions, in isolation or combina-
tion with diagnostic/symptoms Read codes, were consid-
ered in the identification of patients with depression in 
21 studies (50.0%); in six studies, depression was solely 
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defined by the prescription of antidepressants (table 3). 
The list of antidepressant categories was seldom provided; 
of the studies that reported this information, selective 
serotonin reuptake inhibitors were the group most often 
considered (six studies), followed by monoamine oxidase 
inhibitors and tricyclic and related antidepressants drugs 
(three studies each).
Five studies (11.9%) assessed the performance of the 
list of codes to identify patients with depression (table 4). 
The proportion of cases confirmed was reported by two 
studies only: 83.3%19 and 89.6%.20
The list of Read codes used to identify patients with 
depression is provided in online supplementary appendix 
4 tables 3 and  4 provides the list of ICD-10 codes.
Composite outcome of anxiety and depression
Two studies provided data for composite outcomes of 
anxiety and depression (table 1 and online supplemen-
tary appendix 3 table 3). The codelist was available for 
the two studies. The studies reported including codes for 
symptoms as well as diagnosis of anxiety and depression, 
and included prescriptions of antidepressants and anti-
anxiety drugs in the definition of the outcome.
John et al21 compared the performance of 12 different 
algorithms to identify patients with anxiety and depres-
sion in the Secure Anonymised Information Linkage 
Databank; the positive predictive value of the Read codes 
for anxiety and depression diagnoses, symptoms and 
treatments, against the five-item Mental Health Inven-
tory (gold standard), varied between 61% and 76%21 
(table 4). The list of Read codes used to identify patients 
with composite outcomes of anxiety and depression is 
provided in online supplementary appendix 4 table 5.
Cognitive dysfunction (including mild cognitive dysfunction 
and dementia)
Twenty-seven studies reported outcomes of dementia or 
cognitive function (table 1 and online supplementary 
appendix 3 table 4). The codelists were available for 17 
studies (63.0%); in two studies dementia was ascertained 
in primary care data linked to other sources of data. 
All studies included codes for diagnosis of dementia or 
cognitive impairment, and six studies (22.2%) reported 
to have included also codes for symptoms of dementia. 
Twenty-one studies (77.8%) referred to have excluded 
Table 2 Clinical characteristics of the outcomes of interest 
in the studies for which the list of codes was available
Study included codes for N
% of 
total with 
code lists 
available
Anxiety 5 100.0
  Generalised anxiety disorder 5 100.0
  Panic disorder/attacks 4 80.0
  Phobia 4 80.0
  Mixed anxiety and depression 3 60.0
  Stress-related disorders 2 40.0
  Obsession-compulsion 1 20.0
  Post-traumatic stress disorder 1 20.0
Depression 17 100.0
  Unipolar depression 17 100.0
  Depression with psychotic 
symptoms
14 82.4
  Mixed anxiety and depression 10 58.8
  Bipolar disorder 4 23.5
  Depression in dementia 3 17.6
Dementia/cognitive impairment 17 100.0
  Alzheimer’s disease 13 81.3
  Vascular dementia 13 81.3
  Frontotemporal dementia 12 75.0
  Lewy bodies disease 11 68.8
  Mild cognitive impairment only 3 17.6
Fatigue 3 100.0
  Chronic fatigue syndrome/myalgic 
encephalitis
3 100.0
  Neurasthenia 3 100.0
  Post viral fatigue syndrome 3 100.0
  Fibromyalgia 2 66.7
Pain 4 100.0
  Chest pain 1 25.0
  Chronic widespread pain 1 25.0
  Musculoskeletal pain 1 25.0
  Unspecified abdominal pain 1 25.0
Sexual dysfunction (male) 3 100.0
  Erectile dysfunction 3 100.0
  Other male sexual dysfunctions 1 33.3
Sleep disorder 1 100.0
  Insomnia 1 100.0
  Hypersomnia 1 100.0
Fatal and non-fatal self-harm 21 100.0
  Completed suicide 17 80.9
  Completed suicide only 8 38.1
  Completed and attempted suicide 
only
6 28.6
Continued
Study included codes for N
% of 
total with 
code lists 
available
  Completed and attempted suicide, 
and self-harm
4 19.1
  Included deaths of undetermined 
intent
7 33.3
  Attempted suicide/self-harm 4 19.1
Table 2 Continued 
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patients with prior diagnoses of dementia from longitu-
dinal analyses.
Of the 17 studies for which the codelists were 
available, 13 reported codes for Alzheimer’s disease 
(81.3%), 13 for vascular dementia (81.3%), 12 for 
frontotemporal dementia (75.0%) and 11 for Lewy 
bodies disease (68.8%) (table 2). Three studies 
reported data for cognitive impairment without 
dementia (17.6%).
Four studies (14.8%) used prescriptions in the iden-
tification of patients with dementia; all four included 
anticholinesterases and dopaminergic agents 
(table 3).
Five studies22–26 involved validation of the list of codes; 
the proportion of cases confirmed varied between 74% 
and 100% (table 4).
The list of Read codes used in the studies is provided 
in online supplementary appendix 4 table 6; the list 
of ICD-10 codes is provided in online supplementary 
appendix 4 table 7.
Fatigue
Six studies had fatigue as the outcome (table 1 and online 
supplementary appendix 3 table 5). All studies consid-
ered codes for diagnoses of fatigue, and five studies 
also described including codes for symptoms of fatigue. 
The list of codes use to identify patients with fatigue was 
provided in three studies (50.0%).
The three studies for which the codelist was available 
included codes for chronic fatigue syndrome, neuras-
thenia and postviral fatigue syndrome (table 2). Fibromy-
algia was included in two studies (66.7%). None of the 
Table 3 Pharmacological categories used in the studies that used drug prescriptions to identify patients with the outcome of 
interest
Outcome No of studies %
Anxiety 12 100.0
  Studies of anxiety that used drugs prescriptions only 0 0.0
  Studies of anxiety that used drugs prescriptions 1 8.3
Diazepam and lorazepam 1 8.3
Depression 42 100.0
  Studies of depression that used drugs prescriptions only 6 14.3
  Studies of depression that used drugs prescriptions 21 50.0
Antidepressants, categories not further specified 15 35.7
Antidepressants, categories further specified 6 14.3
Tricyclic and related antidepressant drugs 3 7.1
Monoamine oxidase inhibitors 3 7.1
Selective serotonin reuptake inhibitors 6 14.3
Other antidepressant drugs 3 7.1
Dementia 27 100.0
  Studies of dementia that used drugs prescriptions only 0 0.0
  Studies of dementia that used drugs prescriptions 4 14.8
Anticholinesterases 4 14.8
Dopaminergic drugs 4 14.8
Pain 8 100.0
  Studies of pain that used drugs prescriptions only 2 25.0
  Studies of pain that used drugs prescriptions 2 25.0
Analgesics, not otherwise specified 2 25.0
Antidepressants 2 25.0
Antiepileptics 2 25.0
Anaesthetics 2 25.0
Sexual dysfunction (male) 6 100.0
  Studies of sexual dysfunction that used drugs prescriptions only 1 16.7
  Studies of sexual dysfunction that used drugs prescriptions 3 50.0
Phosphodiesterase type-5 inhibitors 2 33.3
Prostaglandin analogues and prostamides 1 16.7
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Table 4 Methods and results of the validation of the outcomes reported in the original studies
Outcome and study 
authors Validation method
# case validations 
completed/# case 
validations attempted % of cases confirmed
Anxiety
Martín-Merino et al, 201018 GP questionnaire 135/140 Among pharmacologically 
treated: 73.5%;
Among not pharmacologically 
treated: 89.6%.
Meier et al, 20042 Record review nr/nr nr
Depression
Becker, 2011 Sensitivity analysis with different 
definitions
nr/nr nr
Hagberg, 2016 Record review nr/nr nr
Martín-Merino et al, 201018 GP questionnaire 135/140 89.6%
Meier et al, 20042 Record review nr/nr nr
Yang et al, 200319 Record review 30/nr 83.3%
Anxiety and depression (composite outcome)
John, 2016 Compared 12 EHR algorithms to results 
of the Mental Health Inventory , a 
subscale of SF-36
2799* Between 61% and 76%, 
depending on the algorithm.
Dementia/cognitive impairment
Imfeld et al, 2013 and 
Imfeld et al, 201522 23
GP questionnaire nr/120 Alzheimer’s disease: 79%;
Vascular dementia: 74%.
Dunn et al, 200524 GP asked to confirm diagnosis 50/200 100%
Dunn et al, 200526 GP questionnaire 95/~100 83%
Strom et al, 201525 GP questionnaire 86/100 88.4%
Strom et al, 201525 Review of free text 1047/1048 1.5% patients excluded as 
not having the diagnosis; 
42.4% confirmed as having 
definite memory loss, 36.8% 
possible memory loss, 3.2% 
undetermined and 16.0% 
unknown.
Pain
Hall et al, 20134 GP questionnaire 48/54 56%
Mansfield et al, 201727 EHR data linked to self-reported pain 
status collected by postal questionnaire
1780* 97%
Becker, 2008 GP questionnaire 176/200 86.4%
Self-harm
Thomas et al 201329 Comparison of cases of suicide and 
self-harm identified in CPRD with 
Read codes, with the cases identified 
in CPRD data linked to HES data, and 
published self-harm incidence data.
74236* 68.4%
Suicide (attempted and completed)
Hagberg, 2016 Record review nr/nr nr
Haste, 1998 GP asked to confirm suicides 77% of uncertain 
deaths/nr
82%
Jick, 1995 Record review nr/nr nr
Meier et al, 20042 Record review nr/nr nr
Continued
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studies assessed the validity of the list of the codes. The 
list of Read codes used in the studies of fatigue is available 
in online supplementary appendix 4 table 8.
Pain
Pain was the outcome in eight studies (table 1 and online 
supplementary appendix 3 table 6). The list of codes 
was available for four of the eight studies. Of these four 
studies, three looked at pain by body site (ie, chest, abdom-
inal, musculoskeletal pain), one study studied widespread 
body pain (table 2). Two studies included drugs in the 
identification of patients with pain; all considered antiepi-
leptics (in the absence of codes for an epilepsy diagnosis), 
anaesthetics, antidepressants and analgesics (table 3).
Three studies validated the list of patients selected with 
the codelist (table 4). The proportion of cases confirmed 
varied between 56% and 86.4%. One study compared 
pain recorded in the EHR with pain reported in a survey; 
in 97% of the self-reported cases of pain, there was an 
entry in the EHR.27
Online supplementary appendix 4 table 9 provides the 
list of codes used in the original studies.
sexual dysfunction
Six studies had sexual dysfunction as an outcome, all 
of which focused on male sexual dysfunction (table 1, 
online supplementary appendix 3 table 7). Three studies 
provided codelists (50.0%). Of these, all included codes 
for erectile dysfunction and one study included codes for 
other male sexual dysfunctions (table 2). Three studies 
included considered the prescription of drugs sufficient 
to ascertain the outcome; two studies considered phos-
phodiesterase type-5 inhibitors (table 3). No study vali-
dated the list of codes used. The list of Read codes used in 
the original studies is available in online supplementary 
appendix 4 table 10.
sleep disorders
Two studies were eligible for sleep disorders (table 1, 
online supplementary appendix 3 table 8); the two studies 
included diagnoses of insomnia, and one included hyper-
somnia as well (50%) (table 2). The list of codes was avail-
able for one study. No validation was reported. Online 
supplementary appendix 4 table 11 provides the list of 
Read codes used in the original study.
Fatal and non-fatal self-harm
Forty-one studies had outcomes related to fatal and 
non-fatal self-harm (table 1 and online supplementary 
appendix 3 table 9). The list of codes used to define the 
outcomes was available for 21 studies (51.2%); 9 studies 
reported using ICD-10 codes.
Of the 21 studies for which the codelist was available, 
17 studies (80.9%) included completed suicide, while 
4 studies focused on attempted suicide only (19.1%). 
Of the 17 studies including completed suicide as an 
outcome, eight reported only completed suicides, six 
considered completed and attempted suicides and four 
included complete and attempted suicide, as well as self-
harm (table 2). All studies where outcomes were identi-
fied using primary care data linked to ONS mortality data 
(gold standard) considered deaths recorded as of unde-
termined intent in the definition of suicide.
Nine studies involved some method of validation of 
the list of cases identified via code search (table 4). Four 
studies referred to have revised the clinical record of the 
patient to determine the final outcome and two studies 
asked the GPs to confirm the events. The proportion of 
Outcome and study 
authors Validation method
# case validations 
completed/# case 
validations attempted % of cases confirmed
Schuerch, 2016 Outcomes identified in CPRD were 
compared with those identified in CPRD 
linked to HES and ONS data.
nr/nr Compared with CPRD data, the 
frequency of the outcomes in 
linked data was approximately 
three times higher.
Yang et al, 200319 Record review 30/nr 83.3%
Suicide (completed)
Arana, 2010 GP questionnaire and record review nr/132 97%
Arana, 2010 GP questionnaire and record review nr/86 87%
Hall, 200928 GP questionnaire and record review 33/33 21.2%
Thomas et al, 201329 Comparison of cases of suicide and 
self-harm identified in CPRD with 
Read codes, with the cases identified 
in CPRD data linked to ONS mortality 
data, and national suicide rates.
1767* 59.7% for men;
46.0% for women.
*Validation attempted and completed for all patients identified in electronic health records database.
CPRD, Clinical Practice Research Datalink; EHR, electronic health record; GP, general practitioner; HES, Hospital Episode Statistics; nr, not 
reported; ONS, Office for National Statistics; SF-36, 36-item Short Form Health Survey. 
Table 4 Continued 
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cases confirmed varied between 21.2% and 97%. Hall28 
assessed the validity of cause of death recording in the 
THIN primary care database through search of the free 
text and death certificate review; the underlying cause of 
death registered in the death certificate was listed as the 
cause of death in the EHR in 70% of the cases. Thomas et 
al29 compared the ascertainment of cases of suicide and 
self-harm using Read codes in CPRD, with those ascer-
tained when data from HES and ONS mortality data were 
available. 26.1% of the cases of suicide identified in the 
ONS mortality data were registered in the CPRD primary 
care database. HES was considered the gold standard for 
self-harm; 68.4% of the cases of self-harm in HES were 
identified as such in CPRD.
Online supplementary appendix 4 table 12 provides the 
list of Read codes used to identify outcomes of fatal and 
non-fatal self-harm in primary care data; online supple-
mentary appendix 4 table 13 includes the lists of ICD-10 
codes using in studies of linked data.
DIsCussIOn
results overview
This review summarised the definitions and combi-
nations of codes used to identify outcomes of anxiety, 
depression, dementia and cognitive impairment, fatigue, 
pain, male sexual dysfunction, sleep disorder and self-in-
jurious behaviour in primary care databases of patients 
in the UK. The list of codes used in the original studies 
was obtained for approximately half of the papers; the 
lack of detailed information on the definition of the 
outcomes in most studies raises important questions as 
to whether studies can be replicated by others. In the 
studies where the codelist was available, for all outcomes, 
there was substantial heterogeneity in the type of codes 
included (eg, diagnoses and symptoms) and drugs 
selected to identify outcomes; for the remaining studies, 
the details provided in the original publications suggest a 
similar pattern. We also noted considerable variability in 
the clinical definition of some outcomes (eg, inclusion/
exclusion of bipolar disorders in studies of depression). 
Validation of codes used to identify these outcomes was 
rarely carried out; where done, positive predictive values 
of case definitions were variable but mostly above 80%. To 
overcome these issues in the current context of limited 
number of studies with validation efforts, it is impera-
tive that researchers develop, validate and make publicly 
available code lists for these outcomes.
strengths and limitations
This review is based on an extensive search of the studies 
involving EHRs in the UK. Errors in study selection and 
data extraction were minimised by the independent assess-
ment of the studies by two investigators. We contacted the 
authors of all original studies where the list of codes had 
not been provided in the original publication to seek this 
information; this largely increased the number of studies 
for which lists of codes were available, and contributed to 
a more detailed characterisation of the combination of 
codes used to define mental health outcomes in primary 
care databases of EHR in the UK.
However, this review has limitations. Some relevant 
studies may have been missed due to imperfect search 
terms, as there is no Medical Subject Headings (MeSH) 
term for the primary care databases, and studies could be 
potentially missed if the keywords did not appear in the 
title and abstract, or due to inaccurate indexing in the 
publications database. We attempted to minimise the risk 
of missing potential eligible studies by using broad search 
terms incorporating both indexing terms and keywords, 
two databases with different indexing systems, and an 
additional manual check of the eligible studies and list of 
bibliographical references from the main EHR databases. 
We only considered studies where mental health or QoL 
variables were the outcomes of interest, limiting gener-
alisability to other contexts. For example, we excluded 
studies where these variables were covariates because we 
expected that detailed information about covariate defi-
nitions would rarely be available. We also excluded studies 
where the mental health or QoL variable was used to 
define the patient population (eg, a study of risk of stroke 
in depressed patients), on the basis that decisions about 
how to define cases may have had quite different motiva-
tions, compared with studies where the condition was the 
outcome of the study, making case definitions difficult to 
meaningfully compare. We included studies that explicitly 
referred to using prescription data as a proxy for the defi-
nition of the condition (eg, treated depression assessed 
by proxy of antidepressant intake), but we acknowledge 
that it was not always clear to decide whether treatment 
of the condition was being used to define the condition. 
This could have resulted in a few studies erroneously 
excluded, even though this should have been minimised 
by the duplication of the search and study selection 
process by two researchers working independently, with 
discussion of all discordant results. It is unclear if the list 
of codes that could not be obtained differ in any system-
atic way to the ones obtained. Some authors expressed 
concerns over intellectual property when sharing the list 
of codes, and this may have been a bigger concern among 
those who put a lot of time and thought into their codel-
ists; on the other hand, authors who have concerns about 
the quality of their codelist may have been less willing to 
share them. Lastly, we summarised the types of codes used 
to define the outcome based on what was stated in orig-
inal studies’ methods sections (because code lists were 
not available for all studies), but this may have been inac-
curate, for example, some studies that reported in their 
methods only including diagnosis codes then provided 
code lists that appeared to also contain symptom codes.
Availability of the list of codes
The list of codes was provided in the original publica-
tions for just over a quarter of the studies. Contacting 
the authors resulted in codelists being made available 
for approximately half of the studies. For the remaining 
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studies, the authors either could not be contacted (eg, 
moved institutions, retired) or could not locate the 
relevant codelist (including for some studies where the 
paper had stated that the codelist would be available on 
request). Provision of codelists within the publication 
or in a web repository would eliminate the difficulties 
of authors having to be contacted and archived codel-
ists retrieved. Most journals currently accept codelists in 
online supplementary appendices. Codelists were hardly 
ever obtained for older studies, especially those published 
before 2000, when email addresses were not routinely 
included in the details of the corresponding authors. We 
searched for alternative contacts in these cases, but not 
always successfully.
Variability in the definition of cases and codelists
Anxiety and depression
Anxiety was often defined with diagnostic and symptoms 
codes, and in a few studies by the prescription of anxio-
lytics and hypnotics. Even though the sensitivity of symp-
toms codes for anxiety is expected to be high, the positive 
predictive value is unknown. Anxiolytics may also result 
in misclassification of the outcomes, as they are currently 
discouraged as first line of treatment for anxiety12 and 
are often prescribed for management of other conditions 
such as insomnia. No study considered antidepressants in 
the definition of anxiety even though these are currently 
used to manage anxiety12; this may have resulted in cases 
of anxiety treated with antidepressants, and where no 
Read code was available, being missed.
The inclusion/exclusion of codes for symptoms may 
have a larger impact in the definition of depression, as 
it has been shown that GPs switched from diagnostic to 
symptoms codes after the introduction of performance 
indicators in the GP contract Quality and Outcomes 
Framework in 200611 and under claims that depression 
was being overdiagnosed.30 31 Codelists solely relying on 
Read codes for diagnosis of depression are, therefore, 
likely to have low sensitivity, but the impact of including/
excluding a specific code will be variable, depending on 
how often that code is used by GPs at the point of providing 
care. In a few studies, depression was defined by proxy of 
antidepressant prescribing, alone or in combination with 
Read codes for symptoms/diagnosis. Considering anti-
depressant prescribing in the definition of depression 
has several issues. Certain types of antidepressants are 
currently used as first line of treatment for other condi-
tions, such as pain and anxiety, and the studies relying 
solely on this information will be affected by misclassifica-
tion of the outcome; some studies took this into account 
by excluding low dose tricyclic antidepressants, usually 
prescribed for pain, from their list of codes used to define 
depression.32–34 Among the studies that did include anti-
depressants in their definition, there was heterogeneity in 
the group of antidepressants included, with some studies 
selecting only a few specific drugs commonly used for the 
treatment of depression. Studies defining depression by 
proxy of antidepressant prescribing only are likely also 
to be affected by changes in the behaviour of antide-
pressant prescribing. In 2004, the National Institute for 
Health and Care Excellence (NICE) issued guidelines 
discouraging antidepressants for mild depression,35 and 
in 2006 a performance indicator in the UK GP Quality 
and Outcomes Framework pay for performance was 
introduced for depression severity assessed with validated 
symptoms questionnaires.36 Following this measure, the 
proportion of new cases of pharmacologically treated 
depression decreased (from 73% in 2003 to 61% in 
201237), but the proportion of recurrent episodes phar-
macologically treated increased from 74.3% to 77.8%.37 
Treatment duration times with antidepressants also 
increased over time38; this may affect the number of new 
episodes of depression identified in the studies. In several 
studies, the authors chose to report separate results for 
antidepressant prescribing, without using this informa-
tion to ascertain the outcome of depression39 40; this may 
partially be due to the difficulties of ascertaining the indi-
cations for which antidepressants were prescribed. John 
et al explored the indications of antidepressants; more 
than half of the new antidepressant prescriptions were for 
depression, with increasing but low incidence of prescrip-
tions for pain and anxiety, but the authors could not iden-
tify the indication for antidepressants in 17% of the new 
prescriptions.41
Regardless of the type of codes included, authors will 
need to often choose the inclusion/exclusion of codes 
relating to the clinical profile of the patients. This may 
have a particular impact for conditions that are highly 
comorbid. For example, the code for ‘mixed anxiety 
and depression’ was sometimes used in the definition of 
anxiety and in the definition of depression; anxiety and 
depression are highly comorbid and the inclusion/exclu-
sion of these patients may have an impact on the results. 
In addition, for depression, the inclusion of codes related 
to depression in the context of bipolar disease, dementia 
and schizophrenia may raise issues as to whether it 
represents a primary depressive episode.
Part of the heterogeneity in the list of codes used to iden-
tify these outcomes may be explained by the complexity of 
these conditions and by the purpose for which these data 
are collected. Electronic healthcare data are primarily 
collected to provide patients with treatment, and distinc-
tions between diagnosis and symptoms may have less 
weight at the point of care than when researchers aim 
to define these conditions using data routinely collected.
Fatal and non-fatal self-harm
Routinely collected primary care data were shown to have 
low sensitivity to detect cases of suicide.29 Thus, record 
linkage to ONS mortality data is of interest; this has the 
advantage of including causes of death other than suicide. 
Ascertainment of the cause of death is not always straight-
forward when the death is non-natural, and several studies 
have included cases of accidents and open verdicts in 
their case definition. Open verdicts have been shown to 
include many similarities with suicides, and several are 
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later registered as suicides; these are recommended to be 
included in studies of suicide.42 Studies varied on whether 
cases of self-harm without suicidal ideation were included 
(eg, Rubino et al reviewed free text to exclude those who 
did not seem to have attempted suicide43). For self-harm, 
linkage to HES data will allow for more cases to be iden-
tified,29 even though authors must consider the balance 
between reduction of sample size and ascertainment of 
the outcome, as linkage is only available for a subset of 
patients.
Pain
The aetiology and location of pain in the studies involved 
in this review varied due to our broad inclusion criteria. 
When pharmacological treatment was included in the 
definition of pain, this was most often done with prescrip-
tions of antidepressants and antiepileptics. Antidepres-
sants such as first-generation tricyclic antidepressants 
have been used for over 30 years to manage neuropathic 
pain (eg, amitriptyline, doxepin, clomipramine and 
dosulepin).44 Antiepileptic drugs reduce neuronal excit-
ability and alleviate pain through several mechanisms.44
Other outcomes
We considered cognitive dysfunction as a composite 
outcome including studies from mild to severe impair-
ments such as those in dementia; between 10% and 
20% of the patients with mild cognitive impairment are 
expected to convert to dementia.45 46 Fewer studies had 
fatigue, sexual dysfunction and sleep disorders as the 
outcome, and no study was eligible for female sexual 
dysfunction. The definition of these outcomes varied little 
across the studies but the small numbers preclude firm 
conclusions. It has been reported that chronic fatigue 
increased prior to 2001,3 but decreased between 2001 
and 2013,47 possibly due to the introduction of diagnostic 
criteria from NICE48; in the same period, increases were 
noted in the diagnoses of fibromyalgia.47 This may reflect 
the complexity of diagnosing fatigue, which is done by 
exclusion of other causes only.48
Validation
Outcomes identified in EHRs may lack of validity: a person 
meeting the operational definition for the outcome based 
on specific codes may not have the diagnosis or vice versa. 
Only a small number of studies assessed validity in their 
studies, and this was almost always about assessing posi-
tive predictive value of the case definition, with sensitivity 
and specificity rarely explored. Of these, some studies 
only stated that validation had been carried out, but did 
not report the results, which makes the performance of 
the case definition unclear. However, the studies that 
reported results tended to show a high proportion of cases 
confirmed by their primary care physician or by further 
investigations (ie, a high positive predictive value). This 
is in accordance with the results of two systematic reviews 
that assessed the validity of the diagnostic coding within 
the CPRD primary care database.8 9 Studies in which 
identified cases were validated by the GP did not usually 
specify how this validation was done—that is, whether the 
GPs confirmed cases by consulting the EHR, referring 
to additional information, relying on memory or using 
other methods. If GPs simply checked the same EHR used 
to identify the case in the first place, resulting estimates 
of positive predictive value would be expected to be high, 
but may be misleadingly optimistic.
Implications
Mental health and QoL-related outcomes are difficult 
to identify in EHR databases; and thus, extra care needs 
to be used when defining these outcomes. The use of 
a particular code can vary between GP practices; for 
example, a study on the interpractice use of Read codes 
for diabetes showed that the most generic code was used 
in 14%–98% of the patients with diabetes in the prac-
tices.49 GPs can derive Read codes for their practice; this 
may raise issues with new codes being added over time,50 
and codelists that need to be updated. It is important that 
authors clearly document the process of selection of the 
codes, so that these are available with clear rationale if 
needed.5 Repositories of lists of codes allow researchers 
to access codelists easily. However, these repositories also 
need funding to be maintained, which limits their stability 
and consequently their use. Some studies of depression 
and dementia referred to using the Read codes recom-
mended by the Quality and Outcomes Framework36; 
these are likely to be highly specific. It is also important 
to better understand the patterns of recording of some of 
these conditions, as changes in the patterns of use of the 
codes may have impact in the list of codes chosen. The 
inclusion of codes for symptoms and prescriptions must 
consider what is known about the use of codes by GPs at 
the point of patient providing care, as data recording in 
this setting is primarily intended to support clinical care. 
Future works are needed to understand how GPs concep-
tualise mental health problems, as these are expected 
to have less stringent definitions than psychiatrists, and 
this could provide insights into more meaningful case 
definitions.
Validation of the outcomes appears to be essential to 
understand the validity of case definitions. A balance 
between sensitivity and specificity may be considered 
depending on the aim of the study5; for depression, for 
example, the inclusion of terms such as ‘low mood’ may 
increase sensitivity, at the expense of decreased speci-
ficity, as some individuals who would not fit more strin-
gent criteria for a diagnosis will be incorrectly classified 
as depressed.5 A particular challenge with validation of 
primary care-based mental health outcomes is quantifying 
false negatives, which requires linkage to a high-quality 
external source of information, to identify cases that may 
have been ‘missed’ in primary care records. The Mental 
Health Dataset, which includes individual patient records 
of adults seeking mental health services in secondary care 
and has recently been made available for linkage with 
CPRD primary care databases, represents an opportunity 
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to assess the proportion of false negatives identified with 
the code lists, at least for more severe outcomes. Until 
then, sensitivity analysis using different lists of codes 
should be done, so that results can be compared and the 
impact of using different code lists evaluated. The conse-
quences of underascertaining mental health outcomes 
are likely to depend on study design; in a cohort design 
this will not generally result in biased relative risks, 
whereas in a case–control context, a bias towards the null 
is likely. Studies might consider to use internal validation 
strategies, by assessing the proportion of patients referred 
for treatment or prescribed a relevant pharmacological 
agent.
Primary care databases of EHRs have made important 
contributions to medicine worldwide, particularly in 
the fields of infectious, respiratory and cardiovascular 
diseases. The burden of mental disorders in high-in-
come countries has increased substantially in the last 
decades,51 and more research is needed to be better 
understand these conditions. Primary care databases of 
EHRs have potential to make huge contributions to this 
area but, for this to happen, we need coordinated efforts 
across funding and research organisations to improve 
data quality. For example, if scientific journals make a 
requirement of having publicly available lists of codes, 
this would likely encourage researchers to spend more 
time defining the outcomes and potentially seek funding 
for validation studies, which in turn could increase the 
awareness of funding institutions for the importance of 
assessing data quality in projects using these data. In the 
meantime, transparency in the list of codes used to define 
these outcomes and reporting of sensitivity analysis with 
different lists of codes are key.
Despite the difficulties of assessing each separate 
outcome, we must take into account that mental health 
disorder symptoms often overlap, and is difficult to disen-
tangle what is attributable to each condition. Lastly, these 
conditions have a long period of exposure to medication 
after symptoms have disappeared, besides a high proba-
bility of relapse and recurrence,52 which may raise issues 
on whether the condition is incident or prevalent.
COnClusIOns
Detailed information about codes used to identify 
outcomes of anxiety, depression, fatigue, cognitive 
dysfunction, sexual dysfunction, pain, sleep disorders, 
and fatal and non-fatal self-harm in studies using EHRs 
from primary care databases in the UK was unavailable 
for around half of studies of these outcomes. Where 
available, there was substantial heterogeneity in the list 
of codes used to ascertain cases. Most studies did not vali-
date case definitions, though when this was done, posi-
tive predictive values were generally high. This review 
focused on common mental health disorders and QoL 
outcomes, but our conclusions are likely to be generalis-
able to other mental health outcomes. Caution is needed 
when interpreting and comparing results between 
studies, as heterogeneity in case definitions may be large. 
Future studies should fully report outcomes definitions, 
use sensitivity analysis to mitigate uncertainties about 
the impact of the case definition on studies’ reported 
outcomes, and seek to validate the list of codes used to 
identify these outcomes.
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5.4 Summary 
 
• EHRs have been extensively used to study mental health and HRQoL-related 
outcomes in the UK, despite difficulties in defining these outcomes in the data. 
• Codelists were available for 17/42 studies of depression; 21/41 studies of fatal 
and non-fatal self-harm; 17/27 studies of dementia/cognitive dysfunction; 5/12 
studies of anxiety; 4/8 studies of pain; 3/6 studies of fatigue and sexual 
dysfunction; 1/2 studies of sleep disorders. 
• Outcome definitions and codelists were heterogeneous. 21 of the 120 studies 
validated their methods; these show positive predictive values above 80%.  
• Anxiety definitions included symptoms in 33% of the studies; one study also 
considered drug prescriptions. Where codelists were available, these most often 
(80-100%) included terms for generalised anxiety disorder, panic and phobias; 
60% included terms for mixed anxiety and depression.  
• Depression definitions included prescriptions in 50% of the studies, and 
symptoms in 14%. Terms for bipolar disorder and depression in dementia were 
present in 25% and 18% of the codelists available, respectively, while terms for 
mixed anxiety and depression were present in 60%.  
• Definitions of cognitive dysfunction were often tailored to the diagnosis of 
specific types of dementia. 15% of the studies considered diagnoses and 
prescriptions of anticholinesterase and dopaminergic drugs, and one study 
reported having included symptoms of dementia in their definition.  
• Fatigue definitions included symptoms in all but one study, and varied little, 
except in the inclusion of fibromyalgia, which was done in two of the six studies 
only.  
• Fatal and non-fatal self-harm definitions included completed suicide only, 
completed and attempted suicide, and completed and attempted suicide plus 
self-harm. Completed suicide was often ascertained in primary care data linked 
to the ONS mortality data; a validated codelist was available for self-harm.  
• For the other outcomes, only two studies reported on sleep disorders, and pain 
definitions varied by the anatomical location; these were too heterogeneous to 
be meaningfully compared. No study of female sexual dysfunction was 
identified. 
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6 Quantification of the associations between breast cancer 
survivorship and adverse mental health-related outcomes: a 
population-based matched cohort study 
6.1 Introduction 
In this chapter, I used data from the UK CPRD GOLD primary care database to 
estimate the risk of adverse mental outcomes in breast cancer survivors, compared to 
women with no history of cancer. This directly responds to Objective 3 of this thesis. A 
matched cohort study design was chosen; the exposed cohort included all eligible 
women with a record of breast cancer in the database, and a random sample of women 
with no prior history of cancer formed the unexposed cohort. The outcomes of this 
study were selected among conditions identified in Chapters 1 and 3, and their 
definition was informed by the systematic review in Chapter 5. 
6.2 Study protocol and ethical approvals 
The study protocol (in Appendix 3) outlined the a priori defined methods and rationale 
for this study. This study received approval from The Independent Scientific Advisory 
Committee for MHRA Database Research (ISAC) (protocol 18_253; Ethics1 in 
Appendix 3) and the London School of Hygiene & Tropical Medicine Ethics Committee 
for Observational Research (ref. 16225; Ethics2 in Appendix 3).  
6.3 Article 
The research article produced to disseminate results is provided in the following pages. 
Appendix 3 of this thesis includes the supplementary materials to the article. This is 
currently under review. 
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Abstract 
Importance: Increasing numbers of women survive breast cancer but the long-term 
mental health impact of having been diagnosed and treated for the disease is unclear. 
Objective: To estimate the risk of anxiety and depression (primary outcomes), and 
seven secondary mental health-related outcomes, in breast cancer survivors compared 
to women with no prior cancer.  
Design: Matched population based cohort study. Median follow-up was 4.5 years in 
the exposed group (inter-quartile range (IQR): 1.9-8.5) and 5.2 years in the comparison 
group (IQR: 2.2-9.3). 
Setting: Primary care practices in the United Kingdom. 
Participants: All adult women diagnosed with an incident breast cancer between 1988 
and 2018 in the Clinical Practice Research Datalink (CPRD) GOLD primary care 
database; women with a prior history of other cancers were excluded. The unexposed 
cohort comprised a random selection of women with no history of cancer, matched to 
exposed women on age and primary care practice.  
Exposure: Breast cancer. 
Main outcome measures: Relative risk of the primary and secondary outcomes. 
Results: 57,571 women diagnosed with breast cancer (mean age 62.3 ± 13.9 years) 
and 230,067 women with no previous cancer were included. Breast cancer survivorship 
was positively associated with the primary outcomes of anxiety (adjusted hazards 
ratio=1.33; 95%CI: 1.29-1.36), and depression (1.35; 1.32-1.38), and the secondary 
outcomes of fatigue (1.28; 1.25-1.31), pain (1.22; 1.20-1.24), sexual dysfunction (1.27; 
1.17-1.38), sleep disorder (1.68; 1.63-1.73) and being prescribed opioid analgesics 
(1.86; 1.83-1.90), but there was no evidence of an association with cognitive 
dysfunction (1.00; 0.97-1.04) or fatal and non-fatal self-harm (1.15; 0.97-1.36). Hazard 
ratios for anxiety and depression reduced over time (p<0.001) but raised risks 
persisted for two and four years, respectively, after cancer diagnosis. For the 
secondary outcomes, increased levels of pain and sleep disorder persisted for at least 
10 years. Younger age was associated with larger increases in the risks of depression, 
cognitive dysfunction, pain, opioid analgesic use and sleep disorders (p-
interaction<0.001 in each case). 
Conclusion: Breast cancer survivorship is associated with raised risks of anxiety and 
depression, as well as other adverse mental health-related outcomes, persisting well 
into the survivorship period.  
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Introduction 
Breast cancer is the most common cancer to occur in women, with over two million 
new cases diagnosed annually worldwide.1 In countries with the highest incidences, 
five-year age-standardized net survival is generally >80%.2 This is resulting in a large 
population of women living beyond a breast cancer diagnosis, including 2.9 million in 
the United States and over 570,000 in the United Kingdom (UK), with numbers 
projected to rise further.3,4 Given this, it is important to understand the long-term 
consequences of breast cancer diagnosis and treatment. Breast cancer survivorship 
has been associated with a wide range of iatrogenic effects including myocardial 
infarction, stroke and cancer.5,6 Evidence on long-term mental health outcomes is less 
clear. 
In a recent systematic review, anxiety, depression, sexual and cognitive dysfunctions, 
and suicide, were found to be more common in breast cancer survivors than in women 
with no history of cancer.7 However, evidence was often drawn from studies at high-risk 
of selection and information bias, likely to be confounded by age and socio-economic 
status, and lacking generalisability to the broader group of women with a history of 
breast cancer.7 Evidence on other outcomes, such as sleep disturbance, was 
insufficient to draw conclusions.7  
The burden of depressive and anxiety disorders is remarkably high, particularly in high-
income settings.8 The efficient planning and delivery of mental health services that suit 
the needs of the largest group of cancer survivors requires timely and robust estimates 
on the risk of clinically assessed outcomes at the population level. We aimed to 
quantify the risk of several adverse mental health-related outcomes in women with a 
history of breast cancer followed in primary care in the UK National Health Service, 
compared to similar women who never had cancer. The primary outcomes were 
anxiety and depression, two common mental disorders primarily managed in primary 
care settings in the UK. Secondary outcomes were cognitive impairment (including 
dementia), fatigue, pain, sleep disorder, sexual dysfunction, and fatal and non-fatal 
self-harm. 
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Methods 
Study design and data sources 
This was a matched cohort study including data from the UK Clinical Practice Research 
Datalink (CPRD) GOLD primary care database (July 2018 version). This database 
includes anonymised electronic health records (EHRs) from 18.4 million patients 
registered with 761 primary care practices across the UK. The data are routinely 
recorded by general practitioners (GP) in the InPS Vision software system, using 
version 2 Read codes,9  and were shown to be broadly representative of the UK 
population in terms of age, sex and ethnicity.10 A subset of CPRD patients in England 
were linked at patient-level, using deterministic methods,11 to the Office for National 
Statistics (ONS) mortality data (containing dates and causes of death),12 patient-
postcode linked Index of Multiple Deprivation (IMD, an area-based measure of 
socioeconomic status),13 and the Hospital Episodes Statistics – Admitted Patient Care 
(HES-APC) database (containing coded diagnostic information from hospital 
admissions).14 
Study populations 
The exposed cohort included all women (≥18 years) with an incident diagnosis of 
breast cancer (list of codes available at https://datacompass.lshtm.ac.uk/1429/) 
recorded between the database inception (1987) and July 2018, and who had ≥12 
months of uninterrupted prior registration meeting CPRD quality control criteria (to 
ensure the exclusion of prevalent breast cancer cases). We excluded women with 
severe mental or neurological disorders (i.e. schizophrenia and other psychotic 
disorders, bipolar disorders, neurocognitive disorders and substance-related 
disorders), or a cancer diagnosis (except non-melanoma skin cancer) prior to breast 
cancer. As treatment for some mental health outcomes might last for several months, 
we excluded from each outcome-specific analysis patients who had that outcome in the 
year before the breast cancer diagnosis (index date). Patients with an outcome last 
recorded >1 year before the index date were not excluded, and the mental disorder 
was assumed to be in remission. 
The comparison group included women with no history of cancer at the index date 
(defined as the date of the breast cancer diagnosis for the matched breast cancer 
patient), except for non-melanoma skin cancer. For each breast cancer survivor, we 
randomly selected four control women with no history of cancer, matched to the cancer 
survivor on age (within a 3-year range), primary care practice, and eligibility of the data 
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for linkage (to enable a sensitivity analyses among patients with linked data). Women 
in the exposed cohort were eligible for selection as controls up to the date of breast 
cancer diagnosis. Similar to the exposed group, women in the unexposed cohort had 
≥12 months of uninterrupted prior registration. Exclusion criteria were the same as 
those applied to the exposed group. 
Primary outcomes definition: anxiety and depression 
The primary outcomes of anxiety and depression were identified by either a diagnostic 
Read code for conditions where anxiety/depression is the cardinal symptom (e.g. 
generalised anxiety disorder, major depressive disorder), or a Read code for a 
symptom (e.g. low mood) accompanied by a prescription of an antidepressant, for 
depression, or an anxiolytic or a relevant antidepressant, for anxiety, within 90 days 
(Methods1 in Appendix 3). The outcome definitions were informed by a systematic 
review on the topic.15 The Read codelists (available at https://datacompass. 
lshtm.ac.uk/1429/) were created using a systematic approach by a practicing GP 
(author GF). 
Secondary outcomes definition: cognitive dysfunction, fatigue, pain, opioid 
analgesics, sleep disorder, sexual dysfunction, fatal and non-fatal self-harm 
The definitions of the outcomes are provided in the Methods1 in Appendix 3; lists of 
codes are available at https://datacompass.lshtm.ac.uk/1429/. Briefly, fatigue, pain and 
sexual dysfunction were defined with Read codes only. Sleep disorder was identified 
using Read codes and combinations of Read codes and prescriptions of 
anxiolytics/hypnotics. Cognitive dysfunction was defined by Read codes, or a 
dementia-specific drug prescription.16 For self-harm, we updated a validated list of 
codes.17 Suicide was defined by International Classification of Diseases, tenth revision 
(ICD-10) codes X60-X84 and Y10-34, excluding Y33.9 where the verdict is pending.18  
Statistical analysis 
Incidence rates were calculated for each outcome in each cohort. Follow-up started at 
the index date (date of breast cancer diagnosis in the exposed cohort; controls took the 
same index date as their matched cases) and terminated at the earliest date of: 
outcome observed, cancer diagnosis other than breast in the exposed cohort, any 
cancer diagnosis in the comparison cohort, death, transference out of the practice, and 
last data collection for the practice. 
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Associations between breast cancer survivorship and each outcome were quantified 
using Cox regression models, with time since index as the underlying time scale, and 
stratifying on matched set to account for matching by age, primary care practice and 
data eligibility for linkage. Robust estimates of the standard errors were used to 
calculate 95% confidence intervals (95%CI). For the subset of patients for which data 
were available, we estimated hazard ratios (HR) adjusted for diabetes mellitus at 
baseline (yes/no), body mass index (BMI) category (<18.50; 18.5-24.9; 25.0-29.9; 30.0-
34.9; 35.0-39.9; ≥40.0 kg/m2), smoking status (non-smoker, current smoker, former 
smoker) and drinking status (never drinker; current drinker; former drinker). The 
directed, acyclic graph is provided in Figure 6.1; covariates definitions are provided in 
Methods2 in Appendix 3. Missing data were not imputed, as the missingness for these 
variables is likely to dependent on the values themselves, a violation of the missing at 
random assumption.19 
We assessed the potential for effect modification by age group at index date (18-34; 
35-44; 45-54; 55-64; 65-74; 75-84; ≥85 years), practice postcode-linked quintile of IMD, 
calendar period of index date (1988-94; 1995-99; 2000-04; 2005-09; 2010-14; 2015-
18), follow-up time (1 year interval up to 5 years, and 5-10 years, an implicit test of 
proportional hazards), cardiovascular comorbidity (yes/no), and history of the outcome 
<1 year before index date (yes/no), by fitting interaction terms between the exposure 
and these variables.  
All analyses were conducted in Stata version 15.20 
 
Sensitivity analysis 
We repeated the analyses including only patients with no history of the outcome before 
the index date. For the subset of patients for whom linked data were available, we ran 
analyses using linked HES-APC data to improve outcome ascertainment, and adjusted 
for deprivation based on the patient postcode (rather than practice postcode). We ran 
analyses with alternative outcome definitions that are expected to have higher 
specificity, to assess the impact of choice of outcome codes on our results. For opioid 
analgesics, we ran the analysis excluding codeine, which can be prescribed for its 
antitussive or antidiarrheal properties. We re-ran the analyses of fatal and non-fatal 
self-harm considering these as two separate outcomes (self-harm and completed 
suicide). 
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Ethical approvals 
The study protocol (Protocol in Appendix 3) was approved by The Independent 
Scientific Advisory Committee for MHRA Database Research (ISAC) (protocol 18_253; 
Ethics1 in Appendix 3) and the London School of Hygiene & Tropical Medicine Ethics 
Committee for Observational Research (ref. 16225; Ethics2 in Appendix 3). Informed 
consent was not required as the data were anonymised. 
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Figure 6.1   Direct acyclic graph. 
 
152
153 
 
Results 
57,571 women with history of breast cancer and 230,067 women with no history of 
cancer were included in the study (Figure 6.2). Overall median follow-up time was 4.5 
years in the exposed group (inter-quartile range (IQR): 1.9-8.5 years) and 5.2 years in 
the comparison group (IQR: 2.2-9.3 years). Outcome specific follow-up time and 
person-time at risk are included in Tables 1A to 1C in Appendix 3. 11,790 breast 
cancer survivors (24%) and 55,609 women in the comparison group (20%) had ≥10 
years of follow-up. Approximately 20% of all participants had anxiety recorded >1 year 
before the index date, and 29% had history of depression (Table 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2   Flowchart of the selection of the study cohorts.  
 
EHR = electronic health records; CPRD =Clinical Practice Research Datalink. 
* Women with research quality follow-up, as defined by CPRD based on systematic checks for data quality 
at both patient and practice level.  
† Almost all had a first record of breast cancer a few days after the recorded date of death. 
 
8,024,580 women in CPRD GOLD primary care database: population-based data collected 
since inception of the database (1988) and July 2018 
62,682 women ≥18 years with a record 
of breast cancer in the EHR* 
5,086 women ineligible for the study: 
 
• 3,419 record of cancer prior to the 
breast cancer 
• 1,307 record of severe mental 
illness before the breast 
cancer diagnosis 
•   360 breast cancer diagnosis 
occurred after end of follow-up 
time † 
24 women (0.04%) excluded 
because no suitable control 
could be identified 
57,595 women with history of breast 
cancer, eligible for matching on primary 
care practice, age (within 3 years) and 
data eligibility for linkage 
Matched 
230,067 women with no record of severe 
mental illness or cancer at the index 
date, eligible for outcome-specific 
analysis 
57,571 women with history of breast 
cancer available for outcome-specific 
analysis (>99.9% of those eligible) 
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Table 6.1   Characteristics of the study participants.* 
  
Women with history 
of breast cancer 
 
Women with no 
history of cancer 
    No. %   No. % 
All participants 57,571 100.0 230,067 100.0 
Socio-demographic  
    
 
Age group at index date (years) † 
    
 
18-34 781 1.4 3,125 1.4 
 
35-44 4,768 8.3 19,059 8.3 
 
45-54 13,039 22.6 52,114 22.7 
 
55-64 14,436 25.1 57,707 25.1 
 
65-74 12,361 21.5 49,395 21.5 
 
75-84 8,386 14.6 33,524 14.6 
 
85+ 3,800 6.6 15,143 6.6 
 
Calendar period of diagnosis 
    
 
1988-1994 2,656 4.6  -   -  
 
1995-1999 4,796 8.3  -   -  
 
2000-2004 11,590 20.1  -   -  
 
2005-2009 16,381 28.5  -   -  
 
2010-2014 15,733 27.3  -   -  
 
2015-2018 6,415 11.1  -   -  
 
Ethnicity 
    
 
White 21,187 36.8 86,187 37.5 
 
South Asian 411 0.7 2,247 1.0 
 
Black 271 0.5 1,384 0.6 
 
Other & mixed 221 0.4 1,228 0.5 
 
Unknown 35,481 61.6 139,021 60.4 
 
Practice deprivation (quintiles of IMD) 
    
 
1 (least deprived) 11,381 19.8 45,502 19.8 
 
2 9,913 17.2 39,618 17.2 
 
3 11,820 20.5 47,239 20.5 
 
4 11,736 20.4 46,899 20.4 
 
5 (most deprived) 12,721 22.1 50,809 22.1 
Lifestyle 
    
 
Body mass index (kg/m2) at index date ‡ 
    
 
<18.50 908  1.6 4,561 2.0 
 
18.50-24.99 20,958 36.4 85,030 37.0 
 
25.00-29.99 17,565 30.5 69,052 30.0 
 
30.00-34.99 8,666 15.1 32,401 14.1 
 
35.00-39.99 3,302 5.7 12,549 5.5 
 
≥40.00 1,490 2.6 6,350 2.8 
 
Unknown 4,682 8.1 20,124 8.7 
 
Alcohol intake at index date 
    
 
Never drinker 7,780 13.5 35,065 15.2 
 
Current drinker 40,438 70.2 156,604 68.1 
 
Former drinker 4,436 7.7 17,181 7.5 
 
Unknown 4,917 8.5 21,217 9.2 
     (Continued) 
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Table 6.1   Continued      
       
 
Smoking status at index date 
    
 
Non-smoker 30,452 52.9 122,985 53.5 
 
Current smoker 9,565 16.6 39,986 17.4 
 
Former smoker 16,343 28.4 60,604 26.3 
 
Unknown 1,211 2.1 6,492 2.8 
Comorbidity 
    
 
History of diabetes at index date 3,844  6.7 14,030  6.1 
 
History of coronary heart disease or stroke  4,648  8.1     18,523  8.1 
Mental health history (>1 year before index date) §  
  
 
  
 
Anxiety       11,986  20.8   45,482  19.8 
 
Depression       16,771  29.1   65,628  28.5 
 
Cognitive dysfunction ¥  -  -  -  - 
 
Fatigue       11,200  19.5   42,578  18.5 
 
Sleep disorder         7,221  12.5    27,528  12.0 
 
Pain     44,829  77.9   173,536  75.4 
 
Sexual dysfunction          1,670  2.9       6,479  2.8 
 
Self-harm          1,652  2.9       6,847  3.0 
 
IMD - Index of multiple deprivation.* Refers to all patients potentially eligible for analyses. The number of 
patients included in the analyses varied by outcome because we excluded women who had that particular 
outcome in the year before the index date, as we assumed that these were likely to still be under treatment 
at the index date. 
† Women with no history of cancer were individually matched by age (within a 3-year age range) to women 
in the exposed group. 
‡ Body mass index was calculated from weight and height records, when available. Missing information 
was supplemented with data from Read codes when possible. Patients with a Read code of obesity 
without indication of the category (e.g. 66C.00 - obesity monitoring) were categorised in the BMI 30.00-
34.99 category; Read codes referent to morbid obesity were included in the BMI≥40 category. 
§ Refers to women who had the outcome recorded at >1 year before the index date. Women who had the 
outcome in the year before the index date were excluded from the cohort. 
¶ After the first record of breast cancer in the exposed group, it was not possible to differentiate between 
this cancer and what could be a recurrence or second breast cancer; therefore only cancers other than 
breast and non-melanoma skin cancer were considered. In the comparison group, all cancers, except non-
melanoma skin ones, were considered. 
¥ Patients with a record of cognitive dysfunction at any point prior to the index date were excluded, as 
changes in cognitive function are often non-reversible.
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Relative and absolute risks of mental health outcomes in breast cancer survivors 
compared with cancer-free controls 
Breast cancer survivors had an increased risk of anxiety (adjusted HR 1.33, 95%CI 
1.29-1.36) and depression (HR=1.35, 95%CI 1.32-1.38) compared with cancer-free 
controls, with adjustment for potential confounders having little influence on effect 
estimates (Table 6.2). The cumulative incidence of anxiety 10 years after diagnosis 
was 16.4% (95%CI 15.9-16.8%); for depression, this figure was 28.5% (95%CI 28.0-
29.1%) (Figure 6.3; Table 2 in Appendix 3). 
Raised risks were also observed for the secondary outcomes of fatigue, pain, sexual 
dysfunction, sleep disorder, and being prescribed an opioid analgesic. The most 
common secondary outcomes after 10 years of follow-up were pain (85.6%), opioid 
analgesics (45.5%), and fatigue (23.9%) (Figure 6.3). 
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Table 6.2   Associations between breast cancer survivorship and adverse mental health outcomes. 
 
     Unadjusted associations *   Adjusted for diabetes, BMI category, 
smoking and drinking status * 
 
No. 
exposed 
No. 
unexposed 
 No. PY at risk No. 
events 
HR 95%CI  No. PY at risk No. 
events 
HR 95%CI 
Primary outcomes               
 Anxiety 55,616 224,138  279,754 1,594,899 26,112 1.35 1.31-1.38   244,766 1,431,613 24,038 1.33 1.29-1.36 
 Depression 54,073 216,355  270,428 1,463,728 44,733 1.37 1.35-1.40   236,146 1,308,004 41,173 1.35 1.32-1.38 
Secondary outcomes               
 Cognitive dysfunction 56,052 224,444  280,496 1,700,632 24,213 1.03 1.00-1.60   245,595 1,532,084 21,956 1.00 0.97-1.04 
 Fatigue 55,911 223,506  279,417 1,547,957 37,245 1.31 1.28-1.34   244,381 1,386,056 34,610 1.28 1.25-1.31 
 Pain 38,771 162,037  200,808 605,762 118,693 1.28 1.26-1.30   172,779 514,616 107,132 1.22 1.20-1.24 
 Sexual dysfunction 57,444 229,577  287,021 1,761,230 2,836 1.34 1.24-1.44   251,340 1,586,969 2,703 1.27 1.17-1.38 
 Sleep disorder 56,210 225,583  281,793 1,628,851 22,800 1.71 1.66-1.76   246,717 1,463,804 20,806 1.68 1.63-1.73 
 Opioid analgesics 52,672 213,190  265,862 1,429,809 62,165 1.95 1.92-1.98   232,154 1,277,168 56,190 1.86 1.83-1.90 
 Fatal and non-fatal 
self-harm 
57,508 229,752 
 
162,971 1,015,108 752 1.16 0.99-1.36   144,083 918,441 672 1.15 0.97-1.36 
95%CI = 95% confidence interval; BMI = body mass index; HR = hazard ratio; PY = person-years.  
* Women with a breast cancer diagnosis were matched with women without cancer on age (within a 3-year range), primary care practice (proxy of socio-economic status), and 
eligibility for data linkage (to avoid loss of precision in subset analyses). 
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Figure 6.3   Risk of anxiety and depression in breast cancer survivors and women with no prior cancer. 
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Effect of age, deprivation, calendar period, follow-up time, cardiovascular comorbidity and 
history of the outcomes on the association between breast cancer survivorship and 
adverse mental health outcomes 
Figure 6.4 shows the association between breast cancer survivorship and anxiety, and 
depression, stratified by potential effect modifiers. HRs for anxiety tended to be larger for younger 
women, in more deprived areas, and in later calendar years; HRs for depression were also larger 
in younger women. For both outcomes, HRs tended to decline over time since diagnosis 
(p≤0.001), and risks were no longer significantly elevated after two years for anxiety and four 
years for depression.  
Effect modification for the secondary outcomes is shown in Figures 6.5A and 6.55B. Similar 
variation by age was found for cognitive dysfunction, pain, opioid analgesics prescribing and 
sleep disorder (p<0.001). HRs for most secondary outcomes also tended to diminish in 
magnitude over time, though statistically raised risks of fatigue, pain, opioid analgesic use, and 
sleep disorder persisted for at least 5-10 years. 
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Figure 6.4   Associations between breast cancer survivorship and anxiety, and depression, by potential effect modifiers. 
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Figure 6.5A  Associations between breast cancer survivorship and cognitive dysfunction, 
fatigue, pain and opioid analgesics, by potential effect modifiers. 
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Figure 6.5B   Associations between breast cancer survivorship and sleep disorder, sexual dysfunction and 
fatal and non-fatal self-harm, by potential effect modifiers. 
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Sensitivity analyses 
Sensitivity analyses yielded generally similar results to the main analyses, with the 
exception of an analysis using a more specific definition for anxiety, which moved the 
association close to the null (Figure 6.6). 
 
 
Figure 6.6   Results of sensitivity analysis. 
 
Anxiety
Main analysis
.   Only patients with no history of the outcome
.   Read codes only (no drug treatment)
.   Read codes for v specific diagnosis
.   Outcome ascertained in CPRD linked to HES data
.   Adjusted for patient-level IMD (CPRD+HES data only)
Depression
Main analysis
.   Only patients with no history of the outcome
.   Read codes only (no drug treatment)
.   Read codes for v specific diagnosis
.   Outcome ascertained in CPRD linked to HES data
.   Adjusted for patient-level IMD (CPRD+HES data only)
Cognitive dysfunction
Main analysis
.   Dementia only (Read codes or drug treatment)
.   Outcome ascertained in CPRD linked to HES data
.   Adjusted for patient-level IMD (CPRD+HES data only)
Fatigue
Main analysis
.   Only patients with no history of the outcome
.   Adjusted for patient-level IMD (CPRD+HES data only)
Sleep disorder
Main analysis
.   Only patients with no history of the outcome
.   Read codes only (no drug treatment)
.   Adjusted for patient-level IMD (CPRD+HES data only)
Pain
Main analysis
.   Only patients with no history of the outcome
.   Adjusted for patient-level IMD (CPRD+HES data only)
Opioid analgesics
Main analysis
.   Only patients with no history of the outcome
.   Excluding codeine
.   Adjusted for patient-level IMD (CPRD+HES data only)
Sexual dysfunction
Main analysis
.   Only patients with no history of the outcome
.   Adjusted for patient-level IMD (CPRD+HES data only)
Fatal and non-fatal self-harm
Main analysis (CPRD+HES data only)
.   Only patients with no history of self-harm
.   Adjusted for patient-level IMD
.   Self-harm only
.   Self-harm only (adjusted for patient-level IMD)
.   Suicide only
.   Suicide only (adjusted for patient-level IMD)
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Discussion 
Compared to women with no history of cancer, breast cancer survivors had higher risks 
of anxiety and depression compared to women with no history of cancer. We also 
found evidence of raised risks of several secondary mental-health related outcomes, 
namely fatigue, pain, sexual dysfunction, sleep disorder, and being prescribed opioid 
analgesics. Younger age at diagnosis and more recent diagnosis were strong 
determinants of increased risk for most outcomes. The excess risks tended to decline 
over time since diagnosis, but risks of depression and anxiety remained significantly 
elevated for at least two and four years. Raised risks of fatigue, pain, opioid use and 
sleep disorders persisted for at least 5-10 years. 
Our findings are consistent with results from previous studies.7 Results remained 
virtually unchanged in sensitivity analyses, except for an analysis using a highly 
specific outcome definition for anxiety; it is plausible that GPs do not use specific codes 
for these disorders in cases where there is another medical condition such as breast 
cancer. The frequency of anxiety and depression in our sample was higher than other 
studies involving EHRs, which have reported incidences below 10%,7 but these studies 
often used data from psychiatric registries, which usually include patients with more 
severe or persistent symptomatology. Our estimates for secondary outcomes were 
consistent with previous literature (e.g. pain and fatigue21,22) but sexual dysfunction was 
much lower compared to the 20-50% reported both in breast cancer survivors and in 
the general female population.7,23 Only 21% of the British women with sexual problems 
seek help for their condition, which may explain the discrepancy.24 
A major strength of this study is the population-based nature of the data, which make 
our results representative of the broad population of breast cancer survivors in the UK. 
Selection bias is unlikely, as registration with a primary care practice is nearly 
universal. The large study size and the wealth of data in the CPRD GOLD primary care 
database permitted the study of several outcomes with sufficient power to detect small 
effects. We accounted for major confounders such as age and socio-economic status; 
matching for GP practice also accounted for practice-level characteristics that are 
difficult to measure (e.g. shared environment). We carried out extensive sensitivity 
analyses exploring different definitions of outcomes, as well as the impact of the data 
sources, to assess the robustness of our results. 
However, this study has limitations. The CPRD GOLD primary care database captures 
>90% of the cancers compared to the cancer registries,25 which may have resulted in a 
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small proportion of women being incorrectly classified as unexposed and biased our 
results towards the null. The alternative of obtaining a list of patients from linked cancer 
registry data would have restricted our study to the roughly 50% of patients in England 
who are eligible for linkage, reducing sample size, power, and generalisability. There is 
a potential for misclassification of the outcomes due to the incompleteness of the 
information registered in EHRs (e.g. diagnoses in secondary care not fed back to the 
GP), or lack of validity of the definitions, even though outcomes defined in our data 
source generally showed high positive predictive values (median 83% of cases 
confirmed for mental and behavioral disorders).26 We sought to maximize 
completeness and validity by conducting a systematic review of outcome definitions 
used in previous studies to inform decisions.15 Unmeasured and residual confounding 
might also affect our results. We were unable to account for menopausal status, 
physical activity and mammography screening, as this information is often not 
registered, though age-matching should to some extent have taken account of 
menopausal status. Data on smoking and alcohol drinking habits relied on patients self-
reporting accurately to their GP. We censored patients diagnosed with cancer during 
follow-up, but we were unable to distinguish between a second primary of the breast 
and recurrence in the exposed group. Lastly, breast cancer survivors may have more 
regular contact with health services making it more likely for conditions to be recorded 
in their records, due to a detection bias. 
Symptoms of anxiety and depression are considered a normal response to the 
diagnosis, but some patients have traumatic reactions, and symptoms of post-traumatic 
stress disorder are not uncommon.27 An increased risk of depression was observed for 
longer, possibly because some women struggle to cope in the long-term. Breast cancer 
is an ominous diagnosis that brings several changes to the woman’s life, including 
concerns over the impact of their disease on significant others, for example their 
children and spouses (e.g. carer roles, financial constrains), and for herself, who has to 
cope with many physical consequences of the cancer treatments. The drivers of raised 
risks of fatigue, sleep disorders, pain and sexual dysfunction cannot be discerned from 
this study, but may include physical consequences of breast cancer treatments (e.g. 
chemotherapy-induced fatigue,28 arthralgias as a side effect of hormone therapy)29 and 
psychological factors, such as body image concerns for sexual dysfunction,30 or anxiety 
for sleep disorders.31 
Effective treatments are available for anxiety and depression, and it is important that 
these women are diagnosed early, and receive appropriate support and treatment. The 
risks were particularly increased during the main treatment period, and screening all 
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women at this point could help identify patients struggling to cope. Mental disorders still 
carry considerable stigma and not all patients will self-present. It is important that 
clinicians at all levels of care are aware of the increased risk of these conditions in 
breast cancer survivors, so that they can provide the necessary support if needed. 
Breast cancer survivors in the UK had low levels of self-efficacy to manage the 
complications of their disease, particularly fatigue and distress.32 Cancer rehabilitation 
interventions with focus on potential physical and mental health consequences of 
breast cancer might reduce the disease burden by empowering women to better 
understand their disease.33 Reducing waiting time for mental health services in general 
will also benefit breast cancer survivors. 
Future studies should explore the possible modifying effect of social support, as 
increased social support may buffer some of the negative effects of stress.34,35 
Consequences of breast cancer treatments, such as lymphoedema, may mediate the 
association between breast cancer survivorship and mental health outcomes, and 
should be the subject of further work. 
In conclusion, breast cancer survivorship was associated with raised risks of anxiety 
and depression, and several other mental health-related outcomes, persisting for 
several years after the cancer diagnosis. 
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6.4 Summary 
 
• This population-based matched cohort study aimed to estimate the risk of a 
range of anxiety and depression (primary outcomes), and seven secondary 
mental health-related outcomes, in breast cancer survivors compared to women 
with no prior cancer. 
• The exposed cohort included all 57,571 women diagnosed with an incident 
breast cancer registered in the CPRD GOLD primary care database between 
1988 and 2018. The comparison cohort was comprised of 230,067 women with 
no previous cancer, randomly selected from the same data source, matched to 
exposed women on age and primary care practice. Median follow-up was 4.5 
years in the exposed group (inter-quartile range (IQR): 1.9-8.5) and 5.2 years in 
the comparison group (IQR: 2.2-9.3). 
• Five years after diagnosis, the most common outcomes in breast cancer 
survivors were pain (70%), depression (19%) and fatigue (15.2%). Recorded 
sexual dysfunction (1%) and fatal and non-fatal self-harm (<1%) were rare. 
• Breast cancer survivorship was positively associated with anxiety (adjusted 
HR=1.33; 95%CI: 1.29 to 1.36), depression (1.35; 1.32 to 1.38), fatigue (1.28; 
1.25 to 1.31), pain (1.22; 1.20 to 1.24), sexual dysfunction (1.27; 1.17 to 1.38), 
sleep disorder (1.68; 1.63 to 1.73) and being prescribed opioid analgesics 
(1.86; 1.83 to 1.90), but there was no evidence of an association with cognitive 
dysfunction (1.00; 0.97 to 1.04) or fatal/non-fatal self-harm (1.15; 0.97 to 1.36). 
• Hazard ratios for anxiety and depression reduced over time (p<0.001) but 
raised risks persisted for two and four years, respectively, after cancer 
diagnosis, while increased levels of pain and sleep disorder persisted for at 
least 10 years. Younger age was associated with larger increases in the risks of 
depression, cognitive dysfunction, pain, opioid analgesic use and sleep 
disorders (p-interaction<0.001 in each case). 
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7 Quantification of the associations between breast cancer 
survivorship and quality of life and mental health:  
a study of patient-reported outcomes 
7.1 Introduction 
This chapter describes the research conducted to answer Aim 2 (i.e. to investigate 
quality of life and mental health in women with a history of breast cancer, compared to 
women with no history of cancer). A cross-sectional study was designed, in which two 
groups of women (one group of breast cancer survivors and one group of women with 
no prior cancer) were asked to complete validated questionnaires that assess HRQoL, 
and anxiety and depressive symptoms. Patient recruitment and the rationale for opting 
for each scale are described in detail in Chapter 4. 
7.2 Study protocol and ethical approvals 
The study protocol is provided in Appendix 4. Favourable ethical opinions for this study 
were obtained from the NHS East of England - Cambridge South Research Ethics 
Committee (Ref: 17/EE/0403; Ethics1 in Appendix 4); the London School of Hygiene & 
Tropical Medicine Observation Research Ethics Committee (Ref: 14417; Ethics2 in 
Appendix 4); the Health Research Authority and the Health and Care Research Wales 
(IRAS Project ID224561: Ethics3 in Appendix 4). 
7.3 Article 
The manuscript that describes the results of this study is provided in the following 
pages. The supplementary tables are provided in Appendix 4.  
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Abstract 
Background: Breast cancer and its treatment may affect long-term health-related 
quality of life (HRQoL) and mental health of survivors, but few studies have quantified 
this. We aimed to assess HRQoL, anxiety, and depressive symptoms in breast cancer 
survivors (>1 year), compared to women with no prior cancer. 
Methods: A matched cross-sectional study of patient-reported outcomes was carried 
out among women included in the UK Clinical Practice Research Datalink GOLD 
primary care database. Breast cancer survivors and women with no prior cancer, 
frequency matched by age and primary care practice, were invited to participate. 
Outcomes were measured via postal questionnaire using the Quality of Life in Adult 
Cancer Survivors Scale (QLACS) and Hospital and Anxiety Depression Scale (HADS). 
Linear and logistic regression models were fitted to estimate adjusted associations 
between breast cancer survivorship and HRQoL domains, and anxiety and depressive 
symptoms.  
Results: 353 BCS (mean time since diagnosis 8.1 years) and 252 women with no prior 
cancer were included. Compared to women with no prior cancer, BCS had poorer 
HRQoL (higher mean QLACS score) in the domains of cognitive problems (adjusted β 
(aβ)=1.4, p=0.01), sexual function (aβ=1.7, p=0.02) and fatigue (aβ=1.3, p=0.01), but 
no evidence of difference in negative feelings, positive feelings, pain, or social 
avoidance. BCS had non-significantly higher odds of probable anxiety (HADS-anxiety 
score ≥11) than controls (adjusted OR (aOR)=1.40, 0.93-2.10), however there was 
strong evidence of a difference when a more sensitive threshold (score ≥8, 
“borderline/probable anxiety”) was used (aOR=1.47, 1.15-1.87). There were no 
differences in odds of probable depression (aOR=1.18, 0.52-2.68). Poorer quality of life 
and mental health outcomes were more pronounced among women with advanced-
stage cancer at diagnosis, and/or treated with chemotherapy.   
Conclusion: BCS had raised risks of problems with cognition, sexual function, fatigue 
and borderline/probable anxiety, particularly where their cancer was advanced and/or 
treated with chemotherapy. 
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Introduction 
Breast cancer is the most common malignancy diagnosed in women in most countries, 
and incidence is still on the rise [1]. Trends in survival from the disease also markedly 
increased in the last decades and five-year age-standardised net survival is now close 
to 90% in the United States, Canada, and several European countries [2]. This is 
resulting in millions of women worldwide living for several years beyond their disease, 
including over 2.7 million in the United States and 500,000 in the United Kingdom (UK) 
[3, 4]. In spite of the increasing prevalence of breast cancer survivors, little is known 
about the long-term impact of breast cancer on the patients’ mental health and health-
related quality of life (HRQoL). 
The National Cancer Research Institute identified several areas related to 
psychological wellbeing and quality of life in the top 20 priorities for patients living with 
and beyond cancer [5]. A large proportion of breast cancer survivors in England have 
been reported to experience issues that may negatively affect HRQoL, such as worries 
of family members getting the disease (73%), weight changes (60%), and stress (58%) 
[6]. These numbers suggest that breast cancer survivors may have poor HRQoL, but 
quantitative data on HRQoL, and its determinants, in this patient population are scarce. 
Furthermore, it is unclear whether differences in HRQoL exist between breast cancer 
survivors and women with no history of cancer. A recent study using primary care 
EHRs showed that breast cancer survivors in the UK were more likely to have anxiety 
and depression, as well as sexual dysfunction, sleep disturbance, fatigue, and pain 
recorded in their clinical record, compared to women with no cancer (unpublished data; 
please refer to Chapter 6 of this thesis). However, recording of some of these 
outcomes in routinely collected health records is likely to be incomplete and susceptible 
to ascertainment bias if cancer survivors are more likely to have problems recorded 
due to more healthcare contact. Collecting data on anxiety and depressive symptoms 
directly from cancer survivors and cancer-free controls may overcome these limitations. 
This study aimed to quantify HRQoL, and anxiety and depressive symptoms, in breast 
cancer survivors (>1 year), compared to women with no prior history of cancer. We 
also investigated socio-demographic and clinical determinants of HRQoL among breast 
cancer survivors. 
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Methods 
Study design and sampling frame 
We designed a matched cross-sectional study including breast cancer survivors and a 
comparison group of women with no prior cancer. Between October 2018 and August 
2019, we invited all primary care practices that were actively contributing with data to 
the Clinical Practice Research Datalink (CPRD) GOLD primary care database in 
August 2018 to participate in the study. CPRD is a UK government research service 
that collects, processes, and releases anonymised electronic health records (EHR) 
from patients attending the UK National Health Service. Patients registered with 
primary care practices that accepted to participate were potentially eligible for the study 
(see details below). 
Patient eligibility criteria 
Inclusion criteria for the breast cancer survivors group were: 1) a prior diagnosis of 
invasive breast cancer at least one year before; 2) aged 18-80 years; 3) alive and 
registered with the practice. To ensure that the recorded breast cancer was incident, 
we required one year of follow-up in CPRD prior to the diagnosis. For the comparison 
group, inclusion criteria were: 1) no history of cancer (except non-melanoma skin 
cancer); 2) alive and registered with the practice; and 3) at least two years of follow-up 
data in CPRD (since we required one year of follow-up before and after cancer to be 
included in the breast cancer group). Exclusion criteria for both groups were: 1) inability 
to complete a self-reported questionnaire (e.g. due to dementia); 2) having had another 
(non-breast) cancer or having been treated for a non-invasive breast tumour. 
Patient selection and recruitment 
The CPRD GOLD primary care database was used to identify all breast cancer 
survivors from the participating practices, as well as a random sample of women with 
no prior cancer from the same practice. Women in the comparison group were 
frequency-matched on age to breast cancer survivors in the same practice. Initially 
controls were matched to exposed women (breast cancer survivors) with a ratio of 1:1, 
but this was revised early in recruitment to 2:1 due to ~50% lower response among 
controls. The authors had full access to the CPRD GOLD primary care database to 
create the list of potentially eligible patients. General practitioners then reviewed the 
records of potentially eligible patients, applied the inclusion and exclusion criteria (vide 
above), and sent the study materials to the eligible patients’ addresses with a pre-paid 
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envelope to return the questionnaires. Patients were recruited between January and 
October 2019. 
Patient-reported outcomes 
Anxiety and depressive symptoms were measured with the Hospital Anxiety and 
Depression Scale (HADS) [7]. This is a 14-item self-reported screening tool for anxiety 
and depressive symptoms in the past week [7]. The recommended cut-offs were used 
to categorise patients as non-case (scores 0-7), borderline (scores 8-10) and probable 
case (scores 11-21) [7]. 
HRQoL was assessed with the Quality of Life in Adult Cancer Survivors Scale 
(QLACS) [8]. This tool includes 47 items, divided in seven generic domains (i.e. 
negative feelings; positive feelings; cognitive problems; pain; sexual function/interest; 
energy/fatigue; and avoidance) and five cancer-specific domains (i.e. financial 
problems; benefits of cancer; distress-family; appearance; distress-recurrence). 
Women with no history of cancer replied to the generic domains only. Items refer to the 
previous four weeks, and responses range between 1 (never) and 7 (always); higher 
scores indicate poorer HRQoL, except for positive feelings and benefits of cancer. 
Demographic and clinical information 
All women were asked to complete a questionnaire with information on education, 
ethnicity, and social support by proxy of living arrangements (alone/not alone). Breast 
cancer survivors provided information about treatments for their cancer, stage of the 
disease at diagnosis, time since last treatment (excluding long-term hormonal therapy), 
menopausal status, and status of the disease (active/remission). The patient-reported 
outcomes were also linked to the patient’s EHR and to the practice-postcode Index of 
Multiple Deprivation (IMD) quintile, via a patient identifier generated by CPRD. The 
research team had no access to patient identifiable information. 
Statistical analysis 
Descriptive HRQoL and anxiety and depressive symptoms  
We calculated domain scores for each patient. When a participant had one missing 
response for an item within a domain, we imputed the mean of the responses to the 
other items within that same domain; if ≥2 responses were missing, the domain score 
was not calculated [9]. The summary score for generic domains of HRQoL was 
calculated by the sum of the domain scores, with reverse scoring for the positive 
feelings domain. For the cancer specific domains, we added all domain scores, 
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excluding the score for ‘benefits of cancer’. Scores were summarised for each group 
using means and measures of dispersion. 
We also calculated mean and median scores for each subscale of HADS. When there 
were three or fewer items missing per subscale, we imputed these as the average of 
the responses in that subscale following proposed methods [10]. 
Comparison of outcomes between breast cancer survivors and controls 
We fitted domain-specific multiple linear regression models, using the domain scores 
as the dependent variable and the following independent variables: patient group 
(exposed vs. control), age group (<60, 60-69, 70-81 years); higher education degree 
(yes/no), and practice postcode-linked quintile of IMD. Interactions between the 
exposure and socio-demographic variables were tested, but not included in the final 
models as these were not significant. 
Outcome-specific logistic regression models were used to estimate the association 
between breast cancer survivorship and abnormal levels of anxiety (HADS-A≥11) and 
depression (HADS-D≥11). Models were further adjusted for age (<60, 60-69, 70-81 
years), higher education degree (yes/no), and quintile of IMD. In an a priori defined 
sensitivity analysis (see protocol, Appendix 4 of this thesis), we used a lower cut-off 
(HADS-A≥8; HADS-D≥8) for caseness, as the standard cut-off ≥11 was found to have 
low sensitivity (50%, 95%CI: 27% to 73%) to detect cases of depression in this patient 
population [11]. 
In a post-hoc analysis, we estimated the effect of stage at diagnosis and chemotherapy 
treatment on the HRQoL and HADS scores of the breast cancer survivors compared to 
women in the comparison group. For this, we fitted domain-specific multivariate linear 
regression models using the scores as the dependent variable, and a three-level 
exposure variable as the independent variable (e.g. for chemotherapy: cancer survivors 
with prior chemotherapy, cancer survivors without prior chemotherapy, controls), 
adjusting for age, education and IMD quintile. 
For all models, robust standard errors were computed to account for patient clustering 
by primary care practice, and regression coefficients (β) and 95% confidence intervals 
(95%CI) were reported. 
Socio-demographic and clinical determinants of HRQoL, and anxiety and 
depressive symptoms in breast cancer survivors 
We used linear regression models to assess the impact of socio-demographic, clinical 
and treatment factors on the generic and cancer-specific domains of HRQoL, and 
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HADS-subscales. Socio-demographic variables were age (<60, 60-69 and 70-81), 
practice postcode-linked IMD quintile, higher education degree (yes/no), and living 
arrangements (alone/not alone). Clinical variables were type of surgery (breast 
conserving/mastectomy), breast reconstruction (yes/no), stage at diagnosis 
(localised/regional or distant metastases), remission status (yes/no), menopausal 
status (pre/postmenopausal), time since diagnosis (<10/≥10 years), and treatment with 
chemotherapy (yes/no), radiotherapy (yes/no), hormone therapy (yes/no) and 
immunotherapy (yes/no). For age at diagnosis, education, stage at diagnosis, and 
exposure to chemotherapy, we fitted models adjusted for socio-demographic factors 
only (age, education, deprivation and country), as well as models adjusted for 
chemotherapy (yes/no) and stage at diagnosis (early/advanced). The regression 
coefficients (β) and respective 95%CIs were reported. 
 
Ethical approvals 
The study protocol was approved by the East of England - Cambridge South Research 
Ethics Committee (Ref: 17/EE/0403; Ethics1 in Appendix 4), the London School of 
Hygiene and Tropical Medicine Interventions Research Ethics Committee (Ref: 14417; 
Ethics2 in Appendix 4) and the Health Research Authority and Health and Care 
Research Wales (IRAS Project ID: 224561; Ethics3 in Appendix 4). Implicit patient 
consent was obtained when the patient posted the completed questionnaires. 
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Results 
353 women with a history of breast cancer and 252 women with no history of cancer, 
from 40 primary care practices, participated in the study (Figure 7.1). Participants and 
non-participants were similarly distributed by country (England, Wales, Scotland, 
Northern Ireland) and deprivation, but participants in the control group tended to be 
older than those in the breast cancer survivor group (Supplementary Table 1 in 
Appendix 4). Mean age was 64.8 years among breast cancer survivors (standard 
deviation (SD) 9.0, range 34-81) and 65.5 years in the non-cancer comparison group 
(SD=9.4; range 36-81 years) (Table 7.1). Breast cancer survivors were on average 8.1 
years post-diagnosis. In both groups, a quarter of the women had a higher education 
degree. 99% of the breast cancer survivors had surgery (35% mastectomy), 80% 
radiotherapy, 49% hormone therapy, and 41% chemotherapy. Most women had been 
diagnosed with localised (54.4%), or locally invasive disease (43.3%). 
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Figure 7.1 Flowchart of patient recruitment.  
 
CPRD – Clinical Practice Research Datalink.  
† 292 reminders were sent; all primary care practices that did not reply to the first invitation were sent at 
least one reminder. 
* Women in the comparison group included a random sample of women with no history of cancer that had 
the same age distribution as the breast cancer survivors in the primary care practice (frequency matching). 
Initially matching occurred on a ratio of one case to one control. We later revised this to one case to two 
controls, to account for lower participation rate in the control group. 
¥ Exclusion criteria included patients with dementia, terminally ill, or with another cancer diagnosis. GPs 
also excluded patients who were not able to complete questionnaires in English, or who had died or 
transferred out of their practice recently. 
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Table 7.1   Characteristics of the study participants.* 
 
 
No history of 
cancer (N=252)  
Breast cancer 
survivors 
(N=353) 
  
N 
 
(%) 
 
  
N 
 
(%) 
 
Age at completion of questionnaire           
34-59 years 71 28.2 
 
100 28.3 
60-69 years 80 31.7 
 
130 36.8 
70-81 years 101 40.1 
 
123 34.8 
Highest education level           
   Up to GCSEs, O levels, or equivalent  78 31.0 
 
127 36.0 
   A levels or equivalent 29 11.5 
 
35 9.9 
   Trade or technical training 52 20.6 
 
54 15.3 
   Undergraduate or post-graduate degree 66 26.2 
 
92 26.1 
   Did not want to disclose 27 10.7 
 
45 12.7 
Ethnicity           
   White 242 96.0 
 
344 97.5 
   Asian / Asian British 6 2.4 
 
1 0.3 
   Did not want to disclose 4 1.6 
 
8 2.3 
IMD deprivation quintile           
1 (most deprived) 53 21.0 
 
71 20.1 
2 36 14.3 
 
54 15.3 
3 26 10.3 
 
53 15.0 
4 98 38.9 
 
140 39.7 
5 (least deprived) 39 15.5 
 
35 9.9 
Living arrangements           
   Not alone 185 73.4 
 
270 76.5 
   Alone 63 25.0 
 
76 21.5 
   Did not want to disclose 4 1.6 
 
7 2.0 
Country           
   England 64 25.4 
 
50 14.1 
   Northern Ireland 16 6.3 
 
33 9.3 
   Scotland 74 29.4 
 
114 32.3 
   Wales 98 38.9 
 
156 44.2 
Time since breast cancer diagnosis           
1-5 years - - 133 37.7 
5-10 years - - 111 31.4 
10-15 years - - 88 24.9 
15-20 years - - 16 4.5 
>20 years - - 5 1.4 
Breast cancer treatments           
   Surgery - - 
 
348 98.6 
      Lumpectomy - - 
 
225 63.7 
      Mastectomy - - 
 
122 34.6 
      Reconstruction - - 
 
42 11.9 
   Radiotherapy - - 
 
282 79.9 
   Chemotherapy - - 
 
143 40.5 
   Hormone therapy - - 
 
174 49.3 
   Immunotherapy - - 
 
6 1.7 
    (Continued) 
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Table 7.1   Continued 
      
Stage at diagnosis           
   Localised to the breast - - 
 
192 54.4 
   Regional metastasis - - 
 
153 43.3 
   Distant metastasis - - 
 
2 0.6 
   Unknown - - 
 
6 1.7 
Time since last treatment for breast cancer           
Undergoing treatment - - 
 
3 0.8 
<12 months - - 
 
2 0.6 
Between 1 and 5 years - - 
 
123 34.8 
More than 5 years - - 
 
217 61.5 
Doesn't know - - 
 
8 2.3 
Disease status at questionnaire response           
   In remission - - 
 
319 90.4 
   Active disease - - 
 
7 2.0 
   Doesn't know 
   
27 7.6 
Menopausal status           
Menopausal at breast cancer diagnosis - - 
 
244 69.1 
Became menopausal during treatments for 
breast cancer 
- - 
 
71 20.1 
Not menopausal - - 
 
31 8.8 
Unknown - - 
 
7 2.0 
* Information on age at questionnaire completion, time since breast cancer diagnosis, practice postcode level of 
deprivation and country were obtained from the EHRs of the participating patients. Information on education, 
ethnicity, living arrangements, treatments for breast cancer, stage at diagnosis, time since last treatment for breast 
cancer, and disease and menopausal status, were collected directly from the patients using a self-reported 
questionnaire.  
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HRQoL, anxiety and depressive symptoms in breast cancer survivors and 
women with no history of cancer 
Table 7.2 shows the mean scores for all HRQoL domains. Fatigue and sexual 
dysfunction were the domains for which women in both groups reported poorer 
HRQoL (i.e. higher scores); breast cancer survivors also had cognitive dysfunction 
amongst the highest scoring domains. The correlation coefficients among HRQoL 
domains are shown in Supplementary Table 2 in Appendix 4. 
Compared to women with no history of cancer, breast cancer survivors had poorer 
HRQoL for cognitive problems (p<0.01), sexual function (p=0.02) and fatigue 
(p<0.01) (Table 7.3); the differences for the other domains were compatible with 
chance variation. Breast cancer survivors had non-significantly higher odds of 
probable anxiety (HADS-anxiety score ≥11) than controls (adjusted OR (aOR)=1.40, 
0.93-2.10), however there was strong evidence of a difference when a more 
sensitive threshold (score ≥8, “borderline/probable anxiety”) was used, (aOR=1.47, 
1.15-1.87). There were no differences in odds of probable depression (aOR=1.08, 
0.78-1.50) (Table 7.4). 
The worse HRQoL and mental health outcomes among breast cancer survivors 
appeared to be driven by higher risk in those treated with chemotherapy and/or 
diagnosed with more advanced disease (Table 7.3). Breast cancer survivors treated 
with chemotherapy reported significantly more negative feelings, cognitive 
problems, sexual dysfunction, fatigue, and anxiety than women with no history of 
cancer; in contrast, differences between breast cancer survivors with no 
chemotherapy exposure and cancer-free controls were smaller and (except for 
fatigue) non-significant. Similarly, breast cancer survivors diagnosed with more 
advanced disease had significantly more negative feelings, cognitive problems, 
sexual dysfunction, and fatigue than women with no history of cancer, while no 
significant differences were seen between survivors of localised cancers and 
cancer-free controls. 
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Table 7.2   Mean scores for HRQoL domains, anxiety and depressive symptoms, in each group of women.  
   No history of cancer (N=252)  Breast cancer survivors (N=353) 
   
No. 
(Imputed*) 
Mean 
score 
SD Range 
% 
Floor 
% 
Ceiling 
 
No. 
(Imputed*) 
Mean 
score 
SD Range 
% 
Floor 
% 
Ceiling 
Quality of Life in Adult Cancer Survivors Scale§              
Generic domains    
     
     
Negative feelings 251 (7) 11.0 4.9 4 - 26 3.7 0.0  343 (22) 11.6 5.3 4 - 28 4.4 0.3 
Positive feelings§ 250 (5) 21.1 5.4 7 - 28 0.0 9.9 
 
344 (18) 20.8 5.7 7 - 28 0.0 10.8 
Cognitive problems  251 (4) 10.5 4.7 4 - 28 6.2 0.8 
 
347 (19) 11.7 5.3 4 - 27 4.9 0.0 
 
Physical pain 249 (4) 11.1 6.5 4 - 28 12.0 0.8 
 
344 (19) 11.2 6.2 4 - 28 9.6 1.5 
Sexual interest/function 227 (8) 12.0 6.4 4 - 28 13.2 2.7 
 
327 (27) 13.7 7.2 4 - 28 13.2 4.9 
 
Energy/Fatigue 251 (1) 12.3 4.8 4 - 24 4.1 0.0 
 
347 (11) 13.3 5.0 4 - 25 3.8 0.0 
 
Social avoidance 251 (21) 9.8 5.6 4 - 28 17.3 0.4 
 
344 (45) 9.9 5.9 4 - 28 25.0 0.6 
  Summary ‡ 226 (0) 75.7 27.7 28 - 157 - - 
 
315 (0) 80.4 29.1 29 - 162 - - 
Cancer-specific domains                
Financial problems - - - - - - 
 
348 (9) 7.2 5.1 4 - 28 46.6 0.6 
Distress related to family - - - - - - 
 
349 (4) 12.3 7.5 
4 - 28 
2.6 7.8 
    Appearance concerns - - - - - - 
 
347 (12) 9.3 5.8 
4 - 28 
20.1 4.9 
    Distress over recurrence - - - - - - 
 
348 (8) 13.9 6.8 
4 - 28 
27.7 0.9 
  Summary - - - - - - 
 
347 (0) 42.5 19.5 
4 - 28 
7.2 2.9 
Benefits of cancer§ - - - - - - 
 
345 (7) 17.0 6.6 
4 - 28 
- - 
                
Hospital Anxiety and Depression Scale 
      
      
  Anxiety 248 (7) 6.4 4.1 0 - 20 5.0 0.4 
 
348 (14) 6.8 4.6 0 - 20 8.1 0.3 
  Depression 249 (4) 3.6 3.3 0 - 17 14.5 0.0 
 
349 (3) 3.6 3.6 0 - 19 17.8 0.0 
SD: standard deviation. 
* Number of patient with score imputed. When one item was missing out of the four items in the domain, we imputed this item with the arithmetic mean of the values in the 
other three items. Mean domain score was not calculated for patients that did not reply to two or more items in a domain. 
§ Higher scores represent poorer HRQoL, except for the domains ‘positive feelings’ and ‘benefits of cancer’. 
‡ Calculated as the sum of all domain scores except for positive feelings. 
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Table 7.3   Comparison of patient-reported outcomes between breast cancer survivors and controls, by chemotherapy and stage at diagnosis. 
     Breast cancer survivors by chemotherapy  Breast cancer survivors by stage at diagnosis 
 Controls  
All breast cancer 
survivors  No chemotherapy  Chemotherapy  Localised  Advanced 
  
 
β* lb   ub  β* lb   ub  β* lb   ub  β* lb   ub  β* lb   ub 
Generic domains                           
Negative feelings Ref.  0.7 -0.1 - 1.4  0.2 -0.7 - 1.0  1.5 0.2 - 2.7  0.2 -0.6 - 1.1  1.3 0.2 - 2.5 
Positive feelings Ref.  -0.4 -1.3 - 0.5 -0.2 -1.2 - 0.8 -0.7 -1.9 - 0.6 -0.3 -1.3 - 0.6 -0.5 -1.8 - 0.8 
Cognitive problems  Ref.  1.4 0.4 - 2.3 0.6 -0.3 - 1.5 2.6 1.3 - 3.8 0.9 -0.1 - 1.9 2.0 0.9 - 3.2 
Pain Ref.  0.0 -1.1 - 1.5 -0.2 -1.6 - 1.2 0.9 -0.8 - 2.6 -0.6 -2.0 - 0.8 1.2 -0.4 - 2.8 
Sexual function Ref.  1.7 0.4 - 3.1 1.2 0.0 - 2.4 
 
2.5 0.7 - 4.4 0.9 -0.5 - 2.2 
 
2.9 1.3 - 4.6 
Energy/Fatigue Ref.  1.3 0.4 - 2.2 1.2 0.2 - 2.1 
 
1.5 0.3 - 2.7 1.0 0.0 - 2.0 
 
1.7 0.6 - 2.9 
Avoidance Ref.  0.1 -1.0 - 1.2 -0.3 -1.5 - 0.8 0.8 -0.6 - 2.2 -0.2 -1.2 - 0.8 0.6 -0.9 - 2.2 
Summary Ref.  5.9 0.0 - 11.9  2.2 -3.7 - 8.2  11.2 3.8 - 18.6  1.8 -4.1 - 7.7  11.1 3.8 - 18.3 
HADS      
 
 
Anxiety Ref.  0.5 -0.1 - 1.0 0.1 -0.6 - 0.8 1.1 0.2 - 2.0 0.4 -0.3 - 1.0 0.8 -0.2 - 1.7 
Depression Ref.  0.1 -0.5 - 0.7   0.1 -0.6 - 0.7   0.2 -0.7 - 1.0 0.0 -0.7 - 0.7   0.3 -0.5 - 1.0 
* Adjusted for age, education and deprivation. 
HADS: Hospital Anxiety and Depression Scale; lb – lower bound of the 95% confidence interval; ub – upper bound of the 95% confidence interval. 
Bold is used to denote statistical significance. 
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Table 7.4   Unadjusted and adjusted associations between breast cancer survivorship and anxiety and depression. 
Anxiety 
 
Depression 
 
Cut-off ≥11 for caseness 
 
Cut-off ≥8 for caseness 
 
Cut-off ≥11 for caseness 
 
Cut-off ≥8 for caseness 
    
No. of 
cases (%) 
Odds 
ratio 95% CI 
 
No. of 
cases (%) 
Odds 
ratio 95% CI 
 
No. of 
cases (%) 
Odds 
ratio 95% CI 
 
No. of 
cases (%) 
Odds 
ratio 95% CI 
Univariate analysis 
 
  
 
No cancer 43 (17.3) Ref 87 (35.1) Ref 9 (3.6) Ref 38 (15.3) Ref 
Breast cancer 79 (22.7) 1.36 0.95 - 1.96 153 (44.0) 1.45 1.14 - 1.86 
 
17 (4.87) 1.37 0.69 - 2.70 54 (15.5) 1.02 0.72 - 1.42 
Multivariate analysis* 
 
   
No cancer 39 (17.7) Ref 79 (35.8) Ref 8 (3.6) Ref 33 (14.9) Ref 
Breast cancer 69 (22.6) 1.40 0.93 - 2.10 137 (44.9) 1.47 1.15 - 1.87 
 
12 (3.9) 1.18 0.52 - 2.68 46 (15.0) 1.08 0.78 - 1.50 
* Adjusted for age at questionnaire completion (<60 years; 60-69 years; 70+ years), education (university degree vs. no university degree) and quintile of practice-level 
postcode linked deprivation. Bold is used to denote statistical significance. 
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Determinants of HRQoL, anxiety and depressive symptoms in breast cancer 
survivors 
Younger age, more advanced disease at diagnosis, receipt of chemotherapy, not being 
menopausal were all strongly associated with poorer HRQoL for both generic and 
cancer-specific domains (Table 7.5). In addition, women with no higher education, and 
who did not live alone had poorer HRQoL for the cancer-specific domains. Symptoms 
of anxiety were associated with younger age, receipt of chemotherapy, and not being 
menopausal (Table 7.6). For depression, only living in a more affluent area was 
associated with more symptoms.  
Figures 7.1 and 7.2 show the variation of the summary scores, as well as individual 
HRQoL domain scores, by age, education, chemotherapy and stage at diagnosis. After 
adjusting for socio-demographic and clinical variables, older women reported 
significantly better HRQoL than women in the youngest age group (34-60 years) for all 
domains except positive feelings, pain, fatigue, benefits of cancer, and family-related 
distress (Table 7.7). Women with higher education had better HRQoL for several 
domains, but only pain, family-related distress and distress with recurrence were 
significantly lower after adjusting for confounders (Table 7.8). Women treated with 
chemotherapy had poorer HRQoL for a number of domains, but significant differences 
were only observed for cognitive problems, appearance concerns, and distress with 
recurrence after adjusting for confounders (Table 7.9). For stage, in adjusted models, 
significantly worse HRQoL in women with more advanced disease, compared to those 
diagnosed with localised tumours, was found for cognitive problems, pain, sexual 
function, financial problems, distress with appearance and recurrence (Table 7.10). 
Anxiety and depression scores did not vary by exposure to chemotherapy, stage at 
diagnosis, or education in adjusted models. However, women aged 70-81 years had 
significantly less anxiety and depressive symptoms, compared to women aged 34-59. 
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Table 7.5   HRQoL in breast cancer survivors by socio-demographic, clinical and treatment 
characteristics (N=353). 
  Generic domains: 
summary score 
 Cancer-specific domains: 
summary score 
    No. Mean SD β 95%CI 
 
No. Mean SD β 95%CI 
Age group            
34-59 years 92 86.4 30.7 Ref.   99 47.4 21.3 Ref.  
 60-69 years 118 81.7 28.7 -4.7 -13.4 to 4.0  129 43.1 18.2 -4.3 -10.3 to 1.7 
70-81 years 105 73.6 27.0 -12.8 -22.9 to -2.6  119 37.9 18.3 -9.5 -14.8 to -4.1 
IMD quintile            
 1 (most deprived) 66 73.6 26.0 Ref.   70 41.3 18.2 Ref.  
 2 50 81.5 30.7 7.9 -0.3 to 16.2   54 42.1 18.8 0.8 -5.8 to 7.4 
 3 48 79.9 23.5 6.3 -2.8 to 15.4  52 42.8 19.5 1.5 -4.1 to 7.1 
  4 120 82.6 30.1 9.0 -0.2 to 18.2  137 42.1 19.3 0.8 -3.6 to 5.3 
 5 (least deprived) 31 85.1 35.4 11.6 -1.9 to 25.0  34 47.2 23.9 5.9 -2.9 to 14.8 
Higher education          
 No 198 82.9 30.3 Ref.   214 44.4 20.6 Ref.  
 Yes 85 76.4 26.2 -6.5 -14.8 to 1.7  91 38.5 16.5 -5.9 -10.5 to -1.3 
Living arrangements          
 Not alone 250 81.6 29.1 Ref.   267 44.0 19.4 Ref.  
 Alone 59 75.1 28.3 -6.5 -15.5 to 2.5  73 38.6 19.5 -5.4 -9.7 to -1.0 
             
Type of surgery            
Lumpectomy 188 80.6 28.1 Ref.  207 41.5 18.1 Ref.  
Mastectomy 112 81.5 31.6 0.94 -6.4 to 8.2 121 45.4 21.3 3.9 -1.1 to 8.9  
Reconstruction            
No 277 79.3 28.8 Ref.  305 41.8 18.9 Ref.  
Yes 38 87.9 30.6 8.6 -1.0 to 18.3 42 47.8 22.8 6.0 -0.02 to 12.1 
Radiotherapy      
 
     
No 59 74.8 31.3 Ref.  68 40.0 17.1 Ref.   
Yes 256 81.6 28.5 6.8 -0.4 to 14.0 279 43.1 20.0 3.1 -0.7 to 7.0 
Chemotherapy      
 
     
No 183 76.6 28.4 Ref.  206 38.1 17.1 Ref.   
Yes 132 85.5 29.4 8.9 3.9 to 13.9 
 
141 49.0 20.9 11.0 7.4 to 14.5 
Hormone therapy      
 
     
No 160 79.3 28.5 Ref.  177 41.4 17.8 Ref.   
Yes 155 81.5 29.8 2.1 -4.1 to 8.4 170 43.7 21.0 2.3 -1.6 to 6.3 
Immune therapy      
 
     
No 309 80.3 29.1 Ref.  341 42.3 19.3 Ref.   
Yes 6 82.2 33.8 1.8 -22.4 to 26.0 6 54.5 26.2 12.2 -7.8 to 32.2 
Stage at diagnosis      
 
     
Early 169 76.7 27.8 Ref.  187 39.8 17.5 Ref.   
Advanced 142 85.3 30.1 8.6 2.4 to 14.9 
 
154 46.5 21.2 6.7 2.0 to 11.4 
Status of disease          
Remission 287 78.8 28.7 Ref.   314 41.1 18.9 Ref.  
Active disease 3 79.3 34.3 0.5 -34.1 to 35.1 6 52.2 21.5 11.0 -8.3 to 30.3 
Menopausal status           
Menopausal 216 77.7 29.1 Ref.  239 40.8 18.6 Ref.  
Not menopausal 99 86.2 28.4 8.5 2.1 to 14.9 108 46.4 20.8 5.6 1.2 to 10.0 
Time since diagnosis            
  ≤10 years 215 80.0 28.9 Ref.    242 42.0 19.9 Ref.  
  >10 years 100 81.1 29.8 1.1 -6.1 to 8.2   105 43.7 18.5 1.6  -3.6 to 6.9 
No.: number; SD: standard deviation.  
Bold text is used to denote that the differences between the two groups were supported by 
some statistical evidence.
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Table 7.6   Anxiety and depressive symptoms in breast cancer survivors by socio-
demographic, clinical and treatment characteristics (N=353). 
 
  Hospital Anxiety and Depression Scale 
 
  Anxiety  Depression 
    No. Mean SD β 95%CI 
 
No. Mean SD β 95%CI 
Age group            
34-59 years 100 7.9 4.4 Ref.   100 4.1 3.8 Ref.  
 60-69 years 129 6.7 4.7 -1.1 -2.5 to 0.18  129 3.6 3.4 -0.5 -1.5 to 0.4 
70-81 years 119 6.0 4.5 -1.8 -3.1 to -0.5  120 3.3 3.6 -0.8 -2.1 to 0.4 
IMD quintile            
 1 (more deprived) 71 7.2 4.6 Ref.   71 2.9 3.4 Ref.   
 2 52 6.3 4.3 -0.8 -2.5 to 0.8  52 3.3 3.1 0.3 -0.4 to 1.0 
 3 52 5.7 4.0 -1.5 -2.7 to -0.3  52 3.3 2.5 0.4 -0.3 to 1.0 
 4 138 7.1 4.7 -0.02 -1.2 to 1.2  139 4.1 3.8 1.2 0.3 to 2.1 
 5 (least deprived) 35 7.2 5.0 0.06 -1.6 to 1.8  35 4.3 4.8 1.4 0.1 to 2.6 
Education            
 No graduate degree 214 6.8 4.7 Ref.    214 3.9 3.7 Ref.  
 Graduate degree 91 7.2 4.0 0.4 -1.0 to 1.8  92 3.0 3.0 -0.8 -1.7 to 0.02 
Living arrangements            
 Not alone 268 7.0 4.6 Ref.   268 3.7 3.6 Ref.  
 Alone 73 6.2 4.6 -0.8 -2.0 to 0.4  74 3.4 3.5 -0.3 -1.3 to 0.8 
Type of surgery        
 Lumpectomy 209 6.6 4.4 Ref.   210 3.5 3.4 Ref.  
 
Mastectomy 119 7.3 4.7 0.7 -0.4 to 1.8  119 3.9 3.8 0.4 -0.6 to 1.3 
Breast reconstruction        
 
No 306 6.7 4.5 Ref.   307 3.6 3.6 Ref.  
 
Yes 41 7.8 4.8 1.1 -0.2 to 2.4  42 3.6 3.5 0.01 -1.1 to 1.1 
Radiotherapy            
 
No 67 6.8 4.6 Ref.    68 3.7 3.6 Ref.  
 
Yes 281 6.8 4.6 0.0 -1.1 to 1.1  281 3.6 3.6 -0.1 -1.0 to 0.8 
Chemotherapy            
 
No 205 6.4 4.7 Ref.    206 3.6 3.6 Ref.  
 
Yes 143 7.5 4.3 1.1 0.2 to 2.0  143 3.7 3.5 0.2 -0.6 to 0.9 
Hormone therapy            
 
No 175 6.8 4.7 Ref.    176 3.6 3.6 Ref.  
 
Yes 173 6.8 4.4 0.0 -1.3 to 1.2  173 3.7 3.6 0.04 -0.8 to 0.9 
Immune therapy            
 
No 342 6.8 4.6 Ref.    343 3.6 3.6 Ref.  
 
Yes 6 7.8 5.2 1.0 -2.9 to 5.0  6 3.5 4.0 -0.1  -3.1 to 2.9 
Stage at diagnosis            
 
Early 187 6.6 4.5 Ref.    188 3.4 3.3 Ref.  
 
Advanced 155 7.2 4.7 0.5 -0.7 to 1.8  155 3.9 3.8 0.5 -0.4 to 1.4 
Current status of disease           
 
Remission 315 6.5 4.5 Ref.    315 3.3 3.3 Ref.  
 
Active disease 7 10.7 7.0 4.2 -2.3 to 10.7  7 6.1 4.8 2.9 -1.2 to 6.9 
Menopausal status            
 
Menopausal 241 6.3 4.5 Ref.    242 3.5 3.5 Ref.  
 
Not menopausal 107 8.0 4.5 1.7 0.5 to 2.8  107 3.9 3.7 0.4 -0.6 to 1.5 
Time since diagnosis          
  <10 years 242 6.7 4.6 Ref.    243 3.6 3.6 Ref.  
  ≥10 years 106 7.1 4.5 0.4 -0.8 to 1.6  106 3.8 3.5 0.2 -0.7 to 1.1 
No.: number; SD: standard deviation. Bold text is used to denote that the differences between 
the two groups were supported by some statistical evidence. 
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Figure 7.2   Mean scores of HRQoL and anxiety and depression, by age at questionnaire response and education (N=353). 
194
  
 
195
 
Figure 7.3  Mean scores of HRQoL and anxiety and depression,  by exposure to chemotherapy and stage at diagnosis in breast cancer 
survivors (N=353). 
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Table 7.7   Associations between age and quality of life, anxiety and depression in breast cancer survivors (N=353). 
 
Age 
 
   Unadjusted association  
Model 1: 
adjusted for socio-demographic 
variables1 
 
Model 2: 
model 1 + stage and chemotherapy 
   
<60 
years 
60-69 
years 
 
70-81 
years 
 
<60 
years 
60-69 
years 
 
70-81 
years 
 
<60 
years 
60-69 
years 
 
70-81 
years 
  
 
 
 β P  β P   β P  β P   β P  β P 
Quality of Life in Adult Cancer Survivors Scale               
 
Generic domains                    
 
  
Negative feelings Ref. -1.0 0.16  -2.1 0.03  Ref. -1.4 0.07  -2.4 0.01  Ref. -1.3 0.10  -2.2 0.03 
  
Positive feelings Ref. 0.3 0.57  1.3 0.12  Ref. 0.6 0.36  1.8 0.04  Ref. 0.4 0.51  1.6 0.08 
  
Cognitive problems Ref. -1.1 0.13  -2.7 <0.001  Ref. -1.6 0.04  -2.7 0.001  Ref. -1.3 0.11  -2.2 0.01 
  
Pain Ref. 0.1 0.87  -0.5 0.62  Ref. -0.1 0.93  -0.7 0.47  Ref. 0.1 0.87  -0.6 0.58 
  
Sexual function Ref. -2.1 0.08  -3.3 0.002  Ref. -3.5 0.01  -4.5 <0.001  Ref. -3.3 0.01  -4.5 <0.001 
  
Energy/Fatigue Ref. -0.3 0.61  -0.3 0.66  Ref. -0.8 0.28  -0.7 0.38  Ref. -0.7 0.32  -0.8 0.35 
  
Avoidance Ref. -0.6 0.47  -2.3 0.02  Ref. -1.1 0.21  -2.4 0.02  Ref. -1.0 0.27  -2.3 0.04 
  
Summary score Ref. -4.7 0.28  -12.8 0.01  Ref. -9.2 0.05  -15.8 0.002  Ref. -8.2 0.08  -14.8 0.01 
 Cancer specific domains                     
  
Financial problems Ref. -2.3 0.01  -3.0 <0.001  Ref. -2.2 0.03  -2.8 <0.001  Ref. -2.1 0.04  -2.6 <0.001 
  
Benefits of cancer Ref. -1.5 0.15  0.7 0.52  Ref. -0.9 0.37  0.5 0.63  Ref. -0.8 0.41  0.5 0.68 
  
Distress-family Ref. 0.3 0.80  -0.3 0.73  Ref. 0.5 0.57  -1.2 0.11  Ref. 0.5 0.57  -1.0 0.21 
  
Appearance Ref. -1.2 0.14  -3.2 <0.001  Ref. -1.6 0.06  -4.1 <0.001  Ref. -1.0 0.26  -3.0 0.001 
  
Distress-recurrence Ref. -1.3 0.22  -3.0 0.002  Ref. -1.5 0.15  -3.4 0.002  Ref. -1.1 0.32  -2.5 0.02 
  
Summary score Ref. -4.3 0.15  -9.5 <0.001  Ref. -4.8 0.12  -11.4 <0.001  Ref. -3.6 0.26  -9.1 0.001 
Hospital Anxiety and Depression Scale              
  
Anxiety Ref. -1.1 0.09  -1.8 0.01  Ref. -1.0 0.14  -1.8 0.01  Ref. -0.9 0.20  -1.7 0.03 
  
Depression Ref. -0.5 0.27  -0.8 0.19  Ref. -0.6 0.21  -1.3 0.04  Ref. -0.6 0.28  -1.3 0.04 
1 Adjusted for education (university degree vs. no degree), practice postcode quintile level of the index of multiple deprivation (IMD), and country (Scotland, Wales, Northern Ireland, England). 
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Table 7.8   Associations between education and quality of life, anxiety and depression in breast cancer survivors (N=353). 
 
Education 
 
   Unadjusted association  
 
Model 1: adjusted for 
socio-demographic variables1 
 
 
Model 2: 
model 1 + stage and chemotherapy 
   
No higher 
education 
Higher education  
No higher 
education 
Higher 
education 
 
No higher 
education 
Higher education 
   
 β P-value   β P-value   β P-value 
Quality of Life in Adult Cancer Survivors Scale         
 Generic domains             
  
Negative feelings Ref. -0.7 0.32  Ref. -0.8 0.25  Ref. -0.7 0.27 
  
Positive feelings Ref. 0.4 0.62  Ref. 0.4 0.63  Ref. 0.3 0.73 
  
Cognitive problems Ref. -0.7 0.22  Ref. -0.9 0.18  Ref. -1.0 0.13 
  
Pain Ref. -1.8 0.01  Ref. -1.9 0.01  Ref. -2.0 0.01 
  
Sexual function Ref. -1.2 0.25  Ref. -1.4 0.16  Ref. -1.4 0.16 
  
Energy/Fatigue Ref. -1.2 0.08  Ref. -1.3 0.07  Ref. -1.3 0.06 
  
Avoidance Ref. -0.4 0.53  Ref. -0.5 0.47  Ref. -0.4 0.52 
  
Summary score Ref. -6.5 0.12  Ref. -7.3 0.08  Ref. -7.4 0.08 
 Cancer-specific domains            
  
Financial problems Ref. -0.6 0.32     Ref. -0.7 0.26    Ref. -0.8 0.23 
  
Benefits of cancer Ref. -0.9 0.27  Ref. -1.1 0.20  Ref. -1.5 0.10 
  
Distress-family Ref. -3.0 <0.001  Ref. -3.0 <0.001  Ref. -3.0 <0.001 
  
Appearance Ref. -0.8 0.32  Ref. -1.1 0.18  Ref. -1.2 0.12 
  
Distress-recurrence Ref. -1.4 0.07  Ref. -1.7 0.04  Ref. -1.9 0.02 
  
Summary score Ref. -5.9 0.01  Ref. -6.5 0.01  Ref. -7.0 0.004 
Hospital Anxiety and Depression Scale           
  
Anxiety Ref. 0.4 0.57  Ref. 0.3 0.69  Ref. 0.3 0.68 
  
Depression Ref. -0.8 0.06  Ref. -0.8 0.10  Ref. -0.7 0.15 
1 Adjusted for age (<60, 60-69, 70-81 years), practice postcode quintile level of the index of multiple deprivation (IMD), and country (Scotland, Wales, Northern Ireland, England). 
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Table 7.9   Associations between exposure to chemotherapy and quality of life, anxiety and depression in breast cancer survivors (N=353). 
 
Chemotherapy exposure 
 
   Unadjusted association  
Model 1: 
adjusted for socio-
demographic variables1 
 
Model 2:  
model 1 + stage at diagnosis 
   
 
No ChT 
 
ChT  No ChT ChT  No ChT ChT 
   
 β P-value   β P-value   β P-value 
Quality of Life in Adult Cancer Survivors Scale         
 
Generic domains           
  
Negative feelings Ref. 1.7 0.004  Ref. 1.3 0.05  Ref. 1.0 0.15 
  
Positive feelings Ref. -0.7 0.21  Ref. -0.4 0.49  Ref. -0.6 0.39 
  
Cognitive problems Ref. 2.0 <0.001  Ref. 1.9 0.003  Ref. 1.6 0.03 
  
Pain Ref. 0.8 0.22  Ref. 0.9 0.29  Ref. -0.1 0.90 
  
Sexual function Ref. 1.6 0.01  Ref. 1.1 0.18  Ref. 0.1 0.91 
  
Energy/Fatigue Ref. 0.1 0.77  Ref. 0.3 0.53  Ref. -0.2 0.66 
  
Avoidance Ref. 1.5 0.01  Ref. 1.0 0.09  Ref. 0.8 0.24 
  
Summary score Ref. 8.9 <0.001  Ref. 8.0 0.02  Ref. 4.4 0.25 
 Cancer specific domains            
  
Financial problems Ref. 2.0 0.003  Ref. 1.4 0.06    Ref. 1.1 0.20 
  
Benefits of cancer Ref. 0.9 0.24  Ref. 0.5 0.58  Ref. 0.0 0.98 
  
Distress-family Ref. 1.2 0.05  Ref. 1.4 0.06  Ref. 1.0 0.20 
  
Appearance Ref. 4.5 <0.001  Ref. 4.2 <0.001  Ref. 3.6 <0.001 
  
Distress-recurrence Ref. 3.2 <0.001  Ref. 3.2 <0.001  Ref. 2.9 <0.001 
  
Summary score Ref. 11.0 <0.001  Ref. 10.1 <0.001  Ref. 8.5 <0.001 
Hospital Anxiety and Depression Scale           
  
Anxiety Ref. 1.1 0.02  Ref. 0.9 0.10  Ref. 0.8 0.14 
  
Depression Ref. 0.2 0.66  Ref. 0.0 0.92  Ref. -0.2 0.63 
1 Adjusted for age (34-59, 60-69, 70-81 years), education (graduate degree: yes/no), practice postcode quintile level of the index of multiple deprivation (IMD), and country (Scotland, Wales, 
Northern Ireland, England). ChT = Chemotherapy. 
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Table 7.10   Associations between stage of at diagnosis and quality of life, anxiety and depression in breast cancer survivors (N=353). 
 
Stage at diagnosis 
 
   Unadjusted association  
Model 1: 
adjusted for socio-
demographic variables1 
 
Model 2:  
model 1 + chemotherapy 
   
Early 
stage 
Regional or 
distant metastases 
 
Early 
stage 
Regional or distant 
metastases 
 
Early 
stage 
Regional or 
distant metastases 
   
 β P-value   β P-value   β P-value 
Quality of Life in Adult Cancer Survivors Scale         
 
Generic domains           
  
Negative feelings Ref. 1.2 0.08  Ref. 1.2 0.07  Ref. 1.2 0.07 
  
Positive feelings Ref. -0.3 0.70  Ref. -0.1 0.85  Ref. -0.1 0.85 
  
Cognitive problems Ref. 1.2 0.01  Ref. 1.2 0.02  Ref. 1.2 0.02 
  
Pain Ref. 2.0 0.003  Ref. 1.9 0.01  Ref. 1.9 0.01 
  
Sexual function Ref. 2.0 0.01  Ref. 2.0 0.01  Ref. 2.0 0.01 
  
Energy/Fatigue Ref. 0.8 0.16  Ref. 0.9 0.13  Ref. 0.9 0.13 
  
Avoidance Ref. 1.1 0.09  Ref. 1.0 0.12  Ref. 1.0 0.12 
  
Summary score Ref. 8.6 0.01  Ref. 9.7 0.002  Ref. 9.7 0.002 
 Cancer specific domains            
  
Financial problems Ref. 1.4 0.01  Ref. 1.0 0.04  Ref. 1.0 0.04 
  
Benefits of cancer Ref. 0.4 0.56  Ref. 0.4 0.48  Ref. 0.4 0.48 
  
Distress-family Ref. 0.8 0.38  Ref. 1.2 0.24  Ref. 1.2 0.24 
  
Appearance Ref. 2.7 <0.001  Ref. 2.9 <0.001  Ref. 2.9 <0.001 
  
Distress-recurrence Ref. 1.8 0.04  Ref. 1.7 0.05  Ref. 1.7 0.05 
  
Summary score Ref. 6.7 0.01  Ref. 6.7 0.004  Ref. 6.7 0.004 
Hospital Anxiety and Depression Scale           
  
Anxiety Ref. 0.5 0.40  Ref. 0.5 0.38  Ref. 0.5 0.38 
  
Depression Ref. 0.5 0.25  Ref. 0.4 0.36  Ref. 0.4 0.36 
1 Adjusted for age (34-59, 60-69, 70-81 years), practice postcode quintile level of the index of multiple deprivation (IMD), and country (Scotland, Wales, Northern Ireland, 
England). 
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Discussion 
Breast cancer survivors had more cognitive problems, sexual dysfunction, fatigue, and 
borderline to abnormal anxiety symptoms compared to women with no history of 
cancer. The poorer quality of life in breast cancer survivors compared to controls 
appeared to be driven by treatment with chemotherapy, and more advanced disease at 
diagnosis. Among breast cancer survivors, younger age, lower education, more 
advanced disease at diagnosis, and treatment with chemotherapy, were all 
independently associated with poorer HRQoL.  
The increased cognitive problems, sexual dysfunction and fatigue in breast cancer 
survivors might be partially explained by the distress caused by the diagnosis and 
treatment, as well as physical and often permanent side effects of the breast cancer 
treatments. The direct toxic effect of chemotherapy regimens to the central nervous 
system may be involved in the pathophysiology of cognitive dysfunction [12, 13]. This is 
consistent with our results, where chemotherapy was independently associated with 
more cognitive problems, compared to both controls and breast cancer survivors not 
exposed to chemotherapy. Cognitive problems were also raised in women diagnosed 
with more advanced disease, independently of treatment with chemotherapy; this is 
also consistent with results from studies showing that post-traumatic stress may also 
be involved in the causation of cognitive dysfunction [14]. Fatigue is common during 
chemotherapy and radiotherapy, and is probably due to psychological and biological 
factors, such as depression and increased pro-inflammatory cytokines [15]. Sexual 
problems are often related to breast cancer treatments that lower circulating levels of 
oestrogen, and body imagine concerns after a surgery that inevitably changes breast 
appearance. 
Our results on HRQoL varying by age, education, stage at diagnosis and treatment are 
consistent with the previous literature [16-20]. Post-traumatic growth, a phenomenon in 
which women appreciate life more after a traumatic event [21], is likely explain the 
better HRQoL of older women as they also had the highest scores for positive feelings 
and benefits of cancer. 
This study has several strengths. We selected patients from the CPRD GOLD primary 
care database, which is representative of the UK population in terms of age, sex, and 
ethnicity [22]. Matching the groups by primary care practice and age is likely to have 
accounted for measurable and some unmeasurable confounding; we further collected 
data for education, ethnicity, and proxy of social support, which are known to be 
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imperfectly recorded in the patients’ clinical records, and this allowed us to account for 
these variables in the analyses. The validity of the tools used to assess outcomes has 
been established. QLACS was specifically developed to assess HRQoL in long-term 
cancer survivors, and it has high validity and reliability, both in cancer patients early 
post-treatment [23] and in long-term survivors [24, 25]. HADS has also been validated 
for use in primary care [26]. Finally, our study was sufficiently powered for the main 
comparison of HRQoL between breast cancer survivors and controls, as we exceeded 
the target sample size. 
However, this study also has limitations. The major threat to the validity of our results 
comes from the low participation rate (35% in the breast cancer survivors group and 
17% in the control group). Even though this participation rate overall surpassed our 
estimate at study design of 20%, and is similar to participation rates in HRQoL studies 
among other cancer survivors in the UK [27], we cannot rule out selection bias where 
psychologically healthier women were more likely to participate. The broad 
demographic determinants of participation were similar between breast cancer 
survivors and controls, but we cannot rule out differential participation associated with 
the outcomes. Another limitation is that clinical information was self-reported, which 
may have led to some information bias, but we expect this to have a minor impact on 
our results. The QLACS was well accepted but some missing responses were 
observed, most often for items related to sexual interest and function, and social 
avoidance; our proportion of missing data was similar to another study assessing 
HRQoL with QLACS among cancer survivors in the UK [23]. It is unclear whether the 
missing responses were related to values themselves, but it is plausible that older 
women may not feel comfortable reporting their sexual function. In addition, older 
women may have fewer opportunities to engage in partnered sexual activity (e.g. 
widowed, erectile dysfunction in partners, etc.), and therefore consider these items not 
applicable to them. For the social avoidance domain, one item was left unanswered 
particularly often – it related to being ‘reluctant to start new relationships’. We think this 
item might have been interpreted by the patients as starting new romantic 
relationships, and thus left blank due to no applicability. 
The results of this study suggest that selected groups of breast cancer survivors in the 
UK may benefit from increased surveillance for mental health and consequences of 
treatment that negatively affect HRQoL, such as cognitive problems, sexual problems 
and fatigue. Early identification and management of problems related to these domains 
is likely to reduce the burden of the disease. In the most recent years, patient 
rehabilitation programs have been made available to help patients better understand 
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their disease and what can be expected from the cancer treatments. This is likely to 
help women to better cope with their disease, as well as raise awareness that help is 
available for these issues, and reduce the stigma associated with sensitive topics such 
as mental health and sexual function. It is also important to raise awareness among 
health care professionals that long-term breast cancer survivors may still experience 
important distress related to their history of cancer. 
Future research on the HRQoL of breast cancer survivors in the UK should focus on 
interventions aimed at preventing declines in HRQoL in the long term after breast 
cancer, interventions aimed at improving HRQoL in patients currently reporting low 
levels of HRQoL, and assessing trends in HRQoL, as it is unclear whether modern 
treatments yield better HRQoL. Studies are also needed to assess whether women 
diagnosed with breast carcinomas in situ differ in terms of HRQoL from both breast 
cancer survivors and women with no history of cancer, as these tumours are treated 
similarly to early stage breast cancer.  
In conclusion, breast cancer survivors in the UK reported raised risk of problems with 
cognition, sexual function, fatigue and borderline/probable anxiety, particularly where 
their cancer was advanced and/or treated with chemotherapy. This information can be 
used to tailor increased surveillance for mental health and HRQoL issues in these 
groups. 
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7.4 Summary 
 
• This cross-sectional study aimed to assess HRQoL, anxiety, and depressive 
symptoms in long-term breast cancer survivors (>1 year), compared to women 
with no prior cancer. 
• The CPRD GOLD primary care database was used to identify all women with 
history of breast in the participating practices, and a random sample of women 
who have never had cancer. The patient’s GP confirmed their eligibility and 
posted the questionnaires. Outcomes were measured using QLACS and HADS. 
• 353 women with a history of breast cancer (mean time since diagnosis 8.1 
years) and 252 women with no prior cancer, from all four UK countries, 
participated in the study. These were 35% of the breast cancer survivors and 
17% of the women with no history of cancer that were invited to participate.   
• Breast cancer survivors had poorer HRQoL (higher mean QLACS score) in the 
domains of cognitive problems (adjusted β (aβ)=1.4, p=0.01), sexual function 
(aβ=1.7, p=0.02) and fatigue (aβ=1.3, p=0.01), compared to women with no 
history of cancer, but we found no evidence of difference in negative feelings, 
positive feelings, pain, or social avoidance. Breast cancer survivors treated with 
chemotherapy or diagnosed with more advanced disease, also had poorer 
HRQoL for the domain of negative feelings (chemotherapy: aβ=1.5, 95%CI: 0.2-
2.7; stage: aβ=1.3, 95%CI: 0.2-1.5).  
• Breast cancer survivors also had non-significantly higher odds of probable 
anxiety (HADS-anxiety score ≥11) than controls (adjusted OR (aOR)=1.40, 
0.93-2.10), however there was strong evidence of a difference when a more 
sensitive threshold (score ≥8, “borderline/probable anxiety”) was used, 
(aOR=1.47, 1.15-1.87). There were no differences in the odds of probable 
depression (aOR=1.18, 0.52-2.68). 
• Poorer HRQoL and mental health outcomes were more pronounced among 
women with advanced-stage cancer at diagnosis, and/or prior treatment with 
chemotherapy. 
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8 Comparison between patient-reported outcomes and data 
recorded in the patients’ electronic health record 
8.1    Introduction 
Objective 6 of this thesis, and s secondary aim of the cross-sectional study described 
in Chapter 7, was to assess the feasibility of using EHRs to study aspects of mental 
health and quality of life that are more typically captured directly from patients. If such 
outcomes could be adequately captured using routinely collected health records data, 
this would allow for much larger and lower-cost studies compared to when direct 
patient involvement is required. This chapter focuses on the comparison between 
information on certain domains of HRQoL that were directly reported by the patients 
participating in the study (N=602), and the data registered in their EHRs in the CPRD 
GOLD primary care database. 
8.2    Methods 
8.3 Identifying patients with poor quality of life (patient-reported outcome) 
The QLACS includes seven generic domains of HRQoL (i.e. negative feelings, positive 
feelings, fatigue, cognitive problems, sexual function, physical pain and avoidance). Of 
these, five are particularly suitable for comparison with the data recorded in the EHR 
because women with distressing levels for these domains may have visited their GP to 
seek help: ‘negative feelings’, ‘cognitive problems’, ‘physical pain’, ‘sexual problems’ 
and ‘fatigue’. Read codes for the ‘social avoidance’ domain are also available, and 
therefore this domain was also included. Data on ‘positive feelings’ were not expected 
to be captured in GP records so are not considered further here. 
The domains of negative feelings, cognitive problems, physical pain, sexual problems, 
fatigue and social avoidance have four items each. Responses to each item are given 
on a Likert-type of scale that varies between 1 (never) and 7 (always). To identify 
women who had high levels of distress for each domain, I calculated the arithmetic 
mean of their responses (i.e. the sum of the individual item scores divided by four; 
mean values range between one and seven). I considered as reporting important levels 
of distress all women with a mean of ≥5 (corresponding to average replies of 
frequently, very often or always) in the domain. As this is an arbitrary cut-off, two 
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sensitivity analyses were conducted: 1) using a lower cut-off of ≥3 (corresponding to 
replies of sometimes and as often as not, in addition to replies of frequently, very often 
or always to most questions); 2) considering as exposed to important levels of distress 
all women who replied ≥5 to at least one item in the domain. 
8.4 Identifying conditions closely related to specific domains of HRQoL in 
electronic health records 
The EHRs data from the 602 patients that participated in the cross-sectional study 
were extracted from the CPRD GOLD primary care database. As patient-reported 
outcomes were collected between January and November 2019, I extracted data from 
the January 2019 version of CPRD, which included data from 1987 up to December 
2018. In a sensitivity analysis, I used data from the CPRD GOLD primary care 
database version of July 2019, which included data collected from primary care 
practices up to June 2019. 
For each domain of HRQoL being assessed, I produced lists of Read codes closely 
related to the QLACS items in the domain (please see Table 8.1 for concepts; lists of 
Read codes are provided in Chapter 6). 
 
Table 8.1   Matching between HRQoL domain and information in the EHRs. 
HRQoL domain QLACS Items 
Search in the EHR for Read 
codes* related to: 
   
Negative 
feelings 
19 Bothered by mood swings 
7   Felt blue or depressed 
9   Worried about little things 
24 Felt anxious 
 
Depression and/or anxiety 
(disorders and symptoms), 
antidepressants, or anxiolytic 
prescription 
Cognitive 
problems 
3 Bothered by having a short attention span 
4 Had trouble remembering things 
2 Difficulty doing things requiring concentration 
23 Bothered by forgetting what started to do 
 
Cognitive impairment; cognitive 
dysfunction symptoms; dementia*; 
dementia-specific drug*. 
Physical pain 13 Bothered by pain preventing activities 
17 Mood disrupted by pain or its treatment 
27 Pain interfered with social activities  
21 Had aches or pains 
 
Pain; painful conditions; 
prescriptions of analgesics. 
Sexual 
problems 
16 Lacked interest in sex 
26 Avoided sexual activity 
12 Dissatisfied with sex life  
10 Bothered by inability to function sexually 
 
Low libido; anorgasmia; 
vaginismus.  
Fatigue 11 Lacked energy to do things wanted to 
14 Felt tired a lot 
1 Had energy to do things wanted to do 
5 Felt fatigued 
 
Low energy; tiredness. 
Social 
avoidance 
18 Avoided social gatherings 
20 Avoided friends 
25 Reluctant to meet new people 
15 Reluctant to start new relationships 
Social isolation, or social 
avoidance. 
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* definitions were based on the systematic review provided in Chapter 5 when possible. QLACS – Quality 
of Life in Adult Cancer Survivors Scale; EHR – electronic health records.  
 
The lists of Read codes were used to identify women with these codes registered in 
their EHR in the 3, 6, 12 and 24 months prior to the date of last data collection from the 
practice. The last collection date varied from practice to practice, but was generally 
within three weeks of the database version (e.g. in the January 2019 version, the date 
of last data collection from the practices was in median 20 days (inter-quartile range: 
19-20) prior to 31 December 2018). 
8.5 Comparison between patient-reported outcomes and information 
recorded in the electronic health records 
To compare the two sources of data, I quantified for each domain:  
1) of the women who reported high levels of distress in the questionnaires, how 
many had similar information in their EHR (sensitivity); 
2) of the women who had information about the domain in the EHR, how many 
reported distressing levels in the questionnaires (positive predictive value). 
Results are shown in tables. 
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8.6    Results 
8.7   Sensitivity of electronic health data in capturing patient-reported 
distress 
Of the 605 women that participated in the study, 100 (17%) reported high levels of 
distress (mean score ≥5) for negative feelings (Table 8.2). 36% of these had 
information related to anxiety and/or depression recorded in their EHR in the three 
months prior to the date of last data collection for the practice, and 50% had a record in 
the previous two years. Distress with pain was reported in the questionnaires by 122 
(21%) of the women, and 52% and 75% of these had symptoms of pain or an analgesic 
prescription recorded the EHR in the previous three and 24 months, respectively. 93 
women reported high levels of distress related to cognitive problems, 155 to sexual 
dysfunction, 157 to fatigue/energy, and 82 to social avoidance. No codes relevant to 
these domains were found in the patients’ EHR up to 24 months prior to the date of last 
data collection for the practice. The results of the sensitivity analysis using data of the 
July 2019 version of CPRD were not meaningfully different (Table 8.3). 
8.8 Positive predictive value of electronic health data for capturing patient-
reported distress 
Of the patients that had information about negative feelings recorded in their EHR (20-
30% of all patients, depending on the length of the time-window used to identify codes), 
only a minority (20-30%) reported distressing levels of negative feelings in the 
questionnaires (Table 8.4). For pain, approximately one-half of the 134 patients who 
had pain recorded in their EHR also reported distressing levels for pain in the 
questionnaires. The positive predictive value tended to decline when older information 
was included in the ascertainment of negative feelings in the EHRs (i.e. when a longer 
time-window/look back period was used). For the other four domains, no codes were 
identified in the EHRs for in the observation period. 
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Table 8.2 Sensitivity analysis using a more recent CPRD data cut: patients scoring above a given threshold in the PRO study that had 
domain-related information in the EHRs by time prior to the last data collection for the practice in the CPRD version January 2019 (N=605 §) 
       
    
PROs 
 
Patients scoring above a given threshold in the PRO 
study that had domain-related information in EHRs, 
by time prior to the last data collection for the practice 
   
Mean 
domain 
cut-off 
  
3mo 6mo 12mo 24mo 
Domain Items in the QLACS Read codes for No. %   No. % No. % No. % No. % 
Negative 
feelings 
19 Bothered by mood swings Depression and/or 
anxiety, 
antidepressants, or 
anxiolytic prescription. 
≥5 100 16.8 
 
36 36.0 37 37.0 47 47.0 51 51.0 
7   Felt blue or depressed ≥3 383 64.5 
 
89 23.2 90 23.5 109 28.5 129 33.7 
9   Worried about little things 1 item ≥5 226 37.4 
 
65 28.8 66 29.2 82 36.3 95 42.0 
24 Felt anxious 
            
Cognitive 
problems 
3 Bothered by having a short attention span Cognitive impairment; 
cognitive dysfunction 
symptoms; dementia; 
dementia-specific 
drug.* 
≥5 93 15.6 
 
0 
 
0 
 
0 
 
0 
 
4 Had trouble remembering things ≥3 391 64.6 
 
0 
 
0 
 
0 
 
0 
 
2 Difficulty doing things requiring 
concentration 
1 item ≥5 192 31.7 
 
0 
 
0 
 
0 
 
0 
 
23 Bothered by forgetting what started to do 
            
Physical 
pain 
13 Bothered by pain preventing activities 
Pain; painful conditions; 
prescriptions of 
analgesics. 
≥5 122 20.6 
 
64 52.5 69 56.6 81 66.4 91 74.6 
17 Mood disrupted by pain or its treatment ≥3 327 55.1 
 
105 32.1 115 35.2 151 46.2 184 56.3 
27 Pain interfered w/social activities  1 item ≥5 229 37.9 
 
85 37.1 93 40.6 119 52.0 140 61.1 
21 Had aches or pains 
            
Sexual 
dysfunction 
16 Lacked interest in sex 
Low libido; anorgasmia; 
vaginismus.  
≥5 155 28.0 
 
0 
 
0 
 
0 
 
0 
 
26 Avoided sexual activity ≥3 375 62.0 
 
0 
 
0 
 
0 
 
0 
 
12 Dissatisfied w/sex life  1 item ≥5 302 49.9 
 
0 
 
0 
 
0 
 
0 
 
10 Bothered by inability to function sexually 
            
Fatigue 11 Lacked energy to do things wanted to 
Low energy; tiredness.  
≥5 157 26.3 
 
0 
 
0 
 
0 
 
0 
 
14 Felt tired a lot ≥3 469 77.5 
 
0 
 
0 
 
0 
 
0 
 
1 Had energy to do things wanted to do  1 item ≥5 533 88.1 
 
0 
 
0 
 
0 
 
0 
 
5 Felt fatigued 
            Social 
avoidance 
18 Avoided social gatherings 
Social isolation; social 
avoidance.  
≥5 82 13.8 
 
0 
 
0 
 
0 
 
0 
 
20 Avoided friends ≥3 292 48.6 
 
0 
 
0 
 
0 
 
0 
 
25 Reluctant to meet new people 1 item ≥5 194 32.1 
 
0 
 
0 
 
0 
 
0 
 
15 Reluctant to start new relationships 
 
                      
EHRs = electronic health records; HRQoL = Health-Related Quality of Life; mo. = month. PRO = Patient-reported outcomes.* Severe cognitive dysfunction was an exclusion criterion for the study. 
§ 605 women participated in the study; due to missing data for some items, the number of women included in the denominator varies slightly by domain.  
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Table 8.3 Patients scoring above a given threshold in the PRO study that had domain-related information in the EHRS by time prior to the 
last data collection for the practice in the CPRD July 2019 version (N=605 §). 
 
    
PROs 
 
Patients scoring above a given threshold in the PRO 
study that had domain-related information in EHRs, 
by time prior to the last data collection for the practice 
   
Mean 
domain 
cut-off  
  
3mo 6mo 12mo 24mo 
Domain Items in the QLACS Read codes for No. %   No. % No. % No. % No. % 
Negative 
feelings 
19 Bothered by mood swings Depression and/or 
anxiety (disorders 
and symptoms), 
antidepressants, or 
anxiolytic prescription 
≥5 100 16.8 
 
37 37.0 37 37.0 48 48.0 55 55.0 
7   Felt blue or depressed ≥3 383 64.5 
 
89 23.2 89 23.2 113 29.1 130 33.9 
9   Worried about little things 1 item ≥5 226 37.4 
 
68 30.1 68 30.1 84 37.2 98 43.4 
24 Felt anxious 
            
Cognitive 
problems 
3 Bothered by having a short attention span Cognitive impairment; 
cognitive dysfunction 
symptoms; dementia; 
dementia-specific 
drug.* 
≥5 93 15.6 
 
0  0  0  0  
4 Had trouble remembering things ≥3 391 64.6 
 
0  0  0  0  
2 Difficulty doing things requiring 
concentration 
1 item ≥5 192 31.7 
 
0  0  0  0  
23 Bothered by forgetting what started to do 
    
        
Physical 
pain 
13 Bothered by pain preventing activities Pain; painful 
conditions; 
prescriptions of 
analgesics. 
≥5 122 20.6 
 
64 52.5 69 56.6 81 66.4 91 74.6 
17 Mood disrupted by pain or its treatment ≥3 327 55.1 
 
106 32.4 116 35.5 152 46.5 185 56.6 
27 Pain interfered w/social activities  1 item ≥5 229 37.9 
 
86 37.6 94 41.1 120 52.4 141 61.6 
21 Had aches or pains 
    
        
Sexual 
dysfunction 
16 Lacked interest in sex 
Low libido; anorgasm; 
vaginismus.  
≥5 155 28.0 
 
0  0  0  0  
26 Avoided sexual activity ≥3 375 62.0 
 
0  0  0  0  
12 Dissatisfied w/sex life  1 item ≥5 302 49.9 
 
0  0  0  0  
10 Bothered by inability to function sexually 
    
        
Fatigue 11 Lacked energy to do things wanted to 
Low energy; 
tiredness.  
≥5 157 26.3 
 
0  0  0  0  
14 Felt tired a lot ≥3 469 77.5 
 
0  0  0  0  
1 Had energy to do things wanted to do  1 item ≥5 533 88.1 
 
0  0  0  0  
5 Felt fatigued 
    
        
Social 
avoidance 
18 Avoided social gatherings 
Social isolation; social 
avoidance.  
≥5 82 13.8 
 
0  0  0  0  
20 Avoided friends ≥3 292 48.6 
 
0  0  0  0  
25 Reluctant to meet new people 1 item ≥5 194 32.1 
 
0  0  0  0  
15 Reluctant to start new relationships 
 
                      
EHR = electronic health records; HRQoL = Health-Related Quality of Life; mo. = month. * Severe cognitive dysfunction was an exclusion criterion for the study. § 605 women participated in the 
study; due to missing data for some items, the number of women included in the denominator varies slightly by domain.  
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Table 8.4 Proportion of women who had information in the EHR who reported distressing levels when inquired about their HRQoL (N=605). 
 
    Patients with info 
for the domain 
in EHR 
 
Patients scoring as distressed, 
according to patient-reported data 
     ≥5 ≥3 
At least 
one item 5 
Domain Items in the QLACS Read codes related to: 
Time prior 
to LDC  
No. %   No. % No. % No. % 
Negative 
feelings 
19 Bothered by mood swings Depression and/or 
anxiety (disorders and 
symptoms), 
antidepressants, or 
anxiolytic prescription. 
  3 mo. 115 19.4 
 
36 31.3 88 77.4 65 55.1 
7   Felt blue or depressed   6 mo. 117 19.7 
 
37 31.6 90 76.9 66 55.0 
9   Worried about little things 12 mo. 142 23.9 
 
47 33.1 109 76.8 82 56.2 
24 Felt anxious 24 mo. 170 28.6 
 
51 30.0 129 75.9 95 54.3 
Cognitive 
problems 
3 Bothered by having a short attention span 
Cognitive impairment; 
cognitive dysfunction 
symptoms; dementia; 
dementia-specific drug.* 
  3 mo. 0  
 
-  -  -  
4 Had trouble remembering things   6 mo. 0  
 
-  -  -  
2 Difficulty doing things requiring 
concentration 
12 mo. 0  
 
-  -  -  
23 Bothered by forgetting what started to do 24 mo. 0  
 
-  -  -  
Physical pain 13 Bothered by pain preventing activities 
Pain; painful conditions; 
prescriptions of 
analgesics. 
  3 mo. 134 22.6 
 
64 47.8 105 78.4 85 62.0 
17 Mood disrupted by pain or its treatment   6 mo. 146 24.6 
 
69 47.3 115 78.8 93 62.4 
27 Pain interfered w/social activities  12 mo. 202 34.1 
 
81 40.1 151 74.8 119 57.8 
21 Had aches or pains 24 mo. 257 43.3 
 
91 35.4 184 71.6 140 53.4 
Sexual 
dysfunction 
16 Lacked interest in sex 
Low libido; anorgasm; 
vaginismus.  
  3 mo. 0  
 
-  -  -  
26 Avoided sexual activity   6 mo. 0  
 
-  -  -  
12 Dissatisfied w/sex life  12 mo. 0  
 
-  -  -  
10 Bothered by inability to function sexually 24 mo. 0  
 
-  -  -  
Fatigue 11 Lacked energy to do things wanted to 
Low energy; tiredness.  
  3 mo. 0  
 
-  -  -  
14 Felt tired a lot   6 mo. 0  
 
-  -  -  
1 Had energy to do things wanted to do  12 mo. 0  
 
-  -  -  
5 Felt fatigued 24 mo. 0  
 
-  -  -  
Social 
avoidance 
18 Avoided social gatherings 
Social isolation; social 
avoidance.  
  3 mo. 0  
 
-  -  -  
20 Avoided friends   6 mo. 0  
 
-  -  -  
25 Reluctant to meet new people 12 mo. 0  
 
-  -  -  
15 Reluctant to start new relationships 24 mo. 0     -  -   -  
EHR = electronic health records; HRQoL = Health-Related Quality of Life; mo. = month. * Severe cognitive dysfunction was an exclusion criterion for the study. § 605 women participated in the 
study; due to missing data for some items, the number of women included in the denominator varies slightly by domain.  
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8.9 Discussion and Conclusions 
The results of this study suggest that EHRs have low sensitivity to detect patients 
experiencing poor HRQoL at a particular point in time, particularly for the domains of 
sexual function, fatigue, cognitive problems and social avoidance; none of the 
patients self-reporting distress in these domains in the questionnaires had 
corresponding codes present in their electronic data. For pain and negative feelings, 
some relevant codes were present in the EHRs, but both sensitivity and positive 
predictive values were <50%, which is likely to be too low to justify the use of EHRs 
data alone as a proxy for patient-reported outcomes in these domains.  
Several factors might have affected the identification of the information in the EHRs, 
and are limitations of this study. First, no data were collected on the date of 
questionnaire response. This means that one cannot identify precisely, for each 
patient, the data from consultations that would have corresponded to when the 
patient-reported outcomes were evaluated. Since the results of the analyses using 
the January 2018 and July 2019 were very similar, this probably had little impact in 
the results. However, the July 2019 version may not capture distress recently 
acquired by patients that replied later in the year. In future follow-up work, I will 
conduct analyses using the January 2020 version, allowing me to consider EHRs 
across the full period of questionnaire data collection. The validity of the approach 
used to identify patients at probably distressed from QLACS scores has been 
untested. This limitation was addressed by using different cut-offs, which showed 
generally the same patterns. Another limitation of this study is that the database 
only captures drugs prescribed to the patients, and widely used drugs for pain and 
fatigue are sold over the counter. The comparison for cognitive problems was also 
limited by the need to exclude patients unable to reply to a self-reported 
questionnaire, which included patients with dementia, and we cannot rule out that 
general practitioners applying the exclusion criteria may have been overly strict in 
applying this criterion and also excluded those with codes for milder cognitive 
impairment (see below). 
The results showed that one in three patients that reported distressing levels of 
negative feelings had similar information recorded in their EHR in the previous three 
months. This is consistent with patients often not seeking primary care for anxiety 
and depressive symptoms, possibly due to stigma associated with mental disorders 
and unawareness of the amenability of mental health symptoms to treatment [247]. 
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Women may have felt more comfortable in disclosing these symptoms in an 
anonymous questionnaire.  
Approximately one-half of the patients that reported poor HRQoL related to pain 
also had information related to pain in the EHR in the previous three months. This 
may be partly explained by patients self-treating pain with widely used over-the-
counter treatments such as paracetamol and non-steroidal anti-inflammatory drugs 
(e.g. ibuprofen). On the other hand, the higher recording of pain compared to 
negative feelings may potentially be explained by patients seeking more often 
primary care for distressing concern that they perceive as being amenable to 
treatment. 
I did not find any records of cognitive dysfunction, social avoidance, sexual 
dysfunction or fatigue entered in the EHRs of the participating patients in the last 24 
months to the data cut-off. A complete absence of entries for social avoidance and 
sexual dysfunction are plausible. Read codes for social avoidance have seldom 
been used in the entire CPRD database, so lack of data on this in a relatively small 
patient group was expected. The absence of sexual problems in the EHRs was 
surprising, but may be explained, at least in part, by the rarity of the outcome 
(estimated in Chapter 6) and by the low proportion of subjects who ever contact 
their GPs for issues related to sexual function [65].  
The lack of recording of cognitive problems and symptoms of fatigue in the EHRs 
was also unexpected. Severe cognitive dysfunction was an exclusion criterion for 
the study; a review of the motives provided by the GPs to exclude patients showed 
a non-negligible frequency of cognitive-related reasons, including cases of dementia 
as well as reasons such as ‘memory problems’. It is possible that cases of mild 
cognitive dysfunction that had sought primary care with these complains were 
excluded, leaving an overrepresentation of women who did not seek primary care 
for their concerns. For fatigue, a manual review of all entries in the EHR of a 
random sample of patients that reported distressing levels of fatigue in the 
questionnaires, revealed a common pattern of multi and complex morbidity, almost 
always with diagnoses where fatigue is implicit (e.g. heart failure, chronic 
obstructive pulmonary disease), but no explicit codes for fatigue. Fatigue is rarely 
seen as an isolated condition, as is more often associated with other diagnoses, 
which may explain the absence of codes in the data for this. This warrants further 
investigation, however, and follow-up work will be carried out on this topic. 
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The comparison of these results to other literature was not possible as, to my 
knowledge, no other study has attempted this comparison.  
In conclusion, even though EHRs contain substantial data related to general 
domains of HRQoL, these do not appear to have good sensitivity and positive 
predictive value to capture outcomes that represent subjective experiences and are 
traditionally ascertained directly from patients. 
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8.10  Summary 
• This chapter compares patient-reported outcomes for HRQoL domains, and 
information capturing similar constructs in patients’ EHRs. 
• Data were compared for six domains (‘negative feelings’, ‘cognitive 
problems’, ‘physical pain’, ‘sexual problems’, ‘fatigue’ and ‘social 
avoidance’), as patients with high levels of distress for issues related to 
these domains may be likely to seek primary care. 
• Patients were considered to report high levels of distress for a domain when 
they reported an average response of ‘often’ to ‘always’ to items in the 
domain (e.g. items for negative feelings shown in Table 8.5, mid-column). 
• Read codes lists were defined for concepts closely related to items in each 
domain (e.g. last column of Table 8.5). 
 
Table 8.5   Example of the HRQoL domain, its items and information searched in the 
EHR. 
HRQoL domain QLACS Items 
Search in the EHR for Read 
codes* related to: 
   
Negative feelings 19 Bothered by mood swings 
7   Felt blue or depressed 
9   Worried about little things 
24 Felt anxious 
 
Depression and/or anxiety (disorders 
and symptoms), antidepressants, or 
anxiolytic prescription 
 
• Of the 100 patients that reported distressing levels of negative feelings, 17% 
had Read codes for similar constructs registered in their EHR in the previous 
three months. 
• Of the 122 patients that reported distress with pain, 50% had Read codes for 
similar constructs registered in their EHR in the previous three months. 
• Of the 605 women that participated in the study, 16% had high levels of 
distress related to cognitive problems, 28% to sexual dysfunction, 26% to 
fatigue/energy, and 14% to social avoidance. However, none had a Read 
codes related to these domains in their EHRs in the last two years. 
• Approximately 30% of the patients with information for anxiety and/or 
depression the EHR reported distress with negative feelings. For pain, 
approximately 50% of the patients that had symptoms of pain or had been 
prescribed analgesics reported distressing levels of pain. 
• Further work will include exploring different outcome definitions for EHR-
based outcomes, and more recent versions of the CPRD GOLD primary 
care database. 
• In conclusion, patient-reported HRQoL outcomes do not appear to be 
captured with adequate sensitivity in EHR data.   
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9 Discussion 
9.1 Introduction 
This closing chapter aims to summarise the main discussion issues, focusing on 
overarching points that cut across the different chapters. Detailed study-specific 
discussion points were previously covered in the relevant individual chapters. 
 
9.2 Summary of key findings 
9.2.1 Aim 1: to quantify relative risk of adverse mental health outcomes in 
breast cancer survivors, compared to women who never had cancer 
Associations between breast cancer survivorship and adverse mental 
health outcomes: a systematic review 
This systematic review included 66 studies that compared mental health conditions 
among breast cancer survivors and women with no history of cancer (Chapter 3). 
The most commonly evaluated outcomes were anxiety (n=23 studies) and 
depression (n=41). Of the 23 studies of anxiety, 12 observed more anxiety in breast 
cancer survivors, including 2/4 studies where ascertainment of anxiety was clinical/ 
prescription-based, and in 10/19 studies where ascertainment of anxiety was based 
on symptoms. Among 41 studies of depression, 22 reported significantly more 
depression in breast cancer survivors, compared to controls; this included seven of 
eight studies where depression was ascertained clinically, and 15/33 studies that 
quantified depressive symptoms. Breast cancer survivors also had statistically 
significantly increased symptoms/frequency of neurocognitive dysfunction (21/28 
studies), sexual dysfunctions (6/7 studies), sleep disturbance (5/5 studies), stress-
related disorders (2/3 studies), suicide (2/2 studies), somatisation (2/2 studies), and 
bipolar and obsessive-compulsive disorders (1/1 study each). 
Identification of mental health and quality of life outcomes in primary 
care databases in the UK: a systematic review 
This study summarised the definitions and combinations of Read and/or ICD codes 
used to identify outcomes of anxiety, depression, fatigue, cognitive and sexual 
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dysfunction, pain, sleep disorders, and fatal and non-fatal self-harm, in studies of 
EHRs from primary care databases in the UK (Chapter 4). 120 studies were eligible. 
Depression was most often defined using codes for diagnoses (37/42 studies) 
and/or antidepressants prescriptions (21/42 studies); six studies included symptoms 
in their definition. Anxiety was defined with codes for diagnoses (12/12 studies); four 
studies also included symptoms. Fatal/non-fatal self-harm was ascertained in 
primary care data linked to the ONS mortality database in nine studies. Three 
studies evaluated domains of cognitive function. Fatigue definitions varied little. No 
studies of female sexual dysfunction were found. Sleep disorders included insomnia 
and hypersomnia. Lists of Read codes were available for approximately one-half of 
the studies, and showed substantial variability; validation of codelists was carried 
out for 21/120 studies. 
Risk of adverse mental health outcomes in women who had breast 
cancer compared to women with no history of cancer in the UK: a 
population based study 
In this matched-cohort study, the aim was to estimate the risk of anxiety and 
depression, as primary outcomes, and fatigue, pain, sexual dysfunction, sleep 
disorder, cognitive dysfunction, and fatal and non-fatal self-harm, as secondary 
outcomes, in breast cancer survivors compared to women with no prior cancer, 
using EHR data routinely collected in primary care (Chapter 6). All women with 
history of incident breast cancer in the CPRD GOLD primary care database were 
included (n=57,571), and individually matched to women with no prior history of 
cancer (n=230,067), on age and primary care practice. Median follow-up time was 
approximately five years in both groups. After controlling for diabetes, body mass 
index, smoking and drinking status, breast cancer survivorship was found to be 
associated with a 33% raised risk of anxiety (HR 1.33 95%CI 1.29-1.36), and a 35% 
raised risk of depression (HR 1.35, 95% CI 1.32-1.38), as well as significantly raised 
risks of the secondary outcomes of fatigue, pain, sexual dysfunction, sleep disorder 
and opioid analgesics. However, there was no evidence of an association with 
cognitive dysfunction or fatal and non-fatal self-harm. The strength of the 
associations reduced over time but raised risks for anxiety and depression persisted 
for two and four years after cancer diagnosis, respectively. Increased levels of pain 
and sleep disorder persisted for at least 10 years. Younger age was associated with 
larger increases in the risks of depression, pain, opioid analgesic use, sleep 
disorders, and cognitive dysfunction (for which there was no association when 
considering all ages together). 
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9.2.2 Aim 2: to investigate quality of life, anxiety, and depressive symptoms in 
breast cancer survivors, compared to women with no history of cancer 
Quality of life of women who had breast cancer compared to women 
with no history of cancer 
A total of 353 breast cancer survivors and 252 women without history of cancer 
participated in the study (Chapter 7). Mean time since diagnosis was 8.1 years. 
Breast cancer survivorship was significantly associated with poorer HRQoL in the 
domains of cognitive problems, sexual function and fatigue, but no evidence of 
difference in negative feelings, positive feelings, pain, or social avoidance. Breast 
cancer survivors had a non-statistically significant 30% higher odds of probable 
anxiety (HADS-anxiety score>10), however there was a statistically significant 46% 
increase in breast cancer survivors when a more sensitive threshold (score≥8, 
“borderline/probable anxiety”) was used. The odds of depression were similar in the 
two groups. Quality of life and mental health was poorer among women with more 
advanced disease and/or treated with chemotherapy. Similarly, among breast 
cancer survivors only, younger age, lower education, more advanced disease at 
diagnosis, and/or prior receipt of chemotherapy were associated with poorer 
HRQoL. Breast cancer survivors who had advanced disease reported more 
cognitive problems, pain, sexual function, financial problems, and distress with 
appearance and recurrence compared to localised disease. Cognitive problems, 
appearance concerns, and distress with recurrence were more common in younger 
women, and in women treated with chemotherapy. 
Comparison between patient-reported outcomes and information in the 
patients’ electronic health records. 
Six hundred and five women participated in the study. One hundred women had 
answers consistent with high levels of negative feelings in the patient-reported 
outcomes. Of these, only 36% had information related to this in the EHRs in the last 
three months before the date of last data collection for the practice, and 50% had a 
record in the previous two years. One hundred and twenty two patients reported 
distress with pain; 52% and 75% of these had symptoms of pain or an analgesic 
prescriptions recorded in their EHR in the previous three and 24 months, 
respectively. A total of 93 women reported high levels of distress related to cognitive 
problems, 155 to sexual dysfunction, 157 to fatigue/energy, and 82 to social 
avoidance. No evidence of this was found in the patients’ EHRs using Read codes 
up to 24 months prior to the date of last data collection for the practice. These 
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results suggest that electronic GP records did not have sufficient sensitivity to 
reasonably capture the subjective experience mental health and HRQoL outcomes 
that we obtained directly from patients in this study. 
 
9.3  Explanation of results and comparison with the literature 
9.3.1 Anxiety 
Breast cancer survivors had increased risk of seeking primary care for anxiety in the 
two years after diagnosis (Chapter 6), and increased borderline/abnormal anxiety 
symptoms were also found in the study of patient-reported outcomes (Chapter 7). 
Similar results found in the studies included in the systematic review (Figure 9.1). 
Clinically relevant symptoms of anxiety and stress-related/adjustment disorders are 
common shortly after diagnosis [248], and are consistent with the stress induced by 
the diagnosis of a life-threatening condition. In Sweden, increased anxiety has been 
reported from the cancer diagnostic work-up [249]. This is in line with our findings, 
where more women were excluded from the exposed cohort in the study of EHRs 
because they had anxiety recorded in the year before the breast cancer diagnosis; 
most women went on to have the outcome registered after the index date. 
The results of the patient-reported outcomes, which included breast cancer 
survivors on average 8.6 years from diagnosis, showed increased risk of anxiety 
only when considering a cut-off of borderline/abnormal. The raised anxiety 
symptomatology shortly after diagnosis is expected to decrease over time, with 
women psychologically adjusting to the new reality [250, 251]. In the long term, 
breast cancer survivors may experience distress with anxiety symptoms that do not 
meet criteria for formal diagnosis, similarly to what has been described in cancer 
patients [252]. Similarly to what has been described elsewhere [253], anxiety 
symptoms in breast cancer survivors were particularly raised in younger women. 
This may be because younger breast cancer survivors have specific concerns 
compared to older ones, such as the impact of their disease and possible death in 
their offspring upbringing, and infertility for women who want (more) children.  
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Figure 9.1   Results for anxiety and depression clinically assessed (Chapter 6), and symptoms 
of anxiety and depression (Chapter 7) (Study ID = ***Carreira et al. 2020) compared to the 
studies identified in the systematic review (Chapter 3). 
 
Women treated with chemotherapy had exacerbated symptoms of anxiety possible 
due to fear of the side effects of chemotherapy and physical changes induced by 
the treatment [254]. HRQoL items for anxiety were included in the domain of 
negative feelings, alongside depression, which precludes a formal comparison of 
the results for anxiety with those for the domain of negative feelings. 
9.3.2 Depression 
Breast cancer survivors had increased risk of depression, compared to women with 
no prior cancer, for up to four years post-diagnosis in the study using primary care 
EHRs (Chapter 6). This is consistent with other studies of depression in breast 
cancer survivors using clinically assessed outcomes (Figure 9.1). One such study, 
by Khan et al [255], that included breast cancer survivors in the UK five or more 
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years post diagnosis, did not find higher odds of being diagnosed with anxiety or 
depression, compared to controls. The absence of evidence for a raised depression 
in the study of patient-reported outcomes (Chapter 7) may represent a lack of effect 
on the risk of depression among participants that were on average 8.1 years out of 
their breast cancer diagnosis, or could reflect a lack of power to detect small 
differences in this outcome. Breast cancer survivors that had a higher education 
degree reported fewer symptoms of depression, which is in line with previous 
studies suggesting that lower socio-economic status is a risk factor for depression, 
possibly due to higher baseline levels of distress and less access and utilization of 
mental health services [13, 256]. Similarly to anxiety, younger women had reported 
more depressive symptoms compared to older women, suggesting poorer 
adjustment amongst this group [253]. This younger group may be more sensitive to 
the negative consequences of breast cancer, such as the impact on loved ones, or 
the lifestyle changes induced by the cancer, among others [257-259]. 
9.3.3 Neurocognitive dysfunction 
Neurocognitive dysfunction has been widely reported in breast cancer survivors 
[150, 268-271], and is thought to arise from the neurotoxic effects of chemotherapy 
[155], psychological symptoms such as post-traumatic stress [272], or exposure to 
hormone therapy [273]. Impairments are usually observed for domains of cognitive 
function such as memory, but these are generally mild and may not completely 
impede most daily activities, even though they may cause distress [274]. 
 
Figure 9.2   Results for cognitive dysfunction, sexual dysfunction, sleep disorder, suicide, and 
fatal and non-fatal self-harm reported in Chapter 6 (Study ID = ***Carreira et al. 2020), 
compared to the studies identified in the systematic review (Chapter 3). 
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The reasons for a lack of association between breast cancer survivorship and 
cognitive dysfunction in the study of EHRs (Chapter 6) require further exploration, 
but the results of Chapter 8 suggest that EHRs may sub optimally capture cases of 
mild cognitive dysfunction (see section 9.4.2 on the ascertainment of the outcomes). 
This might be because patients do not seek their GP with cognitive problems as 
their chief complaint, or that GPs do not record these symptoms using Read codes. 
In the systematic review (Chapter 3), all studies of cognitive dysfunction used 
batteries of cognitive tests to assess the outcomes (Figure 9.2). The results 
obtained by these very specific tools are unlikely to be comparable to assessments 
of cognitive function in everyday clinical practice. In contrast to the results of the 
EHR  study, the analysis of patient-reported outcomes showed long-term breast 
cancer survivors reporting poorer HRQoL related to cognitive problems compared 
with controls (Chapter 7), similarly to other studies [275]. 
9.3.4 Fatigue 
Symptoms of fatigue were more common in breast cancer survivors than in women 
who never had cancer, and the increased risk persisted for 5-10 years after 
diagnosis (Chapter 6). This is consistent with a vast body of research that describes 
fatigue as a common side effect of chemotherapy and radiotherapy [140]. Several 
biological mechanisms have been postulated, including inflammation, alterations in 
leucocytes, anaemia, five hydroxyl tryptophan (5-HT) dysregulation, among others 
[276]. Fatigue is highly debilitating and often interferes with normal daily functioning. 
This is likely to explain the poorer HRQoL related to this domain among breast 
cancer survivors found in Chapter 7, and in other studies [275]. 
9.3.5 Sexual dysfunction 
Even though codes for sexual dysfunction were rarely used in the CPRD GOLD 
primary care database, breast cancer survivors had significantly increased risk 
compared to non-cancer controls (Chapter 6), similarly to studies included in the 
systematic review (Figure 9.2). The study of patient-reported outcomes also found 
poorer HRQoL related to this domain in breast cancer survivors (Chapter 7). Sexual 
dysfunction in breast cancer survivors has a complex aetiology, often including 
vaginal dryness and vaginal atrophy due to oestrogen deprivation, body image 
concerns, low self-esteem, depressive symptoms, among others [277, 278]. 
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9.3.6 Pain 
In CPRD, breast cancer survivors had higher frequency of pain compared to 
controls. It is possible that breast cancer survivors are more in contact with health 
care services, and thus have symptoms more often recorded (Chapter 6). However, 
these patients were also found to have increased prescriptions of analgesic opioids, 
which suggests that their pain may be more severe, as mild symptoms of pain are 
usually managed with paracetamol or nonsteroidal anti-inflammatory drugs. The 
increase in the prescriptions of opioid analgesics over calendar time was observed 
at the same time as symptoms of anxiety decreased; this may be due to improved 
pain management in these patients. No differences in the domain of physical pain 
were observed in the study of patient-reported outcomes (Chapter 7), which may be 
explained by patients having effective pharmacological management of their pain. 
This is also supported by the high proportion of patients reporting poor HRQoL 
related to pain and who had similar information recorded in the EHR, which 
suggests that patients do seek care for symptoms of pain (Chapter 8). 
9.3.7 Sleep disorders 
The increased risk of sleep disorders found in the study of EHRs (Chapter 7) is 
consistent with the few previous studies on this topic (vide Chapter 3). The 
trajectories of sleep disorders after breast cancer diagnosis have seldom been 
investigated, and the results in this thesis represent an important contribution to 
knowledge in this area. The aetiology of sleep disturbances is also largely unclear, 
but may involve comorbid anxiety, vasomotor symptoms may also interfere with 
sleep [279], as well as exposure to steroids [280] or chemotherapy [281]. Sleep is 
not a dimension captured in the QLACS scale, and no patient-reported information 
was available. 
9.3.8 Fatal and non-fatal self-harm 
Suicide and self-harm are relatively rare outcomes which require studies to include 
large samples to have sufficient power to study these associations. Even though we 
included all women with history of breast cancer in the CPRD GOLD primary care 
database, our study was underpowered to detect differences between the two 
groups, should these exist. Similar limitations have affected several locale-specific 
studies [260-265], although a statistically significant raised risk of suicide was 
demonstrated in a large international study of over 721,000 breast cancer survivors 
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[266]. The non-statistically significant raised risk of non-fatal self-harm follows the 
expected direction, as only a small proportion of the patients who attempt suicide 
actually complete it [2]. Self-harm almost always occurs with other mental health 
conditions, as the physical manifestation of the patient’s psychological distress 
[267]. This was the first study, to my knowledge, to address non-fatal self-harm in 
breast cancer survivors compared to non-cancer controls. 
9.4  Strengths and limitations 
9.4.1 Selection of the samples 
The systematic assessment of the literature (Chapter 3) showed that nearly one-half 
of studies had a high risk of selection bias due to recruitment of convenience 
samples and a high proportions of patients refusing to participate in the study. In 
addition, studies were heterogeneous in terms of participants’ characteristics, 
clinical profile of the patients, and inclusion of patients at different times since 
diagnosis. This limited generalisability of results to the broad group of breast cancer 
survivors in the source population. In this thesis, population-based data were used 
to quantify the association between breast cancer survivorship and adverse mental 
health-related outcomes, and to identify patients for the study of quality of life; no 
restrictions were applied in terms of time since diagnosis, stage of the disease, 
disease progression, or comorbidity, and therefore the results in this thesis are more 
likely to apply to the broad population of breast cancer survivors. Selection bias is 
unlikely to have affected the results of the study of EHRs (Chapter 6). However, the 
participation rate in the study of patient-reported outcomes (Chapter 7) was low, and 
this might have introduced bias in the results. Even though participants and non-
participants were similar in age and practice-postcode IMD quintile, they may have 
differed in terms of the outcome, as surveys tend to include healthier women. The 
results of this study may not be generalisable to the whole UK, as participation rate 
was very low in Northern Ireland. 
9.4.2 Ascertainment of the exposure 
All participants in the research presented in Chapters 6, 7 and 9 were identified from 
the CPRD GOLD primary care database, which includes more than 90% of the 
cancers registered in the cancer registry (gold standard, as notification is required 
by law) [217]. This was considered acceptable for the study using EHRs only 
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(Chapter 6), and preferable to the alternative of using primary care data linked to 
data from cancer registries, which is only possible for nearly 50% of the primary 
care practices in England, and would limit sample size and power, in addition to limit 
the generalisability of the results. In the study involving patient-reported outcomes 
(Chapter 7), the lists of potentially eligible patients were selected from the CPRD 
GOLD database using the same methods and GPs were asked to confirm each 
patient’s eligibility, which largely reduced the potential for misclassification of the 
exposure in this study. The results of the exclusions in this study also showed a low 
potential for misclassification in the study of EHRs, especially among breast cancer 
survivors, as only one of the 98 patients excluded from this group was excluded 
because they did not have breast cancer. 
9.4.3 Ascertainment of outcomes 
The CPRD GOLD primary care database is expected to have good sensitivity to 
capture mental health-related clinical diagnoses because of the breadth of the data 
available that includes symptoms, diagnoses and drug prescriptions, among others. 
This is in contrast to the studies of EHRs identified in Chapter 3, which often used 
data from psychiatric registries in the Nordic countries, that are likely to have very 
high specificity, but they may lack sensitivity. For example, the Danish Psychiatric 
Central Research Register includes data on psychiatric admissions, emergency 
room contacts, and outpatient treatments for mental disorders, but does not include 
most of the mild and moderate cases diagnosed and treated in primary care [282]. It 
reassuring that all results point towards similar conclusions. 
A limitation of this thesis is the lack of validation of the outcomes definitions using 
the lists of codes produced for this thesis. The protocol of the study in Chapter 6 
(available in Appendix 3) included plans to externally validate the results of the 
codelists using as gold standard data from the Adult Psychiatric Morbidity Survey 
[283]. However, such comparison was deemed unwise upon further assessment 
because this survey contains data on the frequency of selected mental disorders 
(e.g. generalised anxiety disorder, depressive episodes) in the week before the 
interview, evaluated with the revised Clinical Interview Schedule [284], and 
classified with the ICD-10 diagnostic criteria [223]. This is by far more specific than 
what could be reasonably obtained with EHRs, and thus no comparison was done. 
However, I attempted to minimise this limitation by producing codelists using a 
systematic approach (described in Appendix 3), and the results of previous 
validation studies included in Chapter 5 showed high positive predictive values. 
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The study of patient-reported outcomes (Chapter 7) used questionnaires to collect 
data on HRQoL and symptoms of anxiety and depression. While questionnaires are 
the preferred method to quantify HRQoL [285], the results for anxiety and 
depression should be interpreted as patients being at risk of the disorders, as HADS 
is a screening and not diagnostic tool. 
9.4.4 Study designs 
The study that quantified the risk of adverse mental health outcomes in breast 
cancer survivors compared to controls (Chapter 6) had a longitudinal study design 
and excluded women with evidence of the disorder in the year prior to the breast 
cancer exposure, ensuring that all events were incident. This is an important 
advantage of the research in this thesis compared to the previous studies whose 
cross-sectional design precluded the unequivocal assertion that the onset of the 
mental disorder was posterior to the breast cancer diagnosis (see Chapter 3). 
A cross-sectional study design was chosen to evaluate HRQoL and mental health 
outcomes in breast cancer survivors and women with no history of cancer (Chapter 
7). Unfortunately, resources were not available for a longitudinal study on HRQoL to 
ensure temporality. Despite this, the results of the comparison are still of interest for 
clinical practice, and they showed that women with breast cancer survivors have 
poorer HRQoL for some domains compared to women with no history of cancer. 
9.4.5 Control for confounding 
The breadth of information available in the CPRD GOLD primary care database 
enabled me to estimate the risk of adverse mental health outcomes in breast cancer 
survivors (Chapter 6), while controlling for important confounders such as age and 
deprivation at study design, and other confounders that have rarely been taken into 
account. The confounding effects of body mass index, smoking, and alcohol 
drinking, were also adjusted for, which was seldom done in previous studies. One 
must acknowledge, however, that the quality of the adjustments depended on the 
quality of the data recorded in the EHRs. For some variables, such as smoking 
(current, former or never smokers), no detailed data on frequency or quantity were 
available for analysis. The broad levels of exposure used may not have been 
sufficient to completely remove the effect of smoking or alcohol drinking. In addition, 
missing data for these variables is likely to depend on the values (e.g. a patient with 
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obesity may be more likely to have this recorded in the EHR than a patient with 
normal weight), which precluded multi-imputation of the missing values.  
9.4.6 Role of chance 
The CPRD GOLD primary care database is one of the largest databases of EHRs of 
longitudinal data at patient level, including over 18 million patients, and the study of 
the risk of adverse mental health-related outcomes (Chapter 6) was well powered to 
detect differences in the risk between the two groups. The sample size calculations 
presented in the study protocol showed that the number of breast cancer survivors 
(the limiting factor, since controls would be easier to find) would provide sufficient 
power to estimate associations of similar magnitude of that reported in previous 
studies. The study of patient-reported outcomes (Chapter 7) was also well powered 
to compare HRQoL between the two groups, as well as mean scores of anxiety, but 
was underpowered to compare the mean scores of depression, and anxiety and 
depression categorised with the relevant cut-offs, between the two groups. 
Unfortunately, the sample size calculations showed that 26,340 women (13,170 in 
each group) would need to be invited to participate in the study to reduce the 
potential for an erroneous conclusion in all comparisons. This was not feasible for 
this PhD for reasons of time and cost. The study of patient-reported outcomes was 
still larger than most studies identified in the systematic review (Chapter 3), and 
confidence intervals were reported, when possible, to enable the reader to infer on 
the direction and precision of the estimates. 
9.4.7 Multiple approaches 
A strength of this thesis is the use of multiple approaches (e.g. data routinely 
collected as well as patient-reported outcomes) and study designs (i.e. systematic 
review, matched cohort study, cross-sectional study) to address the aims. Even 
though each approach has limitations, the use of multiple approaches helped to 
overcome those inherent to any single approach. For example, selection bias 
cannot be ruled out from the study of patient-reported outcomes (Chapter 7), but the 
results of the study that used only data from the CPRD GOLD primary care 
database (Chapter 6) are unlikely to have been importantly affected by selection 
bias. On the other hand, patient-reported outcomes allowed for the capture of 
subjective experiences that may negatively affect a patient’s HRQoL, but are less 
likely to be captured in the EHRs. 
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Another strength of the study involving EHRs only (Chapter 6) was that the breadth 
of data in the CPRD GOLD primary care database allowed for multiple outcomes to 
be studied. This provided a comprehensive picture of the burden of mental health-
related conditions in this patient population. The systematic review of the adverse 
mental health outcomes in breast cancer survivors (Chapter 3) included studies 
looking at any adverse mental health outcome, which allowed for the identification of 
outcomes for which not much is known (e.g. sleep disorders), and their subsequent 
study. 
 
 
9.5 Contribution to knowledge 
9.5.1 Summary of the evidence on the associations between breast cancer 
survivorship and mental health conditions 
The main focus of studies of mental health in breast cancer survivors tend to be on 
outcomes of depression and anxiety and as a result systematic reviews on the topic 
also narrowly concentrated on these alone. Chapter 3 not only provides an up-to-
date summary of the evidence available on depression and anxiety but included all 
mental health outcomes listed in DSM/ICD in the search where data were available. 
This added a level of comprehensiveness not previously seen and confirmed the 
paucity of evidence on a range of other outcomes including sleep disorders and 
sexual dysfunction. 
9.5.2 Risk of mental health and quality of life-related outcomes in breast cancer 
survivors in the UK, compared to women who have not had cancer 
Previously, of the 66 studies investigating mental health outcomes in female breast 
cancer survivors compared to those without cancer, only one was conducted in the 
UK [255], including data from three years on breast cancer survivors five or more 
years into the survivorship period, and focused on two outcomes, anxiety and 
depression. The research in this thesis built on this previous work, analysing 31 
years of data, from 1988 to 2018, to evaluate the risk of not only anxiety and 
depression, but seven other mental health and HRQoL-related outcomes and 
investigated associations from as early as the first year after diagnosis. This 
generated evidence for outcomes where none existed (cognitive dysfunction, 
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fatigue, sexual dysfunction, pain, opioid prescriptions, sleep disorders, and fatal and 
non-fatal self-harm), and provided estimates of the risk of anxiety and depression in 
the early period of cancer survivorship. In doing this, it was also demonstrated the 
feasibility of using the CPRD primary care database to study these outcomes. 
9.5.3 Quality of life of breast cancer survivors in the UK compared to women 
who did not have cancer 
Very few studies are available for the HRQoL of breast cancer survivors in the UK. 
Where existing, these most often used tools that only comprised generic domains of 
quality of life, or that were created for the treatment period; both of which may not 
fully capture the experience of living beyond the acute phases of breast cancer 
treatment. In this thesis, HRQoL was measured with a validated tool developed for 
long-term cancer survivors, including domains for generic as well as cancer-specific 
quality of life. The novel research in this thesis provides robust results on the 
comparison of HRQoL in long-term breast cancer survivors in the UK, compared to 
women who never had cancer. The results not only highlighted that breast cancer 
survivors experienced impaired quality of life in the domains of cognitive function, 
fatigue and sexual dysfunction but also identified a high-risk group of the population 
(more advanced disease and/or treated with chemotherapy) with poorer quality of 
life compared to other breast cancer survivors and those without cancer. 
9.5.4 Comparison of data in clinical records and patient-reported outcomes 
EHRs hold information for several domains of HRQoL but its use as a proxy for the 
patients’ HRQoL had never been assessed. The results of this thesis show that 
EHR are unlikely to be a good source of data to study HRQoL. This highlights the 
importance of patient reported outcomes, which even though costly or time 
consuming to collect, adds much needed insight into those quality of life outcomes 
not routinely captured in GP practices. 
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9.6 Implications for clinical practice 
9.6.1 Patient education on the mental health consequences of their disease 
throughout the survivorship continuum 
Patient education for prevention and early detection of treatment-related sequelae 
should start as early as possible (in the pre-operative period) [286], but current 
models focus on physical aspects and overlook mental health [286, 287]. Raising 
patient awareness on mental health conditions is needed, particularly as recent 
research showed that eight in 10 women with breast cancer were not told about the 
potential long-term impact of the cancer on their mental health [288]. Talking about 
mental health and common emotional challenges experienced by other patients 
may help women to understand better their own emotional journey, reduce stigma, 
and encourage patients to raise concerns about their mental health should they 
need. Educational interventions for fatigue, for example, have been shown to 
decrease anxiety and improve HRQoL [289]. 
9.6.2 Increased screening of mental disorders in breast cancer survivors 
followed in primary care may be needed 
The raised risk of several mental disorders in breast cancer survivors calls for 
increased surveillance in primary care, especially among younger women (<60 
years) and women treated with chemotherapy. For depression, a risk prediction 
algorithm is available and may help identify patients at increased risk [290]. NICE 
guidelines also recommend opportunistic screening for depression in adults with a 
chronic health problem [291]. The optimal screening method will depend on the 
specific mental health condition but, when possible, data should be collected using 
validated tools to enable progress monitoring [291]. It should be noted that patients 
may benefit from being asked about fatigue, cognitive and sexual dysfunction, as 
these were shown to negatively affected patients’ HRQoL but were rarely recorded 
in the patients’ EHRs. 
9.6.3 Increased awareness of mental health-related conditions among health-
care professionals is needed 
Increased awareness among health care professionals, particularly primary care 
physicians, of the raised risks of anxiety, depression, fatigue, sexual dysfunction, 
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sleep disturbance and pain is needed to improve detection of the mental health 
conditions. Increased awareness may also help with communication between 
patients and clinicians, particularly about fatigue, cognitive problems, and sexual 
dysfunction, which negatively influence HRQoL. Communication about sex-related 
issues appears to be poor [292], highlighting the need for GPs to raise these issues 
[293]. 
9.6.4 Equipping health care professionals with evidence-based strategies to 
identify and manage mental health conditions in breast cancer survivors 
may be needed 
Identification and management of mental health conditions in breast cancer 
survivors can be challenging due to the short consultation times with a panoply of 
somatic and psychological manifestations [294], and due to uncertainty about 
effectiveness and/or safety of the interventions. For sexual dysfunction, for example, 
clinicians tend to have little training on the topic [293, 295], and some may have 
concerns over the effect of hormonal vaginal treatments in patients with oestrogen-
receptor positive breast cancer [296] and be unaware of the recommendations for 
lubricants and moisturisers [297]. Safety concerns have also been raised for the 
treatment of severe anxiety and depression with antidepressants, as per guidelines 
[53, 298], due to a possible interaction between antidepressants and tamoxifen. 
This is biologically plausible, as both substances are metabolised by cytochrome 
P450, and since antidepressants tend to have a better affinity for the enzyme, there 
is a potential for preferential binding of tamoxifen [299]. Studies have reported 
contradictory results about the increased risk of cancer recurrence in breast cancer 
patients taking antidepressants, with some studies finding no effect for any 
antidepressant [300], while others found increased risk of recurrence in patients 
prescribed paroxetine or trazodone [301]. Whether information is lacking or 
available, there is a need to equip health care professionals with clear guidance on 
what is safe and unsafe, effective and ineffective, as well as unclear interventions in 
these patients. 
9.6.5 Encouraging utilization of cancer rehabilitation services, and other forms 
of social interaction 
Of the variables that were found to be associated with poorer HRQoL (i.e. younger 
age, lower education, chemotherapy treatment), none are amenable to change. 
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However, there is evidence that factors such as social support and physical activity 
exert a protective effect on depression [21-23]. Recently, it has been reported that 
75% of breast cancer survivors in the UK felt more socially isolated at the end of 
treatment than at diagnosis [288]. Raising awareness about the services available 
to patients, and how to access them, cannot be overlooked (e.g. support from 
Breast Cancer Care, or Mind, two UK based charities that provide support to breast 
cancer patients in need). 
 
 
9.7 Implications for public health policy 
9.7.1 Current provision of post-treatment support 
Recognising the need for post-treatment support in cancer survivors, UK countries 
set out organised strategies for patients beyond cancer [302-304]. In England, the 
cancer strategy ‘Achieving World-Class Cancer Outcomes: A Strategy for Cancer 
2015-2020’ includes access to a Recovery Package by 2020 among their goals 
[302]. Development of the cancer strategy included a Health and Wellbeing event, in 
which an overwhelming 96% of patients supported the idea of a breast cancer-
specific health and wellbeing course at the end of treatment [305]. However, data to 
date show that 51% of NHS Hospital trusts do not provide breast cancer-specific 
support events. Breast cancer survivors seeking NHS support for mental health will 
be affected by the long waiting times currently observed. A survey commissioned by 
the Royal College of Psychiatrists revealed that one in four patients with a 
diagnosed mental health condition waited more than three months to access 
treatment in a NHS mental health service after referral [306]. 
9.7.2 Current needs and future planning 
Public health interventions to tackle the burden of mental health conditions ought to 
be comprehensive, including risk reducing and reactive strategies. Preventive 
strategies such as improved patient support and patient education during the 
continuity of care cannot be overemphasized. Breast Cancer Now has created a 
course tailored to breast cancer survivors, which was found to improve patients’ 
HRQoL, emotional wellbeing, and self-management measures [307]. Public health 
organisations should work towards every patient being able to access information 
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that meets their needs. Once significant distress is present, strategies are needed 
for early diagnosis and treatment of these conditions. As many as 41% of women in 
England reported not having received the professional support needed to cope with 
the long-term consequences of their disease [308]. This highlights the need for 
Cancer Alliances to provide or improve access to personalised support, as outlined 
in their priorities for 2019/2020 [308]. 
Mental health services are burdensome for publicly funded health care services, 
and the long-term provision of care that suits patients’ needs is likely to require 
substantial investments, both in physical structures and in personnel. Waiting times 
for access to treatment for common mental health conditions needs to be shortened 
by increasing the supply of services, as current targets (75% of patients referred be 
treated within six weeks [309]) are not being met. Long term planning also needs to 
consider the need to build capacity in delivering psycho-oncology care. 
 
9.8 Implications for further research 
9.8.1 Drivers of the association between breast cancer survivorship and 
adverse mental health outcomes 
One priority area for future research is to investigate the role of mediators of the 
association between breast cancer survivorship and adverse mental health 
outcomes, such as the type of surgery (lumpectomy vs. mastectomy, with and 
without reconstruction), receipt and type of systemic treatment (chemotherapy, 
endocrine and/or immunotherapy), tumour characteristics as well as presence of 
lymphedema. The role of having had disease progression, or another cancer 
diagnosis, also needs to be explored. The effect of age on the likelihood of cognitive 
dysfunction recorded in the EHRs also deserves further attention to ascertain 
whether this is a true increased risk, or differential recording of these codes by GPs. 
The aetiological components of the disorders also need to be explored further. The 
impact of chemotherapy, endocrine therapy and immunotherapy on depression, 
fatigue, sexual dysfunction and pain needs clarification, as these conditions 
negatively affect the patients’ HRQoL and little is known about the exact 
mechanisms by which the risk is increased. Cognitive dysfunction has traditionally 
been linked to the cytotoxic effect of chemotherapy, but recent studies suggest that 
this might be mediated by post-traumatic stress symptoms [272]. A better 
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understanding of the drivers of adverse outcomes would help to identify 
opportunities for intervention, prevention and support. 
9.8.2 Validation of the list of Read codes used to define mental health 
conditions 
Recently, the Mental Health Data Set (MHDS) became available for linkage with the 
CPRD GOLD primary care database. This data set includes data from adult patients 
who accessed mental health services in secondary care and are thought to be 
suffering from a mental illness [310]. This could be used as the gold standard in a 
validation study aiming to assess the validity of Read codelists. 
9.8.3 Longitudinal assessment of HRQoL in breast cancer survivors 
Studies should focus on the longitudinal assessment of HRQoL in breast cancer 
survivors, as results are likely to change by domain across the survivorship period, 
and could help to identify critical periods for intervention (e.g. depression may arise 
on discharge from hospital follow-up, when women often feel isolated [288]). 
9.8.4 Comparison of mental health outcomes in women who had breast cancer, 
women treated for in situ tumours, and women with no history of cancer.  
The introduction of mass screening programs for breast cancer in the last decades 
resulted in many women being detected with in situ tumours, most often ductal 
carcinomas in situ. Patients diagnosed with non-invasive tumours have very good 
prognosis (10-year observed survival for patients surgically treated of 98.5% [311]), 
however, there is the potential for comparable adverse psychological effects as 
treatment modalities are similar to that of early-stage invasive breast cancer. This 
should be the subject of future studies. Also, the mental health impact of screening 
needs to be considered, particularly of false positive results. 
9.8.5 Pressing need for evidence-based interventions for treatment of breast 
cancer survivors with mental health conditions 
The benefit of most interventions for mental health conditions in breast cancer 
survivors needs to be established, including the optimal setting, method, and timing. 
There is an important gap in research about effective treatment strategies for 
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fatigue, sexual dysfunction and cognitive dysfunction, all of which negatively 
affected HRQoL. Trials are also needed to pilot and evaluate the feasibility and 
effect of interventions aiming at raising awareness and screening for mental health 
conditions. The acceptability of the interventions is likely to vary by age and physical 
condition of the patients (e.g. internet-based interventions may have less 
acceptability among senior patients). 
 
9.9 Conclusions 
In conclusion, breast cancer survivors in the United Kingdom have an increased risk 
of anxiety, depression, fatigue, pain, sexual dysfunction, sleep disorder and being 
prescribed opioid analgesics compared to women with no history of cancer. The risk 
of these disorders was particularly elevated in women within the first few years of 
breast cancer survivorship, and more pronounced in younger women. Increased 
risks of fatigue and pain were found to persist for 5-10 years post-diagnosis. In 
addition, breast cancer survivors had poorer HRQoL in the domains of cognitive 
problems, sexual function, and fatigue. Women with advanced-stage cancer at 
diagnosis, and/or treated with chemotherapy, had poorer HRQoL and mental health. 
It is imperative to raise awareness among patients, health-care professionals, and 
policy makers about the specific needs to the largest group of cancer survivors in 
the UK.  
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11.1 Appendix 1   Supplementary materials to the paper in Chapter 3 
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Supplementary Materials 
Supplementary Table 1. MEDLINE search expression in OVID®. 
 
# Search 
1 exp Breast Neoplasms/ 
2 (breast and (cancer* or carcinoma* or tumo?r* or neoplas*)).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] 
3 1 or 2 
 
4 exp catatonia/ or exp depression/ or exp self-injurious behavior/ or exp anxiety/ 
5 mental disorders/ or exp anxiety disorders/ or exp "bipolar and related disorders"/ or exp 
"disruptive, impulse control, and conduct disorders"/ or exp dissociative disorders/ or "feeding 
and eating disorders"/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or 
pica/ or exp mood disorders/ or exp motor disorders/ or neurocognitive disorders/ or amnesia/ 
or cognition disorders/ or auditory perceptual disorders/ or mild cognitive impairment/ or 
consciousness disorders/ or delirium/ or dementia/ or exp neurotic disorders/ or exp 
personality disorders/ or exp "schizophrenia spectrum and other psychotic disorders"/ or 
sexual dysfunctions, psychological/ or exp sleep wake disorders/ or exp somatoform 
disorders/ or exp substance-related disorders/ or exp "trauma and stressor related disorders"/ 
6 (depressi* or dysthymia or catatonia or self-injur* or self-injury or self-injurious or self-
mutilation or "self mutilation" or suicid* or self-harm or "self harm" or "self injury" or anxious* or 
anxiety or (panic adj1 (disorder# or attack#)) or catastrophi* or (mental adj1 (disorder or 
disorders)) or phobia or phobic or neurotic or (compulsive adj1 disorder) or bipolar or neurotic 
or (personality adj1 disorder) or psychotic or psychosis or paranoid or delusional or (sexual 
adj1 (disorder or dysfunction or problem#)) or insomnias or (sleep adj1 (disorder or 
dysfunction or problem#)) or somatoform or (substance adj3 (disorder or problem#)) or stress 
ajd3 disorder or (adjustment adj3 disorder)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
7 4 or 5 or 6 
 
8 (prevalence# or frequenc* or incidence# or risk or rate* or ratio or odds or epidemiolog* or 
percent* or outcomes or hazard).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
9 3 and 7 and 8 
 
10 Humans/ 
11 Animals/ 
12 10 and 11 
13 11 not 12 
 
14 9 not 13 
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Supplementary Table 2. Criteria used to judge the risk of bias in the systematic review studies.  
 
Judgment 
 
Selection bias  Outcome variable: 
information bias 
 Design-specific 
source of bias 
(temporality) 
 Confounding by age and 
socio-economic status 
 Statistical 
methods 
 Missing data  Conflict of 
interest 
               
Low risk of 
bias 
 
Describes the source and 
methods of selection of the 
participants 
AND 
Eligibility criteria given 
AND 
(Participants selected at 
random OR population-based 
study) 
AND 
Proportion of participation 
>50% 
AND/OR 
≤30% of attrition (for cohort 
studies with a pre-defined 
follow up time for the entire 
cohort) 
 Outcome assessed through one of 
the following: 
Psychiatric interviews 
OR 
Evidence of having been prescribed 
anxiolytics (for anxiety) and 
antidepressants (for depression) 
OR 
Record of a diagnostic code for 
mental health (for studies including 
electronic health records) 
OR 
Country's official mortality registry 
data (for completed suicide) 
OR 
Objective data on the trajectories of 
cognitive function over time (for 
neurocognitive dysfunction) 
 The breast cancer 
diagnosis preceded the 
onset of the mental health 
outcome  
OR 
Diagnosis of the relevant 
outcome prior to the BC 
diagnosis taken into 
account by restriction, 
matching or in multivariate 
analysis 
 
 The study attempts to minimise 
confounding using one or more of 
the following: 
 
Matching for age and for an 
indicator of socio-economic status 
(e.g. education, attending the 
same primary care practice, or 
small geographic area) 
AND/OR 
Multivariate analysis, reporting 
mean scores or association 
measures, adjusted for age and a 
socio-economic status indicator 
 Appropriate use 
of statistics for 
primary analysis 
of effect 
(specific to each 
study design 
and data) 
 ≤15% of missing data 
(for studies with 
questionnaires), with or 
without multiple 
imputation methods for 
missing data 
OR 
>15% of missing data, 
with missing data 
imputed using multiple 
imputation methods 
 The study 
authors explicitly 
report the 
existence, or 
not, of conflicts 
of interests 
OR 
The study's 
funding source 
is acknowledged 
               
High risk of 
bias 
 
Participants not selected at 
random 
OR 
Proportion of participation 
≤50% 
OR 
Women selected on the basis 
of a the relevant mental health 
outcome for this review 
OR 
>30% of attrition (for cohort 
studies with a pre-defined 
follow up time for the entire 
cohort) 
 Self-reported intake of anxiolytics 
(for anxiety) OR antidepressants (for 
depression) 
 Unclear whether the onset 
of the mental health 
outcome occurred before 
or after the breast cancer 
diagnosis 
OR 
Diagnoses of mental 
disorders before the onset 
of the BC not considered 
 
 The study only reports crude 
measures of frequency or 
association (e.g. univariate 
association, or mean scores of the 
instrument) 
OR 
(There are differences between the 
two the group of breast cancer 
survivors and the women in the 
comparison group for age OR for 
an indicator of socio-economic 
status) 
 Not appropriate 
use of statistics 
for primary 
analysis of 
effect 
 >15% of missing data 
(for studies using 
questionnaires), with 
missing data imputed 
with a measure of 
central tendency 
 The presence or 
absence of 
conflicts of 
interest is not 
reported and 
thus unknown 
AND 
No study's 
funding source 
is acknowledged 
               
Unclear 
risk of bias 
 
Unknown method of 
participants' recruitment 
OR 
Unknown exclusion criteria 
OR 
Unknown participation rate 
 Outcome assessed using self-
reported scales 
 Not applicable  The study reports mean scores or 
measured of associations that 
were adjusted for an unclear or 
unknown list of potential 
confounders 
 Statistical 
methods not 
reported 
 Proportion of missing 
data not reported (for 
studies involving 
questionnaires) 
 
Not applicable if the 
study uses data from 
diagnoses ascertained 
via electronic records, or 
if formal statistical 
comparisons between 
breast cancer survivors 
and women who did not 
have cancer could not 
be done. 
 Not applicable 
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Supplementary Table 3. Anxiety: main characteristics and results of the studies that compared the risk, prevalence or severity of anxiety (disorders or 
symptoms) between breast cancer survivors (>1 year) and women who did not have cancer. 
 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome 
assessment 
Quantitative measure of the 
outcome  
Relative risk 
estimate 
(RR, OR, SIR, PR) 
P-value or 95% 
confidence 
interval 
Notes 
Type of 
population and 
main 
characteristics 
 
Stage at 
diagnosis 
(%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis/ 
treatment in 
years: mean/ 
median (SD), 
range 
Type of population 
and 
main 
characteristics 
 
Breast cancer 
survivors 
Comparison 
group 
 
Electronic health records 
 
Hjerl et al., 
2002 [1] 
 
Denmark 
 
 
 
(continues) 
Population-based 
 
All 60,431 women 
aged >15 years 
with a first primary 
invasive breast 
cancer registered in 
the national Cancer 
Registry in 
1970-1993. 
 
All ND 4 (ND), 0-15 
 
(Median 
cohort follow 
up: 4 years 
since 
diagnosis; 
range:  
0 to 15) 
Population-based 
 
Danish female 
population 
aged >15 years. 
EHR, first ever 
psychiatric 
admission, as 
registered in the 
Danish Psychiatric 
Central Registry 
 
ICD-8 codes: 
300.81 and 
300.00-300.99, 
except 300.49 
 
Cumulative 
incidence: 
0.25% 
Cumulative 
incidence: 
0.20% 
SIR= 1.3 * 95%CI: 1.1-1.5 
Standardised incidence ratio 
estimated considering all follow 
up time since diagnosis. 
By age: 
30-34: SIR= 1.93 
35-39: SIR= 1.28 
40-44: SIR= 0.91 
45-49: SIR= 0.89 
50-54: SIR= 1.24 
55-59: SIR= 1.56 * 
60-64: SIR= 1.18 
65-69: SIR= 1.42 
70-74: SIR= 1.98 * 
75-79: SIR= 0.47 
80-84: SIR= 1.27 
85-89: SIR= 2.91 
≥90: SIR= 8.74 
By age: 
95%CI:0.69-4.15 
95%CI:0.58-2.38 
95%CI:0.48-1.52 
95%CI:0.54-1.37 
95%CI:0.84-1.76 
95%CI:1.04-2.22 
95%CI:0.69-1.86 
95%CI:0.81-2.26 
95%CI:1.12-3.21 
95%CI:0.08-1.46 
95%CI:0.21-3.91 
95%CI:0.17-12.8 
95%CI:0.50-38.5 
By calendar 
period: 
1970-74: SIR=1.11 
1975-79: SIR=1.15 
1980-84: SIR=1.04 
1985-89: SIR=1.80 * 
1990-93: SIR=0.89 
By calendar period: 
 
95%CI:0.58-1.91 
95%CI:0.78-1.61 
95%CI:0.72-1.45 
95%CI:1.37-2.31 
95%CI:0.55-1.35 
- 
Women aged >15 
years with first 
invasive breast 
cancer registered in 
the national Cancer 
Registry in 1970-
1993 and living 
outside 
Copenhagen city 
area (non-
metropolitan). 
All ND 4 (ND), 0-15 Female population 
aged >15 years and 
living outside 
Copenhagen city 
area (non-
metropolitan).  
EHR, first ever 
psychiatric 
admission, as 
registered in the 
Danish Psychiatric 
Central Registry 
 
ICD-8 codes: 
300.81 and 
300.00-300.99, 
except 300.49 
- - SIR= 1.3 * 95%CI: 1.1-1.5 
Standardised incidence ratio 
estimated considering all follow 
up time since diagnosis. 
1.5 - - SIR= 1.4  95%CI: 0.8-2.1 
 
Approximate SIR values 
estimated from the graphics 
provided in the original study. 
2.5 - - SIR= 1.1 95%CI: 0.6-1.8 
3.5 - - SIR= 1.6 95%CI: 0.9-2.5 
4.5 - - SIR= 1.5 95%CI: 0.6-2.4 
5.5 - - SIR= 0.7 95%CI: 0.3-1.6 
6.5 - - SIR= 1.3 95%CI: 0.5-2.6 
7.5 - - SIR= 1.2 95%CI: 0.4-2.5 
8.5 - - SIR= 0.8 95%CI: 0.3-2.2 
9.5 - - SIR= 0.7 95%CI: 0.2-2.1 
10.5 - - SIR= 0.4 95%CI: 0.1-1.9 
11.5 - - SIR= 1.0 95%CI: 0.3-2.9 
12.5 - - SIR= 2.6 95%CI: 0.8-6.0 
13.5 - - SIR= 0.5 95%CI: 0.1-2.1 
260
5 
 
Hjerl et al., 
2002 [1] 
 
Denmark 
 
(continued) 
Women aged >15 
years with first 
invasive breast 
cancer registered in 
the national Cancer 
Registry in 1970-
1993 and living in 
Copenhagen city 
area (metropolitan). 
All ND 4 (ND), 0-15  
Female population 
aged >15 years and 
living in Copenhagen 
city area 
(metropolitan). 
 
EHR, first ever 
psychiatric 
admission, as 
registered in the 
Danish Psychiatric 
Central Registry 
 
ICD-8 codes: 
300.81 and 
300.00-300.99, 
except 300.49 
 
- - SIR= 1.1 95%CI: 0.8-1.6 Standardised incidence ratio 
estimated considering all follow 
up time since diagnosis. 
1.5 - - SIR= 1.4 95%CI: 0.5-2.5 
Approximate values estimated 
from the graphics provided in the 
original study. 
2.5 - - SIR= 1.5 95%CI: 0.4-3.0 
3.5 - - SIR= 0.7 95%CI: 0.2-2.2 
5.0 - - SIR= 0.8 95%CI: 0.3-1.8 
6.5 - - SIR= 1.3 95%CI: 0.4-4.0 
7.5 - - SIR= 3.3 95%CI: 1.0-7.6 
9.5 - - SIR= 0.5 95%CI: 0.1-1.8 
13.0 - - SIR= 0.7 95%CI: 0.1-2.9 
Hung et al., 
2013 [2] 
 
Taiwan 
Population-based 
 
26,629 women with 
no prior mood 
disorder and 
cancer, with breast 
cancer registered in 
the National Health 
Insurance 
Database in 2000-
2005. 
All ND 2.7 (ND), 
ND-7 
 
(median follow 
up years for 
breast cancer 
survivors: 2.7; 
for matched 
cohort: 3.2) 
Population-based 
 
26,629 women 
randomly selected 
from 1 million women 
who did not have 
breast cancer 
registered in the 
same database, 
individually matched 
for age and Charlson 
comorbidity score 
(categories of 
matching not 
reported). 
 
 
EHR, recorded in 
the Registry for 
Catastrophic 
Illness with an 
ICD-9-CM code for 
anxiety 
(300-300.3, 300.5, 
300.7-300.9) 
Incidence rate: 
49.64 per 
1,000 person-
years 
 
Cumulative 
incidence: 
15% 
Incidence rate: 
40.82 per 
1,000 person-
years 
 
Cumulative 
incidence: 
14% 
RR= 1.22 * 95%CI: 1.16-1.27 
Includes patients diagnosed with 
breast cancer at <1yr. 
 
 
2 
Cumulative 
incidence: 
11% 
Cumulative 
incidence: 
9% RR= 1.22 * † 95%CI: 1.16-1.29 Approximate cumulative 
incidence values estimated from 
the graphics provided in the 
original study. 
4 17% 15%  RR= 1.13 * † 95%CI: 1.09-1.18 
6 22% 20% RR= 1.10 * † 95%CI: 1.06-1.14 
 
Khan et al., 
2010 [3] 
 
United 
Kingdom 
 
Population-based 
 
16,938 women 
aged ≥30 with 
breast cancer 
registered in the 
UK General 
Practice Research 
Database. 
 
All 
 
ND 
 
ND (ND), ≥5 
Population-based 
 
67,649 women who 
did not have breast 
or colorectal cancer 
at beginning of follow 
up; individually 
matched for age (± 1 
year) and primary 
care practice (small 
area). 
 
 
EHR, having 
primary care 
consultations for 
anxiety 
Prevalence: 
5.4% 
Prevalence: 
5.0% 
OR= 1.06 95%CI: 0.97-1.16 
Odds ratio adjusted for Charlson 
comorbidity score, previous 
history of anxiety and death. 
EHR, being 
prescribed an 
anxiolytic at least 
once Prevalence: 
9.0% 
Prevalence: 
7.7% 
OR= 1.08 * 95%CI: 1.01-1.15 
Odds ratio adjusted for Charlson 
comorbidity score, number of 
consultations, and death. 
Yang et al., 
2017 [4] 
 
Sweden 
 
(continues) 
Population based 
 
All 4,402 women 
diagnosed with an 
in situ breast 
cancer at the age 
of 20-80 years 
between 2001-
2009 
0 ND 4.7 (4.4), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.7 
(4.4)) 
Population based 
 
452,507 women 
randomly selected 
from the respondents 
to the 1990 census 
EHR, ICD-10 
diagnostic codes 
for anxiety (F40-
F41) at in patient 
or outpatient 
hospital visits 
Cumulative 
incidence:  
0.9% 
Cumulative 
incidence: 
0.9% 
SIR= 0.99 95%CI: 0.73-1.34 Standardised incidence ratio 
estimated considering all follow 
up time since diagnosis. 
 
 
By age group:  
20-44: SIR= 1.18 
45-54: SIR= 0.97 
55-64: SIR= 0.95 
65-80: SIR= 0.91 
By age group:  
95%CI: 0.59-2.36 
95%CI: 0.57-1.64 
95%CI: 0.53-1.72 
95%CI: 0.45-1.81 
0-0.5 <0.1% 0.1% SIR= 0.53 95%CI: 0.13-2.12 Standardised incidence ratios 
were standardised by calendar 
period (1-year categories), age 
(5-year categories), and region 
of residence (North, Stockholm- 
Gotland, South, Southeast, 
Uppsala-Orebro, West). 
 
0.5-1 0.0% 0.0% - - 
1-2 0.3% 0.2% SIR= 1.62 95%CI: 0.92-2.85 
2-5 0.4% 0.4% SIR= 1.09 95%CI: 0.68-1.73 
5-10 0.2% 0.2% SIR= 0.90 95%CI: 0.47-1.74 
261
6 
 
Yang et al., 
2017 [4] 
 
Sweden 
 
 
(continued) 
Population based 
 
All 4,402 women 
diagnosed with an 
in situ breast 
cancer at the age 
of 20-80 years 
between 2001-
2009 
0 ND 4.7 (4.4), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.7 
(4.4)) 
452,507 women 
randomly selected 
from the respondents 
to the 1990 census 
EHR, being 
prescribed an 
anxiolytic (group 
N05B of the ATC 
classification 
system) 
Cumulative 
incidence:  
4.5% 
Cumulative 
incidence:  
2.8% 
SIR= 1.64 * 95%CI: 1.43-1.88 Standardised incidence ratio 
estimated considering all follow 
up time since diagnosis. 
 
Standardised incidence ratios 
were standardised by calendar 
period (1-year categories), age 
(5-year categories), and region 
of residence (North, Stockholm- 
Gotland, South, Southeast, 
Uppsala-Orebro, West). 
 
The following were significant 
predictors of increased anxiety 
among breast cancer survivors: 
younger age at diagnosis, 
presence of co-morbidities, 
having moderate and high 
histological grade, and having 
had chemotherapy. 
By age group:  
20-44: SIR= 1.52  
45-54: SIR= 1.69 * 
55-64: SIR= 1.57 * 
65-80: SIR= 1.69 * 
By age:  
95%CI: 0.96-2.42 
95%CI: 1.28-2.22 
95%CI: 1.22-2.02 
95%CI: 1.34-2.14 
0-0.5 - - SIR= 3.86 * 95%CI: 3.17-4.71 
0.5-1 - - SIR= 0.93 95%CI: 0.61-1.41 
1-2 - - SIR= 1.28 95%CI: 0.97-1.70 
2-4.5 - - SIR= 0.91 95%CI: 0.64-1.28 
Population based 
 
All 40,849 women 
diagnosed with an 
invasive breast 
cancer at the age 
of 20-80 years 
between 2001-
2009 
I-IV ND 4.5 (4.5), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.4 
(4.5)) 
Population based 
 
452,507 women 
randomly selected 
from the respondents 
to the  1990 census 
EHR, ICD-10 
diagnostic codes 
for anxiety (F40-
F41) at in patient 
or outpatient 
hospital visits 
Cumulative 
incidence: 
1.4% 
Cumulative 
incidence: 
0.9% 
SIR= 1.55 * 95%CI: 1.43-1.68 
By age group:  
20-44: SIR= 1.84 * 
45-54: SIR= 1.56 * 
55-64: SIR= 1.58 * 
65-80: SIR= 1.31 * 
By age group:  
95%CI: 1.54-2.21 
95%CI: 1.34-1.81 
95%CI: 1.35-1.84 
95%CI: 1.10-1.56 
0-0.5 0.2% 0.1% SIR= 2.53 * 95%CI: 2.05-3.13 
0.5-1 0.2% 0.1% SIR= 2.30 * 95%CI: 1.85-2.87 
1-2 0.3% 0.2% SIR= 2.00 * 95%CI: 1.69-2.38 
2-5 0.4% 0.4% SIR= 1.17 * 95%CI: 1.01-1.36 
5-10 
 
0.3% 
 
0.2% 
 
SIR= 1.18 
 
95%CI: 0.97-1.42 
 
Population based 
 
All 40,849 women 
diagnosed with an 
invasive breast 
cancer at the age 
of 20-80 years 
between 2001-
2009 
I-IV ND 4.5 (4.5), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.4 
(4.5)) 
Population based 
 
452,507 women 
randomly selected 
from the respondents 
to the 1990 census 
EHR, being 
prescribed an 
anxiolytic (group 
N05B of the ATC 
classification 
system) 
Cumulative 
incidence: 
6.4% 
Cumulative 
incidence: 
2.5% 
SIR= 2.52 * 95%CI: 2.43-2.62 
By age group:  
20-44: SIR= 3.96 * 
45-54: SIR= 3.04 * 
55-64: SIR= 2.50 * 
65-80: SIR= 2.04 * 
By age group:  
95%CI: 3.56-4.40 
95%CI: 2.81-3.30 
95%CI: 2.33-2.68 
95%CI: 1.91-2.17 
0-0.5 - - SIR= 6.13 * 95%CI: 5.81-6.47 
0.5-1 - - SIR= 1.90 * 95%CI: 1.72-2.10 
1-2 - - SIR= 1.47 * 95%CI: 1.35-1.61 
2-4.5 
 
- 
 
- 
 
SIR= 1.38 * 
 
95%CI: 1.26-1.52 
 
 
Studies involving scales 
 
Cohen et 
al., 2011 [5] 
 
Israel 
Convenience 
sample 
 
56 married Israeli 
Arab breast cancer 
survivors, post 
treatment and free 
of disease recruited 
from one hospital. 
I-III (ND%) 
 
Srg, C: 48.2% 
Srg, M: 51.8% 
Srg, R: 12.5% 
CT: 85.7% 
RT: 85.7% 
HT: 58.9% 
4.8 (4.2), 1-17 Convenience sample 
 
66 married and 
‘healthy’ Arab 
women living in 
Israel, approached in 
community settings; 
individually matched 
for age and 
education (matching 
categories not 
reported). 
 
 
BSI-18 
BSI-18 mean 
score (SD): 
 
2.7 (1.2) 
BSI-18 
mean score 
(SD): 
 
2.2 (0.9) 
- P<0.05 * 
Higher levels of anxiety 
associated with higher levels of 
depression, somatization and 
emotional distress in both groups 
(P<0.001). 
 
Higher levels of anxiety 
associated with lower body image 
in breast cancer survivors only 
(P=0.05). 
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Boehmer et 
al., 2015 [6] 
 
ND 
 
Convenience 
sample 
 
85 lesbian or 
bisexual breast 
cancer survivors 
post-active 
treatment recruited 
via advertisements, 
flyers, etc. (3.5% of 
whom had had 
cancer recurrence). 
I-III (100%) 
 
ND 4.5 (ND), 1-10 Convenience sample 
 
85 lesbian or bisexual 
women with no history 
of cancer, not using 
hormone therapy, 
recruited via flyers, 
advertisements, etc.; 
individually matched 
for age (± 3 years) and 
partner status 
(partnered vs. 
unpartnered).  
 
Anxiolytics intake 
(self-reported) 
 
Prevalence: 
3.5% 
 Prevalence: 
1.2% 
PR=2.92 † 95%CI: 0.31-27.1 
Anxiety was more common in 
women taking any psycho 
pharmacological medication, 
compared to those who did not 
(OR=3.78, 95%CI: 1.76 to 8.09). 
HADS score ≥8 
Prevalence: 
45.2% 
Prevalence: 
36.5% 
PR=1.24 † 95%CI: 0.86-1.78 
Calvio et 
al., 2010 [7] 
 
United 
States 
 
Convenience 
sample 
 
122 breast cancer 
survivors, working 
full-time for ≥1 
year, with computer 
and internet, 
recruited via 
advertisements and 
flyers. 
I (36.9%) 
II (44.3%) 
III (17.2%) 
Srg, ND: 
96.7% 
CT: 82.8% 
RT: 73.0% 
HT: 45.9% 
IT: 13.1% 
3.1 (2.4), 1-10 Convenience sample 
 
113 women without 
cancer, working full-
time for ≥1 year, with 
computer and 
internet, recruited via 
advertisements and 
flyers. 
 
HADS 
HADS mean 
score (SD): 
 
7.8 (3.0) 
HADS 
mean score 
(SD): 
 
7.1 (2.6) 
- P<0.01 * 
Higher HADS scores indicate 
more anxiety symptoms. 
 
Mean scores adjusted for marital 
status (cohabitating with partner 
vs. single/not cohabitating), race 
(Caucasian vs. non-Caucasian), 
ethnicity (Hispanic vs. non-
Hispanic), age (<40, 41-50, 51-65), 
income (0-39,000; 40-59,000; 60-
79,000; 80-89,000; 80-99,000; 
≥100,000), and menopausal status 
(currently going through, 
premenopausal, postmenopausal). 
 
Dahl et al., 
2011 [8] 
 
Norway 
 
Convenience 
sample 
 
337 tumor free 
breast cancer 
survivors treated 
with radiotherapy 
during 1998 and 
2002 in one 
hospital. 
II (ND) 
III (ND) 
Srg, C: 24% 
Srg, M: 76% 
CT: 82% 
RT: 100% 
HT: 81% 
 
3.9 (ND), 2.6-
6.9 
 
Convenience sample 
 
1,685 women 
randomly selected 
from a population-
based sample of 
women with no 
history of cancer who 
provided 
questionnaires with 
complete data; 
individually matched 
for age (± 5 years). 
 
HADS 
HADS mean 
score (SD): 
 
6.3 (2.8) 
 
HADS 
mean score 
(SD): 
 
4.8 (3.7) 
 
- 
 
P<0.001 * 
 
Higher HADS score indicates 
more anxiety symptoms. 
 
Mean scores adjusted for level 
of education, on disability 
pension and menopausal status. 
 
Higher scores of HADS for 
anxiety were associated with 
more insomnia symptoms in 
breast cancer survivors and in 
controls (p<0.001). 
Miao et al., 
2016 [9] 
 
China 
 
 
Convenience 
sample 
 
23 patients with 
breast cancer who 
had been treated 
with chemotherapy 
at a local hospital. 
I-III (100%) CT: 100% 3 (0.3),  Convenience sample 
 
26 age-matched 
healthy controls 
selected amongst 
patients relatives and 
local universities; 
matched for age 
(matching method 
not reported). 
 
HRS-A  
HRS-A mean 
score (SD): 
 
4.96 (1.43) 
HRS-A mean 
score (SD): 
 
4.5 (1.22) 
- P=0.232 
 
Higher HRS-A score indicates 
more anxiety symptoms.  
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Rubino et 
al., 2007 
[10]  
 
Italy  
Convenience 
sample  
 
33 consecutive 
patients who had 
had breast-
reconstruction after 
mastectomy, in 
2001-2002. 
 
ND Srg, M: 100% 
Srg, R: 100% 
 
 
ND (ND), >1 Convenience sample 
 
33 ‘healthy’ women, 
randomly selected 
amongst the 
personnel of the local 
university. 
 
HRS-A,  
applied during 
psychiatric 
interview 
 
Cut-off score: >14 
Prevalence: 
24.2% 
Prevalence: 
0.0% 
 
PR=7.99 * † 
 
95%CI: 1.06-60.34 
PR calculated by the authors of 
the present study. For 
calculation purposes, it was 
assumed that one person in the 
non-cancer group had the 
outcome. 
Boele et al., 
2015 [11] 
 
The 
Netherlands 
Convenience 
sample 
 
Post-menopausal 
breast cancer 
survivors with no 
diagnosis of 
psychiatric illness, 
not treated with 
adjuvant CT, 
selected from the 
medical records of 
the Cancer 
Institute. 
 
ND Srg, ND: 95% 
CT: 0% 
RT: 65% 
HT: 100% / 
0%  
Exposure to 
HT: 3.2 (1.9), 
1.5-7;  
 
Unexposed to 
HT: 2.8 (0.3), 
2.3-3.3. 
Convenience sample 
 
44 friends or family 
members of the 
women who had had 
breast cancer, with 
no history of breast 
cancer, matched for 
age and education 
(method of matching 
not reported). 
 
HSCL-25 
HSCL-25 
mean score 
(SD): 
 
HT: 
11.17 (10.39) 
 
No HT: 
13.57 (11.74) 
 
HSCL-25 
mean score 
(SD): 
 
9.92 (10.55) 
- P=0.30 
 
Higher HSCL-25 score indicates 
more anxiety symptoms. 
 
P adjusted for age and 
estimated premorbid IQ. 
 
Women with higher anxiety 
levels had significantly lower 
processing speed evaluated as 
part of cognitive function. 
Kreukels et 
al., 2008 
[12] 
 
The 
Netherlands 
Convenience 
sample 
 
63 women who had 
non-metastatic 
breast cancer, with 
no history of 
psychiatric 
diseases. 
I-III (100%) CT: 100% 
HT: 40% 
~ 1 
 
(follow up at 
12 months 
after CT) 
Convenience sample 
 
60 friends or family 
of the patients with 
the same age who 
never had cancer, 
matched for age 
(method of matching 
not reported). 
 
HSCL-25 
HSCL-25 
mean score 
(SD): 
 
16.3 (12.2) 
 
HSCL-25 
mean score 
(SD): 
 
8.7 (7.9) - P<0.001 * 
 
Higher HSCL-25 score indicates 
more anxiety symptoms. 
Amir et al., 
2002 [13] 
 
Israel 
 
Convenience 
sample 
 
39 women free of 
cancer symptoms 
for ≥3 years and 
not under active 
treatment, identified 
through 2 hospitals. 
I (46%) 
II (46%) 
III (8%) 
Srg, C: 20% 
Srg, M: 80% 
CT: 66% 
RT: 41% 
HT: 46% 
6.5 (ND), ≥5 Convenience sample 
 
39 women who did 
not experience life-
threatening disease, 
recruited by unknown 
methods, matched 
for age and 
education (method of 
matching not 
reported). 
 
SCL-90 
SCL-90 mean 
score (SD): 
 
0.87 (0.96) 
SCL-90 
mean score 
(SD): 
 
0.49 (0.35) 
- P<0.001 * 
Higher SCL-90 scores indicate 
more anxiety symptoms. 
 
Women who had breast cancer 
and reported PTSD symptoms 
had higher anxiety levels than 
those who did not report PTSD 
symptoms: 1.81 (1.23) vs. 0.67 
(0.76), P<0.01. 
Garcia-
Torres et 
al., 2013 
[14] 
 
Spain 
Convenience 
sample 
 
22 breast cancer 
survivors, free of 
relapse, identified 
by staff of the local 
association against 
cancer. 
 
ND Srg, M: 100% 
CT: 72.7% 
8.2 (5.6), 1-21 Convenience sample 
 
22 women with no 
history of cancer who 
volunteered with the 
same association 
against cancer. 
ISRA 
(trait anxiety) 
ISRA 
mean score 
(SD): 
 
155.13 (71.51) 
ISRA 
mean score 
(SD): 
 
157.29 (82.45) 
- P=0.92 
Correlation between anxiety and 
depression: r = 0.46, p<0.05. 
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Castellon et 
al., 2004 
[15] 
 
United 
States 
 
Convenience 
sample 
 
53 women who had 
breast cancer at or 
before the age of 50, 
with no evidence of 
disease or 
recurrence, and no 
history of psychiatric 
disorder. 
0-II (100%) CT: 34% 
CT+HT: 34% 
ND (ND), 2-5 Convenience sample 
 
19 Healthy women 
recruited via fliers, 
newsletter articles 
and advertisements, 
or amongst the 
acquaintances of the 
hospital staff. 
STAI  
(trait anxiety) 
STAI mean 
score (SD), by 
treatment 
 
No CT: 
31.9 (7.3) 
CT:  
33.1 (8.1) 
STAI mean 
score (SD): 
 
38.0 (9.3) 
- 
 
 
P=0.075 
 
Higher STAI scores indicate more 
anxiety symptoms. 
Weitzner et 
al., 1997 
[16] ‡ 
 
United 
States 
Convenience 
sample 
 
60 women with age 
<70 years, 
education ≥6th 
grade, no history of 
psychiatric 
diagnoses, 
>5 years disease-
free, selected from 
those returning to 
the hospital for 
long-term follow up 
of cancer. 
I (15%) 
II (63%) 
III (22%) 
Srg, M: 100% ND (ND), ≥5 Convenience sample 
 
93 employees or 
volunteer workers at 
the same hospital 
with no personal or 
family history of 
breast cancer, age 
<70 years, education 
≥6th grade, and no 
history of psychiatric 
diagnosis. 
STAI 
(mild to moderate 
trait anxiety)  
Prevalence: 
27% 
Prevalence: 
15% 
PR=1.8 † 95%CI: 0.95-3.41 
Cut-off to be identified as case 
defined as >1 standard deviation 
above the mean. 
 
 
STAI 
(trait anxiety) 
 
 
STAI mean 
score (SD): 
 
35 (ND) 
 
STAI mean 
score (SD): 
 
33 (ND) 
 
- 
 
P<0.05 * 
Adjusted for years of age and 
years of education. 
 
Women with stage III breast 
cancer at diagnosis had more 
trait anxiety compared to the 
other breast cancer survivors 
(P<0.004). 
Trait anxiety in breast cancer 
survivors was predictive of all 
domains of quality of life, except 
family functioning. 
Root et al., 
2015 [17] 
 
United 
States 
Convenience 
sample 
 
113 women aged 
<70 years who had 
breast cancer, were 
post-menopausal at 
diagnosis, receiving 
HT at recruitment, 
with no recurrence, 
no neurological or 
psychiatric 
diagnoses and who 
did not report sleep 
disturbances. 
I (58%) 
II (0%) 
III (33%) 
IV (8%) 
Srg, C: 75% 
Srg, M: 32% 
CT: 52% 
RT: 78% 
HT: 52% 
4.2 (1.2) Convenience sample 
 
37 health women 
with no history of 
cancer or cancer 
treatment, post-
menopausal, with no 
neurological or 
psychiatric 
diagnoses, matched 
for age and 
education (method of 
matching not 
reported). 
 
STAI 
STAI mean 
score (SD): 
 
32.4 (8.6) 
 
STAI mean 
score (SD): 
 
33.1 (1.4) 
 
- P=0.62 
Higher STAI scores indicate more 
anxiety symptoms. 
Castellon et 
al., 2004 
[15] 
 
United 
States 
 
Convenience 
sample 
 
53 women who had 
breast cancer at or 
before the age of 
50, with no 
evidence of 
disease or 
recurrence, and no 
history of 
psychiatric 
disorder. 
 
0-II (100%) CT: 34% 
CT+HT: 34% 
ND (ND), 2-5 Convenience sample 
 
19 Healthy women 
recruited via fliers, 
newsletter articles 
and advertisements, 
or amongst the 
acquaintances of the 
hospital staff. 
STAI  
(state anxiety) 
 
STAI mean 
score (SD), by 
treatment 
 
No CT: 
24.6 (3.6) 
CT:  
28.6 (8.8) 
STAI mean 
score (SD): 
 
33.2 (8.0) 
- 
 
 
P=0.01 * 
 
Higher STAI scores indicate more 
anxiety symptoms. 
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Conroy et 
al., 2013 
[18] 
 
United 
States 
 
 
Convenience 
sample 
 
24 breast cancer 
survivors with 
history of non-
metastatic disease 
and chemotherapy 
treated. 
 
I (29%) 
IIa (33%) 
IIb (25%) 
IIIa (8%) 
IIIb (4%) 
CT: 100% 
RT: 79% 
 
6.4 (2.1), 3.2-
10.2 
Convenience sample 
 
23 healthy women 
matched for age and 
education 
(categories of 
matching not 
reported) 
STAI  
(state anxiety) 
 
STAI mean 
score (SD): 
 
30.2 (7.9) 
STAI mean 
score (SD): 
 
31.9 (9.1) 
- P>0.05 
Higher STAI scores indicate more 
anxiety symptoms. 
McDonald 
et al., 2010 
[19] 
 
ND 
 
Convenience 
sample 
 
29 female breast 
cancer patients 
without 
neurobehavioral 
risk factors 
including 
neurologic, 
medical, or 
psychiatric 
conditions, except 
history of 
depression or 
anxiety. 
 
0 (14%) 
I (35%) 
II (48%) 
IIIA (3%) 
CT: 59% 
RT: 69% 
~1.5 (0.15) Convenience sample 
 
18 healthy controls 
‘demographically 
matched’ (method of 
matching not 
reported). 
STAI 
(state anxiety) 
STAI mean 
score (SD): 
 
CT:  
27.6 (8.8) 
No CT: 
28.3 (11.3) 
 
STAI mean 
score (SD): 
 
25.6 (7.2) 
 
- P>0.05 - 
Prevalence of 
anxiety: 7% 
Prevalence of 
anxiety: 0% 
PR= 1.25 † 95%CI: 0.12-12.65 
Cut off for case: STAI-S T-score 
≥65 
 
Klein et al., 
2011 [20] 
 
France 
Population based 
 
652 breast cancer 
survivors >5 post 
active-treatment, 
randomly selected 
from 3 population-
based cancer 
registries by year of 
diagnosis. 
0-IV (ND) 
 
Srg, C: 64.7% 
Srg, M: 34.6% 
CT: 45.8% 
RT: 83.0% 
HT: 68.0% 
Diagnosed in:  
 
2000: 5.6 
(1.0), 5.0-5.9 
1995: 10.3 
(0.6), 10.0-
10.9  
1990: 15.6 
(1.0), 15.0-
15.9 
Population based 
 
1,188 women with no 
history of cancer 
randomly selected 
from the electoral 
rolls; individually 
matched by age (±10 
years) and place of 
residence (area of 
the cancer registry, 
and urban/rural). 
 
STAI 
(state anxiety) 
 
STAI 
mean score 
(SD):  
 
Diagnosed in: 
2000: 34.4 (ND) 
1995: 34.7 (ND) 
1990: 33.2 (ND) 
STAI 
mean score 
(SD): 
 
28.5 (ND) 
- P<0.001 * 
Higher STAI scores indicate more 
anxiety symptoms. 
 
Mean scores adjusted for age 
group, marital status, education, 
employment status, household 
monthly income comorbidities and 
hospitalization in the last 12 
months. 
Saleeba et 
al., 1996 
[21] ‡ 
 
United 
States 
52 women aged 
<70 years, 
education ≥6th 
grade, no history of 
psychiatric 
diagnoses, >5 
years disease-free, 
selected from those 
under long-term 
follow up of breast 
cancer. 
I (13%) 
II (63%) 
III (23%) 
 
Srg, C: 0% 
Srg, M: 100% 
8.5 (ND), 5-18 
88 women aged <70 
years, with ≥6th 
grade of education, 
no history of 
psychiatric 
diagnoses and 
undergoing routine 
low risk breast 
cancer screening. 
STAI 
(mild to moderate 
state anxiety)  
Prevalence: 
21% 
Prevalence: 
7%  
PR=3.0 * † 95%CI: 1.19-7.57 
Cases defined as state anxiety 
scores above the 85th percentile 
for respective age group. 
STAI 
(state anxiety)  
STAI 
mean score 
(SD):  
 
33.08 (11.50) 
STAI 
mean score 
(SD):  
 
31.82 (8.40) 
- P>0.05 
Higher STAI scores indicate 
more anxiety symptoms. 
ATC = Anatomic Therapeutic Chemical classification system; BSI-18 = Brief Symptom Inventory 18 [22]; CT = chemotherapy; EHR = electronic health records; HADS = 
Hospital Anxiety and Depression Scale [23]; HRS-A = Hamilton Rating Scale for Anxiety [24]; HSCL-25 = The Hopkins Symptom Checklist-25 [25]; HT = hormone therapy; 
ICD-8 = The International Classification of Diseases, Eight Revision; ICD-9-CM = The International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10 = 
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The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; IQR = interquartile range; ISRA = Inventory of Situations and Responses 
to Anxiety [26]; IT = immunotherapy; ND = not defined; OR = odds ratio; PR = prevalence ratio; RR = relative risk; RT = radiotherapy; SCL-90 = Anxiety subscale of the 
Symptoms Checklist-90 [27]; SD = standard deviation; SIR = standardised incidence ratio; Srg, C = Breast conserving surgery; Srg, ND = Surgery, not further specified; Srg, M 
= Mastectomy; Srg, R = Breast reconstructive surgery; STAI = State-Trait Anxiety Inventory [28]; yrs = years; 95%CI = 95% confidence interval.  
* There was some statistical evidence (P<0.05) for a different prevalence, risk or severity of anxiety between breast cancer survivors and women who did not have cancer. 
† Prevalence ratio calculated by the authors of the present study. 
‡ The two studies provided results for different components of anxiety (trait and state) based on the same sample of patients. 
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Supplementary Table 4. Depression: main characteristics and results of the studies that evaluated the risk of depression, or the prevalence or severity of 
depressive symptoms, in breast cancer survivors (>1 year) and women who did not have cancer. 
 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison 
group 
Outcome 
assessment 
Quantitative measure of the 
outcome 
Relative risk 
estimate 
(RR, OR, SIR, PR) 
P-value or 95% 
confidence interval 
Notes 
Type of 
population and 
main 
characteristics 
 
Stage at 
diagnosis 
(%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis/ 
treatment in 
years: mean/ 
median (SD), 
range 
Type of 
population and 
main 
characteristics 
Breast cancer 
survivors 
Comparison 
group 
 
Electronic health records 
 
Suppli et 
al., 
2014 [29] 
 
Denmark 
 
 
 
(continues) 
Population-based 
 
All 44,494 women 
born in 1920-1981 
and living in 
Denmark, who had 
breast cancer 
diagnosed in 1998-
2011, without 
history of other 
cancers or major 
psychiatric 
disorder. 
All ND 5 (ND), 0-15 Population-based 
 
1,997,669  women 
born in 1920-1981 
and living in 
Denmark, without 
history of cancer or 
major psychiatric 
disorder 
EHR, first 
hospital contact 
(in- or 
outpatient) for 
unipolar 
depression, as 
registered in the 
Danish 
Psychiatric 
Central Registry.  
 
ICD-8 codes: 
296.09, 296.29; 
ICD-10 codes: 
F32-33.9 
Incidence rate: 
215 per 100,000 
person-years 
 
Cumulative 
incidence: 1.1% 
Incidence rate: 
171 per 100,000 
person-years 
 
Cumulative 
incidence: 0.8% 
All patients: 
RR= 1.39 * 
All patients: 
95%CI: 1.27-1.52 
Includes patients diagnosed 
with breast cancer at <1yr. 
 
RR adjusted for age (5-year 
intervals), calendar period 
(1998-2000, 2001-2004, 
2005-2008, 2009-2011) and 
Charlson comorbidity index 
score (0, 1, ≥2). 
By age: 
30-39: RR= 0.78 
40-49: RR= 1.56 * 
50-59: RR= 1.35 * 
60-69: RR= 1.41 * 
70-79: RR= 1.25 * 
   ≥80: RR= 1.56 * 
By age: 
95%CI: 0.39-1.55  
95%CI: 1.23-1.96 
95%CI: 1.11-1.63 
95%CI: 1.16-1.71 
95%CI: 1.03-1.51 
95%CI: 1.25-1.93 
By Charlson 
comorbidity index: 
0:   RR= 1.47 * 
1:   RR= 1.41 * 
≥2: RR= 1.02 
By Charlson 
comorbidity index: 
95%CI: 1.31-1.64 
95%CI: 1.18-1.69 
95%CI: 0.77-1.34 
RR adjusted for age (5-year 
intervals), calendar period 
(1998-2000, 2001-2004, 
2005-2008, 2009-2011). 
 
 
0-1 
Cumulative 
incidence: 
0.3% 
Cumulative 
incidence: 
0.2% 
 
 
RR= 1.70 *  
 
 
95%CI: 1.41-2.05 
RR  adjusted for age (5-
year intervals), calendar 
period (1998-2000, 2001-
2004, 2005-2008, 2009-
2011) and Charlson 
comorbidity index score (0, 
1, ≥2). Significant predictors 
of depression among breast 
cancer survivors: Age at 
diagnosis and living alone. 
1-2 0.2% 0.2% RR= 1.48 * 95%CI: 1.19-1.83 
2-3 0.3% 0.2% RR= 1.64 * 95%CI: 1.31-2.06 
3-4 0.2% 0.2% RR= 1.20 95%CI: 0.90-1.60 
4-5 0.2% 0.2% RR= 1.40 * 95%CI: 1.04-1.87 
6-8 0.2% 0.2% RR= 1.13 95%CI: 0.90-1.41 
9-14 0.2% 0.1% RR= 1.09 95%CI: 0.80-1.46 
Population-based 
 
All 35,286 women 
born in 1920-1981 
and living in 
Denmark, who had 
breast cancer 
diagnosed in 1998-
2011 and did not 
use 
antidepressants in 
the 3 years before 
study entry, without 
history of other 
cancers or major 
psychiatric 
disorder. 
All ND 5 (ND), 0-15 Population based 
 
1,860,552 women 
born in 1920-1981 
and living in 
Denmark, without 
history of cancer or 
major psychiatric 
disorder and who 
did not use 
antidepressants 
during the three 
years prior to study 
entry. 
EHR, first 
redeemed 
prescription of 
antidepressants 
(group N06A of 
the ATC 
classification 
system) 
Incidence rate: 
3,772 per 
100,000 person-
years 
 
Cumulative 
incidence: 
17.1% 
Incidence rate: 
1,971 per 
100,000 person-
years 
 
Cumulative 
incidence: 9.4% 
RR= 1.82 * 95%CI: 1.77-1.86 
RR adjusted for age (5-year 
intervals), calendar period 
(1998-2000, 2001-2004, 
2005-2008, 2009-2011) and 
Charlson comorbidity index 
score (0, 1, ≥2). 
 
Predictors of depression 
among breast cancer 
survivors: age at diagnosis, 
living alone, not having 
higher education, having 
comorbidities, positive 
lymph node metastasis. 
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Suppli et 
al., 
2014 [29] 
 
Denmark 
 
(continued) 
Population-based 
 
All 35,286 women 
born in 1920-1981 
and living in 
Denmark, who had 
breast cancer 
diagnosed in 1998-
2011 and did not 
use 
antidepressants in 
the 3 years before 
study entry, without 
history of other 
cancers or major 
psychiatric 
disorder. 
 
All ND 5 (ND), 0-15 Population based 
 
1,860,552 women 
born in 1920-1981 
and living in 
Denmark, without 
history of cancer or 
major psychiatric 
disorder and who 
did not use 
antidepressants 
during the three 
years prior to study 
entry. 
EHR, first 
redeemed 
prescription of 
antidepressants 
(group N06A of 
the ATC 
classification 
system) 
Incidence rate: 
3,772 per 
100,000 person-
years 
 
Cumulative 
incidence: 
17.1% 
Incidence rate: 
1,971 per 
100,000 person-
years 
 
Cumulative 
incidence: 9.4% 
By Charlson 
comorbidity index 
score: 
0:   RR= 2.06 * 
1:   RR= 1.49 * 
≥2: RR= 1.25 * 
By Charlson 
comorbidity index 
score: 
95%CI: 2.00-2.12 
95%CI: 1.40-1.58 
95%CI: 1.15-1.36 
RR adjusted for age (5-year 
intervals), calendar period 
(1998-2000, 2001-2004, 
2005-2008, 2009-2011). 
   By age: 
30-39: RR= 2.07 * 
40-49: RR= 2.12 * 
50-59: RR= 2.12 * 
60-69: RR= 1.89 * 
70-79: RR= 1.59 * 
   ≥80: RR= 1.29 * 
By age: 
95%CI: 1.77-2.43 
95%CI: 1.98-2.27 
95%CI: 2.02-2.23 
95%CI: 1.80-1.99 
95%CI: 1.51-1.68 
95%CI: 1.19-1.40 
 
Includes patients diagnosed 
with breast cancer at <1yr. 
 
RR adjusted for age (5-year 
intervals), calendar period 
(1998-2000, 2001-2004, 
2005-2008, 2009-2011) and 
Charlson comorbidity index 
score (0, 1, ≥2). 
 
  5 (ND), 0-15 Cumulative 
incidence: 17% 
Cumulative 
incidence: 9.4% 
 
RR= 1.82 * 
 
95%CI: 1.77-1.86 
0-1 6.4% 2.1% RR= 3.09 * 95%CI: 2.95-3.22 
1-2 4.2% 2.1% RR= 2.06 * 95%CI: 1.94-2.18 
2-3 3.3% 2.1% RR= 1.60 * 95%CI: 1.49-1.72 
3-4 3.3% 2.1% RR= 1.59 * 95%CI: 1.46-1.72 
4-5 2.7% 2.1% RR= 1.30 * 95%CI: 1.18-1.44 
6-8 2.6% 2.1% RR= 1.23 * 95%CI: 1.15-1.32 
9-14 2.2% 2.0% RR= 1.08 95%CI: 0.98-1.19 
Hjerl et al., 
2002 [1] 
 
Denmark 
 
(continues) 
Population-based 
 
All 60,431 women 
aged >15 years 
with first invasive 
breast cancer 
registered in the 
national Cancer 
Registry in 1970-
1993. 
 
 
All ND 4 (ND), 0-15 Population-based 
 
Danish female 
population 
aged >15 years. 
EHR, first ever 
psychiatric 
admission with 
affective 
disorders, as 
registered in the 
Danish 
Psychiatric 
Central Registry 
ICD-8 codes: 
296.19-296.99, 
298.09, 301.19, 
300.49 
Cumulative 
incidence: 0.7% 
Cumulative 
incidence: 0.5% 
SIR= 1.49 * 95%CI: 1.35-1.63 
Standardised incidence 
ratio estimated considering 
all follow up time since 
diagnosis. 
  (Median 
cohort follow 
up: 4 years 
since 
diagnosis; 
range:  
0 to 15) 
  By calendar 
period: 
1970-74: SIR=1.68 * 
1975-79: SIR=1.60 * 
1980-84: SIR=1.56 * 
1985-89: SIR=1.46 * 
1990-93: SIR=1.25  
 
By calendar period: 
 
95%CI: 1.20-2.27 
95%CI: 1.30-1.94 
95%CI: 1.28-1.88 
95%CI: 1.19-1.77 
95%CI: 0.99-1.55 
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Hjerl et al., 
2002 [1] 
 
Denmark 
 
(continued) 
Population-based 
 
All 60,431 women 
aged >15 years 
with first invasive 
breast cancer 
registered in the 
national Cancer 
Registry in 1970-
1993. 
 
All ND 4 (ND), 0-15 
 
(Median 
cohort follow 
up: 4 years 
since 
diagnosis; 
range:  
0 to 15) 
Population-based 
 
Danish female 
population 
aged >15 years. 
EHR, first ever 
psychiatric 
admission with 
affective 
disorders, as 
registered in the 
Danish 
Psychiatric 
Central Registry 
ICD-8 codes: 
296.19-296.99, 
298.09, 301.19, 
300.49 
- - 
By age group: 
15-29: SIR= 3.24  
30-34: SIR= 0.67  
35-39: SIR= 1.96  
40-44: SIR= 2.92 *  
45-49: SIR= 1.46 * 
50-54: SIR= 2.14 * 
55-59: SIR= 1.39 * 
60-64: SIR= 1.46 * 
65-69: SIR= 1.32  
70-74: SIR= 1.22  
75-79: SIR= 1.09  
80-84: SIR= 1.00  
85-89: SIR= 1.28  
≥90: SIR= 2.43  
By age group: 
95%CI: 0.19-14.3 
95%CI: 0.04-2.94 
95%CI: 0.98-3.44 
95%CI: 2.06-4.00 
95%CI: 1.03-2.00 
95%CI: 1.69-2.67 
95%CI: 1.05-1.81 
95%CI: 1.11-1.89 
95%CI: 0.99-1.73 
95%CI: 0.90-1.61 
95%CI: 0.75-1.51 
95%CI: 0.60-1.53 
95%CI: 0.59-2.39 
95%CI: 0.60-6.30 
 
 
Standardised incidence 
ratio estimated considering 
all follow up time since 
diagnosis. 
Women aged >15 
years with first 
invasive breast 
cancer registered in 
the national Cancer 
Registry in 1970-
1993 and living in 
Copenhagen city 
area (metropolitan). 
All ND 
4 (ND), 0-15 
 
Female population 
aged >15 years 
and living in 
Copenhagen city 
area. 
EHR, first ever 
psychiatric 
admission with 
affective 
disorders, as 
registered in the 
Danish 
Psychiatric 
Central Registry 
ICD-8 codes: 
296.19-296.99, 
298.09, 301.19, 
300.49 
 
- 
 
- 
 
SIR= 1.19 
 
95%CI: 0.95-1.48 
 
Standardised incidence 
ratio estimated considering 
all follow up time since 
diagnosis. 
1.5 - - SIR= 0.9   95%CI: 0.5-1.7 
 
Approximate values 
estimated from the graphics 
provided in the original 
study. 
2.5 - - SIR= 1.2   95%CI: 0.6-2.0 
3.5 - - SIR= 0.9   95%CI: 0.4-1.9 
4.5 - - SIR= 1.1   95%CI: 0.4-2.3 
5.5 - - SIR= 1.7   95%CI: 0.7-3.1 
6.5 - - SIR= 1.3   95%CI: 0.4-2.8 
7.5 - - SIR= 0.6   95%CI: 0.1-1.9 
8.5 - - SIR= 0.7   95%CI: 0.1-2.2 
9.5 - - SIR= 0.4   95%CI: 0.0-1.9 
10.5 - - SIR= 2.5   95%CI: 0.9-5.4 
13.0 
 
- 
 
- 
 
SIR= 0.2  * 
 
95%CI: 0.0-0.9 
 
Women aged >15 
years with first 
invasive breast 
cancer registered in 
the national Cancer 
Registry in 1970-
1993 and living 
outside 
Copenhagen city 
area. 
All ND 4 (ND), 0-15 
 
Female population 
aged >15 years 
and living outside 
Copenhagen city 
area.  
EHR, first ever 
psychiatric 
admission with 
affective 
disorders, as 
registered in the 
Danish 
Psychiatric 
Central Registry 
ICD-8 codes: 
296.19-296.99, 
298.09, 301.19, 
300.49 
 
- - 
SIR= 1.57 * 
 
95%CI: 1.41-1.75 
 
Standardised incidence 
ratio estimated considering 
all follow up time since 
diagnosis. 
 
Approximate values 
estimated from the graphics 
provided in the original 
study. 
1.5 - - SIR= 2.1  * 95%CI: 1.6-2.6 
2.5 - - SIR= 1.3   95%CI: 0.9-1.8 
3.5 - - SIR= 1.5  * 95%CI: 1.1-2.1 
4.5 - - SIR= 1.4   95%CI: 0.9-2.0 
5.5 - - SIR= 1.6  * 95%CI: 1.1-2.4 
6.5 - - SIR= 1.4   95%CI: 0.8-1.9 
7.5 - - SIR= 1.1   95%CI: 0.6-1.8 
8.5 - - SIR= 1.0   95%CI: 0.5-1.8 
9.5 - - SIR= 0.8   95%CI: 0.3-1.6 
10.5 - - SIR= 0.9   95%CI: 0.4-1.8 
11.5 - - SIR= 0.9   95%CI: 0.3-1.9 
12.5 - - SIR= 1.1   95%CI: 0.4-2.3 
13.5 - - SIR= 1.6  95%CI: 0.6-3.1 
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Hung et al., 
2013 [2] 
 
Taiwan 
Population-based 
 
26,629 women with 
no prior mood 
disorder and 
cancer, with breast 
cancer registered in 
the National Health 
Insurance 
Database in 2000-
2005. 
All ND 2.7 (ND), 
ND-7 
 
(median follow 
up years for 
breast cancer 
survivors: 2.7; 
for matched 
cohort: 3.21) 
Population-based 
 
26,629 women 
randomly selected 
from 1 million women 
who did not have 
breast cancer 
registered in the 
National Health 
Insurance Database; 
matched for age and 
Charlson comorbidity 
score (matching, 
categories not 
reported). 
 
 
 
EHR, recorded 
in the Registry 
for Catastrophic 
Illness with an 
ICD-9-CM code 
for major 
depressive 
disorder 
(296.2X-296.3X, 
300.4, 311.X) 
Incidence rate: 
14.55 per 1,000 
person-years 
 
Cumulative 
incidence= 4.4% 
Incidence rate: 
7.51 per 1,000 
person-years 
 
Cumulative 
incidence= 2.6% 
RR=1.94 * 95%CI: 1.76-2.13  
Includes patients diagnosed 
with breast cancer at <1yr. 
2 
4%   2%   RR=2.0 * † 95%CI: 1.80-2.22 Approximate cumulative 
incidence values estimated 
from the graphics provided 
in the original study. 
 
P value for the log-rank test 
comparing the Kaplan-Meier 
curves: P<0.001 
4 
5%   3%   RR=1.7 * † 95%CI: 1.53-1.82 
6 6%   4%   RR=1.5 * † 95%CI: 1.39-1.62 
Earle et al., 
2007 [30] 
 
United 
States 
Convenience 
sample 
 
463 women who 
had non-metastatic 
cancer registered 
with a private 
health care 
insurance company 
and not receiving 
active treatment; 
patients had no 
evidence of 
recurrence.  
Non-
metastatic 
ND ND (ND), ≥5 Convenience 
sample 
 
3,108 women 
without cancer 
registered with a 
private health care 
insure company; 
matched for age and 
clinic location 
(individual matching, 
categories not 
reported). 
 
 
 
EHR, ICD-9 
codes for 
diagnoses of 
psychotic 
depression and 
dysthymia in an 
administrative 
database from a 
health care plan. 
Prevalence: 
22.5% 
Prevalence: 
18.1% 
PR=1.24 * † 
95%CI: 1.03-1.50 
P=0.04 
Breast cancer survivors had 
more visits with mental 
health providers compared 
to women without cancer. 
Kim et al., 
2017 [31] 
 
Korea 
 
Population based 
 
2,130 women who 
had mastectomy for 
breast cancer, 
randomly selected 
from the National 
Health Insurance 
Database 
All Srg, M: 100%  
0 
Population based 
 
8,520 women 
never diagnosed 
with cancer 
randomly selected 
from the same 
database as the 
cases matched for 
age, income, 
region, pre-
operative 
depression 
(individual 
matching, 
categories not 
reported). 
 
 
 
 
EHR, ICD-10 
codes for 
depression 
Prevalence: 
5.5% 
Prevalence: 
2.5% 
 
PR= 2.20 * †  
 
95%CI: 1.76-2.74 
 
- 
1 4.8% 3.1% PR= 1.55 * † 95%CI: 1.24-1.94 
2 4.4% 3.0% PR= 1.47 * † 95%CI: 1.14-1.89 
3 4.4% 3.1% PR= 1.42 * † 95%CI: 1.08-1.87 
4 4.1% 4.0% PR= 1.03 † 95%CI: 0.76-1.39 
5 4.4% 3.5% PR= 1.26 † 95%CI: 0.91-1.75 
6 4.5% 4.3% PR= 1.05 † 95%CI: 0.73-1.49 
7 5.0% 3.9% PR= 1.28 † 95%CI: 0.86-1.91 
8 6.0% 3.9% PR= 1.54 † 95%CI: 0.99-2.39 
9 5.4% 4.7% PR= 1.15 † 95%CI: 0.67-1.98 
10 8.1% 4.5% PR= 1.80 † 95%CI: 0.93-3.47 
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Yang et al., 
2017 [4]  
 
Sweden 
Population based 
 
All 4,402 women 
diagnosed with an 
in situ breast 
cancer at the age of 
20-80 years 
between 2001-2009 
0 ND 4.7 (4.4), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.7 
(4.4)) 
Population based 
 
452,507 women 
randomly selected 
from the 
respondents to the 
1990 census 
EHR, ICD-10 
diagnostic codes 
for depression 
(F32-F33) at in 
patient or 
outpatient 
hospital visits 
Cumulative 
incidence:  1.3% 
Cumulative 
incidence:  1.2% 
SIR= 1.03  
 
95%CI: 0.80-1.34 
 
 
Standardised incidence 
ratios were standardised by 
calendar period (1-year 
categories), age (5-year 
categories), and region of 
residence (North, 
Stockholm- Gotland, South, 
Southeast, Uppsala-Orebro, 
West). 
By age group:  
20-44: SIR= 1.48  
45-54: SIR= 0.84  
55-64: SIR= 1.01  
65-80: SIR= 1.07  
 
By age group:  
95%CI: 0.84-2.61 
95%CI: 0.51-1.36 
95%CI: 0.61-1.68 
95%CI: 0.62-1.85 
 
0-0.5 0.1% 0.1% SIR= 0.77 95%CI: 0.29-2.05 
0.5-1 0.1% 0.1% SIR= 1.14 95%CI: 0.51-2.54 
1-2 0.2% 0.2% SIR= 0.91 95%CI: 0.47-1.74 
2-5 0.6% 0.5% SIR= 1.15 95%CI: 0.78-1.70 
5-10 0.3% 
 
0.3% 
 
SIR= 1.00 
 
95%CI: 0.57-1.76 
 
4.7 (4.4), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.7 
(4.4)) 
EHR, being 
prescribed an 
antidepressant 
(group N06A of 
the ATC 
classification 
system) 
Cumulative 
incidence: 
3.6% 
Cumulative 
incidence: 
2.3% 
SIR= 1.58 * 
 
95%CI: 1.36-1.85 
 
 
Standardised incidence 
ratios were standardised by 
calendar period (1-year 
categories), age (5-year 
categories), and region of 
residence (North, 
Stockholm- Gotland, South, 
Southeast, Uppsala-Orebro, 
West). 
By age group:  
20-44: SIR= 1.36  
45-54: SIR= 1.93 * 
55-64: SIR= 1.54 * 
65-80: SIR= 1.40 * 
By age group:  
95%CI: 0.84-2.23 
95%CI: 1.48-2.53 
95%CI: 1.15-2.07 
95%CI: 1.05-1.87 
0-0.5 - - SIR= 2.09 95%CI: 1.57-2.79 
0.5-1 - - SIR= 1.49 95%CI: 1.04-2.13 
1-2 - - SIR= 1.70 95%CI: 1.30-2.22 
2-4.5 
 
- - SIR= 1.12 95%CI: 0.79-1.59 
Population based 
 
All 40,849 women 
diagnosed with an 
invasive breast 
cancer at the age of 
20-80 years 
between 2001-2009 
I-IV ND 4.5 (4.5), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.4 
(4.5)) 
Population based 
 
452,507 women 
randomly selected 
from the 
respondents to the  
1990 census 
EHR, ICD-10 
diagnostic codes 
for depression 
(F32-F33) at in 
patient or 
outpatient 
hospital visits 
Cumulative 
incidence: 1.9% 
Cumulative 
incidence: 1.2% 
SIR= 1.57 * 
 
95%CI: 1.46-1.69 
 
SIR standardised by 
calendar period, age, and 
region. 
 
Predictors of depression 
among breast cancer 
survivors: having 
comorbidities and positive 
lymph nodes. 
By age group:  
20-44: SIR= 1.69  
45-54: SIR= 1.70 
55-64: SIR= 1.56 
65-80: SIR= 1.38 
By age group:  
95%CI: 1.42-2.01 
95%CI: 1.50-1.93 
95%CI: 1.36-1.79 
95%CI: 1.19-1.59 
0-0.5 0.2% 0.1% SIR= 1.83 * 95%CI: 1.48-2.26 
0.5-1 0.3% 0.1% SIR= 2.48 * 95%CI: 2.07-2.97 
1-2 0.4% 0.2% SIR= 2.04 * 95%CI: 1.76-2.36 
2-5 0.6% 0.5% SIR= 1.29 * 95%CI: 1.14-1.46 
5-10 
 
0.3% 0.3% SIR= 1.18 95%CI: 0.99-1.41 
4.5 (4.5), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.4 
(4.5)) 
EHR, being 
prescribed an 
antidepressant 
(group N06A of 
the ATC 
classification 
system) 
Cumulative 
incidence: 9.2% 
Cumulative 
incidence: 2.2% 
SIR= 1.95 * 
 
95%CI: 1.86-2.04 
 
SIR standardised by 
calendar period, age, and 
region. 
By age group:  
20-44: SIR= 2.43 * 
45-54: SIR= 2.23 * 
55-64: SIR= 2.00 * 
65-80: SIR= 1.64 * 
By age group:  
95%CI: 2.14-2.76 
95%CI: 2.02-2.45 
95%CI: 1.83-2.18 
95%CI: 1.51-1.77 
0-0.5 - - SIR= 2.14 * 95%CI: 1.95-2.36 
0.5-1 - - SIR= 2.62 * 95%CI: 2.40-2.87 
1-2 - - SIR= 1.92 * 95%CI: 1.76-2.09 
2-4.5 - - SIR= 1.34 * 95%CI: 1.20-1.49 
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Khan et al., 
2010 [3] 
 
United 
Kingdom 
Population-based 
 
16,938 women 
aged ≥30 with 
breast cancer 
registered in the UK 
General Practice 
Research 
Database. 
All ND ND (ND), ≥5 Population-based 
 
67,649 women 
who did not have 
breast or colorectal 
cancer at 
beginning of follow; 
individual matching 
for age (± 1 year) 
and primary care 
practice (small 
area). 
 
 
EHR, primary 
care 
consultations for 
depression 
recorded with 
Read codes 
 
Prevalence: 
9.6% 
Prevalence: 
8.9% 
OR= 1.06 95%CI: 1.00-1.14 
Odds ratio adjusted for 
Charlson comorbidity score, 
previous history of 
depression and death. 
EHR, ≥1 
prescription of 
antidepressants 
Prevalence: 
23.7% 
Prevalence: 
20.2% 
OR= 1.16 * 95%CI: 1.11-1.22 
Odds ratio adjusted for 
Charlson comorbidity score, 
number of consultations, 
and death. 
 
Cohort studies involving scales 
 
Aerts et al., 
2014 [32] 
 
ND 
Convenience 
sample 
 
66 women who had 
breast-conserving 
surgery for early 
breast cancer and 
no recurrence 
during follow up. 
‘Early-stage’ 
(100%) 
Srg, C: 100% 
CT: 24.7% 
RT: 76.5% 
HT: 70.3% 
~ 1 
 
(follow up at 
1 year) 
Convenience 
sample 
 
149 women with 
no history of 
cancer recruited in: 
a gynaecology 
outpatient clinic, an 
organisation for 
elderly women and 
online; matched for 
age (method not 
reported). 
 
BDI 
BDI 
mean score (SD) 
 
7.71 (8.00) 
BDI 
mean score (SD) 
 
5.28 (5.34) 
- P=0.02 * 
Higher CES-D scores 
indicate more depressive 
symptoms. 
 
Women who had advanced 
stage or had had relapse 
were excluded at baseline, 
as were those who had 
recurrence or a second 
cancer during follow up. 
Convenience 
sample 
 
48 women who had 
mastectomy for 
early breast cancer 
at one university 
hospital and no 
recurrence during 
follow up. 
 
‘Early-stage’ 
(100%) 
Srg, M: 100% 
CT: 44.1% 
RT: 45.6% 
HT: 54.4% 
~ 1 
 
(follow up at 
1 year) 
BDI 
mean score (SD) 
 
8.85 (6.79) 
BDI 
mean score (SD) 
 
5.28 (5.34) 
- P<0.01 * 
Ancoli-
Israel et al., 
2014 [33] 
 
United 
States 
 
Convenience 
sample 
 
44 women who had 
been diagnosed 
with breast cancer 
1 year before, and 
scheduled to 
receive ≥4 cycles of 
CT, with no 
psychological 
impairments and 
not receiving RT at 
recruitment. 
I (27.9%) 
II (39.7%) 
III (30.9%) 
Unknown 
(1.5%) 
 
Srg, C: 45.6% 
Srg, M: 49.7% 
CT: 100% 
 
~ 1 
 
(follow up at 
1 year after 
CT) 
Convenience 
sample 
 
35 cancer-free 
friends of the 
women who had 
breast cancer with 
no psychological 
impairments at the 
time of recruitment; 
individual matching 
for age (±5 years), 
ethnicity and 
education 
(categories of 
ethnicity and 
education not 
reported). 
 
CES-D 
CES-D 
mean score (SD) 
 
10.0 (ND) 
CES-D 
mean score (SD) 
 
4.8 (ND)  
- P=0.04 * 
Higher CES-D scores 
indicate more depressive 
symptoms. 
 
Mean scores adjusted for 
age and body mass index. 
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Kesler et 
al., 2013 
[34] 
 
United 
States 
 
Convenience 
sample 
 
44 women who had 
breast cancer 
recruited via support 
groups and 
advertisements; 
patients excluded if 
they had had disease 
recurrence or 
relapse. 
I-IIIA Srg, ND: 100% 
CT: 100% 
4.8 (3.4), 
1-12 
Convenience 
sample 
 
38 healthy female 
controls recruited 
through 
advertisements 
CAD 
CAD mean 
score (SD): 
 
 48.8 (8.2) 
CAD mean 
score (SD): 
 
48.0 (7.2) 
- P=0.08 
- 
Bailey et 
al., 2010 
[35] 
 
United 
States 
 
Convenience 
sample 
 
515 patients with 
first primary breast 
cancer, aged >40 
years, with no 
cognitive 
impairment or prior 
history of breast 
cancer, post active 
treatment and who 
spoke English.  
 
0 (34.4%) 
I (51.4%) 
IIA (14.2%) 
Srg, ND: 100% ~ 1 
 
(follow up at 
12 months 
after 
surgery) 
Convenience 
sample 
 
496 women who 
had a 
normal/benign 
mammogram, 
aged >40 years, 
with no cognitive 
impairment or prior 
history of breast 
cancer, and who 
spoke English; 
frequency matched 
for age (40-50, 50-
69, ≥70 years). 
CES-D 
 
Cut-off score for 
case: ≥16  
Prevalence: 
47.4% 
Prevalence: 
52.6% 
PR= 0.9 † 95%CI: 0.80-1.02 
 
Women with more 
advanced disease at 
diagnosis (stage IIA) had 
significantly more 
depression compared to 
those diagnosed at earlier 
stages.  
 
 
 
Hermelink 
et al., 2017 
[36] 
 
Germany 
Convenience 
sample 
 
150 women aged 
18-65 years, newly 
diagnosed with 
breast cancer, with 
no previous history 
of neurological or 
psychotic disorders 
and no previous 
systemic treatment 
for cancer 
0 (7%) 
I (42%) 
II (41.4%) 
III (%9.6) 
CT: 100% 
HT: 73.9%  
vs. 
CT: 0% 
HT: 80.7% 
 
~ 1 
 
(follow up at 
1 year after 
diagnosis) 
 
Convenience 
sample 
 
56 women aged 
18-65 years, who 
never had cancer, 
and attended the 
same institution as 
cases for breast 
imagining and did 
not require further 
tests. 
PHQ-D 
PHQ-D mean 
score 
 
CT: 4.7 (4.5) 
No CT: 4.2 (4.5) 
PHQ-D mean 
score 
 
 
2.7 (3.0) 
- 
P=0.03 * 
 
(for differences 
between the three 
groups) 
Higher PHQ-D mean scores 
indicate more depressive 
symptoms. 
 
Lee et al., 
2011 [37] 
 
Korea 
Convenience 
sample 
 
206 patients aged 
≥18 years who had 
been diagnosed 
with breast cancer 
1 year before 
I-IIA 
(71.2%) 
IIB-III 
(25.0%) 
Srg, C: 82.5% 
Srg, M: 16.4% 
CT: 86.7% 
RT: 82.5% 
HT: 82.2% 
~ 1 
(follow up at 
1 year after 
diagnosis) 
Population-based 
 
Nationally 
representative 
sample of 496 
adult women. SDS 
 
 
SDS mean score 
 
38.1 (0.94) 
SDS mean score 
 
38.8 (0.37) 
 P=0.514 
Mean scores adjusted for 
age, menopausal status, 
comorbidity, marital status, 
educational level, religious 
practice, job status, monthly 
income, body mass index, 
smoking status, drinking 
status, regular exercise, 
propensity score, and 
subscales of social support. 
 
Prevalence: 
49.3% 
Prevalence: 
46.6% 
PR=1.06 †  
95%CI: 0.89-1.25 
P=0.516 
Cut-off score for case: ≥50 
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Cross-sectional studies involving scales 
 
Bizetti Pelai 
et al., 2012 
[38] 
Convenience 
sample 
 
89 women who had 
surgery for breast 
cancer at <10 years 
ND (ND) Srg, BCS: 37% 
Srg, M: 50-63% 
RT: 2-11% 
CT: 24-30% 
CT+RT: 54-60% 
3.7 (ND), ≤10 Convenience 
sample 
 
43 women without 
breast cancer, or 
neurological or 
orthopaedic 
impairments of the 
upper limbs 
BDI 
Prevalence: 
41.6% 
Prevalence: 
28.0% 
PR=1.49 † 95%CI: 0.97-2.28 
Cut-off score for case: ≥10 
Castellon et 
al., 2004 
[15] 
 
United 
States 
 
Convenience 
sample 
 
53 women who had 
breast cancer at or 
before the age of 
50, with no 
evidence of disease 
or recurrence, and 
no history of 
psychiatric 
disorder. 
0-II (100%) CT: 34% 
CT+HT: 34% 
ND (ND), 2-5 Convenience 
sample 
 
19 Healthy women 
recruited via fliers, 
newsletter articles 
and 
advertisements, or 
amongst the 
acquaintances of 
the hospital staff. 
 
BDI 
BDI mean score 
(SD): 
 
No CT: 
7.0 (4.5) 
 
CT: 
6.3 (5.1) 
BDI mean score 
(SD): 
 
7.8 (7.9) 
- P=0.63 - 
Weitzner et 
al., 1997 
[16] 
 
United 
States 
Convenience 
sample 
 
60 women with age 
<70 years, 
education ≥6th 
grade, no history of 
psychiatric 
diagnoses, >5 
years disease-free, 
selected from those 
returning to the 
hospital for long-
term follow up of 
cancer. 
I (15%) 
II (63%) 
III (22%) 
Srg, M: 100% 
 
ND (ND), ≥5 Convenience 
sample 
 
93 employees or 
volunteer workers 
at the same 
hospital with no 
personal or family 
history of breast 
cancer, age <70 
years, education 
≥6th grade, and no 
psychiatric history. 
 
 
BDI 
 
Scale applied as 
part of a 
psychiatric 
interview 
BDI mean score 
(SD): 
 
7 (ND) 
BDI mean score 
(SD): 
 
5 (ND) 
- P<0.003 * 
Adjusted for years of age 
and years of education. 
 
Among breast cancer 
survivors, lower BDI scores, 
indicating less depression, 
were associated with better 
quality of life for all domains 
(P<0.02), except in the 
family one. 
Prevalence: 29% Prevalence: 15% PR= 1.93 * † 95%CI: 1.03-3.61 
Cut-off score for case: >12 
(mild to moderate 
depression) 
Garcia-
Torres et 
al., 2013 
[14] 
 
Spain 
Convenience 
sample 
 
22 breast cancer 
survivors free of 
relapse identified 
by staff of the local 
association against 
cancer. 
 
ND Srg, M: 100% 
CT: 72.7% 
8.2 (5.6), 1-21 Convenience 
sample 
 
22 women with no 
history of cancer 
who volunteered 
with the same 
association against 
cancer. 
BDI-II 
 
BDI-II mean 
score (SD):  
13.13 (7.83) 
 
BDI-II mean 
score (SD): 
8.18 (7.78) 
 
- P=0.02 * 
Correlation between anxiety 
and depression: r = 0.46, 
p<0.05; 
 
Cut-off score for case: >14 
(slight to severe depression) 
 
Cognitive-
affective 
component: 
5.86 (4.06) 
 
Cognitive-
affective 
component: 
3.72 (3.88) 
 
- P=0.03 * 
Motivational-
somatic 
component: 
6.81 (5.07) 
 
Motivational-
somatic 
component: 
3.81 (2.92) 
 
 P=0.02 * 
Prevalence: 40% 
 
Prevalence: 18% 
 
PR= 2.22 † 
 
95%CI: 0.79-6.21 
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Nguyen et 
al., 2013 
[39] 
 
United 
States 
Convenience 
sample 
 
57 women survivors 
of breast cancer, 
aged over 65 years, 
without recurrence, 
recruited from a 
cancer registry 
 
I-IIIA 
(100%) 
RT: 53% 
CT: 47% 
>10 Convenience 
sample 
 
30 healthy female 
adults, selected in 
the community for 
a previous study. 
 
 
BDI-II 
BDI-II mean 
score (SD): 
4.86 (4.07) 
BDI-II mean 
score (SD): 
4.03 (3.38) 
- P=0.39 - 
Cohen et 
al., 2011 [5] 
 
Israel 
Convenience 
sample 
 
56 married Israeli 
Arab breast cancer 
survivors, post 
treatment and free 
of disease recruited 
from one hospital. 
I-III (ND%) 
 
Srg, C: 48.2% 
Srg, M: 51.8% 
Srg, R: 12.5% 
CT: 85.7% 
RT: 85.7% 
HT: 58.9% 
4.8 (4.2), 1-17 Convenience 
sample 
 
66 married and 
healthy Arab women 
living in Israel, 
approached in 
community settings; 
individual matching 
for age and 
education (matching 
categories not 
reported). 
 
BSI-18 
BSI-18 mean 
score (SD): 
2.0 (1.1) 
BSI-18 mean 
score (SD): 
1.8 (0.8) 
- P>0.05 
Higher levels of depression 
associated with higher 
levels of anxiety and 
somatization, and lower 
levels of support in both 
groups (P<0.05). 
 
Higher levels of depression 
associated with lower body 
image in breast cancer 
survivors (P=0.05). 
 
Broeckel et 
al., 2002 
[40] 
 
United 
States 
Convenience 
sample 
 
58 breast cancer 
survivors who had 
a spouse or 
partner, free of 
recurrence for >5 
years, with no 
known neurological 
disorder, and no 
history of other 
cancer. 
 
I (26%) 
II (62%) 
III (10%) 
Unknown 
(2%) 
Srg, C: 50% 
Srg, M: 47% 
CT: 100% 
RT: 71% 
HT: 48% 
 
7.7 (2.3), 5.2-
15.2 
Convenience 
sample 
 
61 women with no 
history of cancer 
who had a spouse 
or partner, 
recruited among 
the friends of the 
women who had 
breast cancer; 
individual matching 
for age (± 6 years). 
 
CES-D 
CES-D mean 
score (SD): 
8.01 (6.34) 
CES-D mean 
score (SD): 
4.75 (4.12) 
- P≤0.05 * 
 
Higher CES-D score 
indicates more depressive 
symptoms. 
 
Correlation between 
depression scores and 
problems in sexual function: 
r = 0.27, P≤0.05 
Claus et al., 
2006 [41] 
 
United 
States 
Population-based  
 
All 795 women 
diagnosed with 
DCIS in 1994-1998, 
with no history of 
invasive breast 
cancer; 
reinterviewed on 
average 6.2 years 
after first interview.   
0 (100%) Srg, C: 35.5% 
Srg, M: 14.0% 
5.8 (1.0), ND Population based 
 
702 women selected 
by random-digit-
dialling methods, 
with no history of 
DCIS or invasive 
breast cancer; 
frequency matched 
for age (± 5 years) 
and geography. 
Reinterviewed on 
average at 6.0 (0.6) 
years after first 
interview. 
 
CES-D 
CES-D mean 
score (95%CI): 
8.3 (7.7-8.9) 
 
CES-D mean 
score (95%CI): 
7.2 (6.6-7.8) 
 
- P<0.05 * 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
Mean scores adjusted for 
age at diagnosis/interview, 
race (white/non-white), 
education (college 
degree/no college) 
menopausal status, 
comorbid conditions 
(myocardial infarction, 
stroke, cancer), marital 
status (married/living as 
married vs. not), time since 
diagnosis and case/control 
status. 
Srg, C: 100% 5.7 (1.1) CES-D mean 
score (SD): 
8.1 (7.2-9.0) 
 
CES-D mean 
score (SD): 
7.2 (6.6-7.8) 
 
- P>0.05 
Srg, C: 100% 
RT: 100% 
5.7 (1.1) CES-D mean 
score (SD): 
8.7 (7.9-9.5) 
 
CES-D mean 
score (SD): 
7.2 (6.6-7.8) 
 
- P<0.05 * 
Srg, M: 100% 6.0 (0.9) 
CES-D mean 
score (SD): 
7.4 (5.8-8.9) 
 
CES-D mean 
score (SD): 
7.2 (6.6-7.8) 
 
- P>0.05 
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Conroy et 
al., 2013 
[18] 
 
 
Convenience 
sample 
 
24 breast cancer 
survivors with 
history of non-
metastatic disease 
and CT treated. 
I (29%) 
IIa (33%) 
IIb (25%) 
IIIa (8%) 
IIIb (4%) 
CT: 100% 
RT: 79% 
 
6.4 (2.1), 3.2-
10.2 
Convenience 
sample 
 
23 healthy women 
matched for age and 
education (matching 
method not 
reported). 
CES-D  
CES-D mean 
score (SD): 
 
7.5 (5.8) 
CES-D mean 
score (SD): 
 
8.7 (6.9) 
- P>0.05 
 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
Koppelmans 
et al., 2012 
[42] 
 
The 
Netherlands 
 
Convenience 
sample 
 
196 women who had 
been treated for 
breast cancer 
between 1976 and 
1995, were aged 
between 50 and 80 
years in 2008, did not 
have recurrence or a 
second primary 
cancer and never 
used adjuvant 
hormone therapy. 
I-III (100%) HT: 0% 
CT: 100% 
21 (4.4), ND  Convenience 
sample 
 
All 1,509 women 
without a history of 
cancer who were 
between 50 and 80 
years of age at the 
time of the 
assessments, 
selected from a 
larger population-
based cohort. 
 
 
 
CES-D 
CES-D mean 
score (SD): 
 
4.7 (8.0) 
CES-D mean 
score (SD): 
 
6.7 (8.4) 
- P<0.05 * 
Mean score adjusted for 
age (format of the variable 
not reported). 
 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
McDonald 
et al., 2010 
[19] 
 
ND 
 
Convenience 
sample 
 
29 female breast 
cancer patients 
without 
neurobehavioral 
risk factors 
including 
neurologic, 
medical, or 
psychiatric 
conditions, except 
history of 
depression or 
anxiety 
0 (14%) 
I (35%) 
II (48%) 
IIIA (3%) 
CT: 59% 
RT: 69% 
~1.5 (0.15) Convenience 
sample 
 
18 healthy controls 
‘demographically 
matched’ 
(matching method 
not reported). 
CES-D 
CES-D mean 
score (SD): 
 
CT:  
6.8 (6.2) 
 
No CT: 
7.5 (10.4) 
CES-D mean 
score (SD): 
 
4.7 (8.9) 
- P>0.05 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
Prevalence of 
depression: 
13.8%  
Prevalence of 
depression: 
5.6% 
PR= 2.46 † 95%CI: 0.30 - 20.20 
Cut-off for case: CES-D 
score ≥16 
Otte et al., 
2010 [43] 
 
United 
States 
Convenience 
sample 
 
246 breast cancer 
survivors free of 
cancer at 
recruitment, with no 
history of other 
cancers and able to 
speak, read and 
write English 
I (ND) 
II (ND) 
III (ND) 
Srg, C: 42% 
Srg, M: 59% 
CT: 89% 
RT: ND 
HT: 33% 
 
5.6 (2.0), 2-10 Convenience 
sample 
 
246 women in 
general good 
health with no 
history of breast 
cancer recruited by 
acquaintance 
referral, self-
referral or from 
corporative group; 
individual matching 
for age (±5 years). 
 
CES-D 
CES-D mean 
score (SD): 
 
11.53 (9.60) 
CES-D mean 
score (SD): 
 
9.00 (9.20) 
- P<0.01 * 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
Depressive scores were 
correlated with sleep-wake 
disturbances (p<0.05).  
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Root et al., 
2015 [17] 
 
 
Convenience 
sample 
 
113 women aged 
<70 years who had 
breast cancer, were 
post-menopausal at 
diagnosis, receiving 
HT at recruitment, 
with no recurrence, 
no neurological or 
psychiatric 
diagnoses and who 
did not report sleep 
disturbances. 
I (58%) 
II (0%) 
III (33%) 
IV (8%) 
Srg, C: 75% 
Srg, M: 32% 
CT: 52% 
RT: 78% 
HT: 52% 
4.2 (1.2) Convenience 
sample 
 
37 health women 
with no history of 
cancer or cancer 
treatment, post-
menopausal, with 
no neurological or 
psychiatric 
diagnoses, 
matched for age 
and education 
(matching method 
not reported). 
 
 
CES-D 
CES-D mean 
score (SD): 
 
8.6 (8.2) 
CES-D mean 
score (SD): 
 
7.8 (6.5) 
- P=0.59 
Higher CES-D score 
indicates more depressive 
symptoms.  
Von Ah et 
al., 2009 
[44] 
 
United 
States 
Convenience 
sample 
 
52 women aged 
≥40 years, who had 
breast cancer and 
had completed 
primary treatment 
≥1 year ago, no 
cancer relapse, no 
metastatic disease 
or other cancer, 
and no history of 
psychiatric 
illnesses, recruited 
from cancer 
support groups, 
advertisements in 
churches and 
community centres, 
or by referral of 
enrolled 
participants. 
 
I-II (50%) 
III (ND) 
Srg, C: 66% 
Srg, M: 33% 
CT: 55.8% 
RT: 80.8% 
HT: 79% 
4.6 (2.8), 1.2-
15.8 
Convenience 
sample 
 
52 women aged 
≥40 years, with no 
history of cancer, 
no history of 
psychiatric 
illnesses, recruited 
from cancer 
support groups, 
advertisements in 
churches and 
community 
centres, or by 
referral of enrolled 
participants; 
individual matching 
for age (±5 years) 
and education (±3 
years). 
 
 
CES-D 
CES-D mean 
score (SD): 
 
10.8 (8.1) 
CES-D mean 
score (SD): 
 
9.5 (8.2) 
- P=0.415 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
Von Ah et 
al., 2012 
[45] 
 
United 
States 
Convenience 
sample 
 
62 non-Hispanic 
African American 
women diagnosed 
with non-metastatic 
breast cancer and 
able to read and 
write English, 
recruited by 
medical record 
review and by self-
referral. 
 
I-IIB 
(85.7%) 
IIIB (14.3%) 
Srg, C: 0% 
Srg, M: 60.3% 
CT & RT: 54.6% 
HT: ND 
 
5.0 (2.7), 2-10 Convenience 
sample 
 
78 African 
American women 
with no history of 
breast cancer, 
recruited through 
community 
advertisements 
and events. 
CES-D 
CES-D mean 
score (SD):  
 
12.2 (11.7) 
CES-D mean 
score (SD): 
 
11.6 (11.0) 
- P=0.757 
Higher CES-D score 
indicates more depressive 
symptoms.  
 
Mean scores adjusted for 
age, income, years of 
education and body mass 
index. 
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Frazzetto et 
al., 2012 
[46] 
 
Italy 
Convenience 
sample 
 
32 women aged 66-
75 years, with 
breast cancer 
recurrence ≥10 
years after initial 
diagnosis, recruited 
in one hospital. 
ND ND ND (ND), ≥10 Convenience 
sample 
 
35 women in ‘good 
health’ previously 
recruited in a 
hospital for a study 
on health-related 
quality of life 
 
 
 
GDS 
Prevalence: 
33.3% 
Prevalence: 
20.0% 
PR= 1.67 † 95%CI: 0.73-3.80 
 
Cut-off score for case: 10-
19 
(mild depression) 
Prevalence: 
50.0% 
Prevalence: 
8.6% 
PR= 5.81 * † 95%CI: 1.87-18.08 
Cut-off score for case: 20-
30 
(severe depression) 
Prevalence: 
83.3% 
Prevalence: 
28.6% 
PR= 2.91 * † 95%CI: 1.69-5.03 
Cut-off score for case: ≥10 
(mild to severe depression) 
Calvio et 
al., 2010 [7] 
 
United 
States 
 
Convenience 
sample 
 
122 breast cancer 
survivors ≥1 year 
post treatment, 
working full-time for 
≥1 year, with 
computer and 
internet, recruited 
via advertisements 
and flyers. 
I (36.9%) 
II (44.3%) 
III (17.2%) 
Srg, ND: 96.7% 
CT: 82.8% 
RT: 73.0% 
HT: 45.9% 
IT: 13.1% 
3.1 (2.4), 1-10 Convenience 
sample 
 
113 women 
without a previous 
cancer diagnosis, 
working full-time 
for ≥1 year, with 
computer and 
Internet, recruited 
via advertisements 
and flyers. 
HADS 
HADS mean 
score (SD): 
 
4.6 (3.3) 
HADS mean 
score (SD): 
 
3.2 (2.7) 
- P<0.001 * 
Higher scores indicate more 
depressive symptoms. 
 
Mean scores adjusted for 
marital status (cohabitating 
with partner vs. single/not 
cohabitating), race 
(Caucasian vs. non-
Caucasian), ethnicity 
(Hispanic vs. non-Hispanic), 
age (<40, 41-50, 51-65), 
income (0-39,000; 40-
59,000; 60-79,000; 80-
89,000; 80-99,000; 
≥100,000), and menopausal 
status (currently going 
through, premenopausal, 
postmenopausal). 
 
 
 
Boehmer et 
al., 2015 [6] 
 
ND 
 
Convenience 
sample 
 
85 lesbian or 
bisexual breast 
cancer survivors 
post-active 
treatment recruited 
via advertisements, 
flyers, etc. (3.5% of 
whom had had 
cancer recurrence) 
I-III (100%) 
 
ND 4.5 (ND), 1-10 Convenience 
sample 
 
85 lesbian or 
bisexual women 
with no history of 
cancer, no 
prophylactic 
mastectomy or 
oophorectomy, and 
not using hormone 
therapy, recruited 
via flyers, 
advertisements, 
etc.; individual 
matching for age 
(± 3 years) and 
partner status 
(partnered vs. 
unpartnered). 
 
 
Antidepressants 
intake 
(self-reported) 
Prevalence: 
34.1% 
Prevalence: 
21.2% 
PR=1.61 † 95%CI: 0.97-2.67 Depression was more 
common in women taking 
any psychopharmacological 
medication, compared to 
those who did not 
(OR=2.29, 95%CI: 1.02 to 
5.15), and less common in 
women with higher levels of 
physical activity (OR= 0.31, 
95%CI: 0.11-0.84). 
HADS 
score ≥8 
Prevalence: 
15.3% 
Prevalence: 
12.9% 
PR=1.19 † 95%CI: 0.56-2.50 
279
24 
 
Dahl et al., 
2011 [8] 
 
Norway 
 
Convenience 
sample 
 
337 tumor free 
breast cancer 
survivors treated 
with radiotherapy 
during 1998 and 
2002 in one 
hospital. 
II (ND) 
III (ND) 
Srg, C: 24% 
Srg, M: 76% 
CT: 82% 
RT: 100% 
HT: 81% 
 
3.9 (ND), 2.6-
6.9 
 
Convenience 
sample 
 
1,685 women 
randomly selected 
from a population-
based sample with 
no history of 
cancer and had 
complete data for 
questionnaires; 
individual matching 
for age (± 5 years). 
 
 
HADS 
 
HADS mean 
score (SD): 
3.1 (3.3) 
HADS mean 
score (SD): 
3.7 (3.1) 
- P<0.001 * 
Mean scores adjusted for 
level of education, on 
disability pension and 
menopausal status. 
 
Higher scores of HADS for 
depression were associated 
in univariate analysis with 
more insomnia symptoms in 
breast cancer survivors and 
in controls (P<0.05). 
Miao et al., 
2016 [9] 
 
 
Convenience 
sample 
 
23 patients with  
breast cancer who 
had been treated 
with chemotherapy 
at a local hospital 
I-III (100%) CT: 100% 3 (0.3),  Convenience 
sample 
 
26 age matched 
healthy controls 
selected amongst 
patients relatives 
and local 
universities 
(matching method 
not reported). 
 
 
 
HRS-D 
Mean score (SD) 
 
5.04 (1.19) 
Mean score (SD) 
 
4.88 (1.23) 
- P=0.650 
Higher score indicates more 
anxiety symptoms 
Rubino et 
al., 2007 
[10]  
 
Italy  
Convenience 
sample  
 
33 consecutive 
patients who had 
had breast-
reconstruction after 
mastectomy, in 
2001-2002. 
ND Srg, M: 100% 
Srg, R: 100% 
 
 
ND (ND), >1 Convenience 
sample 
 
33 women, 
randomly selected 
amongst university 
staff. 
 
 
 
 
HRS-D ‡  
 
Score ≥8 
Prevalence: 
45.4% 
Prevalence: 
12.1% 
PR=3.76 * † 95%CI: 1.39-10.14 
A P-value of 0.02 was 
reported in the article, for 
the chi-square test of 
differences in depression 
between groups. 
Boele et al., 
2015 [11] 
 
The 
Netherlands 
Convenience 
sample 
 
Post-menopausal 
breast cancer 
survivors with no 
psychiatric history, 
who did not receive 
CT, selected from 
medical records. 20 
exposed to HT, 43 
in the Srg+RT 
group.  
ND Srg, ND: 95% 
CT: 0% 
RT: 65% 
HT: 100% / 0%  
Exposure to 
HT: 3.2 (1.9), 
1.5-7;  
 
Unexposed to 
HT: 2.8 (0.3), 
2.3-3.3. 
Convenience 
sample 
 
44 friends or family 
members of the 
women who had 
had breast cancer, 
with no history of 
breast cancer;  
matched for age 
and education 
(method of 
matching not 
reported). 
 
 
 
HSCL-25 
HSCL-25 mean 
score (SD): 
 
HT: 
12.89 (8.40) 
 
 
No HT: 15.46 
(15.82) 
HSCL-25 mean 
score (SD): 
 
11.92 (10.97) 
- P=0.43 
Higher HSCL-25 score 
indicates more depressive 
symptoms. 
 
P-value adjusted for age 
and premorbid IQ. 
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Kreukels et 
al., 2008 
[12] 
 
The 
Netherlands 
Convenience 
sample 
 
63 women who had 
non-metastatic 
breast cancer, with 
no history of 
psychiatric 
diseases. 
I-III (100%) CT: 100% 
HT: 40% 
~ 1 Convenience 
sample 
 
60 friends or family 
of the patients with 
the same age who 
never had cancer; 
matched for age 
(matching method 
not reported). 
 
HSCL-25 
HSCL-25 mean 
score (SD): 
 
17.1 (13.6) 
 
HSCL-25 mean 
score (SD): 
 
9.6 (9.2) 
- P<0.001 * 
Higher HSCL-25 score 
indicates more depressive 
symptoms. 
Min et al., 
2010 [47] 
 
Korea 
Convenience 
sample 
 
52 women who had 
breast cancer 
treated with 
mastectomy and 
followed up 
immediate 
reconstruction with 
latissimus dorsi 
myocutaneous flap, 
recruited in one 
cancer center (3% 
had disease 
recurrence). 
 
0 (15.4%) 
I (40.4%) 
II (30.7%) 
III (13.5%) 
IV (0%) 
 
Srg, M: 100% 
Srg, R: 100% 
 
3.1 (1.3), ND Convenience 
sample  
 
104 ‘healthy 
female volunteers’ 
matched for age 
(matching method 
not reported). 
SDS 
SDS mean score 
(SD): 
 
48.5 (11.6) 
 
SDS mean score 
(SD): 
 
39.9 (9.1) 
- P<0.001 * 
Mean SDS scores in breast 
cancer survivors were 
significantly higher in 
women who had neo 
adjuvant chemotherapy 
compared to those who did 
not. 
Amir et al., 
2002 [13] 
 
Israel 
 
Convenience 
sample 
 
39 women free of 
cancer symptoms 
for ≥3 years and 
not under active 
treatment, identified 
through two 
hospitals. 
I (46%) 
II (46%) 
III (8%) 
Srg, C: 20% 
Srg, M: 80% 
CT: 66% 
RT: 41% 
HT: 46% 
6.5 (ND), ≥5 Convenience 
sample 
 
39 women who did 
not experience any 
life-threatening 
disease; matched 
for age and 
education 
(matching method 
not reported). 
 
SCL-90 
SCL-90 mean 
score (SD): 
 
0.99 (1.07) 
 
SCL-90 mean 
score (SD): 
 
0.66 (0.55) 
 
- P<0.001 * 
Higher SCL-90 scores 
indicate more depressive 
symptoms. 
 
Women who had breast 
cancer and reported PTSD 
symptoms had more 
depressive symptoms than 
those who did not: 2.13 
(1.22) vs. 0.75 (0.75), 
P<0.01. 
ATC = Anatomic Therapeutic Chemical classification system; BC = breast cancer; BDI = Beck Depression Inventory [48]; BDI-II = Beck Depression Inventory-II [49]; BSI-18 = Brief 
Symptom Inventory-18 [22]; CAD = Clinical Assessment of Depression [50]; CES-D = The Center for Epidemiologic Studies, Depression Scale [51]; CT = chemotherapy; EHR = 
electronic health records; GDS = Geriatric Depression Scale [52]; HADS = Hospital Anxiety and Depression Scale [23]; HRS-D = Hamilton Rating Scale for Depression [53]; HSCL-25 = 
Hopkins Symptom Checklist-25 [25]; HT = hormone therapy; ICD-8 = The International Classification of Diseases, Eight Revision; ICD-9-CM = The International Classification of 
Diseases, Ninth Revision, Clinical Modification; ICD-10 = The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; ND = not defined; OR = 
odds ratio; PHQ-D = Patient Health Questionnaire - Depression [54]; PR = prevalence ratio; RR = relative risk; RT = radiotherapy; SCL-90 = Depression subscale of Symptoms Checlist-
90 [27]; SD = standard deviation; SDS = Zung’s self-rating depression scale [55]; SIR = standardised incidence ratio; Srg, C = Breast conserving surgery; Srg, ND = Surgery, not further 
specified; Srg, M = Mastectomy; Srg, R = Breast reconstructive surgery; yrs = years. 
* There was some statistical evidence (P<0.05) for a different prevalence, risk or severity of anxiety between breast cancer survivors and women who did not have cancer. 
† Prevalence ratio calculated by the authors of the present study. 
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Supplementary Table 5. Neurocognitive dysfunction: main characteristics and results of the studies that evaluated the cognitive dysfunction or its 
domains in breast cancer survivors (>1 year) and women who did not have cancer. 
 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome assessment Quantitative measure of the outcome  Relative 
risk 
estimate 
(RR, OR, 
SIR, PR) 
P-value  or 95% 
confidence 
interval 
Notes 
Type of 
population and 
main 
characteristics 
 
Stage at 
diagnosis 
(%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis/ 
treatment in 
years: 
mean/median 
(SD), range 
Type of population 
and 
main 
characteristics 
 
Breast cancer 
survivors 
Comparison group  
 
Cohort studies involving neurocognitive assessment batteries 
 
Ahles et al., 
2010 [56] 
 
United 
States  
Convenience 
sample 
 
46 women, aged 
18-70 years, 
newly diagnosed 
with breast 
cancer, without 
history of 
neurologic 
disorders or axis 
I psychiatric 
disorders, 
consecutively 
recruited from 
one centre. 
0 (16.7%) 
I (47.0%) 
II (28.0%) 
IIIA (8.3%) 
CT: 100% 
 
~1.5 
 
(follow up at 
18 months 
after 
treatment) 
Convenience sample 
 
39 women without 
cancer recruited 
through community 
advertisements; 
frequency matched 
for age and 
education (categories 
of matching not 
reported).  
Change in the 
standardised scores for 
processing speed since 
baseline assessment 
prior to CT.  
 
Processing speed: 
Digit Symbol-Coding 
(WAIS-III), 
Trail Making Test (D-
KEFS), 
Color-Word Interference 
Test (D-KEFS), and 
Grooved Pegboard. 
 
Verbal ability: 
Vocabulary [WASI, Verbal 
Fluency Test (D-KEFS)]. 
 
Verbal memory: 
CVLT-II, 
Logical Memory I and II 
(WMS-III).  
 
Visual memory: 
Faces I and II (WMS-III). 
 
Working memory: 
PASAT. 
 
Sorting: 
Sorting Test (D-KEFS). 
 
Distractibility: CPT. 
 
Reaction time: CPT. 
Mean score (SD) 
 
Processing speed 
-0.01 (0.45)  
Verbal ability 
0.17 (0.87)  
Verbal memory 
0.68 (0.80)  
Visual memory 
1.04 (0.69)  
Working memory 
0.69 (0.65) 
Sorting 
0.52 (0.91)  
Distractibility 
0.20 (0.45) 
Reaction time 
-0.57 (1.14) 
Block design 
0.11 (0.84) 
Mean score (SD) 
 
Processing speed 
0.25 (0.52)  
Verbal ability 
0.17 (0.71)  
Verbal memory 
0.69 (0.69)  
Visual memory 
1.05 (0.80)  
Working memory 
0.64 (0.92)  
Sorting 
0.55 (0.73) 
Distractibility 
0.16 (0.81)  
Reaction time 
0.16 (0.88)  
Block design 
0.18 (0.76) 
 
 - 
- 
Domain scores adjusted 
for age, education, and 
baseline score. 
 
The linear mixed-methods 
model indicated that older 
patients who received 
chemotherapy had lower 
post-treatment processing 
speed performance 
(z-score difference,-0.16 
per 10 years increase in 
age; 95%CI: -0.29 to -
0.04) compared with 
healthy controls. 
 
 Convenience 
sample 
 
64 women, aged 
18-70 years, 
newly diagnosed 
with breast 
cancer, without 
history of 
neurologic 
disorders or axis 
I psychiatric 
disorders, 
consecutively 
recruited from 
one centre. 
0 (16.7%) 
I (47.0%) 
II (28.0%) 
IIIA (8.3%) 
CT: 0% 
 
~1.5 
 
(follow up at 
18 months 
after 
treatment) 
Convenience sample 
 
39 women without 
cancer recruited 
through community 
advertisements; 
frequency matched 
for age and 
education (categories 
of matching not 
reported). 
Mean score (SD) 
 
Processing speed 
-0.09 (0.65) 
Verbal ability 
-0.04 (0.73) 
Verbal memory 
0.38 (0.93) 
Visual memory 
1.02 (0.71) 
Working memory 
0.44 (0.95) 
Sorting 
0.21 (0.86) 
Distractibility 
-0.02 (1.05) 
Reaction time 
-0.28 (0.95) 
Block design 
-0.07 (0.82) 
Mean score (SD) 
 
Processing speed 
0.25 (0.52)  
Verbal ability 
0.17 (0.71)  
Verbal memory 
0.69 (0.69)  
Visual memory 
1.05 (0.80)  
Working memory 
0.64 (0.92)  
Sorting 
0.55 (0.73) 
Distractibility 
0.16 (0.81)  
Reaction time 
0.16 (0.88)  
Block design 
0.18 (0.76) 
- - 
Domain scores adjusted 
for age, education, and 
baseline score. 
 
 
The linear mixed-methods 
model indicated that older 
patients not exposed to 
chemotherapy had lower 
post-treatment 
Processing Speed 
performance 
(z-score difference, -0.11; 
95%CI, -0.21 to -0.001).  
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Collins et 
al., 2014 
[57] 
 
Canada 
Convenience 
sample 
 
60 women, aged 
18-65 years, 
with at least the 
8th grade of 
education, newly 
diagnosed with 
non-metastatic 
breast cancer, 
scheduled to 
receive CT, 
recruited in one 
hospital; patients 
who had disease 
progression 
during follow up 
were excluded. 
 
I-III (100%) CT: 100% ~ 1 
(follow up at 
12 months 
after CT) 
Convenience sample 
 
60 women recruited 
through hospital 
advertisements and 
peer nomination, with 
at least the 8th grade 
of education; 
matched on age, 
education and first 
language (categories 
of matching not 
reported). 
Processing Speed: 
Digit-Symbol Coding & 
Symbol Search (WAIS-
III); TMT-A; TMT-B; 
Processing speed &   
Reaction time indices 
(CNS-VS).  
 
Working Memory: 
Digit Span & Letter-
Number-Sequencing 
(WAIS-III); PASAT; 
ACTT; COWA; Flexibility 
& working memory 
indices (CNS-VS). 
 
Visual Memory 
Visual memory index 
(CNS-VS).  
 
Verbal Memory 
HVLT-; verbal memory 
index (CNS-VS). 
 
Prevalence: 22% Prevalence: 6% PR= 3.67* † 95%CI: 1.21-11.12 
Cut off for case: 
A standardised-
regression based score of 
≥ -2.0 on 3 or more of the 
19 cognitive measures 
Fan et al., 
2005 [58] 
 
Canada 
Convenience 
sample 
 
91 women with 
breast cancer 
without relapse, 
with no psychiatric 
history and no use 
of psychotropic 
medications other 
than 
benzodiazepines 
for nausea, sleep, 
or anxiety. 
ND CT: 100% 
RT: 65% 
HT: 67% 
 
~ 1 
(follow up at 
1 year after 
CT) 
Convenience sample 
 
102 healthy women, 
acquaintances or 
relatives of the 
patients; individual 
matching for age (± 5 
years). 
HSCS, mild dysfunction Prevalence: 30.8% Prevalence: 19.3% PR= 1.60 † 95%CI: 0.93-2.73 
- 
HSCS, moderate to 
severe dysfunction 
Prevalence: 4.4% Prevalence: 3.6% PR= 1.22 † 95%CI: 0.28-5.31 
TMT-A Median score: 44.0 Median score: 45.0 - P= 0.25 
TMT-B Median score: 49.0 Median score: 54.0 - P= 0.0005 * 
~ 2 
(follow up at 
2 year after 
CT) 
HSCS, mild dysfunction Prevalence: 21.3% Prevalence: 11.1% PR= 1.92 † 95%CI: 0.91-4.04 
HSCS, moderate to 
severe dysfunction 
Prevalence: 3.8% Prevalence: 0.0% PR= 3.88 † 95%CI: 0.33-28.77 
TMT-A Median score: 47.0 Median score: 49.0 - P= 0.61 
TMT-B Median score: 50.0 Median score: 53.0 - P= 0.048 * 
Hermelink 
et al., 2017 
[36] 
 
Germany 
Convenience 
sample 
 
150 women with 
breast cancer, 
aged 18-65 
years, with no 
history of 
neurological 
disorders and no 
previous 
systemic 
treatment. 
0 (7%) 
I (42%) 
II (41.4%) 
III (%9.6) 
CT: 100% 
HT: 73.9%  
vs. 
CT: 0% 
HT: 80.7% 
 
~ 1 
(follow up at 
1 year after 
diagnosis) 
 
Convenience sample  
 
56 women aged 18-
65 years, who never 
had cancer, and 
attended the same 
institution as cases 
for breast imagining 
and did not require 
further tests. 
Attention 
TAP; TMT-A, 
 
Memory 
Digit span (WSM-R); 
VLMT. 
 
Executive function 
TMT-B; lexical and 
semantic search (RWT). 
Composite z-score:  
 
No CT: 0.04 (0.45); 
CT: -0.10 (0.42) 
Composite z-score:  
 
0.10 (0.38) 
- P= 0.01 * 
Composite score of overall 
performance calculated as 
the mean across all age- 
and education-adjusted 
cognitive indices (age and 
education categories in the 
models not reported). 
Cognitive change scores 
were further adjusted for 
cognitive scores at 
baseline. 
Composite score, 
change in the first 
year of diagnosis:  
 
No CT: -0.01 (0.38) 
CT: -0.07 (0.37) 
Composite score, 
change in the first year 
of diagnosis  
 
0.11 (0.35) - P=0.02 * 
Prevalence: 17.7% Prevalence: 5.3% RR= 2.43  
95% CI: 0.89 - 
6.65 
≥5 scores below 1.5  
SD and/or ≥4 scores below 
2 SD. 
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Jenkins et 
al., 2006 
[59] 
 
United 
Kingdom 
Convenience 
sample 
 
128 women 
diagnosed with 
early breast 
cancer across 
the UK, with no 
disease 
progression 
‘early breast 
cancer’ 
Srg, M: 26% 
CT: 66.4% 
~ 1 
(follow up at 
12 months 
after CT)  
Convenience sample 
 
49 healthy women 
who were friends or 
family of the patients, 
or from the local 
women’s support 
group 
 
Verbal memory 
Logical memory (WMS); 
Immediate & delayed 
recall (AVLT). 
 
Visual memory 
Complex figure task. 
 
Executive function 
The Stroop task 
 
Working memory 
Spatial span, 
letter/number sequencing 
& digit span (WMS-III) 
 
Processing speed 
Letter cancellation task. 
 
 
 
Prevalence of decline 
on ≥2 measures as 
measured by the 
reliable change 
index: 
 
16.8% 
 
Prevalence of decline 
on ≥2 measures as 
measured by the 
reliable change index: 
 
10.6% 
 
PR= 1.58 †  95%CI: 0.64-3.90 
Reliable change index 
corrected for practice 
effects. 
Phillips et 
al., 2012 
[60] 
 
United 
States 
Convenience 
sample 
 
129 women 
diagnosed with 
breast cancer 
and scheduled 
to receive CT or 
RT; patients with 
recurrence were 
excluded 
0 (10%) 
I (53%) 
II (37%) 
 
Srg, M: 91.5% 
Srg, C: 8.5% 
HT: 62% 
3 
(follow up at 
26 months 
after RT) 
Convenience sample 
 
184 women with no 
history of cancer, 
individual matching 
for age (±5 years) 
and ZIP code. 
Attention 
Trial 1 Color Trails Test; 
Digit & Spatial Span 
(WAIS-III). 
 
Executive functioning 
Digit Symbol Coding 
(WAIS-III); Trial 2 Color 
Trails Test; COWAT. 
 
Nonverbal memory 
Visual Reproduction test 
(WMS-III). 
 
Processing speed 
Ruff 2 & 7 Test. 
 
Verbal memory 
CVLT. 
Score Means (SE) 
 
CT group: 
Attention 
53.55 (0.72) 
Executive functioning 
51.87 (0.81) 
Nonverbal memory 
56.24 (0.95) 
Processing speed 
49.90 (0.84) 
Verbal memory 
50.67 (1.11) 
 
RT group: 
Attention  
51.59 (0.68) 
Executive functioning 
52.30 (0.77) 
Nonverbal memory 
54.97 (0.90) 
Processing speed 
49.03 (0.80) 
Verbal memory 
50.75 (1.05) 
 
 
Score Means (SE) 
 
Attention 
51.78 (0.41) 
Executive functioning 
54.63 (0.46) 
Nonverbal memory 
55.90 (0.54) 
Processing speed 
51.38 (0.48) 
Verbal memory 
51.26 (0.63) 
 
- P<0.05 * 
Score means are 
adjusted for age, T1 
National Adult Reading 
Test scores, and time 
from T1 to T2 
assessments. 
 
Significant group x time 
interaction detected for 
processing speed 
(P=0.009). 
Schagen et 
al., 2006 
[61] 
 
The 
Netherlands 
Convenience 
sample 
 
57 women who 
had breast 
cancer treated 
with RT but not 
CT, and no 
relapse 
I (100%) RT: 100% 
CT: 0% 
HT: 0% 
~1 Convenience sample 
 
60 healthy women, 
friends of the 
participants in the 
study 
24 test indices, covering 
the following domains: 
focused-sustained 
attention, working-verbal-
visual memory, 
processing speed, 
executive function, and 
verbal/motor function 
 
 
 
Prevalence: 22.8% Prevalence: 6.7% OR= 2.1 95%CI: 0.5-8.4 
Odds ratio adjusted for 
age and IQ. 
 
Cognitive impairment 
defined as scoring 2 SD 
below the mean of the 
control group for ≥3 of the 
24 tests. 
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Cross-sectional studies involving neurocognitive assessment batteries 
 
Boele et al., 
2015 [11] 
 
The 
Netherlands 
Convenience 
sample 
 
Post-
menopausal 
breast cancer 
survivors with no 
psychiatric 
history, who did 
not receive CT, 
selected from 
medical records. 
ND Srg, ND: 95% 
CT: 0% 
RT: 65% 
HT: 100% / 0%  
Exposure to 
HT: 3.2 (1.9), 
1.5-7;  
 
Unexposed 
to HT: 2.8 
(0.3), 2.3-
3.3. 
Convenience sample 
 
44 friends or family 
members of the 
women who had had 
breast cancer, with 
no history of breast 
cancer; matched for 
age and education 
(method of matching 
not reported). 
Verbal memory 
AVLT; Visual association 
test. 
 
Visual memory 
WMS. 
 
Working memory 
Letter-number 
sequencing (WAIS-III) 
 
Executive functioning 
Stroop; TMT-B. 
 
Processing speed 
Stroop; TMT-A 
 
Reaction speed 
Fepsy reaction times 
 
Fluency 
Category fluency, 
letter fluency 
 
Motor functioning 
Fepsy tapping 
 
Domain z-scores by 
treatment group:  
 
Verbal memory 
HT: -0.49 (0.66) 
Srg+RT: -0.01 (0.63) 
 
Visual memory 
HT: 0.136 (0.80) 
Srg+RT: -0.25 (1.09) 
 
Working memory  
HT: -0.144 (0.82) 
Srg+RT: 0.08 (1.06) 
 
Executive functioning 
HT: -0.10 (0.92) 
Srg+RT: 0.07 (0.93) 
 
Processing speed 
HT: -0.06 (0.65) 
Srg+RT: -0.01 (0.82) 
 
Reaction speed 
HT: 0.24 (0.79) 
Srg+RT: -0.12 (1.07) 
 
Fluency 
HT: -0.41 (0.78) 
Srg+RT: -0.31 (0.70) 
 
Motor functioning 
HT: 0.29 (0.70) 
Srg+RT: 0.14 (0.84) 
 
 
Domain z-scores: 
 
 
Verbal memory 
-0.001 (0.81) 
 
Visual memory 
0.000 (0.95) 
 
Working memory 
0.001 (1.00) 
 
Executive functioning 
0.000 (0.88) 
 
Processing speed 
0.000 (0.79) 
 
Reaction speed 
0.000 (0.91) 
 
Fluency 
0.000 (0.88) 
 
Motor functioning 
0.000 (0.96) 
- 
 
Verbal memory  
P=0.009 * 
 
Visual memory 
P=0.339 
 
Working memory 
P=0.965 
 
Executive 
functioning 
P=0.444 
 
Processing speed 
P=0.554 
 
Reaction speed 
P=0.529 
 
Fluency 
P=0.012 * 
 
Motor functioning 
P=0.667 
P-value for the three-
group comparison. 
 
Z-scores corrected for 
age and estimated 
premorbid IQ. 
Brezden et 
al., 2000 
[62] 
 
Canada 
 
 
Convenience 
sample 
 
40 women who 
had completed CT 
for breast cancer, 
at least the 8th 
grade of 
education, with no 
history of cognitive 
dysfunction or 
psychiatric 
illnesses and with 
no clinical 
evidence of 
recurrence or 
metastases. 
 
 
 
I-II (ND) CT (100%) 2 (ND), >1 Convenience sample 
 
36 healthy female 
relatives of the 
patients or hospital 
personnel who 
volunteered for the 
study. 
HSCS 
Median score: 34.5  Median score: 26.0 - P>0.05 
When adjusted for age, 
menopausal status, and 
level of education 
(categories not reported), 
the difference was 
significant (P=0.046). 
 
 
Prevalence of 
moderate and severe 
cognitive impairment: 
50% 
Prevalence of 
moderate and severe 
cognitive impairment: 
11% 
PR= 4.5 * † 95%CI: 1.71-12.11 - 
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Calvio et 
al., 2010 [7] 
 
United 
States 
 
Convenience 
sample 
 
122 breast 
cancer survivors 
≥1 year post 
treatment, 
working full-time 
for ≥1 year, with 
computer and 
internet, 
recruited via 
advertisements 
and flyers. 
I (36.9%) 
II (44.3%) 
III (17.2%) 
Srg, ND: 96.7% 
CT: 82.8% 
RT: 73.0% 
HT: 45.9% 
IT: 13.1% 
3.1 (2.4), 1-
10 
Convenience sample 
 
113 women without a 
previous cancer 
diagnosis, working 
full-time for ≥1 year, 
with computer and 
Internet, recruited via 
advertisements and 
flyers. 
 
CNS-VS battery 
 
Composite memory 
Verbal memory 
Visual memory 
Executive function 
Attention  
Composite memory: 
101.7 (18.1) 
 
Verbal memory: 
99.8 (16.6) 
 
Visual memory: 
102.8 (17.1) 
 
Executive function: 
98.6 (9.2) 
 
Attention: 
83.8 (10.3) 
Composite memory: 
97.1 (19.8) 
 
Verbal memory: 
96.0 (20.0) 
 
Visual memory: 
99.3 (17.1) 
 
Executive function: 
94.5 (16.4) 
 
Attention: 
80.2 (17.7) 
- Executive function: 
P<0.001 * 
 
Attention: 
P<0.05 * 
 
All other domains 
P>0.05 
Lower scores indicate 
poorer functioning.  
 
Mean scores adjusted for 
marital status 
(cohabitating with partner 
vs. single/not 
cohabitating), race 
(Caucasian vs. non-
Caucasian), ethnicity 
(Hispanic vs. non-
Hispanic), age (<40, 41-
50, 51-65), income (0-
39,000; 40-59,000; 60-
79,000; 80-89,000; 80-
99,000; ≥100,000), and 
menopausal status 
(currently going through, 
premenopausal, 
postmenopausal). 
 
Castellon et 
al., 2004 
[15] 
 
United 
States 
 
Convenience 
sample 
 
53 women who 
had breast 
cancer at or 
before the age of 
50, with no 
evidence of 
disease or 
recurrence, and 
no history of 
psychiatric 
disorder. 
0-II (100%) CT: 34% 
CT+HT: 34% 
2-5 Convenience sample 
 
19 Healthy women 
recruited via fliers, 
newsletter articles 
and advertisements, 
or amongst the 
acquaintances of the 
hospital staff. 
 
Verbal Fluency 
COWA. 
 
Verbal Learning 
CVLT. 
 
Verbal Memory 
Logical memory (WMS-
R). 
 
Visual Memory 
Visual Reproduction 
(WMS-R); RCFT. 
 
Visuospatial Function 
Block Design (WAIS-III); 
Copy Trial (RCFT). 
 
Psychomotor Speed 
Digit Symbol (WAIS-III); 
TMT-A; TMT-B. 
 
Reaction Time 
CCAP 
 
Executive Attention 
PASAT; Stroop Test. 
 
 
z-scores, no CT nor 
HT: 
Fluency: -0.36 
Verbal Learning: 0.54 
Verbal memory: 0.21 
Visual memory: 0.45 
Visuospatial: 0.42 
Reaction time: -0.20 
Psychomotor speed: 
0.22 
Executive attention: 
-0.01 
 
z-scores, CT (with or 
without HT): 
Fluency: -0.64 
Verbal learning: 0.03 
Verbal memory: 
-0.35 
Visual memory: -0.39 
Visuospatial: -0.51 
Reaction time: -0.49 
Psychomotor speed: 
0.03 
Executive attention:  
-0.41 
 
 
 
 
 
 
 
 
Ref the mean scores of 
the healthy women 
used to calculate the z-
scores.  
- 
 
 
Verbal Fluency: 
P=0.007 * 
 
All other domains: 
p>0.05 
 
- 
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Conroy et 
al., 2013 
[18] 
 
United 
States  
Convenience 
sample 
 
24 breast cancer 
survivors with 
history of non-
metastatic 
disease and 
chemotherapy 
treated. 
I (29%) 
IIa (33%) 
IIb (25%) 
IIIa (8%) 
IIIb (4%) 
CT: 100% 
RT: 79% 
 
6.4 (2.1), 
3.2-10.2 
Convenience sample 
 
23 healthy women; 
matched for age and 
education (matching 
method not 
reported). 
Learning 
AVLT; BLT. 
 
Memory 
AVLT; BLT. 
 
Attention 
Digit span (WAIS-III); 
PASAT. 
 
Language 
WRAT-4; Word Reading 
test; Vocabulary (WASI). 
 
Visuospatial 
Block Design (WASI) 
 
Executive 
Digit span; COWA; Color-
Word Test, Sorting Test, 
& Trail Making Test (D-
KEFS).  
 
Psychomotor 
Symbol Digit, and 
Grooved Pegboard. 
 
 
Age-adjusted domain 
z-scores: 
 
Learning: -0.2 (0.7) 
Memory: -0.3 (0.6) 
Attention: 0.4 (0.6) 
Language: 0.3 (0.8) 
Visuospatial: -0.5 
(1.0) 
Executive: -0.04 (0.7) 
Psychomotor: -0.1 
(0.4) 
Average: -0.1 (0.5) 
 
Age-adjusted domain z-
scores: 
 
Learning: 0.1 (0.7) 
Memory: 0.2 (0.7) 
Attention: 0.03 (0.5) 
Language: -0.03 (0.9) 
Visuospatial: 0.1 (0.9) 
 
Executive: 0.04 (0.6) 
Psychomotor: 0.04 
(0.4) 
Average: 0.1 (0.4) 
 
- 
Memory: P≤0.05 * 
 
All other domains: 
P>0.05 
- 
Ernst et al., 
2002 [63] 
 
 
United 
States 
Convenience 
sample 
 
16 women aged 
65-80 years, 
recruited via 
advertisements. 
‘localised 
breast 
cancer’ 
HT: 100% 
Srg, ND: 100% 
CT: 0% 
4.4 (1.7), 
2-10 
Convenience sample 
 
33 women with no 
history of breast 
cancer; matched for 
age (matching 
method not 
reported). 
 
 
Digit symbol substitution 
test 
Nr of correct 
substitutions (SD): 
7.5 (3.1) 
 
 
Nr of correct 
substitutions (SD): 
7.2 (2.1) 
 
 
- P>0.05 - 
TMT-A 
Time required (SD):  
44.2 (12.2) 
Time required (SD):  
36.9 (10.4) 
- P>0.05 - 
Inagaki et 
al., 2006 
[64] 
 
Japan 
 
Convenience 
sample 
 
105 women who 
had breast 
cancer aged 18-
55 years, with no 
history of 
neurological or 
psychiatric 
disorders other 
than affective or 
anxiety; tumor 
free at 
recruitment. 
 
 
0-I (27.5%) 
 
Srg, C: 49% 
CT: 100% 
HT: 39% 
RT: 48% 
1 Convenience sample 
 
55 healthy subjects 
who lived in the 
same area as the 
patients recruited via 
advertisements in the 
local newspaper; 
matched for region 
(matching method 
not reported). 
 
WMS-R 
Mean domain score 
(SD): 
 
Attention 
99.4 (12.5) 
 
Verbal memory 
96.9 (13.0) 
 
Visual memory 
101.9 (12.1) 
 
Delayed recall 
100.3 (10.4) 
Mean domain score 
(SD):  
 
Attention 
99.6 (13.0) 
 
Verbal memory 
99.2 (14.4) 
 
Visual memory 
101.4 (10.3) 
 
Delayed recall 
100.7 (12.6) 
- 
For all domains: 
P>0.05 
- 
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Kesler et 
al., 2013 
[34] 
 
United 
States 
 
Convenience 
sample 
 
44 women who 
had breast 
cancer recruited 
via support 
groups and 
advertisements; 
patients 
excluded if they 
had had disease 
recurrence or 
relapse 
 
I-IIIA Srg, ND: 100% 
CT: 100% 
4.8 (3.4), 
1-12 
Convenience sample 
 
38 healthy female 
controls recruited 
through 
advertisements 
MMQ; HVLT-R; WAIS 
Mean scores (SD): 
 
HVLT-R total recall: 
49.3 (8.0) 
HVLT-R delayed 
recall: 49.8 (6.4) 
 
MMQ: 42.2 (11.2) 
 
WAIS-IQ: 112 (11) 
Mean score (SD): 
 
HVLT-R total recall: 
57.1 (9.6) 
HVLT-R delayed recall: 
56.0 (8.1)  
 
MMQ: 59.3 (7.4) 
 
WAIS-IQ: 115 (13) 
- 
 
 
P=0.03 * 
 
P=0.02 *  
 
P<0.001 * 
 
P=0.29 
- 
Koppelmans 
et al., 2012 
[42] 
 
The 
Netherlands 
 
 
Convenience 
sample 
 
196 women who 
had been treated 
for breast cancer 
between 1976 
and 1995, were 
aged 50-80 
years in 2008, 
did not have 
recurrence or a 
second primary 
cancer and 
never used 
adjuvant 
hormone 
therapy. 
I-III (100%) HT: 0% 
CT: 100% 
21 (4.4), ND  Convenience sample 
 
All 1,509 women 
without a history of 
cancer who were 50-
80 years of age at 
the time of the 
assessments, 
selected from a 
larger population-
based cohort. 
Learning and memory 
(15-WLT) 
Trial 1: 5.5 (2.2) 
Trial 2: 8.6 (2.4) 
Trial 3: 10.3 (2.6) 
Total: 24.3 (6.2) 
Delayed recall: 8.0 (2.9)
Recognition: 13.8 (1.8) 
Trial 1: 5.9 (2.4) 
Trial 2: 9.0 (2.7) 
Trial 3: 10.6 (2.9) 
Total: 25.5 (6.9) 
Delayed recall: 8.7 (3.2) 
Recognition: 13.8 (2.0) 
- 
P=0.008 * 
P=0.02 * 
P=0.17 
P=0.02 * 
P=0.002 * 
P=0.76 
Adjusted for age and 
education (categories of 
the variables used in the 
models not reported). 
 
Processing speed (LDST) 
 
 
Total correct: 31.8 (6.7)
 
 
Total correct: 32.5 (7.5) 
 
 
- 
 
 
P=0.14 
 
Stroop color-word test 
Word card: 16.8 (3.3) 
Color card: 23.3 (4.4) 
Color-word card:  
45.8 (12.6) 
Word card: 16.5 (3.7) 
Color card: 22.2 (4.9) 
Color-word card:  
43.5 (14.0) 
- 
P=0.14 
P=0.001 * 
P=0.02 * 
Verbal fluency (WTF) 
Total: 24.1 (6.1) 
15sec: 13.8 (4.8) 
Total: 24.2 (6.8) 
15sec: 13.8 (5.4) 
- 
P=0.89 
P=0.95 
Visuospatial (DOT) 
Total correct: 
28.9 (9.2) 
Total correct: 
28.9 (9.7) 
- P=0.99 
Motor speed (PPB) 
Both hands: 
11.1 (1.6) 
Dominant hand: 
13.8 (1.9) 
Nondominant hand: 
12.9 (1.8) 
 
Both hands: 
11.2 (1.8) 
Dominant hand: 
13.8 (2.1) 
Nondominant hand: 
13.4 (2.0) 
 
- 
P=0.56 
 
P=0.81 
 
P=0.001 * 
 
Kreukels et 
al., 2008 
[12] 
 
The 
Netherlands 
 
 
Convenience 
sample 
 
63 women who 
had been treated 
with CT for non-
metastatic 
breast cancer, 
with no history of 
psychiatric 
diseases 
I-III (100%) CT: 100% 
HT: 40% 
~ 1 Convenience sample 
 
60 Female friends or 
relatives of the 
patients with the 
same approximate 
age who never had 
cancer; matched for 
age (matching 
method not 
reported). 
 
TMT-A; Digit Symbol 
(WAIS); Stroop Color 
Word Test; Eriksen Task, 
Working-Memory 
Updating, CVLT, Visual 
Reproduction of the 
WMS, AFM Task, 
TMT-B, Word Fluency, 
Fepsy Finger Tapping. 
Prevalence of 
cognitive impairment: 
33.3% 
Prevalence of cognitive 
impairment: 
10% 
RR= 5.51 * 95%CI: 1.86-16.28 
Cognitive impairment 
defined as 2 standard 
deviations below the 
mean of the healthy 
control group on ≥ 3 tests. 
 
RR adjusted for age and 
premorbid IQ.  
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Lejbak et 
al., 2010 
[65] 
 
Canada 
Convenience 
sample 
 
28 post 
menopausal 
women with 
oestrogen 
positive breast 
cancer, aged 40 
and 80 years, 
recruited from 
the local cancer 
registry and 
oncology centre 
I (100%) HT: 100% 
Srg, ND: 83% 
RT: 67% 
3 (1), 2-5 Convenience sample 
 
37 age-equivalent 
controls recruited 
through mailed 
invitations 
Immediate verbal 
memory: List Learning, 
Story Memory. 
 
Delayed verbal memory 
List Recall, Story Recall. 
 
Complex visuomotor 
attention: Coding 
 
Letter fluency: COWA 
 
Object location memory 
task 
 
Speeded manual 
dexterity: Grooved 
Pegboard 
 
Complex working memory  
Verbal n-Back 
Mean score (SD): 
 
List Learning 
29.0 (5.1) 
 
List Recall 
7.1 (2.2) 
 
Story Memory 
17.1 (3.6) 
 
Story Recall 
9.0 (2.3) 
 
Coding 
42.9 (9.5) 
 
Letter Fluency 
40.0 (10.8) 
 
Object-Location 
47.5 (21.1) 
 
Grooved Pegboard 
80.9 (17.1) 
 
Verbal n-Back 
119.9 (9.7) 
Mean score (SD) 
 
List Learning 
30.3 (3.8) 
 
List Recall 
6.8 (2.2) 
 
Story Memory 
18.4 (3.3) 
 
Story Recall 
9.7 (2.1) 
 
Coding 
49.3 (9.2) 
 
Letter Fluency 
44.3 (11.2) 
 
Object-Location 
44.4 (20.0) 
 
Grooved Pegboard 
67.76 (12.7) 
 
Verbal n-Back 
123.0 (9.5) 
- 
 
 
P=0.24 
 
 
P=0.58 
 
 
P=0.15 
 
 
P=0.23 
 
 
P=0.01 * 
 
 
P=0.03 * 
 
 
P=0.55 
 
 
P<0.01 * 
 
 
P=0.23 
Higher scores indicate 
better performance. 
Miao et al., 
2016 [9] 
 
China 
 
 
Convenience 
sample 
 
 
 
23 patients with  
breast cancer 
who had been 
treated with 
chemotherapy at 
a local hospital 
I-III (100%) CT: 100% 3 (0.3),  Convenience sample 
 
 
26 age matched 
healthy controls 
selected amongst 
patients relatives and 
local universities; 
matched for age 
(matching method 
not reported). 
 
Stroop interference test; 
MoCA 
 
Mean score (SD) 
 
Stroop: 35.04 (8.96) 
 
MoCA: 26.00 (1.34) 
Mean score (SD) 
 
Stroop: 30.17 (6.49) 
 
MoCA: 26.58 (1.74) 
- 
P=0.04 * 
 
P>0.05 
Higher score in the Stroop 
interference test indicates 
worse performance.  
Myers et 
al., 2015 
[66] 
 
United 
States  
 
Convenience 
sample 
 
156 breast 
cancer patients 
recruited across 
24 states using 
newsletters and 
flyers 
I (26%) 
II (47%) 
III (14%) 
IV (5%) 
CT: 100% 
RT: 71.2% 
HT: 49.4% 
 
1-2 Convenience sample 
 
46 healthy controls  
recruited using flyers 
FACT-COG,  
Perceived cognitive 
impairments (PCI) 
Perceived cognitive 
abilities (PCA) 
Mean score (SD): 
PCI: 48.6 (17.2) 
PCA: 17.6 (7.2) 
Mean score (SD): 
PCI: 61.1 (9.4) 
PCA: 19.1 (8.8) 
- 
P<0.05 * 
P>0.05 
Higher scores indicate 
higher cognitive function.  
2-5 PCI: 41.7 (18.3) 
PCA: 15.9 (6.8) 
PCI: 61.1 (9.4) 
PCA: 19.1 (8.8) 
- 
P<0.05 * 
P<0.05 * 
>5 PCI: 50.4 (18.2) 
PCA: 19.0 (6.9) 
PCI: 61.1 (9.4) 
PCA: 19.1 (8.8) - 
P<0.05 * 
P<0.05 * 
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Nguyen et 
al., 2013 
[39] 
 
United 
States 
Convenience 
sample 
 
57 women 
survivors of 
breast cancer, 
aged over 65 
years, without 
recurrence, 
recruited from 
the cancer 
registry 
I-IIIA 
(100%) 
RT: 53% 
CT: 100% 
>10 Convenience sample 
 
30 healthy female 
adults, selected in 
the community for a 
previous study 
 
Intelligence and mental 
status 
WASI; Wide Range 
Achievement Test-III 
reading subtest;  
Folstein mini mental state 
examination. 
 
Attention and working 
memory 
Digit Span, Letter-
Number Sequencing, and 
Arithmetic subtests 
(WAIS-III) 
 
Psychomotor speed 
TMT-A. 
 
Language 
COWA; Boston Naming 
Test 
 
Visuospatial 
RCFT-Copy Condition; 
Benton Facial; 
Recognition Test. 
 
Memory 
AVLT; RCFT-Delay 
Condition. 
Benton Visual Retention 
Test-Revised. 
Executive functioning 
Wisconsin Card Sorting 
Test. TMT-B. 
WASI 
Vocabulary: 
64.5 (7.8) 
Block design: 
33.9 (12.3) 
Similarities: 
36.8 (4.8) 
Matrix design: 
20.6 (6.5) 
 
Wide Range 
Achievement Test-III 
Reading: 48.1 (4.7) 
 
Digit span: 15.5 (3.4) 
 
Letter–Number Seq 
9.1 (2.1) 
 
Arithmetic total 
12.4 (2.8) 
 
TMT 
A time: 37.8 (8.9) 
B-time: 97.0 (35.5) 
 
COWA: 39.4 (15.1) 
 
Boston Naming Test  
57.0 (2.5) 
 
Rey–Osterrieth 
Complex Figure 
Copy: 33.3 (2.0) 
Delay: 15.9 (5.1) 
 
Benton Faces total 
44.4 (3.4) 
 
Benton Visual 
Retention Test total 
5.3 (2.2) 
 
Rey Auditory-Verbal 
Learning Test  
Total: 48.6 (8.3) 
Delay: 10.2 (2.6) 
 
IED: 3.2 (4.2) 
 
Wisconsin: 
Perseverative: 12.5 
(6.9) 
Errors: 11.0 (5.7) 
Categories: 2.9 (1.6) 
 
WASI 
Vocabulary: 
63.7 (6.9) 
Block design: 
34.8 (11.9) 
Similarities: 
36.6 (3.0) 
Matrix design: 
21.8 (6.8) 
 
Wide Range 
Achievement Test-III 
Reading: 50.2 (5.0) 
 
Digit span: 16.9 (4.4) 
 
Letter–Number Seq 
11.0 (2.0) 
 
Arithmetic total 
13.7 (3.2) 
 
TMT 
A time: 29.3 (8.7) 
B-time: 72.4 (26.6) 
 
COWA: 38.8 (11.1) 
 
Boston Naming Test  
56.1 (3.0) 
 
Rey–Osterrieth 
Complex Figure 
Copy: 32.0 (2.9) 
Delay: 15.6 (5.6) 
 
Benton Faces total 
45.5 (3.8) 
 
Benton Visual 
Retention Test total 
4.4 (2.8) 
 
Rey Auditory-Verbal 
Learning Test  
Total: 49.4 (8.7); 
Delay: 10.6 (2.3). 
 
IED: 1.3 (1.0) 
 
Wisconsin: 
Perseverative: 16.6 
(12.2) 
Errors: 14.9 (11.0) 
Categories: 5.0 (1.9) 
- 
P<0.05 *:  
Letter–Number 
Seq; Trail making 
test A and B; 
Boston naming 
test; Rey–
Osterrieth 
Complex Figure; 
Benton Visual 
Retention; Rey 
Auditory-Verbal 
Learning; IED; 
Wisconsin Card 
Sorting categories. 
 
P>0.05 
All other tests.  
 
- 
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Root et al., 
2015 [17] 
 
United 
States 
Convenience 
sample 
 
113 women aged 
<70 years who 
had breast cancer, 
post-menopausal 
at diagnosis, with 
no recurrence, no 
neurological or 
psychiatric 
diagnoses. 
 
I (58%) 
II (0%) 
III (33%) 
IV (8%) 
Srg, C: 75% 
Srg, M: 32% 
CT: 52% 
RT: 78% 
HT: 52% 
4.2 (1.2) Convenience sample 
 
37 health women with 
no history of cancer or 
cancer treatment, post-
menopausal, with no 
neurological or 
psychiatric diagnoses; 
matched for age and 
education (method of 
matching not 
reported). 
FACT-COG 
Mean score (SD) 
 
Memory: 20.4 (5.9) 
Verbal 18.5 (4.8) 
Concentration 12.4 
(3.2) 
Mental acuity 12.0 
(3.4) 
QoL impact 13.7 
(3.0) 
PCI: 56.5 (12.7) 
PCA: 19.5 (6.3) 
Mean score (SD): 
 
Memory: 23.5 (3.2) 
Verbal: 19.2 (3.6) 
Concentration: 13.6 
(2.4) 
Mental acuity: 13.4 
(2.0) 
QoL impact: 14.3 (2.4) 
 
PCI: 59.4 (8.3) 
PCA: 22.7 (4.5) 
- 
P=0.003 * 
P=0.42 
P=0.04 * 
P=0.02 * 
P=0.27 
P=0.20 
P=0.005 * 
- 
Silverman 
et al., 2007 
[67] 
 
United 
States 
 
Convenience 
sample 
 
24 women who 
had breast 
cancer and were 
right handed. 
ND CT+HT: 52% 
CT: 24% 
 
ND (ND), 
5-10 
 
Convenience sample 
 
10 healthy controls 
who had undergone 
PET studies before, 
free of cognitive 
impairments. 
 
RCFT- recall test 
Mean (SD): 
 
20.6 (4.8) 
Mean (SD): 
 
23.8 (6.3) 
- P>0.05 
Lower scores represent 
worse functioning. 
Von Ah et 
al., 2009 
[44] 
 
United 
States 
Convenience 
sample 
 
52 women aged 
≥40 years, who 
had breast 
cancer, recruited 
from cancer 
support groups, 
advertisements 
in the community 
centres, or by 
referral of 
enrolled 
participants. 
I-II (50%) 
III (ND) 
Srg, C: 66% 
Srg, M: 33% 
CT: 55.8% 
RT: 80.8% 
HT: 79% 
4.6 (2.8), 
1.2-15.8 
Convenience sample 
 
52 women aged ≥40 
years, with no history 
of cancer, no history of 
psychiatric illnesses, 
recruited from 
advertisements in 
churches and 
community centres, or 
by referral of enrolled 
participants; individual 
matching for age (±5 
years) and education 
(±3 years). 
 
Memory: 
AVLT 
Sum recall: 48.5 (7.2) 
Delayed recall: 9.6 
(2.8) 
Sum recall: 52.4 (8.1) 
Delayed recall: 10.9 
(2.8) 
-- 
P=0.01 * - 
Attention: 
Digit span (WAIS-III) 
17.8 (4.0) 17.7 (4.1) P=0.89 - 
Attention: 
Symbol digit modalities 
test 
53.6 (8.2) 54.1 (10.4) P=0.79 - 
Executive function: 
COWA 
38.2 (10.9) 42.2 (12.4) P=0.08 - 
Subjective memory 
function: Squire SRS  
92.9 (17.9) 102.9 (22.6) P=0.01 * - 
ACTT = Auditory Consonant Trigrams Test [68]; AFM = Additive factors method task [69]; AVLT = Rey Auditory Verbal Learning Test [70]; BC = breast cancer; BLT = Brown Learning Test [71]; CCAP - 
California Computerized Assessment Package [72]; CNS-VS = CNS vital signs battery [73, 74]; COWA = Controlled Oral Word Association [75]; CPT = Continuous Performance test [76]; CT = 
chemotherapy; CVLT = California Verbal Learning Test [77]; D-KEFS = Delis-Kaplan Executive Function System [78]; DOT = Design organization test [79]; EORTC-QLQ-CF = the European 
Organization for Research and Treatment of Cancer [80]; FACT-COG = Functional Assessment of Cancer Therapy for Cognition [81]; HSCS = High Sensitivity Cognitive Screen [82]; HT = hormone 
therapy; HVLT-R = Hopkins verbal learning test revised [83]; IT = immunotherapy; LDST = Letter Digit Substitution Test [84]; MoCA = Montreal Cognitive Assessment Test [85]; Multifactorial Memory 
Questionnaire Ability Scale [86]; ND = not defined; OR = odds ratio; PASAT = Paced Auditory Serial Addition Test [87]; PCA = Perceived cognitive abilities; PCI = Perceived cognitive impairments; PPB 
= Purdue Pegboard test [88]; PR = prevalence ratio; RCFT = Rey-Osterrieth Complex Figure Test, Copy Condition [89-91]; RT = radiotherapy; RWT = Regensburg word fluency test [92]; SD = standard 
deviation; Srg, C = Breast conserving surgery; Srg, ND = Surgery, not further specified; Srg, M = Mastectomy; Srg, R = Breast reconstructive surgery; SRS = Squire self-report scale [93]; TAP = Test of 
Attentional Performance [94]; TMT-A = Trail Making Test-A [95]; TMT-B = Trail Making Test-B [95]; WAIS-III = Wechsler Adult Intelligence Scale-III [96]; WASI = Wechsler Abbreviated Scale of 
Intelligence [97]; 15-WLT = 15-Word Learning Test [98]; WMS-R = Wechsler Memory Scale-Revised [99]; WRAT = Wide Range Achievement Test [100]; WTF = Word Fluency Test [101]; yrs = years; 
95%CI = 95% confidence interval.  
* There was some statistical evidence (P<0.05) for a different prevalence, risk or severity of anxiety between breast cancer survivors and women who did not have cancer. 
† Prevalence ratio calculated by the authors of the present study. 
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Supplementary Table 6. Sexual dysfunction: main characteristics and results of the studies that provided data on the frequency and/or severity of 
sexual dysfunction in breast cancer survivors (>1 year) and women who did not have cancer. 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison 
group 
Outcome 
assessment 
Prevalence / cumulative incidence of the 
outcome  
Relative risk 
estimate 
(RR, OR, SIR, PR) 
P-value or 95% 
confidence 
interval 
Notes 
Type of 
population and 
main 
characteristics 
 
Stage at 
diagnosis 
(%) 
Breast cancer 
treatments: % 
Time since 
diagnosis/ 
treatment in 
years: mean/ 
median (SD), 
range 
Type of 
population and 
main 
characteristics 
 
 
Breast cancer survivors Comparison 
group 
   
            
Cross-sectional studies 
            
Boehmer et 
al., 2014 
[102] 
 
United 
States 
Convenience 
sample 
 
85 lesbian or 
bisexual breast 
cancer survivors, 
with no metastatic 
breast cancer or 
secondary cancers, 
recruited via 
advertisements, 
flyers, and other 
promotional 
materials distributed 
online and in print 
media (<5% had 
cancer recurrence). 
0 (16.5%) 
I (28.2%) 
II (37.7%) 
III (8.2%) 
Unknown 
(9.4%) 
Srg  C: 41.2% 
Srg, M: 40.0% 
CT: 61.2% 
RT: 58.8% 
HT: 45.9% 
4.5 (2.3), 1-10 Convenience 
sample 
 
85 lesbian or 
bisexual women 
with no history of 
cancer, not using 
hormone 
replacement 
therapy, recruited 
via flyers, 
advertisements, 
etc.; individual 
matching for age 
(± 3 years) and 
partner status 
(partnered vs. 
unpartnered). 
Scale: FSFI Prevalence: 52.5% Prevalence: 4.3% 
All women: 
OR=1.44  
 
Sexually active:  
OR=1.79 
All women: 
95%CI: 0.72-2.90 
 
Sexually active:  
95%CI 0.78-4.07 
 
40% of the cases and 
31% of the controls 
were sexually inactive.  
Scale: FSFI 
Overall score Mean score (SD): 
24.0 (7.2) 
Mean score (SD): 
26.0 (5.3) 
- P=0.08 
Subscales:   Desire 4.3 (2.0) 5.7 (2.2) - P<0.01 * 
Arousal 13.2 (5.3) 14.9 (4.5) - P=0.07 
Lubrication 13.5 (6.0) 11.6 (1.1) - P=0.03 * 
Orgasm 11.1 (4.1) 12.6 (3.2) - P=0.04 * 
Satisfaction 11.0 (3.2) 11.8 (3.2) - P=0.22 
Pain 12.8 (3.2) 14.1 (1.8) - P=0.03 * 
Safarinejad 
et al., 2013 
[103] 
 
Iran 
 
(continues) 
 
 
Convenience 
sample 
 
186 women cancer 
survivors aged 25-
45, with BMI<30 
kg/m2, in a 
relationship and 
attempted 
intercourse weekly, 
with no breast 
cancer recurrence, 
no other cancer, no 
psychopathology, no 
relationship 
disturbances, no 
diabetes or cardiac, 
renal, neurological,  
or liver disease, 
among others; 
identified from the 
cancer registry. 
I (62.4%) 
II (37.6%) 
Srg, C: 100% 
Srg, M: 0% 
CT: 67.7% 
RT: 46.2% 
HT: 79.6% 
 
2.4 (ND), >1 Convenience 
sample 
 
204 women without 
cancer aged 25-45 
in a relationship, 
who attempted 
intercourse weekly, 
in same 
geographical area of 
cases, with 
BMI<30kg/m2, no 
psychopathology, no 
relationship 
disturbances, no 
diabetes or cardiac, 
renal, neurological, 
or liver disease, 
among others, 
recruited from a 
private clinic; 
matched for age 
(matching method 
not reported). 
 
Scale: FSFI  
Prevalence of 
dysfunction: 52.5% 
 
By treatment: 
RT+CT: 44.6% 
CT+HT: 46.2% 
CT+RT+HT: 66.7% 
Prevalence: of 
dysfunction: 
 
28.7% 
 
PR=1.81 * † 
 
By treatment: 
PR= 1.55 * 
PR= 1.61 * 
OR= 8.2 * 
 
95%CI: 1.40-2.34 
 
By treatment: 
95%CI: 1.13-1.98 
95%CI: 1.32-1.90 
95%CI: 6.5-14.2  
Odds ration adjusted 
for age, body mass 
index, occupational 
status, educational 
level, smoking history, 
serum hormonal levels, 
tumour stage and 
grading. The 
categorization of the 
variables included in 
the model were not 
reported. 
FSFI Subscales:   
Desire 
All treatments: 41.9% 
 
By treatment: 
RT+CT: 33% 
CT+HT: 42% 
CT+RT+HT: 53% 
28.0% 
 
PR=1.50 * † 
 
By treatment: 
OR= 1.8 
OR= 3.6 * 
OR= 4.7 * 
95%CI: 1.13-1.98 
 
By treatment: 
95%CI: 0.9-2.2 
95%CI: 2.6-6.8 
95%CI: 2.8-8.7 
Arousal All treatments: 33.9% 
 
By treatment: 
RT+CT: 31% 
CT+HT: 30% 
CT+RT+HT: 50% 
25.0% 
 
PR=1.36 † 
 
By treatment: 
OR= 1.6 
OR= 1.5 
OR= 4.2 * 
95%CI: 0.99-1.85 
 
By treatment: 
95%CI: 0.8-2.8 
95%CI: 0.8-2.8 
95%CI: 2.6-8.2 
Orgasm All treatments: 41.9%  
 
By treatment: 
RT+CT: 33% 
CT+HT: 41% 
CT+RT+HT: 56% 
29.0% 
PR=1.44 * † 
 
By treatment: 
OR= 2.1 
OR= 3.2 * 
OR= 5.2 * 
95%CI: 1.10-1.90 
 
By treatment: 
95%CI: 0.8-3.4 
95%CI: 2.4-7.1 
95%CI: 3.7-10.2 
292
37 
 
Safarinejad 
et al., 2013 
[103] 
 
Iran 
 
(continued) 
 
 
Convenience 
sample 
 
186 women cancer 
survivors aged 25-
45, with BMI<30 
kg/m2, in a 
relationship and 
attempted 
intercourse weekly, 
with no breast 
cancer recurrence, 
no other cancer, 
no 
psychopathology, 
no relationship 
disturbances, no 
diabetes or 
cardiac, renal, 
neurological,  or 
liver disease, 
among others; 
identified from the 
cancer registry. 
 
I (62.4%) 
II (37.6%) 
Srg, C: 100% 
Srg, M: 0% 
CT: 67.7% 
RT: 46.2% 
HT: 79.6% 
 
2.4 (ND), >1 Convenience 
sample 
 
204 women 
without cancer 
aged 25-45 in a 
relationship, who 
attempted 
intercourse 
weekly, in same 
geographical area 
of cases, with 
BMI<30kg/m2,  no 
psychopathology, 
no relationship 
disturbances, no 
diabetes or 
cardiac, renal, 
neurological,  or 
liver disease, 
among others, 
recruited from a 
private clinic; 
matched for age 
(matching method 
not reported). 
Pain All treatments: 39.2% 
By treatment: 
RT+CT: 31% 
CT+HT: 36% 
CT+RT+HT: 59% 
 
Prevalence: 
 
30.0% 
PR=1.31 † 
By treatment: 
OR= 1.2 
OR= 2.2 * 
OR= 5.6 * 
95%CI: 0.99-1.72 
By treatment: 
95%CI: 0.96-1.8 
95%CI: 1.5-3.8 
95%CI: 3.2-11.4 
Odds ratio adjusted for 
age, body mass index, 
occupational status, 
educational level, 
smoking history, serum 
hormonal levels, tumour 
stage and grading. The 
categorization of the 
variables included in the 
model were not reported. 
Lubrication All treatments: 58.1% 
By treatment: 
RT+CT: 56% 
CT+HT: 55% 
CT+RT+HT: 61% 
 
31.0% 
PR=1.87 * † 
By treatment: 
OR= 4.2 * 
OR= 4.1 * 
OR= 6.4 * 
95%CI: 1.48-2.38 
By treatment: 
95%CI: 3.4-8.7 
95%CI: 3.2-8.4 
95%CI: 4.6-12.6 
Satisfaction All treatments: 53.8% 
By treatment: 
RT+CT: 50% 
CT+HT: 53% 
CT+RT+HT: 59% 
 
29.0% 
PR=1.86 * † 
By treatment: 
OR= 3.4 * 
OR= 3.8 * 
OR= 5.7 * 
95%CI: 1.44-2.39 
By treatment: 
95%CI: 1.8-5.8 
95%CI: 2.2-6.1 
95%CI: 3.4-11.4 
Desire 
Mean score (95%CI): 
3.7 (3.1-4.3) 
By treatment: 
RT+CT: 4.4 (3.8-4.7) 
CT+HT: 3.6 (2.9-4.4) 
CT+RT+HT: 3.1 (2.6-3.6) 
 
Mean score 
(95%CI): 
 
4.8 (3.6-5.6) - 
P<0.05 * 
 
By treatment: 
P>0.05 
P<0.05 * 
P<0.05 * 
Women who had 
RT+CT+HT reported 
more sexual 
dysfunction problems 
than women who had 
RT+CT for all domains, 
and more impairments 
than women who had 
CT+HT for arousal, 
lubrication, satisfaction 
and pain.  
Arousal 
4.0 (3.3-4.3) 
By treatment: 
RT+CT: 4.4 (3.6-4.6) 
CT+HT: 4.3 3.6-4.6() 
CT+RT+HT: 3.3 (2.7-3.7) 
 
4.9 (3.5-5.4) - 
P<0.05 * 
By treatment: 
P>0.05 
P>0.05 
P<0.05 * 
Lubrication 
2.8 (2.4-3.3) 
By treatment: 
RT+CT: 3.1 (2.6-3.6) 
CT+HT: 3.1 (2.6-3.5) 
CT+RT+HT: 2.4 (1.9-2.8) 
 
5.1 (3.5-5.8) - 
P<0.05 * 
By treatment: 
P<0.05 * 
P<0.05 * 
P<0.05 * 
Orgasm 
3.7 (3.1-4.1) 
By treatment: 
RT+CT: 4.3 (3.6-4.7) 
CT+HT: 3.6 (3.1-3.9) 
CT+RT+HT: 3.2 (2.7-3.6) 
 
4.7 (3.8-5.8) - 
P<0.05 * 
By treatment: 
P>0.05 
P<0.05 * 
P<0.05 * 
Satisfaction 
3.3 (2.9-3.7) 
By treatment: 
RT+CT: 3.4 (3.0-3.9) 
CT+HT: 3.5 (3.1-4.0) 
CT+RT+HT: 2.9 (2.5-3.3) 
 
5.1 (3.7-5.7) - 
P<0.05 * 
By treatment: 
P<0.05 * 
P<0.05 * 
P<0.05 * 
Pain 
4.6 (3.8-4.7) 
By treatment: 
RT+CT: 4.9 (4.5-5.0) 
CT+HT: 4.4 (4.1-4.6) 
CT+RT+HT: 3.1 (2.7-3.5) 
5.1 (3.8-5.5) - P>0.05 
By treatment: 
P>0.05 
P<0.05 * 
P<0.05 * 
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Claus et al., 
2006 [41] 
 
United 
States 
Population-based  
 
All 795 women in 
Connecticut 
diagnosed with 
DCIS in 1994-
1998, with history 
of invasive breast 
cancer  
0 (100%) Srg, C: 35.5% 
Srg, M: 14.0% 
5.8 (1.0), ND Population based 
 
702 women 
selected by 
random-digit-
dialling methods, 
with no history of 
DCIS or invasive 
breast cancer; 
frequency matched 
by age (± 5 years) 
and geography. 
Scale: MOS-SFS, 
Lack of interest 
Prevalence: 27.9% 
By treatment: 
Srg, C: 25.6% 
Srg, C + RT: 31.0% 
Srg, M: 22.6% 
 
 
Prevalence: 22.3% 
PR= 1.25 * † 
By treatment: 
PR= 1.15 † 
PR= 1.39 * † 
PR= 1.01 † 
95%CI: 1.05-1.49 
By treatment: 
95%CI: 0.90-1.46 
95%CI: 1.14-1.70 
95%CI: 0.70-1.47 
 
Cut-off for case: 
“somewhat of a 
problem” or “very much 
of a problem”. 
Unable to relax 
Prevalence: 19.2% 
By treatment: 
Srg, C: 20.1% 
Srg, C + RT: 18.6% 
Srg, M: 18.7% 
 
 
Prevalence:12.8% 
PR=1.50 * † 
By treatment: 
PR= 1.57 * † 
PR= 1.45 * † 
PR= 1.46 † 
95%CI: 1.16-1.91 
By treatment: 
95%CI: 1.16-2.12 
95%CI: 1.10-1.93 
95%CI: 0.95-2.25 
Difficulty with 
arousal 
Prevalence: 23.0% 
By treatment: 
Srg, C: 25.6% 
Srg, C + RT: 22.3% 
Srg, M: 18.7% 
 
 
Prevalence:15.2% 
PR=1.51 * † 
By treatment: 
PR= 1.68 * † 
PR= 1.47 * † 
PR= 1.23 † 
95%CI: 1.22-1.88 
By treatment: 
95%CI: 1.29-2.19 
95%CI: 1.14-1.89 
95%CI: 0.80-1.87 
Difficulty with 
orgasm 
Prevalence: 20.4% 
By treatment: 
Srg, C: 21.3% 
Srg, C + RT: 20.8% 
Srg, M: 16.8% 
 
 
Prevalence:14.8% 
PR=1.38 * † 
By treatment: 
PR= 1.44 * † 
PR= 1.41 * † 
PR= 1.14 † 
95%CI: 1.10-1.73 
By treatment: 
95%CI: 1.08-1.92 
95%CI: 1.08-1.83 
95%CI: 0.72-1.78 
Broeckel et 
al., 2002 
[40] 
 
United 
States 
Convenience 
sample 
 
58 breast cancer 
survivors who had 
a spouse or 
partner, free of 
recurrence for >5 
years, with no 
known neurological 
disorder, and no 
history of other 
cancer. 
I (26%) 
II (62%) 
III (10%) 
Unknown 
(2%) 
Srg, C: 50% 
Srg, M: 47% 
CT: 100% 
RT: 71% 
HT: 48% 
 
7.7 (2.3), 5.2-
15.2 
Convenience 
sample 
 
61 women with no 
history of cancer 
who had a spouse 
or partner, 
recruited among 
the friends of the 
women who had 
breast cancer; 
individual matching 
for age (± 6 years). 
 
 
Scale: MOS-SFS 
Overall 
Mean score (SD): 
1.95 (1.05) 
Mean score (SD): 
1.50 (0.70) 
- P≤0.01 * 
 
 
Sexual dysfunction 
positively correlated 
with vaginal dryness in 
breast cancer 
survivors. 
Interest 2.06 (1.16) 1.67 (0.83) - P≤0.05 * 
Enjoyment 1.72 (0.94) 1.38 (0.74) - P≤0.01 * 
Arousal 1.87 (1.08) 1.40 (0.83) - P≤0.01 * 
Orgasm 1.78 (1.01) 1.44 (0.80) - P≤0.05 * 
Rubino et 
al., 2007 
[10]  
 
Italy  
Convenience 
sample  
 
33 consecutive 
patients who had 
had breast-
reconstruction after 
mastectomy, in 
2001-2002, in one 
hospital. 
 
 
ND Srg, M: 100% 
Srg, R: 100% 
 
 
ND (ND), >1 Convenience 
sample 
 
33 healthy women, 
randomly selected 
amongst the 
personnel of the 
local university. 
Psychiatric 
interview 
Prevalence: 18.5% Prevalence: 9.1% PR=2.03 † 95%CI: 0.19-21.26 - 
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Vazquez-
Ortiz et al., 
2010 [104] 
 
Spain 
Convenience 
sample 
 
30 women aged 
25-59 years who 
had mastectomy 
≥1 year ago, were 
free of disease, in 
a stable 
heterosexual 
relationship, able 
to read and write 
and with no 
psychological or 
psychiatric 
treatment in the 
last 10 years, 
recruited from 
hospitals. 
I (13.3%) 
II (60.0%) 
III-A 
(26.7%) 
Srg, M: 100% ND (ND), 
2-5 
Convenience 
sample 
 
30 women without 
breast cancer 
aged 25-59, 
assistants to talks 
and workshops 
about woman’s 
health, who did not 
have an 
incapacitating or 
severe disease. 
Scale: SAI-E 
 Arousal 
Mean score (SD): 
68.5 (23.9) 
Mean score (SD): 
72.6 (23.7) 
- P=0.690 
- 
Scale: SAI-E 
Satisfaction 
Mean score (SD): 
72.3 (23.3) 
Mean score (SD): 
76.9 (23.9) 
- P=0.524 
Scale: WSQ 
Sex frequency 
per month: 0 10.0% 3.3% PR=3.33 † 95%CI: 0.33-33.27 
- 
1-3 20.0% 13.3% PR=1.50 † 95%CI: 0.47-4.80 
4-6 33.3% 30.0% PR=1.11 † 95%CI: 0.53-2.34 
7-9 13.3% 20.0% PR=0.67 † 95%CI: 0.21-2.12 
>9 23.3% 33.3% PR=0.70 † 95%CI: 0.31-1.59 
Orgasm frequency 
during sex 
Never (0%) 7.1% 3.3% PR=2.15 † 95%CI: 0.21-22.11 
- 
Sometimes (1-29%) 
 14.3% 10.0% PR=1.43 † 95%CI: 0.36-5.72 
Often (30-58%) 
 17.9% 23.3% PR=0.77 † 95%CI: 0.28-2.10 
Most of the time 
(60-89%) 21.4% 16.7% PR=1.28 † 95%CI: 0.45-3.67 
Almost always 
(90-100%) 39.3% 46.7% PR=0.84 † 95%CI: 0.47-1.51 
BC = breast cancer; CT = chemotherapy; FSFI = Female Sexual Functioning Index [105]; 
HT = hormone therapy; MOS-SFS = MOS Sexual Functioning Scale [106]; ND = not defined; PR = prevalence ratio; RT = radiotherapy; SAI-E = Sexual Arousal and 
Satisfaction Scale - Expanded [107]; SD = standard deviation; Srg, C = Breast conserving surgery; Srg, M = Mastectomy; Srg, R = Breast reconstructive surgery; WSQ = 
Women’s Sexuality Questionnaire [108]. 
* There was some statistical evidence (P<0.05) for a different prevalence, risk or severity of anxiety between breast cancer survivors and women who did not have cancer. 
† Prevalence ratio calculated by the authors of the present study. 
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Supplementary Table 7. Other outcomes: characteristics and results of the studies that provided data on the frequency and/or severity of bipolar 
disorders, obsessive-compulsive problems, post-traumatic stress, sleep-wake disturbances, somatization and suicide in breast cancer survivors (>1 
year) and women who did not have cancer. 
First 
author, 
year of 
publication 
 
Country 
Breast cancer survivors Comparison group Outcome 
assessment 
Prevalence / cumulative incidence 
of the outcome  
Relative risk 
estimate 
(RR, OR, SIR, PR) 
P-value or 95% 
confidence 
interval 
Notes 
Type of population 
and 
main 
characteristics 
 
Stage at 
diagnosis 
(%) 
Breast cancer 
treatments (%) 
Time since 
diagnosis/ 
treatment in 
years: mean/ 
median (SD), 
range 
Type of population 
and 
main 
characteristics 
 
Breast cancer 
survivors 
Comparison 
group 
 
Bipolar disorder 
           
 
   
Hung et al., 
2013 [2] 
 
Taiwan 
Population-based 
 
26,629 women with 
no prior mood 
disorder and cancer, 
with primary breast 
cancer registered in 
the National Health 
Insurance Database 
in 2000-2005. 
All ND 2.7 (ND), 
ND-7 
 
(median 
follow up 
years for 
breast 
cancer 
survivors: 
2.7; for 
matched 
cohort: 3.21) 
Population-based 
 
26,629 women 
randomly selected 
from 1 million women 
with no history of 
breast cancer in the 
same database; 
individual matching 
for age and Charlson 
comorbidity score 
(categories of 
matching not 
reported). 
EHR, recorded 
in the Registry 
for Catastrophic 
Illness with an 
ICD-9-CM code 
for anxiety 
(ICD-9-CM 
codes: 296.0X-
296.1X, 
296.4X-296.8X) 
Cumulative 
incidence: 
0.3% 
Cumulative 
incidence: 
0.1% 
 
 
RR=2.06 * 
 
 
95%CI: 1.37-3.15 
Approximate cumulative 
incidence values estimated 
from the graphics provided in 
the original study. 
 
P value for the log-rank test 
comparing the Kaplan-Meier 
curves: P<0.001 
2 0.3%   0.1%   RR=3.0 * † 95%CI: 2.56-3.39 
4 0.4%   0.2%   RR=2.0 * † 95%CI: 1.82-2.19 
6 0.6%   0.3%   RR=2.0 * † 95%CI: 1.86-2.16 
 
Obsessive-compulsive problems 
              
Amir et al., 
2002 [13] 
 
Israel 
 
Convenience sample 
 
39 women free of 
cancer symptoms for 
≥3 years and not 
under active 
treatment, identified 
in 2 hospitals. 
I (46%) 
II (46%) 
III (8%) 
Srg, C: 20% 
Srg, M: 80% 
CT: 66% 
RT: 41% 
HT: 46% 
6.5 (ND), ≥5 Convenience sample 
 
39 women without any 
life-threatening 
disease, recruited by 
unknown methods; 
matched for age and 
education; matched for 
age and education 
(method of matching 
not reported). 
Scale: SCL-90 
SCL-90 mean 
score (SD): 
 
0.92 (0.70) 
 
SCL-90 mean 
score (SD): 
 
0.68 (0.42) 
 
- P<0.001 * 
Higher SCL-90 scores indicate 
more obsessive-compulsive 
symptoms. 
 
Women who had breast 
cancer and PTSD symptoms 
had more obsessive-
compulsive problems than 
those who did not have PTSD 
symptoms (P<0.01). 
 
Post-traumatic stress 
              
Gurevich et 
al., 2004 
[109] 
 
Canada 
Convenience sample 
 
66 women with a good 
working knowledge of 
English ≥1 year post 
breast cancer 
treatments with 
negative 
mammography before. 
Local (61%) 
Regional 
(30.5%) 
Distant (2%) 
Unknown 
(11%) 
Srg: 96.6% 
CT: 48% 
RT: 71% 
HT: 48% 
6.6 (4.5), ≥1 Convenience sample 
 
69 ‘healthy’ women 
undergoing 
surveillance 
mammography in the 
same hospital. 
Scale: SASRQ 
 
Dissociative 
Re-experiencing 
Avoidance 
Arousal 
Impairment 
Total acute 
stress 
SASRQ mean 
scores (SD): 
1.07 (1.05) 
1.23 (1.25) 
1.34 (1.21) 
1.96 (1.40) 
1.29 (1.30) 
1.37 (1.05) 
SASRQ mean 
scores (SD): 
0.45 (0.80) 
0.58 (0.95) 
0.83 (1.17) 
1.00 (1.21) 
0.66 (1.10) 
0.69 (0.91) 
- 
P<0.0001 * 
P<0.001 * 
P<0.02 * 
P<0.0001 * 
P<0.003 * 
P<0.0001 * 
- 
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Voigt et al., 
2016 [110] 
 
Germany 
Convenience sample 
 
150 women aged 18-
65 years, newly 
diagnosed with 
breast cancer at 
recruitment, with no 
history of psychotic 
disorders  
0 (7%) 
I (42%) 
II (41.4%) 
IIIc (%9.6) 
Srg, M: 26% 
Srg, C: 74% 
CT: 58% 
 
~ 1 Convenience sample  
 
56 women aged 18-
65 years, who never 
had cancer, who 
attended the same 
institution as cases 
for breast imagining 
and did not require 
further tests 
SCID, number of 
PTSD symptoms 
Prevalence of 
PTSD related to 
BC: 2.0% 
 
Prevalence of 
PTSD related to 
stressors other 
than BC: 0.7% 
Prevalence of 
PTSD related to 
stressors other 
than BC: 0% 
 
 
 
PR= 1.51 † 95%CI: 0.17-13.20 
Mean number of PTSD 
symptoms (SD) in breast 
cancer survivors: 1.7 (2.3); 
significantly different from the 
mean number of symptoms in 
controls (P<0.001).  
Yang et al., 
2017 [4] 
 
Sweden 
Population based 
 
All 40,849 women 
diagnosed with an 
invasive breast 
cancer at the age of 
20-80 years between 
2001-2009 
I-IV ND 4.5 (4.5), 0-10 
 
(median (IQR) 
duration of 
follow up: 4.4 
(4.5)) 
Population based 
 
452,507 women 
randomly selected 
from the respondents 
to the 1990 census 
EHR, ICD-10 
diagnostic codes 
for stress-related 
disorders (F430-
2, F438-9) at in 
patient or 
outpatient 
hospital visits 
Cumulative 
incidence: 
0.9% 
Cumulative 
incidence: 
0.5% 
SIR= 1.77 * 
 
95%CI: 1.60-1.95 
 
 
Standardised incidence ratios 
were standardised by 
calendar period (1-year 
categories), age (5-year 
categories), and region of 
residence (North, Stockholm- 
Gotland, South, Southeast, 
Uppsala-Orebro, West). 
 
By age group:  
20-44: SIR= 1.68 * 
45-54: SIR= 1.78 * 
55-64: SIR= 1.89 * 
65-80: SIR= 1.64 * 
 
By age group:  
95%CI: 1.36-2.08 
95%CI: 1.52-2.09 
95%CI: 1.56-2.28 
95%CI: 1.23-2.19 
 
0-0.5 - - SIR= 4.22 * 95%CI: 3.44-5.19 
0.5-1 - - SIR= 2.73 * 95%CI: 2.11-3.52 
1-2 - - SIR= 1.72 * 95%CI: 1.36-2.17 
2-5 - - SIR= 1.36 * 95%CI: 1.14-1.63 
5-10 - - SIR= 0.98 95%CI: 0.73-1.32 
Population based 
 
All 40,849 women 
diagnosed with an 
invasive breast 
cancer at the age of 
20-80 years between 
2001-2009 
0 ND 4.5 (4.5), 0-10 
(median (IQR) 
duration of 
follow up: 4.4 
(4.5)) 
Population based 
 
452,507 women 
randomly selected 
from the respondents 
to the 1990 census 
EHR, ICD-10 
diagnostic codes 
for stress-related 
disorders (F430-
2, F438-9) at in 
patient or 
outpatient 
hospital visits 
Cumulative 
incidence: 
0.6% 
Cumulative 
incidence: 
0.5% 
SIR= 1.02 95%CI: 0.70-1.50 
By age group:  
20-44: SIR= 0.38 
45-54: SIR= 1.06 
55-64: SIR= 1.46 
65-80: SIR= 1.15 
By age group:  
95%CI: 0.09-1.51 
95%CI: 0.60-1.87 
95%CI: 0.76-2.81 
95%CI: 0.37-3.56 
0-0.5 - - SIR= 2.76 * 95%CI: 1.31-5.79 
0.5-1 - - SIR= 0.78 95%CI: 0.20-3.14 
1-2 - - SIR= 1.04 95%CI: 0.43-2.51 
2-5 - - SIR= 0.88 95%CI: 0.46-1.69 
5-10 - - SIR= 0.57 95%CI: 0.18-1.76 
 
Sleep-wake disturbances 
              
Ancoli-
Israel et al., 
2014 [33] 
 
United 
States 
 
Convenience sample 
 
44 women who had 
been newly 
diagnosed with 
breast cancer 1 year 
before, and 
scheduled to receive 
≥4 cycles of CT, with 
no psychological 
impairments and not 
receiving RT at 
recruitment. 
 
 
 
I (27.9%) 
II (39.7%) 
III (30.9%) 
Unknown 
(1.5%) 
 
Srg, C: 45.6% 
Srg, M: 49.7% 
CT: 100% 
 
~ 1 
 
(follow up at 1 
year after CT) 
Convenience sample 
 
35 cancer-free 
friends of the women 
who had breast 
cancer, or 
‘volunteers’, with no 
psychological 
impairments at the 
time of recruitment 
individual matching 
for age (±5 years), 
ethnicity and 
education (categories 
of ethnicity and 
education not 
reported).  
Nocturnal total 
sleep time 
Mean time (SD), 
hours: 
7.01 (0.74) 
Mean time (SD), 
hours: 
7.07 (0.66) 
- P>0.05 
Sleep measure by wrist 
activity, using an actigraph 
during 72 consecutive hours. 
Daytime total 
nap time 
Mean time (SD), 
hours: 
0.49 (0.47) 
Mean time (SD), 
hours:  
0.36 (0.44) 
 P=0.63 
Scale: PSQI 
PSQI mean 
scores (SD): 
7.4 (ND) 
PSQI mean 
scores (SD): 
5.0 (ND) 
- P=0.02 * 
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El Rafihi-
Ferreira et 
al., 2011 
[111] 
 
Brazil 
 
Convenience sample 
 
50 women with a 
previous diagnosis of 
breast cancer without 
encephalopathies or 
severe psychiatric 
disorders. Patients 
were all disease free 
at enrolment.  
I-II (100%) Srg, ND: 40% 
CT: 66% 
RT: 54% 
HT: 77% 
 
3.8 (2.8), 1-10 Convenience sample 
 
50 women without a 
previous cancer 
diagnosis, 
encephalopathies or 
severe psychiatric 
disorders. 
Scale: PSQI Prevalence:40% Prevalence: 50% PR=0.8 † 95%CI: 0.52-1.24 Cut-off for case: score >5 
Cannot get to 
sleep in 30 min 
Prevalence: 42% Prevalence: 38% PR= 1.1 † 95%CI: 0.68-1.79 
Cut-off for case: reported 
problems three or more times 
a week. 
 
Worse sleep quality 
associated with poorer quality 
of life for the social domain, 
and domains of physical and 
psychological health (P<0.05).  
 
Women who had had breast 
cancer and had worse quality 
of sleep reported higher 
depressive symptomatology 
compared to those with good 
quality of sleep (SDS mean 
scores 20.8 (7.12) vs. 16.6 
(3.76), P<0.05).  
Wake up in the 
middle of the 
night or early 
morning 
 
40% 22% PR= 1.82 † 95%CI: 0.98-3.39 
Get up to use 
the bathroom 
 
52% 26% PR= 2.0 * † 95%CI: 1.17-3.43 
Cannot breathe 
comfortably 
 
8% 8% PR= 1.0 † - 
Cough or snore 
loudly 
 
16% 16% PR= 1.0 † - 
Feel too cold 
 
4% 6% PR= 0.67 † 95%CI: 0.12-3.82 
Feel too hot 
 
36% 14% PR= 2.57 * † 95%CI: 1.18-5.61 
Pain 
 
14% 20% PR= 0.70 † 95%CI: 0.29-1.69 
Sleep 
medication 
 
12% 16% PR= 0.75 † 95%CI: 0.28-2.00 
Daytime 
sleepiness 
 
2% 4% PR= 0.50 † 95%CI: 0.05-5.34 
<6h of sleep 18% 14% PR= 1.29 † 95%CI: 0.52-3.18 
Otte et al., 
2010 [43] 
 
United 
States 
 
 
Convenience sample 
 
246 breast cancer 
survivors free of 
cancer at 
recruitment, with no 
history of other 
cancers and able to 
speak, read and write 
English 
I (ND) 
II (ND) 
III (ND) 
Srg, C: 42% 
Srg, M: 59% 
CT: 89% 
RT: ND 
HT: 33% 
 
5.6 (2.0), 2-10 Convenience sample 
 
246 women in general 
good health with no 
history of breast 
cancer recruited by 
acquaintance referral, 
self-referral or from 
corporative group; 
individual matching for 
age (±5 years). 
Scale: PSQI  
Overall score 
PSQI mean 
scores (SD): 
7.31 (3.80) 
PSQI mean 
scores (SD): 
5.80 (3.45) 
- P<0.01 * Adjusted for race (minority vs. 
not minority) and menopausal 
status (pre or post menopausal). 
 
Determinants sleep-wake 
disorders in women who had 
breast cancer: race other than 
Caucasian, having hot flashes, 
poor physical functioning and 
depression. 
Sleep quality 1.20 (ND) 0.85 (ND) - P<0.01 * 
Sleep latency 1.39 (ND) 1.00 (ND) - P<0.01 * 
Sleep 
disturbance 
1.50 (ND) 1.31 (ND) - P<0.01 * 
Sleep 
medication 
0.65 (ND) 0.61 (ND) - P=0.70 
Sleep efficiency 0.59 (ND) 0.57 (ND) - P=0.77 
Sleep duration 0.98 (ND) 0.84 (ND) - P=0.03 * Adjusted for race. 
Daytime 
dysfunction 
0.96 (ND) 0.70 (ND) - P<0.01 * - 
Dahl et al., 
2011 [8] 
 
Norway 
 
Convenience sample 
 
337 tumor free breast 
cancer survivors 
treated with 
radiotherapy during 
1998 and 2002 in 
one hospital. 
II (ND) 
III (ND) 
Srg, C: 24% 
Srg, M: 76% 
CT: 82% 
RT: 100% 
HT: 81% 
 
3.9 (ND), 2.6-
6.9 
 
Convenience sample 
 
1,685 women 
randomly selected 
from a population-
based sample of 
women with no history 
of cancer whose 
questionnaires had 
complete data; 
matched individual 
matching for age (± 5 
years). 
Prevalence of 
regular use of 
hypnotics 
Prevalence: 
15% 
Prevalence: 
4% 
PR=3.75 * † 95%CI: 2.65-5.30 
 
Adjusted for level of 
education, on disability 
pension and menopausal 
status. 
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Von Ah et 
al., 2012 
[45] 
 
United 
States 
Convenience sample 
 
62 non-Hispanic 
African American 
women diagnosed 
with non-metastatic 
breast cancer and 
able to read and 
write English, 
recruited by medical 
record review and by 
self-referral. 
I-IIB 
(85.7%) 
IIIB (14.3%) 
Srg, C: 0% 
Srg, M: 60.3% 
CT & RT: 54.6% 
HT: ND 
 
5.0 (2.7), 2-10 Convenience 
sample 
 
78 African 
American women 
with no history of 
breast cancer, 
recruited through 
community 
advertisements 
and events. 
Scale: PSQI 
PSQI mean 
scores (SD): 
9.0 (4.2) 
PSQI mean 
scores (SD): 
6.1 (4.0) 
- P=<0.001 * 
Mean scores adjusted for 
age, income, years of 
education and body mass 
index. 
 
Somatization 
            
Cohen et 
al., 2011 [5] 
 
Israel 
Convenience sample 
 
56 married Israeli 
Arab breast cancer 
survivors, post 
treatment and free of 
disease recruited 
from one hospital. 
I-III (ND%) 
 
Srg, C: 48.2% 
Srg, M: 51.8% 
Srg, R: 12.5% 
CT: 85.7% 
RT: 85.7% 
HT: 58.9% 
4.8 (4.2), 1-17 Convenience sample 
 
66 married and 
‘healthy’ Arab women 
living in northern Israel, 
approached in 
community settings; 
individual matching for 
age and education 
(matching categories 
not reported). 
Scale: BSI-18 
BSI-18 mean 
score (SD): 
 
2.6 (1.2) 
BSI-18 mean 
score (SD): 
 
1.8 (0.8) 
- P<0.001 * 
 
More somatic symptoms in 
breast cancer survivors were 
associated with lower 
education, religiosity, 
depression, anxiety, emotional 
distress and lower body image 
(P<0.05). 
 
Amir et al., 
2002 [13] 
 
Israel 
 
Convenience sample 
 
39 women free of 
cancer symptoms for 
≥3 years and not 
under active 
treatment, identified 
through two 
hospitals. 
I (46%) 
II (46%) 
III (8%) 
Srg, C: 20% 
Srg, M: 80% 
CT: 66% 
RT: 41% 
HT: 46% 
6.5 (ND), ≥5 Convenience sample 
 
39 women who did not 
experience any life-
threatening disease, 
recruited by unknown 
methods; matched for 
age and education 
(method of matching 
not reported). 
SCL-90 
SCL-90 mean 
score:  
 
0.92 (0.86) 
SCL-90 mean 
score:  
 
0.51 (0.47) 
- P<0.001 * 
 
Higher SCL-90 scores indicate 
more somatic symptoms. 
 
Women who had breast cancer 
and reported PTSD symptoms 
had more somatic symptoms 
than women who did not have 
PTSD symptoms: 1.61 (1.06) 
vs. 0.77 (0.60), P<0.01. 
 
Suicide 
              
Schairer et 
al., 2006 
[112] 
 
Denmark, 
Finland, 
Norway, 
Sweden, 
United 
States 
 
(continues) 
Population based 
 
723,810 one-year 
breast cancer 
survivors diagnosed 
between 1953 and 
2001. 
All ND 8.7 (ND), 1-49 
 
(mean follow 
up duration: 
7.7 years, 
range <1 
month to 49 
years) 
Population-based 
 
General female 
population in each of 
the countries 
Official mortality 
databases in 
each country. 
ICD-7 codes: 
E963 and E970 - 
979; ICD-8 and 
ICD-9: E950 - 
E959; and ICD-
10: X60 - X84. 
Incidence rate:  
1.5 per 10,000 
person-years 
 
Cumulative 
incidence of 
suicide by time 
since diagnosis:  
5 yrs: 0.05% 
10 yrs: 0.10% 
20 yrs: 0.16% 
30 yrs: 0.20% 
Incidence rate:  
1.09 per 10,000 
person-years 
SIR= 1.37 * 95%CI: 1.28-1.47 
- 
By country 
US: SIR= 1.49 * 
Sweden: SIR= 1.27 * 
Denmark: SIR= 1.25* 
Finland: SIR= 1.53 * 
Norway: SIR= 1.40 * 
 
By country 
95%CI: 1.32-1.70 
95%CI: 1.12-1.45 
95%CI: 1.07-1.46 
95%CI: 1.28-1.83 
95%CI: 1.07-1.81 
- 
By calendar period 
1953-59: SIR=1.86* 
1960-69: SIR=1.72* 
1970-79: SIR=1.31* 
1980-89: SIR=1.29* 
1990-2001: 
SIR=1.36* 
By calendar period 
95%CI: 1.20-2.78 
95%CI: 1.42-2.07 
95%CI: 1.15-1.49 
95%CI: 1.15-1.46 
 
95%CI: 1.18-1.57 
- 
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Schairer et 
al., 2006 
[112] 
 
Denmark, 
Finland, 
Norway, 
Sweden, 
United 
States 
 
(continued) 
Population based 
 
723,810 one-year 
breast cancer 
survivors diagnosed 
between 1953 and 
2001. 
All ND 8.7 (ND), 1-49 Population-based 
 
General female 
population in each of 
the countries 
Official mortality 
databases in 
each country. 
ICD-7 codes: 
E963 and E970 - 
979; ICD-8 and 
ICD-9: E950 - 
E959; and ICD-
10: X60 - X84. 
Incidence rate:  
1.5 per 10,000 
person-years 
 
Cumulative 
incidence of 
suicide by time 
since diagnosis:  
5 yrs: 0.05% 
10 yrs: 0.10% 
20 yrs: 0.16% 
30 yrs: 0.20% 
Incidence rate:  
1.09 per 10,000 
person-years 
By race 
White: SIR=1.36 * 
Black: SIR=2.88 * 
Other: SIR=1.02 
By race 
95%CI: 1.27-1.46 
95%CI: 1.44-5.17 
95%CI: 0.44-2.01 
- 
     By age 
<40: SIR=1.34 * 
40-49: SIR=1.42 * 
50-59: SIR=1.50 * 
60-69: SIR=1.26 * 
≥70: SIR=1.24 * 
 
By age 
95%CI: 1.24-1.62 
95%CI: 1.32-1.71 
95%CI: 1.09-1.47 
95%CI: 1.04-1.48 
95%CI: 1.24-1.62 
 
- 
         By time since 
diagnosis, years 
1: SIR=1.51 * 
2: SIR=1.49 * 
3: SIR=1.57 * 
4: SIR=1.31 * 
5-9: SIR=1.30 * 
10-14: SIR=1.28 * 
15-19: SIR=1.25 
20-24: SIR=1.32 
≥25: SIR=1.35 
 
By time since 
diagnosis, years 
95%CI: 1.25-1.82 
95%CI: 1.22-1.82 
95%CI: 1.27-1.93 
95%CI: 1.02-1.66 
95%CI: 1.14-1.49 
95%CI: 1.07-1.54 
95%CI: 0.95-1.62 
95%CI: 0.89-1.90 
95%CI: 0.82-2.12 
 
 
        By stage at 
diagnosis 
Local: SIR=1.38 * 
Regional: SIR=1.55* 
Distant: SIR=2.11 * 
Unknown: SIR=1.05* 
 
By stage at 
diagnosis 
95%CI: 1.24-1.53 
95%CI: 1.34-1.79 
95%CI: 1.16-3.55 
95%CI: 0.73-1.50 
 
Includes only patients from the 
US, Demark, Finland and 
Norway. 
      
 
  By treatment 
Surgery only 
SIR= 1.40 * 
Radiotherapy, no 
chemotherapy 
SIR= 1.46 * 
Chemotherapy, no 
radiotherapy 
SIR= 1.12 
Radiotherapy and 
chemotherapy 
SIR= 1.50 * 
Other/none/unknown 
SIR= 1.84 * 
 
By treatment 
 
95%CI: 1.24-1.58 
 
 
95%CI: 1.27-1.67 
 
 
95%CI: 0.80-1.55 
 
 
95%CI: 1.09-2.02 
 
95%CI: 1.14-2.96 
 
Refers to initial course of 
treatment only; 
 
Includes only patients from the 
US, Demark, Finland and 
Norway. 
 
Breast conserving 
surgery 
SIR= 1.22 
Radical mastectomy 
SIR= 1.30 * 
 
 
 
 
 
95%CI: 0.89-1.64 
 
95%CI: 1.04-1.63 
US women only, 1983-2001. 
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Fang et al., 
2012 [113] 
Population based 
 
74,977 women 
diagnosed with 
primary breast 
cancer between 1991 
and 2006 
All ND >1 
 
(Mean follow 
up time of the 
all cancer 
cohorts was 
4.07 years 
(median 2.65, 
range 0 to 
15.99) 
Population based 
 
Women not 
diagnosed with 
cancer during follow 
up.  
 
ICD‐9 codes 
E950–E959 and 
ICD‐10 codes 
X60–X84 and 
Y870 
- - RR= 1.6 * 95%CI: 1.2-2.1 
RR adjusted for age at follow-up 
(≤49 years, 5-yr groups for 50 to 
74 yrs, ≥75 yrs), calendar period 
at follow-up (5-year groups), 
civil status (cohabitation or non-
cohabitation), socioeconomic 
status (blue-collar, white-collar, 
self-employed, or unclassified), 
and education (≥9 years, <9 
years, or missing). 
BC = breast cancer; BSI-18 = Brief Symptom Inventory-18 [22]; CT = chemotherapy; EHR = electronic health records; HT = hormone therapy; ICD-9-CM = The International 
Classification of Diseases, Ninth Revision, Clinical Modification; IRR = incidence rate ratio; ND = not defined; PR = prevalence ratio; PSQI = Pittsburgh Sleep Quality Index 
[114]; RR = relative risk; RT = radiotherapy; SASRQ = Stanford Acute Stress Reaction Questionnaire [115]; SCL-90 = Somatization subscale of Symptoms Checklist-90 [27]; 
SD = standard deviation; Srg, C = Breast conserving surgery; Srg, M = Mastectomy. 
* There was some statistical evidence (P<0.05) for a different prevalence, risk or severity of anxiety between breast cancer survivors and women who did not have cancer. 
† Prevalence ratio calculated by the authors of the present study. 
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Supplementary Appendix 1.  
 
MEDLINE search expression, applied via OVID, 28 June 2018 
1. CPRD.mp.   
2. Clinical Practice Research.mp.   
3. GPRD.mp.   
4. General Practice Research Database.mp.   
5. The Health Improvement Network.mp.   
6. QRESEARCH.mp.   
7. DIN-LINK.mp.   
8. VAMP.mp.   
9. Value Added Information Medical.mp.   
10. (THIN adj1 (database or dataset or data)).mp.   
11. (Read adj1 (term* or code# or codification)).mp.   
12. (diagnostic adj1 (term* or code#)).mp.   
13. Disease Analyzer.mp.   
14. Primary care clinical informatics unit.mp.   
15. PCCIU.mp.   
16. (optimum patient care adj4 data*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms]   
17. OPCRD.mp.   
18. health information network.mp.   
19. health improvement network.mp.   
20. Q research.mp.   
21. (ResearchOne or (Research One adj2 data*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms]   
22. Doctors Independent Network.mp.   
23. SAIL.mp.   
24. (SAIL adj4 data*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms]   
25. mediplus.mp.   
26. ((general practice or primary care or primary health care) adj4 data*).mp.   
27. longitudinal patient database.mp.   
28. ((EHR or eletronic health record*) adj4 data*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms]   
29. health care database*.mp.   
30. exp "mental disorders"/   
31. exp "behavior and behavior mechanisms"/   
32. exp "behavioral disciplines and activities"/   
33. exp Psychological Phenomena/   
34. exp fatigue/   
35. exp pain/   
36. exp "Sleep Wake Disorders"/   
37. exp central nervous system depressants/   
38. exp muscle relaxants, central/   
39. exp psychotropic drugs/   
40. exp sleep aids, pharmaceutical/  
41. (anxiety or anxious* or panic or anxiolytic* or (stress not oxidat*) or depressi* or dysthymia or antidepress* or 
sexual or erectile or suicid* or self-harm or hopeless* or sleep or insomnia or hypnotic* or cognit* or chemo-fog or 
chemo-brain or pain or fatigue or (mental adj1 (disorder or disorders)) or antipsychotic).mp.   
42. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41   
43. exp United Kingdom/   
44. (UK or Britain or British or England or English or Scotland or Scottish or Wales or Welsh Ireland).mp.   
45. 43 or 44   
46. or/1-29   
47. 42 and 45 and 46 
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EMBASE search expression, applied via OVID, 28 June 2018 
1. CPRD.mp.   
2. Clinical Practice Research.mp.   
3. GPRD.mp.   
4. General Practice Research Database.mp.   
5. The Health Improvement Network.mp.   
6. QRESEARCH.mp.   
7. DIN-LINK.mp.   
8. VAMP.mp.   
9. Value Added Information Medical.mp.   
10. (THIN adj1 (database or dataset or data)).mp.   
11. (Read adj1 (term* or code# or codification)).mp.   
12. (diagnostic adj1 (term* or code#)).mp.   
13. Disease Analyzer.mp.   
14. Primary care clinical informatics unit.mp.   
15. PCCIU.mp.   
16. (optimum patient care adj4 data*).mp.      
17. OPCRD.mp.   
18. health information network.mp.   
19. health improvement network.mp.   
20. Q research.mp.   
21. (ResearchOne or (Research One adj2 data*)).mp.      
22. Doctors Independent Network.mp.   
23. SAIL.mp.   
24. (SAIL adj4 data*).mp.      
25. mediplus.mp.   
26. ((general practice or primary care or primary health care) adj4 data*).mp.   
27. longitudinal patient database.mp.   
28. ((EHR or eletronic health record*) adj4 data*).mp.      
29. health care database*.mp.   
30. or/1-29   
31. UK.mp.      
32. United Kingdom.mp.      
33. England.mp.      
34. Wales.mp.      
35. Scotland.mp.      
36. Northern Ireland.mp.     
37. 31 or 32 or 33 or 34 or 35 or 36   
38. exp central depressant agent/   
39. exp central muscle relaxant/   
40. exp psychotropic agent/   
41. antidepress*.mp.      
42. antipsychotic.mp.      
43. anxiolytic.mp.      
44. exp mental capacity/ or exp mental compliance/ or exp mental concentration/ or exp mental deficiency/ or exp 
mental deterioration/ or exp mental development/ or exp mental development assessment/ or exp mental 
disease/ or exp mental disease assessment/ or exp mental dissociation/ or mental function/ or exp mental health/ 
or exp mental health care/ or exp mental health center/ or exp mental health organization/ or exp mental health 
research/ or exp mental health service/ or exp mental hospital/ or exp mental stress/   
45. depressi*.mp.      
46. dysthymia.mp.      
47. catatonia.mp.      
48. self-injur*.mp.      
49. self injury.mp.      
50. self mutilation.mp.      
51. suicid*.mp.      
52. self-harm.mp.      
53. anxious*.mp.      
54. anxiety.mp.      
55. panic.mp.      
56. catastrophi*.mp.      
57. phobia.mp.      
58. phobic.mp.      
59. neurotic.mp.      
60. compulsive.mp.      
61. bipolar.mp.      
62. neurotic.mp.      
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63. personality.mp.      
64. psychotic.mp.      
65. psychosis.mp.      
66. paranoid.mp.      
67. delusional.mp.  
68. sexual.mp.  
69. insomnia.mp.   
70. exp insomnia/   
71. exp sleep/ or exp sleep disorder/   
72. exp somatoform disorder/   
73. exp substance abuse/ or exp "substance use"/   
74. exp stress/   
75. or/38-74   
76. 30 and 37 and 75 
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Supplementary Appendix 2. Template email sent to corresponding authors of the studies 
for which a list of codes wasn’t provided in the publication. 
 
 
Dear [corresponding author],  
 
I’m currently doing a PhD about mental health and quality of life in breast cancer survivors. 
As part of my PhD, I’m conducting a systematic review of the studies that assessed mental 
health outcomes using electronic health records. The aim of the review is to summarise how 
studies have identified these outcomes in primary care databases in the UK; the review will 
be part of my PhD thesis and we are also planning to publish it in a peer-reviewed journal in 
due course. 
I’m writing to you because a study in which you are the corresponding author was identified 
as eligible (please see title below), and I would kindly ask if you could be of assistance with 
the issues described below. 
 
[title] 
[description of the list of codes needed] 
 
I look forward to hearing from you and thank you in advance for your help. 
 
Best wishes,  
Helena 
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Supplementary appendix 3, table 1. Main characteristics of the eligible studies: anxiety. 
Author, 
year of 
publication 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
// 
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Bouras, 
2016 [1] 
Linked and primary care 
database analysis of the 
incidence and impact of 
psychiatric morbidity 
following gastrointestinal 
cancer surgery in 
England 
Cohort study CPRD, 
HES 
1997-2012 “Diagnosis code [for anxiety] in 
CPRD or HES, or a prescription 
code [for Diazepam or Lorazepam] 
between 36 months before and 12 
months after surgery.” 
Yes None 
stated 
Data available for 
>3 years before 
the index date 
// 
Follow up 
duration: 1 year 
after index date 
 
Study quantified 
the psychiatric 
morbidity before 
and after the 
index date.   
- 
Fardet, 2012 
[2] 
Suicidal behavior and 
severe neuropsychiatric 
disorders following 
glucocorticoid therapy in 
primary care 
Cohort study THIN 1990-2008 Read and Multilex list of codes for 
diagnoses of panic disorder or panic 
attack excluding c odes for anxiety 
No None 
stated 
≥6 months of 
registration with 
the primary care 
practice 
Hazards ratios 
adjusted for past 
history of 
neuropsychiatric 
disorders 
(yes/no) 
Outcome was 
eligible if there 
was no record of 
the outcome in 
the previous 6 
months 
Granerod, 
2016 [3] 
Increased rates of 
sequelae post-
encephalitis in 
individuals attending 
primary care practices in 
the United Kingdom: a 
population-based 
retrospective cohort 
study 
Cohort study CPRD 1998-2012 “Anxiety disorders (including both 
symptom codes and diagnoses such 
as generalised anxiety disorder, 
panic disorder, post-traumatic stress 
disorder and obsessive compulsive 
disorder)” 
Yes None 
stated 
None stated 
// 
At least one 
contact with the 
GP practice in the 
two years after the 
index date 
Analysis 
restricted to 
those at risk of a 
new-onset 
outcome, 
defined as no 
code in the year 
prior to the index 
date. 
- 
Hesdorffer, 
2012 [4] 
Epilepsy, suicidality, and 
psychiatric disorders: a 
bidirectional association 
Matched cohort 
study 
CPRD 1990-2008 Anxiety, not further specified No None 
stated 
At least 3 years of 
data before the 
index date, 1 year 
after the index 
date, and at least 
1 code for a 
medical or drug 
code in the 6 
months before the 
index 
// 
Follow up 3 years 
after index date 
Excluded 
subjects with a 
record of the 
outcome before 
the study date. 
- 
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Khan, 2010 
[5] 
Consulting and 
prescribing behaviour for 
anxiety and depression 
in long-term survivors of 
cancer in the UK 
 
Cohort study CPRD 2003-2006 Consultations for anxiety and 
prescriptions of benzodiazepines 
and Buspirone 
No None 
stated 
None stated 
 
History of 
anxiety prior to 
the analysis 
period included 
in the models 
 
Outcomes 
occurred within 
a 3-year period 
chosen for the 
study 
 
Kurd, 2005 
[6] 
The risk of depression, 
anxiety, and suicidality 
in patients with 
psoriasis: A population-
based cohort study 
Cohort study CPRD 1987-2002 “clinician diagnosis of anxiety and 
related disorders in which anxiety 
symptoms are common” 
No 
 
(refers using 
the same 
codes of 
previous 
studies) 
None 
stated 
None stated Patients with 
history of anxiety 
in the 6 months 
before the index 
date were 
excluded in a 
sensitivity 
analysis.  
- 
Lurie, 2015 
[7] 
Antibiotic exposure and 
the risk for depression, 
anxiety, or psychosis: A 
nested case-control 
study 
Nested case 
control study 
THIN 1995-2013 Anxiety, including codes for 
diagnosis of generalised anxiety 
disorder and phobic anxiety 
Yes None 
stated 
Only records from 
patients that had 
been registered 
with the GP for 
more than 183 
days 
// 
Outcomes were 
considered 
incident if 
occurring at more 
than 183 days 
after the index 
date. 
 
Patients who 
had 
pharmacological 
treatment for a 
specific 
psychiatric 
diagnosis more 
than 90 days 
before the 
diagnosis was 
first recorded 
were excluded. 
 
Patients with 
mixed anxiety 
and depression 
were excluded 
from the 
analysis 
Martin-
Merino, 
2010 [8] 
Prevalence, incidence, 
morbidity and treatment 
patterns in a cohort of 
patients diagnosed with 
anxiety in UK primary 
care 
Cohort study THIN 2002-2004 “Identification codes included all 
Read codes describing anxiety. 
These included codes ranging from 
mild anxiousness symptoms to other 
disorders such as phobia, panic 
attack and generalized and mixed 
anxiety disorders” 
Yes Yes 
 
Record 
review/ 
questionna
ires 
Enrolled for at 
least 2 years with 
the practice and 
have received one 
prescription in the 
previous year; 
patients aged ≥70 
years had to have 
at least 2 visits 
registered in the 
follow up period of 
>1 year. 
 
Patients with 
previous anxiety 
diagnoses were 
excluded, as 
well as those 
who had 5 or 
more 
prescriptions of 
anxiolytics 
before the 
diagnosis. 
- 
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Meier, 2004 
[9] 
The risk of severe 
depression, psychosis or 
panic attacks with 
prophylactic 
antimalarials 
Cohort study CPRD 1990-1999 First time diagnosis of panic attack, 
regardless of referral or treatment, 
identified by OXMIS- and/or- ICD-8-
codes 
No Yes 
 
‘reviewed 
a list of all 
cases to 
determine 
inclusion/ 
exclusion’ 
≥1 year of data 
available before 
index date and 
“some GPRD 
activity (diagnoses 
or prescriptions) 
recorded after the 
index date” // 
Patients were 
censored 18 
months after 
exposure date 
“The base 
population for 
person-time 
analyses 
consisted of all 
subjects free of 
(S) panic 
attacks at the 
start of follow 
up.” 
- 
Schneider, 
2013 [10] 
Antimalarial 
chemoprophylaxis and 
the risk of 
neuropsychiatric 
disorders 
Nested case 
control study 
CPRD 2001-2009 Incident diagnosis of anxiety, not 
further specified 
No None 
stated 
At least 1 year of 
date before the 
index date // 
some activity 
(diagnoses or 
prescriptions) 
recorded after the 
index date 
Excluded 
patients with the 
outcome of 
interest 
observed before 
the index date 
-  
Sheehan, 
2015 [11] 
Mental illness, 
challenging behaviour, 
and psychotropic drug 
prescribing in people 
with intellectual 
disability: UK population 
based cohort study 
Cohort study THIN 1999-2013 Anxiety, including codes for 
symptoms and diagnoses 
Yes None 
stated 
Entry in the cohort 
at least one year 
after registration 
with the practice 
None stated Excludes cases 
of mixed anxiety 
and depression 
Walters, 
2012 [12] 
Recent trends in the 
incidence of anxiety 
diagnoses and 
symptoms in primary 
care 
Cohort study THIN 1998-2008 Anxiety, including symptoms, 
diagnosis, mixed anxiety and 
depression, panic attacks and panic 
disorder 
 
Results were also provided 
separately for: 
- anxiety disorders (eg. chronic 
anxiety, generalised anxiety 
disorder, anxiety state);  
- anxiety symptoms (e.g. 
‘anxiousness’);  
- mixed anxiety and depression; 
- panic attacks and panic disorder. 
No None 
stated 
≥1 year of data 
since registration 
with the practice 
and ‘consistent 
recording of at least 
one medical record 
(e.g. a diagnostic 
entry), one 
additional health 
data record (e.g. 
blood test result) 
and >1 prescriptions 
on average for the 
practice per patient 
per year. 
Excluded 
patients with an 
entry for anxiety 
recorded in the 
previous year. 
Participants 
could have had 
more than one 
episode during 
the follow up, 
provided that 
they were 
separated for 
more than 12 
months.  
CPRD – Clinical Practice Research Datalink; HES – Hospital Episodes Statistics; ICD-10 – International Classification of Diseases, edition 10; ND – not defined; OXMIS – Oxford 
Medical Information System; PCCIU – Primary Care Clinical Informatics Unit Research; THIN – The Health Improvement Network. 
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Supplementary appendix 3, table 2. Main characteristics of the eligible studies: depression. 
Author, 
year of 
publication 
 
Title 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
// 
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Becker, 
2011 [13] 
Risk of incident 
depression in patients 
with Parkinson disease 
in the UK 
Nested case-
control study 
CPRD 1994-2005 ‘To be included in the analysis as a 
valid depression case, a patient had 
to have a code recorded for an 
affective disorder (depression, manic 
disorders, bipolar disorders, or 
unspecified affective disorders) 
during follow-up.’ 
Yes Yes  
 
Pharmacol
ogical 
treatment 
with 
antidepres
sive drugs 
At least 3 years of 
computer EHR 
prior to the index 
date 
// 
None stated. 
Cases who had 
depression 
diagnosed prior 
to the index date 
were excluded; 
- 
Booth, 2015 
[14] 
Impact of bariatric 
surgery on clinical 
depression. Interrupted 
time series study with 
matched controls 
Controlled 
interrupted time-
series study 
CPRD 2000-2012 Clinical depression was identified 
through medical diagnoses for 
depression recorded in clinical or 
referral records as well as through 
prescriptions for anti-depressant 
drugs. 
Yes None 
stated 
At least one year 
of registration with 
the practice prior 
to the index date 
Not applicable - 
Bornand, 
2016 [15] 
The risk of new onset 
depression in 
association with 
influenza - A population-
based observational 
study 
Nested case-
control study 
CPRD 2000-2013 Minimum of three prescriptions for 
one or more antidepressant drugs 
recorded after the incident major 
depression diagnosis (i.e. the index 
date), identified by READ-codes 
based on ICD-10 codes (F32), if 
they started the antidepressant 
therapy within 90 days of the 
depression diagnosis 
Yes None 
stated 
A minimum of 
three years of 
history before the 
index date. 
Excluded 
patients with 
more than two 
prescriptions for 
antidepressants 
at any time prior 
to the index 
date. 
Adjusted for 
history of 
affective 
disorders in the 
models. 
 
Provides data 
for depression 
severity: general 
depression; mild 
depression; 
moderate 
depression; 
severe 
depression; 
other. 
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Bouras, 
2016 [1] 
 
Linked Hospital and 
Primary Care Database 
Analysis of the 
Incidence and Impact of 
Psychiatric Morbidity 
Following 
Gastrointestinal Cancer 
Surgery in England 
Cohort study CPRD 
HES 
1997-2012 “Codes for the diagnoses of (S) 
depression were measured in CPRD 
(S) In HES, ICD-10 codes recorded 
in the first position of a hospital 
episode (signifying the main 
condition treated) for the diagnoses 
of depression. (S) Prescription data 
(S) including antidepressants 
(Fluoxetine, Paroxetine, Sertraline, 
Citalopram, Escitalopram, 
Mitrazapine, and Venlafaxine), (S) 
anxiolytics (Diazepam and 
Lorazepam).” 
Yes None 
stated 
Data available for 
>3 years before 
the study index 
date 
 
// 
 
Follow up 
duration: 1 year 
post diagnosis 
Not applicable - 
Claxton, 
2000 [16]  
Selective serotonin 
reuptake inhibitor 
treatment in the UK: 
Risk of relapse or 
recurrence of 
depression 
Cohort study MediPlus 1993-1995 Re-initiation of any antidepressant 
after a gap of at least 6 months with 
no antidepressant prescription; 
suicide attempt, referral to 
psychotherapy or psychiatrist, 
admission to a mental health facility, 
emergency room use related to 
mental disorders, or 
electroconvulsive therapy and re-
initiation of antidepressant one of the 
above.  
 
Depression first defined as treatment 
with a SSRI and a Read code within 
1 month of the prescription. 
 
Yes None 
stated 
Only patients with 
contact with the 
services during the 
previous 2 years 
of the index date; 
// 
Follow up duration 
of 18 months post 
index date 
Not applicable 
(all patients had 
been treated 
with SSRI) 
Patients 
dementia, 
schizophrenia, 
psychosis and 
manic 
depression were 
excluded.  
Clifford, 
2002 [17] 
Drug or symptom-
induced depression in 
men treated with apha1-
blockers for benign 
prostatic hyperplasia? A 
nested-case control 
study 
 
Nested case-
control study 
 
CPRD 1992-1999 Proxy of antidepressant prescription 
(first prescription of antidepressant) 
No None 
stated 
Registered in 
CPRD for at least 
12 months 
// 
ND 
None stated - 
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Dave, 2010 
[18] 
Incidence of Maternal 
and Paternal Depression 
in Primary Care 
Cohort study THIN 1993-2007 “Read code entry for unipolar 
depression and/or a prescription for 
an antidepressant at the appropriate 
therapeutic dose for treatment of 
depression on a given consultation 
date (S) we eliminated those who 
had an entry for anxiety or panic 
disorder but had no entry for 
depression in their entire 
computerized medical record.” 
 
New episode was considered when 
no diagnosis or prescription had 
been registered in the past year. 
No  
 
Available on 
request 
None 
stated 
None stated Results stratified 
by history of 
previous mental 
disorder 
Mixed anxiety 
and depression 
was included.  
Fardet, 2012 
[2] 
Suicidal behavior and 
severe neuropsychiatric 
disorders following 
glucocorticoid therapy in 
primary care 
 
Cohort study 
 
THIN 1990-2008 ‘Read code for unipolar depression, 
for symptoms of depression, or for a 
prescription for an antidepressant. 
Diagnoses were considered first; 
prescriptions of antidepressants 
were used in defining the outcome 
only when there was no recorded 
diagnosis of a neuropsychiatric 
illness and no other recorded 
indication for the prescription. To 
exclude patients who may have 
received prescriptions for 
antidepressants for anxiety rather 
than for depression, we eliminated 
those who had an entry for anxiety 
or panic disorder but had no entry 
for depression in their entire 
computerized medical record.’ 
No None 
stated 
≥6 months of 
registration with 
the primary care 
practice. 
Hazards ratios 
adjusted for past 
history of 
neuropsychiatric 
disorders 
(yes/no) 
Outcome was 
eligible if there 
was no record of 
the outcome in 
the previous 6 
months 
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Gunnell, 
2009 [19] 
Varenicline and suicidal 
behaviour: a cohort 
study based on data 
from the General 
Practice Research 
Database 
Cohort study CPRD 2006-2008 Depression defined as the start of 
antidepressant therapy 
No None 
stated 
At least 1 years of 
CPRD record 
before index date 
// 
ND 
People who had 
been prescribed 
an 
antidepressant 
within the 
previous 6 
months before 
index date were 
excluded. 
Previous 
psychiatric 
consultations 
considered in 
the models.  
- 
Granerod, 
2016 [3] 
Increased rates of 
sequelae post-
encephalitis in 
individuals attending 
primary care practices in 
the United Kingdom: a 
population-based 
retrospective cohort 
study 
Matched cohort 
study 
CPRD 1998-2012 Depression, consisting of codes for 
depression diagnosis and symptoms 
if evidence of pharmacological 
treatment was present.  
Yes None 
stated 
None stated 
// 
At least one 
contact with the 
GP practice in the 
two years after the 
index date. 
Analysis 
restricted to 
those at risk of a 
new-onset 
outcome, 
defined as no 
code in the year 
prior to the index 
date. 
 
- 
Hagberg, 
2017 [20] 
Risk of Incident 
Antidepressant-Treated 
Depression Associated 
with Use of 5alpha-
Reductase Inhibitors 
Compared with Use of 
alpha-Blockers in Men 
with Benign Prostatic 
Hyperplasia: A 
Population-Based Study 
Using the Clinical 
Practice Research 
Datalink 
Nested case-
control study 
CPRD 1992-2013 A Read code for a depression 
diagnosis and a prescription for an 
antidepressant within 90 days of the 
depression diagnosis. 
No None 
stated 
At least 1 year of 
recorded 
history in the 
database before 
cohort entry;  
Excluded men 
with a diagnosis 
of depression or 
suicidal 
behaviors 
(ideation or 
attempts), or 
men who 
received 
prescriptions for 
antidepressant 
medications 
prior to cohort 
entry. 
- 
319
 64 
Hagberg, 
2016 [21] 
Incidence rates of 
suicidal behaviors and 
treated depression in 
patients with and without 
psoriatic arthritis using 
the Clinical Practice 
Research Datalink 
Nested case 
control study 
 
CPRD 1998-2012 ‘A patient was required to have at 
least one prescription for an 
antidepressant drug in addition to a 
diagnosis code for depression within 
60 days of each other to qualify as a 
case of treated depression.’ 
No Yes, 
record 
review 
At least one year 
of registration with 
the practice prior 
to the index date 
Any patient who 
had a diagnosis 
of depression or 
a prescription for 
an 
antidepressant 
drug recorded 
before the 
cohort entry date 
was excluded 
from the Treated 
Depression sub-
cohort. 
- 
Harris, 2011 
[22] 
Depression indicators in 
a national sample of 
older community and 
care home patients: 
applying the Quality and 
Outcomes Framework 
Cohort study THIN ND-2008 (i) depression case finding with 
assessment tool validated for 
primary care; 
(ii) assessment of depression 
severity in patients with a new 
depression episode. 
 
‘Quality and Outcomes Framework 
Read Codes were used in both 
cases, but no account was taken of 
exceptions recorded by GPs, as 
these may bias comparisons 
between community and care home 
samples.’ 
Yes None 
stated 
Patients registered 
for at least 90 
days with a new 
diagnosis of 
depression in 
period 91-450 
days from end of 
follow up and no 
depression 
severity 
assessment >365 
days before end of 
follow up. 
Not applicable Only practices 
contributing with 
data up to at 
least March 
2008 were 
included.  
Hesdorffer, 
2012 [4] 
Epilepsy, suicidality, and 
psychiatric disorders: a 
bidirectional association 
Matched cohort 
study 
CPRD 1990-2008 Incident major depression, not 
further specified 
No None 
stated 
At least 3 years of 
data before the 
index date, 1 year 
after the index 
date, and at least 
1 code for a 
medical or drug 
code in the 6 
months before the 
index 
// 
Follow up 3 years 
after index date 
 
Excluded 
subjects with a 
record of the 
outcome before 
the study date. 
- 
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Jacob, 2017 
[23] 
Depression Risk in 
Patients with 
Rheumatoid Arthritis in 
the United Kingdom 
Cohort study Disease 
Analyser 
database 
2000-2014 Diagnoses of depression, according 
to the ICD-10 codes 
No None 
stated 
None stated 
// 
Incidence in the 
first 5 years of the 
index date 
None stated - 
Jenkins-
Jones, 2018 
[24] 
Poor compliance and 
increased mortality, 
depression and 
healthcare costs in 
patients with congenital 
adrenal hyperplasia 
Matched cohort 
study 
 
CPRD,  
ONS, 
HES 
inpatient and 
outpatient 
 
 
? Depression defined by Read Codes 
in CPRD, by ICD-10 code in HES 
inpatient data, or by the prescription 
of antidepressants. 
 
Depression was identified not only 
from ongoing records but also from 
patients’ clinical histories dating from 
before the start of data follow-up. 
 
A sensitivity analysis considered 
only those depression outcomes 
identified by both diagnostic (Read 
or ICD-10) code and at least one 
antidepressant prescription. 
Yes None 
stated 
None stated Not applicable: 
the outcome 
was lifetime 
prevalence of 
depression 
rather than 
incident 
occurrence. 
- 
John, 2016 
[25] 
Recent trends in 
primary-care 
antidepressant 
prescribing to children 
and young people: an e-
cohort study 
 
Cohort study SAIL 2003-2013 Incident episode: a Read code for a 
diagnosis or symptom of depression, 
or antidepressant, with no record of 
the given subtype (antidepressant 
prescription or depression diagnosis 
or depression symptom) in the 
previous 12 months; Participants 
could have more than one episode 
recorded across the study period as 
long a period of at least 12 months 
existed between entries within that 
subtype. 
 
Prevalent episode: any record of the 
given subtype (antidepressant 
prescription or depression diagnosis 
or depression symptom)  in a target 
year 
 
Annual recurrent episode: defined as 
the first record in a given year of a 
given subtype where a record of that 
subtype exists previously in that 
individuals GP record. 
 
Yes None 
stated 
Registered with 
the GP practice for 
at least 1 year 
Not applicable Explored the 
indication of the 
antidepressants 
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Kendrick, 
2015 [26] 
Changes in rates of 
recorded depression in 
English primary care 
2003-2013: time trend 
analyses of effects of 
the economic recession, 
and the GP contract 
quality outcomes 
framework 
Cohort study CPRD 2003-2013 “had clinical or referral events 
recorded which included a Read 
code for non-psychotic depressive 
symptoms or diagnoses, or for 
assessment using depression 
symptom questionnaires.” 
 
Prevalence of depression: Read 
code present in the year or quarter;  
 
Incidence of depression: limited to 
patients who had no code for 
depression recorded in the previous 
12 months. 
 
Incidence of first-ever depression: 
no previous code for depression 
diagnosis, symptoms or 
antidepressant treatment recorded 
within 10 year study period, and no 
previous record of depression or 
antidepressant treatment recorded. 
 
Yes None 
stated 
None stated Not applicable  “We excluded 
patients with 
psychotic 
diagnoses 
including bipolar 
disorder, 
psychotic 
depression, and 
schizoaffective 
psychosis, and 
patients 
prescribed 
antidepressants 
for other 
indications 
besides 
depression.” 
Khan, 2010 
[5] 
Consulting and 
prescribing behaviour for 
anxiety and depression 
in long-term survivors of 
cancer in the UK 
 
Matched cohort 
study 
 
CPRD 2003-2006 Consultations for depression and 
prescriptions of as tricyclics, SSRIs 
and MAOIs 
No  
 
(Available 
on request) 
None 
stated 
None stated 
 
// 
 
Follow up 
duration: 3 years 
 
History of 
anxiety prior to 
the analysis 
period was 
included in the 
models 
- 
Kotz, 2017 
[27] 
Cardiovascular and 
neuropsychiatric risks of 
varenicline and 
bupropion in smokers 
with chronic obstructive 
pulmonary disease 
 
Matched cohort 
study 
 
QResearch 2001-2012 Depression, not further specified No None 
stated 
Registered for >12 
months before 
data extraction 
// 
Follow up duration 
6 months 
History of 
neuropsychiatric 
events before 
the index date 
were considered 
as confounders 
- 
Kotz, 2015 
[28] 
Cardiovascular and 
neuropsychiatric risks of 
varenicline: a 
retrospective cohort 
study 
Matched cohort 
study 
 
QResearch 2007-2012 Depression, not further specified No None 
stated 
Registered for >12 
months before 
data extraction 
// 
Follow up duration 
6 months 
History of 
neuropsychiatric 
events before 
the index date 
were considered 
as confounders 
- 
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Kurd, 2005 
[6] 
The risk of depression, 
anxiety, and suicidality 
in patients with 
psoriasis: A population-
based cohort study 
Matched cohort 
study 
 
CPRD 1987-2002 Depression included all clinician 
diagnoses of depressive 
symptomology including bipolar 
disorder, defined by diagnostic Read 
or OXMIS codes 
No 
 
(refers using 
the same 
codes of 
previous 
studies) 
None 
stated 
None stated Patients with 
history of anxiety 
in the 6 months 
before the index 
date were 
excluded in a 
sensitivity 
analysis.  
 
- 
Lurie, 2015 
[7] 
Antibiotic exposure and 
the risk for depression, 
anxiety, or psychosis: A 
nested case-control 
study 
Nested case 
control study 
THIN 1995-2013 At least one Read code of 
depression; not further specified. 
Yes None 
stated 
Only records from 
patients that had 
been registered 
with the GP for 
more than 183 
days 
// 
Outcomes were 
considered 
incidence if 
occurring at more 
than 183 days 
after the index 
date. 
Patients who 
had 
pharmacological 
treatment for a 
specific 
psychiatric 
diagnosis more 
than 90 days 
before the 
diagnosis was 
first recorded 
were excluded. 
 
Patients with 
mixed anxiety 
and depression 
were excluded 
from the 
analysis 
Martin-
Merino, 
2010 [29] 
Study of a cohort of 
patients newly 
diagnosed with 
depression in general 
practice: Prevalence, 
incidence, comorbidity, 
and treatment patterns 
Cohort study, 
descriptive and 
analytical 
THIN 2002-2004 Patients with incident depression 
during the follow up but excluding 
those who had 5 or more 
prescriptions of an antidepressant 
before the depression diagnosis. 
No Yes 
 
GP 
questionna
ires 
Registered for >2 
years with their 
GP practice prior 
to the index date; 
Excluded patients 
aged >69 years 
who had fewer 
than 2 visits during 
the follow-up. 
 
All subjects who 
had a record of 
depression 
before the index 
date were 
excluded.  
Prevalence of 
depression 
calculated as the 
sum of all 
patients who 
had the outcome 
during the study, 
plus those who 
had the outcome 
in the two years 
before the study 
start date.  
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Meier, 2004 
[9] 
The Risk of Severe 
Depression, Psychosis 
or Panic Attacks with 
Prophylactic 
Antimalarials 
Cohort study CPRD 1990-1999 Depression referred to specialist or 
hospital, or if received treatment with 
antidepressants at or after the 
diagnosis date identified by OXMIS- 
and/or- ICD-8-codes 
No Yes 
 
‘reviewed 
a list of all 
cases to 
determine 
inclusion/ 
exclusion’ 
≥1 year of data 
available before 
index date and 
“some GPRD 
activity (diagnoses 
or prescriptions) 
recorded after the 
index date” 
// 
Patients were 
censored 18 
months after 
exposure date 
“The base 
population for 
person-time 
analyses 
consisted of all 
subjects free of 
depression at 
the start of 
follow up.” 
- 
Millson, 
2000 [30] 
Are triptans with 
enhanced lipophilicity 
used for the acute 
treatment of migraine 
associated with an 
increased consulting 
rate for depressive 
illness? 
Cohort study, 
analytical 
CPRD, data 
for the West 
Midlands 
1993-1997 ‘consulting at least once for 
depression’ 
Yes No None stated None Stated - 
Milojevic, 
2017 
[31] 
 
 
Mental health impacts of 
flooding: a controlled 
interrupted time series 
analysis of prescribing 
data in England 
Cohort study General 
practice 
prescribing 
data 
2010-2015 Antidepressants prescription No 
 
(but list of 
antidepress
ants 
provided in 
appendix) 
Not 
applicable 
None stated Not applicable - 
Moore, 2009 
[32] 
Explaining the rise in 
antidepressant 
prescribing: a 
descriptive study using 
the general practice 
research database 
 
Cohort study CPRD 1993-2005 Depression: “first ever 
antidepressant prescription for 
depression diagnosed up to 180 
days before or 90 days after the 
prescribing event, or received a first 
ever diagnosis of depression without 
an associated prescription for 
antidepressants.” 
No None 
stated 
Registered with 
practices 
contributing with 
up to standard 
quality data for the 
entire study period 
Patients only 
included if it was 
the first ever 
events during 
the follow up 
period.  
Provides data 
for treatment 
patterns: chronic 
treatment; 
intermittent 
treatment; short-
term treatment; 
delayed 
treatment; no 
treatment.  
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Morgan, 
2014 [33] 
General practice-
recorded depression 
and antidepressant use 
in young people with 
newly diagnosed Type 1 
diabetes: a cohort study 
using the Clinical 
Practice Research 
Datalink 
 
Matched cohort 
study 
CPRD 1988-2010 Depression identified from diagnosis 
codes (Oxford Medical Information 
System and Read), along with at 
least one antidepressant prescription 
(monoamine oxidase inhibitors, 
selective serotonin reuptake 
inhibitors, tricyclic antidepressants or 
other antidepressants). 
No None 
stated 
None stated Participants with 
depression 
diagnoses or 
prescriptions 
prior to diabetes 
diagnosis (or 
prior to the start 
date for control 
subjects) were 
excluded. 
 
- 
Petersen, 
2006 [34] 
Risk and predictors of 
fatigue after infectious 
mononucleosis in a 
large primary-care 
cohort 
Nested case 
control cohort 
study 
CPRD 1989-2000 Depression, not further specified No 
 
(available 
from the 
authors) 
None 
stated 
At least one year 
of data before 
diagnosis 
// 
At least one year 
of complete follow 
up after diagnosis 
 
Included 
patients who did 
not have fatigue 
in the year 
before onset  
- 
Rait, 2009 
[35] 
Recent trends in the 
incidence of recorded 
depression in primary 
care 
Cohort study THIN 1996-2006 “Diagnoses of 
depression (e.g. ‘depressive 
disorder’) and recorded depressive 
symptoms (e.g. ‘low mood’). new 
episode of diagnosed 
depression was defined as an entry 
in the records where there 
was no previous diagnosis of 
depression coded in the previous 
year. A new episode of depressive 
symptoms was also defined as 
an entry where there had been no 
previous recorded depressive 
symptom code in the previous year.” 
 
No None 
stated 
At least one year 
of follow up data 
// 
ND 
None stated Provides results 
separately for 
diagnoses and 
symptoms of 
depression. 
Shah, 2016 
[36] 
 
 
The mental health and 
mortality impact of death 
of a partner with 
dementia 
Nested case 
control study 
THIN 2005-2008 Depression, not further specified Yes None 
stated 
At least one year 
of data with the 
practice 
None stated - 
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Schneider, 
2013 [10] 
Antimalarial 
chemoprophylaxis and 
the risk of 
neuropsychiatric 
disorders 
Nested case 
control study 
CPRD 2001-2009 Incident diagnosis of depression, not 
further specified 
Yes None 
stated 
At least 1 year of 
date before the 
index date 
// 
some activity 
(diagnoses or 
prescriptions) 
recorded after the 
index date 
 
Excluded 
patients with the 
outcome of 
interest 
observed before 
the index date 
Excluded 
patients with 
history of 
cancer, 
alcoholism, and 
rheumatoid 
arthritis.  
Schneider, 
2010 [37] 
COPD and the risk of 
depression 
Cohort study CPRD 1995-2005 Diagnosis of depression, not further 
specified 
 
In sensitivity analysis, only cases 
with an incident diagnosis of 
depression who receive 
pharmacological treatment within 6 
months of diagnosis were included 
 
Yes None 
stated 
Excluded patients 
with less than 3 
years of active 
recording history 
prior to the date of 
the COPD 
diagnosis 
Patients with 
previous history 
of depression, 
suicide, suicidal 
ideation, etc., 
prior to the index 
date were 
excluded 
Excluded 
patients with 
history of 
cancer, HIV, 
drug abuse, or 
alcoholism prior 
to the index date 
Sheehan, 
2015 [11] 
Mental illness, 
challenging behaviour, 
and psychotropic drug 
prescribing in people 
with intellectual 
disability: UK population 
based cohort study 
 
Cohort study, 
analytical 
 
 
THIN 1999-2013 Read codes for depression 
(including mixed depression-anxiety) 
that the authors’ used in previous 
studies. 
Yes None 
stated 
Entry in the cohort 
at least one year 
after registration 
with the practice 
None stated Excludes cases 
of mixed anxiety 
and depression 
Smeeth, 
2008 [38] 
Effect of statins on a 
wide range of health 
outcomes: A cohort 
study validated by 
comparison with 
randomized trials 
Cohort study 
 
THIN 1995-2006 Depression defined as the start of 
antidepressant pharmacotherapy 
No None 
stated 
None stated People with a 
previous history 
of the outcome 
prior to the index 
date were 
excluded from 
the analysis of 
that outcome. 
 
First year of 
follow up was 
excluded. 
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Smith, 2014 
[39] 
Depression and 
multimorbidity: a cross-
sectional study of 
1,751,841 patients in 
primary care 
Cross-sectional PCCIU ND-2007 “Read code for depression recorded 
within last year and/or 4 or more 
antidepressant prescriptions 
(excluding low-dose tricyclic 
antidepressants) within the last year. 
Low-dose tricyclic antidepressants 
were excluded because they are 
commonly prescribed for chronic 
pain syndromes rather than 
depression.” 
No None 
stated 
Patients alive and 
permanently 
registered with a 
general practice at 
the date of the 
study  
None stated - 
Thomas, 
2013 [40] 
Smoking cessation 
treatment and risk of 
depression, suicide, and 
self harm in the Clinical 
Practice Research 
Datalink: prospective 
cohort study 
Nested case-
control study 
CPRD 
HES 
ONS 
2006-2011 “Incident episodes of depression as 
measured by the date that 
antidepressant treatment was 
initiated (treated depression)” 
 
// 
 
For comparison with previous study, 
depression was also defined with 
Read codes only in CPRD 
 
Yes None 
stated 
At least one year 
of registration with 
the practice prior 
to the index date 
// 
ND 
 
Previous 
psychiatric 
illness, and use 
of psychotropic 
medication 
considered as 
potential 
confounders.  
 
- 
Tyrer, 1999 
[41] 
A study of 
cardiovascular disease, 
depression and 
antidepressants on a 
computerised general 
practice database 
Cohort study 
 
UK 
MediPlus 
1995-1996 ‘new diagnosis of depression and 
treatment, classified by the first 
antidepressant prescribed.’ 
No None 
stated 
At least 12 months 
of data before the 
index date 
// 
Follow up duration 
12 months 
Patients with 
depression in 
the 12 months 
period before 
the cardiac 
event were 
excluded. 
- 
Vallerand, 
2018 [42] 
 
 
Risk of depression 
among patients with 
acne in the U.K.: a 
population-based cohort 
study 
Cohort study, 
analytical 
 
THIN 1986-2012 Read code for major depressive 
disorder 
Yes None 
stated 
None stated 
// 
Follow up for > 2 
years after index 
date 
Patients with 
MDD Read code 
prior to the start 
of follow up were 
excluded 
- 
Walters, 
2011 [43] 
The relationship 
between asthma and 
depression in primary 
care patients: A 
historical cohort and 
nested case control 
study 
Cohort study 
and nested case 
control study 
CPRD 1995-2006 GP recorded diagnosis of 
depression, as defined by 
Read/OXMIS codes) during the 
study period 
No 
 
(codes 
available 
from the 
authors) 
None 
stated 
All patients had at 
least 24 months of 
‘up to standard’ 
data prior to the 
index date of the 
case. 
All cases with a 
recorded 
medical 
diagnosis of 
depression or 
depressive 
symptoms 
before the index 
date were 
excluded from 
the cohort. 
- 
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Yang, 2003 
[44] 
Lipid-lowering drugs and 
the risk of depression 
and suicidal behavior 
Matched cohort 
study 
CPRD 1991 
onwards 
Treated depression (with 
antidepressants) referred to a 
consultant or patient hospitalized for 
depression; excluded patients who 
also had diagnosis of anxiety or with 
specific causes for depression (e.g. 
post-partum depression) 
No Yes 
 
List of 
patients 
referred to 
hospital or 
consultant 
were 
manually 
reviewed; 
referral 
letters 
reviewed.  
≥1 year of data 
available before 
index date 
Patients with 
history of 
depression prior 
to study start 
were excluded 
- 
CPRD – Clinical Practice Research Datalink; EHR – electronic health records; HES – Hospital Episodes Statistics; ICD-10 – International Classification of Diseases, edition 10; 
ND – not defined; PCCIU – Primary Care Clinical Informatics Unit Research; SAIL – SAIL Databank - The Secure Anonymised Information Linkage Databank; THIN – The Health 
Improvement Network; ONS – Office for National Statistics. 
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Supplementary appendix 3, table 3. Main characteristics of the eligible studies: composite outcomes, anxiety and depression. 
Author, 
year of 
publication 
 
Title 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
//  
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
John, 2016 
[45] 
Case-finding for 
common mental 
disorders of anxiety and 
depression in primary 
care: an external 
validation of routinely 
collected data 
Validation study 
using patient 
reported 
outcomes 
SAIL 2000-2009 Outcome: Common mental 
disorders, defined as anxiety and 
depression. 
Read codes for: i) anxiety diagnosis, 
e.g. generalised anxiety disorder; ii) 
anxiety symptoms e.g. anxiousness; 
iii) mixed anxiety and depression; iv) 
panic attacks and panic disorders; v) 
depression diagnoses; vi) 
depression symptoms. Treatment 
defined as having at least one 
prescription for an antidepressant, 
anxiolytic or hypnotic within the year 
around the date of the survey 
answer. Excluded codes for other 
psychosis, phobias, obsessive 
compulsive disorders, post traumatic 
stress disorder, behavioural 
disorders, hyperkinetic disorders, 
conduct disorders, disorders of 
social functioning, and adjustment 
disorders. Defined 12 algorithms 
with current and historical 
symptoms, diagnosis and treatment. 
Yes Yes 
 
Patient 
reported 
outcomes 
At least 6 months 
after registration 
with the practice 
Not applicable 
(no exposure 
under study). 
 
Incidence 
outcome were 
those where no 
previous entry 
had been 
recorded around 
1 year of the 
date of the 
survey answer.  
 
Other outcomes 
were considered 
historical. 
- 
Turner, 2016 
[46] 
Ongoing impairments 
following transient 
ischaemic attack: 
retrospective cohort 
study 
Nested case 
control study 
THIN 2009-2013 Outcome: Psychological impairment, 
defined as anxiety, depression and 
post-traumatic stress disorder. 
 
First consultation after the index 
date with a Read code for symptoms 
or diagnosis of anxiety, depression 
or post-traumatic stress, plus a first 
prescription of an antianxiety or 
antidepressant drug 
Yes None 
stated 
Practice with at 
least one year of 
up to standard 
data, and patients 
registered for at 
least one year with 
the practice. 
// 
Patient alive and 
registered with the 
practice 1 month 
after index 
Not stated. - 
SAIL – SAIL Databank - The Secure Anonymised Information Linkage Databank; THIN – The Health Improvement Network. 
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Supplementary appendix 3, table 4. Main characteristics of the eligible studies: dementia. 
Author, 
year of 
publication 
 
Title 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
//  
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Brown, 2016 
[47] 
Comparison of dementia 
recorded in routinely 
collected hospital 
admission data in 
England with dementia 
recorded in primary care 
Validation study CPRD 
HES 
1990-2012 Read codes for dementia and/or a 
code for a drug specifically 
prescribed for dementia (i.e. 
donepezil, galantamine, memantine 
and rivastigmine). 
Yes Yes 
 
GP 
questionna
ire 
At least 12 months 
before and 12 
months after the 
first HES record of 
dementia 
Not applicable - 
Davies, 
2014 [48] 
Associations of anti-
hypertensive treatments 
with Alzheimer’s 
disease, vascular 
dementia, and other 
dementias 
Nested case-
control study 
CPRD 1997-2008 Alzheimer’s disease, vascular 
dementia, or unspecified/other 
dementias 
 
Created four categories: probable 
Alzheimer’s disease, possible 
Alzheimer’s disease, vascular 
dementia, combine unspecified or 
other dementia.  
 
Yes No None stated Not applicable - 
Donegan, 
2017 [49] 
Trends in diagnosis and 
treatment for people with 
dementia in the UK from 
2005 to 2015: a 
longitudinal 
retrospective cohort 
study 
Cohort study CPRD 2005-2015 Dementia defined using Read codes 
listed for the condition in the Quality 
and Outcomes Framework 
No No Patients were 
eligible for 
analysis if 
registered with the 
practice for the 
entire quarter of 
the year being 
analysed;  
Not applicable 
(descriptive 
study of the 
incident cases of 
dementia) 
- 
Dregan, 
2015 [50] 
Are Inflammation and 
Related Therapy 
Associated with All-
Cause Dementia in a 
Primary Care 
Population? 
Matched cohort 
study 
CPRD 2002-2013 “Medical diagnostic codes were 
used to identify new diagnoses of 
dementia including Alzheimer’s 
disease, vascular dementia, Lewy 
body dementia, frontotemporal 
dementia, dementia in other 
conditions, and unspecified 
dementia.” 
No No None stated Considered 
incident cases 
only 
- 
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Dregan, 
2015 [51] 
Patterns of anti-
inflammatory drug use 
and risk of dementia: a 
matched case-control 
study 
Matched case 
control study 
CPRD 1992-2014 “Medical diagnostic codes were 
used to identify new diagnoses of 
dementia and include non-specific 
dementia (Eu02z), Alzheimer 
disease (F110), vascular dementia 
(Eu01), Lewy body dementia 
(Eu025), senile dementia (E00) and 
dementia in other conditions 
(Eu02).” 
Yes No None stated Considered 
incident 
diagnosis 
- 
Dunn, 2005 
[52] 
Does lithium therapy 
protect against the onset 
of dementia? 
Nested case 
control study 
CPRD 1992-2002 ‘Cases with definite diagnosis of 
Alzheimer disease, vascular 
dementia (with which there is a 
diagnostic overlap), and those with 
uncertain cause of dementia’ 
No Yes 
 
GP 
Questionn
aire 
“At least 4 years o 
research standard 
data preceding the 
date of the 
diagnosis” 
// 
 
Considered 
incident cases 
only 
- 
Dunn, 2005 
[53] 
Association between 
dementia and infectious 
disease: evidence from 
a case-control study 
Nested case 
control study 
CPRD 1992-2002 “We identified cases as all those 
patients with an incident dementia, 
as diagnosed by their GP, a GP 
colleague, or a hospital specialist 
(S) We included cases with a 
recorded diagnosis of Alzheimer 
disease, vascular dementia (with 
which there is diagnostic overlap), 
and those with uncertain cause of 
dementia. Other specified causes of 
dementia were excluded (eg, 
dementia in Parkinson’s disease).” 
No Yes  
 
GP 
questionna
ires 
“At least 4 years of 
research standard 
data preceding the 
date of first 
diagnosis (median 
time from onset of 
symptoms to 
diagnosis has 
been estimated at 
4 years).” 
// 
ND 
Considered 
incident cases 
only  
Cases further 
classified as 
probable or 
possible cases 
of dementia. 
Emdin, 2016 
[54] 
Blood Pressure and Risk 
of Vascular Dementia: 
Evidence From a 
Primary Care Registry 
and a Cohort Study of 
Transient Ischemic 
Attack and Stroke 
Cohort study CPRD 
HES 
ONS 
1990-2003 First record of vascular dementia, in 
one of the databases. For the 
primary analysis, cases of 
Alzheimer’s disease and vascular 
dementia (i.e. mixed dementia) were 
included. 
Yes No Registered with 
the GP practice for 
at least one year 
// 
First 4 years of 
follow up excluded 
from analysis 
First 4 years of 
follow up 
excluded from 
analysis 
- 
Goh, 2014 
[55] 
Angiotensin receptor 
blockers and risk of 
dementia: cohort study 
in UK Clinical Practice 
Research Datalink 
Cohort study CPRD 1995-2010 New diagnosis of dementia, defined 
by Read codes, excluding specific 
causes of dementia (e.g. dementia 
in neoplastic disease). 
Yes No At least 6 months 
of registration with 
the GP practice // 
Outcome 
occurring in the 
first year after the 
index date were 
not considered 
Excluded all 
individuals with 
a record of 
dementia or 
cognitive 
impairment prior 
to the date of 
entry in the 
study 
- 
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Granerod, 
2016 [3] 
Increased rates of 
sequelae post-
encephalitis in 
individuals attending 
primary care practices in 
the United Kingdom: a 
population-based 
retrospective cohort 
study 
Nested case 
control study 
CPRD 1998-2012 “cognitive problems (including 
memory loss, aphasia, difficulty 
processing information, difficulty 
reasoning, difficulty concentrating 
and learning disability)” 
Not 
provided in 
the original 
study but 
obtained 
from the 
authors 
None 
stated 
None stated 
// 
At least one 
contact with the 
GP practice in the 
two years after the 
index date. 
Analysis 
restricted to 
those at risk of a 
new-onset 
outcome, 
defined as no 
code in the year 
prior to the index 
date. 
Dementia 
diagnosis were 
considered 
separately 
Hippisley-
Cox, 2010 
[56] 
Unintended effects of 
statins in men and 
women in England and 
Wales: population based 
cohort study using the 
QResearch database 
Cohort study QResearch 2002-2008 Dementia, defined with Read codes, 
not further specified. 
No; states 
that code 
list is 
available on 
request 
No At least one year 
of registration with 
the practice 
// 
ND 
Incident cases 
included in the 
study 
- 
Imfeld, 2012 
[57] 
Metformin, other 
antidiabetic drugs, and 
risk of Alzheimer’s 
disease: a population-
based case-control 
study 
Nested case 
control study 
CPRD 1998-2008 “either a diagnosis of AD followed by 
at least one prescription for an AD 
drug or vice versa; a diagnosis of 
dementia followed by at least two 
prescriptions for an AD drug; at least 
two recordings of an AD diagnosis; 
an AD diagnosis after a specific 
dementia test (e.g., Mini-Mental 
State Examination (MMSE), Clock 
Drawing Test (CDT), or Abbreviated 
Mental Test (7-min screen)), a 
referral to a specialist (e.g., 
neurologist, geriatrician, or 
psychogeriatrician), an assessment 
based on a neuroimaging technique 
(e.g., magnetic resonance imaging 
(MRI), computed tomography (CT), 
or single-photon emission CT 
(SPECT)); or an AD diagnosis 
preceded or followed by any 
recorded dementia symptoms (e.g., 
memory impairment, aphasia, 
apraxia, or agnosia).” 
 
No Yes 
 
GP 
questionna
ire 
Patients with >3 
years of active 
history in the 
database were 
excluded. 
First time 
diagnosis of 
Alzheimer’s 
disease included 
- 
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Imfeld, 2013 
[58] 
Epidemiology, co-
morbidities, and 
medication use of 
patients with Alzheimer's 
disease or vascular 
dementia in the UK 
 
Descriptive 
cohort study 
CPRD 1998-2008 “A patient was required to have 
either: 1) a diagnosis of AD followed 
by at least one prescription for an 
AD drug or vice versa; 2) a 
diagnosis of unspecific dementia 
followed by at least two prescriptions 
for an AD drug; 3) at least two 
recordings of an AD diagnosis; 4) an 
AD diagnosis after a specific 
dementia test (e.g., Mini Mental 
State Examination, Clock Drawing 
Test, or Abbreviated Mental Test [7-
Minute Screen]), a referral to a 
specialist (e.g., neurologist, 
geriatrician or psycho-geriatrician), 
or an assessment based on 
neuroimaging technique (e.g., 
magnetic resonance imaging, 
computed tomography, or single 
photon emission computed 
tomography); or 5) an AD diagnosis 
preceded or followed by any 
recorded dementia symptoms (e.g., 
memory impairment, aphasia, 
apraxia, or agnosia). In addition, AD 
patients with a recording of any 
other specific dementia diagnosis 
(e.g., VaD, Pick’s disease, or 
dementia with Lewy bodies) after the 
index date were not eligible, as well 
as those AD patients with a 
recording of stroke within two years 
prior to the index date.” 
No Yes 
 
GP 
questionna
ires 
None stated Considered 
incident cases 
during the study 
period only 
“cases were not 
eligible if they 
had had a stroke 
before the index 
date (because 
this is more 
indicative of a 
diagnosis of 
vascular 
dementia 
(VaD)16) or a 
recording of any 
other specific 
dementia 
diagnosis (e.g., 
VaD, Pick’s 
disease, or Lewy 
body dementia) 
after the index 
date.” 
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Imfeld, 2015 
[59] 
Benzodiazepine Use 
and Risk of Developing 
Alzheimer's Disease or 
Vascular Dementia: A 
Case-Control Analysis 
Case control CPRD 1998-2013 “first time diagnosis of AD, VaD, or 
any unspecified dementia (based on 
Read codes) (S), or who received a 
first-time prescription for an 
acetylcholinesterase inhibitor (i.e. 
donepezil, rivastigmine, 
galantamine, or tacrine) or the N-
methyl-D-aspartate (NMDA) receptor 
antagonist memantine (S) To 
increase the probability of including 
only well-defined AD or VaD cases, 
a validated algorithm was applied 
(S) this algorithm was based on 
recordings of specific dementia tests 
[e.g. Mini-Mental State Examination 
(MMSE), Clock Drawing Test (CDT), 
or Abbreviated Mental Test (7-
Minute Screen)], referrals to 
specialists (e.g. neurologists, 
geriatricians or psycho-geriatricians), 
brain imaging [computed 
tomography (CT), magnetic 
resonance imaging (MRI), or single 
photon emission computed 
tomography (SPECT)], or dementia 
symptoms (memory impairment, 
aphasia, apraxia, or agnosia) 
supportive of a diagnosis of a 
specific dementia subtype (i.e. AD or 
VaD).” 
No Yes 
 
GP 
questionna
ire 
At least three 
years of active 
history in the 
database before 
diagnosis 
// 
ND 
Considered 
incident cases 
during the study 
period only 
- 
Jick, 2000 
[60] 
Statins and the risk of 
dementia 
Nested case 
control study 
CPRD 1992-1998 First time diagnosis of dementia or 
Alzheimer’s disease 
No No but 
refers to 
previous 
study 
where the 
validity of 
the same 
list of 
codes was 
assessed 
None stated Incidence cases 
considered only 
- 
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Judge, 2017 
[61] 
Protective effect of anti- 
rheumatic drugs on 
dementia in rheumatoid 
arthritis patients  
 CPRD 1995-2011 Dementia, including Alzheimer’s 
dementia, vascular dementia, and 
mixed dementia. 
Yes No At least one year 
of up to standard 
registration data 
before the index 
date 
// 
ND 
Considered 
incident cases 
only 
- 
Khan, 2011 
[62] 
Long-term health 
outcomes in a British 
cohort of breast, 
colorectal and prostate 
cancer survivors 
Cohort study CPRD 2003-2006 Dementia, defined with Read codes, 
not further specified 
No; states 
that codes 
are 
available 
upon 
request 
No None stated Only incident 
cases were 
considered 
- 
Khosrow-
Khavar, 
2017 [63] 
Androgen deprivation 
therapy and the risk of 
dementia in patients with 
prostate cancer 
Cohort study CPRD 1988-2016 All incident cases of dementia, 
including Alzheimer’s disease 
Yes None 
stated  
(refers to 
validation 
in previous 
studies) 
Patients with less 
than 1 year of 
history in CPRD 
were excluded 
// 
All patients had to 
have at least 1 
year of follow up 
data 
Excluded 
patients with 
previous 
diagnosis of any 
dementia 
- 
Lu, 2016 
[64] 
Gout and the risk of 
Alzheimer’s disease: a 
population-based, BMI-
matched cohort study 
Cohort study THIN 1995-2013 Alzheimer’s disease Yes Not in the 
original 
study; 
refers to a 
previous 
validation 
study 
None stated First diagnoses 
only 
- 
Mehta, 2017 
[65] 
Association of 
Hypoglycaemia With 
Subsequent Dementia in 
Older Patients With 
Type 2 Diabetes Mellitus 
Cohort study CPRD 2002-2012 Dementia defined by Read codes; 
used the same list of codes as 
another previous study. 
No None 
stated 
None stated Excluded 
patients with 
dementia 
diagnosed in the 
year prior to the 
index date 
- 
Mehta, 2016 
[66] 
Development and 
validation of the RxDx-
Dementia risk index to 
predict dementia in 
patients with type 2 
diabetes and 
hypertension 
 
Cohort study CPRD 2003-2012 Dementia, defined with a previously 
validated algorithm (refers to 
previous publication) 
No None 
stated 
None stated Considered 
incident cases 
only 
Sensitivity 
analysis include 
the definition of 
dementia as 
clinical diagnosis 
or drug 
prescription 
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Perera, 
2018 [67] 
Dementia prevalence 
and incidence in a 
federation of European 
Electronic Health 
Record databases: The 
European Medical 
Informatics Framework 
resource 
Cohort study THIN 2004-2012 ‘Codes that clearly indicated a 
dementia diagnosis, rather than 
those that were suggestive’ 
Yes No None stated Not applicable 
(calculated 
incidence 
estimates) 
- 
Qizilbash, 
2015 [68] 
BMI and risk of 
dementia in two million 
people over two 
decades: a retrospective 
cohort study 
Cohort study CPRD 1992-2007 “Patients were classified as having 
dementia if, any of the following 
terms were recorded during follow-
up: dementia, Alzheimer, Lewy body 
disease, Pick’s disease. Dementia 
recorded on a death certificate was 
also used.” 
No None 
stated 
None stated Excluded 
patients with 
dementia 
diagnosed in the 
year prior to the 
index date 
- 
Seshadri, 
2001 [69] 
Postmenopausal 
estrogen replacement 
therapy and the risk of 
Alzheimer disease 
Cohort study CPRD 1992-1998 First-time diagnosis of Alzheimer’s 
disease, senile dementia or 
presenile dementia 
No Yes 
 
Case 
review 
None stated Only first time 
diagnosis were 
included 
- 
Strom, 2015 
[70] 
Statin therapy and risk 
of acute memory 
impairment 
Nested case-
control study 
THIN 1987-2013 “The outcome for this study was the 
onset of acute, reversible memory 
impairment. Using Read codes 
Clinical Terms, version 2 (S), we 
sought codes with descriptions 
specifically pertaining to memory 
loss including amnesia, amnesia 
symptom, memory loss symptom, 
temporary loss of memory, short-
term memory loss, transient global 
amnesia, drug-induced amnestic 
syndrome, non-alcoholic amnestic 
syndrome, amnesia (retrograde), 
memory lapses, minor memory 
lapses, and mild memory 
disturbance.” 
Yes Yes 
 
GP 
questionna
ire for a 
random 
sample 
At least one 365 of 
registration with 
the GP practice 
Patients with 
codes for acute 
memory loss 
before the index 
date were 
excluded.  
Excluded 
patients 
diagnosed with 
dementia 
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Turner, 2016 
[46] 
Ongoing impairments 
following transient 
ischaemic attack: 
retrospective cohort 
study 
Matched-cohort 
study 
THIN 2009-2013 Read codes for diagnoses (such as 
28E0.00: mild cognitive impairment) 
and symptoms (such as 1B1A.12: 
memory loss symptom) related to 
overall cognitive impairment and 
impaired individual cognitive 
domains. ‘Cognitive impairment 
included memory, attention, spatial 
awareness, perception, apraxia and 
executive functioning impairments 
but not a diagnosis of dementia.’ 
Not 
provided in 
the original 
study but 
obtained 
from the 
authors 
None 
stated 
Patients alive and 
registered with the 
practice 1 month 
after the index 
date 
Excluded 
patients with 
fatigue recorded 
on the index 
date 
Dementia 
diagnosis were 
not included 
Walters, 
2016 [71] 
Predicting dementia risk 
in primary care: 
development and 
validation of the 
Dementia risk score 
using routinely collected 
data 
 THIN 2000-2011 Newly recorded dementia 
diagnoses, including Alzheimer’s 
disease, vascular dementia, and 
unspecified or mixed dementia.  
 
Excluding dementia associated with 
Parkinson’s disease, Lewy body 
dementia, Huntingdon, Picks, HIV 
and drug induced and alcohol-
related dementia.  
No but 
available 
upon 
request 
from the 
authors 
No Excluded patients 
with less than one 
year of follow up 
data 
// 
follow up restricted 
to a maximum of 5 
years 
Excluded 
patients with 
dementia, 
cognitive 
impairment or 
memory 
symptoms at 
baseline 
- 
CPRD – Clinical Practice Research Datalink; GP – general practitioner; HES – Hospital Episodes Statistics; THIN – The Health Improvement Network; ONS – Office for National 
Statistics. 
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Supplementary appendix 3, table 5. Main characteristics of the eligible studies: fatigue. 
Author, year of 
publication 
 
Title 
Study title Type of study Database(s) Study period 
(years) 
Outcome 
description 
List of codes 
available 
Validation of 
list of codes 
EHR-related 
eligibility 
criteria for the 
study 
//  
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Donegan, 2013 
[72] 
Bivalent human 
papillomavirus 
vaccine and the 
risk of fatigue 
syndromes in 
girls in the UK 
Ecological and 
self-controlled 
case series 
CPRD 2000-2011 and  
2008-2011 
Chronic fatigue 
syndrome 
including chronic 
fatigue 
syndrome/myalgic 
asthenia, post-
viral fatigue 
syndrome, 
fibromyalgia, and 
neurasthenia. 
 
No 
 
(Obtained from 
the authors) 
None stated None stated 
// 
At least one 
year of follow up 
available 
None stated Sensitivity 
analysis 
considered 
‘incident fatigue’ 
at the earliest 
recording of 
symptoms, 
referrals or 
diagnoses. 
Collin, 2017 [73] Trends in the 
incidence of 
chronic fatigue 
syndrome and 
fibromyalgia in 
the UK, 2001-
2013: a Clinical 
Practice 
Research 
Datalink Study 
Descriptive 
cohort study 
CPRD 2001-2013 Diagnoses of 
chronic fatigue 
syndrome, 
fibromyalgia, 
post-viral fatigue 
syndrome, or 
asthenia/ debility 
diagnosis or 
referral to a 
specialist service 
Yes None stated At least 12 
months of up to 
standard data 
Only new first 
ever diagnosis 
were considered 
Symptoms of 
fatigue were 
considered 
separately. 
Gallagher, 2004 
[74] 
Incidence of 
fatigue 
symptoms and 
diagnoses 
presenting in UK 
primary care 
from 1990 to 
2001. 
Descriptive 
cohort study 
CPRD 1990-2001 Read codes for 
diagnosis of 
chronic fatigue 
syndrome; post-
viral fatigue 
syndrome; 
asthenia/debility. 
Read codes for 
symptoms were 
classified 
separately. 
No 
 
(Stated that was 
available from 
the authors but 
could not be 
obtained) 
None stated Data prior to 
1990 not shown 
due to lower 
numbers than 
expected and 
being the first 
years of data 
collection of the 
database. 
Fatigue 
diagnosis was 
incident if there 
was no record of 
diagnoses in the 
previous year, 
with or without 
previous 
symptoms; 
symptoms were 
incident if there 
was no 
symptoms or 
diagnoses in the 
previous year. 
- 
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Hamilton, 2009 
[75] 
Risk markers for 
both chronic 
fatigue and 
irritable bowel 
syndromes: A 
prospective 
case-control 
study in primary 
care 
Nested case 
control study 
CPRD 1988-2001 List of diagnostic 
codes for post-
viral fatigue 
syndrome;  
chronic fatigue 
syndrome. 
No  
 
(refers to 
another 
publication) 
None stated Only patients 
with complete 
records for 3 
years prior to 
the index date 
were included 
Not applicable - 
Petersen, 2006 
[34] 
Risk and 
predictors of 
fatigue after 
infectious 
mononucleosis 
in a large 
primary-care 
cohort 
Nested case 
control cohort 
study 
CPRD 1989-2000 Read codes for 
diagnoses of 
post-viral debility, 
post-viral fatigue 
syndromes, post-
influenza debility 
and syndrome 
post-viral; 
symptoms of 
tiredness, 
malaise, lethargy, 
debility, and 
fatigue. 
No 
 
(Stated that was 
available from 
the authors but 
could not be 
obtained) 
None stated At least one 
year of data 
before diagnosis 
// 
At least one 
year of complete 
follow up after 
diagnosis 
 
Included 
patients who did 
not have fatigue 
in the year 
before onset  
- 
Turner, 2016 
[46] 
Ongoing 
impairments 
following 
transient 
ischaemic 
attack: 
retrospective 
cohort study 
Nested case-
cohort study 
THIN 2009-2013 First consultation 
after the index 
date with a Read 
code for 
symptoms or 
diagnosis of 
fatigue 
No 
 
Obtained from 
the authors 
None stated Practice with at 
least one year of 
up to standard 
data, and 
patients 
registered for at 
least one year 
with the 
practice. 
// 
Patient alive and 
registered with 
the practice 1 
month after 
index 
Excluded 
patients with 
fatigue recorded 
on the index 
date. 
- 
CPRD – Clinical Practice Research Datalink; THIN – The Health Improvement Network. 
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Supplementary appendix 3, table 6. Main characteristics of the eligible studies: pain. 
Author, 
year of 
publication 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation of 
list of codes 
EHR-related 
eligibility 
criteria for the 
study 
//  
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Becker, 
2007 [76] 
Migraine incidence, 
comorbidity and health 
resource utilization in 
the UK 
 
Nested case-
control study 
CPRD 1994-2001 Migraine diagnosis No Yes 
 
GP 
questionnaire 
None stated First-time 
diagnosis only 
- 
Campbell, 
2015 [77] 
In sickness and in 
health: A cross-sectional 
analysis of concordance 
for musculoskeletal pain 
in 13,507 couples 
Descriptive CiPCA 2005-2006 Widespread body pain:  
“All relevant codes were formed into 
the five most common consultation 
body regions (back, knee, neck, 
shoulder, foot), as well as codes for 
osteoarthritis consultations. A further 
category of ‘any musculoskeletal’ 
consultations were formed inclusive 
of the above body regions and 
conditions, as well as consultations 
for unspecified pain (e.g. arthralgia), 
widespread pain conditions and 
other single body regions where the 
proportion of consultations were too 
few to perform meaningful separate 
analysis (e.g. head, arm, elbow, 
wrist, hand, hip, pelvis, thigh and 
buttock).” 
Yes None stated None stated None stated - 
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Hall, 2006 
[78] 
Epidemiology and 
treatment of neurophatic 
pain: the UK primary 
care perspective 
 
Descriptive CPRD 1992-2002 “A post-herpetic neuralgia record 
was a specific term for post-herpetic 
neuralgia or an acute herpes zoster 
term plus either neuropathy, or 
neuropathic pain, 3-6 months after 
the first acute herpes zoster entry. A 
trigeminal neuralgia record had a 
specific term for this diagnosis. 
Phantom limb pain was defined as a 
specific term or a term for 
amputation plus either a neuropathy 
or neuropathic pain record 3–24 
months after the first amputation 
code. Patients were included in the 
painful diabetic neuropathy cohort if 
their record contained a specific 
term; a term for diabetic neuropathy 
with a prescription for a treatment for 
pain current at the date of diagnosis; 
a record of diabetes and neuropathic 
pain or record of diabetes and both 
neuralgia and a treatment for pain 
current on the date of the neuralgia 
code.” 
 
No None stated At least year of 
up to standard 
data 
None stated - 
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Hall, 2013 
[79] 
An observational 
descriptive study of the 
epidemiology and 
treatment of neuropathic 
pain in a UK general 
population 
Cohort study, 
descriptive 
CPRD 2005-2010 “Five neuropathic pain cohorts (post-
herpetic neuralgia, painful diabetic 
neuropathy, phantom limb pain, 
neuropathic back pain and 
neuropathic postoperative pain) 
were identified from (S) a single 
specific Read code, or a 
combination of Read and therapy 
codes as specified in a case 
definition. Postherpetic neuralgia 
was defined as a specific code for 
post-herpetic neuralgia, or a code for 
acute zoster plus either a code for 
neuropathy, or neuropathic pain, 
between three and six months after 
the first acute zoster entry. Phantom 
limb pain (PLP) was defined as a 
specific code, or a code for 
amputation plus either a code for 
neuropathy or neuropathic pain 
between three and twenty-four 
months after the first amputation 
code. The painful diabetic 
neuropathy cohort included patients 
with a specific code for painful 
diabetic neuropathy; those with a 
code for diabetes and a general 
code for neuropathic pain and a third 
group with a code for diabetic 
neuropathy (or diabetes and 
neuralgia) with a prescription for a 
neuropathic pain treatment which 
was initiated within 28 days of the 
date of the neuropathy/ neuralgia 
code.” 
No Yes 
 
GP 
questionnaire
s 
At least of 1 
year of data of 
good quality for 
research 
 None stated 
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Mansfield, 
2017 [80] 
Identifying patients with 
chronic widespread pain 
in primary care 
Cross sectional  CiPCA 2005-2009 (A) Recurrent region pain, define as: 
“In a period of 5 consecutive years, 
a patient fulfils all of 1-4: 
1. At least 1 consultation for a 
musculoskeletal complaint in the 
axial skeleton (neck and back); 
2. At least 1 consultation for an 
upper- or lower-limb complaint; 
3. At least 1 consultation for a 
regional musculoskeletal complaint 
in each of 3 separate years; 
4. At least 4 consultations for 
regional musculoskeletal complaints 
during the 5-year period.” 
 
(B) “Non specific generalized pain 
conditions, including fibromyalgia, 
fibrositis, rheumatism, myalgia, 
arthralgia, and polyalgia” 
 
Yes Yes Patients not 
registered with 
the practice for 
the full 5-year 
period were 
excluded 
Not applicable 
(cross sectional 
analysis) 
- 
Ruigomez, 
2006 [81] 
Chest pain in general 
practice: incidence, 
comorbidity and 
mortality 
Case control 
study 
CPRD 1996 Chest pain: 
Codes for chest pain that did specify 
the type or location of the symptom.  
Yes None stated Registered with 
the GP for at 
least 2 years  
// 
At least one 
entry in the 
records in the 
last 3 years 
before the study 
 
Excluded 
patients with 
history of pain 
the past 2 years 
- 
Wallander, 
2007 [82] 
Unspecified abdominal 
pain in primary care: 
The role of 
gastrointestinal 
morbidity 
Matched cohort 
study 
CPRD Before 
1996 
Abdominal pain: 
Diagnosis of abdominal pain 
Yes None stated At least one 
entry to the data 
in the three 
years prior to 
the study start. 
Patients were 
excluded if they 
had a record of 
abdominal pain 
of any 
abdominal site 
or type in the 2 
years before the 
study started. 
- 
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Zondervan, 
1999 [83] 
Prevalence and 
incidence of chronic 
pelvic pain in primary 
care: evidence from a 
national general practice 
database 
Cohort study Mediplus UK 
primary care 
database 
 
1991-1995 Chronic pelvic pain: pain in the lower 
abdominal region persisting for at 
least six months.  
 
“Episode of chronic pelvic pain: 
pelvic pain on two or more contacts, 
with at least six months (≥ 183 days) 
between the first and the last contact 
but with no period of more than one 
year (> 365 days) without a pelvic 
pain contact. An episode of chronic 
pelvic pain was defined as starting 
six months after the first contact and 
finishing at the contact preceding a 
pain-free, one-year interval (if any).” 
 
“Excluded pain due to malignancy; 
chronic inflammatory and other 
defined bowel diseases such as 
Crohn’s, coeliac disease, ulcerative 
colitis; acute conditions verified by 
having surgery such as 
appendicectomy, cholecystectomy; 
or pregnancy. Women with pelvic 
pain occurring only during 
menstruation (dysmenorrhoea) or 
sexual intercourse (dyspareunia) 
were also excluded.” 
No None stated None stated Not applicable. 
Monthly 
incidence 
estimated as the 
number of new 
episodes in a 
given month as 
a proportion of 
- 
CiPCA - The Consultations in Primary Care Archive; CPRD – Clinical Practice Research Datalink;. NSAIDS - Nonsteroidal anti-inflammatory drug. 
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Supplementary appendix 3, table 7. Main characteristics of the eligible studies: sexual dysfunction. 
Author, 
year of 
publication 
 
Title 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
// 
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Blumentals, 
2003 [84] 
Antihypertensive 
treatment and erectile 
dysfunction in a cohort 
of type II diabetes 
patients 
Nested case-
control study 
CPRD 1987-2001 Erectile dysfunction, ascertained 
from the diagnosis codes, not further 
specified 
No None 
stated 
None stated None stated - 
Hagberg, 
2016 [85] 
Risk of erectile 
dysfunction associated 
with use of 5-alpha 
reductase inhibitors for 
benign prostatic 
hyperplasia or alopecia: 
population based 
studies using the Clinical 
Practice Research 
Datalink 
Nested case 
control study 
CPRD 1992-2011 Erectile dysfunction: “diagnosis of 
erectile dysfunction or impotence, 
prescription for a phosphodiesterase 
type 5 inhibitor (eg, sildenafil, 
tadalafil, or vardenafil) where the 
strength and quantity prescribed was 
indicated for treatment of erectile 
dysfunction, or record of procedures 
for treatment of erectile dysfunction 
(eg, penile prosthesis, penile 
injection, or other operations for 
treatment of erectile dysfunction).” 
 
Non-erectile dysfunction: including 
ejaculatory disorder, psychosexual 
dysfunction, or low libido 
 
No None 
stated 
At least 3 years of 
history before the 
cohort entry date;  
Incident cases 
considered after 
the index date. 
- 
Khan, 2011 
[62] 
Long-term health 
outcomes in a British 
cohort of breast, 
colorectal and prostate 
cancer survivors: a 
database study 
Cohort study CPRD 2003-2006 Erectile dysfunction: “new 
prescriptions for sildenafil (Viagra, 
Pfizer, NY, United States), 
apomorphone hydrochloride, 
vardenafil (Levitra, Bayer Healthcare 
Pharmaceuticals, New Haven, USA), 
alprostadil (an injectable treatment) 
and tadalafil (Cialis, Lilly, USA)” 
No None 
stated 
None stated Excluded 
patients with 
erectile 
dysfunction 
recorded before 
the index date 
- 
Morant, 
2008 [86] 
Increased sexual 
dysfunction in men with 
storage and voiding 
lower urinary tract 
symptoms 
 
Cross-sectional 
analysis 
THIN 2000-2007 Male sexual dysfunction Yes None 
stated 
None stated None stated - 
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Schlesinger, 
2018 [87] 
Gout and the Risk of 
Incident Erectile 
Dysfunction: A Body 
Mass Index-matched 
Population-based Study 
Cohort study THIN 1995-2012 Erectile dysfunction noted by the 
presence of the Read code E227311 
Yes None 
stated 
At least one year 
of registration with 
the practice before 
the index date 
Excluded 
prevalent cases 
at baseline 
- 
Sultan, 2017 
[88] 
Gout and subsequent 
erectile dysfunction: a 
population-based cohort 
study from England 
Cohort study CPRD, HES 1998-2004 Erectile dysfunction, ascertained 
from the medical codes, not further 
specified 
Yes None 
stated 
At least 1 year of 
follow up data 
Only incident 
cases after the 
index date were 
considered; 
cases in the first 
6 months of 
registration were 
considered 
prevalent. 
- 
CPRD – Clinical Practice Research Datalink; HES – Hospital Episodes Statistics; THIN – The Health Improvement Network. 
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Supplementary appendix 3, table 8. Main characteristics of the eligible studies: sleep disorder. 
Author, 
year of 
publication 
 
Title 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
// 
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
Notes 
Roddy, 2013 
[89] 
The association of gout 
with sleep disorders: A 
cross-sectional study in 
primary care 
 
Matched cohort 
study 
CiPCA 
and 
PiPCA 
2001-2008 Read codes for sleep disorders, 
excluding codes for sleep apnoea 
which were classified separately 
Yes None 
stated 
None stated None stated - 
Wallander, 
2007 [90] 
Morbidity associated 
with sleep disorders in 
primary care: A 
longitudinal cohort study 
Cohort study CPRD 1996 Read codes for sleep disorder 
including insomnia, hypersomnia, 
and sleep disturbance 
Yes None 
stated 
Registered with a 
general 
practitioner for at 
least 2 years and 
having at least 1 
entry in CPRD in 
the previous 3 
years. 
 
Patients with a 
consultation for 
sleep disorders 
during the 2 
years before the 
start of the study 
were excluded. 
- 
CPRD – Clinical Practice Research Datalink; CiPCA - The Consultations in Primary Care Archive; PiPCA - The Prescriptions in Primary Care Archive. 
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Supplementary appendix 3, table 9. Main characteristics of the eligible studies: fatal and non-fatal self-harm. 
Author, 
year of 
publication 
 
Title 
Study title Type of study Database(s) Study 
period 
(years) 
Outcome description List of 
codes 
available 
Validation 
of list of 
codes 
EHR-related 
eligibility criteria 
for the study 
// 
Follow up 
requirements 
Handling of 
outcomes 
occurring prior 
to exposure 
(applicable to 
self-harm only) 
Notes 
Andersohn, 
2010 [91] 
Use of antiepileptic 
drugs in epilepsy and 
the risk of self-harm or 
suicidal behaviour 
Nested case-
control study 
 
CPRD 1990-2005 “Potential cases were identified 
using predefined medical codes of 
self-harm (i.e., without a clear 
suicidal intention [intentional self-
harm]) or suicidal behaviour (i.e., 
with a clear suicidal intention 
[attempted suicide]). Patients who 
died were also considered as 
potential cases if suicidal thoughts 
were recorded within 4 weeks before 
death.” 
Yes Yes, 
record 
review 
At least one year 
of data with the 
GP practice 
Models adjusted 
for history of 
self-harm at 
baseline 
In an additional 
analysis, the 
patients with 
codes for self-
harm without 
explicitly 
mention to 
suicidal 
behaviour were 
excluded. 
Arana, 2010 
[92] 
Suicide-related events in 
patients treated with 
antiepileptic drugs 
Cohort study THIN 1988-2008 “Cases of suicide-related events 
were based on codes for suicide, 
attempted suicide, and intentional 
self-inflicted injuries plus suicide. A 
completed suicide was defined as a 
code for suicidality followed by a 
code for death in the following month 
and a final date of any administrative 
activity in the database or 
disenrollment within 6 months after 
the suicidality code. If the 
disenrollment date occurred more 
than 6 months after a suicidality 
code, we reviewed the patient’s 
profile. Patients with a last medical 
or other health related code that was 
recorded within 1 month after the 
suicide date were also considered to 
have completed suicide.” 
 
No Yes 
 
GP 
questionna
ire, record 
and death 
certificate 
review 
Patients were 
eligible if they 
were enrolled with 
a clinical practice 
for at least 6 
months during the 
study period 
Patients with 
personal or 
family history of 
suicide attempt 
were excluded 
- 
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Carr, 2016 
[93] 
The epidemiology of 
self-harm in a UK-wide 
primary care patient 
cohort, 2001-2013 
 
Descriptive 
cohort study 
CPRD 2001-2013 “Read codes incorporating all cases 
across the spectrum from milder 
forms of non-suicidal behaviour 
through to near-fatal suicide 
attempts (S) We excluded codes 
that referred only to thoughts of self-
harm or suicidal ideation and 
alcohol-related codes, unless intent 
to actively harm oneself was 
specified. 
Yes None 
stated 
None stated None stated None stated 
Carr, 2017 
[94] 
Premature Death 
Among Primary Care 
Patients With a History 
of Self-Harm 
Cohort study CPRD 
ONS 
2001-2013 Suicide, ascertained with ICD-10 
codes in the ONS mortality data; 
including open verdicts. 
Yes Not 
applicable 
At least one year 
of registration with 
the practice prior 
to the index date; 
Not applicable.  - 
Coupland, 
2011 [95] 
Antidepressant use and 
risk of adverse 
outcomes in older 
people: Population 
based cohort study 
Cohort study QResearch, 
ONS 
1996-2007 Read codes for attempted suicide or 
self-harm, not further specified 
No None 
stated 
At least one year 
of registration with 
the practice prior 
to the index date; 
None stated Suicide was also 
an outcome, but 
data for this 
outcome was 
not analysed 
due to small 
numbers.  
Coupland, 
2015 [96] 
Antidepressant use and 
risk of suicide and 
attempted suicide or 
self-harm in people aged 
20 to 64: cohort study 
using a primary care 
database 
Cohort study QResearch, 
ONS 
2000-2011 “code for suicide or an open verdict 
in their linked death certificate, or 
patients who had a Read code for 
attempted suicide or self-harm who 
died within 30 days. 
No 
 
(refers to 
codes used 
in other 
studies 
None 
stated 
At least one year 
of registration with 
the practice prior 
to the index date; 
// 
Most analysis 
restricted to the 
first 5 years of 
follow up. 
Excluded 
patients with a 
previous 
attempted 
suicide or self-
harm event 
recorded at 
baseline 
- 
Fardet, 2012 
[2] 
Suicidal behavior and 
severe neuropsychiatric 
disorders following 
glucocorticoid therapy in 
primary care  
Cohort study THIN 1990-2008 Cases of suicide or suicide attempt No Yes 
 
Review of 
death 
certificates 
≥6 months of 
registration with 
the primary care 
practice 
Hazards ratios 
adjusted for past 
history of 
neuropsychiatric 
disorders 
(yes/no) 
Outcome was 
eligible if there 
was no record of 
the outcome in 
the previous 6 
months 
Donovan, 
1996 [97] 
The use of the General 
Practice Research 
Database (GPRD) to 
examine potential links 
between antidepressant 
medication and the 
incidence of suicide 
Cohort study CPRD 1988-1993 Suicide, not further specified No None 
stated 
None stated Prior suicidal 
history 
considered as a 
risk factor for 
suicide 
- 
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Doyle, 2016 
[98] 
Suicide risk in primary 
care patients diagnosed 
with a personality 
disorder: a nested case 
control study 
Nested case 
control study 
CPRD, ONS 2002-2011 Suicides and open verdicts 
ascertained via linkage to ONS 
mortality data 
Yes 
 
(ICD-10 
codes) 
Not 
applicable 
 
(Data 
linked to 
the gold-
standard) 
At least one year 
of up to standard 
CPRD data 
Not applicable  - 
Gao, 2013 
[99] 
Association between 
body mass index and 
suicide, and suicide 
attempt among British 
adults: The health 
improvement network 
database 
Cohort study 
 
THIN 2000-2007 Suicide: “defined in two ways (S): 1) 
patients with a Read code of suicide 
attempt confirmed by death within 3 
months or 2) patients who did not 
have a Read code of suicide 
attempt, but whose cause of death 
might be suicide. To identify patients 
using the second approach, we first 
searched for all deaths (S) the 
cause of death was reviewed. In 
addition, free text records were 
searched for potential suicide as 
cause of death, including suicide, 
deliberate drug overdose or self-
harm, self-inflicted injuries, 
poisoning, asphyxiation, trauma, and 
acute or multiple organ failure. 
Death certificates for these patients 
were requested for the final verdict 
of the cause of death. 
 
Suicide attempt: “identified using the 
Read codes for suicide and then by 
confirming that the patient was still 
alive for at least 3 months from the 
time of the event.” 
 
No None 
stated 
None stated None stated - 
Gunnell, 
2009 [19] 
Varenicline and suicidal 
behaviour: a cohort 
study based on data 
from the General 
Practice Research 
Database 
Cohort study CPRD 2006-2008 OXMIS and Read terms for fatal and 
non-fatal self-harm.  
No Yes 
 
Record 
review 
At least 1 years of 
CPRD records 
before index date; 
Considered the 
potential 
confounding 
effect of 
previous self-
harm or suicidal 
thoughts in 
analysis.  
 
- 
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Hall, 2009 
[100] 
Validation of death and 
suicide recording on the 
THIN UK primary care 
database 
Validation study THIN 2002-2004 “Coded and free text records were 
searched to identify any entry for 
suicide or a medical cause of death 
which might indicate suicide, 
including trauma, poisoning, 
overdose, asphyxiation, acute or 
multiple organ failure or a 
suggestion that death was 
intentional. An electronic record of 
suicide was accepted.” 
 
Yes Yes 
 
(Validation 
study, 
record 
review) 
None stated Not applicable 
(validation 
study) 
- 
Hagberg, 
2016 [21] 
Incidence rates of 
suicidal behaviors and 
treated depression in 
patients with and without 
psoriatic arthritis using 
the Clinical Practice 
Research Datalink 
Cohort study CPRD 1998-2012 Suicidal behaviours, defined as: 
“diagnosis of suicidal ideation, 
suicide attempt, and/or suicide 
recorded after the cohort entry date. 
(S) If a patient had a code for 
suicide, but had not died, the event 
was classified as a suicide attempt. 
Suicidal ideation, attempts, and 
suicide were considered separately; 
thus a patient may have been 
included in more than one analysis. 
No Yes, 
record 
review 
At least one year 
of registration with 
the practice prior 
to the index date 
Patients with 
suicidal 
behaviors were 
included 
“because 
patients could 
recover from 
suicidal 
behaviors with 
treatment or 
consultation.” 
 
- 
Hayes, 2016 
[101] 
Self-harm, Unintentional 
Injury, and Suicide in 
Bipolar Disorder During 
Maintenance Mood 
Stabilizer Treatment: A 
UK Population-Based 
Electronic Health 
Records Study 
Cohort study THIN 1995-2013 “emergency department or primary 
care attendance for self-harm during 
the period of drug exposure and the 
3 months afterward. This outcome 
included Read codes for intentional 
poisoning, intentional self injurious 
behavior, and self-harm acts of 
uncertain intent. (S) Secondary 
outcomes were unintentional injury 
(eg, falls or motor vehicle crashes) 
seen in primary or secondary care 
and a record of the patient’s suicide 
during this period” 
No Refers to 
previous 
validation 
of the list 
of codes 
None stated Not applicable 
(the outcome 
was diagnoses 
during the 
exposure period) 
- 
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Hesdorffer, 
2012 [4] 
Epilepsy, suicidality, and 
psychiatric disorders: a 
bidirectional association 
Cohort study CPRD 1990-2008 Read codes for suicidality including 
codes for attempted suicide and 
completed suicide. 
No None 
stated 
At least 3 years of 
data before the 
index date, and at 
least 1 code for a 
medical or drug 
code in the 6 
months before the 
index 
// 
At least 1 day of 
data after index 
date; follow up 
duration: 3 years 
after index date 
 
Excluded 
subjects with a 
record of the 
outcome before 
the study date. 
- 
Hesdorffer, 
2016 [102] 
Occurrence and 
Recurrence of 
Attempted Suicide 
Among People With 
Epilepsy 
Cohort study CPRD 1988-2013 Diagnoses of attempted suicide 
identified with Read codes, not 
further specified.  
 
Suicide attempts divided into 
incident or recurrent.  
No None 
stated 
At least 6 month of 
complete records 
before the index 
date and ≥1 
medical or drug 
codes for a 
condition other 
than epilepsy in 
the 6 months 
before the index 
date. 
// 
At least 1 day of 
data post index 
date 
None stated - 
Haste, 1998 
[103] 
Potential for suicide 
prevention in primary 
care? An analysis of 
factors associated with 
suicide.  
Matched cohort 
study 
CPRD 1991-1993 Suicide: “were identified from the 
database in two ways: 1. Patients 
with a record of suicide in the notes; 
and 2. Patients who did not have a 
record of suicide, but whose record 
of cause of death on the database 
suggested that suicide might be 
possible. These causes included 
death from carbon monoxide 
poisoning (excluding accidental 
poisoning), hanging, suicidal or 
accidental overdose, and reference 
to self-inflicted injury. (S) Cases 
where the verdict was open were 
included.” 
No Yes 
 
GP 
confirmatio
n, review 
of death 
certificates 
None stated Not applicable 
(cases of 
completed 
suicide only) 
- 
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Jick, 1995 
[104] 
Antidepressants and 
suicide 
Cohort study CPRD 1988-1993 “Cases of suicide were identified 
from the computer record from 
among all the study subjects who 
died. When the cause of death was 
recorded as suicide or was 
considered to be uncertain, we 
obtained further information from the 
general practitioner and the death 
certificate to determine the final 
diagnosis and means of committing 
suicide.” 
No Yes, GP 
questionna
ire 
At least 6 month of 
registration with 
the practice prior 
to the index date 
Not applicable 
(cases of 
completed 
suicide only) 
- 
Jick, 1998 
[105] 
A study of the relation of 
exposure to quinolones 
and suicidal behaviour 
Nested case 
control study 
CPRD 1991-1995 Three case groups:  
1) committed suicide; 
2) had a diagnosis of attempted 
suicide; 
3) had a diagnosis of suicidal 
ideation. 
 
“If the subject had more than one 
case diagnosis during the study 
period, only the first such diagnosis 
was considered.” 
 
Yes None 
stated 
>18 months of 
information on 
drugs prescribed 
and diagnoses 
recorded prior to 
the index. 
None stated - 
Jick, 2000 
[106] 
Isotretinoin use and risk 
of depression, psychotic 
symptoms, suicide, and 
attempted suicide 
Cohort study CPRD ? Suicide and inpatient or outpatient 
code for attempted suicide 
Yes None 
stated 
Between 5 years 
and 6 months of 
clinical records 
before the index 
date 
// 
At least 1 year of 
records post index 
date 
 
Controlled for 
history of 
attempted 
suicide 
- 
Jick, 2004 
[107] 
Antidepressants and risk 
of suicidal behaviours 
Cohort study CPRD 1993-1999 Nonfatal suicidal behaviour: “Cases 
were those who (1) had a 
first-time recorded diagnosis of 
nonfatal suicidal ideation (S) or 
attempted suicide” 
 
Suicide: patients who committed 
suicide, not further specified. 
 
Yes None 
stated 
At least 2 years of 
registration with 
the practice prior 
to the index date 
None stated  - 
Jick, 2009 
[108] 
Rate of suicide in 
patients taking 
montelukast 
Cohort study CPRD 1998-2007 ‘computer recorded diagnosis of 
suicide’ 
No None 
stated 
None stated None stated  
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Kurd, 2010 
[6] 
The risk of depression, 
anxiety, and suicidality 
in patients with 
psoriasis: A population-
based cohort study 
Matched cohort 
study 
CPRD 1987-2002 ‘Suicidality was defined as diagnosis 
of suicidal ideation, suicide attempt, 
or suicide’, defined by diagnostic 
Read or OXMIS codes. 
No 
 
Refers to 
diagnostic 
codes used 
in other 
publications. 
None 
stated 
None stated In sensitivity 
analysis, the 
patients with a 
diagnosis of the 
outcome 
measured prior 
to or within six 
months of the 
index date were 
excluded. 
- 
Kotz, 2015 
[28] 
Cardiovascular and 
neuropsychiatric risks of 
varenicline: a 
retrospective cohort 
study 
Cohort study QResearch 2007-2012 Fatal and non-fatal self-harm, not 
further specified  
None stated None 
stated 
Registered for >12 
months before 
data extraction 
// 
Follow up duration 
6 months 
History of 
neuropsychiatric 
events 
considered as 
confounders 
- 
Kotz, 2017 
[27] 
Cardiovascular and 
neuropsychiatric risks of 
varenicline and 
bupropion in smokers 
with chronic obstructive 
pulmonary disease 
Cohort study QResearch 2001-2012 Fatal and non-fatal self-harm, not 
further specified 
None stated None 
stated 
None stated 
// 
Follow up duration 
6 months 
History of 
neuropsychiatric 
events 
considered as 
confounders 
- 
Lalmohame
d, 2012 
[109] 
Causes of death in 
patients with multiple 
sclerosis and matched 
referent subjects: A 
population-based cohort 
study 
Cohort study CPRD  
HES 
ONS 
mortality 
2001-2008 Death by accident or suicide 
ascertained in the ONS mortality 
database 
Yes 
(ICD-10 
codes) 
Not 
applicable  
(ONS 
mortality 
database, 
ICD-10 
codes) 
≥1 year of data 
available before 
index date 
None stated - 
Martinez, 
2005 [110] 
Antidepressant 
treatment and the risk of 
fatal and non-fatal self 
harm in first episode of 
depression: nested 
case-control study 
Nested case 
control study 
CPRD 1995-2001 Non-fatal self-harm (drug overdose, 
deliberate self-laceration, poisoning, 
and non-fatal suicide attempts using 
other methods) 
 
Suicide, identified by OXMIS and 
Read codes 
No 
 
Obtained 
from the 
authors 
Yes,  
 
Review of 
the death 
certificates 
and free 
text entries 
≥1 year of data 
available before 
index date 
 
Model adjusted 
for history of 
non-fatal self-
harm  
“People with an 
episode of non-
fatal self harm 
were not 
censored in 
analyses with 
suicide as the 
end point.” 
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Meier, 2004 
[9] 
The Risk of Severe 
Depression, Psychosis 
or Panic Attacks with 
Prophylactic 
Antimalarials 
Cohort study CPRD 1990-1999 Suicide defined by OXMIS and/or 
ICD-8 codes 
No Yes 
 
‘reviewed 
a list of all 
cases to 
determine 
inclusion/ 
exclusion’ 
≥1 year of data 
available before 
index date and 
“some GPRD 
activity (diagnoses 
or prescriptions) 
recorded after the 
index date” 
// 
Patients were 
censored 18 
months after 
exposure date 
 
Not applicable 
(suicide as an 
outcome only) 
- 
Mines, 2005 
[111] 
Prevalence of risk 
factors for suicide in 
patients prescribed 
venlafaxine, fluoxetine, 
and citalopram 
 
Cohort study CPRD 1995-2002 Suicidal behaviour in the year prior 
to index date 
Yes None 
stated 
≥1 year of data 
available 
None stated - 
Osborn, 
2008 [112] 
Suicide and severe 
mental illnesses. Cohort 
study within the UK 
general practice 
research database 
Matched cohort 
study 
 
CPRD 1987-2002 Suicide, not further specified No None 
stated 
None stated None stated  
Rubino, 
2007 [113] 
Risk of suicide during 
treatment with 
venlafaxine, citalopram, 
fluoxetine, and 
dothiepin: retrospective 
cohort study 
Cohort study CPRD 1995-2005 Completed suicide: coding for death 
associated with mention of suicide in 
free text or by code for suicide in the 
medical record and a statement of 
death in the administrative record 
(30 days either way);  
 
First attempted suicide (non-fatal 
event). 
Yes Yes 
 
Free text 
search 
At least one year 
of registration with 
the practice prior 
to the index date 
Suicide attempts 
considered as a 
confounder in 
the models 
“excluded 
records that at 
the review of 
free text notes 
did not seem to 
represent 
attempted 
suicide - for 
example, 
unintentional 
overdose or self 
harm without 
suicidal intent” 
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Schneider, 
2010 [37] 
COPD and the risk of 
depression 
Cohort study CPRD 1995-2005 ‘incident suicide or suicidal ideation’, 
not further specified 
No 
 
Obtained 
from the 
authors 
None 
stated 
Patients with less 
than 3 years of 
active recording 
history prior to the 
date of the COPD 
diagnosis were 
excluded;  
 
Patients with 
previous history 
of depression, 
suicide, suicidal 
ideation, etc., 
prior to the index 
date were 
excluded 
- 
Schuerch, 
2016 [114] 
Impact of varying 
outcomes and 
definitions of suicidality 
on the associations of 
antiepileptic drugs and 
suicidality: comparisons 
from UK Clinical 
Practice Research 
Datalink (CPRD) and 
Danish national 
registries (DNR) 
 
Validation study CPRD 
HES 
ONS 
1996-2009 Suicidal ideation/intent: 
“Recorded medical terms from the 
clinical and referral module, plus 
reasons for transfer out of the 
general practices to identify patients 
with one of these outcomes” 
 
Suicide attempt: 
“Recorded medical terms from the 
clinical and referral module, plus 
reasons for transfer out of the GP-
practice to identify patients with one 
of these outcomes from CPRD.” 
 
Completed suicide: 
“Term of suicidal attempt or ideation 
occurring simultaneously with a 
recording of death (+/- 4 weeks), 
death recorded as reason for leaving 
the practice (registering out), and a 
final date of any administrative 
activity in the database of 
disenrollment within six months after 
suicidality code.” 
 
Yes Yes 
(validation 
study) 
At least 6 months 
of data before the 
index date 
// 
 
Patients with 
history of suicide 
attempts, self-
harm or suicidal 
ideation/intent in 
the 6 months 
before index 
were excluded  
- 
Thomas, 
2013 [40] 
Smoking cessation 
treatment and risk of 
depression, suicide, and 
self harm in the Clinical 
Practice Research 
Datalink: prospective 
cohort study 
Nested case-
control study 
 
CPRD, HES 
and ONS 
mortality 
data 
2006-2011 Incidence fatal and non-fatal self-
harm (as measured by death from 
suicide in the ONS mortality 
database) and hospital admission for 
self-harm (as recorded in the HES 
database). Includes open verdicts.  
Yes for 
ONS 
database; 
no for Read 
codes. 
None 
stated 
At least one year 
of registration with 
the practice prior 
to the index date 
Previous self-
harm considered 
as a potential 
confounder in 
analysis 
- 
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Thomas, 
2013 [115] 
Validation of suicide and 
self-harm records in the 
Clinical Practice 
Research Datalink 
Validation study CPRD, HES, 
ONS 
mortality 
data, and 
Multicentre 
study of self-
harm 
1998-2010 “Cases of suicide and self-harm (the 
‘events’) were identified by 
extracting all records with Read 
codes for suicide, attempted suicide 
and self-harm (S). Given that 
suicide-related Read codes may 
refer to both fatal and nonfatal 
suicide attempts, completed suicides 
within the CPRD were identified 
using the conventional CPRD 
approach of linking patient deaths to 
Read codes for suicide that were 
recorded within 95 days of the 
CPRD derived death dates” 
Yes Yes  
 
(Validation 
study) 
Registered with a 
practice 
contributing with 
up to standard 
data, and having 
acceptable 
records for 
research. 
Not applicable 
(descriptive 
study on the 
incidence of self-
harm) 
- 
Tyrrell, 2016 
[116] 
Changes in poisonings 
among adolescents in 
the UK between 1992 
and 2012: a population 
based cohort study 
Cohort study THIN 1992-2012 “poisonings [categorised] as 
intentional, unintentional, unknown 
intent or alcohol related. Where 
Read codes explicitly described the 
intent using the words ‘deliberate’ or 
‘intentional’ (intentional); ‘accidental’ 
(unintentional); and ‘unknown’ or 
‘unspecified’ (unknown) then they 
were classified as such. The words 
‘suicide’, ‘self-inflicted’, ‘self-
poisoning’ or ‘overdose’ were also 
used to categorise a poisoning as 
intentional, unless otherwise 
specified.” 
No None 
stated 
None stated First poisoning 
within the 
observation 
period 
Multiple events 
occurring in the 
same individual 
within a month 
were counted as 
one event only 
Webb, 2012 
[117] 
Risk of self-harm in 
physically ill patients in 
UK primary care 
Nested case 
control study 
CPRD 2001-2008 Suicidal ideation, defined by Read 
coding descriptions that included the 
terms ‘suicide and self-inflicted,’ 
‘suicide and self-harm,’ ‘para-
suicide’ or ‘attempted suicide.’ 
Cases that died following the code 
were excluded.  
 
No None 
stated 
At least two years 
of up to standard 
CPRD data 
None stated - 
Webb, 2012 
[118] 
Suicide risk in primary 
care patients with major 
physical diseases: A 
case-control study 
Nested case 
control study 
CPRD and 
ONS 
mortality 
data 
2001-2008 Suicides as mentioned in the death 
certificate, and open verdicts. 
Yes Not 
applicable 
(ONS 
mortality 
data) 
At least two years 
of up to standard 
CPRD data 
Not applicable 
(study of suicide 
only) 
- 
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Wijlaars, 
2013 [119] 
Suicide-related events in 
young people following 
prescription of SSRIs 
and other 
antidepressants: A self-
controlled case series 
analysis 
 
Nested case 
control study 
THIN 1995-2009 Suicide attempts, suicidal ideation 
and completed suicide.  
 
Completed suicides: “Read codes 
that were confirmed by a date of 
death within 2 weeks of the suicide 
event date. We searched a cause of 
death, if available.” 
Excluded cases classified as open 
verdicts.  
No  
 
Refers to a 
previous list, 
that was 
updated for 
the study 
Yes  
 
Record 
review 
At least 6 months 
of up to standard 
CPRD data 
Accounted for in 
analysis 
- 
Windfuhr, 
2016 [120] 
Suicide risk linked with 
clinical consultation 
frequency, psychiatric 
diagnoses and 
psychotropic medication 
prescribing in a national 
study of primary-care 
patients 
 
Nested case-
control study 
CPRD and 
ONS 
mortality 
data 
2002-2011 International Classification 
of Disease version 10 (ICD-10) 
codes X60-84, Y10-34 
(excluding Y33.9), Y87.0, Y87.2 
 
Includes open verdicts 
Yes Not 
applicable 
(ONS 
mortality 
data) 
≥1 year of data 
available after up 
to standard data 
None stated - 
Yang, 2003 
[44] 
Lipid-lowering drugs and 
the risk of depression 
and suicidal behaviour 
Matched cohort 
study 
CPRD 1991 
onwards 
Suicidal behaviour, ideation suicidal, 
suicidal plan, suicidal thoughts, 
attempted suicide, threat suicide, 
suicidal drug overdose, drug 
overdose, para suicide and suicide.  
Yes No 
 
(refers to 
previous 
studies 
assessing 
suitability 
of the 
records) 
Patients with 
history of suicidal 
behaviour prior to 
study start were 
excluded 
None stated - 
CPRD – Clinical Practice Research Datalink; THIN – The Health Improvement Network; PCCIU – Primary Care Clinical Informatics Unit; SSRI - selective serotonin re-uptake 
inhibitors; GP – General practice; MAOIs - monoamine oxidase inhibitors; CiPCA - Consultations in primary care archive; PiPCA - Prescriptions in primary care archive.
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Supplementary appendix 4, table 1. List of Read codes used in the studies of anxiety. 
Read code Description Number of studies 
Eu41.00 [X]Other anxiety disorders 5 
Eu41100 [X]Generalized anxiety disorder 5 
Eu41z11 [X]Anxiety NOS 5 
Eu41000 [X]Panic disorder [episodic paroxysmal anxiety] 4 
Eu05400 [X]Organic anxiety disorder 4 
Eu41112 [X]Anxiety reaction 4 
Eu41111 [X]Anxiety neurosis 4 
Eu41z00 [X]Anxiety disorder, unspecified 4 
E202.12 Phobic anxiety 4 
E200200 Generalised anxiety disorder 4 
E200.00 Anxiety states 4 
E200000 Anxiety state unspecified 4 
E200z00 Anxiety state NOS 4 
Eu40.00 [X]Phobic anxiety disorders 3 
Eu40z00 [X]Phobic anxiety disorder, unspecified 3 
Eu41012 [X]Panic state 3 
Eu41011 [X]Panic attack 3 
Eu41y00 [X]Other specified anxiety disorders 3 
Eu41300 [X]Other mixed anxiety disorders 3 
Eu41211 [X]Mild anxiety depression 3 
Eu41113 [X]Anxiety state 3 
E200500 Recurrent anxiety 3 
E200100 Panic disorder 3 
E200111 Panic attack 3 
E200400 Chronic anxiety 3 
1B1V.00 C/O - panic attack 3 
1B13.11 Anxiousness - symptom 3 
1B13.00 Anxiousness 3 
E200300 Anxiety with depression 3 
Eu93200 [X]Social anxiety disorder of childhood 2 
Eu34114 [X]Persistant anxiety depression 2 
Eu40012 [X]Panic disorder with agoraphobia 2 
Eu40y00 [X]Other phobic anxiety disorders 2 
Eu41200 [X]Mixed anxiety and depressive disorder 2 
Eu93y12 [X]Childhood overanxious disorder 2 
Eu41y11 [X]Anxiety hysteria 2 
E2D0.00 Disturbance of anxiety and fearfulness childhood/adolescent 2 
E2D0z00 Disturbance anxiety and fearfulness childhood/adolescent NOS 2 
E202100 Agoraphobia with panic attacks 2 
E292400 Adjustment reaction with anxious mood 2 
E280.00 Acute panic state due to acute stress reaction 2 
Z4I7.00 Acknowledging anxiety 2 
Eu40100 [X]Social phobias 1 
Eu40112 [X]Social neurosis 1 
Eu93000 [X]Separation anxiety disorder of childhood 1 
Eu42100 [X]Predominantly compulsive acts [obsessional rituals] 1 
Eu93100 [X]Phobic anxiety disorder of childhood 1 
Eu42.12 [X]Obsessive-compulsive neurosis 1 
Eu42.00 [X]Obsessive - compulsive disorder 1 
Eu45215 [X]Nosophobia 1 
Eu46z11 [X]Neurosis NOS 1 
Eu40300 [X]Needle phobia 1 
Eu45213 [X]Hypochondriacal neurosis 1 
Eu45212 [X]Dysmorphophobia nondelusional 1 
Eu51511 [X]Dream anxiety disorder 1 
Eu40213 [X]Claustrophobia 1 
Eu60600 [X]Anxious [avoidant] personality disorder 1 
Eu42.11 [X]Anankastic neurosis 1 
Eu40011 [X]Agoraphobia without history of panic disorder 1 
Eu40000 [X]Agoraphobia 1 
R2y2.00 [D]Nervousness 1 
R2y2.12 [D]Nervous tension 1 
R2y2.11 [D]Nerves 1 
1BK..00 Worried 1 
1B12.12 Tension - nervous 1 
E202300 Social phobia, fear of eating in public 1 
E112000 Single major depressive episode, unspecified 1 
E292000 Separation anxiety disorder 1 
Z4I7211 Reducing anxiety 1 
Z4I7100 Recognising anxiety 1 
E29y100 Other post-traumatic stress disorder 1 
E203z00 Obsessive-compulsive disorder NOS 1 
E203100 Obsessional neurosis 1 
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Read code Description Number of studies 
225J.00 O/E - panic attack 1 
2258.00 O/E - anxious 1 
1465.00 H/O: depression 1 
1466.00 H/O: anxiety state 1 
1B1..00 General nervous symptoms 1 
E275711 Compulsive water drinking 1 
E203000 Compulsive neurosis 1 
1P3..00 Compulsive behaviour 1 
E202800 Claustrophobia 1 
E2D0000 Childhood and adolescent overanxiousness disturbance 1 
1B13.12 Anxious 1 
8G94.00 Anxiety management training 1 
Z4L1.00 Anxiety counselling 1 
E203.11 Anancastic neurosis 1 
Z4I7200 Alleviating anxiety 1 
E202200 Agoraphobia without mention of panic attacks 1 
1B12.00 'Nerves' - nervousness 1 
1B12.11 'Nerves' 1 
 
 
Supplementary appendix 4, table 2. ICD codes used in the studies of anxiety. 
Study Databases ICD version List of codes 
Bouras, 2016 CPRD + HES ICD-10 F40-F48 
CPRD – Clinical Practice Research Datalink; HES – Hospital Episode Statistics; ICD - International Classification 
of Diseases. 
364
 109
Supplementary appendix 4, table 3. List of Read codes used in the studies of depression. 
Read code Description Number of studies 
E112.00 Single major depressive episode 14 
E112000 Single major depressive episode, unspecified 14 
E112100 Single major depressive episode, mild 14 
E112200 Single major depressive episode, moderate 14 
E112300 Single major depressive episode, severe, without psychosis 14 
E112z00 Single major depressive episode NOS 14 
E135.00 Agitated depression 14 
E112.11 Agitated depression 13 
E112.12 Endogenous depression first episode 13 
E112.13 Endogenous depression first episode 13 
E112.14 Endogenous depression 13 
E112500 Single major depressive episode, partial or unspec remission 13 
E2B..00 Depressive disorder NEC 13 
E2B1.00 Chronic depression 13 
Eu32.00 [X]Depressive episode 13 
E113.00 Recurrent major depressive episode 12 
E11y200 Atypical depressive disorder 12 
E11z200 Masked depression 12 
Eu32.11 [X]Single episode of depressive reaction 12 
Eu32.12 [X]Single episode of psychogenic depression 12 
Eu32.13 [X]Single episode of reactive depression 12 
Eu32000 [X]Mild depressive episode 12 
Eu32100 [X]Moderate depressive episode 12 
Eu32200 [X]Severe depressive episode without psychotic symptoms 12 
Eu32400 [X]Mild depression 12 
Eu32y00 [X]Other depressive episodes 12 
Eu32z00 [X]Depressive episode, unspecified 12 
Eu33.00 [X]Recurrent depressive disorder 12 
E112400 Single major depressive episode, severe, with psychosis 11 
E113.11 Endogenous depression - recurrent 11 
E130.11 Psychotic reactive depression 11 
Eu32212 [X]Single episode major depression w'out psychotic symptoms 11 
Eu32y11 [X]Atypical depression 11 
Eu32z11 [X]Depression NOS 11 
Eu32z12 [X]Depressive disorder NOS 11 
1B17.00 Depressed 10 
E112600 Single major depressive episode, in full remission 10 
E113000 Recurrent major depressive episodes, unspecified 10 
E113100 Recurrent major depressive episodes, mild 10 
E113200 Recurrent major depressive episodes, moderate 10 
E113300 Recurrent major depressive episodes, severe, no psychosis 10 
E113500 Recurrent major depressive episodes,partial/unspec remission 10 
E113700 Recurrent depression 10 
E113z00 Recurrent major depressive episode NOS 10 
E130.00 Reactive depressive psychosis 10 
E200300 Anxiety with depression 10 
E291.00 Prolonged depressive reaction 10 
Eu32211 [X]Single episode agitated depressn w'out psychotic symptoms 10 
Eu32213 [X]Single episode vital depression w'out psychotic symptoms 10 
Eu32311 [X]Single episode of major depression and psychotic symptoms 10 
Eu32313 [X]Single episode of psychotic depression 10 
Eu32y12 [X]Single episode of masked depression NOS 10 
Eu32z13 [X]Prolonged single episode of reactive depression 10 
Eu33.11 [X]Recurrent episodes of depressive reaction 10 
Eu33.12 [X]Recurrent episodes of psychogenic depression 10 
Eu33.13 [X]Recurrent episodes of reactive depression 10 
Eu33000 [X]Recurrent depressive disorder, current episode mild 10 
Eu33100 [X]Recurrent depressive disorder, current episode moderate 10 
Eu33211 [X]Endogenous depression without psychotic symptoms 10 
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Read code Description Number of studies 
Eu33y00 [X]Other recurrent depressive disorders 10 
Eu33z00 [X]Recurrent depressive disorder, unspecified 10 
Eu34114 [X]Persistant anxiety depression 10 
1B1U.00 Symptoms of depression 9 
1B1U.11 Depressive symptoms 9 
E113600 Recurrent major depressive episodes, in full remission 9 
Eu32300 [X]Severe depressive episode with psychotic symptoms 9 
Eu32312 [X]Single episode of psychogenic depressive psychosis 9 
Eu32314 [X]Single episode of reactive depressive psychosis 9 
Eu32500 [X]Major depression, mild 9 
Eu32600 [X]Major depression, moderately severe 9 
Eu32700 [X]Major depression, severe without psychotic symptoms 9 
Eu32z14 [X] Reactive depression NOS 9 
Eu33214 [X]Vital depression, recurrent without psychotic symptoms 9 
Eu33311 [X]Endogenous depression with psychotic symptoms 9 
Eu33z11 [X]Monopolar depression NOS 9 
Eu34113 [X]Neurotic depression 9 
Eu41200 [X]Mixed anxiety and depressive disorder 9 
Eu41211 [X]Mild anxiety depression 9 
1B17.11 C/O - feeling depressed 8 
E113400 Recurrent major depressive episodes, severe, with psychosis 8 
E204.00 Neurotic depression reactive type 8 
Eu33200 [X]Recurr depress disorder cur epi severe without psyc sympt 8 
Eu33212 [X]Major depression, recurrent without psychotic symptoms 8 
Eu33400 [X]Recurrent depressive disorder, currently in remission 8 
Eu34111 [X]Depressive neurosis 8 
Eu3y111 [X]Recurrent brief depressive episodes 8 
1BT..00 Depressed mood 7 
2257.00 O/E - depressed 7 
E11..12 Depressive psychoses 7 
Eu32800 [X]Major depression, severe with psychotic symptoms 7 
Eu33.14 [X]Seasonal depressive disorder 7 
Eu33313 [X]Recurr severe episodes/major depression+psychotic symptom 7 
Eu33314 [X]Recurr severe episodes/psychogenic depressive psychosis 7 
Eu33315 [X]Recurrent severe episodes of psychotic depression 7 
Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis 7 
9H90.00 Depression annual review 6 
9H91.00 Depression medication review 6 
9H92.00 Depression interim review 6 
9HA0.00 On depression register 6 
E290.00 Brief depressive reaction 6 
Eu33300 [X]Recurrent depress disorder cur epi severe with psyc symp 6 
Eu34100 [X]Dysthymia 6 
E118.00 Seasonal affective disorder 5 
E204.11 Postnatal depression 5 
E290z00 Brief depressive reaction NOS 5 
Eu53011 [X]Postnatal depression NOS 5 
Eu53012 [X]Postpartum depression NOS 5 
1465.00 H/O: depression 4 
1BQ..00 Loss of capacity for enjoyment 4 
8HHq.00 Referral for guided self-help for depression 4 
E02y300 Drug-induced depressive state 4 
Eu33.15 [X]SAD - Seasonal affective disorder 4 
R007z13 [D]Postoperative depression 4 
1BP0.00 Loss of interest in previously enjoyable activity 3 
1BT..11 Low mood 3 
1BU..00 Loss of hope for the future 3 
212S.00 Depression resolved 3 
8CAa.00 Patient given advice about management of depression 3 
9Ov0.00 Depression monitoring first letter 3 
9Ov1.00 Depression monitoring second letter 3 
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Read code Description Number of studies 
9Ov2.00 Depression monitoring third letter 3 
9Ov3.00 Depression monitoring verbal invite 3 
9Ov4.00 Depression monitoring telephone invite 3 
9k4..00 Depression - enhanced services administration 3 
E001300 Presenile dementia with depression 3 
E002100 Senile dementia with depression 3 
E2B0.00 Postviral depression 3 
Eu20400 [X]Post-schizophrenic depression 3 
Eu34112 [X]Depressive personality disorder 3 
Eu92000 [X]Depressive conduct disorder 3 
1JJ..00 Suspected depression 2 
8BK0.00 Depression management programme 2 
9HA1.00 Removed from depression register 2 
9Ov..00 Depression monitoring administration 2 
9k40.00 Depression - enhanced service completed 2 
9kQ..00 On full dose long term treatment depression - enh serv admin 2 
E115.00 Bipolar affective disorder, currently depressed 2 
E11y.00 Other and unspecified manic-depressive psychoses 2 
E211200 Depressive personality disorder 2 
Eu25100 [X]Schizoaffective disorder, depressive type 2 
Eu25111 [X]Schizoaffective psychosis, depressive type 2 
Eu25112 [X]Schizophreniform psychosis, depressive type 2 
Eu32B00 [X]Antenatal depression 2 
Eu33213 [X]Manic-depress psychosis,depressd,no psychotic symptoms 2 
Eu34y00 [X]Other persistent mood affective disorders 2 
Eu34z00 [X]Persistent mood affective disorder, unspecified 2 
Eu3y100 [X]Other recurrent mood affective disorders 2 
Eu3z.00 [X]Unspecified mood affective disorder 2 
1645.00 Excessive fluid intake 1 
1B1J.00 Emotional problem 1 
1B1J.11 Emotional upset 1 
1BO..00 Mood swings 1 
1BP..00 Loss of interest 1 
1BT..12 Sad mood 1 
1S4..00 Mood observations 1 
1S40.00 Dysphoric mood 1 
388J.00 Hospital anxiety and depression scale 1 
388K.00 Geriatric depression scale 1 
388P.00 HAD scale: depression score 1 
388g.00 Beck depression inventory second edition score 1 
62T1.00 Puerperal depression 1 
6896.00 Depression screening using questions 1 
8O82.00 Emotional and psychosocial support and advice 1 
9ON3.00 Stress monitoring default 1 
9ON4.00 Stress monitoring 1st letter 1 
9ON5.00 Stress monitoring 2nd letter 1 
9ON6.00 Stress monitoring 3rd letter 1 
9ON7.00 Stress monitoring verbal inv. 1 
9ON8.00 Stress monitoring phone invite 1 
9ON9.00 Stress monitoring deleted 1 
9ONA.00 Stress monitoring check done 1 
9ONZ.00 Stress monitoring admin.NOS 1 
E002.00 Senile dementia with depressive or paranoid features 1 
E002z00 Senile dementia with depressive or paranoid features NOS 1 
E004300 Arteriosclerotic dementia with depression 1 
E115.11 Manic-depressive - now depressed 1 
E115000 Bipolar affective disorder, currently depressed, unspecified 1 
E115100 Bipolar affective disorder, currently depressed, mild 1 
E115200 Bipolar affective disorder, currently depressed, moderate 1 
E115300 Bipolar affect disord, now depressed, severe, no psychosis 1 
E115400 Bipolar affect disord, now depressed, severe with psychosis 1 
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Read code Description Number of studies 
E115500 Bipolar affect disord, now depressed, part/unspec remission 1 
E115600 Bipolar affective disorder, now depressed, in full remission 1 
E115z00 Bipolar affective disorder, currently depressed, NOS 1 
E11y000 Unspecified manic-depressive psychoses 1 
E11z100 Rebound mood swings 1 
E222 1 
E283.00 Other acute stress reactions 1 
E283z00 Other acute stress reaction NOS 1 
E284.00 Stress reaction causing mixed disturbance of emotion/conduct 1 
E28z.00 Acute stress reaction NOS 1 
E292.00 Adjustment reaction, predominant disturbance other emotions 1 
E292400 Adjustment reaction with anxious mood 1 
E292y00 Adjustment reaction with mixed disturbance of emotion 1 
E292z00 Adjustment reaction with disturbance of other emotion NOS 1 
E294.00 Adjustment reaction with disturbance emotion and conduct 1 
E2C4.00 Mixed disturbance of conduct and emotion 1 
E2C4z00 Mixed disturbance of conduct and emotion NOS 1 
E35 1 
E4J5 1 
Eu02z16 [X] Senile dementia, depressed or paranoid type 1 
Eu3..00 [X]Mood - affective disorders 1 
Eu31.11 [X]Manic-depressive illness 1 
Eu31300 [X]Bipolar affect disorder cur epi mild or moderate depressn 1 
Eu31400 [X]Bipol aff disord, curr epis sev depress, no psychot symp 1 
Eu31500 [X]Bipolar affect dis cur epi severe depres with psyc symp 1 
Eu31600 [X]Bipolar affective disorder, current episode mixed 1 
Eu31y00 [X]Other bipolar affective disorders 1 
Eu31y11 [X]Bipolar II disorder 1 
Eu31z00 [X]Bipolar affective disorder, unspecified 1 
Eu33312 [X]Manic-depress psychosis,depressed type+psychotic symptoms 1 
Eu34.00 [X]Persistent mood affective disorders 1 
Eu3y.00 [X]Other mood affective disorders 1 
Eu3y000 [X]Other single mood affective disorders 1 
Eu3y011 [X]Mixed affective episode 1 
Eu3yy00 [X]Other specified mood affective disorders 1 
Eu4..00 [X]Neurotic, stress - related and somoform disorders 1 
Eu43.00 [X]Reaction to severe stress, and adjustment disorders 1 
Eu43000 [X]Acute stress reaction 1 
Eu43012 [X]Acute reaction to stress 1 
Eu43y00 [X]Other reactions to severe stress 1 
Eu43z00 [X]Reaction to severe stress, unspecified 1 
Eu92.11 [X]Emotional behavioural problems 1 
R007z14 [D]Work stress 1 
ZR2A.00 Beck depression inventory 1 
ZR2A.11 BDI - Beck depression inventory 1 
ZR2B.00 Beck hopelessness scale 1 
ZR2G.00 Behaviour and mood disturbance scale 1 
ZR2h.00 Brief depression rating scale 1 
ZR7..00 Depression anxiety scale 1 
ZR8..00 Depression self rating scale 1 
ZR8..11 DSRS - Depression self rating scale 1 
ZRBY.00 Edinburgh postnatal depression scale 1 
ZRBY.11 EPDS - Edinburgh postnatal depression scale 1 
ZRL6.00 Geriatric depression scale 1 
ZRL6.11 GDS - Geriatric depression scale 1 
ZRL6.12 Geriatric depression score 1 
ZRLU.00 Hamilton rating scale for depression 1 
ZRLU.11 HAMD - Hamilton rating scale for depression 1 
ZRLU.12 HRSD - Hamilton rating scale for depression 1 
ZRLfH00 Health of the Nation Outcome Scale item 7 - depressed mood 1 
ZRLfI00 Health of the Nation Outcome Scale item 7 - depressed mood 1 
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Read code Description Number of studies 
ZRLn.00 Hopelessness scale 1 
ZRLr.00 Hospital anxiety and depression scale 1 
ZRLr.11 HAD - Hospital anxiety and depression scale 1 
ZRLr.12 HADS - Hospital anxiety and depression scale 1 
ZRVM.00 Leeds scale for the self-assessment of anxiety & depression 1 
ZRaH.00 Mood affective checklist 1 
ZRaH.11 MACL - Mood affective checklist 1 
ZRbS.00 Positive and negative affect schedule 1 
ZRby.00 Profile of mood states 1 
ZRby.11 POMS - Profile of mood states 1 
ZRrI.00 Wakefield self-assessment depression inventory 1 
ZRrY.00 WHO depression scale 1 
ZRrc.00 Zung self-rating depression scale 1 
ZRrc.11 SDS - Zung self-rating depression scale 1 
ZV11100 [V]Personal history of affective disorder 1 
ZV11111 [V]Personal history of manic-depressive psychosis 1 
ZV11112 [V]Personal history of manic-depressive psychosis 1 
 
Supplementary appendix 4, table 4. ICD codes used in the studies of depression. 
Study Databases ICD version List of codes 
Bouras, 2016 CPRD + HES ICD-10 F32, F33 
Jenkins-Jones, 2018 CPRD + HES  ICD-10 F32, F33, F41.2, F92.0 
CPRD – Clinical Practice Research Datalink; HES – Hospital Episode Statistics; ICD - International Classification 
of Diseases.
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Supplementary appendix 4, table 5. List of Read codes used in the studies of composite 
outcomes of anxiety and depression. 
Read code Description Number of studies 
Eu32200 [X]Severe depressive episode without psychotic symptoms 2 
Eu33z00 [X]Recurrent depressive disorder, unspecified 2 
Eu33400 [X]Recurrent depressive disorder, currently in remission 2 
Eu33100 [X]Recurrent depressive disorder, current episode moderate 2 
Eu33000 [X]Recurrent depressive disorder, current episode mild 2 
Eu33.00 [X]Recurrent depressive disorder 2 
Eu33200 [X]Recurr depress disorder cur epi severe without psyc sympt 2 
Eu41000 [X]Panic disorder [episodic paroxysmal anxiety] 2 
Eu41y00 [X]Other specified anxiety disorders 2 
Eu33y00 [X]Other recurrent depressive disorders 2 
Eu32y00 [X]Other depressive episodes 2 
Eu41.00 [X]Other anxiety disorders 2 
Eu32100 [X]Moderate depressive episode 2 
Eu41200 [X]Mixed anxiety and depressive disorder 2 
Eu32000 [X]Mild depressive episode 2 
Eu32400 [X]Mild depression 2 
Eu41100 [X]Generalized anxiety disorder 2 
Eu34100 [X]Dysthymia 2 
Eu32z00 [X]Depressive episode, unspecified 2 
Eu32.00 [X]Depressive episode 2 
Eu41z00 [X]Anxiety disorder, unspecified 2 
1B1U.00 Symptoms of depression 2 
E112000 Single major depressive episode, unspecified 2 
E112300 Single major depressive episode, severe, without psychosis 2 
E112500 Single major depressive episode, partial or unspec remission 2 
E112200 Single major depressive episode, moderate 2 
E112100 Single major depressive episode, mild 2 
E112600 Single major depressive episode, in full remission 2 
E112z00 Single major depressive episode NOS 2 
E112.00 Single major depressive episode 2 
E118.00 Seasonal affective disorder 2 
E113500 Recurrent major depressive episodes,partial/unspec remission 2 
E113000 Recurrent major depressive episodes, unspecified 2 
E113300 Recurrent major depressive episodes, severe, no psychosis 2 
E113200 Recurrent major depressive episodes, moderate 2 
E113100 Recurrent major depressive episodes, mild 2 
E113600 Recurrent major depressive episodes, in full remission 2 
E113z00 Recurrent major depressive episode NOS 2 
E113.00 Recurrent major depressive episode 2 
E113700 Recurrent depression 2 
E200500 Recurrent anxiety 2 
E291.00 Prolonged depressive reaction 2 
E2B0.00 Postviral depression 2 
E200100 Panic disorder 2 
2257.00 O/E - depressed 2 
E204.00 Neurotic depression reactive type 2 
E200200 Generalised anxiety disorder 2 
E2B..00 Depressive disorder NEC 2 
1BT..00 Depressed mood 2 
1B17.00 Depressed 2 
E2B1.00 Chronic depression 2 
E200400 Chronic anxiety 2 
E200300 Anxiety with depression 2 
E200.00 Anxiety states 2 
E200000 Anxiety state unspecified 2 
E200z00 Anxiety state NOS 2 
E135.00 Agitated depression 2 
Eu33214 [X]Vital depression, recurrent without psychotic symptoms 1 
Eu3z.00 [X]Unspecified mood affective disorder 1 
Eu40100 [X]Social phobias 1 
Eu40112 [X]Social neurosis 1 
Eu32213 [X]Single episode vital depression w'out psychotic symptoms 1 
Eu32314 [X]Single episode of reactive depressive psychosis 1 
Eu32.13 [X]Single episode of reactive depression 1 
Eu32313 [X]Single episode of psychotic depression 1 
Eu32312 [X]Single episode of psychogenic depressive psychosis 1 
Eu32.12 [X]Single episode of psychogenic depression 1 
Eu32y12 [X]Single episode of masked depression NOS 1 
Eu32311 [X]Single episode of major depression and psychotic symptoms 1 
Eu32.11 [X]Single episode of depressive reaction 1 
Eu32212 [X]Single episode major depression w'out psychotic symptoms 1 
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Read code Description Number of studies 
Eu32211 [X]Single episode agitated depressn w'out psychotic symptoms 1 
Eu32300 [X]Severe depressive episode with psychotic symptoms 1 
Eu33.14 [X]Seasonal depressive disorder 1 
Eu33.15 [X]SAD - Seasonal affective disorder 1 
Eu06y11 [X]Right hemispheric organic affective disorder 1 
Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis 1 
Eu33315 [X]Recurrent severe episodes of psychotic depression 1 
Eu33.13 [X]Recurrent episodes of reactive depression 1 
Eu33.12 [X]Recurrent episodes of psychogenic depression 1 
Eu33.11 [X]Recurrent episodes of depressive reaction 1 
Eu33300 [X]Recurrent depress disorder cur epi severe with psyc symp 1 
Eu3y111 [X]Recurrent brief depressive episodes 1 
Eu33314 [X]Recurr severe episodes/psychogenic depressive psychosis 1 
Eu33313 [X]Recurr severe episodes/major depression+psychotic symptom 1 
Eu43z00 [X]Reaction to severe stress, unspecified 1 
Eu43.00 [X]Reaction to severe stress, and adjustment disorders 1 
Eu32z13 [X]Prolonged single episode of reactive depression 1 
Eu42100 [X]Predominantly compulsive acts [obsessional rituals] 1 
Eu20400 [X]Post-schizophrenic depression 1 
Eu43100 [X]Post - traumatic stress disorder 1 
Eu40.00 [X]Phobic anxiety disorders 1 
Eu34.00 [X]Persistent mood affective disorders 1 
Eu34z00 [X]Persistent mood affective disorder, unspecified 1 
Eu34114 [X]Persistant anxiety depression 1 
Eu41012 [X]Panic state 1 
Eu40012 [X]Panic disorder with agoraphobia 1 
Eu41011 [X]Panic attack 1 
Eu3yy00 [X]Other specified mood affective disorders 1 
Eu3y000 [X]Other single mood affective disorders 1 
Eu3y100 [X]Other recurrent mood affective disorders 1 
Eu43y00 [X]Other reactions to severe stress 1 
Eu34y00 [X]Other persistent mood affective disorders 1 
Eu42y00 [X]Other obsessive-compulsive disorders 1 
Eu3y.00 [X]Other mood affective disorders 1 
Eu41300 [X]Other mixed anxiety disorders 1 
Eu31y00 [X]Other bipolar affective disorders 1 
Eu05300 [X]Organic mood [affective] disorders 1 
Eu05400 [X]Organic anxiety disorder 1 
Eu60513 [X]Obsessive-compulsive personality disorder 1 
Eu42.12 [X]Obsessive-compulsive neurosis 1 
Eu42z00 [X]Obsessive-compulsive disorder, unspecified 1 
Eu42.00 [X]Obsessive - compulsive disorder 1 
Eu4..00 [X]Neurotic, stress - related and somoform disorders 1 
Eu34113 [X]Neurotic depression 1 
Eu3..00 [X]Mood - affective disorders 1 
Eu33z11 [X]Monopolar depression NOS 1 
Eu3y011 [X]Mixed affective episode 1 
Eu41211 [X]Mild anxiety depression 1 
Eu31.13 [X]Manic-depressive reaction 1 
Eu31.12 [X]Manic-depressive psychosis 1 
Eu31.11 [X]Manic-depressive illness 1 
Eu33312 [X]Manic-depress psychosis,depressed type+psychotic symptoms 1 
Eu33213 [X]Manic-depress psychosis,depressd,no psychotic symptoms 1 
Eu32700 [X]Major depression, severe without psychotic symptoms 1 
Eu32800 [X]Major depression, severe with psychotic symptoms 1 
Eu33212 [X]Major depression, recurrent without psychotic symptoms 1 
Eu32600 [X]Major depression, moderately severe 1 
Eu32500 [X]Major depression, mild 1 
Eu33211 [X]Endogenous depression without psychotic symptoms 1 
Eu33311 [X]Endogenous depression with psychotic symptoms 1 
Eu51511 [X]Dream anxiety disorder 1 
Eu34112 [X]Depressive personality disorder 1 
Eu34111 [X]Depressive neurosis 1 
Eu32z12 [X]Depressive disorder NOS 1 
Eu92000 [X]Depressive conduct disorder 1 
Eu32z11 [X]Depression NOS 1 
Eu60511 [X]Compulsive personality disorder 1 
Eu63011 [X]Compulsive gambling 1 
Eu43013 [X]Combat fatigue 1 
Eu31z00 [X]Bipolar affective disorder, unspecified 1 
Eu31700 [X]Bipolar affective disorder, currently in remission 1 
Eu31600 [X]Bipolar affective disorder, current episode mixed 1 
Eu31900 [X]Bipolar affective disorder type II 1 
Eu31800 [X]Bipolar affective disorder type I 1 
Eu31.00 [X]Bipolar affective disorder 1 
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Eu31300 [X]Bipolar affect disorder cur epi mild or moderate depressn 1 
Eu31500 [X]Bipolar affect dis cur epi severe depres with psyc symp 1 
Eu31y11 [X]Bipolar II disorder 1 
Eu31911 [X]Bipolar II disorder 1 
Eu31400 [X]Bipol aff disord, curr epis sev depress, no psychot symp 1 
Eu32y11 [X]Atypical depression 1 
Eu41113 [X]Anxiety state 1 
Eu41112 [X]Anxiety reaction 1 
Eu41111 [X]Anxiety neurosis 1 
Eu41y11 [X]Anxiety hysteria 1 
Eu41z11 [X]Anxiety NOS 1 
Eu42.11 [X]Anankastic neurosis 1 
Eu40011 [X]Agoraphobia without history of panic disorder 1 
Eu40000 [X]Agoraphobia 1 
Eu3z.11 [X]Affective psychosis NOS 1 
Eu34011 [X]Affective personality disorder 1 
Eu43000 [X]Acute stress reaction 1 
Eu43012 [X]Acute reaction to stress 1 
Eu32z14 [X] Reactive depression NOS 1 
ZV11112 [V]Personal history of manic-depressive psychosis 1 
ZV11111 [V]Personal history of manic-depressive psychosis 1 
ZV11100 [V]Personal history of affective disorder 1 
R2y2.00 [D]Nervousness 1 
1BK..00 Worried 1 
E11y000 Unspecified manic-depressive psychoses 1 
E117400 Unspecified bipolar affective disorder,severe with psychosis 1 
E117000 Unspecified bipolar affective disorder, unspecified 1 
E117300 Unspecified bipolar affective disorder, severe, no psychosis 1 
E117200 Unspecified bipolar affective disorder, moderate 1 
E117100 Unspecified bipolar affective disorder, mild 1 
E117600 Unspecified bipolar affective disorder, in full remission 1 
E117z00 Unspecified bipolar affective disorder, NOS 1 
E117.00 Unspecified bipolar affective disorder 1 
E117500 Unspecified bipolar affect disord, partial/unspec remission 1 
E11z000 Unspecified affective psychoses NOS 1 
E211000 Unspecified affective personality disorder 1 
1JJ..00 Suspected depression 1 
E284.00 Stress reaction causing mixed disturbance of emotion/conduct 1 
67J..00 Stress counselling 1 
E202.11 Social phobic disorders 1 
E112400 Single major depressive episode, severe, with psychosis 1 
E002z00 Senile dementia with depressive or paranoid features NOS 1 
E002.00 Senile dementia with depressive or paranoid features 1 
E002100 Senile dementia with depression 1 
1BT..12 Sad mood 1 
8HHq.00 Referral for guided self-help for depression 1 
8HHp.00 Referral for guided self-help for anxiety 1 
Z4I7211 Reducing anxiety 1 
E113400 Recurrent major depressive episodes, severe, with psychosis 1 
Z4I7100 Recognising anxiety 1 
E11z100 Rebound mood swings 1 
E130.00 Reactive depressive psychosis 1 
E130.11 Psychotic reactive depression 1 
E001300 Presenile dementia with depression 1 
E2A2.11 Post-traumatic brain syndrome 1 
E202.00 Phobic disorders 1 
E202.12 Phobic anxiety 1 
E202000 Phobia unspecified 1 
8CAa.00 Patient given advice about management of depression 1 
E200111 Panic attack 1 
E29y100 Other post-traumatic stress disorder 1 
E11y300 Other mixed manic-depressive psychoses 1 
E11yz00 Other and unspecified manic-depressive psychoses NOS 1 
E11y.00 Other and unspecified manic-depressive psychoses 1 
E11z.00 Other and unspecified affective psychoses 1 
E11zz00 Other affective psychosis NOS 1 
E283.00 Other acute stress reactions 1 
E283z00 Other acute stress reaction NOS 1 
E03y200 Organic affective syndrome 1 
9kQ..00 On full dose long term treatment depression - enh serv admin 1 
9HA0.00 On depression register 1 
E203.00 Obsessive-compulsive disorders 1 
E203z00 Obsessive-compulsive disorder NOS 1 
E214100 Obsessional personality 1 
E203100 Obsessional neurosis 1 
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225J.00 O/E - panic attack 1 
2259.00 O/E - nervous 1 
225K.00 O/E - fearful mood 1 
2253.00 O/E - distressed 1 
2258.00 O/E - anxious 1 
E116000 Mixed bipolar affective disorder, unspecified 1 
E116300 Mixed bipolar affective disorder, severe, without psychosis 1 
E116400 Mixed bipolar affective disorder, severe, with psychosis 1 
E116500 Mixed bipolar affective disorder, partial/unspec remission 1 
E116200 Mixed bipolar affective disorder, moderate 1 
E116100 Mixed bipolar affective disorder, mild 1 
E116600 Mixed bipolar affective disorder, in full remission 1 
E116z00 Mixed bipolar affective disorder, NOS 1 
E116.00 Mixed bipolar affective disorder 1 
E11z200 Masked depression 1 
E115.11 Manic-depressive - now depressed 1 
13Y3.00 Manic-depression association member 1 
1BT..11 Low mood 1 
1BU..00 Loss of hope for the future 1 
1BQ..00 Loss of capacity for enjoyment 1 
146D.00 H/O: manic depressive disorder 1 
1465.00 H/O: depression 1 
1466.00 H/O: anxiety state 1 
1B1H.00 Frightened 1 
Z522600 Flooding - obsessional compulsive disorder 1 
1B1T.00 Feeling stressed 1 
16ZB100 Feeling low or worried 1 
E202D00 Fear of death 1 
1B1H.11 Fear 1 
9hC..00 Exception reporting: depression quality indicators 1 
9hC0.00 Excepted from depression quality indicators: Patient unsuita 1 
9hC1.00 Excepted from depression quality indicators: Informed dissen 1 
E112.13 Endogenous depression first episode 1 
E112.12 Endogenous depression first episode 1 
E113.11 Endogenous depression - recurrent 1 
E112.14 Endogenous depression 1 
9N54.00 Encounter for fear 1 
1B1U.11 Depressive symptoms 1 
E11..12 Depressive psychoses 1 
E211200 Depressive personality disorder 1 
9Ov3.00 Depression monitoring verbal invite 1 
9Ov2.00 Depression monitoring third letter 1 
9Ov4.00 Depression monitoring telephone invite 1 
9Ov1.00 Depression monitoring second letter 1 
9Ov0.00 Depression monitoring first letter 1 
9Ov..00 Depression monitoring administration 1 
9H91.00 Depression medication review 1 
8BK0.00 Depression management programme 1 
9H92.00 Depression interim review 1 
9H90.00 Depression annual review 1 
9k4..00 Depression - enhanced services administration 1 
9k40.00 Depression - enhanced service completed 1 
E214.00 Compulsive personality disorders 1 
E214z00 Compulsive personality disorder NOS 1 
E203000 Compulsive neurosis 1 
1P3..00 Compulsive behaviour 1 
E28..11 Combat fatigue 1 
1B1V.00 C/O - panic attack 1 
1B17.11 C/O - feeling depressed 1 
E290z00 Brief depressive reaction NOS 1 
E290.00 Brief depressive reaction 1 
E11..11 Bipolar psychoses 1 
E115600 Bipolar affective disorder, now depressed, in full remission 1 
E115000 Bipolar affective disorder, currently depressed, unspecified 1 
E115200 Bipolar affective disorder, currently depressed, moderate 1 
E115100 Bipolar affective disorder, currently depressed, mild 1 
E115z00 Bipolar affective disorder, currently depressed, NOS 1 
E115.00 Bipolar affective disorder, currently depressed 1 
E115300 Bipolar affect disord, now depressed, severe, no psychosis 1 
E115400 Bipolar affect disord, now depressed, severe with psychosis 1 
E115500 Bipolar affect disord, now depressed, part/unspec remission 1 
E11y200 Atypical depressive disorder 1 
E004300 Arteriosclerotic dementia with depression 1 
1B1H.12 Apprehension 1 
1B13.00 Anxiousness 1 
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8G94.00 Anxiety management training 1 
Z4L1.00 Anxiety counselling 1 
173f.00 Anxiety about breathlessness 1 
6659000 Antidepressant drug treatment started 1 
E214000 Anankastic personality 1 
E203.11 Anancastic neurosis 1 
Z4I7200 Alleviating anxiety 1 
E202200 Agoraphobia without mention of panic attacks 1 
E202100 Agoraphobia with panic attacks 1 
E112.11 Agitated depression 1 
E11..00 Affective psychoses 1 
E211.00 Affective personality disorder 1 
E292400 Adjustment reaction with anxious mood 1 
E282.00 Acute stupor state due to acute stress reaction 1 
E28z.00 Acute stress reaction NOS 1 
E28..00 Acute reaction to stress 1 
E283100 Acute posttrauma stress state 1 
E280.00 Acute panic state due to acute stress reaction 1 
E281.00 Acute fugue state due to acute stress reaction 1 
Z4I7.00 Acknowledging anxiety 1 
1B12.00 'Nerves' - nervousness 1 
9kQ..11 1 
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Supplementary appendix 4, table 6. List of Read codes used in the studies of cognitive 
impairment. 
Read code Description Number of studies 
Eu01.00 [X]Vascular dementia 13 
Eu01200 [X]Subcortical vascular dementia 13 
Eu00112 [X]Senile dementia,Alzheimer's type 13 
Eu00011 [X]Presenile dementia,Alzheimer's type 13 
Eu01100 [X]Multi-infarct dementia 13 
Eu00.00 [X]Dementia in Alzheimer's disease 13 
Eu01.11 [X]Arteriosclerotic dementia 13 
Eu00z11 [X]Alzheimer's dementia unspec 13 
E000.00 Uncomplicated senile dementia 13 
E004.11 Multi infarct dementia 13 
E004.00 Arteriosclerotic dementia 13 
F110000 Alzheimer's disease with early onset 13 
F110.00 Alzheimer's disease 13 
Eu01z00 [X]Vascular dementia, unspecified 12 
Eu01000 [X]Vascular dementia of acute onset 12 
Eu00012 [X]Primary degen dementia, Alzheimer's type, presenile onset 12 
Eu00113 [X]Primary degen dementia of Alzheimer's type, senile onset 12 
Eu01111 [X]Predominantly cortical dementia 12 
Eu00z00 [X]Dementia in Alzheimer's disease, unspecified 12 
Eu00100 [X]Dementia in Alzheimer's disease with late onset 12 
Eu00000 [X]Dementia in Alzheimer's disease with early onset 12 
Eu00200 [X]Dementia in Alzheimer's dis, atypical or mixed type 12 
Eu00013 [X]Alzheimer's disease type 2 12 
Eu00111 [X]Alzheimer's disease type 1 12 
E004000 Uncomplicated arteriosclerotic dementia 12 
E004200 Arteriosclerotic dementia with paranoia 12 
E004300 Arteriosclerotic dementia with depression 12 
E004100 Arteriosclerotic dementia with delirium 12 
E004z00 Arteriosclerotic dementia NOS 12 
F110100 Alzheimer's disease with late onset 12 
Eu01y00 [X]Other vascular dementia 11 
Eu01300 [X]Mixed cortical and subcortical vascular dementia 11 
Eu02.00 [X]Dementia in other diseases classified elsewhere 11 
Eu02300 [X]Dementia in Parkinson's disease 11 
Eu02z00 [X] Unspecified dementia 11 
Eu02z14 [X] Senile dementia NOS 11 
E00..12 Senile/presenile dementia 11 
E002000 Senile dementia with paranoia 11 
E002100 Senile dementia with depression 11 
E001.00 Presenile dementia 11 
E041.00 Dementia in conditions EC 11 
Fyu3000 [X]Other Alzheimer's disease 10 
Eu02500 [X]Lewy body dementia 10 
Eu02y00 [X]Dementia in other specified diseases classif elsewhere 10 
Eu04100 [X]Delirium superimposed on dementia 10 
Eu02z16 [X] Senile dementia, depressed or paranoid type 10 
Eu02z13 [X] Primary degenerative dementia NOS 10 
Eu02z11 [X] Presenile dementia NOS 10 
E001000 Uncomplicated presenile dementia 10 
E002z00 Senile dementia with depressive or paranoid features NOS 10 
E002.00 Senile dementia with depressive or paranoid features 10 
E003.00 Senile dementia with delirium 10 
E00..11 Senile dementia 10 
E001200 Presenile dementia with paranoia 10 
E001300 Presenile dementia with depression 10 
E001100 Presenile dementia with delirium 10 
E001z00 Presenile dementia NOS 10 
Eu02000 [X]Dementia in Pick's disease 9 
Eu02200 [X]Dementia in Huntington's disease 9 
Eu02400 [X]Dementia in human immunodef virus [HIV] disease 8 
Eu02100 [X]Dementia in Creutzfeldt-Jakob disease 8 
F112.00 Senile degeneration of brain 8 
F116.00 Lewy body disease 8 
F111.00 Pick's disease 7 
E012.00 Other alcoholic dementia 6 
E012.11 Alcoholic dementia NOS 6 
Eu10711 [X]Alcoholic dementia NOS 5 
E00z.00 Senile or presenile psychoses NOS 5 
6AB..00 Dementia annual review 5 
Eu02z15 [X] Senile psychosis NOS 4 
Eu02z12 [X] Presenile psychosis NOS 4 
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ZS7C500 Language disorder of dementia 4 
E02y100 Drug-induced dementia 4 
66h..00 Dementia monitoring 4 
R00z011 [D]Memory deficit 3 
e000.00 Uncomplicated senile dementia 3 
Z7CEG00 Transient memory loss 3 
Z7CF811 Short-term memory loss 3 
E00..00 Senile and presenile organic psychotic conditions 3 
2900 SENILE DEMENTIA 3 
Z7CF800 Poor short-term memory 3 
Z7CEH15 Poor memory 3 
2901A PRESENILE DEMENTIA 3 
E00y.00 Other senile and presenile organic psychoses 3 
3A30.00 Memory: present place not knwn 3 
Z7CEH14 Memory problem 3 
1B1A.12 Memory loss symptom 3 
1B1A.00 Memory loss - amnesia 3 
Z7CE611 Memory loss 3 
Z7CEJ00 Memory lapses 3 
Z7CEH00 Memory impairment 3 
1B1A.13 Memory disturbance 3 
Z7CEC11 Loss of memory for recent events 3 
Z7CE615 Loss of memory 3 
1461.00 H/O: dementia 3 
3AE6.00 GDS level 7 - very severe cognitive decline 3 
3AE5.00 GDS level 6 - severe cognitive decline 3 
3AE4.00 GDS level 5 - moderately severe cognitive decline 3 
3AE3.00 GDS level 4 - moderate cognitive decline 3 
3AE2.00 GDS level 3 - mild cognitive decline 3 
3AE1.00 GDS level 2 - very mild cognitive decline 3 
2930 DEMENTIA ARTERIOSCLEROTIC 3 
299 G DEMENTIA AGGRESSIVE 3 
299 B DEMENTIA 3 
E012000 Chronic alcoholic brain syndrome 3 
1B1A.11 Amnesia symptom 3 
ZR1K.00 Alzheimer's disease assessment scale 3 
2901B ALZHEIMER'S DISEASE 3 
ZR1K.11 ADAS - Alzheimer's disease assessment scale 3 
Eu80200 [X]Receptive language disorder 2 
R00z000 [D]Amnesia (retrograde) 2 
ZS78D00 Wernicke's dysphasia 2 
ZS78D13 Wernicke's aphasia 2 
Z7C3500 Unable to use verbal reasoning 2 
Z7C3200 Unable to reason 2 
Z7C5100 Unable to concentrate 2 
1B1A000 Temporary loss of memory 2 
Z7CEF00 Temporary loss of memory 2 
Z7C5313 Short concentration span 2 
Z7C5312 Short attention span 2 
1BR0.11 Short attention span 2 
8HTY.00 Referral to memory clinic 2 
8Hla.00 Referral to dementia care advisor 2 
Z7C5300 Reduced concentration span 2 
1BR..00 Reduced concentration 2 
Z7C5311 Reduced attention span 2 
E00y.11 Presbyophrenic psychosis 2 
Z7CEB12 Poor memory for remote events 2 
Z7CFO00 Poor long-term memory 2 
1BW..00 Poor concentration 2 
Z7CEC12 No memory for recent events 2 
Z7CEK00 Minor memory lapses 2 
Z7CEL00 Mild memory disturbance 2 
E2A1000 Mild memory disturbance 2 
3A40.00 Memory: present year not known 2 
3A20.00 Memory: present time not known 2 
3A10.00 Memory: own age not known 2 
3A50.00 Memory: own DOB not known 2 
3A70.00 Memory: important event not kn 2 
3A80.00 Memory: import.person not knwn 2 
3A91.00 Memory: count down unsuccess. 2 
3AA1.00 Memory: address recall unsucc. 2 
Z7A1500 Memory retraining 2 
Z7CE412 Memory loss symptom 2 
Z7CE614 Memory loss - amnesia 2 
Z7CE413 Memory loss - amnesia 2 
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Z7CE612 Memory gone 2 
Z7CEH11 Memory dysfunction 2 
Z7CE400 Memory disturbance (& amnesia (& symptom)) 2 
Z7CE414 Memory disturbance 2 
Z7CEH12 Memory deficit 2 
Z7CFx00 Memory aided by use of labels 2 
Z7CE415 Loss of memory 2 
Z7CFO11 Long-term memory loss 2 
Z7C5111 Lack of concentration 2 
Z7CE616 LOM - Loss of memory 2 
2901D JACOB- CREUZFELDT DISEASE WITH DEMENTIA 2 
Z7CEN11 Invents experiences to compensate for loss of memory 2 
Z7CEA11 Impairment of working memory 2 
Z7CEA13 Impairment of primary memory 2 
Z7C1.00 Impaired cognition 2 
129B.00 FH: Alzheimer's disease 2 
Z7A1A00 Executive functions training 2 
9hD0.00 Excepted from dementia quality indicators: Patient unsuitabl 2 
9hD1.00 Excepted from dementia quality indicators: Informed dissent 2 
1S21.00 Disturbance of memory for order of events 2 
Z7C3C00 Difficulty using visuospatial reasoning 2 
Z7C3600 Difficulty using verbal reasoning 2 
Z7C3300 Difficulty reasoning 2 
Z7C4A00 Difficulty processing information at normal speed 2 
Z7C4700 Difficulty processing information accurately 2 
Z7C4300 Difficulty processing information 2 
Z7CI100 Difficulty making plans 2 
ZR3V.13 Dementia rating scale 2 
9Ou4.00 Dementia monitoring verbal invite 2 
9Ou3.00 Dementia monitoring third letter 2 
9Ou5.00 Dementia monitoring telephone invite 2 
9Ou2.00 Dementia monitoring second letter 2 
9Ou1.00 Dementia monitoring first letter 2 
3A...12 Dementia assessment 2 
Z7CGP00 Delayed verbal memory 2 
ZR3V.11 DRS - Clinical dementia rating scale 2 
Y0601JS DEMENTIA CLINIC ATTENDANCE 2 
Y060 JS DEMENTIA CLINIC 2 
2919 DEMENTIA ALCOHOLIC 2 
Z73..00 Cognitive intervention strategies 2 
28E..00 Cognitive decline 2 
ZR3V.00 Clinical dementia rating scale 2 
ZR3V.12 CDR - Clinical dementia rating scale 2 
Z7CEH13 Bad memory 2 
ZR2X.12 BDRS - Blessed dementia rating scale 2 
Z7A1400 Attention training 2 
Z7CE600 Amnesia 2 
EU02y..0 2 
X0034 2 
AE..00 2 
Ryu5.00 [X]Symptoms/signs inv cognit, percept, emotion state & behav 1 
Eu80000 [X]Specific speech articulation disorder 1 
Eu81500 [X]Severe learning disability 1 
Eu81700 [X]Profound learning disability 1 
Ryu5000 [X]Other amnesia 1 
Ryu5100 [X]Oth & unspec symptom/sign involv cognit funct/awareness 1 
Eu81600 [X]Mild learning disability 1 
Eu05700 [X]Mild cognitive disorder 1 
Eu81z12 [X]Learning disorder NOS 1 
Eu81z11 [X]Learning disability NOS 1 
Eu81z13 [X]Learn acquisition disab NOS 1 
Eu03.11 [X]Korsakov's psychosis, nonalcoholic 1 
Eu10611 [X]Korsakov's psychosis, alcohol induced 1 
Eu80014 [X]Functional speech articulation disorder 1 
Eu80100 [X]Expressive language disorder 1 
Eu90000 [X]Disturbance of activity and attention 1 
Eu44000 [X]Dissociative amnesia 1 
Ryu5700 [X]Disorientation, unspecified 1 
Eu10712 [X]Chronic alcoholic brain syndrome 1 
Eu80600 [X]Auditory processing disorder 1 
Eu90011 [X]Attention deficit hyperactivity disorder 1 
Eu9y700 [X]Attention deficit disorder 1 
ZS91.12 [X]Attention deficit disorder 1 
Eu04.12 [X]Acute / subacute confusional state, nonalcoholic 1 
ZV40000 [V]Problems with learning 1 
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R045100 [D]Dysphasia 1 
R00zX00 [D]Disorientation, unspecified 1 
R043.00 [D]Aphasia 1 
R00z500 [D]Anterograde amnesia 1 
E011200 Wernicke-Korsakov syndrome 1 
C253.00 Wernicke's encephalopathy 1 
C251.11 Wernicke's encephalopathy 1 
Z7CMB00 Visuospatial agnosia 1 
Z7A1800 Visual processing training 1 
F481J00 Visual disorientation syndrome 1 
F584000 Unspecified other abnormal auditory perception 1 
Z7CH300 Unrealistic planning 1 
Z7C7200 Unable to write 1 
ZT46200 Unable to use verbal communication 1 
ZT49200 Unable to use non-verbal communication 1 
ZT47200 Unable to use language 1 
Z7CI500 Unable to use decision-making strategies 1 
Z7C6200 Unable to tell the time 1 
ZT4f200 Unable to responds to communication by others 1 
Z7C2600 Unable to recognise surroundings 1 
Z7C2200 Unable to recognise sounds 1 
Z7C2D00 Unable to recognise parts of own body 1 
Z7C2L11 Unable to recognise objects visually 1 
Z7C2L00 Unable to recognise objects by sight 1 
Z7C2H00 Unable to recognise objects 1 
Z7C2T00 Unable to recognise familiar people 1 
Z7C2R00 Unable to recognise faces by sight 1 
Z7C2P00 Unable to recognise faces 1 
Z7CFC00 Unable to recall five digit number at five minutes 1 
Z7C8200 Unable to read 1 
Z7C4900 Unable to process information at normal speed 1 
Z7C4600 Unable to process information accurately 1 
Z7C4200 Unable to process information 1 
ZM18200 Unable to plan meals 1 
Z7CH200 Unable to plan 1 
ZN28200 Unable to organise a journey 1 
Z7CI900 Unable to make considered choices 1 
Z7C4C00 Unable to analyse information 1 
1B1S.00 Transient global amnesia 1 
Z7CE700 Transient global amnesia 1 
ZS78600 Transcortical sensory dysphasia 1 
ZS78411 Transcortical motor aphasia 1 
Z7CE711 TGA - Transient global amnesia 1 
ZS78300 Subcortical aphasia 1 
E031.00 Subacute confusional state 1 
Z7A2200 Strategy training for perceptual skills 1 
ZS5..00 Speech and language dyspraxias 1 
ZS...00 Speech and language disorder 1 
ZS73.00 Specific language impairment 1 
ZS73.11 Specific language disorder 1 
Z7CC700 Spatial disorientation 1 
Z7CD400 Slow learner 1 
F483200 Simultaneous visual perception without fusion 1 
1B1A100 Short-term memory loss 1 
28E2.00 Severe cognitive impairment 1 
ZS78A00 Semantic dysphasia 1 
9Nk1.00 Seen in memory clinic 1 
9N0y.00 Seen in learning disabilities clinic 1 
342 CP SENILE PARKINSONISM 1 
Z7CE900 Retrograde amnesia 1 
8HHP.00 Referral to learning disability team 1 
8H4f.00 Referral to learning disabilities psychiatrist 1 
1BR0.00 Reduced concentration span 1 
ZS72.00 Receptive language impairment 1 
ZS78C00 Receptive dysphasia 1 
ZS78C11 Receptive aphasia 1 
Z7A1700 Reality orientation 1 
Z7A1711 RO - Reality orientation 1 
Z7CE911 RA - Retrograde amnesia 1 
ZRbf.00 Psycholinguistic assessments of language process in aphasia 1 
ZD38300 Promoting aphasics communication effectiveness programme 1 
8G96.00 Problem solving therapy 1 
ZS78F00 Posterior dysphasia 1 
1B1Y.00 Poor visual sequential memory 1 
1B1a.00 Poor auditory sequential memory 1 
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F591z00 Perceptive hearing loss NOS 1 
F591.14 Perceptive hearing loss 1 
F591.13 Perceptive deafness 1 
Z7CL700 Perception that things appear grey 1 
Z7CL800 Perception that things appear flat 1 
Z7CLE00 Perception of things changing size 1 
Z7CLH00 Perception of things changing shape 1 
Z7CL911 Perception of things changing colour 1 
E2F2.00 Other specific learning difficulty 1 
F584z00 Other abnormal auditory perception NOS 1 
F584.00 Other abnormal auditory perception 1 
Z7A1600 Orientation training 1 
Z7CC312 Orientation poor 1 
Z7CC311 Orientation confused 1 
E2A1100 Organic memory impairment 1 
918e.00 On learning disability register 1 
29J4.00 O/E - sensory inattention 1 
2B46.11 O/E - sensory dysphasia 1 
2B43.00 O/E - sensory aphasia 1 
2BM3.11 O/E - perceptive deafness 1 
2B45.11 O/E - motor dysphasia 1 
2B42.00 O/E - motor aphasia 1 
2B46.00 O/E - dysphasia - sensory 1 
2B45.00 O/E - dysphasia - motor 1 
2B47.00 O/E - dysphasia - NOS 1 
2B4..12 O/E - dysphasia 1 
2B44.00 O/E - aphasia NOS 1 
2B4..11 O/E - aphasia 1 
ZS78I00 Non-fluent dysphasia 1 
ZS78I11 Non-fluent aphasia 1 
28E1.00 Moderate cognitive impairment 1 
ZS78200 Mixed transcortical dysphasia 1 
ZS78900 Mixed dysphasia 1 
ZS78911 Mixed aphasia 1 
Z7C2700 Mistakes people's identity 1 
28E0.00 Mild cognitive impairment 1 
3A60.00 Memory: present month not knwn 1 
3A11.00 Memory: own age known 1 
Z7A1300 Memory skills training 1 
Z7CFz00 Memory aided by use of lists 1 
Z7CFw00 Memory aided by use of diary 1 
ZS34.11 Learning disability 1 
9HB2.00 Learning disabilities health action plan reviewed 1 
9HB1.00 Learning disabilities health action plan offered 1 
9HB0.00 Learning disabilities health action plan declined 1 
9HB4.00 Learning disabilities health action plan completed 1 
9HB6.11 Learning disabilities annual health check declined 1 
9HB6.00 Learning disabilities annual health assessment declined 1 
9HB5.00 Learning disabilities annual health assessment 1 
Z7CD200 Learning difficulties 1 
ZS3..00 Language-related cognitive disorder 1 
ZS7..00 Language impairment 1 
ZS7C600 Language disorder associated with thought disorder 1 
13ZA.00 Language difficulty 1 
E011100 Korsakov's alcoholic psychosis with peripheral neuritis 1 
E011000 Korsakov's alcoholic psychosis 1 
E040.11 Korsakoff's non-alcoholic psychosis 1 
ZS78D12 Jargon dysphasia 1 
ZS78D11 Jargon aphasia 1 
A411.00 Jakob-Creutzfeldt disease 1 
ZS78212 Isolation dysphasia 1 
Z7CEA12 Impairment of immediate recall 1 
Z7CD300 Impaired ability to learn new material 1 
E201700 Hysterical amnesia 1 
Z7CL100 Heightened visual perception 1 
Z7CL511 Heightened perception of touch 1 
Z7CLO00 Heightened perception of taste 1 
Z7CLP11 Heightened perception of sound 1 
Z7CLN11 Heightened perception of smells 1 
Z7CLN12 Heightened perception of odours 1 
Z7CLN00 Heightened olfactory perception 1 
Z7CLP00 Heightened auditory perception 1 
ZRLfE00 Health of the Nation Outcome Scale item 4 - cognitive probl 1 
Z7CF200 Has delayed recall 1 
ZS78800 Global dysphasia 1 
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3AE..00 Global deterioration scale: assessment of prim deg dementia 1 
ZS78811 Global aphasia 1 
Z7CE500 Forgetful 1 
ZS78E11 Fluent aphasia 1 
1281.00 FH: Senile dementia 1 
ZS71.00 Expressive language impairment 1 
ZS84.00 Expressive language disorder 1 
ZS78G11 Expressive aphasia 1 
9hD..00 Exception reporting: dementia quality indicators 1 
ZS78K00 Efferent motor dysphasia 1 
ZS78K11 Efferent motor aphasia 1 
ZS78.00 Dysphasia 1 
ZT46400 Does not use verbal communication 1 
ZT4J400 Does not use the elements of language 1 
ZT49400 Does not use non-verbal communication 1 
ZT4f400 Does not respond to communication by others 1 
Z7C2900 Does not recognise self 1 
Z7C2A00 Does not recognise photographs of self 1 
Z7CEM00 Distortion of memory 1 
Z7CC600 Disorientation for person 1 
Z7C7300 Difficulty writing 1 
ZT46500 Difficulty using verbal communication 1 
ZT49500 Difficulty using non-verbal communication 1 
Z7CI600 Difficulty using decision-making strategies 1 
ZT4A500 Difficulty using a non-speech system for communication 1 
Z7CJ100 Difficulty solving problems 1 
Z7C8300 Difficulty reading 1 
ZM18500 Difficulty planning meals 1 
Z7C9300 Difficulty performing logical sequencing 1 
ZN28500 Difficulty organising a journey 1 
Z7CI200 Difficulty making decisions 1 
Z7CIA00 Difficulty making considered choices 1 
ZT4g500 Difficulty imitating forms of communication 1 
Z7C4D00 Difficulty analysing information 1 
9HB7.11 Did not attend learning disabilities annual health check 1 
9HB7.00 Did not attend learning disabilities annual health assessmnt 1 
9Ou..00 Dementia monitoring administration 1 
ZS93.11 DAMP - Deficits in attention motor control and perception 1 
ZS78B11 Conduction aphasia 1 
F591y00 Combined perceptive hearing loss 1 
Z7A1.00 Cognitive skills training 1 
ZD15.00 Cognitive neuropsychological language therapy 1 
ZD38200 Cognitive behavioural language therapy 1 
E2E0z00 Child attention deficit disorder NOS 1 
E2E0.00 Child attention deficit disorder 1 
Z7CLK00 Changed perception of time 1 
F11x700 Cerebral degeneration due to Jakob - Creutzfeldt disease 1 
ZS78H00 Broca's dysphasia 1 
ZS78H11 Broca's aphasia 1 
ZS76.00 Auditory processing disorder 1 
E2E0000 Attention deficit without hyperactivity 1 
ZS91.00 Attention deficit disorder 1 
ZS78.11 Aphasia 1 
Z7CE811 Antegrade amnesia 1 
ZS78511 Anomic aphasia 1 
ZS78500 Anomia 1 
Z7CEB00 Amnesia for remote events 1 
Z7CEC00 Amnesia for recent events 1 
Z7CEE00 Amnesia for important personal information 1 
Z7CED00 Amnesia for day to day facts 1 
13Y7.00 Alzheimer's disease society member 1 
ZS7C.00 Acquired language disorder 1 
ZS78100 Acquired dysphasias 1 
9OlA.00 ADHD monitoring invitation third letter 1 
9Ol8.00 ADHD monitoring invitation first letter 1 
ZS91.11 ADD - Attention deficit disorder 1 
Z7C2N00 1 
E0120 1 
6AB.00 1 
Z7C3800 1 
Xa25J 1 
Z7CEB11 1 
Z7CC800 1 
Z7C2J00 1 
X00Rk 1 
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Z7C3B00 1 
Z7A1100 1 
Z7C6300 1 
Z7C9200 1 
Z7C3900 1 
Z7C2F00 1 
Z7C2B00 1 
Z7A1712 1 
Z7A2100 1 
Z7A2300 1 
 
 
 
Supplementary appendix 4, table 7. ICD codes used in the studies of dementia. 
Study Databases ICD version List of codes 
Brown, 2016 CPRD + HES ICD-10 
E512, F00, F01, F02, F03, 
F10.6, F10.7, G30, G31.0 
Emdin, 2016 CPRD + HES ICD-10 F01 
CPRD – Clinical Practice Research Datalink; HES – Hospital Episode Statistics; ICD - International Classification 
of Diseases. 
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Supplementary appendix 4, table 8. List of Read codes used in the studies of fatigue. 
Read code Description Number of studies 
168..00 Tiredness symptom 3 
168..11 Fatigue - symptom 3 
168..12 Lethargy - symptom 3 
1682.00 Fatigue 3 
1683.00 Tired all the time 3 
1684.11 C/O - debility - malaise 3 
168Z.00 Tiredness symptom NOS 3 
8HkW.00 Referral to chronic fatigue syndrome specialist team 3 
8HlL.00 Referral for chronic fatigue syndrome activity management 3 
8Q1..00 Activity management for chronic fatigue syndrome 3 
E205.00 Neurasthenia - nervous debility 3 
E205.12 Tired all the time 3 
Eu46011 [X]Fatigue syndrome 3 
F286.00 Chronic fatigue syndrome 3 
F286.11 CFS - Chronic fatigue syndrome 3 
F286.12 Postviral fatigue syndrome 3 
F286.13 PVFS - Postviral fatigue syn 3 
F286.14 Post-viral fatigue syndrome 3 
F286.15 Myalgic encephalomyelitis 3 
F286.16 ME - Myalgic encephalomyelitis 3 
F286000 Mild chronic fatigue syndrome 3 
F286100 Moderate chronic fatigue syndrome 3 
F286200 Severe chronic fatigue syndrome 3 
R007.00 [D]Malaise and fatigue 3 
R007100 [D]Fatigue 3 
R007211 [D]General weakness 3 
R007300 [D]Lethargy 3 
R007400 [D]Postviral (asthenic) syndrome 3 
R007411 [D]Post viral debility 3 
R007500 [D]Tiredness 3 
R007z00 [D]Malaise and fatigue NOS 3 
168..13 Malaise - symptom 2 
1683.11 C/O - 'tired all the time' 2 
1684.00 Malaise/lethargy 2 
1684.13 C/O - postviral syndrome 2 
1688.00 Exhaustion 2 
1B3..12 Weakness symptoms 2 
E205.11 Nervous exhaustion 2 
Eu46000 [X]Neurasthenia 2 
F03y.12 Myalgic encephalomyelitis 2 
N239.00 Fibromyalgia 2 
N248.00 Fibromyalgia 2 
R007000 [D]Malaise 2 
R007200 [D]Asthenia NOS 2 
R2y3.00 [D]Debility, unspecified 2 
168..14 C/O 'Muzzy head' 1 
1B32.00 Weakness present 1 
8HkW.11 Referral to myalgic encephalomyelitis specialist team 1 
8Q1..11 Activity management for myalgic encephalopathy 1 
A4zy300 Encephalitis lethargica 1 
Eu46y14 [X]Psychasthenia 1 
Eu46y15 [X]Psychasthenia neurosis 1 
R007600 [D]Post polio exhaustion 1 
R007z11 [D]Lassitude 1 
R202.00 [D]Senile asthenia 1 
SN44.00 Exhaustion due to exposure 1 
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Supplementary appendix 4, table 9. List of Read codes used in the studies of pain. 
Read code Description 
Number of 
studies 
NyuAG [X]Uns sof tis d,use/overu/prs 2 
NyuA [X]Other soft tissue disorders 2 
Nyu80 [X]Other myositis 2 
Nyu3 [X]Other joint disorders 2 
Ryu70 [X]Other chronic pain 2 
NyuAF [X]Oth spcf soft tissu disords 2 
Nyu85 [X]Oth spcf disorders/muscle 2 
NyuAA [X]Oth sft tis diso/oth dis CE 2 
Nyu8A [X]Oth disordrs/muscle/dis CE 2 
Nyu9 [X]Disorders/synovium+tendon 2 
Nyu8 [X]Disorders of muscles 2 
Nyu8B [X]Disorder of muscle, unspec 2 
R01zz [D]Nerv/musculoskel.sympt.NOS 2 
R01z [D]Nerv/musculoskel.symp.other 2 
R01 [D]Musculoskeletal symptoms 2 
R01z2 [D]Musculoskeletal pain 2 
R00z2 [D]General aches and pains 2 
N22z Synovium/tendon/bursa dis.NOS 2 
N0950 Stiff joint NEC-site unspecif. 2 
N0958 Stiff joint NEC-other specif. 2 
N240 Rheumatism/fibrositis NOS 2 
N2 Rheumatism, excl.the back 2 
N240z Rheumatism or fibrositis NOS 2 
N2400 Rheumatism NOS - shoulder 2 
N2403 Rheumatic pain 2 
N24z Polyalgia 2 
N09 Other/unspecif.joint disorders 2 
N22yz Other tendon disorder NOS 2 
N233z Other specif.musc.disorder NOS 2 
N06yz Other specif.arthropathy NOS 2 
N06y9 Other spec.arthr.-multipl.site 2 
N09y Other spec. joint disorders 2 
N24 Other soft tissue disorders 2 
N3z Other musculoskeletal dis. NOS 2 
N247 Other musculoskel.limb sympts. 2 
N23y Other muscle/ligament/fascia 2 
N23yz Other musc./lig./fasc.dis.NOS 2 
N096z Other joint symptoms NOS 2 
N0968 Other joint sympt.-other spec. 2 
N0969 Other joint sympt.-multip.site 2 
N09yz Other joint disorders NOS 2 
N09y0 Other joint dis.-site unspec. 2 
N09y8 Other joint dis.-other specif. 2 
N09y9 Other joint dis.-multiple site 2 
N2y Nonarticular rheumatism OS 2 
N2z Nonarticular rheumatism NOS 2 
N39 Nonallopathic lesions, NEC 2 
N39z Nonallopathic lesion NEC NOS 2 
N2411 Myositis unspecified 2 
N2480 Myofascial pain syndrome 2 
N241 Myalgia/myositis unspecified 2 
N241z Myalgia/myositis NOS 2 
N3y Musculoskeletal disorders OS 2 
Ny Musculoskeletal diseases OS 2 
Nz Musculoskeletal diseases NOS 2 
N2402 Muscular rheumatism 2 
N23z Muscle/ligament/fascia dis.NOS 2 
N2410 Muscle pain 2 
N0959 Multiple joint stiffness 2 
N0450 Juv ankylosing spondylitis 2 
N095z Joint stiffness NEC NOS 2 
N095 Joint stiffness NEC 2 
N09zz Joint disorders NOS 2 
N09z Joint disorder NOS 2 
N09z0 Joint disord.NOS-site unspecif 2 
N09z8 Joint disord.NOS-other specif. 2 
N09z9 Joint disord.NOS-multiple site 2 
N096 Joint crepitus 2 
N2401 Fibrositis unspecified 2 
N2412 Fibromyositis NOS 2 
N248 Fibromyalgia 2 
N239 Fibromyalgia 2 
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Number of 
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N23 Fascia disorders 2 
N06zB Chronic arthritis 2 
N06z0 Arthropathy NOS-site unspecif. 2 
N06z8 Arthropathy NOS-other specif. 2 
N06z9 Arthropathy NOS-multiple sites 2 
N06zz Arthropathy NOS 2 
N0z Arthropathies NOS 2 
N06z Arthritis 2 
N0949 Arthralgia of multiple joints 2 
N094z Arthralgia NOS 2 
N0940 Arthralgia - site unspecified 2 
N0948 Arthralgia - other specified 2 
N094 Ache in joint 2 
OX7179KB viral myalgia /ox 1 
7K6T1 release of Torticollis 1 
N2452 neuropathic pain 1 
OX7289CH back pain /ox 1 
Syu4E [X]Unspecif inj should/up arm 1 
NyuB8 [X]Unsp osteopor + pathol frac 1 
Nyu28 [X]Unilat second gonarthrosis 1 
Nyu25 [X]Unilat primary gonarthrosis 1 
Nyu4 [X]Systmc connctv tis disordrs 1 
Nyu4C [X]Sys diso/connctv t/o dis CE 1 
Nyu95 [X]Synovitis+tenosyn/bact d CE 1 
Nyu97 [X]Synovial hypertrophy, NEC 1 
Ryu3 [X]Sym/sign inv nv/muscskel sy 1 
Syu12 [X]Superf inj neck part unsp 1 
Syu84 [X]Sprn/str oth unsp part knee 1 
Syu46 [X]Spr/str oth/un part shl gir 1 
Syu36 [X]Spr/str ot/un pt lum sp/pel 1 
Syu18 [X]Spr/str jt/lg ot/un pt neck 1 
Nyu92 [X]Spontans ruptr/oth tendons 1 
Nyu68 [X]Spondylpthy/oth diseases CE 1 
Nyu66 [X]Spondylpth/o inf+paras d CE 1 
Nyu69 [X]Spondylopathy unspecified 1 
Nyu6 [X]Spondylopathies 1 
Nyu5B [X]Spin osteochondrosis, unsp 1 
Nyu1G [X]Seroposit rheum arthr, unsp 1 
Nyu10 [X]Rheum arthrit+inv/o org/sys 1 
Nyu05 [X]Reactv arthropathy/o dis CE 1 
Eu45y [X]Psychogenic torticollis 1 
NyuE4 [X]Postproc muscsk disord,unsp 1 
Nyu2F [X]Post-traum arthr oth joints 1 
NyuC9 [X]Periostitis/oth inf dis CE 1 
Nyu51 [X]Other+unspecified kyphosis 1 
Nyu64 [X]Other spondylosis 1 
Nyu2D [X]Other specified arthrosis 1 
Nyu1B [X]Other specified arthritis 1 
Nyu65 [X]Other spcfd spondylopathies 1 
Nyu3D [X]Other spcfd joint disorders 1 
NyuAB [X]Other shoulder lesions 1 
Nyu54 [X]Other secondary scoliosis 1 
Nyu50 [X]Other secondary kyphosis 1 
Nyu17 [X]Other secondary gout 1 
Nyu21 [X]Other primary coxarthrosis 1 
Nyu20 [X]Other polyarthrosis 1 
Nyu46 [X]Other overlap syndromes 1 
NyuB1 [X]Other osteoporosis 1 
NyuC [X]Other osteopathies 1 
NyuC5 [X]Other osteonecrosis 1 
NyuC3 [X]Other osteomyelitis 1 
Nyu82 [X]Other ossification/muscle 1 
Nyu37 [X]Other meniscus derangements 1 
Nyu52 [X]Other lordosis 1 
Nyu15 [X]Other juvenile arthritis 1 
Nyu3C [X]Other instability of joint 1 
NyuA4 [X]Other infective bursitis 1 
Nyu53 [X]Other idiopathic scoliosis 1 
Nyu41 [X]Other giant cell arteritis 1 
Nyu56 [X]Other fusion of spine 1 
Nyu55 [X]Other forms of scoliosis 1 
NyuAE [X]Other enthesopathies,NEC 1 
Nyu7 [X]Other dorsopathies 1 
Nyu7A [X]Other dorsalgia 1 
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Nyu36 [X]Other disorders of patella 1 
Nyu44 [X]Other dermatomyositis 1 
Nyu35 [X]Other derangements/patella 1 
NyuB6 [X]Other cyst of bone 1 
NyuC2 [X]Other chronic osteomyelitis 1 
Nyu18 [X]Other chondrocalcinosis 1 
Nyu81 [X]Other calcification/muscle 1 
NyuA1 [X]Other bursitis of knee 1 
NyuA6 [X]Other bursitis NEC 1 
NyuA5 [X]Other bursal cyst 1 
NyuA7 [X]Other bursa disorder 1 
NyuE3 [X]Other biomechanical lesions 1 
NyuB4 [X]Other adult osteomalacia 1 
NyuC0 [X]Other acute osteomyelitis 1 
NyuC4 [X]Other 2ndary osteonecrosis 1 
Nyu47 [X]Oth syst dis/connctv tissue 1 
Nyu91 [X]Oth synovitis+tenosynovitis 1 
Syu40 [X]Oth sup inj should/upp arm 1 
Nyu62 [X]Oth spondylosis+myelopathy 1 
Nyu79 [X]Oth specified dorsopathies 1 
NyuC8 [X]Oth spcfd disorders of bone 1 
Nyu1A [X]Oth spcfc arthropathies,NEC 1 
Nyu12 [X]Oth spcf rheumatd arthritis 1 
Nyu61 [X]Oth spcf inflam spondylpath 1 
NyuD4 [X]Oth spcf disordrs/cartilage 1 
Nyu59 [X]Oth spcf deform dorsopaths 1 
NyuD3 [X]Oth spc osteochondropathies 1 
Syu3K [X]Oth sp inj abd/low back/pel 1 
Nyu2E [X]Oth secondary coxarthrosis 1 
Nyu83 [X]Oth ruptr/muscl(nontraumtc) 1 
Nyu58 [X]Oth recur vertebrl subluxtn 1 
Nyu03 [X]Oth reactive arthropathies 1 
Nyu13 [X]Oth psoriatic arthropathies 1 
Nyu26 [X]Oth post-traum gonarthrosis 1 
Nyu23 [X]Oth post-traum coxarthrosis 1 
NyuB0 [X]Oth osteoporosis+patholog # 1 
Nyu39 [X]Oth intrnl derangemnts/knee 1 
Nyu90 [X]Oth infectve(teno)synovitis 1 
Nyu60 [X]Oth infectv spondylopathies 1 
Nyu45 [X]Oth forms/systemc sclerosis 1 
Nyu43 [X]Oth forms/sys lup erythemat 1 
NyuA9 [X]Oth fibroblastic disorders 1 
Nyu22 [X]Oth dysplastic coxarthrosis 1 
NyuB5 [X]Oth diso/continuity of bone 1 
NyuC6 [X]Oth diso/bone dvlpmnt+grwth 1 
NyuE [X]Oth dis musculosk+connect 1 
Nyu70 [X]Oth cervicl disc displacmnt 1 
Nyu71 [X]Oth cervicl disc degeneratn 1 
Nyu72 [X]Oth cervical disc disorders 1 
Nyu3A [X]Oth articulr cartilag disor 1 
Nyu27 [X]Oth 2ndry gonarthrsis,bilat 1 
Nyu24 [X]Oth 2ndry coxarthrsis,bilat 1 
NyuB2 [X]Osteoporosis/oth disords CE 1 
NyuBC [X]Osteopenia 1 
NyuCA [X]Osteopathy/other inf dis CE 1 
NyuCF [X]Osteopathy/oth diseases CE 1 
NyuCC [X]Osteonecrosis/other dis CE 1 
NyuCB [X]Osteonecros/h'moglobnpth CE 1 
NyuCD [X]Osteitis defrmn/neop dis CE 1 
SR1z1 [X]Op multiple fractures unsp 1 
Nyu00 [X]O strep arthritis+polyarthr 1 
Nyu38 [X]O spontn disrptn/lig(s)knee 1 
Nyu63 [X]O spondylosis+radiculopathy 1 
NyuD2 [X]O spf juvnl osteochondrosis 1 
Nyu42 [X]O spcf necrotiz vasculopath 1 
Nyu3B [X]O spcf joint derangmnts,NEC 1 
Nyu77 [X]O spcf intrvrtbrl disc diso 1 
Nyu94 [X]O spcf diso/synovium+tendon 1 
Nyu19 [X]O spcf crystl arthropathies 1 
Nyu76 [X]O spc intrvrtbl disc degenr 1 
Nyu75 [X]O spc intervert disc displm 1 
NyuB7 [X]O spc diso/bne dnsity+struc 1 
NyuE0 [X]O spc acq defrm/muscskl sys 1 
NyuA3 [X]O sft t d rl/use,overu+prss 1 
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Nyu11 [X]O sero+ve rheumat arthritis 1 
Nyu57 [X]O recur atlantoaxl subluxtn 1 
NyuE2 [X]O postproced muscskel disor 1 
Nyu04 [X]O postinf arthropath/dis CE 1 
NyuC7 [X]O hypertrophc osteoarthrpth 1 
Nyu14 [X]O enteropathic arthrpathies 1 
NyuB3 [X]O drug-indc osteomalac/adlt 1 
Nyu96 [X]O diso/synovm+tendon/dis CE 1 
Nyu93 [X]O contractre/tendon(sheath) 1 
Nyu40 [X]O cond relt/polyarterit nod 1 
NyuC1 [X]O chr h'matogens osteomylit 1 
Nyu4D [X]Necrotis vasculopathy, unsp 1 
Nyu87 [X]Myosits/protzl+paras inf CE 1 
Nyu88 [X]Myositis/oth infects dis CE 1 
Nyu89 [X]Myositis in sarcoidosis CE 1 
Nyu86 [X]Myositi/bacterial dis CE 1 
Nyu84 [X]Muscle wasting and atrophy NEC 1 
SyuA4 [X]Multi disloc/spr/strns,unsp 1 
Nyu4F [X]Mixed connective tissue disease 1 
Nyu74 [X]Lumb+o intvt disc d+radiclp 1 
Nyu73 [X]Lumb+o intrvrt disc d+mylop 1 
Nyu5A [X]Lordosis, unspecified 1 
Nyu16 [X]Juvenile arthritis/o dis CE 1 
Syu1 [X]Injuries to the neck 1 
Syu3 [X]Injabd/low back/lum sp/pel 1 
Syu4 [X]Inj to shoulder/upper arm 1 
Syu8 [X]Inj to knee and lower leg 1 
Nyu1 [X]Inflammatory polyarthropathies 1 
Nyu0 [X]Infectious arthropathies 1 
Nyu1C [X]Gt arthpth/enz d+o inh d CE 1 
Syu16 [X]Fracture other parts neck 1 
Syu44 [X]Fract should/upp arm unsp 1 
Syu15 [X]Fract oth spec cervic vert 1 
SyuA2 [X]Fract inv oth comb bod regn 1 
NyuAH [X]Fibroblastic disord, unspec 1 
NyuA8 [X]Fasciitis,NEC 1 
NyuBB [X]Erosion of bone 1 
SyuA3 [X]Dsl/spr/str,oth comb bod rg 1 
SyuB3 [X]Dsl/sp/st un jt/l leg,lv un 1 
NyuB [X]Disordrs/bone dens+structur 1 
Nyu3E [X]Disorder of patella, unspec 1 
NyuDE [X]Disorder cartilage, unspec 1 
NyuBA [X]Disord bone dens/struc,unsp 1 
Syu17 [X]Disloc oth unsp parts neck 1 
SyuBC [X]Disl/spr/str unsp body reg 1 
Nyu4E [X]Dermatopolymyositis, unspec 1 
Nyu48 [X]Dermat(poly)myosit/neo d CE 1 
Nyu5 [X]Deforming dorsopathies 1 
Nyu1D [X]Crys arthpth/o meta diso,CE 1 
Nyu67 [X]Collapsd vertebra in dis CE 1 
SR1z0 [X]Clsd multiple fracts unspec 1 
NyuD [X]Chondropathies 1 
Nyu7B [X]Cervical disc disord, unsp 1 
Nyu4B [X]Arthrpthy/hyprsens react CE 1 
Nyu1F [X]Arthrpth/o spcf diseases CE 1 
Nyu1E [X]Arthrpth/o en,nut+meta diso 1 
Nyu2 [X]Arthrosis 1 
Nyu4A [X]Arthropathy/o bld disord CE 1 
Nyu49 [X]Arthropathy/neoplast dis CE 1 
Nyu02 [X]Arthrits/o inf+paras dis CE 1 
Nyu01 [X]Arthrit+polyarth/o s bact a 1 
NyuB9 [X]Adult osteomalacia, unspec 1 
Nyu [X]Ad muscskl+con t dis cls tm 1 
NyuCE [X]#bone/neoplastic disease CE 1 
NyuE1 [X]#/bne f insrt/o i,j pr,bn p 1 
EMISREQ|7N945(9) [SO]Lumbosacral joint -Req. 1 
HNGZ018 [RFC] Arthritis 1 
R0420 [D]Swelling in head or neck 1 
R042 [D]Swell.masslump head/neck 1 
R027 [D]Spontaneous bruising 1 
R065A [D]Musculoskeletal chest pain 1 
R137 [D]Musculoskel.ray/scan abnorm 1 
R137z [D]Musculosc xray/scan abn NOS 1 
R022C [D]Lump on knee 1 
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R04zz [D]Head and neck symptoms NOS 1 
R04 [D]Head and neck symptoms 1 
R04z [D]Head and neck other sympt. 1 
R00z2-1 [D]General aches and pains 1 
R065000 [D]CHEST PAIN, UNSPECIFIED 1 
R065z00 [D]CHEST PAIN NOS 1 
R065.00 [D]CHEST PAIN 1 
R090z00 [D]Abdominal pain 1 
R090.00 [D]Abdominal pain 1 
DEGRADE_EVENT_1730_49 [DEGRADE Muscle Injury] 1 
DEGRADE_EVENT_2469_340 [DEGRADE Knee Pain] 1 
DEGRADE_EVENT_3154_40 [DEGRADE Knee Pain] 1 
N135z-2 Wry neck 1 
N05z3 Wrist osteoarthritis NOS 1 
N0943-1 Wrist joint pain 1 
N06z3-1 Wrist arthritis NOS 1 
S5704 Whiplash injury 1 
EGTONWE2 Wedge Compression # Of Dorsal Spine 1 
EGTONWE1 Wedge Compression # Lumbar Spine 1 
N2432 Weber - Christian disease 1 
N2430 Weber - Christian disease 1 
N0974 Walking difficulty-other spec. 1 
N0975 Walking difficulty-multip.site 1 
N0970 Walking difficulty due to unspecified site 1 
N2413 Viral myalgia 1 
N092M Villonodular synovitis of knee 1 
N092z Villonodular synovitis NOS 1 
N092 Villonodular synovitis 1 
N0920 Villonod.synovitis-site unspec 1 
N0921 Villonod.synovitis-shoulder 1 
N0928 Villonod.synovitis-other spec. 1 
N0929 Villonod.synovitis-mult.sites 1 
N2208 Villonod synovitis-tend sheath 1 
N092B Villonod synovitis-sternclav j 1 
N092A Villonod synovitis-shoulder 1 
N092C Villonod synovitis-acromclav j 1 
N330B Vertebral osteoporosis 1 
N320 Vertebral epiphysitis 1 
N1 Vertebral column syndromes 1 
N1y Vertebral column disorders OS 1 
N1z Vertebral column disorder NOS 1 
N0966-2 Unstable knee 1 
N0967-1 Unstable ankle 1 
N066z Unspecified monoarthritis NOS 1 
N066 Unspecified monoarthritis 1 
N1290 Unspec.disc disorder+myelop. 1 
N0650 Unsp.polyarthr.-site unspecif. 1 
N065000 Unsp.polyarthr.-site unspecif. 1 
N0651 Unsp.polyarthr.-shoulder 1 
N065800 Unsp.polyarthr.-other specif. 1 
N0658 Unsp.polyarthr.-other specif. 1 
N065900 Unsp.polyarthr.-multiple site 1 
N0659 Unsp.polyarthr.-multiple site 1 
N3020 Unsp.osteomyelitis-site unspec 1 
N3021 Unsp.osteomyelitis-shoulder 1 
N3028 Unsp.osteomyelitis-other spec. 1 
N3029 Unsp.osteomyelitis-mult.site 1 
N302z Unsp.osteomyelitis NOS 1 
N0660 Unsp.monoarthr.-site unspecif. 1 
N0661 Unsp.monoarthr.-shoulder 1 
N0668 Unsp.monoarthr.-other specif. 1 
N1121 Two lev th spondyl-no myelop 1 
N11B1 Two lev th spondyl + radiculop 1 
N1131 Two lev th spondyl + myelop 1 
N1141 Two lev lumbsac spond-no myelo 1 
N1151 Two lev lumbsac spond + myelop 1 
N1101 Two lev Cx spondyl-no myelop 1 
N1191 Two lev Cx spondyl + radiculop 1 
N1111 Two lev Cx spondyl + myelop 1 
N018 Tuberculous arthritis 1 
N3041 Tuberculosis of thoracic spine 1 
N304 Tuberculosis of spine 1 
N306 Tuberculosis of other bones 1 
N3042 Tuberculosis of lumbar spine 1 
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N3040 Tuberculosis of cervical spine 1 
N3060 Tuberculosis bone-site unspec. 1 
N3061 Tuberculosis bone-shoulder 1 
N3064 Tuberculosis bone-other sites 1 
N3065 Tuberculosis bone-multip.sites 1 
N306z Tuberculosis bone NOS 1 
N22yD Tuberc infec - tendon sheath 1 
N2155 Trochanteric tendinitis 1 
N2157 Trochanteric bursitis 1 
N0874 Triangular fibrocartilage tear 1 
N0875 Triangular fibrocartil detach 1 
N118 Traumatic spondylopathy 1 
N2312 Traumatic myositis ossificans 1 
SE46 Traumatic haematoma 1 
SK Traumatic complicat./unsp.inj. 1 
N061A Traumatic arthropathy-shoulder 1 
N061M Traumatic arthropathy-knee 1 
N061z Traumatic arthropathy NOS 1 
N061 Traumatic arthropathy 1 
N0610 Traumatic arthr.-site unspecif 1 
N0611 Traumatic arthr.-shoulder 1 
N0618 Traumatic arthr.-other specif. 1 
N0619 Traumatic arthr.-multiple site 1 
N061B Traumat arthrop-sternoclav jt 1 
N061C Traumat arthrop-acromioclav jt 1 
S906 Traumat amp at shoulder joint 1 
SA72 Traum.unil.amput.>knee-no comp 1 
N220Q Transient synovitis 1 
N064A Transient arthropathy-shoulder 1 
N064M Transient arthropathy-knee 1 
N064z Transient arthropathy NOS 1 
N064 Transient arthropathy 1 
N064B Transient arthrop-sternoclav j 1 
N0640 Transient arthr.-site unspecif 1 
N0641 Transient arthr.-shoulder 1 
N0648 Transient arthr.-other specif. 1 
N0649 Transient arthr.-multiple site 1 
N064C Transient arthr-acromioclav jt 1 
N135 Torticollis unspecified 1 
Q20y9 Torticollis due to birth injury 1 
16A3 Torticollis - symptom 1 
N2451-1 Toe pain 1 
N2162 Tibial collateral lig.bursitis 1 
N2450-1 Thumb pain 1 
N05z4-2 Thumb osteoarthritis NOS 1 
N3735 Thoracogenic scoliosis 1 
N1485 Thoraco-lumbar ankylosis 1 
N144 Thoracic/lumbosacral neuritis 1 
N144z Thoracic/lumbosac.neuritis NOS 1 
N112-1 Thoracic spondylosis 1 
N112 Thoracic spond.-no myelopathy 1 
N113 Thoracic spond.+ myelopathy 1 
N148B Thoracic spine instability 1 
N1484 Thoracic spine ankylosis 1 
N1401 Thoracic spinal stenosis 1 
N12A2 Thoracic postlaminectomy syndr 1 
N1440 Thoracic nerve root pain 1 
N12z8 Thoracic discitis 1 
N121 Thoracic disc displ.-no myelop 1 
N1292 Thoracic disc disord.+myelop. 1 
N126 Thoracic disc degeneration 1 
S571 Thoracic back sprain 1 
EMISNQTH14 Thoracic back pain 1 
N245-8 Thigh pain 1 
N11B Th spondyl + radiculop 1 
N1406 Th spin stenos due to oth dis 1 
N12C1 Th disc prolapse+radiculopathy 1 
N12B1 Th disc prolapse + myelopathy 1 
N2132-1 Tennis elbow 1 
N2202 Tendon sheath giant cell tumor 1 
ASDFGTE2 Tendon Symptoms 1 
N2456 Tender heel pad 1 
S46B Tear/articulr cart/knee,currnt 1 
S545 Tear of ligament of knee joint 1 
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N000* Systemic lupus erythematosus 1 
N000 Systemic lupus erythematosus 1 
N000z Systemic lupus erythematos.NOS 1 
N0012 Syst scleros induc drugs/chems 1 
N0003 Syst lup eryth + organ/sys inv 1 
N2227 Syphilitic bursitis 1 
N2200 Synovitis or tenosynovitis NOS 1 
N220z-2 Synovitis of knee 1 
N220z Synovitis of knee 1 
N220V Synovitis of knee 1 
N220 Synovitis and tenosynovitis 1 
N220T Synovitis NOS 1 
N2201 Synovit./tenosynovitis+dis EC 1 
N22y4 Synovial plica 1 
N098 Synovial osteochondromatosis 1 
N2240 Synovial cyst unspecified 1 
N0980 Synov osteochondromat-shoulder 1 
N098B Synov osteochondromat-knee 1 
N0981 Synov osteochondromat st-cla j 1 
N0982 Synov osteochondromat ac-cla j 1 
1D24 Symptom: trunk posterior 1 
16J4 Swollen knee 1 
16J3 Swollen joint 1 
16J7 Swollen foot 1 
1834-1 Swollen finger 1 
1JG Suspected inflammatory arthritis 1 
N21z2 Supraspinatus tendonitis 1 
N2113 Supraspinatus tendinitis 1 
N230 Suppurative myositis 1 
SD1y4 Supl inj bk NOS-no mj opn wnd 1 
SD9 Superficialinjuriesunspecif. 1 
SD097 SuperficialInjury:Neck 1 
SD2y1 Superficial injury of scapular NOS 1 
SD6y2 Superficial injury of knee NOS 1 
SDz Superficial injuries NOS 1 
SD0 Superficial Injury: Neck 1 
SD2y0 Superfic injury shoulder NOS 1 
SD2 Superf.inj.shoulder/upper arm 1 
SD1z4 Superf.back inj.NOS+infect. 1 
N3371 Sudek's atrophy 1 
N2167 Subpatellar bursitis 1 
N3y01 Subluxatn complex (vertebral) 1 
N3y02 Sublux stenos of neural canal 1 
N3081 Subacute osteomyelitis-th spin 1 
N3082 Subacute osteomyelitis-lu spin 1 
N3080 Subacute osteomyelitis-Cx spin 1 
N309 Subacute osteomyelitis 1 
N308 Subacute osteomyelitis 1 
N2122 Subacromial impingement 1 
N2116 Subacromial bursitis 1 
S3z2 Stress fracture 1 
N095B Stiff sternoclavic joint NEC 1 
N095A Stiff shoulder NEC 1 
16AZ Stiff neck symptom NOS 1 
16A Stiff neck symptom 1 
N135z Stiff neck NOS 1 
16A2 Stiff neck 1 
N095M Stiff knee NEC 1 
N095C Stiff acromioclavicular joint NEC 1 
S5y41 Sternoclavicular sprain 1 
N0108 Staphylococc arthrit/polyarthr 1 
S5410 Sprn,knee jt,medial collat 1 
S5400 Sprn,knee jt,lat collat lgmt 1 
S520D Sprn triangular fibrocartilage 1 
S520G Sprn shrt intrnsc lgmnt non-sp 1 
S5 Sprains and strains 1 
S50 Sprained shoulder 1 
S54y-99 Sprained knee NOS 1 
S54-99 Sprained knee 1 
S560 Sprain, lumbosacral ligament 1 
S564 Sprain, iliolumbar ligament 1 
S501 Sprain, coraco-clav ligament 1 
S506 Sprain supraspinatus tendon 1 
S505 Sprain subscapularis tendon 1 
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S5071 Sprain shoulder joint posterior 1 
S5070 Sprain shoulder joint anterior 1 
S507 Sprain shoulder joint 1 
S534 Sprain patellar tendon 1 
S503 Sprain infraspinatus tendon 1 
S500 Sprain acromio-clav ligament 1 
S542 Sprain -cruciate knee ligament 1 
S541 Sprain - medial knee ligament 1 
S541-99 Sprain - medial knee ligament 1 
S540-99 Sprain - lateral knee ligament 1 
S540 Sprain - lateral knee ligament 1 
SC07 Sprain - late effect 1 
S57X Spr/str ot/un pt lum sp/pel 1 
ASDFGSP5 Sports Injury 1 
N082 Spontaneous joint dislocation 1 
16B3 Spontaneous bruising 1 
N11z0 Spondylosis-no myelopathy,NOS 1 
N11zz Spondylosis NOS 1 
N11z1 Spondylosis + myelopathy, NOS 1 
N388 Spondylolysis 1 
OXL7561C Spondylolisthesis /ox 1 
N10z Spondylitis NOS 1 
N374 Spine curvature+other condits. 1 
N374z Spine curvature+other cond.NOS 1 
N1400 Spinal stenosis unspec.region 1 
N140z Spinal stenosis NOS 1 
N140-1 Spinal stenosis 1 
N140 Spinal stenosis 1 
N101 Spinal enthesopathy 1 
N222z Specific bursitides NOS 1 
N222 Specific bursitides 1 
F1382 Spasmodic Torticollis 1 
N23y4 Spasm of muscle 1 
N23yE Spasm of back muscles 1 
EGTON309 Sore Neck 1 
N3321 Solitary bone cyst 1 
N0878 Snapping shoulder 1 
N32y Slipped radial epiphysis 1 
N33zA Skeletal fluorosis 1 
N002* Sicca (Sjogren's) syndrome 1 
N2125 Shoulder tendonitis 1 
S50y Shoulder sprain NOS 1 
N245-7 Shoulder pain 1 
N245 Shoulder pain 1 
N2457 Shoulder pain 1 
N0951 Shoulder joint stiffness 1 
UNMAPPC0 Shoulder injury 1 
S221 Shoulder fracture - open 1 
N22y5 Short tendon 1 
N011 Sex acquired reactive arthrop 1 
N0110 Sex acqd reac arthrop-unspec 1 
N0111 Sex acqd reac arthrop-shoulder 1 
N011y Sex acqd reac arthrop-oth spec 1 
N011x Sex acqd reac arthrop-multiple 1 
N011z Sex acq reac arthropathy NOS 1 
SRz0 Severe multiple injuries 1 
N047 Seropositive errosive RA 1 
N04X Seroposit rheum arthr unsp 1 
N040P Seronegative rheumat arthritis 1 
EGTONSE2 Sero-Negative Polyarthritis 1 
N04y1 Sero negative arthritis 1 
N04y10 Sero negative arthritis 1 
N3301 Senile osteoporosis 1 
N2169 Semimembranosus tendinitis 1 
EGTON131 Semi Frozen Shoulder 1 
N3y00 Segmental & somatic dysfunctn 1 
N0505 Secondary multiple arthrosis 1 
N050500 Secondary multiple arthrosis 1 
EMISNQSC20 Scoliosis of thoracic spine 1 
N374A Scoliosis in skelet dysplasia 1 
N374C Scoliosis in neurofibromatosis 1 
N374D Scoliosis in conn tiss anomal 1 
N3739 Scoliosis due to oth treatment 1 
OX735AA Scoliosis Acquired /ox 1 
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N3743 Scoliosis + other condition 1 
N001 Scleroderma 1 
OX353C Sciatica Chronic /ox 1 
N1240 Schmorl's nodes-unspec. region 1 
N1241 Schmorl's nodes-thoracic regn. 1 
N124z Schmorl's nodes-region NOS 1 
N1242 Schmorl's nodes-lumbar region 1 
N124 Schmorl's nodes 1 
N3201 Scheuermann's disease 1 
N2121 Scapulohumeral fibrositis 1 
N146z-1 Sacroiliac strain 1 
N1466 Sacroiliac disorder 1 
S5731 Sacral/coccyx sprain 1 
N0004 SLE with pericarditis 1 
N25 SAPHO syndrome 1 
S5Q2 Rupture supraspinatus tendon 1 
S5Q1 Rupture subscapularis tendon 1 
S5U2 Rupture patellar tendon 1 
N2250 Rupture of synovium unspecif. 1 
N225z Rupture of synovium NOS 1 
N2251-99 Rupture of synovium - knee 1 
N225 Rupture of synovium 1 
S5Q0 Rupture infraspinatus tendon 1 
N2251 Ruptur poplit space synov cyst 1 
N2110 Rotator cuff syndrome unspecif 1 
S504 Rotator cuff sprain 1 
N211 Rotator cuff shoulder syndrome 1 
N2261 Rotator cuff complete rupture 1 
N3385 Rotational mal-union of # 1 
182B Rib pain 1 
EGTON425 Rheumatology 1 
N040N Rheumatoid vasculitis 1 
N0422 Rheumatoid nodule 1 
N040R Rheumatoid nodule 1 
N0421 Rheumatoid lung disease 1 
N040Q Rheumatoid bursitis 1 
N0402 Rheumatoid arthritis-shoulder 1 
N0400 Rheumatoid arthritis-Cx spine 1 
N040D Rheumatoid arthritis of knee 1 
N040 Rheumatoid arthritis 1 
N0403 Rheumatoid arthr-sternoclav jt 1 
N0404 Rheumatoid arthr-acromioclav j 1 
N1351 Rheumatic torticollis 1 
N0420 Rheumatic carditis 1 
OX7149A Rheumatic Arthritis /ox 1 
N040S Rheumat arthr - multiple joint 1 
N2333 Rhabdomyolysis 1 
N042z Rh.arthr.+visc/syst.dis.NOS 1 
N080A Reverse Hill-Sachs lesion 1 
N0871 Reverse Bankart lesion 1 
N12zA Resorption of thoracic disc 1 
N12zE Resorption of lumbar disc 1 
N12z6 Resorption of cervical disc 1 
N3732 Resolving infant.idiopath.scol 1 
N246 Residual soft tiss.foreign bod 1 
N339 Residual foreign body in bone 1 
Ny2 Repetitive strain injury 1 
N33z5 Relapsing polychondritis 1 
N337 Reflex sympathetic dystrophy 1 
N083 Redislocation of joint 1 
S46D Recurrent subluxation of patella 1 
N083D Recurrent sublux shoulder-post 1 
N083F Recurrent sublux shoulder-inf 1 
N083C Recurrent sublux shoulder-ant 1 
N083H Recurrent sublux shoulder-ant 1 
N083q Recurrent sublux - patella 1 
N083z Recurrent joint dislocat.NOS 1 
N0839 Recurrent disloc-multip joints 1 
N083B Recurrent disloc shoulder-post 1 
N083E Recurrent disloc shoulder-inf 1 
N083A Recurrent disloc shoulder-ant 1 
N083G Recurrent disloc shoulder-ant 1 
N083p Recurrent disloc - patella 1 
N083n Recurrent disloc - knee 1 
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N0830 Recurr.joint disloc.-site unsp 1 
N0838 Recurr.joint disloc-other spec 1 
N0831 Recur. disloc.- shoulder joint 1 
N0836-99 Recur. disloc. - knee joint 1 
N083K Recur sublux shoulder-multidir 1 
N083J Recur disloc shoulder-multidir 1 
N1y0 Rec atlantoax subl + myelopath 1 
N01w0 Reactive arthropathy-shoulder 1 
N01w Reactive arthropathy unspecified 1 
N01wB Reactive arthropathy of knee 1 
N038 Reactive arthropathies 1 
N01w2 Reactive arthrop-sternoclav jt 1 
N01w1 Reactive arthr-acromioclav jt 1 
EGTON436 Radiculopathy 1 
N2422 Radiculitis unspecified 1 
N3734 Radiation scoliosis 1 
N3711 Radiation kyphosis 1 
N0706 Radial tear of medial meniscus 1 
N0717 Radial tear of lateral meniscus 1 
N2204 Radial styloid tenosynovitis 1 
N22yC Pyogenic infec - tendon sheath 1 
N010 Pyogenic arthritis 1 
N0100 Pyogenic arthr.-site unspecif. 1 
N0101 Pyogenic arthr.-shoulder regn. 1 
N010y Pyogenic arthr.-other specif. 1 
N010x Pyogenic arthr.-multiple sites 1 
N010z Pyogenic arthr.-NOS 1 
S57z0 Pulled back muscle 1 
OX848ML Pulled Muscle /ox 1 
E2601 Psychogenic Torticollis 1 
N2373 Pseudosarcomatous fibromatosis 1 
N33zC Pseudarth after fusn/arthrodes 1 
S5422 Prt tr,knee,post cruciate lgmt 1 
N12C4 Prol lumb interv disc sciatic 1 
N0010 Progressive systemic sclerosis 1 
N2311 Progressive myositis ossific. 1 
N3733 Progressive infant.idiop.scol. 1 
N051B Primary gonarthrosis, bilat 1 
N050400 Primary general osteoarthrosis 1 
N0504 Primary general osteoarthrosis 1 
N0519 Primary coxarthrosis bilateral 1 
N051C Primary arthrosis of first carpometacarpal joints, bilateral                                                                 1
N2165 Prepatellar bursitis 1 
N3736 Postural scoliosis 1 
N3307 Postsurg malabsorp osteoporos 1 
N3314 Postsur malab osteop+path frct 1 
NyX Postproc muscsk disord,unsp 1 
N2313 Postop.heterotopic calcificat. 1 
N3306 Postoophorectomy osteoporosis 1 
N3312 Postoophorc osteopor+path frct 1 
N3302 Postmenopausal osteoporosis 1 
N331B Postmenop osteopor+path fract 1 
N0380 Postmeningococcal arthritis 1 
N12Az Postlaminectomy syndrome NOS 1 
N12A Postlaminectomy syndrome 1 
N12A0 Postlaminectomy syndr.unspec. 1 
N0381 Postinf arthropath in syphilis 1 
N037 Postimmunization arthropathy 1 
N013 Postdysenteric react arthrop 1 
N0130 Postdys react arthrop-unspec 1 
N0131 Postdys react arthrop-shoulder 1 
N013y Postdys react arthrop-oth spec 1 
N013x Postdys react arthrop-multiple 1 
N013z Postdys react arthrop NOS 1 
16B4 Post-traumatic bruising 1 
N052B Post-traumatic arthrosis of first carpometacarpal joints, bilateral                                                               1
N052C Post-trauma gonarth, unilat 1 
N052A Post-traum gonarthrosis, bilat 1 
N0529 Post-traum coxarthrosis, bilat 1 
N3738 Post-surgical scoliosis 1 
N3721 Post-laminectomy lordosis 1 
N3712 Post-laminectomy kyphosis 1 
N2314 Polymyositis ossificans 1 
N004 Polymyositis 1 
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N20* Polymyalgia rheumatica 1 
N20 Polymyalgia 1 
N065-1 Polyarthropathy NEC 1 
N065.11 Polyarthropathy NEC 1 
N065 Polyarthropathy NEC 1 
N065z Polyarthritis 1 
N065z00 Polyarthritis 1 
N307z Poliomyelitis osteopathy NOS 1 
N3070 Polio.osteopathy-site unspecif 1 
N3071 Polio.osteopathy-shoulder 1 
N3078 Polio.osteopathy-other sites 1 
N3079 Polio.osteopathy-multiple site 1 
N0109 Pneumococc arthrit & polyarthr 1 
N2179 Plantar fasciitis 1 
N2209 Plant thorn synovitis 1 
N2161 Pes anserinus tendin./bursitis 1 
SJz-98 Peripheral nerve injury NOS 1 
N21zz Peripheral enthesopathy NOS 1 
N21 Peripheral enthesopathies 1 
N0705 Periph detach-medial meniscus 1 
N0716 Periph detach-lateral meniscus 1 
N303 Periostitis, no osteomyelitis 1 
N303B Periostitis, no osteomye-th sp 1 
N303C Periostitis, no osteomye-lu sp 1 
N303A Periostitis, no osteomye-Cx sp 1 
N303z Periostitis no osteomyel NOS 1 
N3030 Periostitis - site unspecified 1 
N3031 Periostitis - shoulder 1 
N3038 Periostitis - other sites 1 
N3039 Periostitis - multiple sites 1 
N2120 Periarthritis of shoulder 1 
N21z1 Periarthritis NOS 1 
N3843 Pedicular spondylolisthesis 1 
N0432 Pauciarticular juvenile R.A. 1 
N0456 Pauciartic onset juv ch arth 1 
N331y Pathological fracture OS 1 
N331z Pathological fracture NOS 1 
N082z Pathological dislocation NOS 1 
N331C Pathological # cervical vert 1 
N0820 Patholog.disloc.-site unspecif 1 
N0821 Patholog.disloc.-shoulder 1 
N0828 Patholog.disloc.-other specif. 1 
N082A Path disloc-shoulder joint 1 
N082R Path disloc-patellofem joint 1 
N082B Path disloc-oth joint-shoulder 1 
N0829 Path disloc-multiple joints 1 
N082Q Path disloc-knee joint 1 
N0536-1 Patellofemoral osteoarthritis 1 
N0536 Patellofemoral osteoarthritis 1 
N07y6 Patellofemoral maltracking 1 
N09A Patellofemoral disorder 1 
N2266 Patellar tendon nontraum.rupt. 1 
N2164 Patellar tendinitis 1 
N33z9 Partial epiphyseal arrest 1 
S5421 Part tr,knee,ant cruciate lgmt 1 
N2114 Part thickn rotator cuff tear 1 
S5411 Part tear,knee,mdl collat lgmt 1 
S5401 Part tear,knee,lat collat lgmt 1 
N1y2 Pars interarticular strss frct 1 
N0704 Parr beak tear-post/med menisc 1 
N0715 Parr beak tear-post/lat menisc 1 
N2316 Paralytic calcific/ossif muscl 1 
N243 Panniculitis unspecified 1 
N136 Panniculitis of neck 1 
N243z Panniculitis NOS 1 
N093z Palindromic rheumatism NOS 1 
N093 Palindromic rheumatism 1 
N0930 Palindromic rheum.-site unspec 1 
N0931 Palindromic rheum.-shoulder 1 
N0938 Palindromic rheum.-other spec. 1 
N0939 Palindromic rheum.-multip.site 1 
N211z Painful arc syndrome 1 
N211z-1 Painful arc syndrome 1 
EGTON224 Painful Shoulder 1 
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EGTON279 Painful Right Knee 1 
N131-1 Pain in cervical spine 1 
N245-9 Pain in buttock 1 
N2453 Pain in arm 1 
OX7280AD Pain Neck /ox 1 
OX7873E Pain Knee /ox 1 
N245-95 Pain In Right Leg 1 
N245-97 Pain In Right Arm 1 
N245-96 Pain In Left Leg 1 
N3101 Paget's disease-thoracic spine 1 
N3106 Paget's disease-scapula 1 
N310F Paget's disease-patella 1 
N310x Paget's disease-multiple sites 1 
N3102 Paget's disease-lumbar spine 1 
N3105 Paget's disease-clavicle 1 
N3100 Paget's disease-cervical spine 1 
N310y Paget's disease OS 1 
N310z Paget's disease NOS 1 
N122-1 PID - prolapsed lumbar disc 1 
N129 PID - prol i/v disc + myelop 1 
S102y Othr spec clsd # thorac vert 1 
S411y Othr opn trmtc disloctn shlder 1 
S410y Othr cls trmtc disloc shoulder 1 
SK12z Othershould/upperarminj.NOS 1 
SE08 Othercontusionneck 1 
N06..00 Other/unspecif. arthropathies 1 
N12z2 Other thoracic disc disorders 1 
N22 Other synovium/tendon/bursa 1 
N22y Other synovium/tendon/bursa 1 
N096B Other symptoms - sternoclav jt 1 
N096A Other symptoms - shoulder 1 
N096M Other symptoms - knee 1 
N096D Other symptoms - elbow 1 
N096C Other symptoms - acromioclav j 1 
SD9y Other superficial injury, without mention of infection, NOS 1 
S5y Other sprains and strains 1 
S5yz Other sprains NOS 1 
N11y Other spondyloses/allied dis. 1 
S5W Other specified tendon rupture 1 
S54w Other specified knee sprain 1 
SK1 Other specified injury 1 
N06y Other specified arthropathy 1 
N233 Other specific muscle disorder 1 
N04y Other specif.infl.polyarthrop. 1 
N32yz Other spec.osteochondrop.NOS 1 
N04yz Other spec.infl.polyarthr.NOS 1 
N00y Other spec.diff.collagen dis. 1 
N06y0 Other spec.arthr.-site unspec. 1 
N06y1 Other spec.arthr.-shoulder 1 
N06y8 Other spec.arthr.-other specif 1 
S5yy Other spec sprains and strains 1 
S50w Other shoulder sprain 1 
SK122 Other shoulder injuries 1 
N212 Other shoulder affections NEC 1 
N212z Other shoulder affect.NEC NOS 1 
SK121 Other scapular region injuries 1 
N042 Other rh.arthr.+visc/syst.dis. 1 
N3722 Other post-surgical lordosis 1 
N21y Other periph. enthesopathies 1 
N3272 Other osteochondr dissec-knee 1 
S466 Other opn trm dslctn knee 1 
S497 Other open trmtc dislocation 1 
S49Fz Other open subluxation NOS 1 
S4J3 Other open #-subluxation 1 
S4J1 Other open #-dislocation 1 
N226z Other nontraumatic tendon rupt 1 
SK10y Other neck injuries 1 
SK1x Other multiple injuries 1 
N12z3 Other lumbar disc disorders 1 
N07yy Other knee lig. old disruption 1 
SK170 Other knee injury 1 
N368 Other knee deformity 1 
N045 Other juvenile arthritis 1 
N326 Other juven.osteochondroses 1 
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N0960 Other joint sympt.-site unspec 1 
N0961 Other joint sympt.-shoulder 1 
N09y1 Other joint dis.-shoulder 1 
N08yz Other joint derange.NEC NOS 1 
SK112 Other interscapular injuries 1 
N07yz Other intern.knee derang.NOS 1 
SK1z Other injury NOS 1 
N10y Other inflamm.spondylopathies 1 
N10yz Other inflamm.spondylop.NOS 1 
N30y Other infections+bone disease 1 
N03x Other general dis.+arthropathy 1 
N237z Other fibromatoses NOS 1 
N237 Other fibromatoses 1 
SK10z Other face and neck injuries NOS 1 
S49z Other dislocation NOS 1 
N12z0 Other disc disorders unspecif. 1 
N08 Other derangement of joint 1 
N36y Other deformity of bone 1 
N37y Other curvatures of spine 1 
N02yz Other crystal arthropathy NOS 1 
N02y Other crystal arthropathies 1 
N02y0 Other crystal arth.-site unsp. 1 
N02y1 Other crystal arth.-shoulder 1 
N02yy Other crystal arth.-other spec 1 
N02yx Other crystal arth.-mult.sites 1 
S465 Other cls trm dslctn knee 1 
S49E Other closed traumatic sublux 1 
S4J2 Other closed #-sublux 1 
S4J0 Other closed #-dislocation 1 
N13yz Other cervical syndromes NOS 1 
N13y Other cervical syndromes 1 
N12z1 Other cervical disc disorders 1 
N33 Other bone/cartilage disorders 1 
N31y Other bone involve.in dis.EC 1 
SK114 Other back injuries 1 
N374X Other and unspecified kyphosis 1 
N06 Other and unspecified arthropathies 1 
S462 Other acute meniscus tear 1 
N38yz Other acquired deformity NOS 1 
N38y Other acquired deformity 1 
N38 Other acquired deformity 1 
S4J Other #-dslc or subluxation 1 
N08y0 Oth.joint deran.NEC-site unsp. 1 
N08y1 Oth.joint deran.NEC-shoulder 1 
N08y8 Oth.joint deran.NEC-other spec 1 
N08y9 Oth.joint deran.NEC-mult.sites 1 
N30y0 Oth.inf.+bone dis-site unspec. 1 
N30y1 Oth.inf.+bone dis-shoulder 1 
N30y8 Oth.inf.+bone dis-other sites 1 
N30y9 Oth.inf.+bone dis-multip.site 1 
N30yz Oth.inf.+bone dis-NOS 1 
N07y Oth. internal knee derangement 1 
S49 Oth, mlti+ill-def dislc/sublux 1 
N0401 Oth rheumatoid arthritis-spine 1 
S49F Oth open traumatic subluxation 1 
SRy Oth inj inv mult body reg NEC 1 
S496 Oth cls trmatic dislocation 1 
S49Ez Oth closed subluxation NOS 1 
N33B Osteoradionecrosis 1 
N3746 Osteoporotic kyphosis 1 
N3300 Osteoporosis unspecified 1 
N330C Osteoporosis localized spine 1 
N330A Osteoporosis in endocr disord 1 
N330z Osteoporosis NOS 1 
N330 Osteoporosis 1 
N330D Osteoporos due corticosteroid 1 
N3309 Osteopor,multiple myelomatosis 1 
N3319 Osteopor path # thor vertebrae 1 
N3318 Osteopor path # lumb vertebrae 1 
N331A Osteopor path # cerv vertebrae 1 
N3313 Osteopor of disuse + path frct 1 
N09B Osteophyte 1 
N307 Osteopathy from poliomyelitis 1 
ASDFGOS1 Osteopaenia 1 
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N334B Osteonecrosis in caisson dis 1 
N3349 Osteonecrosis due to drugs 1 
N334A Osteonecr due to prev trauma 1 
N334C Osteonecr due haemoglobinopath 1 
N30 Osteomyelitis/periostitis 1 
N302a Osteomyelitis of vertebra 1 
N302 Osteomyelitis NOS 1 
N33zH Osteolytic lesion 1 
N33zD Osteolysis 1 
N32z3 Osteochondrosis NOS 1 
N32z Osteochondropathy NOS 1 
N32zz Osteochondropathy NOS 1 
N32 Osteochondropathies 1 
N32z2 Osteochondritis of knee 1 
N3270 Osteochondritis dissec-patella 1 
N327y Osteochondr dissec-other site 1 
N3274 Osteochondr dissec-capitellum 1 
N327 Osteochond dissecans 1 
OX7130E Osteoarthrosis Shoulder /ox 1 
OX7130B Osteoarthrosis Knee(S) /ox 1 
OX7131A Osteoarthrosis Cervical Spine /ox 1 
N11z Osteoarthritis spine 1 
N11D1 Osteoarthritis of thoracic spine 1 
N11D3 Osteoarthritis of spine NOS 1 
N11-2 Osteoarthritis of spine 1 
N11D Osteoarthritis of spine 1 
N11D2 Osteoarthritis of lumbar spine 1 
N11D0 Osteoarthritis of cervical spine 1 
N110-2 Osteoarthritis cervical spine 1 
N05z0 Osteoarthritis NOS-site unspec 1 
N05z000 Osteoarthritis NOS-site unspec 1 
N05z7 Osteoarthritis NOS-ankle/foot 1 
N05zM Osteoarthritis NOS, of tibio-fibular joint                                                                     1 
N05zQ Osteoarthritis NOS, of talonavicular joint                                                                                   1
N05zK Osteoarthritis NOS, of sacro-iliac joint                                                                                                                  1
N05zR Osteoarthritis NOS, of other tarsal joint                                                                                    1
N05zF Osteoarthritis NOS, of metacarpophalangeal joint                                                                                                                            1 
N05zT Osteoarthritis NOS, of lesser metatarsophalangeal joint                                        1 
N05zU Osteoarthritis NOS, of interphalangeal joint of toe                                                                          1
N05zD Osteoarthritis NOS, of distal radio-ulnar joint                                                                                                                  1 
N05zE Osteoarthritis NOS of wrist 1 
N05z4 Osteoarthritis NOS of the hand 1 
N05z9 Osteoarthritis NOS of shoulder 1 
N05zL Osteoarthritis NOS of knee 1 
N05zJ Osteoarthritis NOS of hip 1 
N05zC Osteoarthritis NOS of elbow 1 
N05zN Osteoarthritis NOS of ankle 1 
N05zz00 Osteoarthritis NOS 1 
N05zz Osteoarthritis NOS 1 
N05z1 Osteoarthritis -shoulder joint 1 
N05z800 Osteoarthritis - other joint 1 
N05z8 Osteoarthritis - other joint 1 
N05z6-99 Osteoarthritis - knee joint 1 
N05..11 Osteoarthritis 1 
N094K Osteoarthritis 1 
N05 Osteoarthritis 1 
N310 Osteitis deformans-Paget's dis 1 
N311 Osteitis deformans+disease EC 1 
N3350 Osteitis condensans ilii 1 
N335 Osteitis condensans 1 
N31 Osteit.deform./osteop.+dis.EC 1 
N3110 Osteit deformans,neoplast dis 1 
N3y03 Osseous stenos of neural canal 1 
N3y06 Oss/sublx sten intervert foram 1 
S900z Opn wound shoulder+up limb,NOS 1 
SA10 Opn wnd kneelg+ank-no cmplctn 1 
S46A6 Opn trmtc sublux,head fibula 1 
S413z Opn trmtc sublux shoulder NOS 1 
S468 Opn trmtc sublux pat-fem jt 1 
S46A0 Opn trmtc sublux knee jt,unsp 1 
S46A2 Opn trmtc sublux knee jt,post 1 
S46A4 Opn trmtc sublux knee jt,ltrl 1 
S46A1 Opn trmtc sublux knee jt,ant 1 
S46A Opn trmtc sublux knee jt 1 
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S4112 Opn trmtc dslctn shldr jt,post 1 
S411z Opn trmtc disloctn shouldr NOS 1 
S4110 Opn trmtc dislctn shoulder jnt 1 
S49F4 Opn trm sublux,st-clav jt,post 1 
S49F3 Opn trm sublux,st-clav jt,ant 1 
S49F2 Opn trm sublux st-clav jt 1 
S4681 Opn trm sublux pat-fem jt,med 1 
S4680 Opn trm sublux pat-fem jt,ltrl 1 
S49F5 Opn trm sublux laryngl cartlge 1 
S46A5 Opn trm sublux knee jt,rotatry 1 
S46A3 Opn trm sublux knee jt,medial 1 
S4131 Opn trm sublux acromio-clav jt 1 
S4666 Opn trm dslctn, head fibula 1 
S464 Opn trm dslctn patello-fem jt 1 
S4641 Opn trm dslctn pat-fem jt,med 1 
S4640 Opn trm dslctn pat-fem jt lat 1 
S4660 Opn trm dslctn knee, unspec 1 
S4664 Opn trm dslctn knee jt,lateral 1 
S4662 Opn trm dslctn knee jt, post 1 
S4663 Opn trm dslctn knee jt, medial 1 
S4661 Opn trm dslctn knee jt, ant 1 
S4665 Opn trm dslct knee jt,rotatory 1 
S4973 Opn trm dslc,stern-clav jt,ant 1 
S4972 Opn trm dslc sterno-clav jt 1 
S4974 Opn trm dsl,stern-clav jt,post 1 
S4114 Opn trm dislc acromio-clav jt 1 
S413 Opn traumtc subluxatn shoulder 1 
S4130 Opn traumtc sublux shouldr jnt 1 
S411 Opn traumtc disloctn shoulder 1 
S4115 Opn traumatic disloctn scapula 1 
S49B Opn sublux thrcic+lmbr vertbra 1 
S49B1 Opn sublux thoracic spine 1 
S499x Opn sublux mlti cerv vertebrae 1 
S499z Opn sublux cerv vertebra NOS 1 
S4991 Opn sublux atlanto-occipitl jt 1 
S493C Opn spnl dslc+cauda equina lsn 1 
S4934 Opn spnl dslc+ant thrc crd lsn 1 
S4939 Opn spnl dslc+ant lmbr crd lsn 1 
S491B Opn spnl dslc+ant cerv crd lsn 1 
S493B Opn spnl dsl+post lmbr crd lsn 1 
S491D Opn spnl dsl+post cerv crd lsn 1 
S4933 Opn spnl dsl+comp thrc crd lsn 1 
S4938 Opn spnl dsl+comp lmbr crd lsn 1 
S4919 Opn spnl dsl+cerv crd lsn,unsp 1 
S4932 Opn spn dslc+thrc crd lsn,unsp 1 
S4936 Opn spn dslc+post thrc crd lsn 1 
S491C Opn spn dslc+ctrl cerv crd lsn 1 
S491A Opn spn dslc+comp cerv crd lsn 1 
S4935 Opn spn dslc+cent thrc crd lsn 1 
S493A Opn spn dslc+cent lmbr crd lsn 1 
S1150 Opn spn # + unsp lumb crd lesn 1 
S1154 Opn spn # + post lumb crd lesn 1 
S1151 Opn spn # + comp lumb crd lesn 1 
S1153 Opn spn # + cent lumb crd lesn 1 
S1155 Opn spn # + cauda equina lesn 1 
S1152 Opn spn # + ant lumbr crd lesn 1 
S5P1z Opn dvsn,thyroid regn lgmt NOS 1 
S5P1 Opn dvsn,thyroid region lgmt 1 
S5P12 Opn dvsn,thyroid cartilge lgmt 1 
S5P30 Opn dvsn,sternoclavicular lgmt 1 
S5N Opn dvsn,lgmt other part back 1 
S5P11 Opn dvsn,cricothyroid ligament 1 
S5P10 Opn dvsn,cricoarytenoid lgmt 1 
S5K1 Opn dvsn mdl collat lgmt knee 1 
S5K0 Opn dvsn lat collat lgmt knee 1 
S5F1 Opn dvsn coracoclavicular lgmt 1 
S5F0 Opn dvsn acromioclavic lgmt 1 
S5K2 Opn dvs post cruciate lgm knee 1 
S5K3 Opn dvs ant cruciate lgmt knee 1 
S4931 Opn dslc thoracic spine 1 
S4975 Opn dslc laryngl cartilage 1 
S1034 Opn # thorc vert-trnsvrse prcs 1 
S1032 Opn # thorc vert-spondylolysis 1 
S1033 Opn # thorc vert-spinous prcs 1 
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S1036 Opn # thor vert-tricolumnar 1 
S1035 Opn # thor vert-posterior arch 1 
S1055 Opn # lumb vert,posterior arch 1 
S1054 Opn # lumb vert, trnsvrse prcs 1 
S1056 Opn # lumb vert, tricolumnar 1 
S1052 Opn # lumb vert, spondylolysis 1 
S1053 Opn # lumb vert, spinous prcs 1 
S101L Opn # cerv vert, trnsvrse prcs 1 
S101N Opn # cerv vert, tricolumnar 1 
S101J Opn # cerv vert, spondylolysis 1 
S101K Opn # cerv vert, spinous prcs 1 
S101M Opn # cerv vert, post arch 1 
S101D Opn # axis, trnsvrse process 1 
S1018 Opn # atlas-isol arch/art prcs 1 
S89z Open wounds NOS 1 
S90 Open wound shoulder/upper limb 1 
S9020 Open wound shoulder+tendon inv 1 
S9010 Open wound shoulder+complicat. 1 
S9021 Open wound scapular+tendon inv 1 
S900 Open wound of shoulder/upper limb without complication 1 
S9000 Open wound of shoulder region 1 
S87 Open wound of sacroiliac reg. 1 
S84 Open wound of neck 1 
SA100 Open wound of knee 1 
S86 Open wound of back 1 
SA110 Open wound knee+complication 1 
S8z Open wound head/neck/trunk NOS 1 
S8 Open wound head/neck/trunk 1 
S113z Open thoracic #+cord lesn.NOS 1 
S113 Open thoracic #+cord lesion 1 
S49Dz Open subluxation of spine NOS 1 
S49B0 Open subluxation lumbar spine 1 
S4998 Open subluxation C7/T1 1 
S4997 Open subluxation C6/C7 1 
S4996 Open subluxation C5/C6 1 
S4995 Open subluxation C4/C5 1 
S4994 Open subluxation C3/C4 1 
S4993 Open subluxation C2/C3 1 
S49D0 Open sublux spine, unspecified 1 
S49D Open sublux other vertebra 1 
S4990 Open sublux cerv spine, unsp 1 
S499 Open sublux cerv spine 1 
S4992 Open sublux atlanto-axial jt 1 
S49y Open multiple/ill-def.disloc. 1 
S2921 Open mult fract clav scap hum 1 
S115 Open lumbar # + cord lesion 1 
S2115 Open fracture scapula, spine 1 
S2116 Open fracture scapula, neck 1 
S2113 Open fracture scapula, glenoid 1 
S2114 Open fracture scapula, blade 1 
S321 Open fracture of the patella 1 
S105 Open fracture lumbar vertebra 1 
S1260 Open fracture larynx 1 
S2012 Open fracture clavicle, shaft 1 
S101 Open fracture cervical spine 1 
S1012 Open fracture axis 1 
S1011 Open fracture atlas 1 
S5N0 Open dvsn, neck ligament 1 
S5Fz Open dvsn shoulder lgmt NOS 1 
S4911 Open dslc atlanto-occipital jt 1 
S4912 Open dslc atlanto-axial jt 1 
S5Nz Open divisn, back ligament NOS 1 
S5N1 Open division,thoracic lgmt 1 
S5P Open division, other ligament 1 
S5Pz Open division, other lig NOS 1 
S5N2 Open division, lumbar ligament 1 
S5F Open division shoulder lgmt 1 
S5Ky Open division other knee lgmt 1 
S5M5 Open division lumbosacral lgmt 1 
S5K Open division ligament knee 1 
S5Kz Open division knee lgmt NOS 1 
S5M4 Open division iliolumbar lgmt 1 
S4950 Open dislocation spine unspec. 1 
S495z Open dislocation spine NOS 1 
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S491 Open dislocation of neck 1 
S4930 Open dislocation lumbar spine 1 
S466z Open dislocation knee NOS 1 
S497z Open dislocation NOS 1 
S4918 Open dislocation C7/T1 1 
S4917 Open dislocation C6/C7 1 
S4916 Open dislocation C5/C6 1 
S4915 Open dislocation C4/C5 1 
S4914 Open dislocation C3/C4 1 
S4913 Open dislocation C2/C3 1 
S493 Open disloc.thoracic/lumbar 1 
S493z Open disloc.thorac./lumbar NOS 1 
S495 Open disloc.other vertebra 1 
S491x Open disloc.mult.cerv.vertebra 1 
S491z Open disloc.cervical vert.NOS 1 
S4910 Open disloc.cerv.spine unspec. 1 
S111z Open cervical#+cord lesion NOS 1 
S111 Open cervical #+cord lesion 1 
S1263 Open #trachea 1 
S1262 Open #thyroid cartilage 1 
S11y Open #spine+cord lesion unsp. 1 
S2110 Open #scapula-unspecified 1 
S211z Open #scapula NOS 1 
S126z Open #larynx/trachea NOS 1 
S1261 Open #hyoid bone 1 
S2010 Open #clavicle unspecified 1 
S201z Open #clavicle NOS 1 
S3z1 Open #bones unspecified 1 
S4F7 Open #-sublux,patello-fem jt 1 
S4J33 Open #-sublux st-clav jt,post 1 
S4J32 Open #-sublux st-clav jt,ant 1 
S4A30 Open #-sublux shoulder joint 1 
S4A3 Open #-sublux shoulder 1 
S4F3 Open #-sublux knee joint 1 
S4A31 Open #-sublux acrom-clav joint 1 
S4F5 Open #-dslc,patello-fem jt 1 
S4F1 Open #-dslc, knee joint 1 
S4J13 Open #-dslc st-clav jt,post 1 
S4J12 Open #-dslc st-clav jt,ant 1 
S4A10 Open #-dslc shoulder joint 1 
S4A1 Open #-dslc shoulder 1 
S4A11 Open #-dslc acrom-clav joint 1 
S1010 Open # unsp cerv vertebra 1 
S103 Open # thoracic vertebra 1 
S1031 Open # thorac vert, wedge 1 
S1030 Open # thorac vert, burst 1 
S1013 Open # third cerv vertebra 1 
S10y Open # spine, unspecif 1 
S1016 Open # sixth cerv vertebra 1 
S1017 Open # seventh cerv vert 1 
S2112 Open # scapula, coracoid 1 
S2111 Open # scapula, acromion 1 
S211 Open # scapula 1 
S3213 Open # patella, vertical 1 
S3210 Open # patella, transverse 1 
S3214 Open # patella, stellate 1 
S3211 Open # patella, proximal pole 1 
S3212 Open # patella, distal pole 1 
S1051 Open # lumbar vert, wedge 1 
S1050 Open # lumbar vert, burst 1 
S126 Open # larynx and trachea 1 
S1014 Open # fourth cerv vertebra 1 
S1015 Open # fifth cerv vertebra 1 
S2011 Open # clavicle, medial end 1 
S2013 Open # clavicle, lateral end 1 
S201 Open # clavicle 1 
S101H Open # cerv vert, wedge 1 
S101G Open # cerv vert, burst 1 
S101z Open # cerv spine NOS 1 
S101F Open # axis, tricolumnar 1 
S101B Open # axis, spondylolysis 1 
S101C Open # axis, spinous procss 1 
S101E Open # axis, posterior arch 1 
S101A Open # axis, odontoid prcss 1 
399
 144
Read code Description 
Number of 
studies 
S1019 Open # atlas, comminuted 1 
S4113 Op tr ds shd jt,inf(infr-glen) 1 
S4111 Op tr dis shld jt,ant(sub-cor) 1 
S49Bz Op sublx thrc+lmbr vertbra NOS 1 
S49B2 Op spn sublx+thrc crd lsn,unsp 1 
S49B6 Op spn sublx+post thrc crd lsn 1 
S49BB Op spn sublx+post lmbr crd lsn 1 
S49B7 Op spn sublx+lmbr crd lsn,unsp 1 
S49B3 Op spn sublx+comp thrc crd lsn 1 
S49B8 Op spn sublx+comp lmbr crd lsn 1 
S499A Op spn sublx+comp cerv crd lsn 1 
S499C Op spn sublx+cntrl crv crd lsn 1 
S4999 Op spn sublx+cerv crd lsn,unsp 1 
S49B5 Op spn sublx+cent thrc crd lsn 1 
S49BA Op spn sublx+cent lmbr crd lsn 1 
S49BC Op spn sublx+cauda equina lsn 1 
S49B4 Op spn sublx+ant thrc crd lsn 1 
S499D Op spn sublux+post crv crd lsn 1 
S49B9 Op spn sublux+ant lmbr crd lsn 1 
S499B Op spn sublux+ant cerv crd lsn 1 
S4937 Op spn dsl+lmbr crd lsn unsp 1 
S1134 Op spn #+pst thor crd lsn,T1-6 1 
S1133 Op spn #+cnt thor crd lsn,T1-6 1 
S1132 Op spn #+ant thor crd lsn,T1-6 1 
S115z Op spn # incmp lmb crd lsn NOS 1 
S1130 Op sp #+unsp thor crd lsn,T1-6 1 
S1136 Op sp #+unsp thor cd lsn,T7-12 1 
S113A Op sp #+pst thor crd lsn,T7-12 1 
S1139 Op sp #+cnt thor crd lsn,T7-12 1 
S1131 Op sp #+cmpl thor crd lsn,T1-6 1 
S1137 Op sp #+cmp thor crd lsn,T7-12 1 
S1138 Op sp #+ant thor crd lsn,T7-12 1 
S1501 Op multi fractur of thor spine 1 
SR161 Op fract/th wth lw bck+plv+lmb 1 
SR101 Op fract invol head with neck 1 
S113B Op # T7-12incomp cord lsn NOS 1 
S1135 Op # T1-6 incomp cord lsn NOS 1 
S1116 Op # C5-7 unspec cord lesion 1 
S111A Op # C5-7 posterior cord lesn 1 
S111B Op # C5-7 incomp cord les NOS 1 
S1117 Op # C5-7 compl cord lesion 1 
S1119 Op # C5-7 central cord les 1 
S1118 Op # C5-7 anterior cord les 1 
S1110 Op # C1-C4 unspec cord les 1 
S1114 Op # C1-4 post cord lesion 1 
S1115 Op # C1-4 cord les. NOS 1 
S1111 Op # C1-4 compl cord lesion 1 
S1113 Op # C1-4 cent cord lesion 1 
S1112 Op # C1-4 ant cord lesion 1 
N1120 One lev th spondyl-no myelop 1 
N11B0 One lev th spondyl + radiculop 1 
N1130 One lev th spondyl + myelop 1 
N1140 One lev lumbsac spond-no myelo 1 
N1150 One lev lumbsac spond + myelop 1 
N1100 One lev Cx spondyl-no myelop 1 
N1190 One lev Cx spondyl + radiculop 1 
N1110 One lev Cx spondyl + myelop 1 
N0542 Oligoarticular osteoarthritis, unspecified, of upper arm                                                                     1 
N0545 Oligoarticular osteoarthritis, unspecified, of the pelvic region and 
thigh                                                1 
N0546 Oligoarticular osteoarthritis, unspecified, of lower leg                            1 
N0544 Oligoarticular osteoarthritis, unspecified, of hand                                                                          1
N0543 Oligoarticular osteoarthritis, unspecified, of forearm                                                                       1 
N0547 Oligoarticular osteoarthritis, unspecified, of ankle and foot                                                                1
N054 Oligoarticular OA unspecified 1 
N0541 Oligoartic OA, unspec-shoulder 1 
N0549 Oligoartic OA, unspec-multiple 1 
N0540 Oligoartic OA, unsp-unsp sites 1 
N0548 Oligoartic OA unspec-oth site 1 
N2133 Olecranon bursitis 1 
N0720 Old torn meniscus of knee 1 
N070B Old tear post horn med menis 1 
N070A Old tear of medial meniscus 1 
N071C Old tear of lateral meniscus 1 
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N07y9 Old post/lat caps complex tear 1 
N07y3 Old post.cruciate lig.disrupt. 1 
N07yF Old part tear post cruciat lig 1 
N07yA Old part tear med collat lig 1 
N07y7 Old part tear lat collat lig 1 
N07yD Old part tear ant cruciate lig 1 
N07y1 Old med.collat.lig.disruption 1 
N07yC Old med capsular complex tear 1 
N07y0 Old lat.collat.lig.disruption 1 
N07yB Old compl tear med collat lig 1 
N07y8 Old compl tear lat collat lig 1 
N07yG Old comp tear post cruciat lig 1 
N07yE Old comp tear ant cruciate lig 1 
N07y4 Old capsular knee lig.disrupt. 1 
N0701 Old bucket handle tear-medial 1 
N0711 Old bucket handle tear-lat men 1 
N07y2 Old ant.cruciate lig.disrupt. 1 
N067 Ochronotic arthropathy 1 
N054z OA,1 site +,unspecified NOS 1 
N05zP OA NOS-subtalar joint 1 
N05zA OA NOS-sternoclavicular joint 1 
N05zB OA NOS-acromioclavicular join 1 
N05zG OA NOS-PIP joint of finger 1 
N05zH OA NOS-DIP joint of finger 1 
N05zS OA NOS-1st MTP joint 1 
N3381 Nonunion of fracture 1 
N226 Nontraumatic tendon subluxatn 1 
N23y2 Nontraumatic muscle rupture 1 
N2260 Nontraum.unspec.tendon rupture 1 
N392 Nonallopathic lesion-thoracic 1 
N393 Nonallopathic lesion-lumbar 1 
N391 Nonallopathic lesion-cervical 1 
N082Z Non-trau subl acromiocl joint 1 
N044 Nodular fibrositis-chr. rheum. 1 
N2372 Nodular fasciitis 1 
16A1 No stiff neck 1 
16C1 No backache 1 
1229 No FH: Osteoporosis 1 
N2471 Night cramps 1 
N11y2 Neuropathic spondylopathy 1 
N2423 Neuropathic pain 1 
N374B Neuromuscular scoliosis 1 
N3749 Neuromuscular lordosis 1 
N3745 Neuromuscular kyphosis 1 
N14A Neurogenic claudication 1 
N2421 Neuritis unspecified 1 
N2420 Neuralgia unspecified 1 
N242z Neuralg./neurit./radiculit.NOS 1 
N242 Neuralg./neurit./radicul.unsp. 1 
SJ Nerve/spinal cord injuries 1 
EMISNQNE5 Nerve root pain present 1 
SJz Nerve and spinal cord injury NOS 1 
S5700 Neck sprain unspecified 1 
S570z Neck sprain NOS 1 
S570 Neck sprain 1 
N12D Narrowing disc space 1 
N2332 Myositis in sarcoidosis 1 
N2321 Myofibrosis 1 
N241-97 Myalgia/myositis - shoulder 1 
EGTON307 Myalgia 1 
EMISNQMU15 Musculoskeletal symptom 1 
EMISNQMU5 Musculoskeletal pain severe 1 
EMISNQMU2 Musculoskeletal pain present 1 
EMISNQMU4 Musculoskeletal pain moderate 1 
N096-2 Musculoskeletal pain - joints 1 
MAWBYMU1 Musculoskeletal Symptoms 1 
N3 Musculosk.inflam/deform.+other 1 
N232z Muscle wasting/atrophy NEC NOS 1 
N232 Muscle wasting and disuse atrophy NEC 1 
N2322 Muscle wasting NEC 1 
UNMAPM4AB Muscle strain 1 
N23yD Muscle strain 1 
N2410-2 Muscle pain 1 
N231 Muscle ossification 1 
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S5yz1 Muscle injury / strain 1 
N238 Muscle contracture 1 
N231z Muscle calcif./ossificat.NOS 1 
N230D Muscle abscess-shoulder 1 
N230B Muscle abscess-neck 1 
N230C Muscle abscess-back 1 
N230A Muscle abscess 1 
ASDFGMU2 Muscle Symptoms 1 
EGTON110 Muscle Injury 1 
M4A8 Muscle Injury 1 
N2310 Musc.calcif./ossif.unspecified 1 
N0719 Multiple tears-lat meniscus 1 
N0708 Multiple tears of medial meniscus 1 
S101x Multiple open # cerv vert 1 
SR1z Multiple fractures unspecified 1 
S100x Multiple clsd # cerv vert 1 
N099A Multiple clicking joints 1 
S3y Multiple #legs/arms/ribs/stern 1 
S10A2 Multip fracture/cervical spin 1 
N11C2 Multi lev lumbsac spond+radicu 1 
S150 Multi fractures/thoracic spine 1 
S3y1 Mult.open #legs/arms/ribs 1 
S3y0 Mult.closed #legs/arms/ribs 1 
N1122 Mult lev th spondyl-no myelop 1 
N11B2 Mult lev th spondyl+radiculop 1 
N1132 Mult lev th spondyl + myelop 1 
N1142 Mult lev lumbsac spond-no myel 1 
N1152 Mult lev lumbsac spond + myelo 1 
N1102 Mult lev Cx spondyl-no myelop 1 
N1192 Mult lev Cx spondyl+radiculop 1 
N1112 Mult lev Cx spondyl + myelop 1 
S10B6 Mult fractur/lumbar spine+pelv 1 
S292 Mult fract/clav,scapula+humrus 1 
1D17 Morning stiffness - joint 1 
N3323 Monostotic fibrous dysplasia 1 
N0433 Monarticular juvenile R.A. 1 
EMISNQMI188 Mixed connective tissue disease 1 
OX6954MC Mixed Connective Tissue Disease /ox 1 
N2224 Miners' knee 1 
N2172 Metatarsalgia NOS 1 
N063.11 Menopausal arthritis 1 
N063 Menopausal arthritis 1 
N072 Meniscus derangement NEC 1 
N070 Medial meniscus derangement 1 
N070z Medial meniscus derange.NOS 1 
N0703 Medial menisc.post.horn derang 1 
N0700 Medial menisc.derang.unspecif 1 
N0702 Medial menisc.ant.horn derang. 1 
N2131 Medial epicondylitis - elbow 1 
16CA Mechanical low back pain 1 
N3380 Malunion of fracture 1 
N338 Malunion and nonunion of fracture 1 
N11C Lumbosacral spondylosis with radiculopathy 1 
N115 Lumbosacral spond.+ myelopathy 1 
SJ35 Lumbosacral plexus injury 1 
N1441 Lumbosacral neuritis unspecif. 1 
N1463 Lumbosacral instability 1 
N1460 Lumbosacral ankylosis 1 
N114-2 Lumbar spondylosis 1 
N148C Lumbar spine instability 1 
N1486 Lumbar spine ankylosis 1 
N1402 Lumbar spinal stenosis 1 
N12A3 Lumbar postlaminectomy syndr. 1 
SJ321 Lumbar nerve root injury - L2 1 
N12zC Lumbar discitis 1 
N122 Lumbar disc displacement 1 
N1293 Lumbar disc disord.+myelopathy 1 
N127 Lumbar disc degeneration 1 
S572 Lumbar back sprain 1 
N1420 Lumbago with sciatica 1 
N142-4 Lumbago 1 
N140A Lu spin stenos due to oth dis 1 
N12C2 Lu disc prolapse+radiculopathy 1 
N12B2 Lu disc prolapse + myelopathy 1 
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N12C3 Lu disc prol+caud eq compress 1 
N142-1 Low back pain 1 
EGTON264 Low Back Pain 1 
N374W Lordosis unspecified 1 
N3747 Lordosis in skeletal dysplasia 1 
N3748 Lordosis in hip disease 1 
N3742 Lordosis + other condition 1 
N0818 Loose joint body-multip joints 1 
N081z Loose joint body (ex.knee)NOS 1 
N081A Loose body, oth joint-shoulder 1 
N0811 Loose body joint-shoulder 1 
N0819 Loose body in shoulder joint 1 
N073 Loose body in knee 1 
N081 Loose body in joint-excl.knee 1 
N0817 Loose body in joint, joint OS 1 
N0810 Loose body in joint 1 
N07yH Locking knee 1 
N07y5 Locked knee 1 
N0522 Localised, secondary osteoarthritis of the upper arm                                                                                                          1
N0525 Localised, secondary osteoarthritis of the pelvic region and thigh               1 
N0526 Localised, secondary osteoarthritis of the lower leg                                                                         1
N0524 Localised, secondary osteoarthritis of the hand                                                                              1
N0523 Localised, secondary osteoarthritis of the forearm                                                                           1
N0527 Localised, secondary osteoarthritis of the ankle and foot                                                                                     1
N051E Localised, primary osteoarthritis of toe                                                                                                                                                      1
N0512 Localised, primary osteoarthritis of the upper arm                                                               1 
N0515 Localised, primary osteoarthritis of the pelvic region and thigh                                                             1
N0513 Localised, primary osteoarthritis of the forearm                                                                             1 
N0517 Localised, primary osteoarthritis of the ankle and foot                                                                               1
N051F Localised, primary osteoarthritis of elbow                                                                                                                                            1 
N052z Localised secondary OA NOS 1 
N051z Localised primary OA NOS 1 
N0532 Localised osteoarthritis, unspecified, of the upper arm                                                                                                         1
N0537 Localised osteoarthritis, unspecified, of the ankle and foot                       1 
N053z Localised OA unspecified NOS 1 
N053 Localised OA unspecified 1 
N052 Local.secondary osteoarthritis 1 
N0520 Local.secondary OA-site unsp. 1 
N0521 Local.secondary OA-shoulder 1 
N0528 Local.secondary OA-other spec. 1 
N051 Local.primary osteoarthritis 1 
N0510 Local.primary OA-site unspec. 1 
N0511 Local.primary OA-shoulder regn 1 
N0518 Local.primary OA-other specif 1 
N0516 Local.primary OA-lower leg 1 
N0514 Local.primary OA-hand 1 
N0530 Local.OA unsp.-site unspecif. 1 
N0531 Local.OA unsp.-shoulder region 1 
N0538 Local.OA unsp.-other specified 1 
N0534 Local.OA unsp.-hand 1 
N0533 Local.OA unsp.-forearm 1 
N051D Local prim osteoarth wrist 1 
N3308 Local osteoporosis - Lequesne 1 
S5z Ligament sprain NOS 1 
N0001 Libman-Sacks disease 1 
N245-6 Leg pain 1 
N234 Laxity of ligament 1 
SJ43 Latrl cutaneous branch T12 inj 1 
N071 Lateral meniscus derangement 1 
N0714 Lateral meniscus derangem.NOS 1 
N0713 Lateral menisc.post.horn deran 1 
N0710 Lateral menisc.derang.unspecif 1 
N0712 Lateral menisc.ant.horn derang 1 
N2132 Lateral epicondylitis of the elbow 1 
MHTBALA9 Lateral Patella Release 1 
SC08 Late effect-tendon injury 1 
SC05 Late effect-mult./other #bones 1 
SC06 Late effect-dislocation 1 
SC01 Late effect-#spine-no cord les 1 
SC011 Late effect # thoracic vert 1 
SC012 Late effect # lumbar vertebra 1 
SC010 Late effect # cervic vertebra 1 
EGTON119 Laceration Nos 1 
N3744 Kyphosis in skeletal dysplasia 1 
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N3713 Kyphosis due to oth treatment 1 
N3741 Kyphosis + other condition 1 
N373z Kyphoscoliosis or scoliosis NOS 1 
N373 Kyphoscoliosis and scoliosis 1 
N3241 Kohler's dis.(prim.patell.ctr) 1 
N0956 Knee stiff 1 
S54y Knee sprain NOS 1 
S54 Knee sprain 1 
N0106 Knee pyogenic arthritis 1 
N0826 Knee pathological dislocation 1 
1M10 Knee pain 1 
N05z6 Knee osteoarthritis NOS 1 
N05z6-1 Knee osteoarthritis NOS 1 
N0946-1 Knee joint pain 1 
N0946 Knee joint pain 1 
N0846 Knee joint contracture 1 
N0856 Knee joint ankylosis 1 
N0966 Knee gives way 1 
N216z Knee enthesopathy NOS 1 
N06z6-1 Knee arthritis NOS 1 
N06z6 Knee arthritis NOS 1 
ASDFGKN2 Knee Pain? 1 
ASDFGKN6 Knee Pain Does Not Affect Sleep 1 
ASDFGKN4 Knee Pain Affects Sleep? 1 
ASDFGKN5 Knee Pain Affects Sleep 1 
ASDFGKN3 Knee Pain 1 
MUNNUKN1 Knee Pain 1 
MAWBYKN1 Knee Pain 1 
N0836 Knee - recurrent dislocation 1 
N13y1 Klippel's disease 1 
N116 Kissing spine 1 
N002 Keratoconjunctivitis sicca 1 
N0600 Kaschin-Beck dis.-site unspec. 1 
N0601 Kaschin-Beck dis.-shoulder 1 
N0608 Kaschin-Beck dis.-other specif 1 
N0609 Kaschin-Beck dis.-multipl.site 1 
N060z Kaschin-Beck dis.-NOS 1 
N060 Kaschin - Beck disease 1 
N320z Juvenile spine osteochondr.NOS 1 
N3200 Juvenile spine osteochond.unsp 1 
N0455 Juvenile rheumatoid arthritis 1 
N0430 Juvenile rheumatoid arthr.unsp 1 
N043z Juvenile rheumatoid arthr.NOS 1 
N3263 Juvenile osteochondrosis NOS 1 
N326z Juvenile osteochondroses NOS 1 
N3262 Juvenile osteochondritis NOS 1 
N3261 Juvenile epiphysitis NOS 1 
N0030 Juvenile dermatomyositis 1 
N3260 Juvenile apophysitis NOS 1 
N043 Juvenile R.A.- Still's disease 1 
OX7120DA Juvenile Arthritis /ox 1 
N3243 Juv.osteoch.secondary.pat.ctre 1 
N0451 Juv seronegative polyarthritis 1 
N328 Juv osteochondrosis of spine 1 
N0452 Juv arthritis in psoriasis 1 
N0453 Juv arthritis in Crohn's dis 1 
N0454 Juv arth in ulcerative colitis 1 
N0900 Joint effusion-site unspecif. 1 
N0901 Joint effusion-shoulder region 1 
N0908 Joint effusion-other specif. 1 
N09z1 Joint disord.NOS-shoulder 1 
N08z Joint derangement NOS 1 
N08zz Joint derangement NOS 1 
N08z0 Joint derange.NOS-site unspec. 1 
N08z1 Joint derange.NOS-shoulder 1 
N08z7 Joint derange.NOS-other spec. 1 
N08z8 Joint derange.NOS-multipl.site 1 
N05z.11 Joint degeneration 1 
N05z Joint degeneration 1 
N0840 Joint contracture-site unspec 1 
N0841 Joint contracture-shoulder 1 
N0848 Joint contracture-other specif 1 
N0850 Joint ankylosis-site unspecif. 1 
N0851 Joint ankylosis-shoulder 1 
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N0858 Joint ankylosis-other specif. 1 
ASDFGJO2 Joint Symptoms 1 
ASDFGJO3 Joint Pain 1 
N3841 Isthmic spondylolisthesis 1 
S531 Ischiocapsular sprain 1 
N23yB Ischaemic infarction of muscle 1 
N123-1 Intervertebral disc prol. NOS 1 
N12z Intervertebral disc lesion NOS 1 
OX7259AP Intervertebral Disc Prolapsed /ox 1 
N3y05 Intervert disc sten neur canal 1 
N23y0 Interstitial myositis 1 
N07z Internal knee derangement NOS 1 
N07 Internal derangement of knee 1 
N1350 Intermittent torticollis 1 
N090W Intermittent hydrarthrosis 1 
N084E Int rotat contracture-shoulder 1 
N08y Instability of joint 1 
SJ7z Injury to other nerve NOS 1 
SKz Injury NOS 1 
OX9967C Injury Knee /ox 1 
SJ9 Injur/nerv+spinl crd/thorx lev 1 
SJB Inj/nerves/should+upp arm levl 1 
S46C Inj/multipl structures of knee 1 
S5Q6 Inj tendon rotator cuff should 1 
N2166 Infrapatellar bursitis 1 
N10 Inflammatory spondylopathies 1 
N04 Inflammatory polyarthropathy 1 
N04* Inflammatory arthropathy 1 
N10y0 Inflamm.spondylop.in dis. EC 1 
N04z Inflamm.polyarthropathy NOS 1 
S4103 Inferior dislocation shoulder 1 
N2302 Infective myositis-shoulder 1 
N2300 Infective myositis-neck 1 
N2301 Infective myositis-back 1 
N01z Infective arthritis NOS 1 
N01zz Infective arthritis NOS 1 
N302B Infection of thoracic spine 1 
N302G Infection of scapula 1 
N302R Infection of patella 1 
N302Z Infection of multiple bones 1 
N302C Infection of lumbar spine 1 
N302F Infection of clavicle 1 
N302A Infection of cervical spine 1 
N01z0 Infect.arthr.NOS-site unspecif 1 
N01z1 Infect.arthr.NOS-shoulder reg 1 
N01zy Infect.arthr.NOS-other specifi 1 
N01zx Infect.arthr.NOS-multiple site 1 
N12zG Infect intervert disc - pyogen 1 
N01z8 Infec arthritis NOS-shoulder 1 
N01zK Infec arthritis NOS-knee 1 
N01z9 Infec arthr NOS-sternoclav jt 1 
N01zA Infec arth NOS-acromioclav jt 1 
N23y5 Inappropriate firing of muscle 1 
N2124 Impingement syndr of shoulder 1 
N2331 Immobility syndrome 1 
N2159 Iliotibial band syndrome 1 
N1403 Idiopathic th spinal stenosis 1 
N3730 Idiopathic scoliosis 1 
N3303 Idiopathic osteoporosis 1 
N1407 Idiopathic lu spinal stenosis 1 
N3731 Idiopathic kyphoscoliosis 1 
N33z7 Idiopathic hypertrophy of bone 1 
N1300 Idiopathic Cx spinal stenosis 1 
N3316 Idiopath osteopor + path fract 1 
N3348 Idiopath asep necrosis of bone 1 
N1405 Iatrogenic th spinal stenosis 1 
N1409 Iatrogenic lu spinal stenosis 1 
N1302 Iatrogenic Cx spinal stenosis 1 
C04* Hypothyroidism 1 
N2431 Hypertrophy of knee fat pad 1 
N33z4 Hypertrophy of bone 1 
N3382 Hypertrophic non-union of # 1 
N312 Hypertroph.pulm.osteoarthrop. 1 
N02y8 Hydroxyapatite deposition dis 1 
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N2225 Housemaids knee 1 
N0707 Horiz cleavage tear-med menisc 1 
N0718 Horiz cleavage tear-lat menisc 1 
N094K-2 Hip pain 1 
N05z5 Hip osteoarthritis NOS 1 
N05z5-1 Hip osteoarthritis NOS 1 
N0535 Hip osteoarthitis NOS 1 
N0535-2 Hip osteoarthitis NOS 1 
N06z5 Hip arthritis NOS 1 
N0809 Hill-Sachs lesion 1 
N245-5 Heel pain 1 
N0507 Heberden's nodes with arthropathy                                                                             1 
N245-4 Hand pain 1 
N2450 Hand pain 1 
N0944-1 Hand joint pain 1 
N06z4-1 Hand arthritis NOS 1 
N068 Haemophilic arthropathy 1 
N091B Haemarthrosis-sternoclav joint 1 
N0910 Haemarthrosis-site unspecified 1 
N0911 Haemarthrosis-shoulder 1 
N0918 Haemarthrosis-other specified 1 
N0919 Haemarthrosis-multiple joints 1 
N091C Haemarthrosis-acromioclav jt 1 
N0916 Haemarthrosis of the knee 1 
N091A Haemarthrosis of shoulder 1 
N091M Haemarthrosis of knee 1 
N091z Haemarthrosis NOS 1 
N091 Haemarthrosis 1 
N083M Habitual sublux shoulder 1 
N083L Habitual disloc shoulder 1 
N083r Habitual disloc - patella 1 
14G8 H/O: vertebral fracture 1 
14G1 H/O: rheumatoid arthritis 1 
14G2 H/O: osteoarthritis 1 
14GZ H/O: musculo-skeletal dis. NOS 1 
14G3 H/O: knee problem 1 
14J H/O: injury 1 
14G4 H/O: back problem 1 
14T5 H/O: artificial joint 1 
14V5 H/O: arthrodesis 1 
14G H/O: arthritis 1 
14N30 H/O Spinal surgery 1 
16Z2 Growing pains 1 
S3z00 Greenstick fracture 1 
N0230 Gouty arthritis-site unspecif. 1 
N0231 Gouty arthritis-shoulder 1 
N023y Gouty arthritis-other specif. 1 
N023x Gouty arthritis-multiple sites 1 
N023z Gouty arthritis NOS 1 
N023 Gouty arthritis 1 
N2131-1 Golfer's elbow 1 
N200 Gnt cell arter+polymyalg rheum 1 
EGTON444 Gluteal Muscle Injury 1 
N0873 Glenoid labrum tear 1 
N0872 Glenoid labrum detachment 1 
N365 Genu recurvatum - acquired 1 
N050z Generalised osteoarthritis NOS 1 
N050z00 Generalised osteoarthritis NOS 1 
N050 Generalised osteoarthritis - OA 1 
N050.0 Generalised osteoarthritis - OA 1 
N065A Generalised arthritis 1 
N065A00 Generalised arthritis 1 
N05000 Generalised OA-site unspecif. 1 
N0500 Generalised OA-site unspecif. 1 
N050200 Generalised OA-multiple sites 1 
N0502 Generalised OA-multiple sites 1 
N0501 Generalised OA-hand 1 
N224z Ganglion/synovial cyst NOS 1 
N224 Ganglion/synov.cyst - knee 1 
N224-92 Ganglion/synov.cyst - knee 1 
N2243 Ganglion unspecified 1 
N2245 Ganglion of wrist 1 
N2242 Ganglion of tendon sheath 1 
N2246 Ganglion of knee 1 
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N2241 Ganglion of joint 1 
N224C Ganglion of foot 1 
EMISR4QFU2 Fusion Of Lumbar Spine 1 
EMISR4QFU1 Fusion Of Cervical Spine 1 
N2115 Full thickn rotator cuff tear 1 
N210-2 Frozen shoulder 1 
N331N Fragility fracture 1 
N331M Fragility # unsp osteoporosis 1 
S10B Fracture/lumbar spine+pelvis 1 
S10A1 Fracture/2nd cervical vertebra 1 
S10A0 Fracture/1st cervical vertebra 1 
S15 Fracture of thoracic vertebra 1 
S1z Fracture of neck and trunk NOS 1 
S1 Fracture of neck and trunk 1 
S10A Fracture of neck 1 
S10B0 Fracture of lumbar vertebra 1 
N338z Fracture malunion or nonunion NOS 1 
SR1 Fracture involv multi body reg 1 
SR10 Fracture involv head with neck 1 
S4 Fracture dislocation/subluxat 1 
OX8056 Fracture Spine /ox 1 
S3z Fracture NOS 1 
OXL8056LV Fracture Lumbar Vertebra /ox 1 
SR16 Fract/thorx wth lw bck+plv+lmb 1 
N3317 Fract of bone in neoplast dis 1 
N2451 Foot pain 1 
N245-3 Foot pain 1 
1M11 Foot pain 1 
N220B Flexor tenosynovitis of finger 1 
N3660 Flexion deformity of knee 1 
N369 Flexion deformity 1 
N084A Flexion contracture-shoulder 1 
N084a Flexion contracture-knee 1 
N374E Flatback syndrome 1 
N040T Flare of rheumatoid arthritis 1 
N08yA Flail joint 1 
N09C Fistula of joint 1 
N2450-2 Finger pain 1 
N05z4-1 Finger osteoarthritis NOS 1 
N2163 Fibular collat.lig.bursitis 1 
N3324 Fibrous cortical defect 1 
N2405 Fibrositis of neck 1 
N00y1 Fibrosclerosis systemic 1 
N087 Fibrocartilage lesion of joint 1 
MHTBAFH1 Fh: Osteoporosis 1 
N041 Felty's syndrome 1 
N1y1 Fatigue fracture of vertebra 1 
N244 Fasciitis unspecified 1 
N024 Familial chondrocalcinosis 1 
N14y Facet joint syndrome 1 
12I1 FH: Rheumatoid arthritis 1 
1268 FH: Osteoporosis 1 
12I2 FH: Osteoarthritis 1 
12IZ FH: Musculo-skeletal dis. NOS 1 
12I FH: Arthritis 1 
N220D Extensor tenosynovitis of wrist 1 
N220F Extensor tenosynovitis of thumb 1 
N220E Extensor tenosynovitis of finger 1 
N084B Extension contracture-shoulder 1 
N084F Ext rotat contracture-shoulder 1 
N21z7 Exostosis 1 
16C8 Exacerbation of backache 1 
N0506 Erosive osteoarthrosis 1 
N32z1 Epiphysitis NOS 1 
N33z1 Epiphyseal arrest 1 
N00y0 Eosinophilic fasciitis 1 
N216 Enthesopathy of knee 1 
N21z Enthesopathy NOS 1 
N11y1 Enterobacterial spondylitis 1 
1M00-1 Elbow pain 1 
1M00 Elbow pain 1 
N05z2 Elbow osteoarthritis NOS 1 
N06z2 Elbow arthritis NOS 1 
N090B Effusion of sternoclav joint 1 
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N090A Effusion of shoulder 1 
N0909 Effusion of multiple joints 1 
N090M Effusion of knee 1 
N090z Effusion of joint NOS 1 
N090 Effusion of joint 1 
N090C Effusion of acromioclav joint 1 
N0906 Effusion - knee joint 1 
N0906-99 Effusion - knee joint 1 
N3840 Dysplastic spondylolisthesis 1 
N2361 Dupuyt dis-palm + nod no cont 1 
N3305 Drug-induced osteoporosis 1 
N0002 Drug-ind systemic lupus eryth 1 
N3315 Drug-ind osteopor + path fract 1 
N235 Double-jointed (hypermobility) 1 
N1123 Dorsal spondylo w/o myelopath 1 
N3370 Disuse atrophy of bone 1 
N3304 Dissuse osteoporosis 1 
N0000 Disseminated lupus erythemat. 1 
N09AX Disorder of patella unspecified 1 
N33zG Disorder of cartilage, unspec 1 
N33zF Disorder of bone unspecified 1 
S46 Dislocation or subluxation of knee 1 
S4z Dislocation or subluxation NOS 1 
S41z Dislocation of shoulder NOS 1 
S46z Dislocation of knee NOS 1 
S41 Dislocated shoulder 1 
S463-99 Dislocated patella 1 
SR20 Disloc,sprns+strns inv hd+neck 1 
SR2 Dislc,sprns+strns/mult bdy reg 1 
N071B Discoid lateral meniscus 1 
N123 Disc unsp.displ.-no myelopathy 1 
N12B Disc prolapse with myelopathy 1 
N12C Disc prolapse + radiculopathy 1 
N12zz Disc disorders NOS 1 
N129z Disc disorder+myelopathy NOS 1 
N00 Diffuse connective tissue dis. 1 
N097z Difficulty in walking NOS 1 
N097 Difficulty in walking 1 
N23yA Diastasis of muscle 1 
N33z3 Diaphysitis 1 
N0300 Diabetic cheiroarthropathy 1 
N0301 Diabetic Charcot arthropathy 1 
N003X Dermatopolymyositis, unspec 1 
N0031 Dermatopolymyosit,neoplast dis 1 
N003 Dermatomyositis 1 
SC0z Delayed union of fracture 1 
N3386 Delayed union of fracture 1 
S9030 Degloving injury,shoulder area 1 
SA130 Degloving injury knee 1 
N3842 Degenerative spondylolisthesis 1 
N128 Degenerative disc disease NOS 1 
N1404 Degenerativ th spinal stenosis 1 
N1408 Degenerativ lu spinal stenosis 1 
N1301 Degenerativ Cx spinal stenosis 1 
N114 Degeneration of lumbar spine 1 
N114-1 Degeneration of lumbar spine 1 
N0721 Degen lesion artic cart knee 1 
N36y4 Deformity of scapula 1 
N36yD Deformity of patella 1 
N36y3 Deformity of clavicle 1 
N36y2 Deformity of bone 1 
N224D Cyst of tendon sheath 1 
N0722 Cyst of semilunar cartilage 1 
N0709 Cyst of medial meniscus 1 
N071A Cyst of lateral meniscus 1 
N2244 Cyst of bursa 1 
N332z Cyst of bone NOS 1 
N332 Cyst of bone 1 
N11A Cx spondyl + vasc compression 1 
N1303 Cx spin stenos due to oth dis 1 
N12C0 Cx disc prolapse+radiculopathy 1 
N12B0 Cx disc prolapse + myelopathy 1 
N3740 Curvature of spine unspecified 1 
N37zz Curvature of spine NOS 1 
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N37z Curvature of spine NOS 1 
N37 Curvature of spine 1 
N02zK Crystal arthropathy NOS-knee 1 
N02zz Crystal arthropathy NOS 1 
N02z Crystal arthropathy NOS 1 
N02z0 Crystal arthr.NOS-site unspec. 1 
N02z1 Crystal arthr.NOS-shoulder 1 
N02zy Crystal arthr.NOS-other spec. 1 
N02zx Crystal arthr.NOS-multipl.site 1 
N02z9 Cryst arthr NOS-sternoclav jt 1 
N02zA Cryst arthr NOS-acromioclav jt 1 
N02z8 Crys arthr NOS-shoulder 1 
SF20z Crushinjuryshlder+uparmNOS 1 
SFz Crushing injury NOS 1 
SF Crushing injury 1 
SF40 Crush injury multiple sites NEC 1 
SF021 Crush injury larynx 1 
SF311 Crush injury knee 1 
SF110 Crush injury back 1 
SF4z Crush injury 1 
N13y2 Crick in neck 1 
N2472 Cramp 1 
N051A Coxarthr from dysplasia, bilat 1 
N3216 Coxa plana 1 
182B0 Costal margin chest pain 1 
N2123 Coracoid impingement 1 
S502 Coracohumeral sprain 1 
SE30z Contusionshlder+uer arm NOS 1 
SE44 Contusionlwr limbmlti sites 1 
SE00 Contusion, forehead 1 
SEz Contusion with skin intact NOS 1 
SE30 Contusion shoulder or upper arm 1 
SE300 Contusion shoulder area 1 
SE301 Contusion scapular area 1 
SE231 Contusion of lower back 1 
SE232 Contusion of lower back 1 
SE4y Contusion multiple sites NEC 1 
SE41z Contusion knee and lower leg NOS 1 
SE411 Contusion knee 1 
SE0z Contusion face scalp+neck NOS 1 
SE304 Contusion clavicular area 1 
SE23z Contusion back NOS 1 
SE Contusion (bruise) with intact skin 1 
N22y0 Contracture of tendon sheath 1 
N23yC Contracture of muscle 1 
N0849 Contracture of multiple joints 1 
N084z Contracture of joint NOS 1 
N084 Contracture of joint 1 
N Connective tissue diseases 1 
N3y04 Connect tiss sten neural canal 1 
PE1 Congenital sternomastoid torticollis 1 
N3y07 Con tis/disc sten intervrt for 1 
N33C Complex regionl pain syndrom I 1 
S5C Complete tear, knee ligament 1 
S58z Complete tear shoulder joint NOS 1 
S58 Complete tear shoulder joint 1 
N33z8 Complete epiphyseal arrest 1 
N33z6 Compensatory hypertrophy-bone 1 
SK0y Compartmentsyndrome 1 
S5A0D Comp tr shrt intr lig non-sp 1 
N331D Collapsed vertebra NOS 1 
N331 Collapse of vertebra NOS 1 
N331F Collapse of thoracic vertebra 1 
N3310 Collapse of thoracic vertebra 1 
N3311 Collapse of lumbar vertebra 1 
N331G Collapse of lumbar vertebra 1 
N331E Collapse of cervical vertebra 1 
N331L Collap vert due osteopor NOS 1 
N331J Collap lumb vert due to osteo 1 
N331H Collap cerv vert due to osteop 1 
N00z Collagen disease NOS 1 
N331K Coll thorac vert due osteopor 1 
N147z Coccyx disorder NOS 1 
N1472 Coccygodynia 1 
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S5E1 Cmplt tr,thyroid region lgmt 1 
S5E30 Cmplt tr,sternoclavicular lgmt 1 
S5Ez Cmplt tr,other lgmt NOS 1 
S5Cy Cmplt tr,other knee lgmt 1 
S5C1 Cmplt tr,knee,mdl collat lgmt 1 
S5C0 Cmplt tr,knee,lat collat lgmt 1 
S5Cz Cmplt tr,knee lgmt NOS 1 
S581 Cmplt tr,coraco-clav lgmt 1 
S580 Cmplt tr,acromio-clav lgmt 1 
S5A0A Cmplt tr triang fibrocartilage 1 
S5C3 Cmpl tr,knee,ant cruciate lgmt 1 
S5y57 Cmpl tear,lumbosacral lgmt 1 
S5y56 Cmpl tear,iliolumbar lgmt 1 
S5C2 Cmp tr,knee,post cruciate lgmt 1 
S2920 Clsd mult fract clav scap hum 1 
S1000 Clsd # unsp cerv vertebra 1 
S1024 Clsd # thorc vert-trnsvrs prcs 1 
S1026 Clsd # thorc vert - tricolumnr 1 
S1025 Clsd # thorc vert - post prcs 1 
S1020 Clsd # thoracic vert, burst 1 
S1021 Clsd # thoracic vert wedge 1 
S102z Clsd # thorac vert NOS 1 
S1023 Clsd # thor vert-spinous prcss 1 
S1003 Clsd # third cerv vertebra 1 
S2102 Clsd # scapula, coracoid 1 
S1041 Clsd # lumbar vert wedge 1 
S1040 Clsd # lumbar vert burst 1 
S1046 Clsd # lumb vert - tricolumnar 1 
S1004 Clsd # fourth cerv vertebra 1 
S1005 Clsd # fifth cerv vertebra 1 
S2001 Clsd # clavicle medial end 1 
S2003 Clsd # clavical lateral end 1 
S100H Clsd # cerv vert, wedge 1 
S100G Clsd # cerv vert, burst 1 
S100z Clsd # cerv spine NOS 1 
S100F Clsd # axis, tricolumnar 1 
S100D Clsd # axis, transvrse process 1 
S100B Clsd # axis, spondylolysis 1 
S100C Clsd # axis, spinous process 1 
S100E Clsd # axis, posterior arch 1 
S100A Clsd # axis odontoid process 1 
S1009 Clsd # atlas, comminuted 1 
S1106 Clsd # C5-C7 unspec cord les 1 
S110A Clsd # C5-C7 post cord lesion 1 
S110B Clsd # C5-C7 incomp cord les 1 
S1107 Clsd # C5-C7 complete cord les 1 
S1109 Clsd # C5-C7 cent cord lesion 1 
S1108 Clsd # C5-C7 ant cord lesion 1 
S1100 Clsd # C1-C4 unspec cord les 1 
S1104 Clsd # C1-C4 post cord lesion 1 
S1105 Clsd # C1-C4 incomp cord les 1 
S1101 Clsd # C1-C4 complete cord les 1 
S1103 Clsd # C1-C4 cent cord lesion 1 
S1102 Clsd # C1-C4 ant cord lesion 1 
S4120 Cls trmtc subluxatn shldr jnt 1 
S4696 Cls trmtc sublux,head fibula 1 
S467 Cls trmtc sublux pat-fem jt 1 
S4690 Cls trmtc sublux knee jt,unsp 1 
S4692 Cls trmtc sublux knee jt,post 1 
S4694 Cls trmtc sublux knee jt,ltrl 1 
S4691 Cls trmtc sublux knee jt,ant 1 
S469 Cls trmtc sublux knee jt 1 
S4102 Cls trmtc dslctn shldr jtpost 1 
S410z Cls trmtc dislctn shoulder NOS 1 
S49E4 Cls trm sublux,st-clav jt,post 1 
S49E3 Cls trm sublux,st-clav jt,ant 1 
S49E2 Cls trm sublux st-clav jt 1 
S4671 Cls trm sublux pat-fem jt,med 1 
S4670 Cls trm sublux pat-fem jt,ltrl 1 
S49E5 Cls trm sublux laryngl cart 1 
S4695 Cls trm sublux knee jt,rotatry 1 
S4693 Cls trm sublux knee jt,medial 1 
S4121 Cls trm sublux acromio-clav jt 1 
S4656 Cls trm dslctn, head fibula 1 
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S4631 Cls trm dslctn pat-fem jt,med 1 
S4630 Cls trm dslctn pat-fem jt,lat 1 
S4650 Cls trm dslctn knee, unspec 1 
S4654 Cls trm dslctn knee jt,lateral 1 
S4652 Cls trm dslctn knee jt, post 1 
S4653 Cls trm dslctn knee jt, medial 1 
S4651 Cls trm dslctn knee jt, ant 1 
S465z Cls trm dslctn knee NOS 1 
S4655 Cls trm dslct knee jt,rotatory 1 
S4963 Cls trm dslc,stern-clav jt,ant 1 
S4962 Cls trm dslc sterno-clav jt 1 
S4965 Cls trm dslc laryngl cartilage 1 
S4964 Cls trm dsl,stern-clav jt,post 1 
S412 Cls traumtc subluxatn shoulder 1 
S410 Cls traumtc disloctn shoulder 1 
S4105 Cls traumatic disloctn scapula 1 
S49A Cls sublux thrcic+lumbar spine 1 
S49A1 Cls sublux thrcic spine 1 
S49Az Cls sublux thrc+lmbr spine NOS 1 
S498x Cls sublux mlti cerv vertebrae 1 
S4980 Cls sublux cervical spine,unsp 1 
S498 Cls sublux cervical spine 1 
S498z Cls sublux cerv vertebra NOS 1 
S4981 Cls sublux atlanto-occiptl jt 1 
S4982 Cls sublux atlanto-axial jt 1 
S492C Cls spnl dslc+cauda equina lsn 1 
S4924 Cls spnl dslc+ant thrc crd lsn 1 
S4929 Cls spnl dslc+ant lmbr crd lsn 1 
S490B Cls spnl dslc+ant cerv crd lsn 1 
S492B Cls spnl dsl+post lmbr crd lsn 1 
S4923 Cls spnl dsl+comp thrc crd lsn 1 
S4928 Cls spnl dsl+comp lmbr crd lsn 1 
S4922 Cls spn dslc+thrc crd lsn,unsp 1 
S4926 Cls spn dslc+post thrc crd lsn 1 
S490D Cls spn dslc+post cerv crd lsn 1 
S4925 Cls spn dslc+cent thrc crd lsn 1 
S492A Cls spn dslc+cent lmbr crd lsn 1 
S1140 Cls spn # + unsp lumb crd lesn 1 
S1144 Cls spn # + post lumb crd lesn 1 
S1141 Cls spn # + comp lumb crd lesn 1 
S1143 Cls spn # + cent lumb crd lesn 1 
S1145 Cls spn # + cauda equina lesn 1 
S1142 Cls spn # + ant lumbr crd lesn 1 
SR100 Cls fract invol head with neck 1 
S492z Cls dslc thrcic+lmbr spine NOS 1 
S492 Cls dslc thoracic+lumbar spine 1 
S4921 Cls dslc thoracic vertebra 1 
S4920 Cls dslc lumbar spine 1 
S4901 Cls dslc atlanto-occipital jnt 1 
S4902 Cls dslc atlanto-axial joint 1 
S4F6 Cls #-sublux,patello-fem jt 1 
S4J23 Cls #-sublux st-clav jt,post 1 
S4J22 Cls #-sublux st-clav jt,ant 1 
S4F4 Cls #-dslc,patello-fem jt 1 
S4J03 Cls #-dslc st-clav jt,post 1 
S4J02 Cls #-dslc st-clav jt,ant 1 
S1022 Cls # thorc vert-spondylolysis 1 
S1044 Cls # lumbr vert-trnsvrse prcs 1 
S1042 Cls # lumbr vert-spondylolysis 1 
S1043 Cls # lumbr vert-spinous prcss 1 
S1045 Cls # lumb vert-posterior arch 1 
S100L Cls # cerv vert, trnsvrse prcs 1 
S100N Cls # cerv vert, tricolumnar 1 
S100J Cls # cerv vert, spondylolysis 1 
S100K Cls # cerv vert, spinous prcss 1 
S100M Cls # cerv vert, post arch 1 
S1008 Cls # atlas-isol arch/art prcs 1 
S412z Closed traumatic subluxation shoulder NOS 1 
S496z Closed traumatic disloctn NOS 1 
S4100 Closed traumatic dislocation shoulder joint, unspecified 1 
S463 Closed traumatic dislocation of patello-femoral joint 1 
S112z Closed thoracic#+cord lesn.NOS 1 
S112 Closed thoracic #+cord lesion 1 
S49Cz Closed subluxation spine NOS 1 
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S49A0 Closed subluxation lumbar spine 1 
S4988 Closed subluxation C7/T1 1 
S4987 Closed subluxation C6/C7 1 
S4986 Closed subluxation C5/C6 1 
S4985 Closed subluxation C4/C5 1 
S4984 Closed subluxation C3/C4 1 
S4983 Closed subluxation C2/C3 1 
S49C0 Closed sublux spine, unsp 1 
S49C Closed sublux other vertebra 1 
S026 Closed orbital blow-out fracture 1 
S114 Closed lumbar # + cord lesion 1 
S102 Closed fracture thoracic vertebra 1 
S2104 Closed fracture scapula, blade 1 
S2105 Closed fracture scapula spine 1 
S2106 Closed fracture scapula neck 1 
S2103 Closed fracture scapula glenoid 1 
S2101 Closed fracture scapula acromion 1 
S3204 Closed fracture patella, comminuted (stellate) 1 
S320 Closed fracture of the patella 1 
S1250 Closed fracture larynx 1 
S2002 Closed fracture clavicle shaft 1 
S1002 Closed fracture axis 1 
S1001 Closed fracture atlas 1 
S4940 Closed dislocation spine unsp. 1 
S494z Closed dislocation spine NOS 1 
S490 Closed dislocation cervical spine 1 
S4908 Closed dislocation C7/T1 1 
S4907 Closed dislocation C6/C7 1 
S4906 Closed dislocation C5/C6 1 
S4905 Closed dislocation C4/C5 1 
S4904 Closed dislocation C3/C4 1 
S4903 Closed dislocation C2/C3 1 
S494 Closed disloc.other vertebra 1 
S490x Closed disloc.mult.cerv.vert. 1 
S490z Closed disloc.cervic.vert.NOS 1 
S4900 Closed disloc.cerv.spine unsp. 1 
S4960 Closed disloc sternoclavic. jt 1 
S4104 Closed disloc acromioclavic.jt 1 
S110z Closed cervical#+cord lesn.NOS 1 
S110 Closed cervical #+cord lesion 1 
S1253 Closed #trachea 1 
S1252 Closed #thyroid cartilage 1 
S11x Closed #spine+cord lesn.unsp. 1 
S2100 Closed #scapula-unspecified 1 
S210z Closed #scapula NOS 1 
S125z Closed #larynx/trachea NOS 1 
S1251 Closed #hyoid bone 1 
S2000 Closed #clavicle unspecified 1 
S200z Closed #clavicle NOS 1 
S3z0 Closed #bones unspecified 1 
S4F2 Closed #-sublux, knee joint 1 
S4A20 Closed #-sublux shoulder joint 1 
S4A2 Closed #-sublux shoulder 1 
S4A21 Closed #-sublux acrom-clav jt 1 
S4A00 Closed #-dslc shoulder joint 1 
S4A0 Closed #-dslc shoulder 1 
S4F0 Closed #-dslc knee joint 1 
S4A01 Closed #-dslc acrom-clav joint 1 
S10x Closed # spine unspecif 1 
S210 Closed # scapula 1 
S3201 Closed # patella,proximal pole 1 
S3203 Closed # patella, vertical 1 
S3200 Closed # patella transverse 1 
S3202 Closed # patella distal pole 1 
S200 Closed # clavicle 1 
S100 Closed # cervical spine 1 
N063000 Climacteric arthr.-site unsp. 1 
N0630 Climacteric arthr.-site unsp. 1 
N0631 Climacteric arthr.-shoulder 1 
N0638 Climacteric arthr.-other spec. 1 
N063800 Climacteric arthr.-other spec. 1 
N0639 Climacteric arthr.-multip.site 1 
N063900 Climacteric arthr.-multip.site 1 
N063z Climacteric arthr.-NOS 1 
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N063z00 Climacteric arthr.-NOS 1 
N0991 Clicking sternoclavic joint 1 
N0990 Clicking shoulder 1 
N099C Clicking knee 1 
N099 Clicking joint 1 
N0992 Clicking acromioclavicular joint 1 
N33A1 Clavicle pain 1 
S490A Cl spnl dslc+comp cerv crd lsn 1 
S4909 Cl spnl dslc+cerv crd lsn,unsp 1 
S49A2 Cl spn sublx+thrc crd lsn,unsp 1 
S49A6 Cl spn sublx+post thrc crd lsn 1 
S49AB Cl spn sublx+post lmbr crd lsn 1 
S49A7 Cl spn sublx+lmbr crd lsn,unsp 1 
S49A3 Cl spn sublx+comp thrc crd lsn 1 
S49A8 Cl spn sublx+comp lmbr crd lsn 1 
S498A Cl spn sublx+comp cerv crd lsn 1 
S498C Cl spn sublx+cntrl crv crd lsn 1 
S4989 Cl spn sublx+cerv crd lsn,unsp 1 
S49A5 Cl spn sublx+cent thrc crd lsn 1 
S49AA Cl spn sublx+cent lmbr crd lsn 1 
S49AC Cl spn sublx+cauda equina lsn 1 
S49A4 Cl spn sublx+ant thrc crd lsn 1 
S49A9 Cl spn sublx+ant lmbar crd lsn 1 
S498D Cl spn sublux+post crv crd lsn 1 
S498B Cl spn sublux+ant cerv crd lsn 1 
S490C Cl spn dslc+cntrl cerv crd lsn 1 
S4927 Cl spn dsl+lmbr crd lsn unsp 1 
S1124 Cl spn #+pst thor crd lsn,T1-6 1 
S1123 Cl spn #+cnt thor crd lsn,T1-6 1 
S1122 Cl spn #+ant thor crd lsn,T1-6 1 
S1120 Cl sp #+unsp thor crd lsn,T1-6 1 
S1126 Cl sp #+unsp thor cd lsn,T7-12 1 
S112A Cl sp #+pst thor crd lsn,T7-12 1 
S1129 Cl sp #+cnt thor crd lsn,T7-12 1 
S1121 Cl sp #+cmpl thor crd lsn,T1-6 1 
S1127 Cl sp #+cmp thor crd lsn,T7-12 1 
S1128 Cl sp #+ant thor crd lsn,T7-12 1 
S1500 Cl multi fractur of thor spine 1 
SR160 Cl fract/th wth lw bck+plv+lmb 1 
S112B Cl # T7-12incomp cord lsn NOS 1 
S1125 Cl # T1-6 incmpl cord lesn NOS 1 
N301B Chronic osteomyelitis-th spine 1 
N301C Chronic osteomyelitis-lu spine 1 
N301A Chronic osteomyelitis-Cx spine 1 
N301 Chronic osteomyelitis 1 
C052* Chronic lymphocytic thyroiditis (Hashimotos's disease) 1 
16C9 Chronic low back pain 1 
N090X Chronic joint effusion 1 
N3682 Chronic instability of knee 1 
OX7289CB Chronic Backache /ox 1 
N3010 Chron.osteomyelitis-site unsp. 1 
N3011 Chron.osteomyelitis-shoulder 1 
N3018 Chron.osteomyelitis-other spec 1 
N3019 Chron.osteomyelitis-mult.site 1 
N301z Chron.osteomyelitis NOS 1 
N301L Chron multifocal osteomyelitis 1 
N301M Chr osteomyel + draining sinus 1 
N074 Chondromalacia patellae 1 
N33z2 Chondromalacia NOS 1 
N33zB Chondrolysis 1 
N022 Chondrocalcinosis unspecified 1 
N022z Chondrocalcinosis NOS 1 
N02 Chondrocalcinosis 1 
N0220 Chondrocalc.unsp.-site unspec. 1 
N0221 Chondrocalc.unsp.-shoulder reg 1 
N022y Chondrocalc.unsp.-other spec. 1 
N022x Chondrocalc.unsp.-multipl.site 1 
N020z Chondrocalc.dicalc.phos.NOS 1 
N021 Chondrocalc.-pyrophosph.cryst. 1 
N021z Chondrocalc.-pyrophosph.NOS 1 
N020 Chondrocalc.-dicalc.phos.cryst 1 
N0210 Chondroc.-pyrophos.-site unsp. 1 
N0211 Chondroc.-pyrophos.-shoulder 1 
N021y Chondroc.-pyrophos.-other spec 1 
413
 158
Read code Description 
Number of 
studies 
N021x Chondroc.-pyrophos.-mult.sites 1 
N0216 Chondroc.-pyrophos.-knee 1 
N0200 Chondroc.-dical.ph.-site unsp. 1 
N0201 Chondroc.-dical.ph.-shoulder 1 
N020y Chondroc.-dical.ph.-other spec 1 
N020x Chondroc.-dical.ph.-mult.sites 1 
N33zJ Chondritis 1 
182C Chest wall pain 1 
N035 Charcots arthropathy 1 
N132 Cervicocranial syndrome 1 
N133 Cervicobrachial syndrome 1 
N148A Cervico-thoracic instability 1 
N1483 Cervico-thoracic ankylosis 1 
N131 Cervicalgia 1 
N138 Cervicalgia 1 
N13y0 Cervical syndrome NEC 1 
N119 Cervical spondylosis with radiculopathy 1 
N11E Cervical spondylosis 1 
N110-1 Cervical spondylosis 1 
N110 Cervical spond.- no myelopathy 1 
N111 Cervical spond.+ myelopathy 1 
N1489 Cervical spine instability 1 
N1482 Cervical spine ankylosis 1 
N130 Cervical spinal stenosis 1 
N13y3 Cervical root syndrome 1 
N12A1 Cervical postlaminectomy syndr 1 
N137 Cervical post.long.lig.ossific 1 
SJ306 Cervical nerve root injury - C7 1 
SJ305 Cervical nerve root injury - C6 1 
SJ304 Cervical nerve root injury - C5 1 
SJ303 Cervical nerve root injury - C4 1 
SJ30 Cervical nerve root injury 1 
N1113 Cervical myelopathy 1 
N13 Cervical disorder NOS 1 
N12z4 Cervical discitis 1 
N120 Cervical disc displ.-no myelop 1 
N1291 Cervical disc disord.+myelop. 1 
N125 Cervical disc degeneration 1 
S5701 Cervical ant.longit.lig.sprain 1 
N13z Cervical and neck disorders NOS 1 
N12zH Cerv disc disord + radiculopth 1 
N21z0 Capsulitis NOS 1 
N04y0 Caplan's syndrome 1 
N3202 Calve's vertebral osteochondr. 1 
N2454 Calf pain 1 
N2226 Calcium deposit in bursa 1 
N2111 Calcifying tendinitis shoulder 1 
N12zB Calcification of thoracic disc 1 
N22y1 Calcification of tendon NOS 1 
N12zF Calcification of lumbar disc 1 
N23y1 Calcification of ligament 1 
N12z7 Calcification of cervical disc 1 
N23y9 Calcific tendinitis 1 
N2177 Calcaneal spur 1 
N2315 Calc/ossif musc ass with burns 1 
N0011 CREST syndrome 1 
182Z.00 CHEST PAIN NOS 1 
182..00 CHEST PAIN 1 
S1007 C7 closed # - no cord lesion 1 
S1006 C6 closed # - no cord lesion 1 
1D12.00 C/O: stiffness 1 
1D12 C/O: stiffness 1 
16C7 C/O - upper back ache 1 
1A53 C/O - lumbar pain 1 
16C5 C/O - low back pain 1 
N2118 Bursitis of shoulder 1 
N223 Bursitis NOS 1 
N2160-99 Bursitis - knee 1 
N2160 Bursitis - knee 1 
N221 Bunion 1 
16BZ Bruising symptom NOS 1 
16B Bruising symptom 1 
16B2 Bruises easily 1 
SE4z Bruise NOS 1 
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SE41 Bruise - knee/lower leg 1 
SE41-99 Bruise - knee/lower leg 1 
SE23 Bruise - back 1 
N11y0 Brucella spondylitis 1 
N3325 Brown tumour-hyperparathyroid 1 
N301G Brodie's abscess-thorac spine 1 
N301H Brodie's abscess-lumbar spine 1 
N301F Brodie's abscess-cervic spine 1 
N302b Brodie's abscess 1 
N0503 Bouchard's nodes with arthropathy                                                                                    1 
N33z Bone/cartilage disorder NOS 1 
N33z0 Bone/cartilage dis.-unspecif. 1 
N21z3 Bone spur NOS 1 
N33A Bone pain 1 
N33zz Bone or cartilage disorders NOS 1 
N31z Bone involvement in dis.EC NOS 1 
N30z0 Bone infectn.NOS-site unspecif 1 
N30z1 Bone infectn.NOS-shoulder 1 
N30z9 Bone infectn.NOS-multiple site 1 
N30z Bone infection NOS 1 
N30zz Bone infection NOS 1 
N3320 Bone cyst (localised),unspecif 1 
N3y0 Biomec lesn,not elsewh clas 1 
N2112 Bicipital tenosynovitis 1 
N2134 Biceps tendinitis 1 
N0120 Behcet's syndrome arthropathy 1 
N2222 Beat knee 1 
N0870 Bankart lesion 1 
N224A Baker's cyst 1 
N224A-1 Baker's cyst 1 
16 Baker's cyst 1 
16C3 Backache with radiation 1 
16CZ Backache symptom NOS 1 
16C Backache symptom 1 
16C2 Backache 1 
N149 Back stiffness 1 
S57 Back sprain excl. lumbosacral 1 
16... Back sprain NOS 1 
S57z Back sprain NOS 1 
16C4 Back pain worse on sneezing 1 
16C6 Back pain without radiat NOS 1 
N145-2 Back pain unspecified 1 
N143 Back pain - lower 1 
UNMAPPC6 Back injury 1 
N14 Back disorders - other 1 
N14z Back disorder/symptom NOS 1 
OX8479 Back Strain/Sprain /ox 1 
OX7289A Back Pain With Sciatica /ox 1 
N2455 Axillary pain 1 
N3347 Avascular necrosis-other bone 1 
N3345 Avascular necrosis, capitellum 1 
N334 Avascular necrosis - bone 1 
N334z Avascular bone necrosis NOS 1 
N3340 Avasc.bone necrosis site unsp. 1 
N3383 Atrophic non-union of fracture 1 
S5703 Atlanto-occipital joint sprain 1 
N1487 Atlanto-occipital instability 1 
N1480 Atlanto-occipital ankylosis 1 
S5702 Atlanto-axial joint sprain 1 
N1488 Atlanto-axial instability 1 
N1481 Atlanto-axial ankylosis 1 
14OD At risk of osteoporotic fracture 1 
14O9 At risk of osteoporosis 1 
N080z Articular cartilage disord.NOS 1 
N080 Articular cart.disor.excl.knee 1 
N0800 Artic.cart.dis.-site unspecif. 1 
N0801 Artic.cart.dis.-shoulder 1 
N0807 Artic.cart.dis.-other specif. 1 
N0808 Artic.cart.dis.-multiple sites 1 
N080B Artic cart disord oth j-should 1 
N0539 Arthrosis of first carpometacarpal joint, unspecified                                                                        1
OX7131C Arthrosis Spine /ox 1 
N0312 Arthropathy-Whipple's disease 1 
N034 Arthropathy+respiratory disord 1 
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N015 Arthropathy+other viral diseas 1 
N01y Arthropathy+other inf./parasit 1 
N03y Arthropathy+other condition EC 1 
N015z Arthropathy+oth.viral dis. NOS 1 
N014 Arthropathy+oth.bacterial dis. 1 
N017z Arthropathy+helminthiasis NOS 1 
N032 Arthropathy+haematological dis 1 
N031 Arthropathy+gastrointestin.dis 1 
N030 Arthropathy+endocr./metab.dis 1 
N033 Arthropathy+dermatological dis 1 
N01 Arthropathy with infections 1 
N0310 Arthropathy in ulcerative colitis 1 
N069 Arthropathy in neoplastic dis 1 
N0302 Arthropathy in amyloidosis 1 
N0148 Arthropathy in Whipple's disea 1 
N0311 Arthropathy in Crohn's disease 1 
N0320 Arthropathy due to haemophilia 1 
N06z1 Arthropathy NOS-shoulder 1 
N06z4 Arthropathy NOS-hand 1 
N06z3 Arthropathy NOS-forearm 1 
N06z7 Arthropathy NOS, of the ankle and foot 1 
N017 Arthropathy + parasite infectn 1 
N016z Arthropathy + mycoses NOS 1 
N016 Arthropathy + mycoses 1 
N03z Arthropathy + disorders EC NOS 1 
N03 Arthropathy + disorders EC 1 
N0y Arthropathies OS 1 
N0313 Arthropath follow intes bypass 1 
N036 Arthrop-hypersensitivity reacn 1 
N012 Arthrop+Behcet's syndrome 1 
N0121 Arthrop+Behcet's synd-shoulder 1 
N012y Arthrop+Behcet's synd-oth spec 1 
N012x Arthrop+Behcet's synd-multiple 1 
N012z Arthrop+Behcet's synd NOS 1 
N2330 Arthrogryposis 1 
N0 Arthritis/arthrosis 1 
N11 Arthritis of spine 1 
N010A Arthritis in Lyme disease 1 
OX6960T Arthritis Psoriatic /ox 1 
N06z-1 Arthritis 1 
N094F Arthralgia of wrist 1 
N094N Arthralgia of tibio-fibular joint 1 
N094A Arthralgia of shoulder 1 
N094M Arthralgia of knee 1 
N094D Arthralgia of elbow 1 
N094P Arthralgia of ankle 1 
N094H Arthralgia of PIP joint of finger 1 
N094G Arthralgia of MCP joint 1 
N094T Arthralgia of 1st MTP joint 1 
N0942 Arthralgia - upper arm 1 
N094B Arthralgia - sternoclav joint 1 
N0941 Arthralgia - shoulder 1 
N0945 Arthralgia - pelvic/thigh 1 
N0944 Arthralgia - hand 1 
N0943 Arthralgia - forearm 1 
N0947 Arthralgia - ankle/foot 1 
N094C Arthralgia - acromioclav joint 1 
EGTON1 Arthralgia 1 
N0150 Arthr.+oth.viral dis-site unsp 1 
N0151 Arthr.+oth.viral dis-shoulder 1 
N0140 Arthr.+oth.bact.dis-site unsp. 1 
N0141 Arthr.+oth.bact.dis-shoulder 1 
N014y Arthr.+oth.bact.dis-other spec 1 
N014x Arthr.+oth.bact.dis-mult.sites 1 
N014z Arthr.+oth bact. disease NOS 1 
N0160 Arthr.+mycoses-site unspecif. 1 
N0161 Arthr.+mycoses-shoulder region 1 
N016y Arthr.+mycoses-other specified 1 
N016x Arthr.+mycoses-multiple sites 1 
N0170 Arthr.+helminth.-site unspec. 1 
N0171 Arthr.+helminth.-shoulder regn 1 
N017y Arthr.+helminth.-other specif. 1 
N017x Arthr.+helminth.-multiple site 1 
N015y Arthr+oth.viral dis-other spec 1 
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N015x Arthr+oth.viral dis-mult.sites 1 
N03x0 Arthr assoc oth dis-shoulder 1 
N03xB Arthr assoc oth dis-knee 1 
N03x1 Arthr ass oth dis-sternoclav j 1 
N03x2 Arthr ass oth dis-acromioclv j 1 
N01yz Arth+other infect./parasit.NOS 1 
N01y0 Arth+oth.inf/para-site unspec. 1 
N01y1 Arth+oth.inf/para-shoulder reg 1 
N01yy Arth+oth.inf/para-other specif 1 
N01yx Arth+oth.inf/para-multipl.site 1 
N245-2 Arm pain 1 
N32z0 Apophysitis NOS 1 
N006 Antiphospholipid syndrome 1 
1M12 Anterior knee pain 1 
N094W Anterior knee pain 1 
S4101 Anterior dislocation of shoulder 1 
N12z9 Annular tear of thoracic disc 1 
N12zD Annular tear of lumbar disc 1 
N12z5 Annular tear of cervical disc 1 
N148 Ankylosis/instab Cx,Th,Lu spin 1 
N085B Ankylosis other joint-shoulder 1 
N085P Ankylosis of the knee joint 1 
N085A Ankylosis of shoulder joint 1 
N0859 Ankylosis of multiple joints 1 
N085z Ankylosis of joint NOS 1 
N085 Ankylosis of joint 1 
N117 Ankylosing verteb.hyperostosis 1 
N100* Ankylosing spondylitis 1 
N100 Ankylosing spondylitis 1 
N245-1 Ankle pain 1 
1M13 Ankle pain 1 
N05z7-1 Ankle osteoarthritis NOS 1 
N3384 Angular mal-union of fracture 1 
N3322 Aneurysmal bone cyst 1 
N2320 Amyotrophia NOS 1 
N0620 Allergic arthritis-site unsp. 1 
N0621 Allergic arthritis-shoulder 1 
N0628 Allergic arthritis-other spec. 1 
N0629 Allergic arthritis-multip.site 1 
N062z Allergic arthritis-NOS 1 
N062 Allergic arthritis 1 
N337z Algoneurodystrophy NOS 1 
N3373 Algodystrophy of knee 1 
N04y2 Adult-onset Still's disease 1 
N32y0 Adult osteochondrosis of spine 1 
N005 Adult Still's Disease 1 
N370 Adolescent postural kyphosis 1 
N3737 Adolescent idiopath scoliosis 1 
N210 Adhesive capsulitis - shoulde 1 
N2156 Adductor tendinitis 1 
N084D Adduction contracture-shoulder 1 
N0431 Acute polyartic.juvenile R.A. 1 
N300B Acute osteomyelitis-thor spine 1 
N3000 Acute osteomyelitis-site unsp. 1 
N3001 Acute osteomyelitis-shoulder 1 
N300G Acute osteomyelitis-scapula 1 
N300R Acute osteomyelitis-patella 1 
N3008 Acute osteomyelitis-other spec 1 
N3009 Acute osteomyelitis-mult.site 1 
N300C Acute osteomyelitis-lumb spine 1 
N300F Acute osteomyelitis-clavicle 1 
N300A Acute osteomyelitis-cerv spine 1 
N300z Acute osteomyelitis NOS 1 
N300 Acute osteomyelitis 1 
S460 Acute meniscal tear medial 1 
S461 Acute meniscal tear lateral 1 
N090Y Acute joint effusion 1 
N300Z Acute haematogen osteomyelitis 1 
N145 Acute back pain - unspecified 1 
N145-1 Acute back pain - unspecified 1 
N141 Acute back pain - thoracic 1 
N141-1 Acute back pain - thoracic 1 
N142 Acute back pain - lumbar 1 
N142-3 Acute back pain - lumbar 1 
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N12 Acute back pain - disc 1 
N143-1 Acute back pain + sciatica 1 
N06zA Acute arthritis 1 
EGTONAC1 Acromio-Clavicular Dislocation 1 
N384 Acquired spondylolisthesis 1 
N3720 Acquired postural lordosis 1 
N3710 Acquired postural kyphosis 1 
N372z Acquired lordosis NOS 1 
N372 Acquired lordosis 1 
N371z Acquired kyphosis NOS 1 
N371 Acquired kyphosis 1 
N366 Acquired knee deformity NOS 1 
N37z0 Acquired hunchback 1 
N3641 Acquired genu varum 1 
N364z Acquired genu valgum/varum NOS 1 
N364 Acquired genu valgum/varum 1 
N3640 Acquired genu valgum 1 
N385 Acquired deformity spine NOS 1 
N382 Acquired deformity of neck 1 
N38z Acquired deformity NOS 1 
N38y0 Acquired clavicle deformity 1 
1DCC.00 Aching muscles 1 
1DCC Aching muscles 1 
N220H Achilles tenosynovitis 1 
N2174 Achilles tendinitis 1 
N094-1 Ache in joint 1 
S4604 Ac mnscl tr,med,periph,dtchmt 1 
S4614 Ac mnscl tr,lat,periph,dtchmt 1 
S4605 Ac mnscl tear,med,horiz clvge 1 
S4615 Ac mnscl tear,lat,horiz clvge 1 
S4602 Ac menscl tear,med,bckt hndle 1 
S4612 Ac menscl tear,lat,bckt hndle 1 
S4603 Ac meniscal tear,med,radial 1 
S4601 Ac meniscal tear,med,post horn 1 
S4600 Ac meniscal tear,med,ant horn 1 
S4613 Ac meniscal tear,lat,radial 1 
S4611 Ac meniscal tear,lat,post horn 1 
S4610 Ac meniscal tear,lat,ant horn 1 
N22y2 Abscess of tendon 1 
N22yE Abscess of bursa-shoulder 1 
N22yJ Abscess of bursa-knee 1 
N22y3 Abscess of bursa 1 
SD Abrasions 1 
N084C Abduction contracture-shoulder 1 
1969.00 Abdominal pain 1 
EGTON251 ? Frozen Right Shoulder 1 
N11C1 2 lev lumbsac spond+radiculop 1 
N11C0 1 lev lumbsac spond+radiculop 1 
HNG0160 (hn) Sports Injury 1 
HNG0157 (hn) Spinal Injury 1 
HNG0162 (hn) Soft tissue injuries 1 
HNG0163 (hn) Rhematic problems 1 
S11 #Vertebra + cord lesion 1 
S10z #Spine - no cord lesion - NOS 1 
S10 #Spine - no cord lesion 1 
S11z #Spine + cord lesion NOS 1 
S21z #Scapula NOS 1 
S21 #Scapula 1 
S32z #Patella NOS 1 
S104 #Lumbar spine - no cord lesion 1 
S32 #Knee-cap 1 
S20z #Clavicle NOS 1 
S20 #Clavicle 1 
S3zz #Bones NOS 1 
S4F #-dslc/subluxation knee 1 
S4A #-dslc or subluxation shoulder 1 
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Supplementary appendix 4, table 10. List of Read codes used in the studies of male 
sexual dysfunction. 
Read code Description Number of studies 
E227311 Erectile dysfunction 3 
K27y100 Impotence of organic origin 2 
E227300 Impotence 2 
Eu52213 [X]Psychogenic impotence 1 
Eu52212 [X]Male erectile disorder 1 
E227000 Unspecified psychosexual dysfunction 1 
7C25E00 Treatment of erectile dysfunction NEC 1 
7A6G000 Revascularisation for impotence 1 
8IE8.00 Referral to erectile dysfunction clinic declined 1 
8HTj.00 Referral to erectile dysfunction clinic 1 
E227z00 Psychosexual dysfunction NOS 1 
E227.00 Psychosexual dysfunction 1 
E227700 Psychogenic dyspareunia 1 
Z9E9.00 Provision of device for impotence 1 
E227600 Premature ejaculation 1 
7C25F00 Operations on penis for erectile dysfunction NEC 1 
7A6G500 Ligation of penile veins for impotence 1 
E227.11 Lack of libido 1 
E227100 Inhibited sexual desire 1 
E227500 Inhibited male orgasm 1 
E227z11 Fear of ejaculation 1 
K27y700 Erectile dysfunction due to diabetes mellitus 1 
66Au.00 Diabetic erectile dysfunction review 1 
66Av.00 Diabetic assessment of erectile dysfunction 1 
1D1B.00 C/O erectile dysfunction 1 
ZG43600 Advice on technique for impotence 1 
67IA.00 Advice about impotence 1 
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Supplementary appendix 4, table 11. List of Read codes used in the studies of sleep 
disorder. 
Read code Description Number of studies 
1B1B.00 Cannot sleep - insomnia 1 
1B1B.11 C/O - insomnia 1 
1B1B100 Middle insomnia 1 
1B1B200 Late insomnia 1 
1B1Q.00 Poor sleep pattern 1 
E274.00 Non-organic sleep disorders 1 
E274.11 Hypersomnia of non-organic origin 1 
E274.12 Insomnia due to nonorganic sleep disorder 1 
E274000 Unspecified non-organic sleep disorder 1 
E274100 Transient insomnia 1 
E274111 Insomnia NOS 1 
E274200 Persistent insomnia 1 
E274300 Transient hypersomnia 1 
E274311 Hypersomnia NOS 1 
E274400 Persistent hypersomnia 1 
E274500 Jet lag syndrome 1 
E274600 Shifting sleep-work schedule 1 
E274700 Somnambulism - sleep walking 1 
E274800 Night terrors 1 
E274900 Nightmares 1 
E274A00 Sleep drunkenness 1 
E274B00 Repeated rapid eye movement sleep interruptions 1 
E274C00 Other sleep stage or arousal dysfunction 1 
E274D00 Repetitive intrusions of sleep 1 
E274D11 Restless sleep 1 
E274E00 'Short-sleeper' 1 
E274F00 Inversion of sleep rhythm 1 
E274y00 Other non-organic sleep disorder 1 
E274y11 Dreams 1 
E274z00 Non-organic sleep disorder NOS 1 
Eu51.00 [X]Nonorganic sleep disorders 1 
Eu51000 [X]Nonorganic insomnia 1 
Eu51100 [X]Nonorganic hypersomnia 1 
Eu51200 [X]Nonorganic disorder of the sleep-wake schedule 1 
Fy00.00 Disorders of initiating and maintaining sleep 1 
Fy01.00 Disorders of excessive somnolence 1 
Fy02.00 Disorders of the sleep-wake schedule 1 
R005.00 [D]Sleep disturbances 1 
R005.11 [D]Insomnia - symptom 1 
R005.12 [D]Sleep rhythm problems 1 
R005000 [D]Sleep disturbance, unspecified 1 
R005100 [D]Insomnia with sleep apnoea 1 
R005200 [D]Insomnia NOS 1 
R005300 [D]Hypersomnia with sleep apnoea 1 
R005311 [D]Sleep apnoea syndrome 1 
R005312 [D]Syndrome sleep apnoea 1 
R005400 [D]Hypersomnia NOS 1 
R005500 [D]Sleep rhythm inversion 1 
R005600 [D]Sleep rhythm irregular 1 
R005700 [D]Sleep-wake rhythm non-24-hour cycle 1 
R005800 [D]Sleep dysfunction with sleep stage disturbance 1 
R005900 [D]Sleep dysfunction with arousal disturbance 1 
R005z00 [D]Sleep dysfunction NOS 1 
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Supplementary appendix 4, table 12. List of Read codes used in the studies of fatal and 
non-fatal self-harm. 
Read code Description Number of studies 
TK1y.00 Suicide and selfinflicted poisoning by other utility gas 8 
TK21.00 Suicide and selfinflicted poisoning by other carbon monoxide 8 
TK01000 Suicide and self inflicted injury by Amylobarbitone 8 
TK03.00 Suicide + selfinflicted poisoning tranquilliser/psychotropic 8 
TK0z.00 Suicide + selfinflicted poisoning by solid/liquid subst NOS 8 
TK04.00 Suicide + selfinflicted poisoning by other drugs/medicines 8 
TK02.00 Suicide + selfinflicted poisoning by oth sedatives/hypnotics 8 
TK20.00 Suicide + selfinflicted poisoning by motor veh exhaust gas 8 
TK05.00 Suicide + selfinflicted poisoning by drug or medicine NOS 8 
TK07.00 Suicide + selfinflicted poisoning by corrosive/caustic subst 8 
TK01.00 Suicide + selfinflicted poisoning by barbiturates 8 
TK00.00 Suicide + selfinflicted poisoning by analgesic/antipyretic 8 
TK06.00 Suicide + selfinflicted poisoning by agricultural chemical 8 
U200.00 [X]Intent self poison/exposure to nonopioid analgesic 7 
U20..11 [X]Deliberate drug overdose / other poisoning 7 
TK70.00 Suicide+selfinflicted injury-jump from residential premises 7 
TK71.00 Suicide+selfinflicted injury-jump from oth manmade structure 7 
TK72.00 Suicide+selfinflicted injury-jump from natural sites 7 
TK7z.00 Suicide+selfinflicted injury-jump from high place NOS 7 
TK61.00 Suicide and selfinflicted injury by stabbing 7 
TK51.00 Suicide and selfinflicted injury by shotgun 7 
TKx2.00 Suicide and selfinflicted injury by scald 7 
TKxy.00 Suicide and selfinflicted injury by other specified means 7 
TK54.00 Suicide and selfinflicted injury by other firearm 7 
TK52.00 Suicide and selfinflicted injury by hunting rifle 7 
TK30.00 Suicide and selfinflicted injury by hanging 7 
TK6z.00 Suicide and selfinflicted injury by cutting and stabbing NOS 7 
TK60.00 Suicide and selfinflicted injury by cutting 7 
TKx5.00 Suicide and selfinflicted injury by crashing motor vehicle 7 
TKx1.00 Suicide and selfinflicted injury by burns or fire 7 
TK...00 Suicide and selfinflicted injury 7 
TK01400 Suicide and self inflicted injury by Phenobarbitone 7 
TK01100 Suicide and self inflicted injury by Barbitone 7 
TK...14 Suicide and self harm 7 
TK0..00 Suicide + selfinflicted poisoning by solid/liquid substances 7 
TK2..00 Suicide + selfinflicted poisoning by other gases and vapours 7 
TK11.00 Suicide + selfinflicted poisoning by liquified petrol gas 7 
TK2z.00 Suicide + selfinflicted poisoning by gases and vapours NOS 7 
TK10.00 Suicide + selfinflicted poisoning by gas via pipeline 7 
TK1z.00 Suicide + selfinflicted poisoning by domestic gases NOS 7 
TKx0000 Suicide + selfinflicted injury-jumping before moving object 7 
TK31.00 Suicide + selfinflicted injury by suffocation by plastic bag 7 
TK3y.00 Suicide + selfinflicted inj oth mean hang/strangle/suffocate 7 
TK3z.00 Suicide + selfinflicted inj by hang/strangle/suffocate NOS 7 
TK...13 Poisoning - self-inflicted 7 
TK...17 Para-suicide 7 
TK...11 Cause of overdose - deliberate 7 
TK...15 Attempted suicide 7 
U2...13 [X]Suicide 6 
U20C.11 [X]Self poisoning with weedkiller 6 
U20C.12 [X]Self poisoning with paraquat 6 
U20A.11 [X]Self poisoning from glue solvent 6 
U20B.11 [X]Self carbon monoxide poisoning 6 
U2...15 [X]Para-suicide 6 
U20..00 [X]Intentional self poisoning/exposure to noxious substances 6 
U20A.00 [X]Intentional self poison organ solvent,halogen hydrocarb 6 
U20y.00 [X]Intent self poison/exposure to unspecif chemical 6 
U202.00 [X]Intent self poison/exposure to sedative hypnotic 6 
U204.00 [X]Intent self poison/exposure to psychotropic drug 6 
U20C.00 [X]Intent self poison/exposure to pesticide 6 
U20B.00 [X]Intent self poison/exposure to other gas/vapour 6 
U207.00 [X]Intent self poison/exposure to oth autonomic drug 6 
U206.00 [X]Intent self poison/exposure to hallucinogen 6 
U201.00 [X]Intent self poison/exposure to antiepileptic 6 
U20yz00 [X]Intent self poison unspecif chemical unspecif place 6 
U202z00 [X]Intent self poison sedative hypnotic unspecif place 6 
U204z00 [X]Intent self poison psychotropic drug unspecif place 6 
U204100 [X]Intent self poison psychotropic drug at res institut 6 
U20Bz00 [X]Intent self poison other gas/vapour unspecif place 6 
U208z00 [X]Intent self poison oth/unsp drug/medic unspecif place 6 
U207z00 [X]Intent self poison oth autonomic drug unspecif place 6 
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Read code Description Number of studies 
U200z00 [X]Intent self poison nonopioid analgesic unspecif place 6 
U200100 [X]Intent self poison nonopioid analgesic at res institut 6 
U205z00 [X]Intent self poison narcotic drug unspecif place 6 
U201z00 [X]Intent self poison antiepileptic unspecif place 6 
U206400 [X]Intent self pois hallucinogen in street/highway 6 
U20y000 [X]Int self poison/exposure to unspecif chemical at home 6 
U202000 [X]Int self poison/exposure to sedative hypnotic at home 6 
U204000 [X]Int self poison/exposure to psychotropic drug at home 6 
U20C000 [X]Int self poison/exposure to pesticide at home 6 
U208.00 [X]Int self poison/exposure to other/unspec drug/medicament 6 
U20B000 [X]Int self poison/exposure to other gas/vapour at home 6 
U207000 [X]Int self poison/exposure to oth autonomic drug at home 6 
U200000 [X]Int self poison/exposure to nonopioid analgesic at home 6 
U205000 [X]Int self poison/exposure to narcotic drug at home 6 
U201000 [X]Int self poison/exposure to antiepileptic at home 6 
U20y200 [X]Int self poison unspecif chemical school/pub admin area 6 
U202y00 [X]Int self poison sedative hypnotic other spec place 6 
U204y00 [X]Int self poison psychotropic drug other spec place 6 
U20Cy00 [X]Int self poison pesticide other spec place 6 
U20B200 [X]Int self poison other gas/vapour school/pub admin area 6 
U20By00 [X]Int self poison other gas/vapour other spec place 6 
U208y00 [X]Int self poison oth/unsp drug/medic other spec place 6 
U20A400 [X]Int self poison org solvent,halogen hydrocarb,in highway 6 
U200y00 [X]Int self poison nonopioid analgesic other spec place 6 
U205y00 [X]Int self poison narcotic drug other spec place 6 
U2...14 [X]Attempted suicide 6 
TKx7.00 Suicide and selfinflicted injury caustic subst, excl poison 6 
TKxz.00 Suicide and selfinflicted injury by other means NOS 6 
TKx..00 Suicide and selfinflicted injury by other means 6 
TK7..00 Suicide and selfinflicted injury by jumping from high place 6 
TKx3.00 Suicide and selfinflicted injury by extremes of cold 6 
TKx4.00 Suicide and selfinflicted injury by electrocution 6 
TK4..00 Suicide and selfinflicted injury by drowning 6 
TK6..00 Suicide and selfinflicted injury by cutting and stabbing 6 
TKz..00 Suicide and selfinflicted injury NOS 6 
TK1..00 Suicide + selfinflicted poisoning by gases in domestic use 6 
TKx0.00 Suicide + selfinflicted injury-jump/lie before moving object 6 
TK3..00 Suicide + selfinflicted injury by hang/strangulate/suffocate 6 
U2y0.00 [X]Intentionl self harm by oth specif means occurrn at home 5 
U2z0.00 [X]Intentional self harm by unspecif means occurrn at home 5 
U290.00 [X]Intentional self harm by sharp object occurrence at home 5 
U29z.00 [X]Intentional self harm by sharp object occ unspecif place 5 
U2A0.00 [X]Intentional self harm by blunt object occurrence at home 5 
U270.00 [X]Intention self harm by smoke fire/flames occurrn at home 5 
U294.00 [X]Intention self harm by sharp object occ street/highway 5 
U29y.00 [X]Intention self harm by sharp object occ oth specif place 5 
U205.00 [X]Intent self poison/exposure to narcotic drug 5 
U209.00 [X]Intent self poison/exposure to alcohol 5 
U209z00 [X]Intent self poison alcohol unspecif place 5 
U202400 [X]Intent self pois sedative hypnotic in street/highway 5 
U208400 [X]Intent self pois oth/unsp drug/medic in street/highway 5 
U20A000 [X]Intent self pois organ solvent,halogen hydrocarb, home 5 
U200500 [X]Intent self pois nonopioid analgesic trade/service area 5 
U250.00 [X]Intent self harm oth/unspecif firearm disch occ at home 5 
U2D6.00 [X]Intent self harm crash motor vehic occ indust/constr area 5 
U2zy.00 [X]Intent self harm by unspecif means occ oth specif place 5 
U2zz.00 [X]Intent self harm by unspecif means occ at unspecif place 5 
U2z2.00 [X]Intent self harm by unspec mean occ sch/ins/pub adm area 5 
U27z.00 [X]Intent self harm by smoke fire/flames occ unspecif place 5 
U274.00 [X]Intent self harm by smoke fire/flame occ street/highway 5 
U291.00 [X]Intent self harm by sharp object occ resident instit'n 5 
U2yz.00 [X]Intent self harm by oth specif means occ unspecif place 5 
U2y1.00 [X]Intent self harm by oth specif means occ resid instit'n 5 
U2B0.00 [X]Intent self harm by jumping from high place occ at home 5 
U2B4.00 [X]Intent self harm by jump from high place occ street/h'way 5 
U211.00 [X]Intent self harm by hangng strangult/suffoct resid instit 5 
U21z.00 [X]Intent self harm by hangng strangul/suffoct unspecif plce 5 
U21y.00 [X]Intent self harm by hangng strangul/suffoct oth spec plce 5 
U210.00 [X]Intent self harm by hanging strangulat/suffocat occ home 5 
U221.00 [X]Intent self harm by drowning/submersn occ resid instit'n 5 
U22z.00 [X]Intent self harm by drown/submersn occ unspecified place 5 
U22y.00 [X]Intent self harm by drown/submersn occ oth specif place 5 
U2D0.00 [X]Intent self harm by crash of motor vehicl occurrn at home 5 
U2D4.00 [X]Intent self harm by crash motor vehicl occ street/highway 5 
U2A3.00 [X]Intent self harm by blunt object occ sports/athlet area 5 
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U2A1.00 [X]Intent self harm by blunt object occ resident instit'n 5 
U242.00 [X]Int slf hrm rifl s'gun/lrg frarm dis sch/ins/pub adm area 5 
U208000 [X]Int self poison/exposure to oth/unsp drug/medicam home 5 
U209y00 [X]Int self poison alcohol other spec place 5 
U20Az00 [X]Int self pois org solv,halogen hydrocarb, unspec place 5 
U241.00 [X]Int self harm rifl s'gun/lrg frarm disch occ resid instit 5 
U2C4.00 [X]Int self harm jump/lying befr mov obje occ street/highway 5 
U2C1.00 [X]Int self harm jump/lying befr mov obje occ resid instit'n 5 
U2Cy.00 [X]Int self harm jump/lying bef mov obje occ oth specif plce 5 
U2Bz.00 [X]Int self harm by jump from high place occ unspecif place 5 
U2By.00 [X]Int self harm by jump from high place occ oth specif plce 5 
U2B6.00 [X]Int self harm by jump from high place indust/constr area 5 
TK5z.00 Suicide and selfinflicted injury by firearms/explosives NOS 5 
TK5..00 Suicide and selfinflicted injury by firearms and explosives 5 
TKx6.00 Suicide and selfinflicted injury by crashing of aircraft 5 
TK60111 Slashed wrists self inflicted 5 
TK60100 Self inflicted lacerations to wrist 5 
U202.13 [X]Overdose - temazepam 4 
U202.11 [X]Overdose - sleeping tabs 4 
U202.15 [X]Overdose - nitrazepam 4 
U202.12 [X]Overdose - diazepam 4 
U202.16 [X]Overdose - benzodiazepine 4 
U202.17 [X]Overdose - barbiturate 4 
U204.11 [X]Overdose - antidepressant 4 
U202.18 [X]Overdose - amobarbital 4 
U204.12 [X]Overdose - amitriptyline 4 
U204.13 [X]Overdose - SSRI 4 
U2z..00 [X]Intentional self harm by unspecified means 4 
U27..00 [X]Intentional self harm by smoke, fire and flames 4 
U29..00 [X]Intentional self harm by sharp object 4 
U2y..00 [X]Intentional self harm by other specified means 4 
U2B..00 [X]Intentional self harm by jumping from a high place 4 
U26..00 [X]Intentional self harm by explosive material 4 
U22..00 [X]Intentional self harm by drowning and submersion 4 
U2D..00 [X]Intentional self harm by crashing of motor vehicle 4 
U2A..00 [X]Intentional self harm by blunt object 4 
U200400 [X]Intent self pois nonopioid analgesic in street/highway 4 
U28z.00 [X]Intent self harm by steam hot vapour/obj occ unspec place 4 
U280.00 [X]Intent self harm by steam hot vapour/hot obj occ at home 4 
U24..00 [X]Intent self harm by rifle shotgun/larger firearm disch 4 
U25..00 [X]Intent self harm by other/unspecified firearm discharge 4 
U2C..00 [X]Intent self harm by jumping / lying before moving object 4 
U21..00 [X]Intent self harm by hanging strangulation / suffocation 4 
U212.00 [X]Inten slf harm hang strang/suffc sch oth ins/pub adm area 4 
U209000 [X]Int self poison/exposure to alcohol at home 4 
U41..00 [X]Hanging strangulation + suffocation undetermined intent 4 
U4Bz.00 [X]Fall jump/push frm high plce undt intnt occ unspecif plce 4 
U720.00 [X]Sequelae of intentional self-harm 3 
U2...11 [X]Self inflicted injury 3 
U44..00 [X]Rifle shotgun+larger firearm discharge undetermin intent 3 
U40y.00 [X]Poisoning/exposure, ? intent, to unspecif chemical 3 
U402.00 [X]Poisoning/exposure, ? intent, to sedative hypnotic 3 
U404.00 [X]Poisoning/exposure, ? intent, to psychotropic drug 3 
U40C.00 [X]Poisoning/exposure, ? intent, to pesticide 3 
U40B.00 [X]Poisoning/exposure, ? intent, to other gas/vapour 3 
U400.00 [X]Poisoning/exposure, ? intent, to nonopioid analgesic 3 
U405.00 [X]Poisoning/exposure, ? intent, to narcotic drug 3 
U409.00 [X]Poisoning/exposure, ? intent, to alcohol 3 
U40..00 [X]Poisoning/expos to noxious substance,undetermined intent 3 
U408.00 [X]Poison/exposure, ?intent, to other/unspec drug/medicament 3 
U408000 [X]Poison/exposure ?intent, to oth/unsp drug/medicam home 3 
U409000 [X]Poison/exposure ?intent, to alcohol at home 3 
U40y600 [X]Poison/expos ?intent unspec chemic indust/construct area 3 
U200.11 [X]Overdose - paracetamol 3 
U200.12 [X]Overdose - ibuprofen 3 
U200.13 [X]Overdose - aspirin 3 
U45..00 [X]Other+unspecified firearm discharge undetermined intent 3 
U2...00 [X]Intentional self-harm 3 
U28..00 [X]Intentional self harm by steam hot vapours / hot objects 3 
U216.00 [X]Intent self harm by hang strangl/suffc indust/constr area 3 
U220.00 [X]Intent self harm by drowning/submersion occurrn at home 3 
U206000 [X]Int self poison/exposure to hallucinogen at home 3 
U2...12 [X]Injury - self-inflicted 3 
U410.00 [X]Hanging strangulat+suffocat undet intent occurrn at home 3 
U4B..00 [X]Falling jumping/pushed from high place undeterm intent 3 
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U30..11 [X]Deliberate drug poisoning 3 
ZX1R.00 Throwing self in front of vehicle 3 
ZX1Q.00 Throwing self in front of train 3 
TK53.00 Suicide and selfinflicted injury by military firearms 3 
TK01z00 Suicide and self inflicted injury by barbiturates 3 
TK2y.00 Suicide + selfinflicted poisoning by other gases and vapours 3 
TKx0z00 Suicide + selfinflicted inj-jump/lie before moving obj NOS 3 
ZX1N.00 Stabbing self 3 
ZX1M.00 Shooting self 3 
ZX1K.12 Setting self alight 3 
ZX1K.11 Setting fire to self 3 
ZX1H200 Self-suffocation 3 
ZX1H100 Self-strangulation 3 
ZX1K.00 Self-incineration 3 
ZX1J.00 Self-electrocution 3 
ZX1H.00 Self-asphyxiation 3 
SL...15 Overdose of drug 3 
SL...14 Overdose of biological substance 3 
TKy..00 Late effects of selfinflicted injury 3 
ZX1Q.11 Jumping under train 3 
ZX1B.00 Jumping from height 3 
ZX1B300 Jumping from cliff 3 
ZX1B100 Jumping from building 3 
ZX1B200 Jumping from bridge 3 
TK...12 Injury - self-inflicted 3 
ZX18.00 Hanging self 3 
SLHz.00 Drug and medicament poisoning NOS 3 
ZX15.00 Drowning self 3 
U72..00 [X]Sequel intentn self-harm assault+event of undeterm intent 2 
ZX1LD00 [X]Self mutilation 2 
U40y000 [X]Poison/exposure ?intent, to unspecif chemical at home 2 
U40C000 [X]Poison/exposure ?intent, to pesticide at home 2 
U40A.00 [X]Pois/exposure,?intent,to organ solvent,halogen hydrocarb 2 
U40y400 [X]Pois/expos ?intent unspecif chemical in street/highway 2 
U40yz00 [X]Pois/expos ?intent to unspecif chemical unspecif place 2 
U402z00 [X]Pois/expos ?intent to sedative hypnotic unspecif place 2 
U408z00 [X]Pois/expos ?intent to oth/unsp drug/medic unspecif place 2 
U409z00 [X]Pois/expos ?intent to alcohol unspecif place 2 
U40B400 [X]Pois/expos ?intent other gas/vapour in street/highway 2 
U409400 [X]Pois/expos ?intent alcohol in street/highway 2 
U406y00 [X]Pois/exp ?intent to hallucinogen other spec place 2 
U404300 [X]Pois/exp ?intent psychotropic drug in sport/athletic area 2 
U40A300 [X]Pois/exp ?intent org solvent,halogen hydrocarb,sport area 2 
U409200 [X]Pois/exp ?intent alcohol school/pub admin area 2 
U205.11 [X]Overdose - heroin 2 
U2Az.00 [X]Intentional self harm by blunt object occ unspecif place 2 
U206z00 [X]Intent self poison hallucinogen unspecif place 2 
U209400 [X]Intent self pois alcohol in street/highway 2 
U292.00 [X]Intent self harm sharp obj occ sch oth ins/pub adm area 2 
U2yy.00 [X]Intent self harm oth specif means occ oth specif place 2 
U2y6.00 [X]Intent self harm oth specif means occ indust/constr area 2 
U2z1.00 [X]Intent self harm by unspecif means occurrn resid instit'n 2 
U27y.00 [X]Intent self harm by smoke fire/flame occ oth specif plce 2 
U295.00 [X]Intent self harm by sharp object occ trade/service area 2 
U296.00 [X]Intent self harm by sharp object occ indust/constr area 2 
U2B1.00 [X]Intent self harm by jump from high place occ resid instit 2 
U213.00 [X]Intent self harm by hang strangl/suffc sport/athlet area 2 
U2Dz.00 [X]Intent self harm by crash motor vehic occ unspecif place 2 
U2A2.00 [X]Intent self harm blunt obj occ sch oth ins/pub adm area 2 
U20Ay00 [X]Int self pois org solv,halogen hydrocarb,oth spec place 2 
U200600 [X]Int self pois nonopioid analgesic indust/construct area 2 
U282.00 [X]Int self harm by steam hot vapor/obj sch/ins/pub adm area 2 
U4C..00 [X]Falling lying running befor/into moving obj undet intent 2 
U4B6.00 [X]Fall jump/push frm high plce undt intn indust/constr area 2 
U47..00 [X]Exposure to smoke, fire and flames, undetermined intent 2 
U470.00 [X]Exposure to smoke fire+flame undeterm intent occ at home 2 
U42..00 [X]Drowning and submersion, undetermined intent 2 
U4D7.00 [X]Crashng of motor vehicle undetermined intent occ on farm 2 
U4D0.00 [X]Crashng of motor vehicle undetermined intent occ at home 2 
U4D..00 [X]Crashing of motor vehicle, undetermined intent 2 
U4D3.00 [X]Crash of motor vehicle undeterm intent sport/athlet area 2 
U4A5.00 [X]Contct wth blunt obj undet intent occ trade/service area 2 
U4A3.00 [X]Contct wth blunt obj undet intent occ sport/athletic area 2 
U4A0.00 [X]Contact wth blunt object undetermined intent occ at home 2 
U48..00 [X]Contact with steam hot vapours+objects undetermn intent 2 
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U49..00 [X]Contact with sharp object, undetermined intent 2 
U49z.00 [X]Contact with sharp obj undeterm intent occ unspecif place 2 
U4A..00 [X]Contact with blunt object, undetermined intent 2 
U4Az.00 [X]Contact with blunt obj undeterm intent occ unspecif place 2 
ZX1S.00 Throwing self onto floor 2 
1BDA.00 Thoughts of deliberate self harm 2 
1BD3.00 Suicidal plans 2 
1BD1.00 Suicidal ideation 2 
1B19.11 Suicidal - symptom 2 
1B19.00 Suicidal 2 
ZX19200 Slapping self 2 
ZX1I.00 Self-scalding 2 
ZX1L300 Self-mutilation of penis 2 
ZX1L100 Self-mutilation of hands 2 
ZX1L200 Self-mutilation of genitalia 2 
ZX1L600 Self-mutilation of ears 2 
ZX1L.00 Self-mutilation 2 
ZX1G.00 Scratches self 2 
ZX19100 Punching self 2 
TN...11 Poisoning undetermined - accidentally or purposely inflicted 2 
ZX1E.00 Pinching self 2 
ZX1C.00 Nipping self 2 
14K1.00 Intentional overdose of prescription only medication 2 
TN0..00 Injury ?accidental, poisoning by solid/liquid substances 2 
TN0z.00 Injury ?accidental, poisoning by solid or liquid subst NOS 2 
TN2y.00 Injury ?accidental, poisoning by other spec gas or vapour 2 
TN04.00 Injury ?accidental, poisoning by other spec drug/medicament 2 
TN02.00 Injury ?accidental, poisoning by other sedative/hypnotic 2 
TN2..00 Injury ?accidental, poisoning by other gases 2 
TN21.00 Injury ?accidental, poisoning by other carbon monoxide 2 
TN20.00 Injury ?accidental, poisoning by motor vehicle exhaust gas 2 
TN11.00 Injury ?accidental, poisoning by liquid petrol gas 2 
TN1..00 Injury ?accidental, poisoning by gases in domestic use 2 
TN1z.00 Injury ?accidental, poisoning by gas in domestic use NOS 2 
TN10.00 Injury ?accidental, poisoning by gas distributed by pipeline 2 
TN05.00 Injury ?accidental, poisoning by drug or medicament NOS 2 
TN06.00 Injury ?accidental, poisoning by corrosive/caustic substance 2 
TN08.00 Injury ?accidental, poisoning by arsenic or its compounds 2 
TN00.00 Injury ?accidental, poisoning by analgesic or anti-pyretic 2 
TN07.00 Injury ?accidental, poisoning by agricultural chemicals 2 
TN3..00 Injury ?accidental, hanging, strangulation and suffocation 2 
TN30.00 Injury ?accidental, hanging 2 
TN01300 Injury ?accidental poisoning by Pentobarbitone 2 
ZRLfC12 HoNOS item 2 - non-accidental self injury 2 
ZX19.00 Hitting self 2 
ZX13.00 Cutting self 2 
ZX13.11 Cuts self 2 
ZX12.00 Burning self 2 
ZX11.00 Biting self 2 
ZX11.11 Bites self 2 
SL90.00 Antidepressant poisoning 2 
8G6Z.00 Anti-suicide psychotherapy NOS 2 
8G6..00 Anti-suicide psychotherapy 2 
SL90z00 Anti-depressant poisoning NOS 2 
U4z..00 [X]Unspecified event, undetermined intent 1 
U4zz.00 [X]Unspecif event undeterm intent occurrn unspecif place 1 
U4z3.00 [X]Unspecif event undeterm intent occurrn sport/athlet area 1 
U4zy.00 [X]Unspecif event undeterm intent occurrn oth specif place 1 
U4z6.00 [X]Unspecif event undeterm intent occurrn indust/constr area 1 
SyuG.00 [X]Toxic effects of substances chiefly nonmedicinal source 1 
SyuG700 [X]Toxic effects of other specified gases, fumes & vapours 1 
SyuGH00 [X]Toxic effect of paints and dyes, NEC 1 
SyuGJ00 [X]Toxic effect of other specified substances 1 
SyuG900 [X]Toxic effect of other pesticides 1 
SyuG800 [X]Toxic effect of other insecticides 1 
SyuGC00 [X]Toxic effect of other ingested (parts of) plant(s) 1 
SyuG000 [X]Toxic effect of other alcohols 1 
U2E..00 [X]Self mutilation 1 
U406.00 [X]Poisoning/exposure, ? intent, to hallucinogen 1 
SyuFM00 [X]Poisoning by other psychotropic drugs, NEC 1 
SyuFB00 [X]Poisoning by other opioids 1 
SyuFW00 [X]Poisoning by other laxatives, incl intestin atonia drugs 1 
SyuFT00 [X]Poisoning by other antihypertensive drugs, NEC 1 
SyuFD00 [X]Poisoning by other and unspecified narcotics 1 
SyuFA00 [X]Poisoning by other analgesics, not elsewhere classified 1 
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SyuF900 [X]Poisoning by oth nonsteroidal anti-inflamm drugs [NSAID] 1 
SyuFc00 [X]Poisoning by oth & unspecif drugs & biologic substances 1 
SyuF.00 [X]Poisoning by drugs and biological substances 1 
U40Bz00 [X]Pois/expos ?intent to other gas/vapour unspecif place 1 
U409100 [X]Pois/expos ?intent to alcohol at res institut 1 
U408400 [X]Pois/expos ?intent oth/unsp drug/medic in street/highway 1 
U40yy00 [X]Pois/exp ?intent to unspecif chemical other spec place 1 
U40By00 [X]Pois/exp ?intent to other gas/vapour other spec place 1 
U202.14 [X]Overdose - flurazepam 1 
U4y..00 [X]Other specified events, undetermined intent 1 
U4y0.00 [X]Other specified event undetermind intent occurrn at home 1 
U4y3.00 [X]Oth specif event undetermin intent occ sport/athlet area 1 
Eu15000 [X]Mnt/beh dis due oth stim inc caffein: acute intoxication 1 
Eu18000 [X]Mental & behav dis due vol solvents: acute intoxication 1 
Eu17000 [X]Mental & behav dis due to use tobacco: acute intoxication 1 
Eu11000 [X]Mental & behav dis due to use opioids: acute intoxication 1 
Eu14000 [X]Mental & behav dis due to use cocaine: acute intoxication 1 
Eu10000 [X]Mental & behav dis due to use alcohol: acute intoxication 1 
Eu13000 [X]Mental & behav dis due seds/hypntcs: acute intoxication 1 
Eu16000 [X]Mental & behav dis due hallucinogens: acute intoxicatn 1 
Eu12000 [X]Mental & behav dis due cannabinoids: acute intoxication 1 
Eu1A000 [X]Ment behav dis due use crack cocaine: acute intoxication 1 
U39..11 [X]Intentionally shot with shotgun 1 
U38..11 [X]Intentionally shot with handgun 1 
U41z.00 [X]Hangng strangult+suffoct undet intent occ unspecif place 1 
U4B0.00 [X]Fallng jumpng/push frm high place undet intent occ home 1 
U81..00 [X]Evid of alcohol involv determind by level of intoxication 1 
U4D1.00 [X]Crashng of motor vehicle undeterm intent resident instit 1 
U466.00 [X]Contct wth explosiv materl undet intnt indust/constr area 1 
U4A6.00 [X]Contct wth blunt obj undet intent occ industr/constr area 1 
U46..00 [X]Contact with explosive material, undetermined intent 1 
U4Ay.00 [X]Contact with blunt obj undeter intent occ oth specif plce 1 
U1AC.11 [X]Accidental poisoning with weedkiller 1 
U1A2.13 [X]Accidental poisoning with temazepam 1 
U1A2.11 [X]Accidental poisoning with sleeping tablets 1 
U1AC.12 [X]Accidental poisoning with paraquat 1 
U1A0.11 [X]Accidental poisoning with paracetamol 1 
U1A2.15 [X]Accidental poisoning with nitrazepam 1 
U1A0.12 [X]Accidental poisoning with ibuprofen 1 
U1A5.11 [X]Accidental poisoning with heroin 1 
U1A2.12 [X]Accidental poisoning with diazepam 1 
U1A2.16 [X]Accidental poisoning with benzodiazepine 1 
U1A2.17 [X]Accidental poisoning with barbiturate 1 
U1A0.13 [X]Accidental poisoning with aspirin 1 
U1A4.11 [X]Accidental poisoning with antidepressant 1 
U1A4.12 [X]Accidental poisoning with amitriptyline 1 
U1A4.13 [X]Accidental poisoning with SSRI 1 
U1AA.11 [X]Accidental poisoning from glue solvent 1 
U1AD.00 [X]Accidental poisoning by and exposure to amfetamine 1 
U1A..00 [X]Accidental poisoning by + exposure to noxious substances 1 
U1A..12 [X]Accidental drug overdose / other poisoning 1 
U1A..11 [X]Accidental drug / other poisoning 1 
U1AB.11 [X]Accidental carbon monoxide poisoning 1 
U1Ay.00 [X]Accident poisoning/exposure to unspecif chemical 1 
U1A2.00 [X]Accident poisoning/exposure to sedative hypnotic 1 
U1A4.00 [X]Accident poisoning/exposure to psychotropic drug 1 
U1AC.00 [X]Accident poisoning/exposure to pesticide 1 
U1AB.00 [X]Accident poisoning/exposure to other gas/vapour 1 
U1A7.00 [X]Accident poisoning/exposure to oth autonomic drug 1 
U1A0.00 [X]Accident poisoning/exposure to nonopioid analgesic 1 
U1A5.00 [X]Accident poisoning/exposure to narcotic drug 1 
U1A6.00 [X]Accident poisoning/exposure to hallucinogen 1 
U1A3.00 [X]Accident poisoning/exposure to antiparkinson drug 1 
U1A1.00 [X]Accident poisoning/exposure to antiepileptic 1 
U1A9.00 [X]Accident poisoning/exposure to alcohol 1 
U1AD000 [X]Accident poisoning by and exposure to amphetamine - home 1 
U1Ay700 [X]Accident poison/exposure to unspecif chemical on farm 1 
U1Ay000 [X]Accident poison/exposure to unspecif chemical at home 1 
U1A2000 [X]Accident poison/exposure to sedative hypnotic at home 1 
U1A4000 [X]Accident poison/exposure to psychotropic drug at home 1 
U1AC700 [X]Accident poison/exposure to pesticide on farm 1 
U1AC000 [X]Accident poison/exposure to pesticide at home 1 
U1A8.00 [X]Accident poison/exposure to other/unspec drug/medicament 1 
U1AB700 [X]Accident poison/exposure to other gas/vapour on farm 1 
U1AB000 [X]Accident poison/exposure to other gas/vapour at home 1 
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U1A8000 [X]Accident poison/exposure to oth/unsp drug/medicam home 1 
U1A7000 [X]Accident poison/exposure to oth autonomic drug at home 1 
U1A0000 [X]Accident poison/exposure to nonopioid analgesic at home 1 
U1A5000 [X]Accident poison/exposure to narcotic drug at home 1 
U1A1000 [X]Accident poison/exposure to antiepileptic at home 1 
U1A9000 [X]Accident poison/exposure to alcohol at home 1 
U1AA.00 [X]Accid poison/exposure to organ solvent,halogen hydrocarb 1 
U1Ay500 [X]Accid poison/expos unspecif chemical trade/service area 1 
U1Ayz00 [X]Accid poison/expos to unspecif chemical unspecif place 1 
U1Ay100 [X]Accid poison/expos to unspecif chemical at res institut 1 
U1A2z00 [X]Accid poison/expos to sedative hypnotic unspecif place 1 
U1A4100 [X]Accid poison/expos to psychotropic drug at res institut 1 
U1ABz00 [X]Accid poison/expos to other gas/vapour unspecif place 1 
U1A8100 [X]Accid poison/expos to oth/unsp drug/medicam res institut 1 
U1A8z00 [X]Accid poison/expos to oth/unsp drug/medic unspecif place 1 
U1A7z00 [X]Accid poison/expos to oth autonomic drug unspecif place 1 
U1A0z00 [X]Accid poison/expos to nonopioid analgesic unspecif place 1 
U1A5z00 [X]Accid poison/expos to narcotic drug unspecif place 1 
U1A9z00 [X]Accid poison/expos to alcohol unspecif place 1 
U1AA000 [X]Accid poison/expos organ solvent,halogen hydrocarb, home 1 
U1A3500 [X]Accid poison/expos antiparkinson drug trade/service area 1 
U1A9500 [X]Accid poison/expos alcohol trade/service area 1 
U1A9400 [X]Accid poison/expos alcohol in street/highway 1 
U1Ay200 [X]Acc poison/expos unspecif chemical school/pub admin area 1 
U1A4200 [X]Acc poison/expos psychotropic drug school/pub admin area 1 
U1AA100 [X]Acc poison/expos org solvent,halogen hydrocarb,res instit 1 
U1A9200 [X]Acc poison/expos alcohol school/pub admin area 1 
U1ADz00 [X]Acc poison by and exposure to amphetamine - unspec places 1 
Sy...00 [X] Injury and poisoning classification terms 1 
U60F412 [X] Adverse reaction to acetylcysteine 1 
ZV15600 [V]Personal history of poisoning 1 
ZV4C400 [V]Occupational exposure to toxic agents in agriculture 1 
ZV71A00 [V]Obs for suspected toxic effect from ingested substance 1 
SLC7100 Zinc salt poisoning 1 
SM01100 Wood alcohol causing toxic effect 1 
SLEz.00 Water, mineral or uric acid metabolism poisoning NOS 1 
SLE..00 Water, mineral and urate metabolism poisoning 1 
SL42300 Warfarin sodium poisoning 1 
SL42400 Warfarin poisoning 1 
SL35z00 Vitamin poisoning NOS 1 
SL35.00 Vitamin poisoning NEC 1 
SL35100 Vitamin D poisoning 1 
SL35000 Vitamin A poisoning 1 
SL44300 Urokinase poisoning 1 
SLE7.00 Uric acid drug poisoning 1 
SLE7.11 Urate metabolism drug poisoning 1 
SM9z.00 Unspecified substance causing toxic effect NOS 1 
SL50000 Unspecified opium poisoning 1 
SL30400 Tripelennamine poisoning 1 
SL60100 Trimethadione poisoning 1 
SL92200 Trifluperidol poisoning 1 
SM23100 Trichloroethylene causing toxic effect 1 
SL90300 Trazodone poisoning 1 
SL95z00 Tranquilliser poisoning NOS 1 
SL9..11 Tranquilliser poisoning 1 
TE57.00 Toxic reactions caused by other plants 1 
F036200 Toxic encephalitis due to thallium 1 
F036100 Toxic encephalitis due to mercury 1 
F036000 Toxic encephalitis due to lead 1 
SMC..00 Toxic effect of tobacco and nicotine 1 
SM57.00 Toxic effect of tin and its compounds 1 
SM9A.00 Toxic effect of rodenticides 1 
SMX..00 Toxic effect of paints and dyes, NEC 1 
SM9X.00 Toxic effect of nitroglycerin & oth nitric acids & ester 1 
SM79.00 Toxic effect of hydrogen sulfide 1 
SM15.00 Toxic effect of homologues of benzene 1 
SM98.00 Toxic effect of herbicides and fungicides 1 
SMB..00 Toxic effect of formaldehyde 1 
SM78.00 Toxic effect of fluorine gas and hydrogen fluoride 1 
SM23200 Toxic effect of chloroform 1 
SM7A.00 Toxic effect of carbon dioxide 1 
SLG7.00 Topical dental drug poisoning 1 
SL85.00 Topical and infiltration anaesthetic agent poisoning 1 
SL16200 Tiabendazole poisoning 1 
SL27.00 Thyroid hormone and thyroid derivatives poisoning 1 
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SL27z00 Thyroid hormone and thyroid derivative poisoning NOS 1 
SL27300 Thyroglobulin poisoning 1 
SL91400 Thioridazine poisoning 1 
SLE1100 Theophylline poisoning 1 
SL04000 Tetracycline poisoning 1 
SL04z00 Tetracycline group poisoning NOS 1 
SL04.00 Tetracycline group poisoning 1 
SM23000 Tetrachloroethylene causing toxic effect 1 
SL85300 Tetracaine poisoning 1 
SL21300 Testosterone poisoning 1 
SLF5200 Terpin hydrate poisoning 1 
SL3z.00 Systemic agent poisoning NOS 1 
SLB2.00 Sympathomimetic poisoning 1 
SM31200 Sulphuric acid causing toxic effect 1 
SM73.00 Sulphur dioxide causing toxic effect 1 
SL1x400 Sulphone poisoning 1 
SL10.00 Sulphonamide poisoning 1 
SL10200 Sulfamethoxazole poisoning 1 
SL10000 Sulfadiazine poisoning 1 
1BD4.00 Suicide risk 1 
ZRn3.00 Suicide intent score subscale - attempt circumstances 1 
SN47100 Suffocation by strangulation 1 
SL06300 Streptomycin poisoning 1 
SL44200 Streptokinase poisoning 1 
SL97.11 Stimulant poisoning 1 
SM2z.00 Solvents causing toxic effect NOS 1 
SLC7000 Sodium morrhuate poisoning 1 
SM32200 Sodium hydroxide causing toxic effect 1 
SM90100 Sodium cyanide causing toxic effect 1 
SM96.00 Soap and detergent causing toxic effect 1 
SM96.12 Soap - toxic effect 1 
SLF1.00 Smooth muscle relaxant poisoning 1 
SL7z.11 Sleeping drug poisoning 1 
SLF2.00 Skeletal muscle relaxant poisoning 1 
ZX1..00 Self-injurious behaviour 1 
ZX...00 Self-harm 1 
ZX...11 Self-damage 1 
SL7..12 Sedative poisoning 1 
SL7z.00 Sedative and hypnotic drug poisoning NOS 1 
SL7..00 Sedative and hypnotic drug poisoning 1 
SL70500 Secobarbital poisoning 1 
SL51100 Salicylic acid salt poisoning 1 
SL51z00 Salicylate poisoning NOS 1 
SL51.00 Salicylate poisoning 1 
SLF7100 Salbutamol poisoning 1 
ZX1..12 SIB - Self-injurious behaviour 1 
SM02200 Rubbing alcohol causing toxic effect 1 
SL06200 Rifampicin poisoning 1 
SLF..12 Respiratory system drug poisoning 1 
SL14500 Quinine poisoning 1 
SLC0300 Quinidine poisoning 1 
SL14400 Pyrimethamine poisoning 1 
SL53.00 Pyrazole derivative poisoning 1 
SL9z.00 Psychotropic agent poisoning NOS 1 
SL9..00 Psychotropic agent poisoning 1 
SL97.00 Psychostimulant poisoning 1 
SL96400 Psilocybin poisoning 1 
SL45100 Protamine sulphate poisoning 1 
SLF0200 Prostaglandin poisoning 1 
SLC0200 Propranolol poisoning 1 
SM70100 Propane causing toxic effect 1 
SL91300 Promazine poisoning 1 
SL14300 Proguanil poisoning 1 
SL22300 Progestogen poisoning 1 
SL91200 Prochlorperazine poisoning 1 
SLC0100 Procainamide poisoning 1 
SL6x000 Primidone poisoning 1 
8G61.00 Potential suicide care 1 
SM32100 Potassium hydroxide causing toxic effect 1 
SM90000 Potassium cyanide causing toxic effect 1 
SL25.00 Posterior pituitary hormone poisoning 1 
SL94600 Poisoning by temazepam 1 
SLD3100 Poisoning by saline and osmotic laxatives 1 
SL3..00 Poisoning by primarily systemic agents 1 
SLX..00 Poisoning by oth & unspec antipsychotics & neuroleptics 1 
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SL29.00 Poisoning by mineralocorticoids and their antagonists 1 
SLD0200 Poisoning by histamine H2-receptor antagonists 1 
SL20300 Poisoning by glucocorticoids and synthetic analogues 1 
SL...16 Poisoning by drug and biological substances 1 
SL6x100 Poisoning by carbamazepine 1 
SLC9.00 Poisoning by calcium-channel blockers 1 
SLC6400 Poisoning by angiotensin-converting-enzyme inhibitors 1 
SL...00 Poisoning 1 
SM82.12 Plants - toxic effect 1 
1BDB.00 Plans for deliberate self harm without intent 1 
SL16100 Piperazine poisoning 1 
SLB0200 Pilocarpine poisoning 1 
SM7y000 Phosgene causing toxic effect 1 
SM93500 Phosdrin causing toxic effect 1 
SL61000 Phenytoin poisoning 1 
SL53100 Phenylbutazone poisoning 1 
SLB3000 Phenoxybenzamine poisoning 1 
SL91z00 Phenothiazine poisoning NOS 1 
SL91.00 Phenothiazine poisoning 1 
SLD1200 Phenolphthalein poisoning 1 
SM30000 Phenol causing toxic effect 1 
SL70400 Phenobarbital poisoning 1 
SL42200 Phenindione poisoning 1 
SL52200 Phenacetin poisoning 1 
SLH4.00 Pharmaceutical excipient poisoning 1 
SM1z.00 Petroleum product causing toxic effect NOS 1 
SM1..00 Petroleum product causing toxic effect 1 
SM14.00 Petroleum ether causing toxic effect 1 
SM10.00 Petrol unspecified causing toxic effect 1 
SL86.00 Peripheral nerve and plexus-blocking anaesthetic poisoning 1 
SL70300 Pentobarbitone poisoning 1 
SL34000 Penicillinase poisoning 1 
SL00z00 Penicillin poisoning NOS 1 
SL00.00 Penicillin poisoning 1 
SL00300 Penicillin G poisoning 1 
E022.00 Pathological drug intoxication 1 
E014.00 Pathological alcohol intoxication 1 
SM93300 Parathion causing toxic effect 1 
SLB0.00 Parasympathomimetic poisoning 1 
SL60000 Paramethadione poisoning 1 
SM13.00 Paraffin wax causing toxic effect 1 
SL52100 Paracetamol poisoning 1 
SL1x300 Para-aminosalicylic acid poisoning 1 
SLC5200 Papaverine poisoning 1 
SLD4100 Papain poisoning 1 
SLD4000 Pancreatin poisoning 1 
SL04300 Oxytetracycline poisoning 1 
SL21200 Oxymetholone poisoning 1 
SL22z00 Ovarian hormone poisoning NOS 1 
SL22.00 Ovarian hormone and synthetic substitute poisoning 1 
SLC5.00 Other vasodilator poisoning 1 
SL95.00 Other tranquilliser poisoning 1 
F377.00 Other toxic agent polyneuropathy 1 
SL3y.00 Other systemic agent poisoning 1 
SM9y.00 Other substance causing toxic effect 1 
SL0y.00 Other specific antibiotic poisoning 1 
SM2yz00 Other solvents causing toxic effect NOS 1 
SM2..00 Other solvents causing toxic effect 1 
SM2y.00 Other solvents causing toxic effect 1 
SLGx.00 Other skin and mucous membrane drug poisoning 1 
SL7y.00 Other sedative and hypnotic poisoning 1 
SLFy.00 Other respiratory system drug poisoning 1 
SL9y.00 Other psychotropic agent poisoning 1 
SM94.00 Other pesticides causing toxic effect NEC 1 
SM8y.00 Other noxious substance eaten as food causing toxic effect 1 
SM9..00 Other nonmedicinal substances causing toxic effect 1 
SL5x.00 Other non-narcotic analgesic poisoning 1 
SLF3.00 Other muscle drug poisoning 1 
SLE6.00 Other mineral salt poisoning NEC 1 
SM5y.00 Other metals causing toxic effect OS 1 
SM5yz00 Other metals causing toxic effect NOS 1 
SM5..00 Other metals causing toxic effect 1 
SLC6.00 Other hypertensive agent poisoning 1 
SM71.00 Other hydrocarbon gas causing toxic effect 1 
SL2y.00 Other hormone or synthetic derivative poisoning 1 
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SLDy.00 Other gastrointestinal agent poisoning 1 
SM7..00 Other gases, fumes or vapours causing toxic effect 1 
SM7y.00 Other gas, fume or vapour causing toxic effect 1 
SM7yz00 Other gas, fume and vapour causing toxic effect NOS 1 
SLHy.00 Other drug and medicament poisoning OS 1 
SLHyz00 Other drug and medicament poisoning NOS 1 
SLE4z00 Other diuretic poisoning NOS 1 
SLC1100 Other digitalis glycoside poisoning 1 
SLAy.00 Other central nervous system stimulant poisoning 1 
SLD3.00 Other cathartic poisoning 1 
SL93.00 Other antipsychotics/neuroleptics/tranquilliser poisoning 1 
SL15.00 Other antiprotozoal drug poisoning 1 
SL30x00 Other antihistamine poisoning 1 
SL6x.00 Other anticonvulsant poisoning 1 
SL1..00 Other anti-infective poisoning 1 
SL1y.00 Other anti-infective poisoning 1 
SLH..00 Other and unspecified drug and medicament poisoning 1 
SL5yz00 Other analgesic or antipyretic poisoning NOS 1 
SL5y.00 Other analgesic and antipyretic poisoning 1 
SM0y.00 Other alcohol causing toxic effect 1 
SM93z00 Organophosphate and carbamate causing toxic effect NOS 1 
SM93.00 Organophosphate and carbamate causing toxic effect 1 
SLF1100 Orciprenaline poisoning 1 
SL22000 Oral contraceptive poisoning 1 
SL50.12 Opiate poisoning 1 
SL50z00 Opiate or narcotic poisoning NOS 1 
SLA1z00 Opiate antagonist poisoning NOS 1 
SLA1.00 Opiate antagonist poisoning 1 
SL50.00 Opiate and narcotic poisoning 1 
SL03100 Oleandomycin poisoning 1 
SL22100 Oestrogen poisoning 1 
SL01200 Nystatin poisoning 1 
SM8z.00 Noxious substance eaten as food causing toxic effect NOS 1 
SM8..00 Noxious substance eaten as food causing toxic effect 1 
SLB2100 Noradrenalin poisoning 1 
SM...00 Nonmedicinal agent causing toxic effects 1 
SL5xz00 Non-narcotic analgesic poisoning NOS 1 
SMz..00 Non-medicinal agent causing toxic effect NOS 1 
SL82100 Nitrous oxide poisoning 1 
SM72.00 Nitrogen oxides causing toxic effect 1 
SM72000 Nitrogen dioxide causing toxic effect 1 
SL1y100 Nitrofuran derivative poisoning 1 
SM31100 Nitric acid causing toxic effect 1 
SL94500 Nitrazepam poisoning 1 
SLC4100 Nitrate poisoning 1 
SM5y300 Nickel compounds causing toxic effect 1 
SL50.11 Narcotic poisoning 1 
SL54300 Naproxen poisoning 1 
SL21100 Nandrolone poisoning 1 
SM81.00 Mushrooms causing toxic effect 1 
SLF..11 Muscle drug poisoning 1 
SL50500 Morphine poisoning 1 
1BD2.00 Morbid thoughts 1 
SL90200 Monoamine oxidase inhibitor poisoning 1 
1BD6.00 Moderate suicide risk 1 
SL76.00 Mixed sedative poisoning NEC 1 
SL07400 Mitomycin poisoning 1 
SL04200 Minocycline poisoning 1 
SM01.00 Methyl alcohol causing toxic effect 1 
SL80100 Methocarbamol poisoning 1 
SL74.00 Methaqualone compound poisoning 1 
SM01000 Methanol causing toxic effect 1 
SL50200 Methadone poisoning 1 
SM5z.00 Metals causing toxic effect NOS 1 
SL12300 Mercury compound poisoning 1 
SM50.00 Mercury causing toxic effect 1 
SL31600 Mercaptopurine poisoning 1 
SL95100 Meprobamate poisoning 1 
SL50400 Meperidine (pethidine) poisoning 1 
SL54400 Mefenamic acid poisoning 1 
SL...13 Medicinal poisoning 1 
SL94400 Medazepam poisoning 1 
SL96200 Marihuana poisoning 1 
SM93200 Malathion causing toxic effect 1 
SLD0100 Magnesium trisilicate poisoning 1 
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SLD3000 Magnesium sulphate poisoning 1 
T180.00 MVTA - accid poisoning - exhaust gas of moving motor vehicle 1 
SL90211 MAOI - monoamine oxidase inhibitor poisoning 1 
SL96100 Lysergide (LSD) poisoning 1 
1BD7.00 Low suicide risk 1 
SL94300 Lorazepam poisoning 1 
SLG2.12 Local detergent poisoning 1 
SLG2.11 Local astringent poisoning 1 
SLG2.00 Local astringent and detergent poisoning 1 
SLG0.00 Local anti-infective and anti-inflammatory poisoning 1 
SL8z.00 Local anaesthetic poisoning NOS 1 
SLA0000 Lobeline poisoning 1 
44W8100 Lithium level high - toxic 1 
SM70.00 Liquefied petrol gas causing toxic effect 1 
SL85100 Lidocaine poisoning 1 
SL27100 Levothyroxine sodium poisoning 1 
SL6y200 Levodopa (L-dopa) poisoning 1 
SL12200 Lead compound poisoning 1 
SM4z.00 Lead compound causing toxic effect NOS 1 
SM4..00 Lead and lead compounds causing toxic effect 1 
SM41000 Lead acetate causing toxic effect 1 
TH02.00 Late effects of accidental poisoning 1 
SC...00 Late effects injury/poisoning/toxic effects/external causes 1 
SC41.00 Late effect of poison due to nonmedical substance 1 
SC40.00 Late effect of poison drug/medicament/biological substance 1 
SC41.11 Late effect of poison 1 
SCz..00 Late effect injury/poison/toxin effect/external cause NOS 1 
SL83000 Ketamine poisoning 1 
SM12.00 Kerosene causing toxic effect 1 
SLG4.12 Keratoplastic poisoning 1 
SL1x200 Isoniazid poisoning 1 
SLD1.00 Irritant cathartic poisoning 1 
SM5y200 Iron compounds causing toxic effect 1 
SL40z00 Iron and iron compound poisoning NOS 1 
SL40.00 Iron and iron compound poisoning 1 
SL28000 Iodide poisoning 1 
SP35000 Intoxication by serum 1 
E250.14 Intoxication - alcohol 1 
1BDC.00 Intent of deliberate self harm with detailed plans 1 
SL23.00 Insulins and antidiabetic poisoning 1 
SL23400 Insulin poisoning 1 
TN...00 Injury undetermined whether accidentally/purposely inflicted 1 
TNz..00 Injury undetermined accidental or purposely inflicted NOS 1 
TM21.00 Injury due to legal intervention by poisoning by gas 1 
Sz...00 Injury and poisoning NOS 1 
S....00 Injury and poisoning 1 
TN3y.00 Injury ?accidental, other means of hang/strangle/suffocate 1 
TN9..00 Injury ?accidental, late effects 1 
TN3z.00 Injury ?accidental, hanging/strangulation/suffocation NOS 1 
TN70.00 Injury ?accidental, fall from residential premises 1 
TN71.00 Injury ?accidental, fall from other man-made structure 1 
TN72.00 Injury ?accidental, fall from natural site 1 
TN7z.00 Injury ?accidental, fall from high place NOS 1 
TN7..00 Injury ?accidental, fall from high place 1 
TN4..00 Injury ?accidental, drowning 1 
TN61.00 Injury ?accidental, by stabbing instrument 1 
TN51.00 Injury ?accidental, by shotgun 1 
TN82.00 Injury ?accidental, by scald 1 
TN8y.00 Injury ?accidental, by other specified means 1 
TN8..00 Injury ?accidental, by other means 1 
TN54.00 Injury ?accidental, by other firearm 1 
TN8z.00 Injury ?accidental, by means NOS 1 
TN80100 Injury ?accidental, by lying before moving object 1 
TN80.00 Injury ?accidental, by jumping or lying before moving object 1 
TN80000 Injury ?accidental, by jumping before moving object 1 
TN52.00 Injury ?accidental, by hunting rifle 1 
TN50.00 Injury ?accidental, by handgun 1 
TN5..00 Injury ?accidental, by firearms and explosives 1 
TN5z.00 Injury ?accidental, by firearm or explosive NOS 1 
TN83.00 Injury ?accidental, by extremes of cold 1 
TN55.00 Injury ?accidental, by explosive 1 
TN84.00 Injury ?accidental, by electrocution 1 
TN6z.00 Injury ?accidental, by cutting or stabbing instrument NOS 1 
TN60.00 Injury ?accidental, by cutting instrument 1 
TN6..00 Injury ?accidental, by cutting and stabbing instruments 1 
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TN85.00 Injury ?accidental, by crashing of motor vehicle 1 
TN86.00 Injury ?accidental, by crashing of aircraft 1 
TN87.00 Injury ?accidental, by caustic substances, except poisoning 1 
TN81.00 Injury ?accidental, by burns or fire 1 
SL54100 Indometacin poisoning 1 
SL31.12 Immunosuppressive poisoning 1 
SL90100 Imipramine poisoning 1 
SL54200 Ibuprofen poisoning 1 
SL7..11 Hypnotic poisoning 1 
SLC6z00 Hypertensive agent poisoning NOS 1 
SLB1200 Hyoscine poisoning 1 
SL95000 Hydroxyzine poisoning 1 
SL13.11 Hydroxyquinoline poisoning 1 
SM31000 Hydrochloric acid causing toxic effect 1 
SL61.00 Hydantoin derivative poisoning 1 
SL47100 Human fibrinogen poisoning 1 
SL2z.00 Hormone or synthetic substitute poisoning NOS 1 
SL2..00 Hormone and synthetic substitute poisoning 1 
1BD5.00 High suicide risk 1 
SL50100 Heroin poisoning 1 
SL42100 Heparin poisoning 1 
SL12z00 Heavy metal anti-infective poisoning NOS 1 
SL12.00 Heavy metal anti-infective poisoning 1 
SL3y000 Heavy metal agonist poisoning 1 
1BD..00 Harmful thoughts 1 
SL81.00 Halothane poisoning 1 
SL92000 Haloperidol poisoning 1 
SL96z00 Hallucinogen poisoning NOS 1 
SL96.00 Hallucinogen poisoning 1 
SLG4.00 Hair treatment poisoning 1 
14K0.00 H/O: repeated overdose 1 
14K..00 H/O: poisoning 1 
SL24211 Growth hormone poisoning 1 
SL01100 Griseofulvin poisoning 1 
SL24100 Gonadotrophin poisoning 1 
SL54000 Gold salt poisoning 1 
SLDz.00 Gastrointestinal agent poisoning NOS 1 
SLD..00 Gastrointestinal agent poisoning 1 
SM7z.00 Gases, fumes or vapours causing toxic effect NOS 1 
SLC3z00 Ganglion-blocker poisoning NOS 1 
SLC3.00 Ganglion-blocker poisoning 1 
SM03z00 Fusel oil causing toxic effect NOS 1 
SLE4100 Furosemide poisoning 1 
SM74.00 Freon causing toxic effect 1 
SL41000 Folic acid poisoning 1 
SL94200 Flurazepam poisoning 1 
SL91100 Fluphenazine poisoning 1 
SL31500 Fluorouracil poisoning 1 
SL1y000 Flucytosine poisoning 1 
SL40100 Ferrous sulphate poisoning 1 
SL40000 Ferric salt poisoning 1 
SLG..00 Eye, otorhinolaryngological, skin and dental drug poisoning 1 
SLG5z00 Eye drug poisoning NOS 1 
SLG5.00 Eye drug poisoning NEC 1 
SLG..12 Eye drug poisoning 1 
SLF5.00 Expectorant poisoning 1 
SM00z00 Ethyl alcohol causing toxic effect NOS 1 
SM00.00 Ethyl alcohol causing toxic effect 1 
SL6y100 Ethopropazine poisoning 1 
SL82000 Ether poisoning 1 
SM00000 Ethanol causing toxic effect 1 
SL1x000 Ethambutol poisoning 1 
SLE4000 Ethacrynic acid poisoning 1 
SL03000 Erythromycin poisoning 1 
SL03.00 Erythromycin and macrolide poisoning 1 
SLF0000 Ergot alkaloid poisoning 1 
E230200 Episodic acute alcoholic intoxication in alcoholism 1 
SL34.00 Enzyme poisoning NEC 1 
SLG3.00 Emollients, demulcents and protectant poisoning 1 
SLD2.00 Emollient cathartic poisoning 1 
SLD6.00 Emetic drug poisoning 1 
SLE5.00 Electrolyte agent poisoning 1 
SL97200 Ecstasy poisoning 1 
SLG6.00 Ear, nose and throat drug poisoning NEC 1 
SLz..00 Drug, medicament or biological substance poisoning NOS 1 
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SL...12 Drug poisoning 1 
SL04100 Doxycycline poisoning 1 
SLE..11 Diuretic poisoning 1 
SLC4000 Dipyridamole poisoning 1 
SL30100 Diphenhydramine poisoning 1 
SLD2000 Dioctyl sulphosuccinate poisoning 1 
SM02000 Dimethyl carbinol causing toxic effect 1 
SL50700 Dihydrocodeine poisoning 1 
SLC1000 Digoxin poisoning 1 
SLD4.00 Digestant poisoning 1 
SL94100 Diazepam poisoning 1 
SLHy100 Diagnostic agent NEC, poisoning 1 
SL50600 Dextropropoxyphene poisoning 1 
SLF4000 Dextromethorphan poisoning 1 
SM96.11 Detergent toxic effect 1 
SM00100 Denatured alcohol causing toxic effect 1 
ZX1..13 Deliberate self-harm 1 
SL07300 Daunorubicin poisoning 1 
SL07100 Dactinomycin poisoning 1 
SM92200 DDT causing toxic effect 1 
SL31400 Cytarabine poisoning 1 
SL31300 Cyclophosphamide poisoning 1 
SLC5000 Cyclandelate poisoning 1 
SM90z00 Cyanides causing toxic effect NOS 1 
SM90.00 Cyanides and hydrocyanic acid causing toxic effect 1 
ZX13100 Cutting own wrists 1 
SL42000 Coumarin poisoning 1 
SL20000 Cortisone derivative poisoning 1 
SL24000 Corticotropin poisoning 1 
SM3..00 Corrosives/acids/caustic alkalis causing toxic effect 1 
SM3z.00 Corrosive/acid/caustic alkali causing toxic effect NOS 1 
SM30z00 Corrosive aromatics causing toxic effect NOS 1 
SLC4.00 Coronary vasodilator poisoning 1 
SM5y100 Copper salts causing toxic effect 1 
E230100 Continuous acute alcoholic intoxication in alcoholism 1 
SL22200 Combined oestrogen and progesterone poisoning 1 
SLE7100 Colchicine poisoning 1 
SL50300 Codeine (methylmorphine) poisoning 1 
SL85000 Cocaine poisoning 1 
SLC6000 Clonidine poisoning 1 
SM56.00 Chromium causing toxic effect 1 
SLB0z00 Cholinergic poisoning NOS 1 
SLB0.11 Cholinergic poisoning 1 
SL91000 Chlorpromazine poisoning 1 
SL30000 Chlorphenamine poisoning 1 
SL14000 Chloroquine poisoning 1 
SM75100 Chloroacetophenone causing toxic effect 1 
SM76.00 Chlorine gas causing toxic effect 1 
SM92.00 Chlorinated hydrocarbon causing toxic effect 1 
SL94000 Chlordiazepoxide poisoning 1 
SL02000 Chloramphenicol poisoning 1 
SL31200 Chlorambucil poisoning 1 
SL71.00 Chloral hydrate poisoning 1 
SL13000 Chiniofon poisoning 1 
SLH2.11 Chelating agent poisoning 1 
SLAz.00 Central nervous system stimulant poisoning NOS 1 
SLA..00 Central nervous system stimulant poisoning 1 
SL80z00 Central nervous system muscle-tone depressant poisoning NOS 1 
SL80.00 Central nervous system muscle-tone depressant poisoning 1 
SL8..00 Central nervous system depressants and anaesthetic poisoning 1 
SLH0000 Central appetite depressant poisoning 1 
SL05000 Cefalexin poisoning 1 
SM32z00 Caustic alkalis causing toxic effect NOS 1 
SM32.00 Caustic alkalis causing toxic effect 1 
Tz...00 Causes of injury and poisoning NOS 1 
T....00 Causes of injury and poisoning 1 
T8...11 Cause of overdose - accidental 1 
SLC..00 Cardiovascular drug poisoning 1 
SLCz.00 Cardiovascular agent poisoning NOS 1 
SLC0.00 Cardiac rhythm drug poisoning 1 
SLC1.00 Cardiac glycoside poisoning 1 
SM21.00 Carbon tetrachloride causing toxic effect 1 
SM6..00 Carbon monoxide causing toxic effect 1 
SM93000 Carbaryl causing toxic effect 1 
SL80000 Carbamate poisoning 1 
433
 178
Read code Description Number of studies 
SLB1400 Caramiphen poisoning 1 
SL96000 Cannabis poisoning 1 
SL97100 Caffeine poisoning 1 
SM55.00 Cadmium causing toxic effect 1 
SM70000 Butane causing toxic effect 1 
SL70200 Butabarbitone poisoning 1 
SL31100 Busulfan poisoning 1 
SL07200 Bleomycin poisoning 1 
SL...11 Biological substance poisoning 1 
SL23100 Biguanide poisoning 1 
SLC0400 Beta blocker poisoning 1 
SM53.00 Beryllium causing toxic effect 1 
SM82.00 Berries and other plants causing toxic effect 1 
SM82.11 Berries - toxic effect 1 
SLE3000 Benzothiazide poisoning 1 
SL94z00 Benzodiazepine poisoning NOS 1 
SL94.00 Benzodiazepine poisoning 1 
SM20.00 Benzene causing toxic effect 1 
SL70z00 Barbiturate poisoning NOS 1 
SL70.00 Barbiturate poisoning 1 
SL70100 Barbitone poisoning 1 
SL31000 Azathioprine poisoning 1 
SLB..00 Autonomic nervous system drug poisoning 1 
SLB1000 Atropine poisoning 1 
1BD8.00 At risk of DSH - deliberate self harm 1 
TL22.00 Assault by poisoning by other gases or vapours 1 
TL20.00 Assault by poisoning by drugs or medicines 1 
TL2z.00 Assault by poisoning NOS 1 
TL2..00 Assault by poisoning 1 
SL51000 Aspirin poisoning 1 
SL11.00 Arsenical anti-infective poisoning 1 
SM51.00 Arsenic causing toxic effect 1 
SL52z00 Aromatic analgesic poisoning NOS 1 
SL52.00 Aromatic analgesic poisoning NEC 1 
SLF4z00 Antitussive poisoning NOS 1 
SL28.00 Antithyroid agent poisoning 1 
SL54z00 Antirheumatic poisoning NOS 1 
SL54.00 Antirheumatic poisoning 1 
SL5y200 Antipyretic poisoning, NEC 1 
SL5..12 Antipyretic poisoning 1 
SL6y.00 Antiparkinsonism drug poisoning 1 
SL6yz00 Antiparkinsonian drug poisoning NOS 1 
SL31z00 Antineoplastic or immunosuppressive poisoning NOS 1 
SL07.00 Antineoplastic antibiotic poisoning 1 
SL31.00 Antineoplastic and immunosuppressive poisoning 1 
SL14z00 Antimalarial drug poisoning NOS 1 
SL14.00 Antimalarial drug poisoning 1 
SLC2.00 Antilipaemic and antiarteriosclerotic poisoning 1 
SL30.13 Antihistamine poisoning 1 
SL01.00 Antifungal antibiotic poisoning 1 
SL30.12 Antiemetic poisoning 1 
SLD5z00 Antidiarrhoeal poisoning NOS 1 
SLD5.00 Antidiarrhoeal poisoning 1 
SL6xz00 Anticonvulsant poisoning NOS 1 
SL6..11 Anticonvulsant poisoning 1 
SL6z.00 Anticonvulsant or antiparkinsonian drug poisoning NOS 1 
SL6..00 Anticonvulsant and antiParkinsonian drug poisoning 1 
SL42z00 Anticoagulant poisoning NOS 1 
SL42.00 Anticoagulant poisoning 1 
SL45z00 Anticoagulant agonist poisoning NOS 1 
SL45.00 Anticoagulant agonist poisoning 1 
SLB0100 Anticholinesterase poisoning 1 
SL0z.00 Antibiotic poisoning NOS 1 
SL0..00 Antibiotic poisoning 1 
SLF7z00 Antiasthmatic poisoning NOS 1 
SL30.00 Antiallergic and antiemetic drug poisoning 1 
SL1z.00 Anti-infective poisoning NOS 1 
SLD0.00 Anti-gastric acid drug poisoning 1 
SLF6.00 Anti-common cold drug poisoning 1 
SL16.00 Anthelmintic drug poisoning 1 
SL24.00 Anterior pituitary hormone poisoning 1 
SLD0z00 Antacid drug poisoning NOS 1 
SLD0.11 Antacid drug poisoning 1 
SL21.12 Androgen poisoning 1 
SL21z00 Androgen or anabolic poisoning NOS 1 
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SL21.00 Androgen and anabolic poisoning 1 
SL5z.00 Analgesic, antipyretic or antirheumatic poisoning NOS 1 
SL5..00 Analgesic, antipyretic and antirheumatic drug poisoning 1 
SL5y100 Analgesic poisoning, NEC 1 
SL5..11 Analgesic poisoning 1 
SLA0.00 Analeptic poisoning 1 
SL8..11 Anaesthetic poisoning 1 
SL21.11 Anabolic steroid poisoning 1 
SM03000 Amyl alcohol causing toxic effect 1 
SL00000 Ampicillin poisoning 1 
SL01000 Amphotericin B poisoning 1 
SL70000 Amobarbital poisoning 1 
SL90000 Amitriptyline poisoning 1 
SLF7000 Aminophylline poisoning 1 
SL97000 Amfetamine poisoning 1 
SL6y000 Amantadine poisoning 1 
SLD0000 Aluminium hydroxide poisoning 1 
SLE7000 Allopurinol poisoning 1 
SLH3.00 Alcohol deterrent poisoning 1 
E230.11 Alcohol dependence with acute alcoholic intoxication 1 
SM0z.00 Alcohol causing toxic effect NOS 1 
SM0..00 Alcohol causing toxic effect 1 
SL4..00 Agents affecting blood constituents, causing poisoning 1 
TJF5100 Adverse reaction to ipecacuanha 1 
TJF5000 Adverse reaction to acetylcysteine 1 
SLC8000 Adrenochrome poisoning 1 
SLB2.11 Adrenergic poisoning 1 
SL20z00 Adrenal cortico-steroid poisoning NOS 1 
SL20.00 Adrenal cortico-steroid poisoning 1 
761H300 Administration of activated charcoal 1 
E230000 Acute alcoholic intoxication, unspecified, in alcoholism 1 
E230z00 Acute alcoholic intoxication in alcoholism NOS 1 
E230.00 Acute alcoholic intoxication in alcoholism 1 
SM31z00 Acids causing toxic effect NOS 1 
SM31.00 Acids causing toxic effect 1 
SL32.00 Acidifying agent poisoning 1 
SLB0000 Acetylcholine poisoning 1 
SM2y000 Acetone causing toxic effect 1 
SL23000 Acetohexamide poisoning 1 
SLE2000 Acetazolamide poisoning 1 
T80yz00 Accidental poisoning-oth analgesic,antipyretic,antirheum NOS 1 
T830z00 Accidental poisoning- phenothiazine-based tranquillisers NOS 1 
T832z00 Accidental poisoning- benzodiazepine-based tranquilliser NOS 1 
T953100 Accidental poisoning from seeds 1 
T954.00 Accidental poisoning from other plants 1 
T955y00 Accidental poisoning from other fungi 1 
T955.00 Accidental poisoning from mushrooms and other fungi 1 
T955z00 Accidental poisoning from mushrooms and fungi NOS 1 
T955000 Accidental poisoning from mushrooms 1 
T95..00 Accidental poisoning from foodstuffs and poisonous plants 1 
T953z00 Accidental poisoning from berries or seeds NOS 1 
T953.00 Accidental poisoning from berries and seeds 1 
T953000 Accidental poisoning from berries 1 
T937400 Accidental poisoning by zinc phosphide 1 
T916300 Accidental poisoning by white washes 1 
T885.00 Accidental poisoning by water,mineral,uric acid metab drugs 1 
T937300 Accidental poisoning by warfarin 1 
T981z00 Accidental poisoning by utility gas NOS 1 
T88z.00 Accidental poisoning by unspecified drugs 1 
T83z.00 Accidental poisoning by tranquillisers NOS 1 
T83..00 Accidental poisoning by tranquillisers 1 
T930500 Accidental poisoning by toxaphene 1 
T964700 Accidental poisoning by thallium compounds 1 
T937200 Accidental poisoning by thallium 1 
T993.00 Accidental poisoning by tear gas 1 
T910.00 Accidental poisoning by synthetic detergents and shampoos 1 
T941200 Accidental poisoning by sulphuric acid 1 
T991.00 Accidental poisoning by sulphur dioxide 1 
T937100 Accidental poisoning by squill and derivatives 1 
T92z.00 Accidental poisoning by solvent NOS 1 
T96z.00 Accidental poisoning by solid and liquid substances NOS 1 
T942000 Accidental poisoning by sodium hydroxide 1 
T911.00 Accidental poisoning by soap products 1 
T887z00 Accidental poisoning by skin, eye, ENT and dental drug NOS 1 
T887000 Accidental poisoning by skin drugs 1 
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T82z.00 Accidental poisoning by sedatives and hypnotics NOS 1 
T903300 Accidental poisoning by secondary propyl alcohol 1 
T913000 Accidental poisoning by scouring agents 1 
T803z00 Accidental poisoning by salicylates NOS 1 
T803.00 Accidental poisoning by salicylates 1 
T937z00 Accidental poisoning by rodenticides NOS 1 
T937.00 Accidental poisoning by rodenticides 1 
T815.00 Accidental poisoning by quinalbarbitone 1 
T805.00 Accidental poisoning by pyrazole derivatives 1 
T84z.00 Accidental poisoning by psychotropic agents NOS 1 
T841400 Accidental poisoning by psilocin 1 
T932200 Accidental poisoning by propoxur 1 
T980200 Accidental poisoning by propane 1 
T830300 Accidental poisoning by promazine 1 
T830200 Accidental poisoning by prochlorperazine 1 
T881.00 Accidental poisoning by primarily systemic agents 1 
T912.00 Accidental poisoning by polishes 1 
T965z00 Accidental poisoning by plant foods and fertilisers NOS 1 
T965.00 Accidental poisoning by plant foods and fertilisers 1 
T965000 Accidental poisoning by plant food 1 
T973.00 Accidental poisoning by piped natural gas 1 
T938200 Accidental poisoning by phosphine 1 
T805100 Accidental poisoning by phenylbutazone 1 
T830.00 Accidental poisoning by phenothiazine-based tranquillisers 1 
T940011 Accidental poisoning by phenol 1 
T814.00 Accidental poisoning by phenobarbitone 1 
T804200 Accidental poisoning by phenacetin 1 
T920.00 Accidental poisoning by petroleum solvents 1 
T923.00 Accidental poisoning by petroleum solids 1 
T920200 Accidental poisoning by petroleum naphtha 1 
T921.12 Accidental poisoning by petroleum fuels 1 
T920z00 Accidental poisoning by petrol solvents NOS 1 
T923z00 Accidental poisoning by petrol solids NOS 1 
T92..00 Accidental poisoning by petrol products 1 
T921.00 Accidental poisoning by petrol fuels and cleaners 1 
T921z00 Accidental poisoning by petrol fuel or cleaner NOS 1 
T921200 Accidental poisoning by petrol 1 
T802100 Accidental poisoning by pethidine 1 
T813.00 Accidental poisoning by pentobarbitone 1 
T80y000 Accidental poisoning by pentazocine 1 
T935500 Accidental poisoning by paraquat 1 
T923000 Accidental poisoning by paraffin wax 1 
T804100 Accidental poisoning by paracetamol 1 
T916z00 Accidental poisoning by paint or varnish NOS 1 
T887300 Accidental poisoning by otorhinolaryngological drugs 1 
T98..00 Accidental poisoning by other utility gas + carbon monoxide 1 
T981.00 Accidental poisoning by other utility gas 1 
T83yz00 Accidental poisoning by other tranquillisers NOS 1 
T83y.00 Accidental poisoning by other tranquillisers 1 
T924z00 Accidental poisoning by other solvents NOS 1 
T924.00 Accidental poisoning by other solvents 1 
T96y.00 Accidental poisoning by other solid and liquid substances OS 1 
T96..00 Accidental poisoning by other solid and liquid substances 1 
T82y.00 Accidental poisoning by other sedatives and hypnotics OS 1 
T82..00 Accidental poisoning by other sedatives and hypnotics 1 
T84..00 Accidental poisoning by other psychotropic agents 1 
T916.00 Accidental poisoning by other paints and varnishes 1 
T802z00 Accidental poisoning by other opiates NOS 1 
T802.00 Accidental poisoning by other opiates 1 
T807.00 Accidental poisoning by other non-narcotic analgesics 1 
T9...00 Accidental poisoning by other non-drug substances 1 
T964.00 Accidental poisoning by other metals + compounds and fumes 1 
T934.00 Accidental poisoning by other insecticides 1 
T99y.00 Accidental poisoning by other gases and vapours OS 1 
T99yz00 Accidental poisoning by other gases and vapours NOS 1 
T99..00 Accidental poisoning by other gases and vapours 1 
T95y.00 Accidental poisoning by other foods 1 
T901.00 Accidental poisoning by other ethyl alcohol and its products 1 
T85..00 Accidental poisoning by other drugs acting on nervous system 1 
T88y.00 Accidental poisoning by other drugs OS 1 
T88yz00 Accidental poisoning by other drugs NOS 1 
T88..00 Accidental poisoning by other drugs 1 
T94y.00 Accidental poisoning by other corrosives and caustics 1 
T913z00 Accidental poisoning by other cleaning agents NOS 1 
T913.00 Accidental poisoning by other cleaning agents 1 
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T90y.00 Accidental poisoning by other alcohols 1 
T966y00 Accidental poisoning by other adhesives 1 
T851.00 Accidental poisoning by oth central nervous syst depressants 1 
T80y.00 Accidental poisoning by oth analgesics,antipyretic,antirheum 1 
T931z00 Accidental poisoning by organophosphorus insecticides NOS 1 
T931.00 Accidental poisoning by organophosphorus insecticides 1 
T930.00 Accidental poisoning by organochlorine insecticides 1 
T936000 Accidental poisoning by organic mercurials 1 
T802300 Accidental poisoning by opium 1 
T843100 Accidental poisoning by opiate antagonists 1 
T887200 Accidental poisoning by ophthalmological drugs 1 
T855100 Accidental poisoning by noradrenalin 1 
T807z00 Accidental poisoning by non-narcotic analgesics NOS 1 
T916200 Accidental poisoning by non-lead paints 1 
T990.00 Accidental poisoning by nitrogen oxides 1 
T941100 Accidental poisoning by nitric acid 1 
T832500 Accidental poisoning by nitrazepam 1 
T964600 Accidental poisoning by nickel compounds 1 
T806200 Accidental poisoning by naproxen 1 
T886.00 Accidental poisoning by muscle + respiratory system drugs 1 
T887100 Accidental poisoning by mucous membrane drugs 1 
T982.00 Accidental poisoning by motor vehicle exhaust gas 1 
T802200 Accidental poisoning by morphine 1 
T840200 Accidental poisoning by monoamine oxidase inhibitors 1 
T933.00 Accidental poisoning by mixtures of insecticides 1 
T935400 Accidental poisoning by mixtures herbicides+plant food etc 1 
T825.00 Accidental poisoning by mixed sedatives NEC 1 
T901100 Accidental poisoning by methylated spirit 1 
T938100 Accidental poisoning by methyl bromide 1 
T902.00 Accidental poisoning by methyl alcohol 1 
T823.00 Accidental poisoning by methaqualone compounds 1 
T902000 Accidental poisoning by methanol 1 
T801.00 Accidental poisoning by methadone 1 
T964z00 Accidental poisoning by metals + compounds and fumes NOS 1 
T961000 Accidental poisoning by mercury, unspecified 1 
T961z00 Accidental poisoning by mercury, NOS 1 
T961200 Accidental poisoning by mercury fumes 1 
T961.00 Accidental poisoning by mercury and its compounds and fumes 1 
T832400 Accidental poisoning by medazepam 1 
T964500 Accidental poisoning by manganese and its compounds 1 
T931300 Accidental poisoning by malathion 1 
T841100 Accidental poisoning by lysergide, LSD 1 
T922.00 Accidental poisoning by lubricating oils 1 
T832300 Accidental poisoning by lorazepam 1 
T852.00 Accidental poisoning by local anaesthetic 1 
T852100 Accidental poisoning by lignocaine 1 
T960000 Accidental poisoning by lead, unspecified 1 
T960z00 Accidental poisoning by lead, NOS 1 
T915.00 Accidental poisoning by lead paints 1 
T960.00 Accidental poisoning by lead and its compounds and fumes 1 
T916000 Accidental poisoning by lacquers 1 
T806400 Accidental poisoning by ketoprofen 1 
T921300 Accidental poisoning by kerosene 1 
T903z00 Accidental poisoning by isopropyl alcohol NOS 1 
T903100 Accidental poisoning by isopropanol 1 
T964400 Accidental poisoning by iron compounds 1 
T934z00 Accidental poisoning by insecticides NOS 1 
T806100 Accidental poisoning by indomethacin 1 
T840100 Accidental poisoning by imipramine 1 
T806300 Accidental poisoning by ibuprofen 1 
T854200 Accidental poisoning by hyoscine 1 
T941000 Accidental poisoning by hydrochloric acid 1 
T850100 Accidental poisoning by hydantoin derivatives 1 
T91z.00 Accidental poisoning by household agents NOS 1 
T91..00 Accidental poisoning by household agents 1 
T880.00 Accidental poisoning by hormones and synthetic substitutes 1 
T800.00 Accidental poisoning by heroin 1 
T935z00 Accidental poisoning by herbicides NOS 1 
T935.00 Accidental poisoning by herbicides 1 
T981300 Accidental poisoning by heating gas NOS 1 
T831000 Accidental poisoning by haloperidol 1 
T851200 Accidental poisoning by halogenated hydrocarbon derivatives 1 
T841.00 Accidental poisoning by hallucinogens 1 
T841z00 Accidental poisoning by hallucinogen NOS 1 
T806000 Accidental poisoning by gold salts 1 
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T966z00 Accidental poisoning by glues and adhesives NOS 1 
T966.00 Accidental poisoning by glues and adhesives 1 
T966000 Accidental poisoning by glues 1 
T884.00 Accidental poisoning by gastrointestinal system drugs 1 
T470.00 Accidental poisoning by gases or fumes on ship 1 
T99z.00 Accidental poisoning by gases and vapours NOS 1 
T921100 Accidental poisoning by gas oils 1 
T97..00 Accidental poisoning by gas distributed by pipeline 1 
T936z00 Accidental poisoning by fungicides NOS 1 
T936.00 Accidental poisoning by fungicides 1 
T938.00 Accidental poisoning by fumigants 1 
T95z.00 Accidental poisoning by foodstuffs and poisonous plants NOS 1 
T965100 Accidental poisoning by fertilisers 1 
T982000 Accidental poisoning by exhaust gas-stationary farm tractor 1 
T982z00 Accidental poisoning by exhaust gas from motor vehicle NOS 1 
T982100 Accidental poisoning by exhaust gas from gas engine 1 
T901z00 Accidental poisoning by ethyl alcohol NOS 1 
T901300 Accidental poisoning by ethanol, NOS 1 
T8...00 Accidental poisoning by drugs, medicines and biologicals 1 
T882.00 Accidental poisoning by drugs affecting blood constituents 1 
T85z.00 Accidental poisoning by drugs acting on nervous system NOS 1 
T8z..00 Accidental poisoning by drugs NOS 1 
T914.00 Accidental poisoning by disinfectants 1 
T935300 Accidental poisoning by diquat 1 
T930300 Accidental poisoning by dieldrin 1 
T832100 Accidental poisoning by diazepam 1 
T800.11 Accidental poisoning by diamorphine 1 
T887400 Accidental poisoning by dental drugs 1 
T901000 Accidental poisoning by denatured alcohol 1 
T938000 Accidental poisoning by cyanides 1 
T967.00 Accidental poisoning by cosmetics 1 
T94z.00 Accidental poisoning by corrosives and caustics NOS 1 
T94..00 Accidental poisoning by corrosives and caustics NEC 1 
T940.00 Accidental poisoning by corrosive aromatics 1 
T964300 Accidental poisoning by copper salts 1 
T981400 Accidental poisoning by cooking gas NOS 1 
T802000 Accidental poisoning by codeine 1 
T852000 Accidental poisoning by cocaine 1 
T971.00 Accidental poisoning by coal gas NOS 1 
T853.00 Accidental poisoning by cholinergics 1 
T830000 Accidental poisoning by chlorpromazine 1 
T99y000 Accidental poisoning by chlorine 1 
T832000 Accidental poisoning by chlordiazepoxide 1 
T930100 Accidental poisoning by chlordane 1 
T935200 Accidental poisoning by chlorates 1 
T820.00 Accidental poisoning by chloral hydrate 1 
T88y000 Accidental poisoning by central appetite depressants 1 
T942z00 Accidental poisoning by caustic alkalis NOS 1 
T942.00 Accidental poisoning by caustic alkalis 1 
T883.00 Accidental poisoning by cardiovascular system drugs 1 
T983.00 Accidental poisoning by carbon monoxide-other domestic fuel 1 
T970.00 Accidental poisoning by carbon monoxide from piped gas 1 
T98y.00 Accidental poisoning by carbon monoxide from other sources 1 
T98yz00 Accidental poisoning by carbon monoxide from oth source NOS 1 
T98z.00 Accidental poisoning by carbon monoxide NOS 1 
T983z00 Accidental poisoning by carbon monoxide - domestic fuel NOS 1 
T940000 Accidental poisoning by carbolic acid 1 
T932100 Accidental poisoning by carbaryl 1 
T932.00 Accidental poisoning by carbamates 1 
T841000 Accidental poisoning by cannabis derivatives 1 
T842100 Accidental poisoning by caffeine 1 
T964200 Accidental poisoning by cadmium and its compounds 1 
T980100 Accidental poisoning by butane 1 
T993000 Accidental poisoning by bromobenzyl cyanide 1 
T822.00 Accidental poisoning by bromine compounds 1 
T822000 Accidental poisoning by bromides 1 
T964100 Accidental poisoning by brass fumes 1 
T964000 Accidental poisoning by beryllium and its compounds 1 
T832.00 Accidental poisoning by benzodiazepine-based tranquillisers 1 
T930000 Accidental poisoning by benzene hexachlorine 1 
T924000 Accidental poisoning by benzene 1 
T81z.00 Accidental poisoning by barbiturates NOS 1 
T81..00 Accidental poisoning by barbiturates 1 
T811.00 Accidental poisoning by barbitone 1 
T854000 Accidental poisoning by atropine 1 
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T803000 Accidental poisoning by aspirin 1 
T963000 Accidental poisoning by arsenic, unspecified 1 
T963100 Accidental poisoning by arsenic compounds 1 
T963.00 Accidental poisoning by arsenic and its compounds and fumes 1 
T804.00 Accidental poisoning by aromatic analgesics NEC 1 
T806z00 Accidental poisoning by antirheumatics NOS 1 
T806.00 Accidental poisoning by antirheumatics 1 
T840z00 Accidental poisoning by antidepressants NOS 1 
T840.00 Accidental poisoning by antidepressants 1 
T850z00 Accidental poisoning by anticonvulsant/anti-parkin drug NOS 1 
T850.00 Accidental poisoning by anticonvulsant + anti-parkinson drug 1 
T850.11 Accidental poisoning by anticonvulsant 1 
T854.00 Accidental poisoning by anticholinergics 1 
T86..00 Accidental poisoning by antibiotics 1 
T850.12 Accidental poisoning by anti-parkinsonism drug 1 
T87..00 Accidental poisoning by anti-infectives 1 
T80..00 Accidental poisoning by analgesics,antipyretic,antirheumatic 1 
T80z.00 Accidental poisoning by analgesics,antipyretic,antirheum NOS 1 
T842000 Accidental poisoning by amphetamine 1 
T840000 Accidental poisoning by amitriptyline 1 
T900.00 Accidental poisoning by alcoholic beverages 1 
T90..00 Accidental poisoning by alcohol, NEC 1 
T90z.00 Accidental poisoning by alcohol NOS 1 
T93..00 Accidental poisoning by agricultural chemical preparations 1 
T855.00 Accidental poisoning by adrenergics 1 
T855000 Accidental poisoning by adrenalin 1 
T941z00 Accidental poisoning by acids NOS 1 
T941.00 Accidental poisoning by acids 1 
T981000 Accidental poisoning by acetylene 1 
T930200 Accidental poisoning by DDT 1 
T983300 Accidental poisoning by CO- kerosene in domestic stove/fire 1 
T983100 Accidental poisoning by CO- coke in domestic stove/fireplace 1 
T983000 Accidental poisoning by CO- coal in domestic stove/fireplace 1 
T98y100 Accidental poisoning by CO - kiln vapour 1 
T98y200 Accidental poisoning by CO - fuels in industrial use 1 
T98y000 Accidental poisoning by CO - blast furnace gas 1 
T93z.00 Accidental poisoning agricultural chemical preparations NOS 1 
T9z..00 Accidental poisoning NOS 1 
T77z.00 Accident/poisoning occurred in residential institution NOS 1 
T85y.00 Accid. poisoning by other drugs acting on nervous system OS 1 
T470500 Accid poison gas/fume on ship - swimmer injured 1 
SL24011 ACTH - adrenocorticotropic hormone poisoning 1 
 
 
Supplementary appendix 4, table 13. ICD codes used in the studies of fatal self-harm. 
Study ICD version List of codes 
Carr, 2017 ICD-10 V01-Y98 
Coupland, 2015 ICD-10 not provided 
Doyle, 2016 ICD-10 X60-X84, Y10-34 (excluding Y33.9), Y87.0 and Y87.2 
Lalmohamed, 2012 ICD-10 V01-Y99 
Meier, 2004 ICD-10 not provided 
Schuerch, 2016 ICD-10 X60-X84, Y10-Y34 
Thomas, 2013 ICD-10 X60-X84, Y10-34 (excluding Y33.9) 
Webb, 2012 ICD-10 X60-X84, Y10-34 (excluding Y33.9) 
Windfuhr, 2016 ICD-10 X60-X84, Y10-34 (excluding Y33.9), Y87.0 and Y87.2 
ICD - International Classification of Diseases 
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11.3 Appendix 3   Supplementary materials to the paper in Chapter 6 
Carreira H, Williams R, Funston G, Stanway S, Krishnan Bhaskaran 
Risk of adverse mental health outcomes in women with history of 
breast cancer: a matched population-based cohort study in the 
United Kingdom (1988-2018) 
(submitted) 
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Protocol Risk of adverse mental health outcomes in women with a history of 
breast cancer in the United Kingdom: a matched population-based cohort study 
 
Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ and justification provided 
A. Study Title (Max. 255 characters) 
 
Risk of adverse mental health outcomes in women with a history of breast cancer in the United Kingdom: a 
matched population-based cohort study 
 
B. Lay Summary (Max. 250 words) 
 
Women with a history of breast cancer are the largest group of cancer survivors in the general population. A breast 
cancer diagnosis may impact on mental health, and breast cancer treatments, which are necessary to control the 
disease, can result in side effects that may negatively affect the women’s quality of life. This study aims to 
understand whether women who have had breast cancer have different mental health several years post-treatment, 
compared to women who did not have cancer. For this, we will compare the risk of being diagnosed with anxiety 
and depression, the primary outcomes of this study, in women who have had breast cancer and in women who 
never had cancer, attending general practitioner (GP) practices in the UK. We will also compare GP recorded 
declines in the patients’ memory and thinking capacities, feelings of tiredness and weakness (fatigue), pain, 
insomnia, sexual problems, or self-harm and suicide (secondary outcomes), between the two groups, and explore 
factors that may be associated with increased risk of these outcomes. The results of this study can be used to 
better understand the needs of the women who carry on lives beyond breast cancer. 
 
C. Technical Summary (Max. 300 words) 
 
The aim of this study is to estimate the relative risk of anxiety and depression (primary outcomes), and fatigue, pain, 
sleep disorders, neurocognitive and sexual dysfunctions, and fatal and non-fatal self-harm (secondary outcomes), 
in breast cancer survivors compared to non-cancer controls. This study will be a matched cohort study, utilising 
data from the CPRD GOLD primary care database. Outcome-specific algorithms will be developed and validated to 
identify outcomes in the data. Algorithm development will consider Read codes for diagnoses, prescriptions, 
referrals and symptoms; prevalence and incidence estimates by age-group and sex will be computed for a random 
sample of patients selected from CPRD GOLD primary care database. Validation will be against external sources of 
data, namely published data from population-based surveys in the UK. To estimate the associations between breast 
cancer survivorship and the primary and secondary outcomes, we will identify all women exposed to breast cancer 
in the CPRD GOLD primary care database, and randomly select an age- and primary-care-practice-matched cohort 
of women without prior cancer in a ratio of 1:4. Cox regression models will be used to estimate hazard ratios 
adjusted for important confounders, and to explore the role of effect modifiers; the proportionality of hazards will be 
tested graphically and inferentially. 
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D. Outcomes to be measured 
 
• Anxiety 
• Depression 
• Fatigue 
• Cognitive impairment 
• Pain 
• Sexual dysfunction 
• Sleep disorders 
• Completed suicide 
• Self-harm 
 
E. Objectives, Specific Aims and Rationale 
 
General objective 
To quantify the relative risk of common adverse mental health outcomes in breast cancer survivors compared to 
women who did not have cancer in the United Kingdom. 
 
Specific aims 
1. To develop and validate algorithms to identify patients with anxiety and depression (primary outcomes), and 
fatigue, mild cognitive impairment, pain, sleep disturbance, sexual dysfunction, and fatal and non-fatal self-
harm (secondary outcomes) in the CPRD GOLD primary care database. 
2. To compare the risk of developing anxiety and depression (primary outcomes), and of recorded fatigue, mild 
cognitive impairment, pain, sleep disturbance, sexual dysfunction, and fatal and non-fatal self-harm 
(secondary outcomes), between women with a history of breast cancer and women who did not have cancer. 
3. To estimate association between breast cancer history and anxiety/depression by presence of common 
complications of the breast cancer treatments (i.e. lymphoedema, pain, mild cognitive impairment, fatigue, 
sexual dysfunction, sleep disorders) and exposure to endocrine therapy. 
 
Rationale 
It is currently unclear if the long-term mental health of breast cancer survivors differs from that of comparable 
women who never had cancer. This study will directly address this evidence gap, and help inform prevention and 
treatment needs relating to the mental health of breast cancer survivors. 
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F. Study Background 
 
Women with a history of breast cancer are the largest group of cancer survivors in the United Kingdom (UK). 
Approximately 570,000 women were estimated to be living beyond a breast cancer diagnosis in 2010; this figure 
was projected to rise to1.5 million women by 2040 [1]. 
Evidence on the mental health of breast cancer survivors in the UK suggests high levels of distress in this group. 
Capelan et al [2] reported that 60% of women post treatment for early breast cancer had ≥1 unmet needs; the most 
common were hot flushes, fatigue, pain, worry, fear or anxiety, and sleep problems. A third of the women who 
participated in the Standardisation of Radiotherapy Trial (START) [3] had relevant symptoms of anxiety at baseline; 
five years later, this proportion was 29%. Similar results were observed for depression, albeit the absolute 
frequency was lower: 12% scored above normal level at baseline, and 11% at the five-year evaluation [3]. The 
worse recollections reported by a sample of women in the UK seven years after diagnosis included the anxiety 
related to the future’s uncertainty (38%), the chemotherapy and related side effects (25%), and the shock of the 
cancer diagnosis (18%) [4]. Other reported concerns were the breast removal and body image implications in 
sexuality (8%), the suffering induced by their disease in their loved ones (7%), the co-morbidities (6%), and the side 
effects of radiotherapy and hormone therapy (6%) [4]. All of these may negatively affect the women’s mental status. 
Indeed, a study on the quality of life of breast cancer survivors one to five years post-diagnosis in England 
described lower scores than what had been described in other studies of the general population [5].  
In the UK, women post-treatment for breast cancer are often followed in hospital outpatient clinics, where they may 
receive psychological support, and in primary care [6]. In the latter setting, evidence on the relative risk of adverse 
mental health outcomes in breast cancer survivors, compared to women who did not have cancer, is scant. A 
systematic review of quantitative studies that evaluated adverse mental health outcomes in breast cancer survivors 
and in the background female population identified one single study from the UK. In this study, Khan et al [7] used 
routinely collected primary care data to study the pattern of consultations and prescriptions for anxiety and 
depression in women with a history of breast cancer for ≥5 years. The results showed significantly increased odds 
of being prescribed with antidepressants or anxiolytics, even though there was no strong statistical evidence of 
increased odds of consulting for these conditions. The frequency of anxiety and depression among women 
diagnosed at <5 years is unknown. Population-based studies conducted elsewhere [8-12] reported highest risks of 
anxiety and depression shortly after the breast diagnosis, which declined over time. It is currently unclear if this 
same pattern is observed in the UK. In addition, the studies identified in the systematic review suggest that breast 
cancer survivors may be at increased risk of other outcomes, such as sleep disturbance, neurocognitive and sexual 
dysfunctions; no study addressed these in population-based samples of breast cancer survivors in the UK. 
Furthermore, to our knowledge, the frequency of fatigue, pain, and fatal and non-fatal self-harm, in breast cancer 
survivors in the UK is unknown, even though these relate to unmet needs often reported by breast cancer survivors. 
The Clinical Practice Research Datalink primary care database includes data prospectively collected on symptoms, 
diagnoses, prescriptions, and referrals, for over 5.8 million women being followed in primary care since the late 
1980s [13], and therefore it represents a unique opportunity to assess the risk of these outcomes at population-
level.  
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The aim of this study is to quantify the relative risk of adverse mental health outcomes in women with a history of 
breast cancer the UK, compared to women with no cancer background. The primary outcomes will be anxiety and 
depression, two common mental disorders that are commonly managed in primary care settings. Secondary 
outcomes will be fatigue, mild cognitive impairment, pain, sleep disorder, sexual dysfunction, and fatal and non-fatal 
self-harm; part of the contribution of this study will be to establish the feasibility or otherwise of using electronic 
health records to assess some of these less-studied outcomes. 
G. Study Type 
 
Hypothesis testing 
Study null hypothesis: There are no differences in the risks of anxiety and depression (primary outcomes), fatigue, 
mild cognitive impairment, pain, sleep disturbance, sexual dysfunction, and fatal and non-fatal self-harm (secondary 
outcomes), between women with a history of breast cancer and women who never had cancer receiving primary 
care in the UK. 
H. Study Design 
 
The research aims will be addressed with a matched cohort study design. 
Two cohorts will be assembled from the CPRD GOLD primary care database: 
(1) The exposed cohort will include women diagnosed with a breast cancer (list of Read codes available in 
appendix 2) after at least 12 months of uninterrupted up-to-standard follow-up in CPRD (to ensure that the breast 
cancer is an incident event).  
(2) A comparison cohort will be assembled by randomly selecting, for each woman with a breast cancer diagnosis, 
up to 4 women of similar age (3-year range), attending the same GP practice and with at least 12 months of 
uninterrupted up-to-standard data quality for research, but with no history of cancer at the date of the breast cancer 
diagnosis of the matched breast cancer patient. 
The index date will be the date of breast cancer diagnosis for the exposed group; comparison patients will take the 
same index date as their exposed match. Please see section L for more details. 
Inclusion criteria for both cohorts are: female sex, aged ≥18 years, and having a clinical record with at least 12 
months of uninterrupted up-to-standard data quality for research (as measured by CPRD) before the breast cancer 
diagnosis date (to ensure the cancer record represents incident disease). Exclusions will be the diagnosis of severe 
mental illness (i.e. organic mental disorder, mental disorders due to substances, schizophrenia, delusional 
disorders, or manic or bipolar episodes), having a history of the specified mental health outcome in the year before 
index date; and having had a diagnosis of any other cancer prior to the index date. 
All women will be followed from the index date until the earliest date of: outcome observed, a cancer diagnosis, 
death recorded, transference out of the practice; last data collection for the practice. 
Matching will allow close control of key covariates, include GP practice that is difficult to adjust for in a statistical 
model (too many levels), and has the practical advantage of reducing the size of the comparison group (which 
might otherwise include several million women) by restricting to the most relevant comparison patients. 
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I. Feasibility counts 
 
Feasibility counts presented below are based on the January 2018 version of the CPRD GOLD primary care 
database.  
We identified 65,136 women who had a diagnosis of breast cancer (Read codes provided in appendix 2) while aged 
between 18 and 80 years, registered with a primary care practice contributing with data to CPRD, and whose 
individual records were acceptable for research. Non-interrupted one year of follow up before the cancer diagnosis 
(index date) was not available for 6,757 women, and 6,044 women were further excluded because they had a 
lifetime diagnosis of severe mental illness or another cancer before their breast cancer diagnosis (see section J for 
the inclusion and exclusion criteria).  
Hence, 52,335 women with a history of breast cancer were identified as eligible for this study; the table below 
provides details of the distribution by age and calendar period of diagnosis. 
 
Table 1   Distribution of women with breast cancer history who are eligible for this study, by age and calendar 
period of diagnosis. 
 N % 
   
All study participants 52,335 (100.0) 
   
Calendar period of diagnosis   
1989-1994 3,184 (6.1) 
1995-1999 4,768 (9.1) 
2000-2004 10,934 (20.9) 
2005-2009 14,705 (28.1) 
2010-2014 13,805 (26.4) 
≥2015 4,939 (9.4) 
   
Age at diagnosis (years)   
18-24 24 (0.1) 
25-34 771 (1.5) 
35-44 4,916 (9.4) 
45-54 12,235 (25.3) 
55-64 14,910 (28.5) 
65-74 12,811 (24.5) 
75-80 5,668 (10.8) 
   
 
 
A comparison group of women without cancer (4 controls per breast cancer case) will be randomly selected from 
the same data source, same primary care practice and within a 3-year age range. 
 
Appendix 2 to this protocol (available from the authors) provides the list of Read codes used to identify women with 
a history of breast cancer in the CPRD GOLD primary care database. The list of Read codes used to identify cancer 
diagnoses other than the breast one (exclusion criterion) has been published elsewhere [14]. A provisional list of 
Read codes to identify women with several mental illnesses (exclusion criterion) was defined for the purpose of this 
calculation; the final list will be refined in due course. 
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J. Sample size considerations 
 
Table 2 shows the minimum relative risk that could be detected with the 52,335 women identified in the CPRD 
GOLD primary care database, for different probabilities of type I (α) and type II error (β). These estimates were 
obtained with the command ‘power’ in Stata v15 [15]. 
 
Table 2   Minimum RR that can be detected with the 52,355 women with a history of breast cancer and 209,420 
women who did not have cancer, for different probabilities of type I and type II errors, and baseline risk of the 
outcomes. 
Outcome 
 
α 
 
β 
 
% of outcome in 
unexposed group 
[ref] 
Min. HR 
possible to be 
estimated 
RR/HR estimated 
in other studies 
[ref] 
      
Primary outcomes       
      
Anxiety, diagnoses 0.05 0.20 5  [7]  1.05 1.06 [7] 
1.08 [7] 
1.22 [11] 
1.25 [8] 
 
0.01 0.20 5  [7]  1.06 
0.05 0.10 5  [7]   1.06 
0.01 0.10 5  [7]   1.07 
    
0.05 0.20 20  [11]   1.02 
0.01 0.20 20  [11]   1.03 
0.05 0.10 20  [11]   1.03 
0.01 0.10 20  [11]   1.03 
      
Anxiety, prescription of 
 anxiolytics 
0.05 0.20 3  [10] 1.07 1.08 [7] 
2.52 [10] 
 
0.01 0.20 3  [10] 1.08 
0.05 0.10 3  [10] 1.08 
0.01 0.10 3  [10] 1.09 
    
0.05 0.20 8  [7] 1.04 
0.01 0.20 8  [7] 1.05 
0.05 0.10 8  [7] 1.05 
0.01 0.10 8  [7] 1.06 
      
Depression, diagnoses 
 
0.05 0.20 3  [11] 1.07 1.06 [7] 
1.39 [9] 
1.49 [8]  
1.94 [11] 
0.01 0.20 3  [11] 1.08 
0.05 0.10 3  [11] 1.08 
0.01 0.10 3  [11] 1.09 
    
0.05 0.20 9  [7] 1.04 
0.01 0.20 9  [7] 1.05 
0.05 0.10 9  [7] 1.04 
0.01 0.10 9  [7] 1.05 
      
Depression, 
prescription of 
antidepressants 
0.05 0.20 2  [10] 1.08 1.16 [7] 
1.95 [10] 0.01 0.20 2  [10]   1.10 
0.05 0.10 2  [10] 1.09 
0.01 0.10 2  [10] 1.11 
    
0.05 0.20 20  [7]   1.02 
0.01 0.20 20  [7]   1.03 
0.05 0.10 20  [7]   1.03 
0.01 0.10 20  [7]   1.03 
(continues) 
HR – hazard ratio. RR – risk ratio. Bold is used to denote where the minimum risk ratio that could be detected with the available sample size is 
lower than the lowest estimate reported in the literature. 
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Table 2 (continued)  Minimum RR that can be detected with the 52,355 women with a history of breast cancer and 
209,420 women who did not have cancer, for different probabilities of type I and type II errors, and baseline risk of 
the outcomes. 
Outcome 
 
α 
 
β 
 
% of outcome in 
unexposed group 
[ref] 
Min. HR 
possible to be 
estimated 
RR/HR estimated 
in other studies 
[ref] 
      
Secondary outcomes *      
      
Sexual dysfunction 0.05 0.20 4.1  [16] 1.06 1.03 [16] 
2.27 [17] 0.01 0.20 4.1  [16]  1.07 
0.05 0.10 4.1  [16]  1.07 
0.01 0.10 4.1  [16]  1.08 
    
0.05 0.20 9.1  [17] 1.04 
0.01 0.20 9.1  [17] 1.05 
0.05 0.10 9.1  [17] 1.04 
0.01 0.10 9.1  [17] 1.05 
 
 
     
Suicide 0.05 0.20 0.0008**  [18] 1.47 1.37 [18] 
1.6 [19] 0.01 0.20 0.0008**  [18] 1.60 
0.05 0.10 0.0008**  [18] 1.57 
0.01 0.10 0.0008**  [18] 1.70 
      
Fatal and 
non-fatal self-harm 
0.05 0.20 0.005  [18, 20] 1.17 1.03 [21] 
1.37 [18] 0.01 0.20 0.005  [18, 20] 1.21 
0.05 0.10 0.005  [18, 20] 1.20 
0.01 0.10 0.005  [18, 20] 1.24 
      
Sleep disturbances 0.05 0.20 50  [22] 1.01 0.8 [22] 
0.01 0.20 50  [22] 1.02 
0.05 0.10 50  [22] 1.02 
0.01 0.10 50  [22] 1.02 
      
Prescription of 
hypnotics 
0.05 0.20 4  [23] 1.06 3.75 [23] 
0.01 0.20 4  [23] 1.07 
0.05 0.10 4  [23] 1.07 
0.01 0.10 4  [23] 1.08 
      
Mild cognitive 
impairment 
0.05 0.20 5  [24]     1.05 1.58 [25] 
1.60 [26] 
2.43 [24] 
3.67 [27] 
 
 
0.01 0.20 5  [24] 1.06 
0.05 0.10 5  [24] 1.06 
0.01 0.10 5  [24] 1.07 
    
0.05 0.20 19  [26]    1.02 
0.01 0.20 19  [26]    1.03 
0.05 0.10 19  [26]    1.03 
0.01 0.10 19  [26]    1.04 
HR – hazard ratio. RR – risk ratio. Bold is used to denote where the minimum risk ratio that could be detected with the available 
sample size is lower than the lowest estimate reported in the literature. 
* No population-based studies have been identified reporting the relative risk of sexual dysfunctions, pain, fatigue, sleep disorders or 
cognitive dysfunction in breast cancer survivors compared to the non-cancer female population. Thus, the relative risk reported in 
the column for the other studies comes from studies involving convenience samples of cancer survivors. Pain and fatigue are often 
evaluated using psychometric instruments whose mean scores are summarised as means for between-group comparisons; no 
studies were identified providing data for the prevalence of pain and fatigue in breast cancer survivors and in women who did not 
have cancer, and thus these two outcomes were not included in the table. 
** Calculated as the proportion of suicides in the exposed group divided by the inverse of the standardised mortality ratio reported in 
the original study.  
 
The available sample size is expected to be sufficient for detecting clinically significant increases of anxiety and 
depression (primary outcomes) in breast cancer survivors compared to the women who did not have cancer. 
For the secondary outcomes, sample size is likely to be enough to assess differences in sleep disturbance 
measured by hypnotics’ prescription, and mild cognitive impairment. However, the available sample size will have 
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relatively small power to detect small differences in suicide between women with history of breast cancer and those 
who did not have cancer, because this is a rare outcome, but we will still have enough power to detect associations 
of a magnitude seen in some previous studies; data from our analysis can also contribute to future meta-analyses. 
 
K. Planned use of linked data (if applicable): 
 
The following linkages will be requested: 
Death registration data from the Office for National Statistics (ONS)  
HES Admitted Patient Care (HES-APC) 
Index of Multiple Deprivation 2015 (IMD), practice and patient level 
Data coming from these data sets will supplement information available in the CPRD GOLD primary care database, 
but linked data will be used in sensitivity analysis only.  
Data from the ONS-mortality and HES-APC databases will be important to increase the completeness and validity 
of some outcomes. For example, for suicide, only 26% of the suicides registered in the ONS mortality data (gold 
standard) were captured in CPRD, indicating low sensitivity of this source [28]. Similarly for non-fatal self-harm, only 
68% of the cases registered in HES-APC could be identified in CPRD [28]. Of note, patients who had the outcome 
recorded in the year prior to the index date will be excluded, and thus this finer definition of the outcomes will impact 
patients’ selection and patients’ who are identified as having had the outcome. Information on the exposure will not 
be supplemented by data from HES-APC.  
Patient-level quintiles of IMD will be used to control for socioeconomic status, which is a major confounder of the 
association between breast cancer history and adverse mental health outcomes. Even though women in the 
comparison group are selected from the same primary care practice of the index-case, and thus IMD at practice 
level will not vary by matched set, the patient-level IMD will allow for a finer adjustment of socioeconomic status. 
Practice level of IMD is requested to allow us to study effect modification in the full dataset.  
We acknowledge that analyses including linked data will be restricted to the subset of practices and patients who 
consent to the linkage scheme (~75% of the practices in England); the coverage periods for the dataset will be 
taken into account (see table below). This will result in reductions in sample size and potentially impact the power of 
the study to reject the null-hypothesis. Thus, these data will be used in sensitivity analysis only. 
 
Table 3 Coverage period of the data included in the databases that will be linked to the CPRD GOLD primary care 
database. 
Database Coverage period 
HES Admitted Patient Care (APC) April 1997 – December 2017 
ONS death registration January 1998 – February 2018 
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L. Definition of the Study population 
 
Breast cancer cohort 
The study population will consist of all adult women recorded in the CPRD GOLD primary care database as having 
had an incident breast cancer (Read codes provided in appendix 2) diagnosed during up-to-standard follow-up and 
prior to the most recent version of the CPRD GOLD primary care database available after all approvals have been 
obtained. 
Inclusion criteria: 
1. Female sex, aged ≥18 years; 
2. Recorded with a breast cancer diagnosis during CPRD follow-up; 
3. Clinical record with at least 12 months of uninterrupted up-to-standard data quality for research (as 
measured by CPRD) before the breast cancer diagnosis date (to ensure the cancer record represents 
incident disease). 
Exclusion criteria: 
1. Diagnosis of severe mental illness before the breast cancer diagnosis (i.e. organic mental disorder, mental 
disorders due to substances, schizophrenia, delusional disorders, or manic or bipolar episodes) (a 
provisional list of Read codes was defined for feasibility counts); 
2. History of the specified mental health outcome in analysis in the year before the breast cancer diagnosis 
(list of Read codes to be defined in objective 1 of this study);  
3. Diagnosis of any other cancer prior to breast cancer (Read codes available from Ranopa et al. [14]). 
 
M. Selection of comparison group(s) or controls 
 
Non-cancer comparison cohort 
A comparison cohort will be assembled by randomly selecting, for each index case, up to 4 women of similar age 
(3-year range), attending the same GP practice, but with no history of cancer at the index date. Matching will also 
consider the eligibility of the patients’ data for linkage, to ensure that matched-sets have the same probability of 
having had the information recorded when conducting sub-set analysis using linked data. Controls will be selected 
using nearest neighbour matching methods without replacement [29]. Women in the non-cancer comparison cohort 
who meet one or more exclusion criteria will be excluded, as well as their index case.  
Women diagnosed with breast cancer during the follow up period will be censored from the unexposed group at the 
date of the cancer diagnosis, but will be eligible to separately contribute in the exposed group from this date (with 
corresponding unexposed matches).  
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N. Exposures, Outcomes and Covariates 
 
 
Exposure: breast cancer 
Women will be considered exposed at the day of the breast cancer diagnosis (index date), denoted by the first entry 
of one or more of the Read codes provided in appendix 2.  
 
 
Primary outcomes: anxiety and depression 
To our knowledge, there is no validated list of Read codes to identify anxiety and depression in the CPRD GOLD 
primary care database. Algorithms will be developed and tested to identify anxiety and depression cases in CPRD. 
The algorithms will be chiefly determined by clinical diagnoses of anxiety and depression registered in the EHR with 
Read codes, and supplemented with information from drug prescriptions, referrals, and symptoms (if deemed 
suitable). Please see section N, plan of analysis for specific aim 1, for more details on the construction and 
validation of algorithms.  
 
 
Secondary outcomes: fatigue, mild cognitive impairment, pain, sleep disturbance, sexual dysfunction, and 
fatal and non-fatal self-harm 
Similarly, we will develop and test outcome-specific algorithms that identify events using a hierarchy of data on 
clinical diagnoses, prescriptions, referrals and symptoms. 
In sensitivity analysis, we will consider linked data (see section J for data linkage requested) to develop more 
precise definitions of the outcomes, when possible. For example, two definitions of suicide will be considered: (1) 
considering Read codes only to identify suicides in CPRD; (2) considering Read codes for suicide as well as death 
registration data where suicide was recorded as primary cause of death (ICD-10 codes provided in appendix 3) 
 
Covariates 
Variables considered as potential confounders or effect modifiers of the association between breast cancer history 
and anxiety and depression (the primary outcomes of this study) are described below. The directed, acyclic graph 
(DAG) in appendix 4 (available from the authors) explicitly describes the assumptions of the causal relations 
between the variables that underpin the choice. Please refer to the data analysis (section N) for details on which 
variables will be considered for sensitivity analyses only. 
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Potential confounders 
• Age at diagnosis (categorical variable, in 10-year age bands) 
Defined as the absolute difference between the year of breast cancer diagnosis and year of birth. Age is a 
strong risk factor for breast cancer and for mental disorders. 
• Alcohol drinking habits at diagnosis (categorical variable: current drinker, former drinker, never drinker) 
Excess alcohol drinking is a well-established risk factor for breast cancer [30], besides being positively 
associated with anxiety and depression [31-33]. The most recent data on alcohol drinking habits prior to 
index date will be used in analysis. Current drinking will be further sub-divided into high, moderate, low or 
unknown intake of alcohol.  
• Body mass index at diagnosis (categorical variable: underweight, normal weight, overweight, obesity class 
I, obesity class II and above) 
Calculated as BMI=(weight/height2). Higher body mass index is protective against breast cancer in pre- 
menopausal women, but a risk factor for breast cancer post-menopause [34]. Obesity increases the risk of 
anxiety and depression [35, 36]. The most recent recording of BMI prior to index date will be used in 
analysis. The BMI values will be categorised into 5 categories: <18.5 kg/m2 (underweight), 18.5-24.9 kg/m2  
(normal weight), 25.0-29.9 kg/m2 (overweight), 30.0-34.9 kg/m2 (obesity class I), ≥35.0 kg/m2 (obesity class 
II and above). Read codes for body weight categories recorded in the year prior to the breast cancer 
diagnosed will be considered to supplement missing information for this variable. 
• Calendar period of diagnosis (categorical variable: ≤1994; 1995-1999; 2000-2004; 2005-2009; 2010-2014; 
>2014) 
Even though calendar time per se does not change the risk of breast cancer, the risk of being diagnosed 
with breast cancer changed over time, probably due to increase awareness of the disease along with 
widespread use of mammography to screen for breast cancer. Time has also contributed for mental 
disorders being more likely to be diagnosed, due to raises awareness and increased recognition of the 
importance of mental disorders among health care professionals. 
• Diabetes mellitus (dichotomous variable: yes/no) 
Diabetes mellitus has been associated with an increased risk of breast cancer [37] and depression [38]. 
Algorithms previously defined elsewhere will be applied to identify patients with diabetes mellitus in the 
CPRD GOLD primary care database [39, 40].  
• Level of deprivation (categorical variable: quintiles of patient-level IMD). 
The IMD is an ecological measure of deprivation for small areas in England that combines information from 
seven domains (income, employment, education, health deprivation, crime, barriers to housing, and living 
environment), and ranks the small area from 1 (most deprived) to 32,844 (least deprived). Patients will be 
categorised in quintiles of IMD, with quintile 1 representing those least deprived and quintile 5 those most 
deprived. 
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• Menopausal status (dichotomous variable: premenopausal/postmenopausal) 
Menopausal status is a potential confounder of the association between breast cancer history and 
depression, as the risk of breast cancer increases with menopause [30], and so does the risk of depression 
[42]. However, information on menopausal status is not easily available in the CPRD database. We will 
therefore produce results stratified by an age cut-off, as a proxy of the menopausal status of the women. 
The cut-off will be the mean/median age at natural menopause in the UK. 
• Smoking history at diagnosis (categorical variable: current smoker, former smoker, never smoker) 
Information on Read codes available on the data will be used to classify patients by smoking history. The 
most recent data on smoking prior to index date will be used in analysis. 
 
Potential effect modifiers 
• Living alone (dichotomous variable: yes/no) 
Ascertained from the CPRD GOLD primary care data using Read codes (list provided in [41]) and the 
patient’s family number (variable ‘famnum’ from the patient file). Women living in household of <2 people 
will be classified as living alone. 
• Residing in a care home (dichotomous variable: yes/no). 
This variable will be defined from the CPRD GOLD primary care database, using Read codes (list provided 
in [41]), and information gathered in the family number variable (‘famnum’). For the latter, ‘care home’ will 
be defined as a household with >3 individuals aged ≥65 years and if their total count was more than of 
individuals <65 years. 
• Ethnicity (categorical variable: White, South Asian, Black, Others and mixed) 
Ethnicity data recorded in the CPRD GOLD primary care database will be categorised in five groups, 
following the categories defined in the UK 2011 Census: White, South Asian, Black, Others and mixed. This 
variable will be derived from Read codes available in the CPRD GOLD primary care database and from 
HES, since the combined data sources increase completeness from 55% to 79% [41]. For analysis, four 
groups will be considered: White, South Asian, Black, Others and mixed. 
• Previous mental health history (categorical variable: yes/no) 
Mental health history will be defined as having had an episode of anxiety- or depression-related disorders 
(primary outcomes) or any the secondary outcomes, ever recorded at more than 1 year before the breast 
cancer diagnosis (patients who had the outcome in the year before the breast cancer diagnosis will be 
excluded from the cohort). These will be identified based on the algorithms defined in aim 1 of this study. 
• History of stroke or coronary heart disease at diagnosis (two dichotomous variables: yes/no) 
These will include ischaemic heart disease (angina and myocardial infarction) and stroke, which are 
amongst the leading causes of disability-adjusted life years in females in the UK. These will be identified 
through Read codes recorded in the CPRD GOLD primary care database. 
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• Socioeconomic status (IMD quintiles of deprivation) 
The IMD is an ecological measure of deprivation for small areas in England (Lower Super Output Areas). It 
combines information from seven domain indices (income, employment, education, health deprivation, 
crime, barriers to housing, and living environment). The index ranks the areas from 1 to 32,844; usually the 
quintiles are used for research purposes: from 1 (most deprived) up to 5 (least deprived). The IMD is linked 
to the primary care data using the postcode of the patient or practice. 
 
Potential mediators of the association between breast cancer history and anxiety/depression 
• Sequelae from cancer treatments (six separate binary variables (yes/no): lymphoedema, pain, mild 
cognitive impairment, fatigue, sexual dysfunction, sleep disorder)  
Lymphoedema will be defined using Read codes for the condition, in the CPRD GOLD primary care 
database. Pain, mild cognitive impairment, fatigue, sexual dysfunction, and sleep disorder are secondary 
outcomes of this study, and will be identified based on the algorithms defined in aim 1 of this study. Patients 
will be classified as having had one of these conditions if there was more than one record for these 
conditions within a 6-month interval. 
• Exposed to endocrine treatment for breast cancer: binary variable (yes/no). 
This will be defined from the CPRD GOLD primary care database using Read codes for at least two 
prescriptions of anastrozole, tamoxifen, exemestane, or letrozole [43] within a 6-month period. 
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O. Data/ Statistical Analysis 
 
Primary analyses 
Specific aim 1. To develop and validate algorithms to identify patients with anxiety and depression  
 
Algorithm development  
A systematic review is currently under way to identify the lists of Read codes previously used to define anxiety and 
depression of primary care databases in the UK. The systematic review search expressions are provided in 
appendix 5. 
 
(A) Raw data tabulations 
 
We will estimate the number and proportion of patients recorded during the observation period with: 
1) Diagnostic Read code for anxiety/depression; 
2) Prescription of anxiolytics/antidepressants; 
3) Referred to mental health services; 
4) Symptoms of anxiety/depression. 
Proportions will be estimated by calendar year. 
 
(B) Simpler algorithm 
We will estimate the additional contribution of prescriptions, referrals and symptoms to identify cases of 
anxiety/depression in CPRD. Referrals and prescriptions of anxiolytics/antidepressants will be considered as 
sufficient to identify cases of anxiety/depression if a Read code for symptoms of anxiety/depression, respectively, 
were recorded during the previous year. The reasons for this are threefold: (1) there is good evidence that GPs 
switched from anxiety/depression diagnostic codes to symptomatic ones [44, 45], following claims of over diagnosis 
of these conditions; (2) antidepressants and anxiolytics have also other indications, including anxiety disorders for 
antidepressants [46], which raise questions of the use of these data their own to identify these outcomes; (3) 
pharmacological treatment of mild depression has been discouraged since 2004 [47], and thus referrals to 
psychotherapy may help to capture milder cases. 
 
(C)  Complex algorithm 
A more detailed algorithm will be developed considering that some drugs are prescribed for both depression and 
anxiety, in addition to manage vasomotor symptoms, which may be more frequent in breast cancer survivors than in 
women who did not have cancer. An example for depression is given in appendix 6. We will estimate the number of 
patients with anxiety/depression at each step, to evaluate how much each category adds to what has been 
previously recorded. 
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Algorithm validation  
A random sample of 1 million patients of both sexes will be selected from the CPRD GOLD primary care database. 
We will apply each algorithm and produce descriptive statistics stratified by likelihood of having the outcome, 
including: 
- Number and proportion of patients with the anxiety, depression or both, by 3-year calendar period; 
- Number and proportion of patients with the anxiety, depression or both, by 3-year calendar period, age and 
sex; 
- Number and proportion of patients with the anxiety and depression by 3-year calendar period and country 
in the UK. 
For each outcome, we will compare the estimates obtained with others obtained from the literature, prioritising 
national surveys of population-based data such as the following: 
- Adult Psychiatric Morbidity Survey 2007 [48] and 2014 [49];  
- Measuring National Well-being programme, made available by the Office for National Statistics (includes 
prevalence of those in the UK with some evidence indicating depression or anxiety, since 2013, by country 
in the UK and English regions, and by 10-year age groups up to 75 years) [50]. 
The final algorithm will be chosen by considering information in the numeric value closer to the estimates obtained 
from the literature. 
 
Sensitivity analysis 
Proportion estimates considering the presence of symptomatic codes within the previous year will be re-calculated 
to consider shorter periods of time (i.e. 3 and 6 months).  
 
Specific aim 2. Risk of mental health outcomes in women who had breast cancer compared to women who 
did not have cancer 
 
Primary outcomes analysis – depression and anxiety 
Main analysis 
Descriptive statistics including number of events observed and person-years at risk will be computed, overall and 
stratified by the covariates listed in section M (see above). Medical procedures for the diagnosis of breast cancer 
are likely to cause anxiety. To deal with this we planned to exclude patients who had a record of anxiety diagnosed 
within 1 year before the breast cancer; this could result in patients with higher levels of trait anxiety being excluded 
from the analysis. We will calculate the number and proportion of patients who were excluded because they had the 
outcome in the year prior to the breast cancer, stratified by month. We will also describe how many of those who 
were excluded from analysis had an outcome after the breast cancer diagnosis by age-group. The quintiles of the 
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distribution of the number of consultations (defined using the ‘consid’ variable) will be described, as this can indicate 
the patterns of seeking care between women with a history of cancer, compared to those who did not.  
The association between breast cancer history and anxiety and breast cancer history and depression, will be 
quantified using Cox regression models with time since index as the underlying time scale, and stratifying on 
matched set to account for matching by age and primary care practice. Follow up will begin at the index date (vide 
section M for definition of the exposure) and will terminate when an outcome is observed. Women will be censored 
at the earliest date of any of these: cancer recurrence, other cancer diagnosis, death, transference out of the 
practice; if these events don’t occur, censoring will be observed at the date of last data collection for the practice. 
Crude measures of the association between breast cancer history and anxiety and depression will be reported 
stratifying by the covariates described in section M. 
 
Cox multivariate regression analysis will be use to estimate hazard ratios adjusted for calendar period of breast 
cancer diagnosis, menopausal status, and diabetes mellitus at baseline (see list of confounders in section L, 
covariates, for the definition of these variables). 
Interaction terms between the exposure and the following variables will be added, to explore effect modification by 
ethnicity (White, South Asian, Black, Others and mixed), place of residence (care home vs. household), co-
habitation status (living alone vs. cohabiting), SES (quintiles of IMD), having mental health disorders history (yes vs. 
no), having history of stroke (yes vs. no) and coronary heart disease (yes vs. no). 
Confidence intervals will be calculated using robust estimates of the standard errors, to account for the fact that 
patients may also contribute with time at risk in the unexposed cohort prior to their cancer diagnosis. 
The proportional hazards assumption will be tested in two ways: 1) graphically, by plotting the cumulative rates on a 
log scale; 2) inferentially, by applying a likelihood ratio test to the estimates obtained for the entire period of 
observation and for time split into intervals. 
 
Sensitivity analyses 
Sensitivity analyses planned for this study will include a subset of patients only; this is because they use variables 
from linked data, which is available for a fraction of the patients only, and include variables amenable to have 
missing data (i.e. BMI, alcohol intake, smoking and patient-level IMD). Regarding the latter, we will quantify the 
completeness of each variable to decide on their inclusion in the final models. Analyses including variables with 
missing data will be restricted to patients with complete data for covariates (complete case analysis), if missing data 
is likely to be missing not a random. The following sensitivity analyses are planned: 
1) The main analysis will be repeated further adjusting for age at diagnosis (continuous variable, since matching 
allowed for 3-year gap), patient quintile level of IMD, alcohol drinking patterns prior to index date, smoking 
history and body mass index categories prior to index date. 
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2) We will exclude women diagnosed with the outcome of interest in the year prior to the cancer diagnosis. To  
account for the fact that treatment for these conditions may often last for more than one year, and that mild 
anxiety and depression may be treated in psychological services and not result in visits to the GP, we will 
repeated the main analysis including only patients who had 5 years of complete follow up prior to the index 
date and did not have the outcome recorded at any point during this period.  
 
Multiple comparisons 
We acknowledge that this study includes multiple comparisons for each outcome, and several outcomes. Thus, P-
values in the range ~0.01-0.05 be considered as some statistical evidence of an effect and interpreted cautiously. 
Sample size considerations considering a 0.01 probability of type I error (α) are provided in see section I. 
 
Specific aim 3. To estimate association between breast cancer history and anxiety/depression by presence 
of lymphoedema, pain, mild cognitive impairment, fatigue, sexual dysfunction, sleep disorders, and having 
done endocrine therapy, during the follow up period. 
 
We will estimate the cumulative incidence and period prevalence of lymphoedema, pain, mild cognitive impairment, 
fatigue, sexual dysfunction, and sleep disorders, in breast cancer survivors during the overall follow up period and 
by 5-year of follow up period. 
We will estimate the hazards of developing anxiety and depression (the main outcomes) for three groups of 
patients: 1) breast cancer survivors who did not develop the common complication (i.e. lymphoedema, pain, mild 
cognitive impairment, fatigue, sexual dysfunction, sleep disorders) up to time t; 2) breast cancer survivors who have 
had the common complication at time t; 3) women who never had cancer. A Cox regression model will be used to 
estimate the association between time-updated exposure and the main outcomes (anxiety and depression), having 
as reference the hazard observed for the women who did not have cancer. The exposure variable will be time-
updated; this means that women who develop a common complication will contribute with information to group 1 
until the date at which they develop the complication of interest; after this point they will contribute with information 
to group 2. All models will be adjusted for calendar period of breast cancer diagnosis. 
Confidence intervals will be calculated using robust estimates of the standard errors. Sensitivity analyses planned in 
objective 2 will be applied to this objective as well.  
 
Secondary outcomes analyses – fatigue, mild cognitive impairment, pain, sleep disturbance, sexual 
dysfunction, fatal and non-fatal self-harm 
The steps outlined above will be repeated for the secondary outcomes. Sensitivity analysis will follow the same 
rationale as described for the primary analysis. 
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P. Plan for addressing confounding 
 
The confounding effect of age and socio-economic status (SES) will be limited at the study design phase, as 
women who had breast cancer will be individually matched to women who never had cancer by age and primary 
care practice. Variables considered as important confounders will be included in the multivariate Cox regression 
models (vide section M, covariates). 
 
Q. Plans for addressing missing data 
 
There are no plans for using multiple imputation methods in this study. Three variables in the main analysis are 
likely to have missing data: body mass index, smoking and alcohol intake. The probability of these values being 
recorded in the patients’ medical records is likely to depend on the actual value (e.g. obese patients may have their 
weight more often assessed and smoking may be more often recorded in patients who visit the GP for 
complications of smoking (e.g. chronic obstructive pulmonary disease). This is a direct violation of the missing at 
random assumption needed for multiple imputation. We will therefore conduct a complete case analysis, which is a 
valid method when missingness is conditionally independent of the outcome [52]. 
 
R. Patient or user group involvement (if applicable) 
 
Patients with history of breast cancer involved with the Independent Cancer Patients’ Voice, a breast cancer 
support charity, commented on the study protocol.  
 
S. Plans for disseminating and communicating study results, including the presence or absence of any 
restrictions on the extent and timing of publication 
 
The results of this study will be presented at scientific conferences in the area, and submitted for publication in 
peer-reviewed journals. 
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related to this work. Dr. Bhaskaran reports grants from Wellcome Trust, the Royal Society, Medical Research 
Council, and British Heart Foundation, outside the submitted work. 
 
459
                                             
 ISAC Protocol Application Form September 2018 19 
T. Limitations of the study design, data sources, and analytic methods 
 
Validity of the mental health diagnosis in the CPRD GOLD primary care database 
The validity and the completeness of the recording of the mental disorders in CPRD have not been evaluated, and 
this will limit our results. The diagnosis and treatment of depression has also changed over time, as a result of the 
2004 NICE guidelines (discouraging the treatment of mild depression with antidepressants) and the Quality and 
Outcomes Framework scheme in 2006, which recommended validated questionnaires to evaluate its severity [8, 9]. 
As for completeness, mental disorders such as depression and anxiety are managed at the primary care level, and 
therefore the potential for recording is high. Nevertheless, some of these conditions, especially in the sub-threshold 
or milder severities, may not result in GP visits and go therefore undiagnosed [10]. 
 
Unmeasured and residual confounding 
This study is also limited by the lack of historical data on potential confounders, such as physical activity. Residual 
confounding will not be possible to rule out for variables such as smoking [53]. 
 
Multiple indications of the psychotropic medicines (complex algorithm definition) 
In clinical practice, several classes of pharmacological agents are currently used to manage anxiety and depressive 
disorders, and many of these pharmacological agents are used to treat other physical and mental disorders 
(appendix 7). An example of this is illustrated by the guidelines. The National Institute for Health and Care 
Excellence (NICE) issued guidelines for recognition and management of depression in people who have a physical 
chronic condition such as cancer [54], and for management of generalized anxiety disorder (GAD) and panic 
disorder [46]. Low- or high-intensity psychological interventions (e.g. low intensity: individual non-facilitated or 
guided self-help; high intensity: cognitive behavioural therapy) are recommended as the first line for GAD, mild 
depression and long-term insomnia (>4 weeks) [46]. Pharmacological treatment is recommended for persisting 
GAD, moderate to severe depression and insomnia that causes severe daytime dysfunction. SSRI are currently 
recommended for GAD; benzodiazepines are most often restricted to crisis and not recommended for long-term use 
[46]. This will raise issues on the indication under which the patient has been prescribed the medicine. We will 
select all pharmacological agents used to treat each of the outcomes, and seek experts’ advice on which drugs are 
often prescribed. In any case, this offers a potential for misclassification (thought to be non-differential). 
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Methods1 Definition of outcomes 
 
Search and selection of Read codes and pharmacological drugs 
We searched the dictionary of codes using keywords defined by a general practitioner experienced in 
using the codes in clinical practice (GF). We then identified the relevant parent code for the outcome, 
and included all Read codes within that group. Finally, we added all codes identified in a 
comprehensive systematic review of the lists of Read codes used to identify mental health and quality 
of life outcomes in primary care databases of electronic health records in the UK (Carreira et al, BMJ 
Open, 2019). Two researchers (HC and GF) independently assigned each Read code to a certainty 
group, compared and agreed the final list of codes (available online). 
Drugs for anxiety, depression, sleep disorders and pain were identified in product dictionary by 
searching formulations listed in the British National Formulary (BNF) as indicated to treat these 
conditions. The final list of products was checked for suitability by a GP (GF) and irrelevant products 
were excluded (e.g. doxepin topical). 
 
 
Primary outcomes 
 
Anxiety 
Anxiety was defined with Read codes, if the Read code was considered sufficiently specific. When the 
Read code referred to typical symptoms of anxiety, which are not necessarily pathological, we 
considered the patient to have anxiety only if they had been prescribed with a drug with anxiety within 
90 days of the Read code. 
Read codes for the following conditions were included/excluded from our definition: 
Included Excluded 
Generalised anxiety disorder Specific phobias (e.g. heights) 
Panic disorder Somatic symptoms disorder 
Agoraphobia  
Social anxiety disorder  
Mixed anxiety and depression  
Obsessive compulsive disorders *  
Trauma- and stress-related disorders* with anxiety, 
including PTSD, acute stress disorder, and adjustment 
disorder with anxiety 
 
N.B. ‘Included’ and ‘Excluded’ refer to symptoms and diagnoses of the conditions listed. 
* In DSM-5, published in 2013, obsessive-compulsive and stress-related disorders are classified separately from 
anxiety disorders. This was a major change from previous editions of the DSM, in which these two categories 
were considered as anxiety disorders. The data for this study refer to patients under observation during 1988 and 
2018 (or part of this period); it is unclear how, or if, the changes in nosology affected the use of Read codes by 
GPs at the point of patient care. In addition, the accuracy of the Read codes to identify each of the sub conditions 
is likely to be sub-optimal at any given point in time. For these reasons, we decided to include OCDs and stress-
related disorders in our definition of anxiety. See below, in the depression section, a note about adjustment 
disorders with anxiety. 
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Drugs indicated to treat anxiety according to the British National Formulary: 
Substance name 
Alprazolam 
Amitriptyline hydrochloride/ Chlordiazepoxide 
Buspirone hydrochloride 
Chlordiazepoxide hydrochloride 
Diazepam 
Duloxetine hydrochloride 
Escitalopram oxalate 
Lorazepam 
Meprobamate 
Moclobemide 
Oxazepam 
Oxprenolol hydrochloride 
Paroxetine hydrochloride 
Pericyazine 
Perphenazine 
Pregabalin 
Trazodone hydrochloride 
Venlafaxine hydrochloride 
 
 
International Classification of Diseases, 10th revision, codes for anxiety: 
ICD-10 codes Description 
     F40 1. Phobic anxiety disorders 
     F41 2. Other anxiety disorders 
     F42 3. Obsessive-compulsive disorder 
     F43 4. Reaction to severe stress, and adjustment disorders 
     F44 5. Dissociative [conversion] disorders 
     F48 6. Other neurotic disorders 
 
 
Definition used in sensitivity analysis including specific diagnoses: 
Included (Read codes for diagnoses only) Excluded 
Panic disorder All symptom codes (e.g. ‘anxious’) 
Generalized anxiety disorder  
Mixed anxiety and depression  
Obsessive-compulsive disorder  
Acute stress disorder  
Post-traumatic stress disorder  
Anxiety disorder, NOS  
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Depression 
We used Read codes alone to classify patients with depression, if the Read code was considered 
sufficiently specific. When the Read code referred to typical symptoms of depression that could not be 
sufficient to classify as a depressive episode, we checked whether there as a prescription of a drug 
commonly used to depression within 90 days, and considered patients to be depressed if yes. 
Read codes for the following conditions were included/excluded from our definition: 
Included Excluded 
Major depressive disorder Bipolar and related disorders (incl. bipolar I, II 
and cyclothymic disorder) 
Dysthymia Premenstrual dysphoric disorder 
Recurrent depressive disorder Suicide † 
Mixed anxiety and depression Self-harm † 
Disruptive mood dysregulation disorder Maternal depression 
Depression in dementia (or other condition)  
Trauma- and stress-related disorders* with 
depressed mood, including adjustment 
disorders with depressed mood* 
 
N.B. ‘Included’ and ‘Excluded’ refer to symptoms and diagnoses of the conditions listed.  
* See note on anxiety table. Adjustment disorders are considered to be a short-term reaction to a stressor (i.e. 
diagnosed usually within 3 months of the onset of the stressor). The core symptoms of adjustment disorders 
overlap with those of the anxiety and depressive disorders, which would be diagnosed if the symptoms persist for 
longer than a 6-month period after the terminus of the stressor. The potential for misclassification between 
adjustment and depressive disorders is high, as they share the same symptomatology and treatment. The data 
for this study will include patients recently diagnosed with breast cancer (included in the cohort in the day of the 
cancer recording in the CPRD GOLD primary care database). To avoid misclassification of the outcome, we 
included adjustment disorders in our definitions of anxiety and depression. 
† Self-harm and suicide most often occur in patients with a depressive disorder. We will examine these two 
outcomes separately.  
 
 
Drugs indicated to treat depression according to the British National Formulary: 
Substance name 
Agomelatine 
Amitriptyline Hydrochloride 
Amitriptyline Hydrochloride/ Perphenazine 
Citalopram hydrobromide 
Citalopram hydrochloride 
Clomipramine hydrochloride 
Dosulepin hydrochloride 
Dosulepin Hydrochloride 
Duloxetine hydrochloride 
Escitalopram oxalate 
Fluoxetine hydrochloride 
Fluvoxamine maleate 
Imipramine hydrochloride 
Isocarboxazid 
Lofepramine hydrochloride 
Mianserin hydrochloride 
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Substance name 
Mirtazapine 
Moclobemide 
Nortriptyline hydrochloride 
Nortriptyline Hydrochloride 
Paroxetine hydrochloride 
Phenelzine sulfate 
Reboxetine mesilate 
Sertraline 
Sertraline hydrochloride 
Tranylcypromine sulfate 
Trazodone Hydrochloride 
Trimipramine maleate 
Venlafaxine hydrochloride 
Venlafaxine Hydrochloride 
Vortioxetine hydrobromide 
 
 
International Classification of Diseases, 10th revision codes for depression: 
ICD-10 codes Description 
     F32 7. Depressive episode 
     F33 8. Recurrent depressive disorder 
     F34 9. Persistent mood [affective] disorders 
     F41.2 10. Mixed anxiety and depressive disorder 
     F92.0 11. Depressive conduct disorder 
 
 
Definition used in sensitivity analysis including specific diagnoses: 
Included (Read codes for diagnoses only) Excluded 
Depressive episode All symptom codes (e.g. ‘depressed’) 
Major depression  
Seasonal affective disorder  
Dysthymia  
Mixed anxiety and depression  
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Secondary outcomes 
 
Cognitive dysfunction  
Cognitive dysfunction was defined by Read codes for impairments in domain of cognitive function 
(e.g. ‘amnesia symptom’, ‘orientation confused’), or Read codes related to cognitive assessments 
(e.g. ‘mini-mental state examination’, ‘unable to remember own date of birth’), Read codes for 
dementia and drugs commonly used to treat dementia. 
We used a broad definition of cognitive dysfunction because we were interested in mild cognitive 
dysfunction, which is often reported by women with history of breast cancer after diagnosis and 
treatment. However, changes to cognitive dysfunction, especially those in older adults, may not lead 
to primary care until it becomes troublesome for the patient or their family. At this point, the patient 
may be diagnosed with more severe levels of cognitive dysfunction, and we would not be able to 
identify an outcome of ‘mild cognitive dysfunction’ in the CPRD primary care database. As loss of 
cognitive function is a gradual process, we defined cognitive dysfunction using codes that ranged 
from mild cognitive dysfunction to dementia. We also included codes for scales/tests because we 
assumed that patients who have had a cognitive assessment registered by their GP might have 
relevant cognitive complains. Drugs were considered sufficient to ascertain the outcome because 
these are very specific to dementia. 
 
Read codes for the following conditions were included/excluded from our definition: 
Included Excluded 
Mild cognitive impairment Delirium 
Alzheimer’s disease Dementia in Creutzfeldt-Jakob disease † 
Vascular dementia Dementia in Huntington's disease † 
Frontotemporal dementia Dementia in Parkinson's disease † 
Dementia in Pick's disease Dementia in human immunodeficiency virus [HIV] disease † 
Unspecified dementia Normal pressure hydrocephalus † 
† We excluded dementia with well-described cause, which is unlikely to be associated with a cancer history. 
 
Drugs indicated to treat dementia according to the British National Formulary: 
Substance name 
Donepezil hydrochloride 
Galantamine hydrobromide 
Memantine hydrochloride 
 
International Classification of Diseases, 10th revision codes for dementia: 
ICD-10 codes Description 
     F00 Dementia in Alzheimer disease 
     F01 Vascular dementia 
     F02.0 Dementia in Pick disease 
     F03 Unspecified dementia 
     F06.7 Mild cognitive disorder 
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Fatigue 
Patients were classified as having had fatigue using Read codes (list of Read codes available online). 
We included/excluded the following conditions in our definition of fatigue: 
 
Included Excluded 
Chronic fatigue syndrome/ myalgic encephalitis Combat fatigue 
Neurasthenia Fatigue in pregnancy 
Post viral fatigue syndrome * Fibromyalgia † 
 
N.B. ‘Included’ and ‘Excluded’ refer to symptoms and diagnoses of the conditions listed. We included symptoms 
such as ‘tired all the time’ because GPs may be less likely to diagnose chronic fatigue syndrome if symptoms can 
be attributed to the breast cancer treatments.  
* Post-viral fatigue syndrome our definition of fatigue because there is a high potential for misclassification of 
these outcomes at primary care level, as viral infections are common. 
† Studies have shown a considerable overlap between fatigue and fibromyalgia, with at least 75% of the patients 
diagnosed with fibromyalgia report fatigue (Clin Rev Allergy Immunol. 2015 Oct;49(2):100-51). We expect these 
patients to be captured by the terms for fatigue defined in the conditions of interest for this study. 
 
 
Pain  
Pain was defined using Read codes for pain of specific regions of the body (e.g. chest pain), and of 
known conditions that may be caused by treatments (e.g. arthralgia in patients who are treated with 
hormone therapy, or post-surgical pain), unspecified pain (e.g. pain symptom). Pain syndromes (e.g. 
fibromyalgia) were included. Read codes for pain scales were also considered as evidence of pain, as 
we assumed that this would not be offered to the patient if s/he did not complain of pain. Codes for 
rheumatoid arthritis and arthroses were excluded, as well as codes for fractures. We also excluded 
codes for pain of known aetiology that is unlikely to be related to breast cancer treatments (e.g. post-
herpetic pain, diabetic neuropathic pain, menstrual pain, fractures, accidents, etc.). 
 
 
Opioid analgesics 
All opioid analgesics listed in the British National Formulary were considered eligible. We did not 
include codes for treatment of opioid dependency. 
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Sleep disorder 
Sleep disorder was defined with Read codes, if the Read code was considered sufficiently specific. 
When the Read code referred to symptoms or possible treatment of sleep disorder (e.g. ‘poor sleep 
pattern’, ‘sleep hygiene behaviour education’), we considered the patient to have a sleep disorder 
only if they had been prescribed with an anxiolytic/hypnotic (table below) within 90 days of the code. 
 
Read codes for the following conditions were included/excluded from our definition: 
Included Excluded 
Insomnia Narcolepsy 
Hypersomnia  Breathing-related disorders (including sleep apnoea) 
Circadian rhythm sleep-wake disorders Cataplexy 
Parasomnias  
N.B. ‘Included’ and ‘Excluded’ refer to symptoms and diagnoses of the conditions listed.  
 
 
Drugs indicated to treat sleep disorders according to the British National Formulary: 
Substance name 
Temazepam 
Nitrazepam 
Diazepam 
Zopiclone 
Clomethiazole 
Promethazine hydrochloride 
Promethazine teoclate 
Zolpidem tartrate 
Codeine phosphate/promethazine hydrochloride 
Clomethiazole edisilate 
Flunitrazepam 
Flurazepam hydrochloride 
Lormetazepam 
Oxazepam 
Promethazine hydrochloride/paracetamol 
Loprazolam mesilate 
Melatonin 
Promethazine hydrochloride/pholcodine 
Pethidine hydrochloride/promethazine hydrochloride 
Paracetamol/promethazine hydrochloride/ dextromethorphan hydrobromide 
Dextromethorphan hydrobromide/promethazine hydrochloride/ paracetamol 
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Female sexual dysfunction 
We included only Read codes in our definition of sexual dysfunction. We included Read codes for 
scales of sexual function (e.g. Derogatis Sexual Dysfunction Inventory) because the patient is likely to 
have had subjective complains of sexual function in order for the GP to apply the test. 
 
We considered the follow clinical disorders as relevant outcomes:  
Included Excluded 
Female orgasmic disorder Paraphilia 
Female arousal disorder Excess sex drive 
Dyspareunia Sexual orientation related codes 
 
We acknowledge that codes for improved sexual function are likely to indicate that a disorder has 
been present; these were nevertheless excluded as the date of the disorder cannot be ascertained. 
In addition, prescriptions for sexual dysfunction are not likely to capture accurately the disorder, as it 
may include lubricants that are often sold over the counter, or creams containing oestrogen that may 
be under prescribed to breast cancer survivors due to concerns related with oestrogen positive 
receptor tumours. 
 
Fatal and non-fatal self-harm 
Fatal and non-fatal self-harm included codes for intentional self-harm and suicidal ideation, using an 
updated version of a previously validated list of Read codes (Br J Clin Pharmacol 2013; 76(1): 145-
57), and International Classification of Diseases, tenth revision, (ICD-10) codes for completed suicide. 
Completed suicide was defined using the ICD-10 codes X60-X84 and Y10-34, excluding Y33.9 where 
the verdict is pending. 
 
International Classification of Diseases, 10th revision codes for self-harm: 
ICD-10 codes Description 
     X60-X84 Intentional self-harm 
     Y10-Y34 Event of undetermined intent 
     Y87.0 Sequelae of intentional self-harm 
     Y87.2 Sequelae of events of undetermined intent 
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Methods2 Definition of covariates 
 
Alcohol and smoking status  
Information on alcohol drinking and smoking status was obtained from primary care records, and 
patients were assigned into the following categories for each variable: non-users, current users, and 
former users. For these three variables, we prioritised information registered in the year prior to the 
index date, or up to 30 days after the index date; where this was unavailable we used information 
recorded at any point prior to the index date, and if still missing, we used information recorded at any 
point in the clinical record. 
Body mass index 
Body mass index (BMI) (kg/m2) was computed as weight divided by the square of height, using a 
previously defined algorithm to ascertain this information from the clinical records (BMJ Open 2013; 
3(9): e003389). Patients were classified in BMI categories, according to the World Health 
Organization proposed cut-offs for Caucasian populations.  
Cardiovascular comorbidity 
Cardiovascular comorbidity was defined as having a record of stroke or ischaemic heart disease 
(angina and coronary heart disease) before the study index date, or up to 30 days after the index 
date. 
Deprivation 
Deprivation was defined by quintiles of the practice-postcode linked Index of Multiple Deprivation 
(IMD), which is an ecological measure of deprivation for small areas in England (Lower Super Output 
Areas). For a subset of patients, patient-postcode linked quintile of IMD was available.  
Diabetes mellitus 
Diabetes mellitus was defined as having had a Read code for type I or type II diabetes mellitus 
recorded up to 30 days after the index date (assuming that any event recorded within the first month 
would be prevalent).  
Ethnicity 
Ethnicity (White, South Asian, Black, Others and mixed) was defined in accordance with previously 
defined algorithms (J Public Health (Oxf) 2014; 36(4): 684-92). 
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Table 1(A) Characteristics of the patients excluded from analysis, and follow up time for anxiety, depression and cognitive dysfunction. 
 
 Anxiety  Depression  Cognitive dysfunction 
 Unexposed  Exposed  Unexposed  Exposed  Unexposed  Exposed 
Patients eligible for analysis, N (%) 230,067 (100.00)  57,571 (100.00)  230,067 (100.00)  57,571 (100.00)  230,067 (100.00)  57,571 (100.00) 
                  
Exclusions from outcome-specific analysis, N (%) 5,929 (2.58) 
 
1,955 (3.40) 
 
13,712 (5.96) 
 
3,498 (6.08)  5,623 (2.44) 
 
1,519 (2.64) 
 
Patients excluded who had the outcome recorded 
after the index date, N (%) 
2,707 (45.7) 
 
896 (45.8) 
 
8,511 (62.1) 
 
2,175 (62.2)  - - 
 
- - 
 
Mean time (SD) between the mental health 
outcome diagnosis and the index date, days 
214 (109) 
 
218 (110) 
 
212 (109) 
 
214 (110)  - - 
 
- - 
 
Age at index date (years) 
           
 
     
 
    Mean (SD) 60 (14) 
 
60 (13) 
 
61 (14) 
 
61 (14)  74 (13.12) 
 
74 (13.30) 
 
    Minimum-maximum 21-101 
 
24-102 
 
19-101 
 
22-101  28-103 
 
29-101 
             
Total number of patients included in analysis (%) 224,138  (97.42)   55,616  (96.60)    216,355  (94.04)    54,073  (93.92)   224,444 (97.56)    56,052    (97.36)  
Total number of person-years at risk 1,306,784 
 
288,115 
 
1,202,647 
 
261,081    1,385,179 
 
315,453 
Duration of follow up (years)                                    
  Mean (SD) 5.83 (4.79)   5.18 (4.57)   5.56 (4.74)   4.83 (4.48)  6.17 (4.94)  5.63 (4.71) 
  Median 4.61     3.89     4.26     3.44    5.00 
 
 4.38 
 
Outcomes during follow-up, N 20,224  5,888  34,558  10,175  19,845  4,368 
SD: standard deviation.
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Table 1(B) Characteristics of the patients excluded from analysis, and follow up time for fatigue, sexual dysfunction and sleep disorders. 
 
 Fatigue  Sexual dysfunction  Sleep disorder 
 Unexposed  Exposed  Unexposed  Exposed  Unexposed  Exposed 
Patients eligible for analysis, N (%) 230,067 (100.00)  57,571 (100.00)  230,067 (100.00)  57,571 (100.00)  230,067 (100.00)  57,571 (100.00) 
                  
Exclusions from outcome-specific analysis, N (%) 6,561 (2.85) 
 
1,660 (2.88) 
 
490 (0.21) 
 
127 (0.22)  4,484 (1.95) 
 
1,361 (2.36) 
 
Patients excluded who had the outcome recorded 
after the index date, N (%) 
2,409 (36.7) 
 
609 (36.7) 
 
87 (17.8) 
 
12 (9.5)  1,822 (40.6) 
 
622 (45.7) 
 
Mean time (SD) between the mental health 
outcome diagnosis and the index date, days 
208 (110) 
 
211 (107) 
 
203 (111) 
 
202 (106)  206 (106) 
 
215 (106) 
 
Age at index date (years) 
           
 
     
 
    Mean (SD) 62 (14) 
 
63 (14) 
 
53 (9) 
 
51 (10)  67 (15) 
 
65 (15) 
 
    Minimum-maximum 19-101 
 
26-103 
 
21-92 
 
21-77  21-99 
 
19-101 
             
Total number of patients included in analysis (%) 223,506  (97.10)   55,911  (97.10)    229,577  (99.8)    57,444  (99.8)   225,583 (98.10)    56,210    (97.60)  
Total number of person-years at risk 1,266,975 
 
280,982 
 
1,435,837 
 
325,393  1,338,065 
 
290,786 
Duration of follow up (years)                                    
  Mean (SD) 5.67 (4.73)   5.03 (4.48)   6.25 (4.98)   5.66 (4.75)  5.93 (4.85)  5.17 (4.60) 
  Median 4.44     3.69     5.09     4.40    4.71 
 
 3.86 
 
Outcomes during follow-up, N 28,886  8,359  2,153  683  16,798  6,002 
SD: standard deviation. 
474
 34 
Table 1(C) Characteristics of the patients excluded from analysis, and follow up time for pain, opioid analgesics, and fatal/non-fatal self-harm. 
 
 Pain  Opioids analgesics  Fatal and non-fatal self-harm 
 Unexposed  Exposed  Unexposed  Exposed  Unexposed  Exposed 
Patients eligible for analysis, N (%) 230,067 (100.00)  57,571 (100.00)  230,067 (100.00)  57,571 (100.00)  132,647 (100.00)  33,168 (100.00) 
                  
Exclusions from outcome-specific analysis, N (%) 68,030 (29.57) 
 
18,800 (32.66) 
 
16,877 (7.34) 
 
4,899 (8.51)  315 (0.24) 
 
63 (0.19) 
 
Patients excluded who had the outcome recorded 
after the index date, N (%) 
54,493 (80.10) 
 
14867 (79.08) 
 
12,547 (74.3) 
 
3,855 (78.69)  80 (25.4) 
 
14 (22.2) 
 
Mean time (SD) between the mental health 
outcome diagnosis and the index date, days 
215 (107.80) 
 
214 (109.78) 
 
217 (108) 
 
215 (111)  229 (110) 
 
218 (110) 
 
Age at index date (years) 
           
 
     
 
    Mean (SD) 63 (14) 
 
63 (14) 
 
66 (14) 
 
67 (13)  54 (13) 
 
52 (17) 
 
    Minimum-maximum 19-102 
 
19-103 
 
27-91 
 
25-91  30-102 
 
25-91 
             
Total number of patients included in analysis (%) 162,037  (70.43)   38,771  (67.34)    213,190  (92.7)    52,672  (91.5)   132,332 (99.8)    33,105    (99.8)  
Total number of person-years at risk 505,451 
 
100,312 
 
1,181,155 
 
248,654  831,516 
 
190,182 
Duration of follow up (years)                                    
  Mean (SD) 3.12 (3.30)   2.59 (2.88)   5.54 (4.70)   4.72 (4.49)  6.28 (4.98)  5.74 (4.76) 
  Median 1.99     1.59     4.27     3.36    5.13 
 
 4.50 
 
Outcomes during follow-up, N 94,171  24,522  44,850  17,315  794  182 
SD: standard deviation.
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Table 2 Incidence of adverse mental health-related outcomes in breast cancer survivors and women who did not have cancer. 
 
  Women with no history of cancer   Women with history of breast cancer 
  1 year   5 years   10 years   1 year   5 years   10 years 
  % 95%CI   % 95%CI   % 95%CI   % 95%CI   % 95%CI   % 95%CI 
Anxiety 2.0 1.9 - 2.1   8.2 8.1 - 8.4   13.8 13.6 - 14.0   3.9 3.8 - 4.1   10.6 10.3 - 10.9   16.4 15.9 - 16.8 
Depression 4.0 3.9 - 4.0   14.8 14.6 - 15.0   24.0 23.7 - 24.3   7.1 6.9 - 7.3   19.4 19.0 - 19.8   28.5 28.0 - 29.1 
Cognitive 
dysfunction 
1.1 1.1 - 1.2   5.8 5.7 - 5.9   13.2 12.9 - 13.4   1.0 0.9 - 1.1   5.7 5.4 - 5.9   13.1 12.7 - 13.6 
Fatigue 2.7 2.6 - 2.8   11.4 11.3 - 11.6   19.9 19.7 - 20.2   4.0 3.8 - 4.1   15.2 14.8 - 15.5   23.9 23.4 - 24.5 
Pain 22.1 21.9 - 22.4   61.0 60.7 - 61.3   79.1 78.8 - 79.4   27.0 26.6 - 27.5   69.7 69.2 - 70.3   85.6 85.1 - 86.2 
Sexual 
dysfunction 
0.2 0.2 - 0.2   0.8 0.8 - 0.9   1.5 1.4 - 1.5   0.2 0.2 - 0.3   1.2 1.1 - 1.4   2.0 1.8 - 2.1 
Sleep disorder 1.6 1.5 - 1.6   6.6 6.5 - 6.8   11.6 11.4 - 11.7   4.7 4.6 - 4.9   10.8 10.5 - 11.1   16.0 15.5 - 16.4 
Opioid 
analgesics 
4.2 4.1 - 4.3   17.7 17.5 - 17.9   31.1 30.8 - 31.3   12.2 12.0 - 12.5   30.8 30.3 - 31.2   45.5 44.9 - 46.1 
Fatal and non-
fatal self-harm 
0.1 0.1 - 0.1   0.5 0.5 - 0.6   0.9 0.8 - 1.0   0.1 0.1 - 0.2   0.5 0.5 - 0.6   0.9 0.8 - 1.0 
95%CI: 95% confidence interval. 
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Summary 
 
We aim to assess the quality of life (QoL), and presence and severity of anxiety and 
depressive symptoms, in women who have had breast cancer diagnosed at ≥1 year, 
compared to women who did not have cancer. 
The Clinical Practice Research Datalink (CPRD) primary care database will be used to 
select a random sample of breast cancer survivors (≥1 year), whose general practitioner 
(GP) agrees to participate in the study (see below), and who were registered with the 
practice for ≥1 year before and after the breast cancer diagnosis. Age-matched women who 
never had cancer will be randomly selected from the same practice. Staff at each practice 
will mail the study materials to the eligible women, who will complete the questionnaires and 
send those to the CPRD Intervention Studies Team for processing. 
In addition, a secondary objective of this study is to assess whether PROs can be 
reasonably studied by using electronic health records (EHR), as these would involve fewer 
resources. For this, the EHR of the participating women will be collated from the CPRD 
primary care database and the results will be compared to those reported by the patients. 
 
  
479
Study protocol: Mental health and quality of life in women who had breast cancer, v4 3 
Table of Contents 
 
Summary .............................................................................................................................. 2 
1 Background .................................................................................................................... 4 
2 Aims and objectives ........................................................................................................ 6 
3 Plan of investigation ........................................................................................................ 7 
3.1 Study type ................................................................................................................ 7 
3.2 Study site ................................................................................................................. 7 
3.3 Study design ............................................................................................................ 7 
3.4 Study population....................................................................................................... 7 
3.5 Comparison group .................................................................................................... 7 
3.6 Recruitment of the participants ................................................................................. 7 
4 Data to be collected ........................................................................................................ 9 
4.1 Health-related quality of life ...................................................................................... 9 
4.2 Anxiety and depression ............................................................................................ 9 
4.3 Clinical and socio-demographic data ........................................................................ 9 
5 Data/statistical analysis ................................................................................................. 10 
6 Plan for addressing missing data .................................................................................. 16 
7 Sample size .................................................................................................................. 17 
8 Feasibility counts .......................................................................................................... 20 
9 Pilot study ..................................................................................................................... 21 
10 Limitations of the study design, data sources and analytical methods ........................ 22 
11 Patient or user group involvement .............................................................................. 23 
12 Plans for disseminating and communicating study results .......................................... 24 
13 Timetable .................................................................................................................... 25 
14 References ................................................................................................................. 26 
15 Appendices ................................................................................................................. 30 
Appendix 1. List of read codes to identify breast cancer patients [50]. ............................. 31 
Appendix 2. Items of the Quality of Life in Adult Cancer Survivors Scale (QLACS) grouped 
by domain ....................................................................................................................... 32 
Appendix 3. Quality of Life in Adult Cancer Survivors Scale (QLACS) [36] ...................... 34 
Appendix 4. Generic domains of HRQoL [36] .................................................................. 36 
Appendix 5. Hospital Anxiety and Depression Scale [37] ................................................ 37 
Appendix 6. Clinical information ...................................................................................... 38 
Appendix 7. Demographic information ............................................................................. 39 
 
  
480
Study protocol: Mental health and quality of life in women who had breast cancer, v4 4 
1 Background 
Breast cancer is the most common malignancy diagnosed in women in the United Kingdom 
(UK), excluding non-melanoma skin cancer [1]. The five-year age-standardised net survival 
for patients diagnosed with breast cancer in 2005-09 was 81% [2]. Breast cancer survivors 
are the largest group of cancer survivors in the UK [3, 4]: approximately 570,000 women 
were estimated to be living with or beyond breast cancer in 2010; this corresponds to 1,803 
per 100,000 women [4]. The increasing trends in incidence and survival [1, 2] suggest that 
the number of breast cancer survivors will continue to increase in the next decades [4]. 
Even though women now live longer after the breast cancer diagnosis, the disease is 
perceived as life threatening and a major cause of emotional distress [5]. Common reactions 
to the diagnosis include anxiety, feelings of loneliness, fear of death, hopelessness, anger, 
suicidal thoughts and existential issues [6, 7]. In addition to the sorrow of the diagnosis, most 
women undergo a long and complex journey of aggressive treatments [8] with iatrogenic 
effects that are likely to have a long-term negative impact on their mental health and health-
related quality of life (HRQoL) [9, 10]. For example, surgery for tumour removal and lymph 
node status assessment may cause lymphoedema [11] and/or persistent pain [12], in 
addition to a life-long scar, which may change women’s body image [13]. Chemotherapy 
may result in cognitive impairments [14, 15] and/or cause amenorrhea in pre-menopausal 
women, bringing fertility concerns (for women who want children) and vasomotor symptoms 
such as hot flushes, night sweats, breast sensitivity and/or pain [16, 17]. In the long-term, 
women also have to re-adapt to social and intimate relationships (including with their spouse 
[18] and offspring [19-21]), and deal with the fear of cancer recurrence and death [22]. 
Patients often report the social, mental and cognitive functioning as important outcomes of 
their disease [23-26]. However, few studies [27, 28] focused on the mental health and 
HRQoL of large samples of cancer survivors in the UK. The Clinical Practice Research 
Datalink (CPRD) primary care database gathers data for consultations occurring in a large 
number of general practices in the UK. This database currently includes data for more than 
11.3 million patients, from over 600 general practices [29]. The cohort of cancer survivors in 
this database is one of the largest in the world with data prospectively and routinely collected 
at primary care level. As most mental disorders are also managed at primary care level [30, 
31], the CPRD primary care database offers a unique opportunity to study long-term mental 
disorders in women who have had breast cancer. The information available for some 
domains of HRQoL may also represent an opportunity to study what are normally patient 
reported outcomes at a much lower cost but there has been no study evaluating the extent 
to which EHR data can be reasonably used to study HRQoL. 
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Khan et al used the CPRD primary care data to evaluate the pattern of consultations for 
anxiety and depression in 2003-2005, as well as the prescription of antidepressants and 
anxiolytics, among 16,938 breast cancer survivors (>5 years) and 67,649 women without 
breast cancer [27]. This study showed that breast cancer survivors had significantly 
increased odds of being prescribed antidepressants and anxiolytics but not of consulting for 
anxiety or depression, compared to women who did not have breast cancer [27]. The 
interpretation of these results is not straightforward because: 1) patients consulting for 
anxiety or depression are likely to represent the most severe cases, as these disorders, 
especially in the sub-threshold or milder severities, are often undiagnosed [31] and their 
burden underestimated; 2) cancer survivors may have more contact with the health services 
and be therefore more likely to be diagnosed and/or treated for anxiety or depressive 
symptoms, compared to women who did not have breast cancer; 3) antidepressants may 
also be prescribed to breast cancer survivors as treatment for hot flushes [32], one of the 
commonest side effects of endocrine treatments [33], and it is unclear if the frequency of 
prescription of antidepressants for hot flushes differs between women who have had breast 
cancer and women who never had cancer. Considering this, it is unclear how well the data 
registered in the EHR represent the burden of anxiety and depressive conditions in the 
population. In addition, a population-based cohort study conducted in Denmark described a 
significantly increased risk of depression in the first years after diagnosis, whose magnitude 
and significance reduced over time [34]. Corresponding estimates for the five years after the 
diagnosis are not available in the UK. 
The aim of this study is to investigate the HRQoL, and the presence and severity of anxiety 
and depressive symptoms, in breast cancer survivors (>1 year) and in women who did not 
have cancer. A secondary objective of this study is to compare the outcomes reported by the 
patients to the data available in the EHR. In doing so, we will assess the feasibility of using 
EHR to study outcomes that are usually reported directly by patients.   
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2 Aims and objectives 
 
Aims 
The primary aim of this study is to investigate the health-related quality of life (HRQoL), and 
the presence and severity of anxiety and depressive symptoms, in female breast cancer 
survivors (>1 year) compared to women who did not have cancer. 
The secondary aim is to assess the feasibility of studying outcomes that are usually reported 
directly be patients by relying on the EHR data. 
 
Specific objectives 
1. To describe cancer-specific measures of HRQoL in breast cancer survivors, and to 
explore the impact of demographic and clinical factors; 
2. To compare measures of HRQoL between breast cancer survivors and women who did 
not have cancer and to evaluate the impact of clinical and demographic variables; 
3. To compare the severity of anxiety and depressive symptoms in breast cancer survivors 
and in women who did not have cancer, and to assess the impact of demographic and 
clinical variables; 
4. To compare patient reported HRQoL, and anxiety and depressive symptoms, with the 
information registered in the EHR for similar constructs. 
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3 Plan of investigation 
 
3.1 Study type 
Descriptive. 
 
3.2 Study site 
England, Wales, Scotland and Northern Ireland. 
 
3.3 Study design 
Cross-sectional. 
 
3.4 Study population 
Women aged 18 to 80 years old, diagnosed with a first primary cancer of the breast at one 
year or more ago at the recruitment date, and who had been registered for at least two years 
with a general practice contributing with ‘up to standard’ data to CPRD at the moment of the 
recruitment.  
 
3.5 Comparison group 
Adult women (18-80 years) without a previous cancer diagnosis, selected from the same 
primary care practices of the cancer patients. 
 
3.6 Recruitment of the participants 
Participants will be recruited from primary care practices contributing with data to the CPRD 
primary care database, via their GP. GPs working in practices considered ‘active’ (i.e. 
contributing with data to CPRD at the time of recruitment), and whose data quality at 
practice level has been judged as ‘up to standard’ by the CPRD internal quality procedures, 
will be invited by the CPRD Intervention Studies Team to participate in the study. Refusal to 
participate in the study will be recorded. 
 
Breast cancer survivors 
The EHR of the women registered with the GPs who accept to participate in the study will be 
collated. We will create a list of women who had a breast cancer recorded in the EHR using 
the list of Read codes provided in Appendix 1. We will then restrict the list to women aged 
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18-80 years, who were registered with the same primary care practice for at least one year 
before the breast cancer diagnosis, and who are currently alive, registered with the same 
practice, and have passed the first anniversary of their cancer diagnosis. A list of Read 
codes for other cancers [35] will be used to further exclude women who have had any other 
malignancy diagnosed before or after the breast cancer. 
A random list of potentially eligible breast cancer survivors from each general practice will be 
selected. The number of women to be randomly selected from each practice will be 
calculated as the total number of women necessary for the study multiplied by the number of 
breast cancer survivors in the practice divided by the total number of potentially eligible 
breast cancer survivors in all practices. 
The list of potentially eligible breast cancer survivors will be provided to the GP, and s/he will 
apply the following exclusion criteria: 
a) The woman had a another cancer (not detected in the EHR), or has been treated for 
a non-invasive breast tumour; 
b) The woman is considered unable to complete a self-administered questionnaire 
written in English for any reason. 
The number of women excluded by the GP under each criterion will be recorded. Breast 
cancer survivors not excluded will be eligible for the study and invited to participate.  
 
Women who did not have cancer 
A list of Read codes [35] will be used to exclude patients who have had cancer from the list 
of patients attending the same practices as the cancer survivors. In addition, patients who 
have not been registered continuously for the last two years with the practice and outside 
the age range 18-80 years will be excluded. Women still in the list are potentially eligible. 
The number of women to be selected from each practice will be calculated as: total number 
of women without cancer necessary for the study times the number of women without 
cancer in the practice divided by the total number of women without cancer in all practices. 
For each practice, we will then calculate the proportion of breast cancer survivors in the 
following age groups: 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-80. The final list of 
potentially eligible controls will be created by randomly selecting women with the same age 
distribution as of the breast cancer survivors of that same practice. 
This list of potentially eligible controls will be sent to the GPs, and s/he will confirm that the 
women did not have a cancer and apply exclusion criteria a) and b). 
Women not excluded will be considered eligible controls and invited to participate in the 
study.  
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4 Data to be collected 
 
4.1 Health-related quality of life 
Information on HRQoL will be collected using the Quality of Life in Adult Cancer Survivors 
Scale (QLACS) [36]. The QLACS was developed to take into account the specific needs of 
long-term cancer survivors, including issues that continue after treatment, new issues that 
arise during the period post-cancer, late physical effects of the cancer treatments and 
positive aspects of surviving to cancer [36]. It includes 47 items, divided in 7 generic and 5 
cancer-specific domains (Appendix 2). 
Breast cancer survivors will be asked to reply to all 47 items of the QLCAS (Appendix 3). 
Women who never had cancer will reply to the 28 items of the generic domains (Appendix 
4). 
 
4.2 Anxiety and depression 
Data on anxiety and depressive symptoms will be collected with the Hospital Anxiety and 
Depression Scale (HADS, 5) [37]. This is a 14-item self-reported screening tool for anxiety 
and depressive symptoms in the past week. It contains two sub-scales, one for anxiety 
(HADS-A) and another for depression (HADS-D), with 7 items each [37]. This scale has 
been validated for use in primary care [38] and was used in primary care studies in the UK 
[39-41]. 
 
4.3 Clinical and socio-demographic data 
Breast cancer survivors will be asked to provide information about the type of treatments 
received, the stage of their disease at diagnosis, the time since the last treatment (excluding 
long-term hormonal therapy), their menopausal status before and after the treatment, and 
how the cancer responded to the treatment (Appendix 6). 
For all women, we will also collect data on potential confounders of the association between 
cancer history and mental health outcomes: education, ethnicity and social support 
(Appendix 7). Information on other potential confounders, such as co-morbidities or age at 
diagnosis will be obtained from the EHR.  
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5 Data/statistical analysis 
 
Proportion of participation and exclusions 
The proportion of GPs who accept to participate in the study will be calculated for the whole 
of the UK, by country within the UK, and by region. 
The proportion of patients considered by the GP as ineligible will be reported separately for 
breast cancer survivors and women who did not have cancer. 
The proportion of breast cancer survivors who accept to participate in the study will be 
calculated, as well as the proportion of women who did not have cancer. The denominator 
will include all women in each group to whom questionnaires were sent, even though we 
expect a minor proportion of envelopes returned because the patient may have moved or 
died, or the address may not be correct. 
 
 
Objective 1: To describe cancer-specific measures of HRQoL in breast cancer 
survivors, and to explore the impact of demographic and clinical factors. 
The QLACS includes 19 items for 5 cancer-specific domains of HRQoL (Appendix 2). 
Answers are provided on an ordinal Likert-type of scale, with values for individual items 
ranging from 1 to 7 [36]. For each breast cancer survivor, we will group the items by domain 
and calculate the sum of the individual scores under each domain [36]. All but one domain 
include 4 items; the “family distress” domain includes 3 items, and the sum of the individual 
scores will be rescaled to make the metric comparable with other domains. Values for each 
domain will range between 4 and 28. The range (minimum and maximum) scores will be 
reported for each domain, as well as the proportion of patients who score at the minimum 
and maximum values (floor and ceiling effects, respectively). 
A mean or median score (depending on distribution) for each domain will be calculated from 
the individual-level sums of scores of the breast cancer survivors. Standard deviation will be 
calculated to quantify the dispersion of the data. The correlation coefficient among the mean 
scores of the domains will be reported. 
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A summary score for the cancer specific domains will be calculated by adding the 
mean/median scores of four domains (‘financial problems’, ‘distress-family’, ‘appearance’, 
and ‘distress-recurrence’); the mean/median score for ‘benefits from cancer’ is not included. 
We will use linear regression models to estimate the association between the cancer-
specific HRQoL domain scores and patients factors, such as stage at diagnosis or type of 
surgery. The dependent variable will be the sum of the individual items reported by each 
patient for that particular domain. The linear regression coefficients (β) from the regression 
models and the corresponding 95% confidence intervals will be reported. 
 
Objective 2: To compare generic measures of HRQoL between breast cancer 
survivors and women who did not have cancer, and to evaluate the impact of 
demographic and clinical variables. 
The QLACS includes 28 items for 7 generic domains of HRQoL, with values for individual 
items ranging from 1 to 7 [36] (Appendix 4). 
The items will be grouped by domain (Appendix 2), and we will calculate, for each woman, 
the sum of the individual scores under each domain [36]. For each group of participants (i.e. 
breast cancer survivors and women who did not have cancer), the range (minimum and 
maximum) of the scores will be reported for each domain, as well as the proportion of 
women who score at the minimum and maximum values of the domain. 
A mean or median score, depending on the distribution of the data, will be obtained for each 
group of women, by calculating the mean/median of the sum of the scores for each woman 
in that group. The respective standard deviation will be reported. 
A summary score for the generic domains will be calculated as the sum of the individual 
domain scores. 
The student’s two-sample t-test, or a non-parametric alternative if needed (i.e. Mann-
Whitney distribution free test), will be used to assess the evidence for a difference in the 
summary scores for each domain between the two groups. 
Linear regression will be used to evaluate the impact of cancer diagnosis on the mean 
scores of HRQoL, adjusting for potential confounders. The role of socio-economic and 
clinical variables will be explored. The model fit and the linear regression coefficients (β) will 
be reported as well as the 95% confidence intervals. 
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Objective 3: To compare the severity of depressive and anxiety symptoms in breast 
cancer survivors and in women who did not have cancer, and to assess the impact of 
clinical and demographic variables. 
The Hospital Anxiety and Depression Scale contains two sub-scales, one for anxiety (HADS-
A) and another for depression (HADS-D), with 7 items each [37]. Each item is rated from 0 
to 3 and the total score for each sub-scale ranges between 0 and 21; higher scores 
represent higher symptoms of depression or anxiety [37]. 
To evaluate the severity of the depressive and anxiety symptoms in each group, the mean or 
median score, as appropriate, will be calculated for each sub-scale. The student’s t-test or 
the Mann-Whitney test will be used to compare the mean/median score of depressive and of 
anxiety symptoms between cancer survivors and women who did not have cancer.  
To identify patients with clinically relevant symptoms of depression or anxiety, the authors of 
the scale propose the cut-off of 0-7 for non-cases, 8-10 for borderline cases and 11-21 for 
probable cases, in both subscales.  
The proportion of patients falling into the three categories (non-case, borderline, probable 
case) will be estimated for breast cancer survivors and for controls. 
A chi-squared test will be used to assess whether there is evidence of differences in the 
proportion of patients in these categories between the two groups. A test for trend will be 
used to evaluate if there are increasing changes over the categories in each group. 
The participants will then be categorised as having or not having clinically relevant levels of 
depressive or anxiety symptoms (cut off >10). Logistic regression models will be used to 
estimate the association between breast cancer history and clinically relevant levels of 
anxiety, and breast cancer history and clinically relevant symptoms of depression. The 
impact of clinical and demographic variables will be explored in the regression models. 
Crude and adjusted odds ratios, and respective 95% confidence intervals, will be reported. 
Alexander et al. [42] evaluated the performance of the HADS as a screening test for major 
depressive disorder and anxiety in breast cancer survivors who were between 3 months and 
2 years after main treatment conclusion (gold standard: non-patient Structured Clinical 
Interview for the Diagnostic and Statistical Manual of mental disorders (SCID)). Using the 
proposed cut-off of >10, the HADS-D had a sensitivity of 50% (95% confidence interval 
(95%CI): 27 to 73) and a specificity of 97% (95%CI: 93 to 99) [42]. However, the HADS-A 
had a sensitivity of 71% (95%CI: 30 to 95) and specificity of 87% (95%CI: 81 to 91) [42]. 
Even though the optimal cut-off for this population has not been established, a sensitivity of 
50% may be too low to be acceptable in clinical practice, and therefore we will conduct a 
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sensitivity analysis considering the cut-off of ≥8 to classify women as having clinically 
relevant symptoms of anxiety or depression. 
 
Objective 4: To compare the information reported by the patients for HRQoL, and for 
depressive and anxiety symptoms, with the information registered in the EHR for 
similar constructs 
HRQoL 
The QLACS includes seven generic domains of HRQoL (Appendix 4). Of these, five are 
particularly suitable for comparison with the data recorded in the EHR because women with 
distressing levels for these domains may have visited their GP to seek help: ‘negative 
feelings’, ‘cognitive problems’, ‘physical pain’, ‘sexual problems’ and ‘fatigue’. Read codes 
for the ‘social avoidance’ domain are also available, and therefore we included also this 
domain. 
For each woman, we will calculate the mean score for each domain (mean values will range 
between 1 and 7). Then, we will consider as reporting important levels of distress all women 
with a mean score of ≥5 (corresponding to replies of frequently, very often or always to most 
questions) in the domains of negative feelings, cognitive problems, physical pain, sexual 
problems and fatigue. Two sensitivity analyses will be conducted: 1) using a lower cut-off of 
≥3 (corresponding to replies of sometimes and as often as not, in addition to replies of 
frequently, very often or always to most questions); 2) considering as exposed to important 
levels of distress all women who replied ≥5 to at least one item in the domain.  
To identify evidence of the corresponding outcomes in the EHR, we will produce a list of 
Read codes closely related to the QLACS items for each domain (table 1). This list of Read 
codes will be used to identify women (who have had and who did not have breast cancer) 
with these outcomes registered in their EHR in the previous year (or since the first 
anniversary of diagnosis, if a cancer was diagnosed at less than 2 years). 
 
 
Table 1   Domains and respective items of the QLACS scale, and conditions related to each domain. 
Domain Items in the QLACS Read codes* related to: 
   
Negative 
feelings 
19 Bothered by mood swings; 
7   Felt blue or depressed; 
9   Worried about little things; 
24 Felt anxious 
 
Depression, anxiety 
Cognitive 
problems 
3 Bothered by having a short attention span 
4 Had trouble remembering things 
Mild cognitive impairment 
Cognitive dysfunction 
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Domain Items in the QLACS Read codes* related to: 
2 Difficulty doing things requiring concentration 
23 Bothered by forgetting what started to do 
 
Physical pain 13 Bothered by pain preventing activities 
17 Mood disrupted by pain or its treatment 
27 Pain interfered w/social activities  
21 Had aches or pains 
 
Pain reported as a symptom 
 
Prescriptions of analgesics 
Sexual 
problems 
Sexual interest: 
16 Lacked interest in sex 
26 Avoided sexual activity 
 
Sexual function 
12 Dissatisfied w/sex life  
10 Bothered by inability to function sexually 
 
Sexual dysfunction 
Hypoactive sexual disorder 
Prescription of topical oestrogens 
Fatigue 11 Lacked energy to do things wanted to 
14 Felt tired a lot 
1 Had energy to do things wanted to do  
5 Felt fatigued 
 
Fatigue 
Low energy 
Social 
avoidance 
18 Avoided social gatherings 
20 Avoided friends 
25 Reluctant to meet new people 
15 Reluctant to start new relationships 
 
Social isolation 
Social difficulties 
Non aggressive unsocial conduct 
disorder 
* This will also be based on the systematic review of the Read codes used to identify mental health outcomes in 
primary care databases. 
 
 
We will estimate the proportion of women who reported distressing levels for these domains, 
and the proportion of women who have a recording of a similar construct in the EHR, 
separately for breast cancer survivors and for women who did not have cancer. 
To estimate how much inquiring the patient adds to the information registered in the EHR, 
we will calculate the probability of: 
1) having information for a particular domain registered in the EHR, among women who 
reported distressing levels for that domain (sensitivity);  
2) not having any information registered in the EHR for a particular domain among 
women who did not report distressing levels for that domain (specificity); 
3) reporting distressing levels for a particular domain among women who had 
information for that domain registered in the EHR (positive predictive value); 
4) not reporting distressing levels for a particular domain among women who did not 
have data for that domain registered in the EHR (negative predictive value). 
All probabilities will be calculated separately for breast cancer survivors and for women who 
did not have cancer. 
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Anxiety and depression 
The scores of the HADS-A and HADS-D will be used to classify women as having clinically 
relevant levels of anxiety and of depressive symptoms, respectively, using >10 as cut-off. 
The proportion of women scoring above this threshold will be calculated. 
Women with a diagnosis of an anxiety and/or depressive disorder will be identified in the 
EHR through a list of Read codes. This list will be based on a systematic review of the 
literature to identify mental disorders in primary care databases. Women with a Read code 
for a depressive or anxiety disorder diagnosed in the last year will be considered depressed 
or anxious. A sensitivity analysis will include Read codes for symptoms of depression and/or 
anxiety, to account for the difficulties in the diagnosis of these conditions. 
We will calculate, for each group of women and for each disorder, the probability of:  
1) having a diagnosis of anxiety/depression registered in the EHR among women who 
scored above the threshold in the HADS scale (sensitivity);  
2) not having a diagnosis of anxiety/depression registered in the EHR among women 
who did not score above the threshold in the HADS scale (specificity); 
3) scoring above the threshold in the HADS scale among women who had a diagnosis 
of anxiety/depression recorded in the EHR (positive predictive value); 
4) not scoring above the threshold in the HADS scale among women who did not have 
a diagnosis of anxiety/depression recorded in the EHR (negative predictive value). 
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6 Plan for addressing missing data 
 
We estimate that 5% of the women will have missing data for at least one item of the 
QLACS. This is a conservative estimate based on literature (the highest proportion of 
missing items was 3.2% [43]). The HADS has been shown to have excellent acceptability 
[37] and the proportion of missing items is usually small. 
We will explore the pattern of missingness of the items by demographic and clinical 
variables. For that purpose, a variable will be created to denote records with incomplete 
information and we will explore the association between this variable and clinical and 
demographic variables. If the missingness can be explained by the other variables in the 
dataset, we will consider that it is missing at random, and specify a multiple imputation 
model to better represent the distribution from which the missing data came. 
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7 Sample size 
 
We estimate that a sample of 260 breast cancer survivors and 260 women who did not have 
cancer are required to detect differences of the size reported in the literature. As 
participation rate in this type of studies has been low (approximately 20%), we believe that 
1,400 women in each group need to be invited. 
 
HRQoL 
Table 2 provides details of the sample size calculation for the comparison of the summary 
scores of HRQoL, and of the mean scores of the generic domains of HRQoL, between 
breast cancer survivors and women who did not have cancer. 
 
 
Table 2   Estimated sample size to compare the mean values of HRQoL in breast cancer 
survivors and women who did not have cancer. 
 
HRQoL mean score 
breast cancer 
survivors (SD) 
HRQoL mean 
score normative 
data (SD) 
Sample size 
per group † 
Adjusted* sample 
size 
per group 
     
Summary score 68.5 (22.7) 1 60.9 (21.5) 133 800 
Summary score 70.5 (26.6) 2 60.9 (21.5) 100 600 
Summary score 75.5 (26.3) 2 60.9 (21.5) 43 350 
     
Generic domains     
     Negative feelings   9.7 (3.8)   7.1 (3.5) 31 300 
     Positive feelings 22.1 (4.7) 20.3 (6.3) 85 550 
     Cognitive problems   9.8 (5.0)   8.3 (2.7) 113 700 
     Sexual problems 11.8 (6.8)   9.0 (3.4) 58 400 
     Physical pain   9.7 (6.1)   7.8 (4.8) 131 800 
     Fatigue 11.8 (5.4) 10.3 (4.6) 176 1,000 
     Social avoidance   8.2 (4.3)   6.9 (2.8) 123 750 
     
† Assuming an alpha of 0.05 and power of 80%. 
* Calculated as the estimated sample size rounded upwards to the next 10 subjects (to take into account the 
uncertainty of the estimation process) divided by 0.2 (the estimated proportion of participation), and added a 100 
patients to account for other variables to be studied. 
1 Women diagnosed with breast cancer at 18-24 months [44]. 
2 Women diagnosed with breast cancer at 5 years of more [36, 43]. 
 
The summary mean scores for the generic domains of the QLACS among breast cancer 
survivors were obtained from the literature [36, 43, 44]. The mean/median scores of the 
generic domains among women who did not have cancer have not been reported. However, 
in a study involving long-term survivors of breast, bladder, head and neck, gynaecologic, 
prostate and colorectal cancer [36], patients with colorectal cancer ranked the lowest 
summary score (indicating better HRQoL) for the generic domains of HRQoL (mean 60.9, 
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SD=21.5). We used this score as a conservative estimate of the summary score of HRQoL 
in the general population, assuming that women who never have had cancer will not have 
worse HRQoL than the cancer patients who experience the best HRQoL. The same 
assumption was applied to estimate the sample size for the specific domains of HRQoL. 
 
Anxiety and depression 
Table 3 provides sample size estimates for the comparison of the mean scores of the two 
subscales of the HADS. As shown in the table, one study found a difference in mean HADS-
Depression scores of just 0.6; to detect such a small difference would require 447 women 
per group, which would be beyond available resources. However, another study has 
calculated that differences of less than 1.4 in mean HADS-depression scores are not 
clinically important [45], and only around 75 patients per group would be required to detect 
differences above this level. For anxiety we would require 253 women per group to detect 
the minimum previously observed differences on the HADS scale.  
Table 3   Estimated sample size to compare the mean scores of anxiety and depression between 
breast cancer survivors and women from the general population. 
 
Mean score breast 
cancer survivors 
(SD) 
Mean score 
normative data 
(SD) 
Sample size 
per group † 
Adjusted* sample 
size  
per group 
     
HADS-Anxiety 6.3 (2.8) [46] 4.8 (3.7) [46] 76 500 
HADS-Anxiety 7.8 (3.0) [47] 7.1 (2.6) [47] 253 1,400 
     
HADS-Depression 3.1 (3.3) [46] 3.7 (3.1) [46] (447) (2,350) 
HADS-Depression 4.6 (3.3) [47] 3.2 (2.7) [47] 73 500 
     
* Calculated as the estimated sample size rounded upwards to the next 10 subjects (to take into account the 
uncertainty of the estimation process) divided by 0.2 (the estimated proportion of participation), and added a 100 
patients to account for other variables to be studied. 
 
Table 4 provides estimates of the number of women necessary to compare the prevalences 
of anxiety and depression, as determined by the cut-offs of the HADS [48]. 
 
Table 4   Estimated sample size to compare the prevalences of anxiety and depression between 
breast cancer survivors and women from the general population. 
Outcome α β % of outcome in 
unexposed 
group [ref] 
Estimated 
risk ratio 
[ref] 
Sample size 
per group † 
Adjusted* 
sample size  
per group 
       
Anxiety 0.05 0.20 36.5   [48] 1.44   [48] 150 850 
       
Depression 0.05 0.20 12.9   [48] 1.21   [48] 2,614 13,170 
       
* Calculated as the estimate sample size rounded upwards to the next 10 subjects (to take into account the 
uncertainty of the estimation process) divided by 0.2 (the estimated proportion of participation), and added a 100 
patients to account for other variables to be studied. 
 
According to the calculations, over 13,000 breast cancer survivors and 13,000 women who 
did not have cancer would be needed to compare the prevalence of depression between the 
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two groups of women. Recruiting more than 1,500 women for this study is not feasible, and 
therefore we chose the sample size necessary to compare the mean scores of anxiety and 
depression between the two groups (n=1,400 in each group, as outlined above and in Table 
3).  
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8 Feasibility counts 
 
A total of 43,704 women with breast cancer, and who were at least one year post-diagnosis, 
were identified in the July 2015 cut of the CPRD primary care database. Of these, 21,564 
women had acceptable records from practices contributing with ‘up to standard’ data. A total 
of 8,763 women were still registered in practices that contributed with data to CPRD during 
the year of 2016, of which 7,498 (86%) were aged between 18 and 80 years old. Table 5 
describes the distribution of the patients by region within England. 
 
Table 5   Number of women and general practices with active records (as per June 2016) in the 
CPRD primary care database, by region. 
Region code Region label 
No. of 
practices 
No. of 
patients 
    
1 North East 3 91 
2 North West 28 1,139 
3 Yorkshire & The Humber 3 160 
4 East Midlands 0 0 
5 West Midlands 18 763 
6 East of England 10 557 
7 South West 17 658 
8 South Central 27 1,304 
9 London 35 1,007 
10 South East Coast 47 1,819 
    
 Total 188 7,437 
 
The estimated sample size (1,400) corresponds to 19% of the women potentially eligible for 
the study. 
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9 Pilot study 
 
 
We will invite all GPs working in practices contributing with ‘up to standard’ data to CPRD at 
the time of recruitment to participate in the study. 
Packages containing paper questionnaires will be sent to 140 breast cancer survivors and 
140 women who did not have cancer (10% of those to be invited), randomly selected from 
the list of patients attending the first practices to sign up for the study. The pilot phase will 
run for 1 month. After that time, we will estimate: 
1) the proportion of participation in each group; 
2) the age distribution of the participants in each group; 
3) the number of questionnaires with missing items. 
Sample size calculations will be revised, if necessary. Afterwards, paper questionnaires will 
be sent out to the remainder of women to be invited, up to the estimated sample size. 
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10 Limitations of the study design, data sources and analytical methods 
 
We will use the CPRD primary care database to classify women as exposed or not to breast 
cancer. CPRD has been shown to capture more than 90% of the cancer diagnoses 
registered in the cancer registries [49]. This is considered acceptable for this project, even 
though a small proportion of the women may be incorrectly classified as unexposed. We will 
request that the GP revises the list of patients to exclude potentially misclassified cases.  
We expect a substantial proportion of patients to decline to participate in the study, as 
shown by the proportion of participation in previous studies. Selection bias may occur if the 
patients who accept to participate in the study differ systematically from those who do not. 
We will compare the demographic characteristics of the women who participate in the study 
with the broad characteristics of the women who had breast cancer in the CPRD primary 
care database. Also, we assumed a similar participation rate by age-group between women 
with breast with and without cancer. We will compare the age-distribution of the final 
samples and take age into account in multivariate analyses if necessary. 
Women who are unable to complete a self-administered questionnaire due to advanced 
disease (e.g. terminally ill, patients with dementia or severe mental illnesses) will be 
excluded from the study. Therefore, the generalizability of our results will be limited women 
with a relatively good cognitive function.  
The QLACS was validated in the United States but not in the UK population of cancer 
survivors. However, no translation is required and the entire scale will be applied, which 
makes unlikely the occurrence of substantial bias. 
This study will have limited power to detect a strong association between having had a 
breast cancer and depression as defined by the cut-offs of the HADS scale. Our primary 
outcome will be the difference of the mean scores of each sub-scale, for which this study will 
have enough power.  
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11 Patient or user group involvement 
 
Two women who never had cancer revised the invitation letter, participant information 
sheets and questionnaires for women in the non-cancer comparison group. 
Breast cancer survivors identified through the Independent Cancer Patients’ Voice (a patient 
advocate group and charity) revised the materials for breast cancer survivors. Comments 
from each group were incorporated into the study materials. 
We will also ask selected members of the public and breast cancer survivors to comment on 
the report produced to share the study results prior to making these available. 
  
500
Study protocol: Mental health and quality of life in women who had breast cancer, v4 24 
12 Plans for disseminating and communicating study results, including the 
presence or absence of any restrictions on the extent and timing of 
publication 
 
We plan to disseminate the results with the publication of an article in a peer-reviewed 
scientific journal. We will also present preliminary finding at scientific meetings. 
 
To share the results with the general public, we will make the study results publicly available 
online. We will create a study’s webpage on the website of the London School of Hygiene & 
Tropical Medicine. The website address for this webpage will be included in the participant 
information packs. A summary of findings from the study will be posted on the study 
webpage in due course. Anyone visiting this webpage (whether a participant, invitee, 
general practitioner or any interested member of the public) will be able to provide a contact 
email address through the webpage to subscribe for updates. The study researchers will use 
these contact email addresses for the sole purpose of letting interested parties know about 
updates to the study webpage. 
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13 Timetable 
 
 
 
 
 
Plan Duration
End of data collection: 8
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Appendix 1. List of read codes to identify breast cancer patients [50]. 
 
Read Code Description 
  B34..11 CA FEMALE BREAST 
B36..00 LOCAL RECURRENCE OF MALIGNANT TUMOUR OF BREAST 
B340100 MALIGNANT NEOPLASM OF AREOLA OF FEMALE BREAST 
B346.00 MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST 
B341.00 MALIGNANT NEOPLASM OF CENTRAL PART OF FEMALE BREAST 
B34y000 MALIGNANT NEOPLASM OF ECTOPIC SITE OF FEMALE BREAST 
B34..00 MALIGNANT NEOPLASM OF FEMALE BREAST 
B34z.00 MALIGNANT NEOPLASM OF FEMALE BREAST NOS 
B343.00 MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST 
B345.00 MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST 
B340.00 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST 
B340000 MALIGNANT NEOPLASM OF NIPPLE OF FEMALE BREAST 
B340z00 MALIGNANT NEOPLASM OF NIPPLE OR AREOLA OF FEMALE BREAST NOS 
B34y.00 MALIGNANT NEOPLASM OF OTHER SITE OF FEMALE BREAST 
B34yz00 MALIGNANT NEOPLASM OF OTHER SITE OF FEMALE BREAST NOS 
B342.00 MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST 
B344.00 MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST 
B347.00 MALIGNANT NEOPLASM, OVERLAPPING LESION OF BREAST 
BB93.00 [M]COMEDOCARCINOMA NOS 
BBM9.00 [M]CYSTOSARCOMA PHYLLODES, MALIGNANT 
BB91100 [M]INFILTRATING DUCT AND LOBULAR CARCINOMA 
BB91.00 [M]INFILTRATING DUCT CARCINOMA 
BB9G.00 [M]INFILTRATING DUCTULAR CARCINOMA 
BB9H.00 [M]INFLAMMATORY CARCINOMA 
BB91000 [M]INTRADUCTAL PAPILLARY ADENOCARCINOMA WITH INVASION 
BB94.00 [M]JUVENILE BREAST CARCINOMA 
BB9F.00 [M]LOBULAR CARCINOMA NOS 
BB9D.00 [M]MEDULLARY CARCINOMA WITH LYMPHOID STROMA 
BB9K.00 [M]PAGET'S DISEASE AND INFILTRATING BREAST DUCT CARCINOMA 
BB9K000 [M]PAGET'S DISEASE AND INTRADUCTAL CARCINOMA OF BREAST 
BB9J.11 [M]PAGET'S DISEASE, BREAST 
BB9J.00 [M]PAGET'S DISEASE, MAMMARY 
BB94.11 [M]SECRETORY BREAST CARCINOMA 
Byu6.00 [X]MALIGNANT NEOPLASM OF BREAST 
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Appendix 2. Items of the Quality of Life in Adult Cancer Survivors Scale 
(QLACS) grouped by domain 
 
 
Domain Item of the Quality of Life in Adult Cancer Survivors scale [36] 
 
Generic 
 Negative feelings 
  19 Bothered by mood swings 
  7   Felt blue or depressed 
  9   Worried about little things 
  24 Felt anxious 
   
 Positive feelings 
  8   Enjoyed life 
  28 Content with life 
  6   Felt happy 
  22 Had a positive outlook on life 
   
 Cognitive problems 
  3   Bothered by having a short attention span 
  4   Had trouble remembering things 
  2   Difficulty doing things requiring concentration 
  23 Bothered by forgetting what started to do 
   
 Pain 
  13 Bothered by pain preventing activities 
  17 Mood disrupted by pain or its treatment 
  27 Pain interfered w/social activities 
  21 Had aches or pains 
   
 Sexual interest 
  16 Lacked interest in sex 
  26 Avoided sexual activity 
   
 Energy/fatigue 
  11 Lacked energy to do things wanted to 
  14 Felt tired a lot 
  1 Had energy to do things wanted to do 
  5 Felt fatigued 
   
 Sexual function 
  12 Dissatisfied w/sex life 
  10 Bothered by inability to function sexually 
  
 Social avoidance 
  18 Avoided social gatherings 
  20 Avoided friends 
  25 Reluctant to meet new people 
  15 Reluctant to start new relationships 
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Domain Item of the Quality of Life in Adult Cancer Survivors scale [36] 
   
Cancer-specific 
 
 Financial problems 
  43 Had money problems from cancer 
  45 Financial problems from loss of income due to cancer 
  30 Financial problems from cost of cancer surgery or tx 
  37 Problems with insurance because of cancer 
   
 Benefits 
  40 Cancer helped recognize what important in life 
  41 Better able to deal w/stress because of cancer 
  32 Cancer helped cope better w/problems 
  29 Appreciated life more because of cancer 
   
 Distress-family 
  34 Worried whether family had cancer causing genes 
  31 Worried family members were at risk for cancer 
  42 Worried family should have genetic tests - cancer 
   
 Appearance 
  35 Felt unattractive b/c of cancer or its treatment 
  33 Self-conscious about appearance because of cancer 
  44 Felt treated differently b/c of changes in appearance 
  38 Bothered by hair loss from cancer treatments 
  
 Distress-recurrence 
  39 Worried about cancer coming back 
  46 When felt pain, worried it was cancer again 
  36 Worried about dying from cancer 
  47 Preoccupied with concerns about cancer 
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Appendix 3. Quality of Life in Adult Cancer Survivors Scale (QLACS) [36] 
 
We would like to ask you about some things that can affect the quality of people’s lives. Some of 
these questions may sound similar, but please be sure to answer each one. Below is a scale ranging 
from never to always. Please indicate how often each of these statements has been true for you in the 
past four weeks. [Select one answer for each question] 
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In the past 4 weeks… 
1 You had the energy to do the things you wanted to do. 1 2 3 4 5 6 7 
2 You had difficulty doing activities that require 
concentrating. 
1 2 3 4 5 6 7 
3 You were bothered by having a short attention span. 1 2 3 4 5 6 7 
4 You had trouble remembering things. 1 2 3 4 5 6 7 
5 You felt fatigued. 1 2 3 4 5 6 7 
6 You felt happy. 1 2 3 4 5 6 7 
7 You felt blue or depressed. 1 2 3 4 5 6 7 
8 You enjoyed life. 1 2 3 4 5 6 7 
9 You worried about little things. 1 2 3 4 5 6 7 
10 You were bothered by being unable to function sexually. 1 2 3 4 5 6 7 
11 You didn’t have energy to do the things you wanted to 
do. 
1 2 3 4 5 6 7 
12 You were dissatisfied with your sex life. 1 2 3 4 5 6 7 
13 You were bothered by pain that kept you from doing the 
things you wanted to do. 
1 2 3 4 5 6 7 
14 You felt tired a lot. 1 2 3 4 5 6 7 
15 You were reluctant to start new relationships. 1 2 3 4 5 6 7 
16 You lacked interest in sex. 1 2 3 4 5 6 7 
17 Your mood was disrupted by pain or its treatment. 1 2 3 4 5 6 7 
18 You avoided social gatherings. 1 2 3 4 5 6 7 
19 You were bothered by mood swings. 1 2 3 4 5 6 7 
20 You avoided your friends. 1 2 3 4 5 6 7 
21 You had aches or pains. 1 2 3 4 5 6 7 
22 You had a positive outlook on life. 1 2 3 4 5 6 7 
23 You were bothered by forgetting what you started to do. 1 2 3 4 5 6 7 
24 You felt anxious. 1 2 3 4 5 6 7 
25 You were reluctant to meet new people. 1 2 3 4 5 6 7 
26 You avoided sexual activity. 1 2 3 4 5 6 7 
27 Pain or its treatment interfered with your social activities. 1 2 3 4 5 6 7 
28 You were content with your life. 1 2 3 4 5 6 7 
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The next set of questions asks specifically about the effects of your cancer or its treatment. Again, 
for each statement, indicate how often each of these statements has been true for you in the past 
four weeks. 
29 You appreciated life more because of having had 
cancer. 
1 2 3 4 5 6 7 
30 You had financial problems because of the cost of 
cancer surgery or treatment. 
1 2 3 4 5 6 7 
31 You worried that your family members were at risk of 
getting cancer. 
1 2 3 4 5 6 7 
32 You realized that having had cancer helps you cope 
better with problems now. 
1 2 3 4 5 6 7 
33 You were self-conscious about the way you look 
because of your cancer or its treatment. 
1 2 3 4 5 6 7 
34 You worried about whether your family members might 
have cancer-causing genes. 
1 2 3 4 5 6 7 
35 You felt unattractive because of your cancer or its 
treatment. 
1 2 3 4 5 6 7 
36 You worried about dying from cancer. 1 2 3 4 5 6 7 
37 You had problems with insurance because of cancer. 1 2 3 4 5 6 7 
38 You were bothered by hair loss from cancer treatment. 1 2 3 4 5 6 7 
39 You worried about cancer coming back. 1 2 3 4 5 6 7 
40 You felt that cancer helped you to recognize what is 
important in life. 
1 2 3 4 5 6 7 
41 You felt better able to deal with stress because of 
having had cancer. 
1 2 3 4 5 6 7 
42 You worried about whether your family members 
should have genetic tests for cancer. 
1 2 3 4 5 6 7 
43 You had money problems that arose because you had 
cancer. 
1 2 3 4 5 6 7 
44 You felt people treated you differently because of 
changes to your appearance due to your cancer or its 
treatment. 
1 2 3 4 5 6 7 
45 You had financial problems due to a loss of income as 
a result of cancer. 
1 2 3 4 5 6 7 
46 Whenever you felt a pain, you worried that it might be 
cancer again. 
1 2 3 4 5 6 7 
47 You were preoccupied with concerns about cancer. 1 2 3 4 5 6 7 
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Appendix 4. Generic domains of HRQoL [36] 
We would like to ask you about some things that can affect the quality of people’s lives. Some of 
these questions may sound similar, but please be sure to answer each one. Below is a scale ranging 
from never to always. Please indicate how often each of these statements has been true for you in the 
past four weeks. [Select one answer for each question] 
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In the past 4 weeks… 
1 You had the energy to do the things you wanted to do. 1 2 3 4 5 6 7 
2 You had difficulty doing activities that require 
concentrating. 
1 2 3 4 5 6 7 
3 You were bothered by having a short attention span. 1 2 3 4 5 6 7 
4 You had trouble remembering things. 1 2 3 4 5 6 7 
5 You felt fatigued. 1 2 3 4 5 6 7 
6 You felt happy. 1 2 3 4 5 6 7 
7 You felt blue or depressed. 1 2 3 4 5 6 7 
8 You enjoyed life. 1 2 3 4 5 6 7 
9 You worried about little things. 1 2 3 4 5 6 7 
10 You were bothered by being unable to function sexually. 1 2 3 4 5 6 7 
11 You didn’t have energy to do the things you wanted to 
do. 
1 2 3 4 5 6 7 
12 You were dissatisfied with your sex life. 1 2 3 4 5 6 7 
13 You were bothered by pain that kept you from doing the 
things you wanted to do. 
1 2 3 4 5 6 7 
14 You felt tired a lot. 1 2 3 4 5 6 7 
15 You were reluctant to start new relationships. 1 2 3 4 5 6 7 
16 You lacked interest in sex. 1 2 3 4 5 6 7 
17 Your mood was disrupted by pain or its treatment. 1 2 3 4 5 6 7 
18 You avoided social gatherings. 1 2 3 4 5 6 7 
19 You were bothered by mood swings. 1 2 3 4 5 6 7 
20 You avoided your friends. 1 2 3 4 5 6 7 
21 You had aches or pains. 1 2 3 4 5 6 7 
22 You had a positive outlook on life. 1 2 3 4 5 6 7 
23 You were bothered by forgetting what you started to do. 1 2 3 4 5 6 7 
24 You felt anxious. 1 2 3 4 5 6 7 
25 You were reluctant to meet new people. 1 2 3 4 5 6 7 
26 You avoided sexual activity. 1 2 3 4 5 6 7 
27 Pain or its treatment interfered with your social activities. 1 2 3 4 5 6 7 
28 You were content with your life. 1 2 3 4 5 6 7 
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Appendix 5. Hospital Anxiety and Depression Scale [37]  
 
Hospital Anxiety and Depression Scale (HADS)  
This questionnaire is designed to help clinicians to know how you feel. Read each item below and underline the 
reply which comes closest to how you have been feeling in the past week. 
Don’t take too long over your replies, your immediate reaction to each item will probably be more accurate than a 
long, thought-out response. 
 
 I feel tense or ‘wound up’  I feel as if I am slowed down  
      Most of the time       Nearly all the time  
      A lot of the time       Very often  
      From time to time, occasionally       Sometimes  
      Not at all       Not at all  
 I still enjoy the things I used to enjoy  I get a sort of frightened feeling like 
‘butterflies’ in the stomach 
 
      Definitely as much       Not at all  
      Not quite so much       Occasionally  
      Only a little       Quite often  
      Hardly at all       Very often  
 I get a sort of frightened feeling as if 
something awful is about to happen 
 I have lost interest in my appearance  
      Very definitely and quite badly       Definitely  
      Yes, but not too badly       I don’t take as much care as I should  
      A little, but it doesn’t worry me       I may not take quite as much care  
      Not at all       I take just as much care as ever  
 I can laugh and see the funny side of things  I feel restless as if I have to be on the move  
      As much as I always could       Very much indeed  
      Not quite so much now       Quite a lot  
      Definitely not so much now       Not very much  
      Not at all       Not at all  
 Worrying thoughts go through my mind  I look forward with enjoyment to things  
      A great deal of the time       As much as I ever did  
      A lot of the time       Rather less than I used to  
      Not too often       Definitely less than I used to  
      Very little       Hardly at all  
 I feel cheerful  I get sudden feelings of panic  
      Never       Very often indeed  
      Not often       Quite often  
      Sometimes       Not very often  
      Most of the time       Not at all  
 I can sit at ease and feel relaxed  I can enjoy a good book or radio or television 
programme 
 
      Definitely       Often  
      Usually       Sometimes  
      Not often       Not often  
      Not at all       Very seldom  
 
Now check that you have answered all the questions 
 
 
 HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994.  
Record form items originally published in Acta Psychiatrica Scandinavica, 67, 361–70, copyright © Munksgaard International Publishers Ltd, 
Copenhagen, 1983. This edition first published in 1994 by nferNelson Publishing Company Ltd, now GL Assessment Limited, 1st Floor 
Vantage London, Great West Road, Brentford TW8 9AG United Kingdom; GL Assessment is part of GL Education www.gl-
assessment.co.uk. This form may not be reproduced by any means without first obtaining permission from the publisher. Email: 
permissions@gl-assessment.co.uk. All rights reserved including translations. 
HADS copyright © R.P. Snaith and A.S. Zigmond, 1983, 1992, 1994.  
Record form items originally published in Acta Psychiatrica Scandinavica, 67, 361–70,  
copyright © Munksgaard International Publishers Ltd, Copenhagen, 1983. 
This edition first published in 1994 by nferNelson Publishing Company Ltd, now  GL Assessment Limited, 
1st Floor Vantage London, Great West Road, Brentford TW8 9AG United Kingdom 
GL Assessment is part of GL Education www.gl-assessment.co.uk  
This form may not be reproduced by any means without first obtaining permission from the publisher.  
Email: permissions@gl-assessment.co.uk 
All rights reserved including translations 
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Appendix 6. Clinical information 
1. What treatments have you received for your breast cancer? (Tick all that apply) 
□ Surgery 
□ Radiotherapy 
□ Chemotherapy (excluding hormone treatment) 
□ Hormone treatment 
□ Monoclonal antibodies / immunotherapy 
□ Don’t know / can’t remember 
  
1.1 If you have had breast surgery, do any of the following apply to you? (Tick all that apply) 
□ I have had a lumpectomy (partial removal of the breast) 
□ I have had a mastectomy (complete removal of the breast) 
□ I have had a bilateral mastectomy (complete removal of the two breasts) 
□ I have had a breast reconstruction 
□ I am awaiting or considering breast reconstruction 
□ None of these apply to me 
□ Don’t know / can’t remember 
  
2. At the time of the diagnosis, your cancer was: 
□ Localised to the breast only (without involving lymph nodes) 
□ Spread to the lymph nodes in the axilla 
□ Spread beyond the breast and the lymph nodes (metastatic) 
□ Don’t know / can’t remember 
  
2.1 Please select your stage at diagnosis: 
□ Stage I 
□ Stage II 
□ Stage III 
□ Stage IV 
□ Don’t know / can’t remember 
  
3. How long is it since you completed your initial cancer treatment? 
(Treatment includes any chemotherapy, radiotherapy or surgery for your breast cancer. When answering 
this question please do not include hormone treatments such as Tamoxifen.) 
□ I am still having my initial treatment 
□ It is less than 3 months since my initial treatment 
□ It is between 3 and 12 months since my initial treatment 
□ It is between 1 and 5 years since my initial treatment 
□ It is more than 5 years since my initial treatment 
□ Don’t know / can’t remember 
  
4. Regarding your menopausal status before and after the breast cancer diagnosis: 
□ My menstrual periods had finished when my cancer was diagnosed 
□ My menstrual periods finished during my treatments for breast cancer 
□ I had periods before the cancer diagnosis and continued to have them during/after the treatments 
□ Don’t know / can’t remember 
  
5. Is your cancer currently in remission? (Complete remission means that there is no sign of cancer in 
your body) 
□ Yes 
□ No 
□ Don’t know 
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Appendix 7. Demographic information 
 
1. Which of these qualifications do you have? 
□ Up to GCSEs, O levels, or equivalent 
□ A levels or equivalent 
□ Undergraduate degree (for example BA, BSc) 
□ Post-graduate degree 
□ Trade, technical or vocational training 
□ Do not wish to disclose 
  
2. What is your ethnic group? 
□ White 
□ Mixed / Multiple ethnic groups 
□ Asian / Asian British 
□ Black / African / Caribbean / Black British 
□ Other ethnic group 
□ Do not wish to disclose 
  
3. Which statement best describes your living arrangements? 
□ I live with partner / spouse 
□ I live with family / friends 
□ I live alone 
□ I live in a nursing home or other long term care home 
□ Other 
□ Do not wish to disclose 
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East of England - Cambridge South Research Ethics Committee 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
 
 
15 April 2019 
 
Ms Helena I M Carreira 
Keppel Street 
EPH - NCDE 
WC1E 7HT 
 
 
Dear Ms Carreira, 
 
Study title: Mental health and quality of life of female breast cancer 
survivors compared to women who did not have cancer, and 
feasibility of using electronic health records’ data to study 
patient reported outcomes 
REC reference: 17/EE/0403 
Amendment number:  
Amendment date: 04 April 2019 
IRAS project ID: 224561 
 
Thank you for submitting the above amendment, which was received on 04 April 2019.  It is 
noted that this is a modification of an amendment previously rejected by the Committee (our 
letter of 26 March 2019 refers). 
 
The modified amendment has been considered on behalf of the Committee by the Chair.  
 
Ethical opinion 
 
I am pleased to confirm that the Committee has given a favourable ethical opinion of the 
modified amendment on the basis described in the notice of amendment form and 
supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved are: 
 
Document   Version   Date   
Notice of Modified Amendment    04 April 2019  
Participant information sheet (PIS)  5  29 March 2019  
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
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Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
HRA Learning 
 
We are pleased to welcome researchers and research staff to our HRA Learning Events 
and online learning opportunities– see details at: https://www.hra.nhs.uk/planning-and-
improving-research/learning/ 
 
17/EE/0403:     Please quote this number on all correspondence 
 
Yours sincerely, 
 
 
Dr Leslie Gelling 
Chair 
 
E-mail: nrescommittee.eastofengland-cambridgesouth@nhs.net 
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                                  Observational / Interventions Research Ethics Committee
Ms Helena Carreira  
LSHTM
10 August 2018 
Dear   Helena ,
Study Title: Mental health and quality of life of breast cancer survivors compared to women who did not have cancer, and feasibility of using electronic health records’ data to study
patient reported outcomes 
LSHTM  ethics ref:  14417  
Thank you for your application for the above research, which has now been considered by the Observational Committee.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Investigator CV CV_HelenaCarreira 01/09/2017 1
Investigator CV CV_KrishnanBhaskaran 01/09/2017 1
Investigator CV CV_RachaelWilliams 01/09/2017 1
Protocol / Proposal PRO_study_protocol_v1 18/09/2017 1
Protocol / Proposal PRO_study_protocol_v3_tracked_changes 11/07/2018 3
Information Sheet PIS_v3 11/07/2018 3
Advertisements Invitation letter_BCS_v3 11/07/2018 3
Advertisements Invitation_WWC_v3 11/07/2018 3
Local Approval 224561 17-0403 FIFO 24.11.2017 11/07/2018 1
Covering Letter 14417 REC_further clarifications_03082018 03/08/2018 2
 
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for
review using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the
project by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerely,
Page 1 of 2
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Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/  
Page 2 of 2
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Ms Helena I M Carreira 
PhD student 
London School of Hygiene & Tropical Medicine 
Keppel street 
EPH - NCDE 
WC1E 7HT 
 
Email: hra.approval@nhs.net 
Research-permissions@w ales.nhs.uk 
 
13 September 2018 
 
Dear Ms Carreira    
 
 
 
 
Study title: Mental health and quality of life of female breast cancer 
survivors compared to women who did not have cancer, and 
feasibility of using electronic health records’ data to study 
patient reported outcomes 
IRAS project ID: 224561  
REC reference: 17/EE/0403   
Sponsor London School of Hygiene & Tropical Medicine 
 
I am pleased to confirm that HRA and Health and Care Research Wales (HCRW) Approval has 
been given for the above referenced study, on the basis described in the application form, protocol, 
supporting documentation and any clarifications received. You should not expect to receive anything 
further relating to this application. 
 
How should I continue to work with participating NHS organisations in England and Wales? 
You should now provide a copy of this letter to all participating NHS organisations in England  and 
Wales, as well as any documentation that has been updated as a result of the assessment .  
 
Following the arranging of capacity and capability, participating NHS organisations should formally 
confirm their capacity and capability to undertake the study. How this will be confirmed is detailed in 
the “summary of assessment” section towards the end of this letter. 
 
You should provide, if you have not already done so, detailed instructions to each organisation as to 
how you will notify them that research activities may commence at site following their confirmation of 
capacity and capability (e.g. provision by you of a ‘green light’ email, formal notification following a site 
initiation visit, activities may commence immediately following confirmation by participating 
organisation, etc.). 
 
 
HRA and Health and Care 
Research Wales (HCRW) 
Approval Letter 
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It is important that you involve both the research management function (e.g. R&D office) supporting 
each organisation and the local research team (where there is one) in setting up your study . Contact 
details of the research management function for each organisation can be accessed here. 
 
How should I work with participating NHS/HSC organisations in Northern Ireland and 
Scotland? 
HRA and HCRW Approval does not apply to NHS/HSC organisations within the devolved 
administrations of Northern Ireland and Scotland. 
 
If you indicated in your IRAS form that you do have participating organisations in either of these 
devolved administrations, the final document set and the study wide governance report (including this 
letter) has been sent to the coordinating centre of each participating nation. You should work with the 
relevant national coordinating functions to ensure any nation specific checks are complete, and with 
each site so that they are able to give management permission for the study to begin.  
 
Please see IRAS Help for information on working with NHS/HSC organisations in Northern Ireland and 
Scotland.  
 
How should I work with participating non-NHS organisations? 
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with your non-
NHS organisations to obtain local agreement in accordance with their procedures. 
 
What are my notification responsibilities during the study? 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC 
favourable opinion, gives detailed guidance on reporting expectations for studies, including: 
 Registration of research 
 Notifying amendments 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of changes in 
reporting expectations or procedures. 
 
I am a participating NHS organisation in England or Wales. What should I do once I receive this 
letter? 
You should work with the applicant and sponsor to complete any outstanding arrangements so you 
are able to confirm capacity and capability in line with the information provided in this letter.  
 
The sponsor contact for this application is as follows: 
 
Name: Ms Patricia Henley 
Tel: 44 (0) 20 7636 2268 
Email: RGIO@lshtm.ac.uk  
 
Who should I contact for further information? 
Please do not hesitate to contact me for assistance with this application. My contact details are below.  
 
Your IRAS project ID is 224561. Please quote this on all correspondence. 
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Yours sincerely 
 
Miss Lauren Allen 
Senior Assessor 
 
Email: hra.approval@nhs.net  
 
Copy to: Ms Patricia Henley 
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List of Documents 
 
The final document set assessed and approved by HRA and HCRW Approval is listed below.   
 
 Document   Version   Date   
Contract/Study Agreement template [GP Site Agreement]      
Covering letter on headed paper [Cover letter]  1  11 September 2017  
Covering letter on headed paper [Cover letter and further 
clarifications]  
1  10 November 2017  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Sponsor insurance details]  
1  26 July 2017  
IRAS Application Form [IRAS_Form_14092017]    14 September 2017  
Letter from funder [Grant offer]  1  14 January 2015  
Letter from sponsor [Sponsorship confirmation]  1  26 July 2017  
Letter from statistician [Comments statistician]  1  25 August 2017  
Letters of invitation to participant [Invitation to participate in research 
(GPs)]  
2  10 November 2017  
Letters of invitation to participant [Invitation letter_BCS - Clean]  3  13 July 2018  
Letters of invitation to participant [Invitation letter_BCS - Tracked 
Changes]  
3  13 July 2018  
Letters of invitation to participant [Invitation_WWC - Clean]  3  13 July 2018  
Letters of invitation to participant [Invitation_WWC - Tracked 
Changes]  
3  13 July 2018  
Non-validated questionnaire [Breast cancer clinical information]  1  11 September 2017  
Non-validated questionnaire [Demographic information]  1  11 September 2017  
Non-validated questionnaire [Contact details]  1  11 September 2017  
Notice of Substantial Amendment (non-CTIMP)  Substantial 
Amendment 
1  
13 July 2018  
Participant information sheet (PIS) [Clean]  3  13 July 2018  
Participant information sheet (PIS) [Tracked Changes]  3  13 July 2018  
Research protocol or project proposal [Clean]  3  01 May 2018  
Research protocol or project proposal [Tracked Changes]  3  01 May 2018  
Summary CV for Chief Investigator (CI) [Curriculum vitae]  1  07 September 2017  
Summary CV for student [Curriculum vitae - Helena Carreira]  1  07 September 2017  
Summary CV for supervisor (student research) [Curriculum vitae 
Rachael Williams]  
1  07 September 2017  
Summary CV for supervisor (student research) [Curriculum vitae 
Krishnan Bhaskaran]  
1  07 September 2017  
Validated questionnaire [Hospital Anxiety and Depression Scale]  1  11 September 2017  
Validated questionnaire [Quality of Life in Adult Cancer Survivors 
Scale]  
1  11 September 2017  
Validated questionnaire [Quality of Life in Adult Cancer Survivors 
Scale - Generic Domains]  
1  11 September 2017  
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Summary of assessment 
The following information provides assurance to you, the sponsor and the NHS in England and Wales 
that the study, as assessed for HRA and HCRW Approval, is compliant with relevant standards. It also 
provides information and clarification, where appropriate, to participating NHS organisations in 
England and Wales to assist in assessing, arranging and confirming capacity and capability. 
 
Assessment criteria  
Section HRA Assessment Criteria Compliant with 
Standards? 
Comments 
1.1 IRAS application completed 
correctly 
Yes 
 
Participating GP surgeries have not yet 
been identified.   
    
2.1 Participant information/consent 
documents and consent 
process 
Yes 
 
No comments 
 
    
3.1 Protocol assessment Yes 
 
No comments 
    
4.1 Allocation of responsibilities 
and rights are agreed and 
documented  
Yes 
 
The sponsor intends to use the GP 
practice agreement provided as the 
agreement with participating GP 
practices.  
4.2 Insurance/indemnity 
arrangements assessed 
Yes 
 
Where applicable, independent 
contractors (e.g. General Practitioners) 
should ensure that the professional 
indemnity provided by their medical 
defence organisation covers the 
activities expected of them for this 
research study 
4.3 Financial arrangements 
assessed  
Yes 
 
A grant funding letter from the MRC has 
been provided.   
GPs will be reimbursed for checking the 
pre-screened list of patients codes and 
posting the survey to patients.  
    
5.1 Compliance with the Data 
Protection Act and data 
Yes No comments 
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Section HRA Assessment Criteria Compliant with 
Standards? 
Comments 
security issues assessed  
5.2 CTIMPS – Arrangements for 
compliance with the Clinical 
Trials Regulations assessed 
Not Applicable No comments 
 
5.3 Compliance with any 
applicable laws or regulations 
Yes 
 
No comments 
 
    
6.1 NHS Research Ethics 
Committee favourable opinion 
received for applicable studies 
Yes 
 
No comments 
 
6.2 CTIMPS – Clinical Trials 
Authorisation (CTA) letter 
received 
Not Applicable No comments 
6.3 Devices – MHRA notice of no 
objection received 
Not Applicable No comments 
 
6.4 Other regulatory approvals 
and authorisations received 
Not Applicable No comments 
 
 
Participating NHS Organisations in England and Wales 
This provides detail on the types of participating NHS organisations in the study and a statement as to whether 
the activities at all organisations are the same or different.  
There is one site type. GP practices will be responsible for sending questionnaires to potential 
participants who have been identified using data held by the CPRD primary care database.  
 
The Chief Investigator or sponsor should share relevant study documents with participating NHS 
organisations in England and Wales in order to put arrangements in place to deliver the study. The 
documents should be sent to both the local study team, where applicable, and the office providing 
the research management function at the participating organisation. Where applicable, the local 
LCRN contact should also be copied into this correspondence.   
 
If chief investigators, sponsors or principal investigators are asked to complete site level forms for 
participating NHS organisations in England and Wales which are not provided in IRAS, the HRA or 
HCRW websites, the chief investigator, sponsor or principal investigator should notify the HRA 
immediately at hra.approval@nhs.net or HCRW at Research-permissions@wales.nhs.uk. We will 
work with these organisations to achieve a consistent approach to information provision.  
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Principal Investigator Suitability 
This confirms whether the sponsor position on whether a PI, LC or neither should be in place is correct for each 
type of participating NHS organisation in England and Wales, and the minimum expectations for education, 
training and experience that PIs should meet (where applicable). 
A key contact should be identified at the GP practices. The key contact will be responsible for 
sending study information to potential participants.  
 
GCP training is not a generic training expectation, in line with the HRA/HCRW/MHRA statement on 
training expectations. 
 
HR Good Practice Resource Pack Expectations 
This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement checks 
that should and should not be undertaken 
All activity at the GP practices will be conducted by practice staff therefore access arrangements will 
not be applicable.  
 
Other Information to Aid Study Set-up  
This details any other information that may be helpful to sponsors and participating NHS organisations in 
England and Wales to aid study set-up. 
The applicant has indicated that they do not intend to apply for inclusion on the NIHR CRN Portfolio. 
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Supplementary table 1   Comparison between participants and non-participants, by group, 
age, country, and deprivation. 
 
  No cancer group 
(No. 1,460) 
 Breast cancer survivors 
(No. 1,018) 
  Refused Participated  Refused Participated 
  No. % No. %  No. % No. % 
           
Total 1,208 82.7 252 17.3  665 65.3 353 34.7 
           
Age          
 18-39 17 94.4 1 5.6  5 71.4 2 28.6 
 40-49 107 87.0 16 13.0  45 70.3 19 29.7 
 50-59 263 83.0 54 17.0  168 68.0 79 32.0 
 60-69 355 81.6 80 18.4  200 60.6 130 39.4 
 70-81 466 82.2 101 17.8  247 66.8 123 33.2 
           
Country          
 England 233 78.5 64 21.6  95 65.5 50 34.5 
 Northern Ireland 239 93.7 16 6.3  83 71.6 33 28.5 
 Scotland 356 82.8 74 17.2  241 67.9 114 32.1 
 Wales 380 79.5 98 20.5  246 61.2 156 38.8 
           
Practice IMD          
 1 (most deprived) 209 79.8 53 20.2  97 57.7 71 42.3 
 2 239 86.9 36 13.1  97 64.2 54 35.8 
 3 138 84.2 26 15.9  123 69.9 53 30.1 
 4 440 81.8 98 18.2  277 66.4 140 33.6 
 5 (least deprived) 182 82.4 39 17.7  71 67.0 35 33.0 
IMD – Index of Multiple Deprivation. 
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Supplementary table 2   Correlation coefficients between the different domains of HRQoL (N=605).  
 
  
Generic domains of QLACS 
  
Cancer-specific domains of QLACS 
 
    
Negative 
feelings 
Positive 
feelings 
Cognitive 
problems Pain 
Sexual 
function 
Energy/ 
fatigue Avoidance   
Financial 
problems 
Benefits 
of cancer 
Distress- 
family Appearance 
Distress-
recurrence 
Generic domains              
 Negative feelings 1 
            
 Positive feelings -0.61 1 
           
 Cognitive problems 0.62 -0.40 1 
          
 Pain 0.49 -0.43 0.44 1 
         
 Sexual interest 0.48 -0.41 0.44 0.40 1 
        
 Energy/fatigue 0.68 -0.57 0.59 0.64 0.47 1 
       
 Avoidance 0.70 -0.58 0.54 0.47 0.53 0.63 1 
      
Cancer-specific domains            
 Financial problems 0.28 -0.26 0.37 0.36 0.26 0.29 0.31 
 
1 
    
 Benefits of cancer -0.21 0.46 -0.13 -0.15 -0.17 -0.17 -0.19 
 
0.03 1 
   
 Distress-family 0.29 -0.19 0.32 0.25 0.13 0.28 0.25 
 
0.36 0.11 1 
  
 Appearance 0.49 -0.36 0.45 0.37 0.37 0.36 0.43 
 
0.52 -0.04 0.41 1 
 
 Distress-recurrence 0.53 -0.37 0.46 0.36 0.34 0.44 0.37 
 
0.42 0.01 0.49 0.56 1 
HRQoL = Health-Related Quality of Life; QLACS = Quality of Life in Adult Cancer Survivors scale. 
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